Ticker,Company,Price,Drug,Indication,Stage,Date,Catalyst,Shares
SNDX,Syndax Pharmaceuticals Inc.,21.86,Niktimvo (axatilimab-csfr),Chronic Graft versus host disease (cGvHD) ,BLA Filing,02/01/2024 ET,"BLA submitteed to the FDA, noted January 2, 2024.",86.14M
Add to portfolio,,,,,,,,
INCY,Incyte Corporation,65.45,Niktimvo (axatilimab-csfr),Chronic Graft versus host disease (cGvHD) ,BLA Filing,02/01/2024 ET,"BLA submitteed to the FDA, noted January 2, 2024.",195.28M
Add to portfolio,,,,,,,,
LBPH,Longboard Pharmaceuticals Inc.,25.1,Bexicaserin (LP352) - (DEEp OCEAN),Adolescent and adult patients with developmental and epileptic encephalopathies (DEEs) ,Phase 1/2,02/01/2024 ET,"Phase 1b/2a top-line data reported a median seizure reduction of 53.3% in countable motor seizures compared to 20.8% in the placebo group across the DEE study population, noted January 2, 2024.",39.05M
Add to portfolio,,,BTD,,,,,
ATAI,ATAI Life Sciences N.V.,1.69,EMP-01,Post-Traumatic Stress Disorder (PTSD) ,Phase 1,02/01/2024 ET,"Phase 1 was well-tolerated, and treatment-related adverse events (AEs) were all expected and generally dose-dependent, noted on January 2, 2024.",214.34M
Add to portfolio,,,,,,,,
AVXL,Anavex Life Sciences Corp.,6.05,ANAVEX 2-73-RS-003 - (EXCELLENCE),Pediatric Rett Syndrome ,Phase 2/3,02/01/2024 ET,"Phase 2/3 results missed a primary endpoint on the LS Mean difference (SE) points between treated and placebo, noted January 2, 2024.",85.89M
Add to portfolio,,,View Clinical Trial Data,,,,,
ATXI,Avenue Therapeutics Inc.,12,AJ201,Spinal and bulbar muscular atrophy (SBMA) ,Phase 1/2,02/01/2024 ET,"Phase 1b/2 enrollment completed, noted January 2, 2024.",3.18M
Add to portfolio,,,,,,,,
SPRO,Spero Therapeutics Inc.,1.52,Tebipenem HBr (SPR994) - (PIVOT-PO),"Complicated urinary tract infection (cUTI), including acute pyelonephritis (AP) ",Phase 3,02/01/2024 ET,"Phase 3 dosing initiated, noted January 2, 2024.",56.28M
Add to portfolio,,,,,,,,
CTXR,Citius Pharmaceuticals Inc.,0.81,Mino-Lok,Catheter related blood stream infection (CRBSI) ,Phase 3,02/01/2024 ET,"Phase 3 enrollment was completed, noted January 2, 2024.",17.01M
Add to portfolio,,,View Clinical Trial Data,,,,,
NVS,Novartis AG,—,Farabursen (RGLS8429) (MAD),Autosomal Dominant Polycystic Kidney Disease (ADPKD) ,Phase 1b,02/01/2024 ET,"Phase 1b third cohort completed, noted January 2, 2024.",1.98B
Add to portfolio,,,ODD,,,,,
AGIO,Agios Pharmaceuticals Inc.,24.02,PYRUKYND (Mitapivat) - (ENERGIZE),Thalassemia ,Phase 3,03/01/2024 ET,"Phase 3 data reported that the trial met its primary endpoint and key secondary endpoints, noted January 3, 2024.",58.1M
Add to portfolio,,,View Clinical Trial Data,,,,,
TEVA,Teva Pharmaceutical Industries Limited American Depositary Shares,10.95,AVT06 - (EYLEA biosimilar),Eye disorders ,Phase 3,03/01/2024 ET,"Phase 3 data reported that the trial met its primary endpoint, noted January 3, 2024.",1.15B
Add to portfolio,,,,,,,,
ALVO,Alvotech,11.68,AVT06 - (EYLEA biosimilar),Eye disorders ,Phase 3,03/01/2024 ET,"Phase 3 data reported that the trial met its primary endpoint, noted January 3, 2024.",301.81M
Add to portfolio,,,,,,,,
DYN,Dyne Therapeutics Inc.,14.77,DYNE-101 - (ACHIEVE),Myotonic Dystrophy Type 1 (DM1) ,Phase 1/2,03/01/2024 ET,"Phase 1/2 MAD data reported a dose-dependent splicing correction and increase in muscle delivery and DMPK knockdown while also showing functional improvement in myotonia, noted January 3, 2024.",142.26M
Add to portfolio,,,ODD,,,,,
,,,FTD,,,,,
,,,BTD,,,,,
DYN,Dyne Therapeutics Inc.,14.77,DYNE-251 - (DELIVER),Duchenne muscular dystrophy (DMD) ,Phase 1/2,03/01/2024 ET,"Phase 1/2 initial data reported a mean absolute dystrophin level of 0.88% of normal and a 0.28% change from baseline at 6 months, noted January 3, 2024.",142.26M
Add to portfolio,,,FTD,,,,,
,,,ODD,,,,,
,,,BTD,,,,,
ATHA,Athira Pharma Inc.,3.03,Fosgonimeton (ATH-1017) - (LIFT-AD),Alzheimer’s disease ,Phase 2/3,03/01/2024 ET,"Phase 2/3 trial enrollment completed, noted January 3, 2024.",3.94M
Add to portfolio,,,View Clinical Trial Data,,,,,
APLM,Apollomics Inc.,0.96,Uproleselan,Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) ,Phase 3,03/01/2024 ET,"Phase 3 enrollment completed, noted January 3, 2024.",1.1M
Add to portfolio,,,View Clinical Trial Data,,,,,
GLYC,GlycoMimetics Inc.,3.03,Uproleselan,Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) ,Phase 3,03/01/2024 ET,"Phase 3 enrollment completed, noted January 3, 2024.",13.89M
Add to portfolio,,,View Clinical Trial Data,,,,,
CMMB,Chemomab Therapeutics Ltd.,0.53,nebokitug (CM-101) - (SPRING),Primary Sclerosing Cholangitis ,Phase 2,03/01/2024 ET,"Phase 2 early enrollment completed, noted January 3, 2023.",5.19M
Add to portfolio,,,FTD,,,,,
SLRX,Salarius Pharmaceuticals Inc.,0.64,Seclidemstat,Myelodysplastic Syndromes (MDS) and Chronic Myelomonocytic Leukemia (CMML) ,Phase 1/2,03/01/2024 ET,"Additional Phase 1/2 data reported that an additional Ewing sarcoma patient treated with seclidemstat, topotecan and cyclophosphamide (TC) has achieved a partial response as demonstrated by at least a … read more",509.71K
Add to portfolio,,,,,,,,
INTS,Intensity Therapeutics Inc.,7.99,INT230-6,Advanced Soft Tissue Sarcoma ,Phase 3,03/01/2024 ET,"FDA provided ""Study May Proceed"" letter, noted January 3, 2024.",47.06M
Add to portfolio,,,ODD,,,,,
ENVB,Enveric Biosciences Inc.,1.32,EB-003 (EVM301 series),Mental health disorders ,Preclinical,03/01/2024 ET,"Preclinical development to commence in early 2024, with IND submission planned in 2024, noted January 3, 2024.",3.25M
Add to portfolio,,,,,,,,
IFRX,InflaRx N.V.,1.83,INF904,Chronic Autoimmune and Inflammatory Diseases ,Phase 1,04/01/2024 ET,Phase 1 MAD results from 24 healthy volunteers showed that study was well tolerated in participants over the entire dose range and resulted in no safety signals of concern. The overall percentage of A … read more,59.35M
Add to portfolio,,,,,,,,
GLYC,GlycoMimetics Inc.,3,GMI-1687,Healthy volunteers ,Phase 1a,04/01/2024 ET,"Phase 1a Initial results demonstrated that subcutaneous dosing achieved target therapeutic plasma concentration and linear pharmacokinetics with rapid renal clearance across all dosing levels, noted … read more",13.89M
Add to portfolio,,,,,,,,
ADCT,ADC Therapeutics SA,1.88,ADCT-601 (mipasetamab uzoptirine),"Soft tissue sarcomas, pancreatic cancer and AXL-expressing non-small cell lung cancer (NSCLC) ",Phase 1b,04/01/2024 ET,"Preliminary Phase 1 data shows the maximum-tolerated dose has been reached, and the study is currently in dose optimization, noted Janaury 4, 2024.",112.5M
Add to portfolio,,,,,,,,
ADCT,ADC Therapeutics SA,1.88,ADCT-901,Solid tumors ,Phase 1,04/01/2024 ET,"Program discontinued due to limited signs of efficacy in the dose escalation phase and to reallocate capital to prioritized programs, noted January 4, 2024.",112.5M
Add to portfolio,,,,,,,,
ALDX,Aldeyra Therapeutics Inc.,3.34,ADX-629,Sjögren-Larsson Syndrome (SLS) ,Phase 1/2,04/01/2024 ET,Phase 2 biomarker results observed in adult cohort proposed expansion to include pediatric patients expected to be submitted to the FDA in the 1H 2024.,59.9M
Add to portfolio,,,,,,,,
ALDX,Aldeyra Therapeutics Inc.,3.34,ADX-246,Systemic Immune-Mediated Diseases and atopic dermatitis ,Phase 1,04/01/2024 ET,"Phase 1 expanded to include patients with atopic dermatitis, noted Janaury 4, 2024.",59.9M
Add to portfolio,,,,,,,,
KNSA,Kiniksa Pharmaceuticals Ltd.,19.13,Abiprubart (KPL-404),Rheumatoid arthritis ,Phase 2,04/01/2024 ET,"Phase 2 trial met its primary endpoint, noted January 4, 2024.",74.11M
Add to portfolio,,,,,,,,
RYTM,Rhythm Pharmaceuticals Inc.,43.31,Bivamelagon (LB54640),Healthy overweight adults ,Phase 1,04/01/2024 ET,"Phase 1 has shown targeted effect on MC4 receptor without hyperpigmentation, noted January 4, 2024.",66.42M
Add to portfolio,,,ODD,,,,,
SNGX,Soligenix Inc.,0.91,SGX302/hypericin sodium,Psoriasis ,Phase 2a,04/01/2024 ET,"Phase 2a data reported that two patients reached a disease status of ""Almost Clear"" represented by an Investigator Global Assessment (IGA) score of 1, noted January 4, 2024.",4.29M
Add to portfolio,,,,,,,,
PRTG,Portage Biotech Inc.,1.35,IMM60 - (PORT-2),Refractory NSCLC & Melanoma ,Phase 1,04/01/2024 ET,"Phase 2 paused after a review of Portage's funding requirements, noted January 4, 2024.",2.28M
Add to portfolio,,,,,,,,
MRK,Merck & Company Inc.,116.27,IMM60 - (PORT-2),Refractory NSCLC & Melanoma ,Phase 1,04/01/2024 ET,"Phase 2 paused after a review of Portage's funding requirements, noted January 4, 2024.",2.5B
Add to portfolio,,,,,,,,
IMMP,Immutep Limited,2.41,Eftilagimod alpha - INSIGHT-004,Solid tumors ,Phase 1,04/01/2024 ET,"Phase 1 dosing initiated, noted January 4, 2024.",145.46M
Add to portfolio,,,,,,,,
APLT,Applied Therapeutics Inc.,3.79,AT-001 - (ARISE-HF),Diabetic cardiomyopathy (DbCM) ,Phase 3,04/01/2024 ET,"Phase 3 topline data demonstrated that while a trend favored active treatment, the difference between active and placebo treated groups (0.30 ml/kg/min) was not statistically significant, noted Januar … read more",144.01M
Add to portfolio,,,View Clinical Trial Data,,,,,
APLT,Applied Therapeutics Inc.,3.79,AT-001 - (ARISE-HF),Diabetic cardiomyopathy (DbCM) ,Phase 3,04/01/2024 ET,"Phase 3 topline data demonstrated that while a trend favored active treatment, the difference between active and placebo treated groups (0.30 ml/kg/min) was not statistically significant, noted Januar … read more",144.01M
Add to portfolio,,,View Clinical Trial Data,,,,,
TBPH,Theravance Biopharma Inc.,10.37,YUPELRI (revefenacin) - (PIFR-2),Chronic obstructive pulmonary disease (COPD) ,Phase 3,05/01/2024 ET,"Phase 4 data reported that the trial did not show a statistically significant difference between YUPELRI and Spiriva HandiHaler on the primary endpoint, noted January 5, 2024.",50.36M
Add to portfolio,,,,,,,,
CVAC,CureVac N.V.,4.34,CV0601,COVID-19 vaccine ,Phase 2,05/01/2024 ET,"Phase 2 data reported a meaningful immune responses and favorable reactogenicity profiles across all tested doses, including the lowest tested dose, noted January 5, 2024.",224.34M
Add to portfolio,,,,,,,,
GSK,GSK plc American Depositary Shares (Each representing two),38.51,XMT-2056,HER2-Expressing Tumors ,Phase 1,05/01/2024 ET,"Phase 1 clinical trial restarting; plan to advance dose escalation in 2024, noted January 5, 2024.",2.03B
Add to portfolio,,,ODD,,,,,
MRSN,Mersana Therapeutics Inc.,2.27,XMT-2056,HER2-Expressing Tumors ,Phase 1,05/01/2024 ET,"Phase 1 clinical trial restarting; plan to advance dose escalation in 2024, noted January 5, 2024.",4.99M
Add to portfolio,,,ODD,,,,,
FBIO,Fortress Biotech Inc.,2.42,"Emrosi (Minocycline Hydrochloride ER Capsules, 40 mg) (DFD-29) - (MVOR-2)",Papulopustular Rosacea ,NDA Filing,05/01/2024 ET,"NDA submitted to the FDA, noted January 5, 2024.",29.75M
Add to portfolio,,,,,,,,
DERM,Journey Medical Corporation,5.05,"Emrosi (Minocycline Hydrochloride ER Capsules, 40 mg) (DFD-29) - (MVOR-2)",Papulopustular Rosacea ,NDA Filing,05/01/2024 ET,"NDA submitted to the FDA, noted January 5, 2024.",24.38M
Add to portfolio,,,,,,,,
NOVN,Novan Inc.,0,ZELSUVMI (berdazimer topical gel),Molluscum Contagiosum ,Approved,05/01/2024 ET,"FDA Approved on January 5, 2023.",28.02M
Add to portfolio,,,,,,,,
LGND,Ligand Pharmaceuticals Incorporated,70.83,ZELSUVMI (berdazimer topical gel),Molluscum Contagiosum ,Approved,05/01/2024 ET,"FDA Approved on January 5, 2023.",19.6M
Add to portfolio,,,,,,,,
PTHS,Pelthos Therapeutics Inc.,—,ZELSUVMI (berdazimer topical gel),Molluscum Contagiosum ,Approved,05/01/2024 ET,"FDA Approved on January 5, 2023.",3.04M
Add to portfolio,,,,,,,,
VINC,Vincerx Pharma Inc.,1.36,VIP236,Solid tumors ,Phase 1,08/01/2024 ET,"Phase 1 update observed that 15 patients have been treated, showing a promising safety profile and preliminary evidence of clinical activity with once every 3-week dosing, noted January 8, 2024.",5.23M
Add to portfolio,,,,,,,,
VINC,Vincerx Pharma Inc.,1.36,VIP943 (anti-CD123),Hematologic malignancies ,Phase 1,08/01/2024 ET,"Phase 1 enrollment in the second cohort of the VIP943 trial is nearly complete. Preliminary pharmacokinetic results from the first cohort trial showed very little free payload in circulation, consiste … read more",5.23M
Add to portfolio,,,,,,,,
VINC,Vincerx Pharma Inc.,1.36,Enitociclib (VIP152) in combination with venetoclax and prednisone - (NIH trial),Peripheral T-cell lymphoma (PTCL) and 2 double-hit diffuse large b-cell lymphoma (DH-DLBCL) ,Phase 1,08/01/2024 ET,"Phase 1 preliminary data from investigators from the National Institutes of Health (NIH) reported 2 partial responses (PR) in 3 PTCL patients and 1 PR in DH-DLBCL in ongoing dose-escalation trial, not … read more",5.23M
Add to portfolio,,,,,,,,
ARGX,argenx SE,413.29,Empasiprubart (ARGX-117) - (ARDA),Multifocal motor neuropathy (MMN) ,Phase 2,08/01/2024 ET,"Phase 2 topline data reported that treatment demonstrated a 91% reduction in the need for IVIg rescue compared to placebo, noted January 8, 2024.",60.99M
Add to portfolio,,,,,,,,
ABSI,Absci Corporation,4.18,ABS-101,Inflammatory bowel disease (IBD) ,Preclinical,08/01/2024 ET,"Preclinical data support profile for development of a potential best-in-class drug. IND submission expected in 1Q 2025; Phase 1 trials anticipated to initiate shortly after, noted January 8, 2024.",149.52M
Add to portfolio,,,,,,,,
VERU,Veru Inc.,0.56,Enobosarm with semaglutide (Wegovy) - (PLATEAU),Obesity ,IND-Enabling,08/01/2024 ET,"IND submitted to the FDA, noted January 8, 2024.",14.65M
Add to portfolio,,,,,,,,
BIOR,Biora Therapeutics Inc.,1.28,BT-600 + NaviCap Platform,Ulcerative Colitis (UC) ,Phase 1,08/01/2024 ET,"Phase 1 dosing initiated, noted January 8, 2024.",4.52M
Add to portfolio,,,,,,,,
ALT,Altimmune Inc.,11.39,Pemvidutide - (MOMENTUM),"Non-alcoholic steatohepatitis (NASH)/ (MASH) - Healthy, Overweight and Obese Volunteers ",Phase 2,08/01/2024 ET,"Phase 2 results presented at NASH-TAG Conference reported that treatment resulted in reductions of up to 76.4% in relative LFC, 15.2 IU/L in serum ALT, and 149.7ms in cT1 at 24 weeks January 6, 2024.",88.26M
Add to portfolio,,,FTD,,,,,
,,,View Clinical Trial Data,,,,,
CLRB,Cellectar Biosciences Inc.,3.2,Iopofosine (CLR 131) - (CLOVER-WaM),Waldenstrom’s macroglobulinemia ,Phase 2b,08/01/2024 ET,"Phase 2b trial met its primary endpoint, noted January 8, 2024.",3.19M
Add to portfolio,,,BTD,,,,,
,,,View Clinical Trial Data,,,,,
ITOS,iTeos Therapeutics Inc.,11.14,Belrestotug (EOS-448/GSK4428859A) - (TIG-007) + iberdomide,Relapsed/refractory multiple myeloma (r/r MM) ,Phase 1/2,08/01/2024 ET,"Phase 1/2 was deprioritized after trial assessment, noted January 8, 2024.",44.21M
Add to portfolio,,,,,,,,
BMY,Bristol-Myers Squibb Company,51.19,Belrestotug (EOS-448/GSK4428859A) - (TIG-007) + iberdomide,Relapsed/refractory multiple myeloma (r/r MM) ,Phase 1/2,08/01/2024 ET,"Phase 1/2 was deprioritized after trial assessment, noted January 8, 2024.",2.04B
Add to portfolio,,,,,,,,
GSK,GSK plc American Depositary Shares (Each representing two),38.94,Belrestotug (EOS-448/GSK4428859A) - (TIG-007) + iberdomide,Relapsed/refractory multiple myeloma (r/r MM) ,Phase 1/2,08/01/2024 ET,"Phase 1/2 was deprioritized after trial assessment, noted January 8, 2024.",2.03B
Add to portfolio,,,,,,,,
CLNN,Clene Inc.,0.35,CNM-Au8 - (VISIONARY-MS),Multiple Sclerosis ,Phase 2,08/01/2024 ET,"Phase 2 long term data demonstrated improvement of vision as measured by low contrast visual acuity (LCLA), noted Janaury 8, 2024.",9.99M
Add to portfolio,,,View Clinical Trial Data,,,,,
ABBV,AbbVie Inc.,158.39,lutikizumab (ABT-981),Hidradenitis suppurativa (HS) ,Phase 2,08/01/2024 ET,"Phase 2 300 mg weekly or 300 mg dose every other week showed higher response rates in HiSCR 50 at week 16 than those treated with placebo, noted January 8, 2024.",1.77B
Add to portfolio,,,,,,,,
OKYO,OKYO Pharma Limited,1.89,urcosimod (OK-101),Dry Eye Disease (DED) ,Phase 2,08/01/2024 ET,Phase 2 data presented at the Biotech Showcase showed that dose was statistically significant drug effects were observed in FDA-recognized efficacy endpoints as early as the 15-day first visit after d … read more,33.84M
Add to portfolio,,,,,,,,
NVO,Novo Nordisk A/S,105.64,Icosema - (COMBINE 3),Type 2 diabetes ,Phase 3,08/01/2024 ET,"Phase 3a trial completed, noted January 8, 2024",4.47B
Add to portfolio,,,,,,,,
MNMD,Mind Medicine (MindMed) Inc.,4.39,MM-120 (LSD),Attention Deficit Hyperactivity Disorder (ADHD) ,Phase 2a,08/01/2024 ET,"Phase 2a trial did not meet its primary endpoint, noted January 8, 2024.",75.55M
Add to portfolio,,,,,,,,
NRIX,Nurix Therapeutics Inc.,9.96,NX-2127,"B-cell malignancies, chronic lymphocytic leukemia (CLL) ",Phase 1b,08/01/2024 ET,"The company expects to resolve partial hold to enable the introduction of newly manufactured drug product into the ongoing Phase 1 clinical trial., noted January 8, 2024.",76.88M
Add to portfolio,,,,,,,,
INCY,Incyte Corporation,65.82,INCB123667,"Late-stage cancers, ovarian cancer ",Phase 1,08/01/2024 ET,"Phase 1 early clinical activity was observed with several patients with amplified/overexpression of CCNE1, a cell cycle regulator and potential predictive biomarker, achieving partial response (PR), n … read more",195.28M
Add to portfolio,,,,,,,,
INCY,Incyte Corporation,65.82,Ruxolitinib Cream (Opzelura),Adults with hidradenitis suppurativa (HS) ,Phase 2,08/01/2024 ET,"Phase 2 primary endpoint was met in its randomized, placebo-controlled study, noted on January 8, 2024.",195.28M
Add to portfolio,,,,,,,,
NVS,Novartis AG,103.22,Scemblix - (ASC4FIRST),1L Chronic myeloid leukemia (CML) ,Phase 3,08/01/2024 ET,"Phase 3 trial met its primary endpoint, noted January 8, 2024.",1.98B
Add to portfolio,,,BTD,,,,,
CYBN,Cybin Inc.,0.39,CYB004 (IV) and SPL028 (IM),Generalized anxiety disorder (GAD) ,Phase 1,08/01/2024 ET,"Intravenous (IV) CYB004 demonstrated robust and rapid-onset psychedelic effects at lower doses compared to native DMT, suggesting potential as a short-acting, scalable treatment. Intramuscular (IM) do … read more",23.59M
Add to portfolio,,,,,,,,
FATE,Fate Therapeutics Inc.,4.12,FT825/ONO-8250,Solid Tumors ,Phase 1,08/01/2024 ET,"Phase 1 trial initiated, noted January 8, 2024.",115.33M
Add to portfolio,,,,,,,,
BPMC,Blueprint Medicines Corporation,85.31,BLU-945 with osimertinib - (SYMPHONY),Treatment-resistant EGFR-driven NSCLC ,Phase 1/2,08/01/2024 ET,"Phase 1/2 discontinued investment based on the evolving external landscape, emerging clinical data and partnering considerations, noted January 8, 2024.",64.58M
Add to portfolio,,,,,,,,
BPMC,Blueprint Medicines Corporation,85.31,BLU-451 - (CONCERTO),EGFR exon 20 insertion-positive NSCLC ,Phase 1/2,08/01/2024 ET,"Phase 1/2 discontinued investment based on the evolving external landscape, emerging clinical data and partnering considerations, noted January 8, 2024.",64.58M
Add to portfolio,,,,,,,,
SMMT,Summit Therapeutics Inc.,2.97,Ivonescimab plus chemotherapy - (AK112-201),Non-small cell lung cancer (NSCLC) ,Phase 2,08/01/2024 ET,"Phase 2 data reported that the 1-year overall survival rate was 85.6%, and the 2-year overall survival rate was 64.8% for patients in Cohort 1 with squamous histology NSCLC, noted January 8, 2024.",744.44M
Add to portfolio,,,,,,,,
ORIC,Oric Pharmaceuticals Inc.,8.24,ORIC-944,Metastatic castration resistant prostate cancer (mCRPC) ,Phase 1b,08/01/2024 ET,"Phase 1b data demonstrated potential best-in-class profile, including half-life >10 hours, robust target engagement and well tolerated safety profile, supporting advancement for combination developmen … read more",97.12M
Add to portfolio,,,,,,,,
BMEA,Biomea Fusion Inc.,15.94,Icovamenib (BMF-219) - (COVALENT-112),Type 1 diabetes (T1D) ,Phase 2,08/01/2024 ET,"Phase 2 was initiated, noted January 8, 2024.",59.51M
Add to portfolio,,,,,,,,
NUVB,Nuvation Bio Inc. Class A,1.55,NUV-1511,Advanced solid tumors ,IND-Enabling,08/01/2024 ET,"IND cleared by FDA, noted January 8, 2024.",342.27M
Add to portfolio,,,,,,,,
AFMD,Affimed N.V.,6.61,AFM24-102 and TECENTRIQ (atezolizumab),"EGFR Expressing Solid Tumors, Non-small cell lung cancer, and Gastric/gastroesophageal junction (GEJ) cancer ",Phase 1/2,08/01/2024 ET,"Phase 1/2a follow-up showed that three of the initially reported responses have now been confirmed (1 CR, 2 PR) and one still awaiting a confirmatory scan, noted January 8, 2024.",15.23M
Add to portfolio,,,FTD,,,,,
AVIR,Atea Pharmaceuticals Inc.,3.1,Bemnifosbuvir (AT-527) - (SUNRISE-3),COVID-19 ,Phase 3,08/01/2024 ET,"Phase 3 8-week study showed a 98% SVR4, which exceeds our efficacy criterion of >90% for continuing the study, noted January 8, 2024",79.36M
Add to portfolio,,,FTD,,,,,
,,,View Clinical Trial Data,,,,,
ELTX,Elicio Therapeutics Inc.,5.45,ELI-002 (AMPLIFY-201),Solid Tumors ,Phase 1/2,09/01/2024 ET,"Phase 1/2 data presented in a paper on Nature Medicine showed that ELI-002 administered as a monotherapy induced robust, polyfunctional, and durable KRAS specific CD4+ and CD8+ T cell responses. Tumor … read more",16.34M
Add to portfolio,,,,,,,,
ALPMY,Astellas Pharma Inc. ADR,12.04,Zolbetuximab,HER2-negative gastric or gastroesophageal junction (GEJ) adenocarcinoma whose tumors are CLDN18.2-positive ,CRL,09/01/2024 ET,"CRL issued by the FDA on January 9, 2024.",1.79B
Add to portfolio,,,,,,,,
VCEL,Vericel Corporation,37.31,NexoBrid (CIDS),Severe burns - pediatric ,BLA Filing,09/01/2024 ET,"sBLA filing review and accepted by the FDA, noted January 9, 2024.",50.46M
Add to portfolio,,,,,,,,
MDWD,MediWound Ltd.,12.49,NexoBrid (CIDS),Severe burns - pediatric ,BLA Filing,09/01/2024 ET,"sBLA filing review and accepted by the FDA, noted January 9, 2024.",11.25M
Add to portfolio,,,,,,,,
CRBP,Corbus Pharmaceuticals Holdings Inc.,7.22,CRB-601,Solid tumors ,IND-Enabling,09/01/2024 ET,"IND cleared by the FDA, noted January 9, 2024",12.26M
Add to portfolio,,,,,,,,
ALC,Alcon Inc.,76.44,TRYPTYR (acoltremon ophthalmic solution) 0.003%,Dry eye disease (DED) ,Phase 3,09/01/2024 ET,"Phase 3 pivotal efficacy and safety study met the primary endpoint , noted January 9, 2024.",494.62M
Add to portfolio,,,,,,,,
ALC,Alcon Inc.,76.44,AR-15512 (AVX-012) - (COMET-2),Dry eye disease ,Phase 3,09/01/2024 ET,"Phase 3 pivotal efficacy and safety study met the primary endpoint , noted January 9, 2024.",494.62M
Add to portfolio,,,View Clinical Trial Data,,,,,
MRSN,Mersana Therapeutics Inc.,3.25,Emiltatug Ledadotin (XMT-1660) - (Emi-Le),Metastatic triple-negative breast cancer (TNBC) ,Phase 1,10/01/2024 ET,"Phase 1 data reported that treatment was generally well tolerated, with no Grade 4 or 5 treatment-related adverse events (TRAEs) reported, noted January 10, 2025.",4.99M
Add to portfolio,,,FTD,,,,,
FDMT,4D Molecular Therapeutics Inc.,19.14,4D-150 - (SPECTRA),Wet Age-Related Macular Degeneration (wet AMD) ,Phase 2,10/01/2024 ET,"Phase 2 32-week interim data reported that 3E10 vg/eye achieved an 86% reduction in injection burden vs. projected on-label aflibercept 2mg Q8W and dose response with 61% reduction vs. 1E10 vg/eye, wi … read more",46.7M
Add to portfolio,,,RMAT,,,,,
CMND,Clearmind Medicine Inc.,2.93,CMND-100,Alcohol use disorder (AUD) ,IND-Enabling,10/01/2024 ET,"IND submitted March 16, 2023. Phase 1/2a trial sites selected noted May 22, 2023. Type A meeting completed, noted January 10, 2024.",5.38M
Add to portfolio,,,,,,,,
ACRS,Aclaris Therapeutics Inc.,1.01,ATI-1777-AD-202,Atopic dermatitis ,Phase 2b,10/01/2024 ET,"Phase 2b topline data on ATI-1777 2% QD showed a trend toward significance, ATI-1777 2% BID achieved a statistically significant result in the primary efficacy endpoint at week 4, noted January 10, 2 … read more",108.33M
Add to portfolio,,,View Clinical Trial Data,,,,,
VYNE,VYNE Therapeutics Inc.,2.24,Repibresib Gel (VYN201),Vitiligo ,Phase 1b,10/01/2024 ET,"Phase 1b biomarker data reported a median reduction in MMP-9 of 40.8% in lesional skin compared to baseline for subjects in the 2.0% cohort, noted January 10, 2024.",25.47M
Add to portfolio,,,,,,,,
EYPT,EyePoint Pharmaceuticals Inc.,20.23,EYP-1901 - (VERONA),Diabetic macular edema (DME) ,Phase 2,10/01/2024 ET,"Phase 2 dosing initiated, noted January 10, 2024.",68.93M
Add to portfolio,,,,,,,,
BPTH,Bio-Path Holdings Inc.,11.2,BP1002,Refractory/relapsed lymphoma and chronic lymphocytic leukemia ,Phase 1,10/01/2024 ET,"Phase 1 first cohort completed, noted January 10, 2024.",8.31M
Add to portfolio,,,,,,,,
SANA,Sana Biotechnology Inc.,7.18,SC291 - (ARDENT),"Solid tumors, B-cell lymphomas and leukemias ",Phase 1,10/01/2024 ET,Phase 1 early data discussed at the JPMorgan Healthcare Conference showed in a presentation that three patients saw at least a reduction in their disease while two patients had no detectable disease a … read more,237.81M
Add to portfolio,,,,,,,,
MRK,Merck & Company Inc.,117.88,KEYTRUDA with external beam radiotherapy (EBRT) plus concurrent chemotherapy - (KEYNOTE-A18),Cervical cancer ,Approved,12/01/2024 ET,"FDA Approved on January 12, 2024.",2.5B
Add to portfolio,,,,,,,,
ARQT,Arcutis Biotherapeutics Inc.,3.47,"ZORYVE (roflumilast) cream, 0.15%",Atopic dermatitis ,Phase 3,15/01/2024 ET,"Additional Phase 3 data reported that at Week 4, a statistically significant greater percentage of patients achieved a 50% reduction in EASI scores (EASI-50), with 69.2% of patients treated with roflu … read more",119.91M
Add to portfolio,,,,,,,,
ANIP,ANI Pharmaceuticals Inc.,55.41,Indomethacin Oral Suspension - (Indocin generic),"Rheumatoid arthritis, ankylosing spondylitis, osteoarthritis, acute gouty arthritis, bursitis, and tendinitis ",Approved,16/01/2024 ET,"Approved January 16, 2024.",21.7M
Add to portfolio,,,,,,,,
CLRB,Cellectar Biosciences Inc.,3.7,CLR 121225 (225Ac-CLR 121225),PLE cancer ,Preclinical,16/01/2024 ET,"Preclinical data reported tumor volume reduction in a dose dependent manner with the highest dose providing near complete eradication of the tumor, noted January 16, 2024.",3.19M
Add to portfolio,,,,,,,,
ALLK,Allakos Inc.,1.19,Lirentelimab (AK002) - (MAVERICK),Chronic Spontaneous Urticaria ,Phase 2b,16/01/2024 ET,"Phase 2b trial did not meet its primary endpoint, noted January 16, 2024.",90.38M
Add to portfolio,,,,,,,,
ALLK,Allakos Inc.,1.19,Lirentelimab (AK002) - (ATLAS),Atopic Dermatitis ,Phase 2,16/01/2024 ET,"Phase 2 trial did not meet its primary endpoint, noted January 16, 2024.",90.38M
Add to portfolio,,,,,,,,
HALO,Halozyme Therapeutics Inc.,36.36,HYQVIA (Immune Globulin Infusion 10% with Recombinant Human Hyaluronidase),Chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) ,Approved,16/01/2024 ET,"Approved January 16, 2024.",116.97M
Add to portfolio,,,,,,,,
TAK,Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of),15.01,HYQVIA (Immune Globulin Infusion 10% with Recombinant Human Hyaluronidase),Chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) ,Approved,16/01/2024 ET,"Approved January 16, 2024.",3.15B
Add to portfolio,,,,,,,,
CRSP,CRISPR Therapeutics AG,63.43,CASGEVY (exagamglogene autotemcel [exa-cel],Beta-thalassemia ,Approved,16/01/2024 ET,"FDA Approved on January 16, 2024.",90.95M
Add to portfolio,,,FTD,,,,,
,,,ODD,,,,,
VRTX,Vertex Pharmaceuticals Incorporated,437.49,CASGEVY (exagamglogene autotemcel [exa-cel],Beta-thalassemia ,Approved,16/01/2024 ET,"FDA Approved on January 16, 2024.",256.39M
Add to portfolio,,,FTD,,,,,
,,,ODD,,,,,
SRPT,Sarepta Therapeutics Inc.,115.39,SRP-9003-301 - (EMERGENE),Limb-girdle muscular dystrophy type 2E (LGMD2E) ,Phase 3,16/01/2024 ET,"Phase 3 screening initiated, noted January 16, 2024.",97.71M
Add to portfolio,,,FTD,,,,,
BGNE,BeiGene Ltd.,173.25,DKN-01 with bevacizumab - (DeFianCe),Colorectal cancer ,Phase 2,16/01/2024 ET,"Phase 2 part B data due at ASCO GI on January 20, 2024. Phase 2 part A data showed a 30% ORR and 93% DCR across heterogenous second-line CRC patients. Subgroup analysis reveals greatest benefit in lef … read more",106.62M
Add to portfolio,,,,,,,,
ONC,BeOne Medicines Ltd.,—,DKN-01 with bevacizumab - (DeFianCe),Colorectal cancer ,Phase 2,16/01/2024 ET,"Phase 2 part B data due at ASCO GI on January 20, 2024. Phase 2 part A data showed a 30% ORR and 93% DCR across heterogenous second-line CRC patients. Subgroup analysis reveals greatest benefit in lef … read more",110.03M
Add to portfolio,,,,,,,,
LPTX,Leap Therapeutics Inc.,3.47,DKN-01 with bevacizumab - (DeFianCe),Colorectal cancer ,Phase 2,16/01/2024 ET,"Phase 2 part B data due at ASCO GI on January 20, 2024. Phase 2 part A data showed a 30% ORR and 93% DCR across heterogenous second-line CRC patients. Subgroup analysis reveals greatest benefit in lef … read more",41.44M
Add to portfolio,,,,,,,,
RCUS,Arcus Biosciences Inc.,16.9,AB680 + Zimberelimab (AB122) - (ARC-8),Pancreatic Cancer ,Phase 1b,16/01/2024 ET,"Phase 1 data showed a median overall survival was 15.7 months for all patients treated with 100 mg quemliclustat-based regimens in the ARC-8 study, which exceeds the historical benchmark data for chem … read more",106.43M
Add to portfolio,,,,,,,,
ADAG,Adagene Inc.,3.78,muzastotug (ADG126) combined with KEYTRUDA (pembrolizumab) - (ADG126-P001/KEYNOTE-C98),Solid tumors ,Phase 1/2,16/01/2024 ET,"Phase 1/2 data from first tranche of MSS CRC patients treated with ADG126 10 mg/kg every three weeks (Q3W) in dose expansion showed clinical benefit including confirmed responses at higher, more freq … read more",47.11M
Add to portfolio,,,,,,,,
ACXP,Acurx Pharmaceuticals Inc.,4.52,Ibezapolstat,C. difficile Infection ,Phase 2b,17/01/2024 ET,"Phase 2b data showed that that ibezapolstat outperformed vancomycin, a standard of care to treat patients with CDI, with eradication of fecal C. difficile at Day 3 of treatment in 15 of 16 patients (9 … read more",1.58M
Add to portfolio,,,FTD,,,,,
,,,View Clinical Trial Data,,,,,
EVGN,Evogene Ltd.,0.79,BMC128 with Opdivo,"Non-small cell lung cancer (NSCLC), melanoma or renal cell carcinoma ",Phase 1,17/01/2024 ET,"Phase 1 first patient dosed July 26, 2022. Phase 1 trial enrollment completed, noted January 17, 2024",6.51M
Add to portfolio,,,,,,,,
BMY,Bristol-Myers Squibb Company,49.4,BMC128 with Opdivo,"Non-small cell lung cancer (NSCLC), melanoma or renal cell carcinoma ",Phase 1,17/01/2024 ET,"Phase 1 first patient dosed July 26, 2022. Phase 1 trial enrollment completed, noted January 17, 2024",2.04B
Add to portfolio,,,,,,,,
KANT,Kineta Inc.,—,KVA12123 with KEYTRUDA (pembrolizumab) - (VISTA-101),Solid tumors ,Phase 1/2,17/01/2024 ET,"Phase 1/2 update reported that KVA12123 was well tolerated with no dose limiting toxicities (DLT) or cytokine related adverse events at any dose level, noted January 17, 2024.",13.54M
Add to portfolio,,,,,,,,
REGN,Regeneron Pharmaceuticals Inc.,929.13,Ateganosine (THIO-101),Non-small cell lung cancer (NSCLC) ,Phase 2,17/01/2024 ET,"Phase 2 data reported a 100% preliminary disease control rate (DCR) in second-line and 88% in third-line, in highly difficult-to-treat patients who already progressed through previous lines of treatme … read more",105.99M
Add to portfolio,,,ODD,,,,,
,,,FTD,,,,,
MAIA,MAIA Biotechnology Inc.,1.48,Ateganosine (THIO-101),Non-small cell lung cancer (NSCLC) ,Phase 2,17/01/2024 ET,"Phase 2 data reported a 100% preliminary disease control rate (DCR) in second-line and 88% in third-line, in highly difficult-to-treat patients who already progressed through previous lines of treatme … read more",32.99M
Add to portfolio,,,ODD,,,,,
,,,FTD,,,,,
LSTA,Lisata Therapeutics Inc.,2.94,LSTA1,Glioblastoma multiforme (GBM) ,Phase 2a,17/01/2024 ET,"Phase 2a trial initiated, noted January 17, 2024.",8.76M
Add to portfolio,,,ODD,,,,,
CATX,Isoray. (DE),0.44,212Pb-VMT01,MC1R-positive metastatic melanoma ,Phase 1/2,17/01/2024 ET,"Phase 1/2 second dose escalation cohorts recruitment commenced, noted January 17, 2024.",74.26M
Add to portfolio,,,FTD,,,,,
CNSP,CNS Pharmaceuticals Inc.,35.33,Berubicin,Glioblastoma (GBM) (adult) ,Phase 2,17/01/2024 ET,"Enrollment completed, noted January 17, 2024.",574.58K
Add to portfolio,,,FTD,,,,,
,,,ODD,,,,,
,,,View Clinical Trial Data,,,,,
PFE,Pfizer Inc.,27.32,CRDF-004,Metastatic colorectal cancer (mCRC) ,Phase 1b,17/01/2024 ET,"Phase 1b findings highlight the safety and promising efficacy of onvansertib in combination with standard-of-care, noted January 17, 2024.",5.69B
Add to portfolio,,,,,,,,
CRDF,Cardiff Oncology Inc.,1.47,CRDF-004,Metastatic colorectal cancer (mCRC) ,Phase 1b,17/01/2024 ET,"Phase 1b findings highlight the safety and promising efficacy of onvansertib in combination with standard-of-care, noted January 17, 2024.",66.53M
Add to portfolio,,,,,,,,
IXHL,Incannex Healthcare Inc.,4.47,IHL-42X - (RePOSA),Obstructive sleep apnea (OSA) ,Phase 2/3,17/01/2024 ET,"Phase 2/3 IRB approved protocol to asses drug in patients, noted January 17, 2024.",347.71M
Add to portfolio,,,,,,,,
PBLA,Panbela Therapeutics Inc.,6.65,CPP-1X (eflornithine),Neuroblastoma ,Phase 1,18/01/2024 ET,"Phase 1 data reported that 2 partial responses (PR), 4 minor responses (MR), 10 Stable disease (SD), 7 progressive disease (PD) and 1 unevaluable patient, noted January 18, 2024.",4.85M
Add to portfolio,,,,,,,,
MTVA,MetaVia Inc.,—,DA-1241,Metabolic dysfunction-associated steatohepatitis (MASH) ,Preclinical,18/01/2024 ET,"Pre-clinical results demonstrated that once daily oral administration in rats, of sitagliptin alone (180 mg/kg/day), DA-1241 alone (100 mg/kg/day), or sitagliptin in combination with DA-1241 (up to 18 … read more",24.2M
Add to portfolio,,,,,,,,
CLDX,Celldex Therapeutics Inc.,39.66,Barzolvolimab - (CindU),"Chronic inducible urticaria (CIndU), cold urticaria (ColdU) and symptomatic dermographism (SD), Chronic Spontaneous Urticaria (CSU) ",Phase 2,18/01/2024 ET,"Phase 2 data reported that the trial met primary endpoint with clinically meaningful and statistically significant decreases in urticaria disease activity across multiple dose groups, noted January 18 … read more",66.41M
Add to portfolio,,,,,,,,
CHRS,Coherus Oncology Inc.,2.4,Casdozokitug (casdozo),Non-small cell lung cancer (NSCLC) ,Phase 2,18/01/2024 ET,"Phase 2 data presented at ASCO GI demonstrated early activity with 38% objective response rate including three complete responses, noted January 18, 2024.",116.23M
Add to portfolio,,,,,,,,
DCPH,Deciphera Pharmaceuticals Inc.,13.89,QINLOCK (ripretinib) - (INTRIGUE),Gastrointestinal Stromal Tumors (GIST) - second-line ,Phase 3,18/01/2024 ET,"Phase 3 long term data median overall survival of 35.5 months versus 31.5 months for sunitinib in the all-Patient intent-to treat-population, noted Janaury 18, 2024.",86.48M
Add to portfolio,,,BTD,,,,,
,,,View Clinical Trial Data,,,,,
ZLAB,Zai Lab Limited,23.56,QINLOCK (ripretinib) - (INTRIGUE),Gastrointestinal Stromal Tumors (GIST) - second-line ,Phase 3,18/01/2024 ET,"Phase 3 long term data median overall survival of 35.5 months versus 31.5 months for sunitinib in the all-Patient intent-to treat-population, noted Janaury 18, 2024.",109.96M
Add to portfolio,,,BTD,,,,,
,,,View Clinical Trial Data,,,,,
NVS,Novartis AG,104.33,LUTATHERA (lutetium Lu 177) - (NETTER-P),Gastroenteropancreatic neuroendocrine tumors (GEP-NETs) ,Phase 3,19/01/2024 ET,Phase 3 data reported that treatment reduced the risk of disease progression or death by 72% as first-line therapy in patients with somatostatin receptor-positive (SSTR+) well-differentiated grade 2/3 … read more,1.98B
Add to portfolio,,,,,,,,
AZN,AstraZeneca PLC,65.53,IMFINZI (Durvalumab) + TACE - (EMERALD-1),Locoregional Hepatocellular carcinoma (HCC) ,Phase 3,19/01/2024 ET,"Phase 3 data presented at ASCO GI reported that treatment reduced the risk of disease progression or death by 23% compared to TACE alone, noted January 19, 2024.",3.1B
Add to portfolio,,,View Clinical Trial Data,,,,,
TEVA,Teva Pharmaceutical Industries Limited American Depositary Shares,11.18,SIMLANDI (adalimumab-ryvk) - (Humira biosimilar),Inflammatory diseases ,BsUFA,19/01/2024 ET,"FDA facility reinspection in Iceland has concluded, the company also received a form 483 with one observation, noted January 19, 2024. Alvotech believes it is in position to receive approval on BsUFA … read more",1.15B
Add to portfolio,,,,,,,,
ALVO,Alvotech,14.14,SIMLANDI (adalimumab-ryvk) - (Humira biosimilar),Inflammatory diseases ,BsUFA,19/01/2024 ET,"FDA facility reinspection in Iceland has concluded, the company also received a form 483 with one observation, noted January 19, 2024. Alvotech believes it is in position to receive approval on BsUFA … read more",301.81M
Add to portfolio,,,,,,,,
TEVA,Teva Pharmaceutical Industries Limited American Depositary Shares,11.18,SELARSDI (ustekinumab-aekn) - (STELARA biosimilar),moderate to severe plaque psoriasis and for active psoriatic arthritis in adults and pediatric patients 6 years and older. ,BsUFA,19/01/2024 ET,"FDA facility reinspection in Iceland has concluded, the company also received a form 483 with one observation, noted January 19, 2024. Alvotech believes it is in position to receive approval on BsUFA … read more",1.15B
Add to portfolio,,,,,,,,
ALVO,Alvotech,14.14,SELARSDI (ustekinumab-aekn) - (STELARA biosimilar),moderate to severe plaque psoriasis and for active psoriatic arthritis in adults and pediatric patients 6 years and older. ,BsUFA,19/01/2024 ET,"FDA facility reinspection in Iceland has concluded, the company also received a form 483 with one observation, noted January 19, 2024. Alvotech believes it is in position to receive approval on BsUFA … read more",301.81M
Add to portfolio,,,,,,,,
RCUS,Arcus Biosciences Inc.,15.34,AB680 + Zimberelimab (AB122) - (ARC-8),Pancreatic Cancer ,Phase 1b,19/01/2024 ET,"Phase 1b results presented at the ASCO Gastrointestinal Cancers Symposium reported that a 37% reduction in risk of death and a 5.9-month improvement in mOS, noted January 19, 2024.",106.43M
Add to portfolio,,,,,,,,
BMY,Bristol-Myers Squibb Company,49.53,Opdivo (nivolumab) plus Yervoy - (CheckMate -8HW),Microsatellite Instability–High or Mismatch Repair Deficient Metastatic Colorectal Cancer ,Phase 3,20/01/2024 ET,"Presentation of data reported that it demonstrated significant efficacy benefit compared to chemotherapy as first-line treatment in MSI-H/dMMR mCRC, noted January 20, 2023.",2.04B
Add to portfolio,,,,,,,,
AZN,AstraZeneca PLC,66.12,Ampligen (rintatolimod) with Imfinzi (durvalumab) - (DURIPANC),Pancreatic Cancer ,Phase 1/2,22/01/2024 ET,"Phase 1b/2 trial approved by Netherlands, noted June 27, 2023. Phase 1b/2 enrollment commenced January 22, 2024.",3.1B
Add to portfolio,,,,,,,,
AIM,AIM ImmunoTech Inc.,0.42,Ampligen (rintatolimod) with Imfinzi (durvalumab) - (DURIPANC),Pancreatic Cancer ,Phase 1/2,22/01/2024 ET,"Phase 1b/2 trial approved by Netherlands, noted June 27, 2023. Phase 1b/2 enrollment commenced January 22, 2024.",2.71M
Add to portfolio,,,,,,,,
CLRB,Cellectar Biosciences Inc.,3.64,Iopofosine (CLR 131) - (CLOVER-WaM),Waldenstrom’s macroglobulinemia ,Phase 2b,22/01/2024 ET,"Phase 2b complete CNS clearance reported in one patient, noted January 22, 2024.",3.19M
Add to portfolio,,,BTD,,,,,
,,,View Clinical Trial Data,,,,,
TVRD,Tvardi Therapeutics Inc.,—,KORSUVA (CR845/difelikefalin) oral - (KICK),Stage 3-4 Chronic Kidney Disease-Associated Pruritus ,Phase 3,22/01/2024 ET,"Phase 3 trial was discontinued to focus resources on the notalgia paresthetica (NP) program, noted on January 22, 2024.",9.38M
Add to portfolio,,,,,,,,
SGMT,Sagimet Biosciences Inc.,18.42,Denifanstat - (FASCINATE-3),Nonalcoholic steatohepatitis (NASH) ,Phase 2b,22/01/2024 ET,"Phase 2b topline data reported NASH resolution without worsening of fibrosis with ≥2-point reduction in NAS (NAFLD Activity Score) in 36% of denifanstat-treated patients vs 13% with placebo (p=0.002), … read more",32.52M
Add to portfolio,,,BTD,,,,,
AGEN,Agenus Inc.,11.77,Neoadjuvant botensilimab plus balstilimab - (NEST-1),Colorectal cancer ,Phase 2,22/01/2024 ET,"Phase 2 trial data presented at ASCO-GI showed a major tumor regression in 67.5% of patients. The study achieved durable elimination of ctDNA, a critical biomarker for cancer clearance and long-term d … read more",31.86M
Add to portfolio,,,,,,,,
IONS,Ionis Pharmaceuticals Inc.,51.01,DAWNZERA (Donidalorsen),Hereditary Angioedema (HAE) ,Phase 3,22/01/2024 ET,"Phase 3 topline data met the primary endpoint with a statistically significant reduction in the rate of HAE attacks in patients treated every 4 weeks or patients treated every 8 weeks, noted January 2 … read more",159.39M
Add to portfolio,,,View Clinical Trial Data,,,,,
SEEL,Seelos Therapeutics Inc.,10.24,SLS-002,Acute Suicidal Ideation and Behavior in patients with Major Depressive Disorder (ASIB in MDD) ,Phase 2,22/01/2024 ET,"EoP2 minutes with FDA agreed that the primary endpoint in a Phase 3 trial could be the change from baseline in the Montgomery-Åsberg Depression Rating Scale (MADRS) total score at Day 16, rather than … read more",435.96K
Add to portfolio,,,View Clinical Trial Data,,,,,
SPRB,Spruce Biosciences Inc.,2.44,Tildacerfont - (CAHmelia-204),Congenital Adrenal Hyperplasia (good disease control) ,Phase 2b,22/01/2024 ET,"Phase 2b enrollment completed exceeding target enrollment (100/90), noted January 22, 2024.",563.04K
Add to portfolio,,,View Clinical Trial Data,,,,,
SXTP,60 Degrees Pharmaceuticals Inc.,0.75,ARAKODA (tafenoquine),Babesiosis ,Phase 2,22/01/2024 ET,"Type C meeting with FDA on January 17, 2024, concluded that the company now plans to conduct a pivotal clinical study in support of a future indication, noted January 22, 2024.",4.1M
Add to portfolio,,,ODD,,,,,
GILD,Gilead Sciences Inc.,77.62,Trodelvy (sacituzumab govitecan-hziy; SG) vs. docetaxel - (EVOKE-01),Non-small cell lung cancer (NSCLC) ,Phase 3,22/01/2024 ET,"Phase 3 trial did not meet its primary endpoint, noted January 22, 2024.",1.24B
Add to portfolio,,,,,,,,
CRBP,Corbus Pharmaceuticals Holdings Inc.,7.3,CRB-701 (SYS6002) with Pembrolizumab,"Solid tumors, Locally advanced or metastatic urothelial carcinoma ",Phase 1,23/01/2024 ET,"Phase 1 dose escalation data from 2024 ASCO GU reported an anti tumor responses across multiple doses were observed, with the first confirmed stable disease at 0.6mg/kg and the first confirmed partial … read more",12.26M
Add to portfolio,,,FTD,,,,,
ARTL,Artelo Biosciences Inc.,1.38,ART26.12,Chemotherapy-Induced Pain ,Preclinical,23/01/2024 ET,"Preclinical data reported that ART26.12 (10 and 25 mg/kg BID for 15 days) with oxaliplatin prevented thermal hyperalgesia, mitigated mechanical allodynia, and attenuated OXA-induced weight loss, noted … read more",1.32M
Add to portfolio,,,,,,,,
LLY,Eli Lilly and Company,627.56,AK-OTOF,Hearing loss ,Phase 1/2,23/01/2024 ET,"Phase 1/2 clinical trial showed that hearing restoration was observed within 30 days of a single administration of AK-OTOF in the initial AK-OTOF-101 study participant, noted January 23, 2024.",946.46M
Add to portfolio,,,,,,,,
VNDA,Vanda Pharmaceuticals Inc.,3.71,VCA-894A,"Charcot-Marie-Tooth disease, axonal, type 2S (CMT2S), caused by cryptic splice site variants within IGHMBP2 ",IND-Enabling,23/01/2024 ET,"Orphan drug designation, noted June 2, 2023. IND clearance by the FDA on January 23, 2024.",59.09M
Add to portfolio,,,ODD,,,,,
HRTX,Heron Therapeutics Inc.,2.2,ZYNRELEF (bupivacaine and meloxicam) extended-release,Soft tissue and orthopedic surgical procedures ,Approved,23/01/2024 ET,"FDA Approved on January 23, 2024.",153.29M
Add to portfolio,,,,,,,,
URGN,UroGen Pharma Ltd.,15.04,ZUSDURI (VesiGel UGN-102 (mitomycin)) - (ENVISION),Low grade non-muscle invasive bladder cancer (LG-NMIBC) ,NDA Filing,24/01/2024 ET,"NDA was submitted to FDA on January 24, 2024",46.26M
Add to portfolio,,,View Clinical Trial Data,,,,,
ANVS,Annovis Bio Inc.,9.09,Buntanetap,Parkinson's Disease (PD) ,Phase 3,24/01/2024 ET,"Phase 3 data release postponed due to ongoing data cleaning efforts to ensure the accuracy and reliability of the study results, noted January 24, 2024.",19.49M
Add to portfolio,,,,,,,,
ENSC,Ensysce Biosciences Inc.,1.5,PF614-MPAR-102 - (MPAR),Overdose Protection ,Phase 1,25/01/2024 ET,"Phase 1 data presented at the HEAL Initiative Scientific Meeting reported that the trial successfully met its overdose protection endpoints, noted January 25, 2024.",2.97M
Add to portfolio,,,BTD,,,,,
PBLA,Panbela Therapeutics Inc.,3.25,SBP-101 in combination with Gemcitabine and Nab-Paclitaxel - (ASPIRE),Pancreatic Ductal Adenocarcinoma (PDA) ,Phase 2/3,25/01/2024 ET,"Phase 2/3 enrollment exceeded 50% moving faster than expected, full enrollment anticipated 1Q 2025, noted January 25, 2024.",4.85M
Add to portfolio,,,,,,,,
VERA,Vera Therapeutics Inc.,25.31,Atacicept - (ORIGIN 3),IgA Nephropathy ,Phase 2b,25/01/2024 ET,"Phase 2b OLE data reported a 59% reduction in Gd-IgA1, a reduction in the percentage of participants with hematuria to 41%, and a 47% reduction in UPCR in the PP analysis, noted January 25, 2024.",63.82M
Add to portfolio,,,BTD,,,,,
,,,View Clinical Trial Data,,,,,
CYTK,Cytokinetics Incorporated,82.91,Aficamten - (FOREST-HCM) (OLE),Non-obstructive hypertrophic cardiomyopathy (HCM) ,Phase 2,25/01/2024 ET,"Phase 2 sub-study data reported statistically significant improvements in measures of cardiac structure and function including left ventricular mass index (-11.4 g/m2 ±19.4, p=0.03), maximum left vent … read more",119.66M
Add to portfolio,,,,,,,,
EXEL,Exelixis Inc.,22.09,CABOMETYX (cabozantinib) and TECENTRIQ (atezolizumab) - (CONTACT-02),Castration-Resistant Prostate Cancer ,Phase 3,25/01/2024 ET,"Phase 3 data presented at ASCO GU showed a reduction of the risk of disease progression or death by 35% in patients. While a trend toward OS improvement was observed, the data were immature and did no … read more",269.2M
Add to portfolio,,,View Clinical Trial Data,,,,,
IPSEY,Ipsen ADR,27.99,CABOMETYX (cabozantinib) and TECENTRIQ (atezolizumab) - (CONTACT-02),Castration-Resistant Prostate Cancer ,Phase 3,25/01/2024 ET,"Phase 3 data presented at ASCO GU showed a reduction of the risk of disease progression or death by 35% in patients. While a trend toward OS improvement was observed, the data were immature and did no … read more",328.12M
Add to portfolio,,,View Clinical Trial Data,,,,,
SRRK,Scholar Rock Holding Corporation,14.91,SRK-439 with apitegromab - (EMBRAZE),Obesity ,Preclinical,25/01/2024 ET,"Preclinical data supports the potential of SRK-439 to preserve lean muscle mass as part of healthy weight loss, noted January 25, 2024.",96.13M
Add to portfolio,,,,,,,,
PCSA,Processa Pharmaceuticals Inc.,5.1,NGC-Capecitabine (PCS6422),Gastrointestinal Cancer ,Phase 1b,25/01/2024 ET,"Phase 1b preliminary efficacy data reported that of the 11 cancer patients receiving one of the two highest doses of NGC-Cap, five have completed an efficacy evaluation at this time, and four of these … read more",50.35M
Add to portfolio,,,,,,,,
EPIX,ESSA Pharma Inc.,6.8,EPI-7386 and XTANDI (enzalutamide),Castration-resistant prostate cancer ,Phase 1/2,25/01/2024 ET,"Phase 1/2 data due presented at ASCO GU reported that 88% of patients (14 of 16) achieved PSA50, 81% of patients (13 of 16) achieved PSA90, 69% of patients (11 of 16) achieved PSA90 in less than 90 da … read more",47.31M
Add to portfolio,,,,,,,,
REGN,Regeneron Pharmaceuticals Inc.,948.87,Dupixent (dupilumab),Eosinophilic esophagitis (EoE) in 1-11 year olds ,Approved,25/01/2024 ET,"Approved January 25, 2024.",105.99M
Add to portfolio,,,,,,,,
SNY,Sanofi,47.88,Dupixent (dupilumab),Eosinophilic esophagitis (EoE) in 1-11 year olds ,Approved,25/01/2024 ET,"Approved January 25, 2024.",2.46B
Add to portfolio,,,,,,,,
BMY,Bristol-Myers Squibb Company,49.04,BMS-986365 (CC-94676) - (rechARge),Metastatic CRPC ,Phase 1,25/01/2024 ET,"Phase 1 data reported that treatment induces effective and durable suppression of AR signaling, overcomes resistance to existing AR pathway inhibitors (ARPI) therapies and shows promising clinical act … read more",2.04B
Add to portfolio,,,,,,,,
CRBP,Corbus Pharmaceuticals Holdings Inc.,29.49,CRB-701 (SYS6002) with Pembrolizumab,"Solid tumors, Locally advanced or metastatic urothelial carcinoma ",Phase 1,26/01/2024 ET,"Phase 1 dose escalation data from 2024 ASCO GU reported an ORR of 43% in the mixed tumor population, with no dose discontinuations or reductions in the study to date, noted January 26, 2024.",12.26M
Add to portfolio,,,FTD,,,,,
MRK,Merck & Company Inc.,119.33,KEYTRUDA (pembrolizumab) - (AMBASSADOR (A031501) KEYNOTE-123),Localized muscle-invasive urothelial carcinoma (MIUC) ,Phase 3,26/01/2024 ET,"Phase 3 data reported that treatment doubled median DFS as adjuvant therapy versus observation – 29 months versus 14 months, noted January 26, 2024.",2.5B
Add to portfolio,,,,,,,,
BMY,Bristol-Myers Squibb Company,49.13,Opdivo Qvantig (nivolumab and hyaluronidase-nvhy) Injection,"Solid tumors, Metastatic clear cell renal cell carcinoma (ccRCC) ",Phase 3,27/01/2024 ET,"Phase 3 results presented at ASCO GU reported that with subcutaneous nivolumab demonstrating an ORR of 24.2% vs. 18.2% with IV Opdivo, noted January 27, 2024.",2.04B
Add to portfolio,,,,,,,,
HALO,Halozyme Therapeutics Inc.,34.21,Opdivo Qvantig (nivolumab and hyaluronidase-nvhy) Injection,"Solid tumors, Metastatic clear cell renal cell carcinoma (ccRCC) ",Phase 3,27/01/2024 ET,"Phase 3 results presented at ASCO GU reported that with subcutaneous nivolumab demonstrating an ORR of 24.2% vs. 18.2% with IV Opdivo, noted January 27, 2024.",116.97M
Add to portfolio,,,,,,,,
MRK,Merck & Company Inc.,119.79,KEYTRUDA (KEYNOTE-564),Renal cell carcinoma (RCC) ,Phase 3,29/01/2024 ET,"Additional Phase 3 data reported that treatment reduced the risk of disease recurrence or death by 32%, noted January 29, 2024.",2.5B
Add to portfolio,,,,,,,,
NNVC,NanoViricides Inc.,1.17,NV-CoV-2 (NV-387),"RSV (Respiratory Syncytial Virus), Coronavirus, Smallpox/Mpox related Ectromelia virus infection ",Phase 1b,29/01/2024 ET,"Phase 1a/1b healthy subjects section of trial completed with no adverse events reported, noted January 29, 2024.",17.43M
Add to portfolio,,,,,,,,
AZN,AstraZeneca PLC,66.17,GC012F,Early-line treatment of multiple myeloma (ELMM). ,IND-Enabling,29/01/2024 ET,"IND was cleared by the FDA on January 29, 2024.",3.1B
Add to portfolio,,,,,,,,
ACXP,Acurx Pharmaceuticals Inc.,3.68,Ibezapolstat,C. difficile Infection ,Phase 2b,29/01/2024 ET,"Phase 2b trial showed that 100% (5 of 5) of ibezapolstat-treated patients who agreed to observation for up to three months following Clinical Cure of CDI experienced no recurrence of infection, noted … read more",1.58M
Add to portfolio,,,FTD,,,,,
,,,View Clinical Trial Data,,,,,
SRPT,Sarepta Therapeutics Inc.,120.5,SRP-5051 - (MOMENTUM),Duchenne muscular dystrophy ,Phase 2,29/01/2024 ET,"Phase 2 data at target dose (~30 mg/kg), SRP-5051 dosed monthly resulted in mean dystrophin expression of 5.17% and mean exon skipping of 11.11% at 28 weeks (n=20), noted January 29, 2024.",97.71M
Add to portfolio,,,View Clinical Trial Data,,,,,
PALI,Palisade Bio Inc.,14.4,PALI-2108,Moderate-to-severe ulcerative colitis (UC) ,Preclinical,29/01/2024 ET,"Preclinical data demonstrated PALI-2108 to be safe and well tolerated, noted January 29, 2024.",9.12M
Add to portfolio,,,,,,,,
TAK,Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of),14.77,GAMMAGARD LIQUID [Immune Globulin Infusion (Human) 10% solution],Adults with chronic inflammatory demyelinating polyneuropathy (CIDP) ,Approved,29/01/2024 ET,"FDA Approved on January 29, 2024.",3.15B
Add to portfolio,,,,,,,,
LIXT,Lixte Biotechnology Holdings Inc.,2.15,LB-100 with doxorubicin,Ovarian clear cell carcinoma (OCCC) ,Phase 1/2,29/01/2024 ET,"Phase 1b/2 dosing was initiated, noted January 29, 2024.",4.56M
Add to portfolio,,,,,,,,
IKT,Inhibikase Therapeutics Inc.,3.21,Risvodetinib - (IkT-148009) - (201 trial),Parkinson’s disease ,Phase 1,29/01/2024 ET,Phase 1 study published at Journal of Parkinson's Disease showed that data demonstrated that Risvodetinib was well tolerated up to 7 days of daily dosing with no serious adverse events in healthy volu … read more,74.52M
Add to portfolio,,,,,,,,
KRBP,Kiromic BioPharma Inc.,1.77,Deltacel-01 - (KB-GDT-01),Stage 4 Metastatic Non-Small Cell Lung Cancer ,Phase 1,29/01/2024 ET,"Phase 1 efficacy results from first patient reported a stabilization of the disease, indicating a preliminary progression-free survival of one and one-half months, noted January 29, 2024.",1.53M
Add to portfolio,,,FTD,,,,,
ALVO,Alvotech,15.25,"AVT03-GL-P01 (denosumab) - (PROLIA Biosimilar, Xgeva Biosimilar)",Osteoporosis in postmenopausal women and for bone loss in adult men and women ,Phase 1,29/01/2024 ET,"Pk trial met its primary endpoints, noted January 29, 2024.",301.81M
Add to portfolio,,,,,,,,
RCUS,Arcus Biosciences Inc.,15.72,Domvanalimab + zimberelimab vs. zimberelimab vs. chemotherapy - (ARC-10),Non Small Cell Lung Cancer (NSCLC) ,Phase 3,30/01/2024 ET,"Phase 3 trial discontinued January 30, 2024.",106.43M
Add to portfolio,,,View Clinical Trial Data,,,,,
KURA,Kura Oncology Inc.,20.85,Ziftomenib (in combination with SoC cytarabine/daunorubicin (7+3) and venetoclax/azacitidine (ven/aza))- (KOMET-007),Acute myeloid leukemia (AML) ,Phase 1,30/01/2024 ET,"Phase 1 combinations demonstrated encouraging preliminary evidence of clinical activity in patients with refractory/relapsed disease after failure of other agents, including venetoclax, a setting with … read more",86.8M
Add to portfolio,,,,,,,,
KYKOF,Kyowa Kirin Co. Ltd.,—,Ziftomenib (in combination with SoC cytarabine/daunorubicin (7+3) and venetoclax/azacitidine (ven/aza))- (KOMET-007),Acute myeloid leukemia (AML) ,Phase 1,30/01/2024 ET,"Phase 1 combinations demonstrated encouraging preliminary evidence of clinical activity in patients with refractory/relapsed disease after failure of other agents, including venetoclax, a setting with … read more",540M
Add to portfolio,,,,,,,,
SCYX,SCYNEXIS Inc.,1.96,SCY-247,Pulmonary mucormycosis ,Preclinical,30/01/2024 ET,"Preclinical data reported that SCY-247 resulted in 40% and 50% survival at 21 days post infection for the intermediate (32 mg/kg) and high doses (48 mg/kg), respectively, compared to 0% survival in th … read more",41.92M
Add to portfolio,,,,,,,,
ITRM,Iterum Therapeutics plc,1.58,ORLYNVAH (Oral Sulopenem),Uncomplicated urinary tract infections (uUTI) ,Phase 3,30/01/2024 ET,"Phase 3 data met the primary endpoint of non-inferiority to augmentin; and demonstrated statistical superiority, noted January 30, 2024.",44.66M
Add to portfolio,,,,,,,,
VRTX,Vertex Pharmaceuticals Incorporated,446.08,Suzetrigine (VX-548),Acute Pain following bunionectomy or abdominoplasty surgery ,Phase 3,30/01/2024 ET,"Phase 3 trial data reported a statistically significant improvement on the primary endpoint of the time-weighted sum of the pain intensity difference from 0 to 48 hours (SPID48) compared to placebo, n … read more",256.39M
Add to portfolio,,,,,,,,
NVS,Novartis AG,99.74,Sabatolimab (MBG453) - (STIMULUS),Myelodysplastic syndromes (MDS) ,Phase 3,31/01/2024 ET,"Phase 3 trial did not meet its primary endpoint, noted January 31, 2024.",1.98B
Add to portfolio,,,FTD,,,,,
,,,View Clinical Trial Data,,,,,
OTLK,Outlook Therapeutics Inc.,7.72,ONS-5010 / LYTENAVA (bevacizumab-vikg) - (NORSE EIGHT),Wet age-related macular degeneration (wet AMD) ,Phase 3,31/01/2024 ET,"Special Protocol Assessment (SPA) dosing initiated, noted January 31, 2024.",44.42M
Add to portfolio,,,BTD,,,,,
NVO,Novo Nordisk A/S,113.92,Semaglutide - (STEP HFpEF),"Heart failure with preserved ejection fraction (HFpEF) and obesity, Type 2 diabetes ",Phase 3,31/01/2024 ET,"Phase 3 reported that KCCQ-CSS estimated treatment difference between semaglutide 2.4 mg and placebo of 7.8, noted January 31, 2024.",4.47B
Add to portfolio,,,,,,,,
RHHBY,Roche Holding AG ADR,32.97,Vabysmo - (BALATON),Macular edema due to branch and central retinal vein occlusion (BRVO and CRVO) ,Phase 3,01/02/2024 ET,"Phase 3 data reported that patients who recieved Vabysmo as a first-line treatment gained 18.1 letters on the eye chart, while people switched from aflibercept to Vabysmo gained 18.8 letters, noted Fe … read more",6.36B
Add to portfolio,,,,,,,,
EDAP,EDAP TMS S.A.,6.34,Transrectal High-intensity focused ultrasound (TR-HIFU),Rectal Deep Infiltrating Endometriosis ,Phase 3,01/02/2024 ET,"Phase 3 enrolment completed, noted February 1, 2024.",37.39M
Add to portfolio,,,,,,,,
AZN,AstraZeneca PLC,64.65,Attruby (Acoramidis) - (ATTRibute-CM),Amyloid cardiomyopathy (ATTR-CM) ,Phase 3,02/02/2024 ET,"Additional Phase 3 data reported improved functions and quality of life at 30 months, noted February 2, 2024.",3.1B
Add to portfolio,,,View Clinical Trial Data,,,,,
BBIO,BridgeBio Pharma Inc.,33.91,Attruby (Acoramidis) - (ATTRibute-CM),Amyloid cardiomyopathy (ATTR-CM) ,Phase 3,02/02/2024 ET,"Additional Phase 3 data reported improved functions and quality of life at 30 months, noted February 2, 2024.",191.17M
Add to portfolio,,,View Clinical Trial Data,,,,,
LQDA,Liquidia Corporation,13.58,L606 (liposomal treprostinil),Pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD) ,Phase 2,02/02/2024 ET,"Open-label trial data presented at the Pulmonary Vascular Research Institute (PVRI) reported that treatment demonstrate sustained plasma levels up to 12 hours, supporting twice daily administration, n … read more",86.09M
Add to portfolio,,,,,,,,
FDMT,4D Molecular Therapeutics Inc.,17.49,4D-150 - (PRISM),Wet age-related macular degeneration (AMD) ,Phase 2,03/02/2024 ET,"Phase 2 data reported that the high dose 4D-150 resulted in an 89% reduction in the annualized anti-VEGF injection rate; 84% of patients received 0 or 1 injection, and 63% were injection-free through … read more",46.7M
Add to portfolio,,,RMAT,,,,,
LCTX,"Lineage Cell Therapeutics, Inc.",0.98,RG6501 - (OpRegen),Geographic atrophy (GA) ,Phase 1/2,03/02/2024 ET,"Additional Phase 1/2a data presented at the Angiogenesis, Exudation, and Degeneration Meeting reported that all patients with extensive delivery to GA showed improvement in outer retinal structure on … read more",228.36M
Add to portfolio,,,,,,,,
KOD,Kodiak Sciences Inc,4.03,KSI-501 (KSI-501ABC) - (DAYBREAK),Retinal diseases w/ inflammatory component ,Phase 1,03/02/2024 ET,"Phase 1 trial initial data presented at the Angiogenesis, Exudation, and Degeneration reported that monthly dosing of KSI-501 was safe and well-tolerated, noted February 3, 2024.",52.82M
Add to portfolio,,,,,,,,
BRTX,BioRestorative Therapies Inc,3.45,BRTX-100,Chronic lumbar disc disease ,Phase 2,04/02/2024 ET,"Phase 2 initial data presented at ORS reported that Visual Analog Scale, Oswestry Disability Index, Roland Morris Disability Questionnaire, and Functional Rating Index collected at weeks 26 and 52 pos … read more",7.98M
Add to portfolio,,,FTD,,,,,
EYPT,EyePoint Pharmaceuticals Inc.,27.79,DURAVYU (EYP-1901) - (LUGANO),Wet age-related macular degeneration (AMD) ,Phase 2,05/02/2024 ET,"Phase 2 subgroup analysis reported numerical superiority in change in BCVA along with strong anatomic control compared to the aflibercept control group, noted February 5, 2024.",68.93M
Add to portfolio,,,,,,,,
KYKOF,Kyowa Kirin Co. Ltd.,15.85,OTL-203 - (HURCULES),Mucopolysaccharidosis type I (MPS-I) ,Phase 3,05/02/2024 ET,"Global Phase 3 registrational trial enrolment initiated across the US and Europe, noted February 5, 2024.",540M
Add to portfolio,,,FTD,,,,,
PLRX,Pliant Therapeutics Inc.,15.8,Bexotegrast (PLN-74809) - (INTEGRIS-PSC),Primary sclerosing cholangitis (PSC) ,Phase 2a,05/02/2024 ET,"Phase 2a data reported that 320 mg group met its primary and secondary endpoints demonstrating that bexotegrast was well tolerated over a 12-week treatment period, noted February 5, 2024.",61.39M
Add to portfolio,,,FTD,,,,,
,,,View Clinical Trial Data,,,,,
RANI,Rani Therapeutics Holdings Inc.,3.69,"RT-111 (RaniPill Containing Ustekinumab Biosimilar, CT-P43)","Plaque psoriasis, active psoriatic arthritis, moderate to severe Crohn's disease, and moderate to severe ulcerative colitis ",Phase 1,05/02/2024 ET,Phase 1 data showed that it well-tolerated and delivered ustekinumab with high bioavailability. Data provided clinical validation of our ability to successfully transform an injectable large molecule … read more,71.87M
Add to portfolio,,,,,,,,
THAR,Tharimmune Inc.,6.15,TH104 (AV104),Primary biliary cholangitis (PBC) ,Phase 1,05/02/2024 ET,"Phase 1 dosing of first patient completed, noted February 5, 2024.",4.64M
Add to portfolio,,,,,,,,
ARCT,Arcturus Therapeutics Holdings Inc.,35.07,Kostaive (ARCT-154),COVID-19 variant vaccine ,Phase 3,05/02/2024 ET,"Phase 3 results demonstrated continuous advantage of sa-mRNA over conventional mRNA vaccine in terms of duration of immune response, noted February 5, 2024.",27.15M
Add to portfolio,,,,,,,,
CSLLY,CSL Ltd. ADR,96.43,Kostaive (ARCT-154),COVID-19 variant vaccine ,Phase 3,05/02/2024 ET,"Phase 3 results demonstrated continuous advantage of sa-mRNA over conventional mRNA vaccine in terms of duration of immune response, noted February 5, 2024.",968.41M
Add to portfolio,,,,,,,,
AIMD,Ainos Inc.,1.08,VELDONA,Mild COVID-19 ,Phase 2,05/02/2024 ET,"Company submitted the clinical hold complete response to the FDA for conducting a Phase 2 trial of its low-dose oral interferon (IFN)-alpha formulation, noted February 5, 2024.",4.66M
Add to portfolio,,,,,,,,
VRTX,Vertex Pharmaceuticals Incorporated,428.89,VX-121/tezacaftor/VX-561 - (SKYLINE-102),Cystic Fibrosis ,Phase 3,05/02/2024 ET,"Phase 3 study met all primary and key secondary endpoints in two randomized controlled trials in people with CF ages 12 years and older, noted February 5, 2024.",256.39M
Add to portfolio,,,,,,,,
GSK,GSK plc American Depositary Shares (Each representing two),41.01,Blenrep,Multiple myeloma ,Phase 3,06/02/2024 ET,"Additional Phase 3 data reported a 59% reduction in risk of disease progression or death, noted February 6, 2024.",2.03B
Add to portfolio,,,,,,,,
SGMO,Sangamo Therapeutics Inc.,0.52,Civaparvovec (ST-920) - (STAAR),Fabry disease ,Phase 1/2,06/02/2024 ET,Phase 1/2 clinical data reported a statistically significant improvements in disease severity were reported in the Fabry Outcome Survey adaptation of the Mainz Severity Score Index (FOS-MSSI) age-adju … read more,301.71M
Add to portfolio,,,FTD,,,,,
,,,ODD,,,,,
LLY,Eli Lilly and Company,702.66,Tirzepatide - (SYNERGY-NASH),"Nonalcoholic steatohepatitis (NASH), Metabolic dysfunction-associated steatohepatitis (MASH) ",Phase 2,06/02/2024 ET,"Phase 2 trial met its primary endpoint, noted February 6, 2024.",946.46M
Add to portfolio,,,,,,,,
GANX,Gain Therapeutics Inc.,4.47,"GT-02287, GT-02329",GBA1 and Idiopathic Parkinson's Disease ,Preclinical,06/02/2024 ET,"Preclinical data presented at the WORLDSymposium reported that GT-02287 restored motor function in a mouse model, even following a delayed administration of the drug candidate after the initial toxic … read more",35.95M
Add to portfolio,,,,,,,,
LLY,Eli Lilly and Company,702.66,VERZENIO (Abemaciclib) - (CYCLONE-2),Prostate Cancer ,Phase 3,06/02/2024 ET,"Phase 3 trial was not successful, noted February 6, 2024.",946.46M
Add to portfolio,,,View Clinical Trial Data,,,,,
ABEO,Abeona Therapeutics Inc.,4.3,UX111 - (ABO-102),Sanfilippo syndrome type A (MPS IIIA) ,Phase 1/2,06/02/2024 ET,"Phase 1/2 presented at the WORLDSymposium demonstrated treatment resulted in rapid and sustained decreased levels of heparan sulfate, noted February 6, 2024.",51.28M
Add to portfolio,,,,,,,,
RARE,Ultragenyx Pharmaceutical Inc.,45.89,UX111 - (ABO-102),Sanfilippo syndrome type A (MPS IIIA) ,Phase 1/2,06/02/2024 ET,"Phase 1/2 presented at the WORLDSymposium demonstrated treatment resulted in rapid and sustained decreased levels of heparan sulfate, noted February 6, 2024.",96.37M
Add to portfolio,,,,,,,,
INKT,MiNK Therapeutics Inc.,0.94,AGENT-797,Acute respiratory distress (ARDS) secondary to COVID-19 ,Phase 1/2,06/02/2024 ET,"Phase 1/2 data showed that agenT-797 holds significant promise in improving patient survival and reducing secondary infections, all while maintaining a favorable safety profile, noted February 6, 2024 … read more",4.52M
Add to portfolio,,,,,,,,
REGN,Regeneron Pharmaceuticals Inc.,—,Libtayo (cemiplimab-rwlc),High-risk cutaneous squamous cell carcinoma (CSCC) after surgery ,Phase 3,06/02/2024 ET,"Phase 3 data from ASCO reported a 68% reduction in the risk of disease recurrence or death, noted June 2, 2025.",105.99M
Add to portfolio,,,,,,,,
HCM,HUTCHMED (China) Limited,13.7,Fruquintinib and Paclitaxel - (FRUTIGA),Gastric Cancer ,Phase 3,07/02/2024 ET,"Phase 3 data presented at ASCO plenary series noted that the median PFS for patients who received fruquintinib plus paclitaxel was 5.6 months, compared to 2.7 months for those who received paclitaxel … read more",174.43M
Add to portfolio,,,View Clinical Trial Data,,,,,
RGNX,REGENXBIO Inc.,14.57,RGX-202 - (AFFINITY DUCHENNE),Duchenne Muscular Dystrophy (DMD) ,Phase 1/2,07/02/2024 ET,"Phase 1/2 dose 2 levels completed; additionally, the company reported interim safety and efficacy data where the third patient at dose level 1 demonstrates the largest increase in microdystrophin expr … read more",50.51M
Add to portfolio,,,ODD,,,,,
,,,FTD,,,,,
VRPX,Virpax Pharmaceuticals Inc.,3.81,Probudur,Post-operative pain ,Phase 2,07/02/2024 ET,"Phase 2 initial data reported that two doses of Probudur showed reduction in incision-induced pain behaviors, noted February 7, 2023.",1.28M
Add to portfolio,,,,,,,,
BCTX,BriaCell Therapeutics Corp.,3.94,Bria-IMT - (BRIA-ABC),Advanced breast cancer ,Phase 2,07/02/2024 ET,"Additional Phase 2 data reported a disease control rate of 50%, noted February 7, 2024.",1.76M
Add to portfolio,,,,,,,,
ALEC,Alector Inc.,6.4,Latozinemab (AL001) - (INFRONT-3),Frontotemporal Dementia ,Phase 3,07/02/2024 ET,"Breakthrough Therapy Designation granted by the FDA, noted February 7, 2024",101.21M
Add to portfolio,,,BTD,,,,,
,,,View Clinical Trial Data,,,,,
GSK,GSK plc American Depositary Shares (Each representing two),41.27,Latozinemab (AL001) - (INFRONT-3),Frontotemporal Dementia ,Phase 3,07/02/2024 ET,"Breakthrough Therapy Designation granted by the FDA, noted February 7, 2024",2.03B
Add to portfolio,,,BTD,,,,,
,,,View Clinical Trial Data,,,,,
SAVA,Cassava Sciences Inc.,25.4,Simufilam (PTI-125) - (RETHINK-ALZ),Alzheimer’s disease ,Phase 3,07/02/2024 ET,"Phase 3 24-month data reported that treated patients scores declined by an average of 1.04 points on ADAS-Cog11, noted February 7, 2024.",48.31M
Add to portfolio,,,View Clinical Trial Data,,,,,
RGNX,REGENXBIO Inc.,14.57,clemidsogene lanparvovec (RGX-121) - (CAMPSIITE),MPS II (Hunter Syndrome) ,Phase 3,07/02/2024 ET,"Phase 3 topline data reported that trial met primary endpoint, noted February 7, 2024.",50.51M
Add to portfolio,,,RMAT,,,,,
,,,RPDD,,,,,
,,,FTD,,,,,
,,,ODD,,,,,
DNLI,Denali Therapeutics Inc.,16.95,DNL126,MPS IIIA (Sanfilippo syndrome Type A) ,Preclinical,07/02/2024 ET,"Preclinical mouse-model data shared at the WORLDSymposium reported that ETV:SGSH lowered substrate accumulation in the CNS and improved cognitive deficits, noted February 7, 2024.",146.21M
Add to portfolio,,,,,,,,
DNLI,Denali Therapeutics Inc.,16.95,Tividenofusp alfa (DNL310) - (COMPASS),Hunter syndrome MPS II ,Phase 1/2,07/02/2024 ET,"Phase 1/2 data at WORLDSymposium showed additional improvement and stabilization in clinical outcomes in MPS II with 104 weeks of tividenofusp alfa (DNL310) treatment in the open-label, single-arm stu … read more",146.21M
Add to portfolio,,,BTD,,,,,
ALEC,Alector Inc.,6.25,AL101/GSK4527226 - (PROGRESS-AD),Early Alzheimer's disease (AD) ,Phase 2,08/02/2024 ET,"Phase 2 dosing initiated, noted February 8, 2024.",101.21M
Add to portfolio,,,,,,,,
GSK,GSK plc American Depositary Shares (Each representing two),41.08,AL101/GSK4527226 - (PROGRESS-AD),Early Alzheimer's disease (AD) ,Phase 2,08/02/2024 ET,"Phase 2 dosing initiated, noted February 8, 2024.",2.03B
Add to portfolio,,,,,,,,
ADVM,Adverum Biotechnologies Inc.,19.7,"Ixo-vec (ixoberogene soroparvovec, ADVM-022) - (ARTEMIS)",Wet age-related macular degeneration (AMD) ,Phase 2,08/02/2024 ET,"Phase 2 data presented at the Macula Society Annual Meeting on the 2E11 and 6E10 doses demonstrated maintenance of visual and anatomic outcomes, noted February 8, 2024.",20.98M
Add to portfolio,,,FTD,,,,,
,,,RMAT,,,,,
AIM,AIM ImmunoTech Inc.,0.38,Ampligen (AMP-518),Post-COVID conditions ,Phase 2,08/02/2024 ET,ase 2 efficacy results offer preliminary evidence that Ampligen may reduce fatigue in subjects with Post-COVID conditions. Safety results showed Ampligen is generally well tolerated in the treatment o … read more,2.71M
Add to portfolio,,,,,,,,
BDRX,Biodexa Pharmaceuticals plc,1.3,MTX110 - (MAGIC-G1),Recurrent Glioblastoma (GBM) ,Phase 1,08/02/2024 ET,"Phase 1 PFS data reported that one patient had a survival rate of 12 months from the start of treatment, while 3 patients remain in the study, noted February 8, 2024.",505.06K
Add to portfolio,,,FTD,,,,,
AMLX,Amylyx Pharmaceuticals Inc.,15.46,AMX0035 - (HELIOS),Wolfram Syndrome ,Phase 2,08/02/2024 ET,"Phase 2 enrollment completed, noted February 8, 2024.",89.17M
Add to portfolio,,,ODD,,,,,
ATHA,Athira Pharma Inc.,3.17,ATH-1105,Amyotrophic Lateral Sclerosis (ALS) ,Preclinical,08/02/2024 ET,"Preclinical data reported that ATH-1105 treatment results in significant, consistent beneficial effects both in cell culture and in vivo models of ALS, noted February 8, 2024.",3.94M
Add to portfolio,,,,,,,,
TAK,Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of),13.95,Oveporexton (TAK-861-2001),Narcolepsy type 1 (NT1) ,Phase 2b,09/02/2024 ET,"Phase 2b trial met its primary and secondary endpoints, noted February 9, 2024.",3.15B
Add to portfolio,,,,,,,,
CNTA,Centessa Pharmaceuticals plc,9.26,SerpinPC - (PRESent-3),Hemophilia B ,Phase 2a,09/02/2024 ET,"Phase 2a data presented at EAHAD reinforce confidence in SerpinPC's novel mechanism of action as we continue to advance the registrational studies, noted February 9, 2024.",134.07M
Add to portfolio,,,ODD,,,,,
,,,View Clinical Trial Data,,,,,
OKYO,OKYO Pharma Limited,1.71,Urcosimod (OK-101),Neuropathic corneal pain (NCP) ,IND-Enabling,09/02/2024 ET,"IND cleared by the FDA, noted February 9, 2024.",33.84M
Add to portfolio,,,FTD,,,,,
NRXP,NRX Pharmaceuticals Inc.,5.12,NRX-101,Bipolar Depression and Suicidal Ideation ,Phase 2/3,09/02/2024 ET,"hase 2b/3 enrollment completed, noted February 9, 2024.",19.71M
Add to portfolio,,,BTD,,,,,
,,,FTD,,,,,
,,,View Clinical Trial Data,,,,,
IRON,Disc Medicine Inc.,68.29,MWTX-003 - (DISC-3405),Polycythemia vera (PV) ,Phase 1,09/02/2024 ET,"Orphan drug designation granted by the FDA on February 9, 2024",34.77M
Add to portfolio,,,FTD,,,,,
,,,ODD,,,,,
ANTX,AN2 Therapeutics Inc.,5.1,EBO-301,Treatment-Refractory MAC Lung Disease ,Phase 2/3,12/02/2024 ET,"Phase 2/3 enrollment voluntary pause enables time to evaluate study data further and for the independent DSMB to conduct an unblinded assessment and recommend next steps, which could include changes t … read more",27.33M
Add to portfolio,,,,,,,,
CSLLY,CSL Ltd. ADR,94.17,CSL112 -(AEGIS-II),Acute myocardial infarction (AMI) ,Phase 3,12/02/2024 ET,"Phase 3 study did not meet its primary endpoint, noted February 12, 2024.",968.41M
Add to portfolio,,,,,,,,
LRMR,Larimar Therapeutics Inc.,7.83,Nomlabofusp (CTI-1601),Friedreich’s ataxia (FA) ,Phase 2,12/02/2024 ET,"Phase 2 study showed that treatment was generally well tolerated following repeated subcutaneous injections in patients in the 25 and 50 mg cohorts with no serious adverse events, noted February 12, 2 … read more",85.59M
Add to portfolio,,,ODD,,,,,
BTAI,BioXcel Therapeutics Inc.,1.95,BXCL701 and KEYTRUDA (pembrolizumab),Neuroendocrine Prostate Cancer (NEPC) ,Phase 2a,12/02/2024 ET,"Fast Track designation granted by the FDA on February 12, 2024.",14.56M
Add to portfolio,,,FTD,,,,,
PYPD,PolyPid Ltd.,6.84,D-PLEX100 - (SHIELD II),Surgical Site Infection ,Phase 3,12/02/2024 ET,"Phase 3 trial 100th patient enrollment, noted February 12, 2024.",10.19M
Add to portfolio,,,View Clinical Trial Data,,,,,
NUVL,Nuvalent Inc.,83.55,Neladalkib (NVL-655) - (ALKove-1),ALK non-small cell lung cancer (NSCLC) ,Phase 1/2,12/02/2024 ET,"Phase 1/2 trial initiated, noted February 12, 2024.",72.1M
Add to portfolio,,,BTD,,,,,
TAK,Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of),14.02,EOHILIA (budesonide oral suspension),People 11 years and older with eosinophilic esophagitis (EoE) ,Approved,12/02/2024 ET,"FDA approved on February 12, 2024.",3.15B
Add to portfolio,,,,,,,,
JAGX,Jaguar Health Inc.,5.36,Mytesi (crofelemer),Moderate-to-severe diarrhea including Vibrio cholerae ,Phase 1,12/02/2024 ET,"Orphan Drug Designation (ODD) submited to the FDA, noted February 12, 2024.",2.17M
Add to portfolio,,,ODD,,,,,
SGMO,Sangamo Therapeutics Inc.,0.81,Civaparvovec (ST-920) - (STAAR),Fabry disease ,Phase 1/2,12/02/2024 ET,"Type-D meeting with the FDA agreed in a that data from a single, adequate, and well-controlled study may form the primary basis of approval of a BLA for isaralgagene civaparvovec, noted February 12, 2 … read more",301.71M
Add to portfolio,,,FTD,,,,,
,,,ODD,,,,,
TNXP,Tonix Pharmaceuticals Holding Corp.,11.84,TNX-102 SL - (OASIS),"Acute stress reaction (ASR), acute stress disorder (ASD), and posttraumatic stress disorder (PTSD) ",Phase 2,12/02/2024 ET,"FDA Cleared IND on February 12, 2024.",8.77M
Add to portfolio,,,FTD,,,,,
ANIX,Anixa Biosciences Inc.,4.46,Chimeric endocrine receptor T-cell (CER-T),Ovarian Cancer ,Phase 1,12/02/2024 ET,"Phase 1 2nd cohort dosing initiated, noted February 12, 2024.",32.92M
Add to portfolio,,,,,,,,
KTRA,TuHURA Biosciences Inc.,0.12,REM-001,Cutaneous Metastatic Breast Cancer (CMBC) ,Phase 3,12/02/2024 ET,"Phase 3 was initiated, noted February 12, 2024.",55.66M
Add to portfolio,,,FTD,,,,,
FDMT,4D Molecular Therapeutics Inc.,27.85,4D-310 - (INGLAXA),Fabry Disease ,Phase 1/2,12/02/2024 ET,"Phase 1/2 interim data presented at the WORLDSymposium 2024 demonstrated clinically meaningful cardiac endpoint improvements through 12-24 months in contractility (echocardiography), peak VO2 (cardiop … read more",46.7M
Add to portfolio,,,,,,,,
PHRRF,PharmaTher Holdings Ltd,0.13,KETARX (ketamine),Surgical pain management ,ANDA Filing,12/02/2024 ET,"ANDA continues to be under review by the FDA and has provided preliminary thoughts on possible deficiencies identified by Quality, noted February 12, 2024.",91.02M
Add to portfolio,,,FTD,,,,,
BMRN,BioMarin Pharmaceutical Inc.,88.18,Valoctocogene roxaparvovec (BMN 270-303) - (GENEr8-3),Hemophilia A ,Phase 3,12/02/2024 ET,"Phase 3 trial data presented at EAHAD after liver biopsy analysis suggests efficient hepatocyte transduction occurred, noted February 9, 2024.",192.01M
Add to portfolio,,,View Clinical Trial Data,,,,,
KRYS,Krystal Biotech Inc.,108.73,KB707 - (KYANITE-1),Solid Tumors ,IND-Enabling,13/02/2024 ET,"The FDA cleared IND and granted fast-track designation on February 13, 2024.",28.94M
Add to portfolio,,,FTD,,,,,
,,,RPDD,,,,,
KALV,KalVista Pharmaceuticals Inc.,14.85,EKTERLY (sebetralstat),Hereditary Angioedema (HAE) ,Phase 3,13/02/2024 ET,"Phase 3 clinical trial met all primary and key secondary endpoints and demonstrated a favorable safety profile, noted February 13, 2024.",50.52M
Add to portfolio,,,View Clinical Trial Data,,,,,
CADL,Candel Therapeutics Inc.,1.8,CAN-3110,Glioma ,Phase 1,13/02/2024 ET,"Fast track designation granted by the FDA on February 13, 2024.",54.9M
Add to portfolio,,,FTD,,,,,
,,,ODD,,,,,
LCTX,"Lineage Cell Therapeutics, Inc.",1.02,AST-OPC1 SCiSTAR - (DOSED),Cervical spinal cord injury ,IND-Enabling,13/02/2024 ET,"INDa cleared by the FDA on February 13, 2024.",228.36M
Add to portfolio,,,ODD,,,,,
,,,RMAT,,,,,
RCKT,Rocket Pharmaceuticals Inc.,28.97,KRESLADI (marnetegragene autotemcel),Leukocyte Adhesion Deficiency-I (LAD-I) ,PDUFA,13/02/2024 ET,"PDUFA date extended by 3 months to June 30, 2024.",107.9M
Add to portfolio,,,,,,,,
CALC,CalciMedica Inc.,5.23,Auxora - (KOURAGE),Acute kidney injury (AKI) with associated acute hypoxemic respiratory failure (AHRF) ,IND-Enabling,13/02/2024 ET,"IND cleared by the FDA, noted February 13, 2024.",13.97M
Add to portfolio,,,,,,,,
ROIV,Roivant Sciences Ltd.,10.8,RVT-2001,Transfusion-Dependent Anemia in Patients with Lower-Risk MDS ,Phase 1/2,13/02/2024 ET,Phase 1/2 development discontinued after interim data analysis.,682.88M
Add to portfolio,,,,,,,,
PTIX,Protagenic Therapeutics Inc.,0.97,PT00114,Major Depressive Disorder (MDD) / Generalized Anxiety Disorder (GAD) / Post-Traumatic Stress Disorder (PTSD) ,Phase 1/2,13/02/2024 ET,"Phase 1/2 demonstrated safety at a low dose of 125 micrograms in the initial cohort of patients, with zero reported adverse reactions among subjects, noted February 13, 2024.",588.96K
Add to portfolio,,,,,,,,
PBYI,Puma Biotechnology Inc,6.21,Alisertib - (PUMA-ALI-4201) - (ALISCA-Lung1),Small Cell Lung Cancer (SCLC) ,Phase 2,13/02/2024 ET,"Phase 2 was initiated, noted on February 13, 2024.",50.37M
Add to portfolio,,,ODD,,,,,
OCUL,Ocular Therapeutix Inc.,5.62,AXPAXLI (OTX-TKI) - (SOL-1),Wet Age-related Macular Degeneration (AMD) ,Phase 3,13/02/2024 ET,"Phase 3 first three subjects have been screened and dosed with first aflibercept injection, noted February 13, 2024.",174M
Add to portfolio,,,,,,,,
MACK,Merrimack Pharmaceuticals Inc.,7.51,Onivyde (NALIRIFOX),Pancreatic cancer ,Approved,13/02/2024 ET,"FDA Approved on February 13, 2024.",14.79M
Add to portfolio,,,FTD,,,,,
,,,View Clinical Trial Data,,,,,
IPSEY,Ipsen ADR,27.94,Onivyde (NALIRIFOX),Pancreatic cancer ,Approved,13/02/2024 ET,"FDA Approved on February 13, 2024.",328.12M
Add to portfolio,,,FTD,,,,,
,,,View Clinical Trial Data,,,,,
TAK,Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of),14.05,Eohilia (formerly TAK-721),Eosinophilic esophagitis ,Approved,13/02/2024 ET,"Approved February 13, 2024.",3.15B
Add to portfolio,,,,,,,,
OPT,Opthea Limited,2.92,Sozinibercept (OPT-302) with Aflibercept - (COAST),Age-related macular degeneration (AMD) ,Phase 3,14/02/2024 ET,"Phase 3 patient enrollment completed, noted February 14, 2024.",171M
Add to portfolio,,,View Clinical Trial Data,,,,,
KRBP,Kiromic BioPharma Inc.,2.56,Deltacel-01 - (KB-GDT-01),Stage 4 Metastatic Non-Small Cell Lung Cancer ,Phase 1,14/02/2024 ET,"Phase 1 initiated, noted February 14, 2024.",1.53M
Add to portfolio,,,FTD,,,,,
DTIL,Precision BioSciences Inc.,11.99,PBGENE-HBV - (ELIMINATE-B),Chronic Hepatitis B Virus (HBV) ,Preclinical,14/02/2024 ET,"Pre-IND meeting with FDA provided feedback on overall design for the proposed first-in-human clinical study as well as feedback on the toxicology and specificity assessments, noted February 14, 2024.",11.79M
Add to portfolio,,,FTD,,,,,
GLSI,Greenwich LifeSciences Inc.,10.2,GP2 (GLSI-100) - (FLAMINGO-01),HER2 positive breast cancer ,Phase 3,14/02/2024 ET,"DSMB recommended to continue the study as is without modification. No serious adverse events related to GLSI-100 have been reported to date, noted February 14 2024.",13.63M
Add to portfolio,,,FTD,,,,,
,,,View Clinical Trial Data,,,,,
ARVN,Arvinas Inc.,49.37,Vepdegestrant (ARV-471) - (TACTIVE-U),Solid Tumors ,Phase 1b,14/02/2024 ET,"Phase 1b umbrella trial combination to be initiated in other arms, noted February 14, 2024.",73.42M
Add to portfolio,,,,,,,,
AZN,AstraZeneca PLC,60.73,Ampligen (rintatolimod) with Imfinzi (durvalumab) - (DURIPANC),Pancreatic Cancer ,Phase 1/2,14/02/2024 ET,"Phase 1b/2 dosing commenced on February 14, 2024.",3.1B
Add to portfolio,,,,,,,,
AIM,AIM ImmunoTech Inc.,0.41,Ampligen (rintatolimod) with Imfinzi (durvalumab) - (DURIPANC),Pancreatic Cancer ,Phase 1/2,14/02/2024 ET,"Phase 1b/2 dosing commenced on February 14, 2024.",2.71M
Add to portfolio,,,,,,,,
ATRA,Atara Biotherapeutics Inc.,19.26,ATA3219,"B-cell non-Hodgkin's lymphoma (NHL), Lupus Nephritis ",Preclinical,14/02/2024 ET,"IND submitted to the FDA, noted February 14, 2024.",7.02M
Add to portfolio,,,,,,,,
ANVS,Annovis Bio Inc.,10.37,Buntanetap (ANVS401),Alzheimer’s disease (AD) ,Phase 2/3,14/02/2024 ET,"Phase 2/3 last patient completed, noted February 14, 2024.",19.49M
Add to portfolio,,,ODD,,,,,
SILO,Silo Pharma Inc.,1.69,SP-26,Fibromyalgia / Chornic pain ,Preclinical,14/02/2024 ET,"The preclinical study demonstrated successful drug delivery, noted February 14, 2024.",9.4M
Add to portfolio,,,,,,,,
INKT,MiNK Therapeutics Inc.,1,"Botensilimab plus balstilimab, agenT-797",Gastric cancer ,Phase 2,14/02/2024 ET,"Phase 2 trial initiated, noted February 14, 2024.",4.52M
Add to portfolio,,,,,,,,
AMPE,Ampio Pharmaceuticals Inc.,1.82,OA-201,Osteoarthritis ,Preclinical,14/02/2024 ET,Preclinical efficacy results from recently completed pre-IND enabling studies with OA-201 reported that the efficacy results of these studies do not support an Investigational New Drug (IND) submissio … read more,1.14M
Add to portfolio,,,,,,,,
MESO,Mesoblast Limited,1.93,Revascor (Rexlemestrocel-L) - (DREAM-HF),Heart failure ,Phase 3,14/02/2024 ET,"Orphan drug designation was granted on February 14, 2024.",128.12M
Add to portfolio,,,RMAT,,,,,
,,,RPDD,,,,,
,,,ODD,,,,,
,,,View Clinical Trial Data,,,,,
RPTX,Repare Therapeutics Inc.,6.95,RP-1664 - (LIONS),Adult and adolescent with TRIM37-high tumor cells to treat Solid Tumors ,Phase 1,15/02/2024 ET,"Phase 1 dosing initiated, noted February 15, 2024.",42.96M
Add to portfolio,,,,,,,,
APLT,Applied Therapeutics Inc.,3.75,govorestat (AT-007) - (INSPIRE),Sorbitol Dehydrogenase Deficiency (SORD Deficiency) ,Phase 3,15/02/2024 ET,"Phase 3 study met the interim primary endpoint, noted February 15, 2024.",144.01M
Add to portfolio,,,ODD,,,,,
IONS,Ionis Pharmaceuticals Inc.,45.28,TRYNGOLZA (olezarsen),Familial Chylomicronemia Syndrome (FCS) ,Phase 3,15/02/2024 ET,"Orphan Drug Designation granted by the FDA, noted February 15, 2024.",159.39M
Add to portfolio,,,ODD,,,,,
,,,View Clinical Trial Data,,,,,
CRDL,Cardiol Therapeutics Inc.,1.48,CardiolRx - (MAvERIC-Pilot),Recurrent Pericarditis ,Phase 2,15/02/2024 ET,"FDA has granted Orphan Drug Designation (ODD), noted February 15, 2024.",83.73M
Add to portfolio,,,ODD,,,,,
ONCY,Oncolytics Biotech Inc.,1.16,Pelareorep and mFOLFIRINOX with and without atezolizumab - (GOBLET),Colorectal and advanced anal cancers ,Phase 1,15/02/2024 ET,"Phase 1 Stage 1 data showed a near tripling of Objective Response Rate compared to checkpoint inhibitor monotherapy, including a Complete Response, and supports expansion, additionally an enrollment e … read more",100.36M
Add to portfolio,,,,,,,,
MNKD,MannKind Corporation,3.71,Afrezza (Technosphere Insulin) - (INHALE-1),Pediatric type 1/2 diabetes ,Phase 3,15/02/2024 ET,"Phase 3 enrollment goal reached, noted February 15, 2024.",306.83M
Add to portfolio,,,View Clinical Trial Data,,,,,
AUPH,Aurinia Pharmaceuticals Inc,6.02,Aritinercept (AUR200),BAFF/APRIL (B-Cell Activating Factor) ,Phase 1,15/02/2024 ET,"Phase 1 was discontinued due to resource allocation, noted February 15, 2024.",135.1M
Add to portfolio,,,,,,,,
AUPH,Aurinia Pharmaceuticals Inc,6.02,AUR300,M2 Macrophage ,IND-Enabling,15/02/2024 ET,"The trial was discontinued due to resource allocation, noted on February 15, 2024.",135.1M
Add to portfolio,,,,,,,,
ENSC,Ensysce Biosciences Inc.,0.89,PF614-102,Severe pain ,Phase 3,15/02/2024 ET,"Phase 3 additional results from the two-part PF614‑102 study are very significant as we believe they demonstrate a clear dose relationship between PF614 and oxycodone, which is the foundation for the … read more",2.97M
Add to portfolio,,,,,,,,
FBIO,Fortress Biotech Inc.,1.86,Triplex - (COLT),Cytomegalovirus (CMV) ,Phase 1,16/02/2024 ET,Phase 1 data results demonstrated the potential benefit of vaccinating donors with dose to enhance CMV protective immunity and reduce CMV events in recipients of allogeneic hematopoietic cell transpla … read more,29.75M
Add to portfolio,,,,,,,,
CASI,CASI Pharmaceuticals Inc.,5.8,FOLOTYN (Pralatrexate Injection) - (PROPEL),Peripheral T-cell lymphoma ,Phase 1,16/02/2024 ET,"Phase 1 dosing initiated in China, noted February 16, 2024.",15.49M
Add to portfolio,,,,,,,,
RHHBY,Roche Holding AG ADR,31.01,XOLAIR (omalizumab) - (OUtMATCH),Food allergy ,Approved,16/02/2024 ET,"FDA Approved on February 16, 2024.",6.36B
Add to portfolio,,,,,,,,
IOVA,Iovance Biotherapeutics Inc.,9.15,AMTAGVI (Lifileucel (LN-144)) - (TILVANCE-301),Refractory metastatic melanoma ,Approved,16/02/2024 ET,"FDA Approved on February 16, 2024.",361.85M
Add to portfolio,,,,,,,,
AZN,AstraZeneca PLC,63.3,TAGRISSO (Osimertinib) - (FLAURA2),Non-small cell lung cancer (NSCLC) ,Approved,17/02/2024 ET,"Approved February 17, 2024.",3.1B
Add to portfolio,,,View Clinical Trial Data,,,,,
AZN,AstraZeneca PLC,64.06,TAGRISSO (osimertinib) - (LAURA),"Unresectable, Stage III epidermal growth factor receptor-mutated (EGFRm) non-small cell lung cancer (NSCLC) ",Phase 3,19/02/2024 ET,"Phase 3 data reported that the trial showed statistically significant and highly clinically meaningful improvement in progression-free survival (PFS), noted February 19, 2024.",3.1B
Add to portfolio,,,BTD,,,,,
RAPT,RAPT Therapeutics Inc.,6.87,Zelnecirnon (RPT193),Asthma ,Phase 2a,20/02/2024 ET,"Phase 2a trial initiated March 29, 2023. Phase 2a trial placed on clinical hold February 20, 2024.",16.54M
Add to portfolio,,,,,,,,
RAPT,RAPT Therapeutics Inc.,6.87,Zelnecirnon (RPT193),Atopic dermatitis ,Phase 2a,20/02/2024 ET,"Phase 2b trial initiated May 23, 2022. Phase 2b trial placed on hold February 20, 2024.",16.54M
Add to portfolio,,,,,,,,
IMRX,Immuneering Corporation,6.76,Atebimetinib (IMM-1-104) + mGnP,"Solid tumors, pancreatic cancer, melanoma ",Phase 1,20/02/2024 ET,"Fast Track Designation granted by the FDA on February 20, 2024.",36.32M
Add to portfolio,,,FTD,,,,,
,,,ODD,,,,,
IRON,Disc Medicine Inc.,66.42,DISC-0974,Patients with non-dialysis dependent chronic kidney disease (NDD-CKD) and anemia ,Phase 1/2,20/02/2024 ET,"Phase 1b/2 ongoing. FDA granted Fast Track designation, noted February 20, 2024.",34.77M
Add to portfolio,,,FTD,,,,,
SNY,Sanofi,44.97,Duvakitug (TEV-'574/SAR447189) - (RELIEVE UCCD),Moderate-to-severe inflammatory bowel disease (IBD); this includes ulcerative colitis (UC) and Crohn's disease (CD) ,Phase 2b,20/02/2024 ET,"PK data reported rapid and sustained suppression of free TL1A, noted February 20, 2024.",2.46B
Add to portfolio,,,,,,,,
TEVA,Teva Pharmaceutical Industries Limited American Depositary Shares,13.07,Duvakitug (TEV-'574/SAR447189) - (RELIEVE UCCD),Moderate-to-severe inflammatory bowel disease (IBD); this includes ulcerative colitis (UC) and Crohn's disease (CD) ,Phase 2b,20/02/2024 ET,"PK data reported rapid and sustained suppression of free TL1A, noted February 20, 2024.",1.15B
Add to portfolio,,,,,,,,
ARVN,Arvinas Inc.,50.6,ARV-102,Parkinson's Disease in Healthy Volunteers ,Phase 1,20/02/2024 ET,"Phase 1 dosing commenced, noted February 20, 2024.",73.42M
Add to portfolio,,,,,,,,
SPRY,ARS Pharmaceuticals Inc.,7.52,Neffy (epinephrine nasal spray),Allergic reactions (type I) including anaphylaxis ,Phase 3,20/02/2024 ET,Phase 3 topline data showed that Repeated doses of neffy under nasal allergen challenge demonstrated a pharmacokinetic profile greater than or similar to injection and a pharmacodynamic profile greate … read more,98.83M
Add to portfolio,,,,,,,,
JNJ,Johnson & Johnson,156.58,TECVAYLI (teclistamab),Relapsed or refractory (R/R) multiple myeloma. ,Approved,20/02/2024 ET,"Supplemental approval granted by the FDA, noted February 20, 2024.",2.41B
Add to portfolio,,,,,,,,
GSK,GSK plc American Depositary Shares (Each representing two),41.19,Cabenuva (cabotegravir + rilpivirine) - (LATITUDE),HIV ,Phase 3,21/02/2024 ET,"Phase 3 interim data reported that demonstrated superior efficacy in maintaining viral load suppression compared to daily oral therapy in individuals with a history of ART adherence challenges, noted … read more",2.03B
Add to portfolio,,,,,,,,
KZIA,Kazia Therapeutics Limited,0.32,Paxalisib (GDC-0084) with radiotherapy,Brain Metastases ,Phase 1,21/02/2024 ET,"Phase 1 trial met its primary endpoint, noted February 21, 2024.",1.36M
Add to portfolio,,,FTD,,,,,
ENLV,Enlivex Therapeutics Ltd.,3.22,Allocetra,Sepsis ,Phase 2,21/02/2024 ET,"Phase 2 enrollment completed, noted February 21, 2024.",23.85M
Add to portfolio,,,View Clinical Trial Data,,,,,
NRSN,NeuroSense Therapeutics Ltd.,1.25,PrimeC - (PARADIGM),Amyotrophic Lateral Sclerosis (ALS) ,Phase 2b,21/02/2024 ET,"Additional Phase 2b 6 month data reported a reduction of the risk of ALS disease complications or death by up to 53%, noted February 21, 2024.",23.99M
Add to portfolio,,,,,,,,
MNPR,Monopar Therapeutics Inc.,1.12,MNPR-101-Zr (uPAR),Solid tumors ,Preclinical,22/02/2024 ET,"Preclinical data to date demonstrated compelling and durable anti-tumor benefits with MNPR-101 conjugated to therapeutic radioisotopes, noted February 22, 2024.",6.17M
Add to portfolio,,,,,,,,
ELEV,Elevation Oncology Inc.,2.7,EO-3021 (SYSA1801) with ramucirumab + dostarlimab,Advanced Unresectable or Metastatic Solid Tumors Likely to Express Claudin 18.2 ,Phase 1,22/02/2024 ET,"Phase 1 first patient dosed in Japan, noted February 22, 2024.",59.22M
Add to portfolio,,,FTD,,,,,
TARS,Tarsus Pharmaceuticals Inc.,31.54,TP-05 - (Carpo),Lyme disease ,Phase 2a,22/02/2024 ET,"Phase 2a data demonstrated a statistically significant benefit in killing ticks compared to placebo, noted February 22, 2024.",42.21M
Add to portfolio,,,,,,,,
ATXI,Avenue Therapeutics Inc.,10.67,BAER-101,Absence epilepsy ,Preclinical,22/02/2024 ET,"Preclinical data reported full suppression of seizure activity with a minimal effective dose (MED) of 0.3 mg/kg, noted February 22, 2024.",3.18M
Add to portfolio,,,,,,,,
PHVS,Pharvaris N.V.,27.78,Deucrictibant (PHVS416) - (CHAPTER-3),Hereditary angioedema - prophylactic use ,Phase 2,22/02/2024 ET,Phase 2 data reported that deucrictibant significantly reduced the monthly attack rate by 84.5% (p=0.0008) in participants dosed at 40 mg/day and 79.3% (p=0.0009) in participants dosed at 20 mg/day co … read more,54.49M
Add to portfolio,,,,,,,,
ATNM,Actinium Pharmaceuticals Inc.,6.74,Iomab-B - (SIERRA),Acute myeloid leukemia (AML) ,Phase 3,22/02/2024 ET,"Phase 3 data shared at ASTCT reported that a median overall survival of 5.49 months versus 1.66 months, noted February 22, 2023.",31.2M
Add to portfolio,,,View Clinical Trial Data,,,,,
GMDA,Gamida Cell Ltd.,0.36,NAM-NK (GDA-201),Follicular and diffuse large B cell lymphomas ,Phase 1/2,22/02/2024 ET,"Phase 1/2 results presented at the Tandem Meetings, Transplantation & Cellular Therapy (TCT) Meetings reported that EAP data for omidubicel are consistent with Phase 3 trial results, noted February 2 … read more",154.05M
Add to portfolio,,,,,,,,
VTYX,Ventyx Biosciences Inc.,5.77,Tamuzimod (VTX002),Ulcerative Colitis (UC) ,Phase 2,22/02/2024 ET,"Phase 2 open-label extension data reported that both both doses of VTX002 achieved nominal statistical significance for all key secondary endpoints, noted February 22, 2024.",71.31M
Add to portfolio,,,,,,,,
REGN,Regeneron Pharmaceuticals Inc.,981.2,Dupixent (dupilumab) - (NOTUS),Chronic obstructive pulmonary disease (COPD) ,PDUFA priority review,23/02/2024 ET,"PDUFA Priority Review date June 27, 2024.",105.99M
Add to portfolio,,,,,,,,
BDRX,Biodexa Pharmaceuticals plc,1.49,Tolimidone,Type 2 diabetes ,Preclinical,23/02/2024 ET,"Preclinical data reported inconclusive data, noted February 23, 2024.",505.06K
Add to portfolio,,,,,,,,
COGT,Cogent Biosciences Inc.,7.44,Bezuclastinib - (SUMMIT),Non-Advanced Systemic Mastocytosis ,Phase 1b,23/02/2024 ET,"Additional Part 1b data from AAAAI reported that 51% week 12 mean change in Total Symptom Score (TSS), including 70% of patients achieving ≥50% reduction in TSS at week 12, noted February 23, 2024.",139.7M
Add to portfolio,,,View Clinical Trial Data,,,,,
CMND,Clearmind Medicine Inc.,1.88,CMND-100,Alcohol use disorder (AUD) ,Phase 1/2,23/02/2024 ET,"Phase 1/2a approval to commence dosing, noted February 23, 2024.",5.38M
Add to portfolio,,,,,,,,
BDRX,Biodexa Pharmaceuticals plc,1.49,MTX110 - (PNOC015),Diffuse Midline Glioma (DMG) ,Phase 1,23/02/2024 ET,"Phase 1 results reported that the median overall survival (OS) of patients in the study was 16.5 months, noted February 23, 2024.",505.06K
Add to portfolio,,,,,,,,
TEVA,Teva Pharmaceutical Industries Limited American Depositary Shares,12.89,SIMLANDI (adalimumab-ryvk) - (Humira biosimilar),Inflammatory diseases ,Approved,23/02/2024 ET,"Approved February 23, 2024.",1.15B
Add to portfolio,,,,,,,,
ALVO,Alvotech,16.03,SIMLANDI (adalimumab-ryvk) - (Humira biosimilar),Inflammatory diseases ,Approved,23/02/2024 ET,"Approved February 23, 2024.",301.81M
Add to portfolio,,,,,,,,
CLDX,Celldex Therapeutics Inc.,37.75,Barzolvolimab (CDX-0159),Chronic spontaneous urticaria (CSU) ,Phase 2,24/02/2024 ET,"Phase 2 data presented at AAAAI reported that treatment demonstrated strong improvement in UAS7 independent of omalizumab status at Week 12, noted February 24, 2024.",66.41M
Add to portfolio,,,,,,,,
KALV,KalVista Pharmaceuticals Inc.,13.69,EKTERLY (sebetralstat),Hereditary Angioedema (HAE) ,Phase 3,25/02/2024 ET,"Phase 3 additional data presented at AAAAI reported that 94% of attacks required only one dose to achieve primary endpoint, noted February 25, 2024.",50.52M
Add to portfolio,,,View Clinical Trial Data,,,,,
GSK,GSK plc American Depositary Shares (Each representing two),41.99,Blujepa (Gepotidacin) - (EAGLE 2/3),Uncomplicated urinary tract infection (uUTI) ,Phase 3,26/02/2024 ET,"EAGLE-1 trial met its primary endpoint, noted February 26, 2024.",2.03B
Add to portfolio,,,View Clinical Trial Data,,,,,
ALLK,Allakos Inc.,1.46,AK006,Prurigo nodularis ,Preclinical,26/02/2024 ET,"Preclinical data presented at AAAAI showed evidence of MRGPRX2 mast cell activation and activated macrophages on skin lesions, noted February 26, 2024.",90.38M
Add to portfolio,,,,,,,,
KRYS,Krystal Biotech Inc.,157,KB407 - (CORAL-1),Cystic Fibrosis ,Phase 1,26/02/2024 ET,"Phase 1 data reported that no severe or serious adverse events were observed in patients treated in Cohort 1, noted February 26, 2024.",28.94M
Add to portfolio,,,,,,,,
TNYA,Tenaya Therapeutics Inc.,5.69,TN-301,Heart Failure with Preserved Ejection Fraction ,Preclinical,26/02/2024 ET,"Preclinical data reported that treatment achieved comparable or superior efficacy and was shown to have a distinctive multi-modal mechanism of action versus empagliflozin, noted February 26, 2024.",162.98M
Add to portfolio,,,,,,,,
BGNE,BeiGene Ltd.,160.26,BRUKINSA (zanubrutinib) + Obinutuzumab - (ROSEWOOD),Follicular Non-Hodgkin Lymphoma ,Approved,26/02/2024 ET,"Approval noted February 26, 2024.",106.62M
Add to portfolio,,,,,,,,
ONC,BeOne Medicines Ltd.,—,BRUKINSA (zanubrutinib) + Obinutuzumab - (ROSEWOOD),Follicular Non-Hodgkin Lymphoma ,Approved,26/02/2024 ET,"Approval noted February 26, 2024.",110.03M
Add to portfolio,,,,,,,,
TCRX,TScan Therapeutics Inc.,6.79,"TSC-100, TSC-101 - (ALLOHA)",Hematologic malignancies ,Phase 1,26/02/2024 ET,"Phase 1 presented at Tandem Meetings showed that all eight (100%) treatment-arm patients are relapse-free and have achieved and maintained complete donor chimerism following treatment, noted February … read more",56.75M
Add to portfolio,,,RMAT,,,,,
MTNB,Matinas Biopharma Holdings Inc.,0.27,Oral amphotericin b (MAT2203) - (EnACT),Cryptococcal meningitis ,Phase 3,26/02/2024 ET,"Phase 3 update from ongoing Compassionate/Expanded use access of the 19 patients enrolled in the program, 15 have available follow-up and 4 recently initiated or will soon commence treatment with MAT2 … read more",5.09M
Add to portfolio,,,,,,,,
JANX,Janux Therapeutics Inc.,15.1,PSMA-TRACTr (JANX007) - (ENGAGER-PSMA-01),Metastatic castration-resistant prostate cancer (mCPRC) ,Phase 1,26/02/2024 ET,"Phase 1 updated clinical data at KOL illustrated a potential best-in-class profile: promising efficacy with favorable safety profile in heavily pretreated subjects with late-stage mCRPC, noted Februar … read more",60.09M
Add to portfolio,,,,,,,,
JANX,Janux Therapeutics Inc.,15.1,EGFR-TRACTr (JANX008),"Metastatic colorectal cancer (mCRC), squamous cell carcinoma of the head and neck (SCCHN) and non-small cell lung cancer (NSCLC) ",Phase 1,26/02/2024 ET,"Phase 1 data at KOL display differentiated safety and encouraging signs of efficacy in heavily pretreated subjects with different solid tumor types, noted February 26, 2024.",60.09M
Add to portfolio,,,,,,,,
GILD,Gilead Sciences Inc.,71.36,Biktarvy,HIV ,Approved,26/02/2024 ET,"Approved for expanded indication to treat people with HIV (PWH) who have suppressed viral loads with known or suspected M184V/I resistance, noted February 26, 2024.",1.24B
Add to portfolio,,,,,,,,
NERV,Minerva Neurosciences Inc,2.8,Roluperidone (MIN-101),Schizophrenia ,CRL,27/02/2024 ET,"CRL issued by the FDA, noted February 27, 2024.",6.99M
Add to portfolio,,,,,,,,
VKTX,Viking Therapeutics Inc.,85.05,VK2735 - (VENTURE),Obesity ,Phase 2,27/02/2024 ET,"Phase 2 study met primary and all secondary endpoints, demonstrating reductions in body weight, noted February 27, 2024.",113.04M
Add to portfolio,,,,,,,,
TARS,Tarsus Pharmaceuticals Inc.,39.22,TP-04 - (Galatea),Rosacea ,Phase 2a,27/02/2024 ET,Phase 2a topline data reported statistically significant improvements (p<0.05) in inflammatory lesions and Investigator's Global Assessment (IGA) score compared to vehicle at Week 12 TP-04 was genera … read more,42.21M
Add to portfolio,,,,,,,,
ACXP,Acurx Pharmaceuticals Inc.,3.13,Ibezapolstat,C. difficile Infection ,Phase 2b,27/02/2024 ET,"Phase 2b FDA confirmed that trial adequate information was submitted for EoP2 meeting, noted February 27, 2024.",1.58M
Add to portfolio,,,FTD,,,,,
,,,View Clinical Trial Data,,,,,
CGON,"CG Oncology, Inc.",46.35,cretostimogene - (PIVOT-006) (EAP),Non-Muscle Invasive Bladder Cancer (NMIBC) ,Phase 3,27/02/2024 ET,"Phase 3 dosing initiated, noted February 27, 2024.",76.25M
Add to portfolio,,,,,,,,
PPBT,Purple Biotech Ltd.,0.67,NT219 in combination with cetuximab,Recurrent/metastatic squamous cell carcinoma of the head and neck (R/M SCCHN) ,Phase 1,27/02/2024 ET,"Phase 2 was well tolerated with anti-tumor activity at relevant higher dose levels observed with 29% Objective Response Rate (ORR) and 71% Disease Control Rate (DCR), noted February 27, 2024.",2.65M
Add to portfolio,,,,,,,,
GANX,Gain Therapeutics Inc.,4.63,"GT-02287, GT-02329",GBA1 and Idiopathic Parkinson's Disease ,Phase 1,27/02/2024 ET,"Phase 1 dosing initiated, noted February 27, 2024.",35.95M
Add to portfolio,,,,,,,,
PTN,Palatin Technologies Inc.,2.45,PL9643 - (MELODY-1),Dry eye disease (DED) ,Phase 3,28/02/2024 ET,"Phase 3 final results reported met the first co-primary endpoint in the Intent-to-Treat Analysis, however did not meet the co-primary endpoint showing superiority over vehicle, noted February 28, 2024. read less",46.48M
Add to portfolio,,,View Clinical Trial Data,,,,,
IXHL,Incannex Healthcare Inc.,6.27,PSX-001 (Psilocybin treatment) - (PsiGAD2),Generalized anxiety disorder (GAD) ,Phase 2,28/02/2024 ET,"Phase 2 topline data reported that the trial met its primary endpoint, noted February 28, 2024.",347.71M
Add to portfolio,,,,,,,,
CMPX,Compass Therapeutics Inc.,1.74,CTX-8371,Solid Tumors ,Preclinical,28/02/2024 ET,"Preclinical data reported that CTX-8371 demonstrates enhanced anti-tumor activity relative to approved anti-PD-1 blockers and anti-PD-L1 blockers in a series of in vitro and in vivo experimental settings, noted February 28, 2024. read less",138.28M
Add to portfolio,,,,,,,,
SILO,Silo Pharma Inc.,1.62,SPC-15,Post-traumatic stress disorder (PTSD) ,Preclinical,28/02/2024 ET,"Preclinical data reported rapid absorption of SPC-15 with good exposure over a 24-hour period, suggesting a once-per-day human intranasal dosing regimen would be optimal, noted February 28, 2024.",9.4M
Add to portfolio,,,,,,,,
HCM,HUTCHMED (China) Limited,15.21,Amdizalisib (HMPL-689),Follicular Lymphoma and Marginal Zone Lymphoma ,Phase 2,28/02/2024 ET,"Phase 2 topline FL results reported that the trial met its primary endpoint, noted February 28, 2024.",174.43M
Add to portfolio,,,BTD,,,,,
,,,View Clinical Trial Data,,,,,
SNSE,Sensei Biotherapeutics Inc.,0.84,Solnerstotug (formerly SNS-101) with Libtayo - (VISTA),One microsatellite stable (MSS) endometrial cancer ,Phase 1,28/02/2024 ET,"Phase 1 initial safety data reported that in the monotherapy dose escalation arm, 13/16 patients (81%) experienced at least one treatment-emergent adverse event (TEAE), with the majority of adverse events (AEs) Grade 1 or 2. In the combination dose escalation arm, 10/17 patients (59%) experienced at least one TEAE, with the majority of AEs Grade 1 or 2, noted February 28, 2024. read less",1.26M
Add to portfolio,,,,,,,,
REGN,Regeneron Pharmaceuticals Inc.,987.61,Solnerstotug (formerly SNS-101) with Libtayo - (VISTA),One microsatellite stable (MSS) endometrial cancer ,Phase 1,28/02/2024 ET,"Phase 1 initial safety data reported that in the monotherapy dose escalation arm, 13/16 patients (81%) experienced at least one treatment-emergent adverse event (TEAE), with the majority of adverse events (AEs) Grade 1 or 2. In the combination dose escalation arm, 10/17 patients (59%) experienced at least one TEAE, with the majority of AEs Grade 1 or 2, noted February 28, 2024. read less",105.99M
Add to portfolio,,,,,,,,
VANI,Vivani Medical Inc.,3.74,NPM-115 (exenatide implant) - (LIBERATE-1),Subdermal implants in development for chronic weight management ,Preclinical,28/02/2024 ET,"Preclinical data showed that implant generated significant weight loss comparable to injectable semaglutide (Ozempic/Wegovy) from a single administration with expected twice-yearly dosing, noted February 28, 2024. read less",59.24M
Add to portfolio,,,,,,,,
AVIR,Atea Pharmaceuticals Inc.,4.37,Bemnifosbuvir and ruzasvir (RZR) - (C-FORWARD),Hepatitis C Virus (HCV) ,Phase 2,28/02/2024 ET,"Phase 2 final data from the 60-patient lead-in cohort reported that the SVR4 rate exceeded the protocol-defined efficacy criterion of ≥90% SVR4 for continuing the study, noted February 28, 2024.",79.36M
Add to portfolio,,,,,,,,
BLRX,BioLineRx Ltd.,1.32,"Motixafortide (BL-8040), gemcitabine, nab-paclitaxel and LIBTAYO (cemiplimab) - (Columbia University trial) - (CheMo4METPANC)",First-line pancreatic ductal adenocarcinoma (PDAC) ,Phase 2,28/02/2024 ET,"Phase 2 trial initiated, noted February 28, 2024.",3.72M
Add to portfolio,,,View Clinical Trial Data,,,,,
KANT,Kineta Inc.,—,KVA12123 with KEYTRUDA (pembrolizumab) - (VISTA-101),Solid tumors ,Phase 1/2,29/02/2024 ET,"Phase 1/2 initial data reported a partial Response in 1 patient with a PD-L1 negative mucoepidermoid carcinoma and a 54% reduction in target lesions and a complete response in non-target lesions, noted March 12, 2024. Phase 1/2 new enrollment terminated, noted February 29, 2024. read less",13.54M
Add to portfolio,,,,,,,,
IMUX,Immunic Inc.,1.47,IMU-838 - (CALLIPER),Progressive Multiple Sclerosis ,Phase 2,29/02/2024 ET,"Phase 2 interim data presented at ACTRIMS reported that serum NfL was decreased in the treatment group by 22.4%, noted February 29, 2024.",98.65M
Add to portfolio,,,View Clinical Trial Data,,,,,
IMUX,Immunic Inc.,1.47,IMU-838 - (CALVID-1),COVID-19 ,Phase 2,29/02/2024 ET,"Additional Phase 2 data reported that 80% of patients who received placebo reported fatigue, compared to 50% who received 45 mg vidofludimus calcium, noted February 29, 2024.",98.65M
Add to portfolio,,,View Clinical Trial Data,,,,,
IRWD,Ironwood Pharmaceuticals Inc.,9.43,Apraglutide - (STARS),Short Bowel Syndrome with Intestinal Failure (SBS-IF) ,Phase 3,29/02/2024 ET,"Phase 3 top-line data reported that the trial met its primary endpoint, however two key secondary endpoints were specific to colon-in-continuity patients in assessing at least one day/week off PS versus baseline and reaching enteral autonomy at week 48, both of which were not achieved, noted February 29, 2024. read less",162.43M
Add to portfolio,,,View Clinical Trial Data,,,,,
CLNN,Clene Inc.,8.05,CNM-Au8 - (VISIONARY-MS),Multiple Sclerosis ,Phase 2,29/02/2024 ET,"Phase 2 full clinical results presented at ACTRIMS Forum reported that treatment demonstrated significant improvement of vision as measured by low contrast letter acuity (LCLA) through 35 months from randomization, noted February 29, 2024. read less",9.99M
Add to portfolio,,,View Clinical Trial Data,,,,,
IMNN,Imunon Inc.,1.14,IMNN-101 - (IMUNON),SARS-CoV-2 variant XBB.1.5 ,Preclinical,29/02/2024 ET,"Challenge study data reported that a single dose produced IgG neutralizing antibody and T-cell responses, noted February 29, 2024.",2.52M
Add to portfolio,,,,,,,,
CUE,Cue Biopharma Inc.,2.08,CUE-101 and KEYTRUDA (pembrolizumab) - (KEYNOTE-A78),HPV16+ head and neck cancer ,Phase 1,29/02/2024 ET,"Phase 1 data reported from the Multi-disciplinary Head and Neck Cancers Symposium that overall response rate (ORR) of 47% in first line (1L) patients treated with CUE-101 and pembrolizumab, compared to the historical ORR of 19% reported in the KEYNOTE-48 trial, noted February 29, 2024. read less",76.85M
Add to portfolio,,,FTD,,,,,
CRDF,Cardiff Oncology Inc.,1.77,"Onvansertib, FOLFIRI and AVASTIN (bevacizumab) - (ONSEMBLE)",KRAS-Mutated Colorectal Cancer ,Phase 2,29/02/2024 ET,"Phase 2 data reported a 50% ORR rate in Bev Naive patients and 0% ORR in Bev Exposed patients, noted February 29, 2024.",66.53M
Add to portfolio,,,,,,,,
TGTX,TG Therapeutics Inc.,17.22,BRIUMVI (ublituximab-xiiy) - (ENHANCE),Relapsing forms of Multiple Sclerosis (RMS) ,Phase 3,29/02/2024 ET,"Phase 3b data presented at ACTRIMS reported that 18 (86%) of participants completed the infusion without interruption or slowing, with a median infusion duration of 60 min, noted February 29, 2024.",158.67M
Add to portfolio,,,View Clinical Trial Data,,,,,
RYTM,Rhythm Pharmaceuticals Inc.,43.42,Setmelanotide - (DAYBREAK),Variants in one of 31 additional genes with MC4R pathway relevance ,Phase 2,29/02/2024 ET,"Phase 2 data showed that nearly 97% of followed patients were relapse-free at 90 days post Zeposia discontinuation; patients that did relapse showed no evidence of rebound effect, noted February 29, 2024. read less",66.42M
Add to portfolio,,,View Clinical Trial Data,,,,,
ATRA,Atara Biotherapeutics Inc.,19.45,ATA3219,"B-cell non-Hodgkin's lymphoma (NHL), Lupus Nephritis ",IND-Enabling,29/02/2024 ET,"IND cleared by the FDA, noted February 29, 2024",7.02M
Add to portfolio,,,,,,,,
CGEM,Cullinan Therapeutics Inc.,18.51,CLN-619 - (MICB),Relapsed or Refractory Multiple Myeloma ,IND-Enabling,01/03/2024 ET,"IND Clearaed by the FDA, noted March 1, 2024.",59.07M
Add to portfolio,,,,,,,,
BIVI,BioVie Inc.,1.89,NE3107,Parkinson's disease ,Phase 2a,01/03/2024 ET,"Additional Phase 2a data reported significant improvement of -2.4 points for the sleep/fatigue domain of the Non-Motor Symptom Scale (NMSS) in Parkinson's Disease, whereas placebo patients experienced a worsening of +1.0 points, noted March 1, 2024 read less",7.53M
Add to portfolio,,,,,,,,
BIVI,BioVie Inc.,1.89,NE3107,Alzheimer’s disease ,Phase 3,01/03/2024 ET,"Additional Phase 3 data reported that due to the exclusion of data from so many sites the trial missed statistical significance but showed promising directional data on cognitive and functional measures. NE3107-treated patients saw an advantage compared to placebo of -0.95 (68% slowing of decline) on CDR-SB, -0.94 (26%) on ADAS-COG-12, -0.43 (139%) on ADAS-CGIC, -0.03 (27%) on ADCOMS, +1.02 (40%) on MMSE, and +3.08 (47%) on ADCS-ADL, noted March 1, 2024. read less",7.53M
Add to portfolio,,,,,,,,
KRBP,Kiromic BioPharma Inc.,2.36,Deltacel-01 - (KB-GDT-01),Stage 4 Metastatic Non-Small Cell Lung Cancer ,Phase 1,01/03/2024 ET,"Phase 1 third patient enrolled completed treatment, noted March 1, 2024",1.53M
Add to portfolio,,,FTD,,,,,
LEXX,Lexaria Bioscience Corp.,2.92,HYPER-H23-1 (DehydraTECH-CBD),Hypertension ,IND-Enabling,01/03/2024 ET,"IND Cleared by the FDA, noted March 1, 2024",19.56M
Add to portfolio,,,,,,,,
SLS,SELLAS Life Sciences Group Inc.,1,Tambiciclib (SLS009) (GFH009) with venetoclax,"Hematologic malignancies, acute myeloid leukemia (AML), chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL) and lymphoma ",Phase 1,01/03/2024 ET,"Phase 1 dose-escalation topline data for the heavily pretreated AML patients showed evidence of anti-tumor activity increasing with higher dose levels and no significant safety issues. Treatment with SLS009 resulted in a complete remission (CR) with no minimal residual disease (MRD) after three cycles as a monotherapy in an AML patient who had failed prior venetoclax plus azacytidine (aza/ven) therapy. The CR lasted eight months with the patient achieving one year survival at the latest assessment. This is the first time that a relapsed/refractory (r/r) AML patient achieved a CR with CDK9 inhibition monotherapy. Notably, the median survival for patients relapsed after aza/ven therapy is approximately 2.5 months. All key study objectives were met regarding pharmacokinetic (PK), pharmacodynamic (PD), safety, and clinical activity, noted March 1, 2024. read less",105.3M
Add to portfolio,,,ODD,,,,,
,,,FTD,,,,,
,,,RPDD,,,,,
JNJ,Johnson & Johnson,160.8,RYBREVANT (amivantamab) - (PAPILLON),Non-small cell lung cancer ,Approved,01/03/2024 ET,"FDA approved on March 1, 2024.",2.41B
Add to portfolio,,,,,,,,
WHWK,Whitehawk Therapeutics Inc.,—,Nab-sirolimus - (AMPECT),Malignant PEComa (Perivascular epithelioid cell tumour) ,Phase 2,01/03/2024 ET,"Phase 2 long-term efficacy and safety results demonstrated 40 months median duration of response and median survival >53 months, noted March 1, 2024.",47.13M
Add to portfolio,,,,,,,,
RNA,Avidity Biosciences Inc.,18.86,Delpacibart etedesiran (del-desiran) - (MARINA-OLE),Myotonic dystrophy type 1 (DM1) ,Phase 2,04/03/2024 ET,"Phase 2 preliminary data anticipated at the MDA conference showed reversal of disease progression in multiple functional measures, noted March 4, 2024.",128.65M
Add to portfolio,,,BTD,,,,,
NVO,Novo Nordisk A/S,—,Efruxifermin - (HARMONY),Nonalcoholic Steatohepatitis ,Phase 2b,04/03/2024 ET,"Phase 2b 96-week results reported that the 50mg (75%, p<0.001) and 28mg (46%, p=0.07) EFX groups demonstrated ≥1 stage improvement in fibrosis without worsening of MASH, approximately three- and two-fold the placebo rate (24%), noted March 4, 2024. read less",4.47B
Add to portfolio,,,FTD,,,,,
,,,BTD,,,,,
,,,View Clinical Trial Data,,,,,
AKRO,Akero Therapeutics Inc.,31.07,Efruxifermin - (HARMONY),Nonalcoholic Steatohepatitis ,Phase 2b,04/03/2024 ET,"Phase 2b 96-week results reported that the 50mg (75%, p<0.001) and 28mg (46%, p=0.07) EFX groups demonstrated ≥1 stage improvement in fibrosis without worsening of MASH, approximately three- and two-fold the placebo rate (24%), noted March 4, 2024. read less",79.99M
Add to portfolio,,,FTD,,,,,
,,,BTD,,,,,
,,,View Clinical Trial Data,,,,,
CLRB,Cellectar Biosciences Inc.,4.24,CLR 131 (iopofosine) in combination with external beam radiation (EBRT),Head & neck cancer ,Phase 1,04/03/2024 ET,"Phase 1 data reported the complete remission was achieved in 64% of patients, with an ORR of 73%, noted March 4, 2024.",3.19M
Add to portfolio,,,,,,,,
NVS,Novartis AG,98.29,Zolgensma (onasemnogene abeparvovec) - (SMART),Spinal muscular atrophy (SMA) ,Phase 3,04/03/2024 ET,"Phase 3b data reported that nearly all patients treated maintained or improved motor milestones after 52 weeks, with most switching to the one-time gene therapy from another chronically administered disease-modifying therapy, noted March 4, 2024. read less",1.98B
Add to portfolio,,,,,,,,
INDP,Indaptus Therapeutics Inc.,2.36,Decoy-20 - (INDP-D101),Advanced/metastatic solid tumors ,Phase 1,04/03/2024 ET,"Phase 1 data following completion of second cohort trial of Decoy 20 leads the independent Safety Review Committee to recommend initiating a multi-dosing cohort, noted March 4, 2024. Single dose cohort data expected to be published at a scientific conference in 2024 read less",1.11M
Add to portfolio,,,,,,,,
BCDA,BioCardia Inc.,6.83,CardiAMP (BCDA-01),Ischemic Heart Failure ,Phase 3,04/03/2024 ET,"Phase 3 data reported that patients had 37% relative risk reduction in heart death equivalent and 9% relative risk reduction in non-fatal major adverse cardiac and cerebrovascular events (MACCE) at mean 20-month follow-up compared to control patients on guideline-directed heart medications alone, noted March 4, 2024. read less",5.8M
Add to portfolio,,,BTD,,,,,
,,,View Clinical Trial Data,,,,,
VTVT,vTv Therapeutics Inc.,14.01,Cadisegliatin (TTP399),Type 1 Diabetes ,Phase 3,04/03/2024 ET,"Phase 3 announced the submission of the study protocol to the FDA to initiate the trial, noted March 4, 2024.",3.19M
Add to portfolio,,,View Clinical Trial Data,,,,,
LNTH,Lantheus Holdings Inc.,65.36,DEFINITY (Perflutren Lipid Microsphere),Ultrasound enhancing agent for use in pediatric patients with suboptimal echocardiograms ,Approved,04/03/2024 ET,"FDA approved on March 4, 2024.",67.99M
Add to portfolio,,,,,,,,
MTEM,Molecular Templates Inc.,3.85,MT-6402,Solid tumors ,Phase 1,04/03/2024 ET,"Phase 1 dose-escalation data showed that treatment appears generally well-tolerated at the 63 and 83 mcg/kg doses with no Grade 4 or Grade 5 adverse events and no instances of CLS seen at any dose, noted March 4, 2024. read less",6.58M
Add to portfolio,,,FTD,,,,,
NRXP,NRX Pharmaceuticals Inc.,5.2,NRX-101,Bipolar Depression and Suicidal Ideation ,Phase 2/3,04/03/2024 ET,"Phase 2/3 last patient dosed, noted March 4, 2024.",19.71M
Add to portfolio,,,BTD,,,,,
,,,FTD,,,,,
,,,View Clinical Trial Data,,,,,
PCVX,Vaxcyte Inc.,71.55,VAX-24,Pneumococcal Disease in infants ,Phase 2,04/03/2024 ET,"Phase 2 enrollment completed, noted March 4, 2024.",129.82M
Add to portfolio,,,,,,,,
BCDA,BioCardia Inc.,6.83,Allogeneic CardiALLO,Heart failure ,Phase 1/2,04/03/2024 ET,"Data presented at the Technology and Heart Failure Therapeutics Conference (THT) reported that first patient has been enrolled and treated in the low dose group and is doing well clinically, noted March 4, 2024. read less",5.8M
Add to portfolio,,,,,,,,
GSK,GSK plc American Depositary Shares (Each representing two),42.09,"Cabenuva (cabotegravir, rilpivirine) - (CAB-ULA)",HIV treatment and prevention dosed at intervals of at least four months ,Phase 1,04/03/2024 ET,"Phase 1 data show for the first time a new ultra-long-acting cabotegravir formulation (CAB-ULA) that doubles the current dosing interval, noted March 4, 2024.",2.03B
Add to portfolio,,,,,,,,
PFE,Pfizer Inc.,25.51,"Cabenuva (cabotegravir, rilpivirine) - (CAB-ULA)",HIV treatment and prevention dosed at intervals of at least four months ,Phase 1,04/03/2024 ET,"Phase 1 data show for the first time a new ultra-long-acting cabotegravir formulation (CAB-ULA) that doubles the current dosing interval, noted March 4, 2024.",5.69B
Add to portfolio,,,,,,,,
APGE,Apogee Therapeutics Inc.,59.3,APG777 - (APEX),"Healthy volunteers, Atopic dermatitis (AD) ",Phase 1,05/03/2024 ET,"Phase 1 interim data reported a half-life of approximately 75 days across doses tested and Pharmacodynamic (PD) data showed deep and sustained inhibition of key AD biomarkers pSTAT6 and TARC for ~3 months, noted March 5, 2024. read less",59.6M
Add to portfolio,,,,,,,,
GSK,GSK plc American Depositary Shares (Each representing two),42.25,Cabotegravir ultra long-acting (CAB-ULA) - (4 month dosing),HIV ,Phase 1,05/03/2024 ET,"Phase 1 data reported that intramuscular dosing of CAB-ULA has a safety and pharmacokinetic (PK) profile that supports a longer dose interval, noted March 5, 2024.",2.03B
Add to portfolio,,,,,,,,
NVO,Novo Nordisk A/S,123.76,Semaglutide - (FLOW),Renal impairment in people with type 2 diabetes and chronic kidney disease (CKD) ,Phase 3,05/03/2024 ET,"Phase 3 trial stopped early due to efficacy, based on a recommendation from an Independent Data Monitoring Committee. The trial achieved its primary endpoint by demonstrating a statistically significant and superior reduction in kidney disease progression, major adverse cardiovascular events (MACE) and death of 24% for people treated with semaglutide 1.0 mg compared to placebo, noted March 5, 2024. read less",4.47B
Add to portfolio,,,,,,,,
CASI,CASI Pharmaceuticals Inc.,5.66,BI-1206 with rituximab - (China trial),Non-Hodgkin's Lymphoma (NHL) ,Phase 1,05/03/2024 ET,"Phase 1 initial data showed promising responses including a long-lasting complete response for patients with difficult-to-treat disease, noted March 5, 2024.",15.49M
Add to portfolio,,,,,,,,
MNPR,Monopar Therapeutics Inc.,1.06,MNPR-101-Zr (uPAR),Solid tumors ,Preclinical,05/03/2024 ET,"Addtional preclinical data demonstrated highly preferential uptake in the tumor. The new imaging data released today support the tumor-targeting ability of MNPR-101, noted March 5, 2024.",6.17M
Add to portfolio,,,,,,,,
ALNY,Alnylam Pharmaceuticals Inc.,149.68,Zilebesiran - (KARDIA-2),Hypertension ,Phase 2,05/03/2024 ET,"Phase 2 trial met the primary endpoint, noted March 5, 2024.",131.08M
Add to portfolio,,,,,,,,
RGNX,REGENXBIO Inc.,24.61,RGX-202 - (AFFINITY DUCHENNE),Duchenne Muscular Dystrophy (DMD) ,Phase 1/2,05/03/2024 ET,"Phase 1/2 new three-month assessment in first patient at dose level 2 demonstrates robust microdystrophin expression. Patient aged 12 years at dosing had expression level at 75.7% of control, noted March 5, 2024. read less",50.51M
Add to portfolio,,,ODD,,,,,
,,,FTD,,,,,
CRVO,CervoMed Inc.,13,Neflamapimod - (AscenD-LB),Dementia with Lewy bodies (DLB) ,Phase 2a,05/03/2024 ET,"Phase 2a data presented at AD/PD reported that there was a mean 3.7 pg/mL increase GFAP levels in placebo vs. mean 12.3 pg/mL reduction with neflamapimod, noted March 5, 2024.",9.25M
Add to portfolio,,,,,,,,
GANX,Gain Therapeutics Inc.,4.66,"GT-02287, GT-02329",GBA1 and Idiopathic Parkinson's Disease ,Preclinical,05/03/2024 ET,"Preclinical data presented at AD/PD reported that GT-02287, through its interaction with glucocerebrosidase (GCase) in the endoplasmic reticulum (ER), aids correct GCase folding, preventing ER retention, ER stress, and ER-associated degradation of mutated GCase enzyme, noted March 5, 2024. read less",35.95M
Add to portfolio,,,,,,,,
IMMP,Immutep Limited,2.61,Eftilagimod Alpha with weekly paclitaxel - (AIPAC-003),Metastatic breast cancer (MBC) ,Phase 2/3,05/03/2024 ET,"Phase 2/3 90mg data reported a 50% overall response rate, including one complete response and two partial responses, and a 100% disease control rate overall, noted March 5, 2024.",145.46M
Add to portfolio,,,FTD,,,,,
LLY,Eli Lilly and Company,776.31,Rezpegaldesleukin (LY3471851) - (REZOLVE-AA),Severe to very severe alopecia areata (AA) ,Phase 2b,05/03/2024 ET,https://www.biopharmcatalyst.com/company/NKTR/news/189917,946.46M
Add to portfolio,,,FTD,,,,,
NKTR,Nektar Therapeutics,0.88,Rezpegaldesleukin (LY3471851) - (REZOLVE-AA),Severe to very severe alopecia areata (AA) ,Phase 2b,05/03/2024 ET,https://www.biopharmcatalyst.com/company/NKTR/news/189917,19.02M
Add to portfolio,,,FTD,,,,,
ONCY,Oncolytics Biotech Inc.,1.03,mFOLFIRINOX +/- atezolizumab and pelareorep - (PanCAN),Pancreatic Ductal Adenocarcinoma (PDAC) ,Phase 1/2,05/03/2024 ET,"Company submitted an amendment to GOBLET to initiate a new Phase 1/2 cohort, noted March 5, 2024.",100.36M
Add to portfolio,,,FTD,,,,,
,,,ODD,,,,,
LIPO,Lipella Pharmaceuticals Inc.,0.81,LP-410,Graft-Versus-Host Disease (GVHD) ,IND-Enabling,05/03/2024 ET,"IND cleared by the FDA noted, March 5, 2024.",4.62M
Add to portfolio,,,ODD,,,,,
IBRX,ImmunityBio Inc.,4.82,Anktiva (N-803),HIV ,Phase 1,05/03/2024 ET,"Phase 1 pilot study experienced a marked decrease in the burden of infection, and the procedures were found to be safe and well tolerated, noted March 5, 2024.",945.25M
Add to portfolio,,,View Clinical Trial Data,,,,,
OPK,Opko Health Inc.,0.93,SAR441236,human immunodeficiency virus (HIV) ,Phase 1,05/03/2024 ET,"Phase 1 study delivers first clinical safety and pharmacokinetic data as proof of concept for the use of multispecific antibodies in humans, noted March 5, 2024.",793.78M
Add to portfolio,,,,,,,,
GILD,Gilead Sciences Inc.,71.4,Bictegravir and Lenacapavir - (ARTISTRY-1),HIV ,Phase 2/3,05/03/2024 ET,"Phase 2/3 data reported that all three treatment groups had robust virologic suppression at six months, with consistently low viral loads throughout the study, noted March 5, 2024.",1.24B
Add to portfolio,,,,,,,,
NVS,Novartis AG,98.42,Wyost (denosumab-bddz) and Jubbonti (denosumab-bddz) interchangeable,multiple myeloma and in patients with bone metastases from solid tumors ,Approved,05/03/2024 ET,"FDA biosimilar of Xgeva (denosumab) and Prolia (denosumab) approved on March 5, 2024.",1.98B
Add to portfolio,,,,,,,,
BTAI,BioXcel Therapeutics Inc.,2.96,BXCL501 - (SERENITY III),Agitation associated with bipolar I or II disorder or schizophrenia ,Phase 3,06/03/2024 ET,"A Type C meeting with FDA feedback resulted in an amended Phase 3 trial planned for the at-home setting, noted March 6, 2024.",14.56M
Add to portfolio,,,,,,,,
VNDA,Vanda Pharmaceuticals Inc.,3.91,HETLIOZ (tasimelteon),Insomnia ,CRL,06/03/2024 ET,"CRL issued by FDA on March 6, 2024.",59.09M
Add to portfolio,,,,,,,,
BMEA,Biomea Fusion Inc.,15.8,Icovamenib (BMF-219) - (COVALENT-111),"Healthy volunteers, type 2 diabetes ",Phase 1/2,06/03/2024 ET,"Phase 1/2 data presented at ATTD reported that across 100mg QD, 200mg QD, and 100mg BID cohorts, 38% of patients had ≥0.5% HbA1c reduction, and 23% of patients had ≥1.0% HbA1c reduction at Week 26, noted March 6, 2024. read less",59.51M
Add to portfolio,,,,,,,,
XOMA,XOMA Royalty Corporation,25,RZ358 - (sunRIZE),"Congenital hyperinsulinism (HI), non-islet cell tumors (NICTs) that have uncontrolled hypoglycemia ",Preclinical,06/03/2024 ET,"Preclinical data reported that data demonstrated the ability of RZ358 to similarly blunt both IGF-2 and insulin-mediated insulin-receptor signaling, at levels of these ligands that are disease-relevant in humans, noted March 6, 2024. read less",12.09M
Add to portfolio,,,BTD,,,,,
,,,View Clinical Trial Data,,,,,
RZLT,Rezolute Inc.,1.8,RZ358 - (sunRIZE),"Congenital hyperinsulinism (HI), non-islet cell tumors (NICTs) that have uncontrolled hypoglycemia ",Preclinical,06/03/2024 ET,"Preclinical data reported that data demonstrated the ability of RZ358 to similarly blunt both IGF-2 and insulin-mediated insulin-receptor signaling, at levels of these ligands that are disease-relevant in humans, noted March 6, 2024. read less",90.81M
Add to portfolio,,,BTD,,,,,
,,,View Clinical Trial Data,,,,,
KURA,Kura Oncology Inc.,22.7,KO-2806 and adagrasib in combination with cabozantinib - (FIT-001),Clear cell renal cell carcinoma (ccRCC) ,Phase 1,06/03/2024 ET,"Phase 1 dosing initiated, noted March 6, 2024.",86.8M
Add to portfolio,,,,,,,,
BMY,Bristol-Myers Squibb Company,51.98,KO-2806 and adagrasib in combination with cabozantinib - (FIT-001),Clear cell renal cell carcinoma (ccRCC) ,Phase 1,06/03/2024 ET,"Phase 1 dosing initiated, noted March 6, 2024.",2.04B
Add to portfolio,,,,,,,,
ASLN,ASLAN Pharmaceuticals Limited,5.35,eblasakimab versus dupilumab,human tissue model of chronic obstructive pulmonary disease (COPD) ,Preclinical,06/03/2024 ET,"Preclinical new translational data from a head-to-head study of eblasakimab and dupilumab in a human tissue model of COPD shows eblasakimab performed better than dupilumab in improving airway function and enhancing bronchodilation at the same concentrations, noted March 6, 2024. read less",2.83M
Add to portfolio,,,,,,,,
COYA,Coya Therapeutics Inc.,9.67,COYA 302,Frontotemporal dementia (FTD) ,Preclinical,06/03/2024 ET,"Preclinical biomarker data shared at the AD/PD 2024 Conference clearly depicts a compromised peripheral immune environment present in patients with FTD that, we believe, contributes to the pathophysiology of the disease process, noted March 5, 2024. IND filing intended later in 2024 and Phase 2 initiation, noted March 6, 2024. read less",16.73M
Add to portfolio,,,,,,,,
BHC,Bausch Health Companies Inc.,9.23,RELISTOR (methylnaltrexone bromide: MNTX),Resectable head and neck squamous cell carcinoma ,Phase 2,06/03/2024 ET,"Phase 2 initiated sponsored by Salix Pharmaceuticals, noted March 6, 2024.",369.79M
Add to portfolio,,,,,,,,
REGN,Regeneron Pharmaceuticals Inc.,972.1,Ateganosine (THIO-101),Non-small cell lung cancer (NSCLC) ,Phase 2,06/03/2024 ET,"Phase 2 third-line ombination THIO 180mg + cemiplimab achieved 38% overall response rate (ORR) in difficult-to-treat, noted March 6, 2024",105.99M
Add to portfolio,,,ODD,,,,,
,,,FTD,,,,,
MAIA,MAIA Biotechnology Inc.,1.47,Ateganosine (THIO-101),Non-small cell lung cancer (NSCLC) ,Phase 2,06/03/2024 ET,"Phase 2 third-line ombination THIO 180mg + cemiplimab achieved 38% overall response rate (ORR) in difficult-to-treat, noted March 6, 2024",32.99M
Add to portfolio,,,ODD,,,,,
,,,FTD,,,,,
GILD,Gilead Sciences Inc.,71.04,Islatravir (MK-8591D) and Lenacapavir - (ISLEND),Human immunodeficiency virus (HIV) ,Phase 2,06/03/2024 ET,"Phase 2 data reported that one participant (1.9%) treated with islatravir and lenacapavir had a viral load of more than 50 copies/mL at Week 24; the participant later suppressed on islatravir and lenacapavir at Week 30. No participants in the Biktarvy group had a viral load of more than 50 copies/mL at Week 24, noted March 6, 2024. read less",1.24B
Add to portfolio,,,View Clinical Trial Data,,,,,
MRK,Merck & Company Inc.,122.23,Islatravir (MK-8591D) and Lenacapavir - (ISLEND),Human immunodeficiency virus (HIV) ,Phase 2,06/03/2024 ET,"Phase 2 data reported that one participant (1.9%) treated with islatravir and lenacapavir had a viral load of more than 50 copies/mL at Week 24; the participant later suppressed on islatravir and lenacapavir at Week 30. No participants in the Biktarvy group had a viral load of more than 50 copies/mL at Week 24, noted March 6, 2024. read less",2.5B
Add to portfolio,,,View Clinical Trial Data,,,,,
GSK,GSK plc American Depositary Shares (Each representing two),42.27,Cabenuva (cabotegravir + rilpivirine) - (LATITUDE),HIV ,Phase 3,06/03/2024 ET,"Phase 3 data reported that 24.1% of participants on LA-ART experienced regimen failure compared to 38.5% on SOC, noted March 6, 2024.",2.03B
Add to portfolio,,,,,,,,
ZLAB,Zai Lab Limited,19.8,ZEJULA (niraparib) - (NORA),Platinum-Sensitive Recurrent Ovarian Cancer (PSROC) ,Phase 3,06/03/2024 ET,"Phase 3 data reported that treatment demonstrated a favorable OS trend versus placebo in this disease setting, regardless of BRCA-gene mutation status. No new safety signals were identified during the long-term follow up period subsequent to the primary analysis, noted March 6, 2024. read less",109.96M
Add to portfolio,,,,,,,,
GILD,Gilead Sciences Inc.,71.04,Biktarvy - (ALLIANCE),HIV/HBV Coinfection ,Phase 3,06/03/2024 ET,"Phase 3 data reported that 97% percent (71/73) of participants treated with Biktarvy achieved viral suppression (HIV-1 RNA < 50 copies /ml) as did 97% (36/37) of participants treated with the DTG-based regimen, noted March 6, 2024. read less",1.24B
Add to portfolio,,,,,,,,
DYN,Dyne Therapeutics Inc.,26.78,DYNE-251 - (DELIVER),Duchenne muscular dystrophy (DMD) ,Phase 1/2,06/03/2024 ET,"Phase 1/2 initial data show levels of exon skipping, dystrophin, and PDPF increased at 6 months vs. baseline, noted March 6, 2024.",142.26M
Add to portfolio,,,FTD,,,,,
,,,ODD,,,,,
,,,BTD,,,,,
BMY,Bristol-Myers Squibb Company,51.88,Opdivo (nivolumab) plus Yervoy (ipilimumab),Urothelial carcinoma ,Approved,07/03/2024 ET,"Approved March 7, 2024.",2.04B
Add to portfolio,,,,,,,,
MNMD,Mind Medicine (MindMed) Inc.,9,MM-120 (LSD),Generalized Anxiety Disorder (GAD) ,Phase 2b,07/03/2024 ET,"Phase 2b data 12-week data reported that the trial met its key secondary endpoint and maintained a clinically and statistically significant HAM-A reductions compared to placebo at 12 weeks with a 65% clinical response rate and 48% clinical remission rate, noted March 7, 2024. read less",75.55M
Add to portfolio,,,FTD,,,,,
,,,BTD,,,,,
FBIO,Fortress Biotech Inc.,2.07,MB-101 - (City of Hope),High-Grade Glioma ,Phase 1,07/03/2024 ET,"Phase 1 data reported well-tolerated and 50% of patients achieved stable disease or better with two partial responses and two complete responses lasting 7.5 and 66+ months, noted March 7, 2024.",29.75M
Add to portfolio,,,,,,,,
MBIO,Mustang Bio Inc.,1.39,MB-101 - (City of Hope),High-Grade Glioma ,Phase 1,07/03/2024 ET,"Phase 1 data reported well-tolerated and 50% of patients achieved stable disease or better with two partial responses and two complete responses lasting 7.5 and 66+ months, noted March 7, 2024.",7.24M
Add to portfolio,,,,,,,,
GSK,GSK plc American Depositary Shares (Each representing two),43.22,BLENREP (belantamab mafodotin) and POMALYST (Pomalidomide) and Dexamethasone - (DREAMM-8),Multiple Myeloma ,Phase 3,07/03/2024 ET,"Phase 3 trial met its primary endpoint, noted March 7, 2024",2.03B
Add to portfolio,,,View Clinical Trial Data,,,,,
IMRN,Immuron Limited,4.55,Travelan - (CHIM),Enterotoxigenic Escherichia coli (ETEC) ,Phase 2,07/03/2024 ET,"Phase 2 interim data reported that the intended attack rate for this study was approximately 70%. The attack rate for the Placebo group of this study was only 37%, noted March 7, 2024.",6.71M
Add to portfolio,,,,,,,,
TELO,Telomir Pharmaceuticals Inc.,8.7,Telomir-1,Age-related conditions ,Preclinical,07/03/2024 ET,"Preclinical data reported that Telomir-1 was observed to cause cell cytotoxicity at a concentration of 500 M in both MRC-5 and HUVEC cells, noted March 7, 2024.",32.28M
Add to portfolio,,,,,,,,
APVO,Aptevo Therapeutics Inc.,6.6,ALG.APV-527,Solid tumors ,Phase 1,07/03/2024 ET,"Phase 1 data reported 2 stable disease responses, noted March 7, 2024.",3.29M
Add to portfolio,,,,,,,,
ATHA,Athira Pharma Inc.,3.58,Fosgonimeton (ATH-1017) - (SHAPE),Parkinson’s disease dementia ,Phase 2,08/03/2024 ET,"Phase 2 data presented at AD/PD reported that changes in ADAS-Cog13 observed in the fosgonimeton 40 mg dose arm were suggestive of a pro-cognitive effect, noted March 8, 2024.",3.94M
Add to portfolio,,,View Clinical Trial Data,,,,,
AMLX,Amylyx Pharmaceuticals Inc.,3.36,AMX0035 - (A35-004 PHOENIX),Amyotrophic Lateral Sclerosis (AML) ,Phase 3,08/03/2024 ET,"Phase 3 topline results did not meet the primary endpoint, noted March 8, 2024.",89.17M
Add to portfolio,,,,,,,,
KYTX,Kyverna Therapeutics Inc.,28.67,KYV-101,Non-relapsing and progressive forms of multiple sclerosis ,Phase 1,08/03/2024 ET,"Phase 1 trial with Stanford University commenced, noted March 8, 2024.",43.25M
Add to portfolio,,,,,,,,
NVO,Novo Nordisk A/S,132.12,Wegovy (Semaglutide),Cardiovascular risk reduction in adults with obesity ,Approved,08/03/2024 ET,"Approved March 8, 2024.",4.47B
Add to portfolio,,,,,,,,
ABOS,Acumen Pharmaceuticals Inc.,4.37,Sabirnetug (ACU193) - (INTERCEPT-AD),Alzheimer’s disease (AD) ,Phase 1,08/03/2024 ET,"Phase 1 biomarker results presented at PD/AD support sabirnetug's downstream pharmacological effects in the brain in early AD, noted March 8, 2024.",60.57M
Add to portfolio,,,FTD,,,,,
MNKD,MannKind Corporation,5.27,Afrezza Combined With Insulin Degludec - (INHALE-3),Type 1 Diabetes ,Phase 3,08/03/2024 ET,"Phase 4 data presented at ATTD reported that post-meal hyperglycemia was significantly reduced by 20% with inhaled insulin compared with rapid-acting insulin delivered through MDI or insulin pumps, noted March 8, 2024. read less",306.83M
Add to portfolio,,,,,,,,
TLSA,Tiziana Life Sciences Ltd,0.49,Foralumab (Intranasal),Alzheimer’s Disease ,Phase 1,08/03/2024 ET,"IND clearance by FDA, noted August 15, 2023. Phase 1 data presented at the AD/PD Conference on March 8, 2024.",111.46M
Add to portfolio,,,,,,,,
ARQT,Arcutis Biotherapeutics Inc.,11.15,Roflumilast Cream (ARQ-151) - (DERMIS-1),Plaque psoriasis ,Phase 3,09/03/2024 ET,"Additional data shared at AAD reported a clinically meaningful response in >70% of patients, noted March 9, 2024.",119.91M
Add to portfolio,,,,,,,,
MLTX,MoonLake Immunotherapeutics,47.05,Nanobody sonelokimab - (IZAR),Active psoriatic arthritis (PsA) ,Phase 2b,10/03/2024 ET,"Phase 2b 24-week data reported that 52% of patients achieved ACR50+PASI100 and up to 61% of patients achieved Minimal Disease Activity (MDA), noted March 10, 2024.",64.23M
Add to portfolio,,,,,,,,
ARQT,Arcutis Biotherapeutics Inc.,10.04,ZORYVE (roflumilast) Cream 0.05%,Atopic Dermatitis - ages of 2-5 years old ,Phase 3,10/03/2024 ET,"Phase 3 data to be shared at late-breaking presentation at AAD reported significant improvements in atopic dermatitis across multiple efficacy endpoints and all timepoints, noted March 10, 2024.",119.91M
Add to portfolio,,,,,,,,
LXRX,Lexicon Pharmaceuticals Inc.,2.81,Zynquista (sotagliflozin),Type 1 Diabetes and chronic kidney disease (CKD) ,NDA Filing,11/03/2024 ET,"After public Notice of Opportunity for Hearing (NOOH) proceeding in late 2023, the FDA issued feedback for sotagliflozin resbmisssion, noted March 11, 2024.",363.4M
Add to portfolio,,,,,,,,
AMGN,Amgen Inc.,273.41,Otezla - (SPROUT),Plaque psoriasis in pediatric patients ,Phase 3,11/03/2024 ET,"Phase 3 results data presented at AAD reported that 56.3% of patients who received Otezla through week 52 achieved static Physician Global Assessment (sPGA) response, noted March 11, 2024.",538.36M
Add to portfolio,,,,,,,,
INCY,Incyte Corporation,60.79,Ruxolitinib Cream (Opzelura),Adults with hidradenitis suppurativa (HS) ,Phase 2,11/03/2024 ET,"Phase 2 additional data reported that more than three quarters (79.2%) of on-treatment patients achieved at least a 50% reduction in AN count (AN50), 54.2% achieved a 75% reduction (AN75), 20.8% achieved 90% reduction (AN90), and 20.8% achieved complete clearance (100% reduction, AN100), surpassing the 56.3%, 25.0%, 12.5% and 12.5% reductions, respectively, in the vehicle control group, noted March 11, 2024. read less",195.28M
Add to portfolio,,,,,,,,
INCY,Incyte Corporation,60.79,Povorcitinib (INCB54707),Prurigo Nodularis ,Phase 2,11/03/2024 ET,"Phase 2 data reported that the trial met its primary endpoint, noted March 11, 2024.",195.28M
Add to portfolio,,,,,,,,
ASLN,ASLAN Pharmaceuticals Limited,13.04,Eblasakimab (ASLAN004) - (TREK-DX),Atopic dermatitis (AD) ,Phase 2b,11/03/2024 ET,"Phase 2b preliminary review of blinded data from 22 patients treated to date, 45% (10/22) of patients saw at least a 90% reduction in their EASI score (EASI-90) and 50% (11/22) of patients achieved a vIGA score of 0 or 1 (clear or almost clear skin) after 16 weeks, noted March 11, 2024. read less",2.83M
Add to portfolio,,,,,,,,
NRIX,Nurix Therapeutics Inc.,14.13,NX-2127,"B-cell malignancies, chronic lymphocytic leukemia (CLL) ",Phase 1b,11/03/2024 ET,"Phase 1a/1b clinical hold lifted by the FDA, noted March 11, 2024.",76.88M
Add to portfolio,,,,,,,,
SONN,Sonnet BioTherapeutics Holdings Inc.,2.07,SON-080 - (SB211),Chemotherapy Induced Peripheral Neuropathy (CIPN) ,Phase 1/2,11/03/2024 ET,"Phase 1b/2a cleared after review by the independent DSMB, noted March 11, 2024.",6.75M
Add to portfolio,,,,,,,,
APRE,Aprea Therapeutics Inc.,6.77,APR-1051 - (ACESOT-1051),Solid tumors ,IND-Enabling,11/03/2024 ET,"IND cleared by the FDA, noted March 11, 2024.",5.83M
Add to portfolio,,,,,,,,
LLY,Eli Lilly and Company,733.16,Lebrikizumab,Moderate-to-severe atopic dermatitis ,Phase 3,11/03/2024 ET,"Phase 3 data reported that 68% of people experienced significant improvement of at least 75% in disease extent and severity (EASI-75), noted March 11, 2024.",946.46M
Add to portfolio,,,,,,,,
VTYX,Ventyx Biosciences Inc.,8.04,VTX3232,Parkinson's disease ,Phase 1,11/03/2024 ET,"Phase 1 clinical update presented at virtual investor event showed that treatment was well-tolerated with no dose-limiting toxicities identified. All treatment-emergent adverse events were graded mild or moderate, noted March 11, 2024. read less",71.31M
Add to portfolio,,,,,,,,
VTYX,Ventyx Biosciences Inc.,8.04,VTX2735,"Healthy volunteers, cryopyrin-associated periodic syndrome (CAPS) ",Phase 2,11/03/2024 ET,"Phase 2 trial ongoing, with clinical update presented at virtual investor event showed that treatment demonstrated clinically meaningful improvements in disease activity, including an 85% mean reduction in the Key Symptom Score during Treatment Period 1, noted March 11, 2024. read less",71.31M
Add to portfolio,,,,,,,,
VTYX,Ventyx Biosciences Inc.,8.04,Tamuzimod (VTX002),Ulcerative Colitis (UC) ,Phase 2,11/03/2024 ET,"Phase 2 OLE clinical update presented at the virtual investor event data continues to support the potentially differentiated profile of VTX002 in ulcerative colitis, with robust rates of clinical remission and endoscopic remission observed among participants completing 52 weeks of treatment with VTX002, noted March 11, 2024. read less",71.31M
Add to portfolio,,,,,,,,
NVCR,NovoCure Limited,15.99,Tumor Treating Fields (TTFields) - (INNOVATE-3),Ovarian cancer ,Phase 3,11/03/2024 ET,"Phase 3 exploratory subgroup analysis finds that pegylated liposomal doxorubicin (PLD) -naïve patients randomized to receive TTFields therapy and paclitaxel had a median overall survival of 16.0 months compared to 11.7 months in PLD-naïve patients treated with paclitaxel alone, noted March 11, 2024. read less",111.8M
Add to portfolio,,,View Clinical Trial Data,,,,,
TVTX,Travere Therapeutics Inc.,7.99,FILSPARI (sparsentan),IgA nephropathy (IgAN) ,sNDA Filing,11/03/2024 ET,"sNDA submitted to the FDA, noted March 11, 2024.",89.14M
Add to portfolio,,,,,,,,
LGND,Ligand Pharmaceuticals Incorporated,72.25,FILSPARI (sparsentan),IgA nephropathy (IgAN) ,sNDA Filing,11/03/2024 ET,"sNDA submitted to the FDA, noted March 11, 2024.",19.6M
Add to portfolio,,,,,,,,
JNJ,Johnson & Johnson,159.92,PN-235 (JNJ-77242113) - (FRONTIER 1),Plaque psoriasis ,Phase 2b,11/03/2024 ET,"Phase 2b data presented at AAD reported that response rates were maintained from Week 16 to Week 52 with the highest PASI 75 response observed in the 100 mg twice daily group (78.6% at 16 weeks and 76.2% at 52 weeks), noted March 11, 2024 read less",2.41B
Add to portfolio,,,View Clinical Trial Data,,,,,
PTGX,Protagonist Therapeutics Inc.,30.12,PN-235 (JNJ-77242113) - (FRONTIER 1),Plaque psoriasis ,Phase 2b,11/03/2024 ET,"Phase 2b data presented at AAD reported that response rates were maintained from Week 16 to Week 52 with the highest PASI 75 response observed in the 100 mg twice daily group (78.6% at 16 weeks and 76.2% at 52 weeks), noted March 11, 2024 read less",62.21M
Add to portfolio,,,View Clinical Trial Data,,,,,
JNJ,Johnson & Johnson,159.92,PN-235 (JNJ-77242113) - (FRONTIER 1),Plaque psoriasis ,Phase 2b,11/03/2024 ET,"Phase 2b data presented at AAD reported that response rates were maintained from Week 16 to Week 52 with the highest PASI 75 response observed in the 100 mg twice daily group (78.6% at 16 weeks and 76.2% at 52 weeks), noted March 11, 2024. read less",2.41B
Add to portfolio,,,View Clinical Trial Data,,,,,
PTGX,Protagonist Therapeutics Inc.,30.12,PN-235 (JNJ-77242113) - (FRONTIER 1),Plaque psoriasis ,Phase 2b,11/03/2024 ET,"Phase 2b data presented at AAD reported that response rates were maintained from Week 16 to Week 52 with the highest PASI 75 response observed in the 100 mg twice daily group (78.6% at 16 weeks and 76.2% at 52 weeks), noted March 11, 2024. read less",62.21M
Add to portfolio,,,View Clinical Trial Data,,,,,
ALMS,Alumis Inc.,—,Izokibep,Hidradenitis Suppurativa (HS) ,Phase 2b,11/03/2024 ET,"Phase 2b long-term data reported that data demonstrated no evidence of increased safety liability with longer-term treatment and increased duration of therapy was associated with further clinical improvements over time, noted March 11, 2024. read less",104.06M
Add to portfolio,,,,,,,,
ALMS,Alumis Inc.,—,Izokibep,Psoriatic arthritis (PsA) ,Phase 2,11/03/2024 ET,"Phase 2 data reported that the trial met its primary endpoint, noted March 11, 2024.",104.06M
Add to portfolio,,,,,,,,
VTRS,Viatris Inc.,11.84,Glatiramer (GA Depot),Primary Progressive Multiple Sclerosis (PPMS) ,CRL,11/03/2024 ET,"CRL announced March 11, 2024.",1.17B
Add to portfolio,,,,,,,,
ACAD,ACADIA Pharmaceuticals Inc.,24.13,NUPLAZID (pimavanserin) - (Advance-2),Adjunctive treatment in patients with negative symptoms of schizophrenia ,Phase 3,11/03/2024 ET,"Phase 3 study did not meet its primary endpoint, noted March 11, 2024.",168.71M
Add to portfolio,,,View Clinical Trial Data,,,,,
TERN,Terns Pharmaceuticals Inc.,7.43,TERN-701 - (CARDINAL),Chronic myeloid leukemia (CML) ,Phase 1,11/03/2024 ET,"Orphan drug designation grated by the FDA, noted March 11, 2024",87.51M
Add to portfolio,,,ODD,,,,,
LRMR,Larimar Therapeutics Inc.,8.63,Nomlabofusp (CTI-1601),Friedreich’s ataxia (FA) ,Phase 2,11/03/2024 ET,"Phase 2 OLE dosing initiated, noted March 11, 2024.",85.59M
Add to portfolio,,,ODD,,,,,
PSTV,PLUS THERAPEUTICS Inc.,1.61,REYOBIQ (rhenium Re186 obisbemeda) - (ReSPECT-LM),Leptomeningeal metastases (LM) ,Phase 1,11/03/2024 ET,"Phase 1 Cohort 5 dosing completed, noted March 11, 2024.",99.26M
Add to portfolio,,,FTD,,,,,
,,,ODD,,,,,
NVS,Novartis AG,—,Farabursen (RGLS8429) (MAD),Autosomal Dominant Polycystic Kidney Disease (ADPKD) ,Phase 1b,12/03/2024 ET,"Phase 1b MAD data from the second cohort, reported that a mechanistic dose response was observed at a 2mg/kg dose level based on urinary biomarker analyses, noted March 12, 2024.",1.98B
Add to portfolio,,,ODD,,,,,
PFE,Pfizer Inc.,27.23,ADCETRIS (brentuximab vedotin) with lenalidomide and rituximab - (ECHELON-3),Relapsed/refractory diffuse large B-cell lymphoma (DLBCL) ,Phase 3,12/03/2024 ET,"Phase 3 data reported a statistically significant and clinically meaningful improvement in overall survival (OS) compared to lenalidomide and rituximab plus placebo, noted March 12, 2024.",5.69B
Add to portfolio,,,,,,,,
KANT,Kineta Inc.,—,KVA12123 with KEYTRUDA (pembrolizumab) - (VISTA-101),Solid tumors ,Phase 1/2,12/03/2024 ET,"Phase 1/2 initial data reported a partial Response in 1 patient with a PD-L1 negative mucoepidermoid carcinoma and a 54% reduction in target lesions and a complete response in non-target lesions, note … read more",13.54M
Add to portfolio,,,,,,,,
CRNX,Crinetics Pharmaceuticals Inc.,40.75,Paltusotine,Carcinoid syndrome associated with neuroendocrine tumors (NETs) ,Phase 2,12/03/2024 ET,"Phase data from treatment demonstrated rapid and sustained reductions in the frequency and severity of flushing episodes and bowel movements. Results confirm initial positive data previously reported, … read more",94.18M
Add to portfolio,,,,,,,,
CYBN,Cybin Inc.,0.42,CYB003 - (EXTEND and EMBRACE),Major Depressive Disorder (MDD) and Alcohol use disorder (AUD) ,Phase 2,13/03/2024 ET,"Additional Phase 2 durability data reported with significant improvement in depression symptoms at four months with 75% of patients in remission from depression after two doses, noted March 13, 2024.",23.59M
Add to portfolio,,,BTD,,,,,
SLN,Silence Therapeutics Plc,25.61,Zerlasiran (formerly SLN360) - (ALPACAR-360),Cardiovascular diseases and Polycythemia vera ,Phase 2,13/03/2024 ET,"Phase 2 study met its primary endpoint, noted March 13, 2024.",46.8M
Add to portfolio,,,,,,,,
PRTC,PureTech Health plc,25.81,LYT-200,Relapsed/refractory AML and MDS ,Phase 1b,13/03/2024 ET,"Phase 1b orphan drug designation granted by FDA, noted March 13, 2024.",24.17M
Add to portfolio,,,ODD,,,,,
,,,FTD,,,,,
SGMO,Sangamo Therapeutics Inc.,0.79,STAC-BBB,Neurological diseases ,Preclinical,13/03/2024 ET,"Preclinical data reported robust penetration of the BBB and widespread transgene expression throughout the brain, and the treatment was well tolerated in NHPs, with no notable treatment related pathological findings in brain, spinal cord or peripheral tissues, noted March 13, 2024. read less",301.71M
Add to portfolio,,,,,,,,
LLY,Eli Lilly and Company,—,STAC-BBB,Neurological diseases ,Preclinical,13/03/2024 ET,"Preclinical data reported robust penetration of the BBB and widespread transgene expression throughout the brain, and the treatment was well tolerated in NHPs, with no notable treatment related pathological findings in brain, spinal cord or peripheral tissues, noted March 13, 2024. read less",946.46M
Add to portfolio,,,,,,,,
XOMA,XOMA Royalty Corporation,25.61,Mezagitamab (TAK-079) - (TAK-079-1004),Primary Immune Thrombocytopenia ,Phase 2,13/03/2024 ET,"Phase 2 topline data reported that treatment was safe and well tolerated, with all mezagitamab doses tested demonstrated a higher platelet response rate than placebo, noted March 13, 2024.",12.09M
Add to portfolio,,,,,,,,
TAK,Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of),14.13,Mezagitamab (TAK-079) - (TAK-079-1004),Primary Immune Thrombocytopenia ,Phase 2,13/03/2024 ET,"Phase 2 topline data reported that treatment was safe and well tolerated, with all mezagitamab doses tested demonstrated a higher platelet response rate than placebo, noted March 13, 2024.",3.15B
Add to portfolio,,,,,,,,
PHIO,Phio Pharmaceuticals Corp.,9.18,PH-762,Cutaneous Squamous Cell Carcinoma ,Phase 1b,13/03/2024 ET,"Phase 1b new trial sites opened, noted March 13, 2024.",5.73M
Add to portfolio,,,,,,,,
SPRB,Spruce Biosciences Inc.,5.19,Tildacerfont - (CAHmelia-203),Congenital Adrenal Hyperplasia (poor disease control) ,Phase 2b,13/03/2024 ET,"Phase 2b top-line data reported that trial did not meet its primary endpoint, noted March 13, 2024.",563.04K
Add to portfolio,,,View Clinical Trial Data,,,,,
SPRB,Spruce Biosciences Inc.,5.19,Tildacerfont - (CAHptain-205),Pediatric Classic Congenital Adrenal Hyperplasia ,Phase 2,13/03/2024 ET,"Phase 2 top-line data reported that 73% of all patients (22 of 30 patients) met the efficacy endpoint of A4 or GC reduction from baseline at 12 weeks with no treatment-related SAEs reported, noted March 13, 2024. read less",563.04K
Add to portfolio,,,,,,,,
MIRM,Mirum Pharmaceuticals Inc.,27.77,LIVMARLI (maralixibat),Progressive Familial Intrahepatic Cholestasis (PFIC) ,Approved,13/03/2024 ET,"Approval announced March 13, 2024.",50.24M
Add to portfolio,,,View Clinical Trial Data,,,,,
CALC,CalciMedica Inc.,4.34,Auxora - (KOURAGE),Acute kidney injury (AKI) with associated acute hypoxemic respiratory failure (AHRF) ,Preclinical,13/03/2024 ET,"Preclinical data consistent with clinical observations made with Auxora, supporting the KOURAGE trial, noted March 13, 2024.",13.97M
Add to portfolio,,,,,,,,
IMNN,Imunon Inc.,0.87,IMNN-101 - (IMUNON),SARS-CoV-2 variant XBB.1.5 ,IND-Enabling,13/03/2024 ET,"IND filed to FDA, noted March 13, 2024.",2.52M
Add to portfolio,,,,,,,,
IONS,Ionis Pharmaceuticals Inc.,43.16,ION224,"metabolic dysfunction-associated steatohepatitis (MASH), previously referred to as nonalcoholic steatohepatitis (NASH) ",Phase 2,13/03/2024 ET,"Phase 2 achieved statistically significant liver histologic improvement as measured by at least a 2-point reduction in NAFLD Activity Score (NAS), noted March 13, 2024.",159.39M
Add to portfolio,,,View Clinical Trial Data,,,,,
PCRX,Pacira BioSciences Inc.,30.29,PCRX-201 (enekinragene inzadenovec) - (ASCEND),Osteoarthritis of the knee ,Phase 1,13/03/2024 ET,"Additional 104-week data presented at ACR reported MRI B-score change from baseline ranged from 2.3 to 5.4 in the not pretreated cohort and from 2.6 to 5.9 in the steroid pretreated cohort, noted November 17, 2024. RMAT designation granted March 13, 2024. read less",44.93M
Add to portfolio,,,RMAT,,,,,
OCGN,"Ocugen, Inc.",1.04,OCU410 - (ArMaDa),Geographic Atrophy (GA) ,Phase 1/2,13/03/2024 ET,"Phase 1/2 dosing initiated March 13, 2024.",292.3M
Add to portfolio,,,,,,,,
IMRX,Immuneering Corporation,2.9,Atebimetinib (IMM-1-104) + mGnP,"Solid tumors, pancreatic cancer, melanoma ",Phase 1,14/03/2024 ET,"Phase 1 topline data reported that 100% suppression of acquired RAS alterations was observed in evaluable patients profiled for ctDNA and treated with IMM-1-104, with 53% of patients had ≥ 1 target lesion(s) regress when treated with IMM-1-104 at either 320mg or 240mg, noted March 14, 2024. read less",36.32M
Add to portfolio,,,FTD,,,,,
,,,ODD,,,,,
NVCT,Nuvectis Pharma Inc.,9.15,NXP800,Ovarian Clear Cell Carcinoma ,Phase 1b,14/03/2024 ET,"Phase 1b preliminary data reported that a 33% response rate and 100% disease control rate, defined as partial response (""PR"") plus stable disease (""SD""), in patients evaluated for efficacy, noted March 14, 2024. read less",25.46M
Add to portfolio,,,FTD,,,,,
,,,ODD,,,,,
GERN,Geron Corporation,1.75,RYTELO (imetelstat) - (IMerge),Myelodysplastic syndromes with transfusion-dependent (TD) anemia ,NDA Filing,14/03/2024 ET,"Advisory committee voted 12 to 2 in favor, noted March 14, 2024.",638.02M
Add to portfolio,,,View Clinical Trial Data,,,,,
MDGL,Madrigal Pharmaceuticals Inc.,243.57,Rezdiffra (resmetirom),Non-alcoholic steatohepatitis (NASH) with liver fibrosis (also known as MASH) ,Approved,14/03/2024 ET,"Approved on March 14, 2024.",22.29M
Add to portfolio,,,BTD,,,,,
,,,View Clinical Trial Data,,,,,
BGNE,BeiGene Ltd.,168.9,TEVIMBRA,Esophageal Squamous Cell Carcinoma (ESCC) ,Approved,14/03/2024 ET,"Approved March 14, 2024.",106.62M
Add to portfolio,,,,,,,,
ONC,BeOne Medicines Ltd.,—,TEVIMBRA,Esophageal Squamous Cell Carcinoma (ESCC) ,Approved,14/03/2024 ET,"Approved March 14, 2024.",110.03M
Add to portfolio,,,,,,,,
BMY,Bristol-Myers Squibb Company,51.11,Breyanzi (lisocabtagene maraleucel),Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) ,Approved,14/03/2024 ET,"Approved March 14, 2024.",2.04B
Add to portfolio,,,,,,,,
BGNE,BeiGene Ltd.,168.9,Tislelizumab-jsgr (Tevimbra),Esophageal squamous cell carcinoma (ESCC) ,Approved,14/03/2024 ET,"Approved March 14, 2024.",106.62M
Add to portfolio,,,,,,,,
ONC,BeOne Medicines Ltd.,—,Tislelizumab-jsgr (Tevimbra),Esophageal squamous cell carcinoma (ESCC) ,Approved,14/03/2024 ET,"Approved March 14, 2024.",110.03M
Add to portfolio,,,,,,,,
AQST,Aquestive Therapeutics Inc.,6.09,Anaphylm (AQ-109)- (103),Anaphylaxis ,Phase 3,15/03/2024 ET,"Phase 3 trial met all primary and secondary pharmacokinetic endpoints, noted March 15, 2024.",99.72M
Add to portfolio,,,,,,,,
JSPR,Jasper Therapeutics Inc.,25.08,Briquilimab (JSP191),Fanconi Anemia (FA) ,Phase 1/2,15/03/2024 ET,"Additional Phase 1/2 data reported that all six patients with Fanconi Anemia treated with briquilimab achieved full donor engraftment and full blood count recovery and briquilimab was well tolerated, noted March 15, 2024. read less",16.25M
Add to portfolio,,,,,,,,
JNJ,Johnson & Johnson,156.89,CARVYKTI (ciltacabtagene autoleucel) - (CARTITUDE-4),Multiple Myeloma ,BLA Filing,15/03/2024 ET,"Adcom resulted votes 11 to 0 supporting favorable risk-benefit assessment, noted March 15, 2024.",2.41B
Add to portfolio,,,,,,,,
LEGN,Legend Biotech Corporation,64.02,CARVYKTI (ciltacabtagene autoleucel) - (CARTITUDE-4),Multiple Myeloma ,BLA Filing,15/03/2024 ET,"Adcom resulted votes 11 to 0 supporting favorable risk-benefit assessment, noted March 15, 2024.",183.65M
Add to portfolio,,,,,,,,
OPTN,OptiNose Inc.,1.88,XHANCE,Chronic sinusitis ,Approved,15/03/2024 ET,"Approved March 15, 2024.",10.13M
Add to portfolio,,,View Clinical Trial Data,,,,,
TSVT,2seventy bio Inc.,4.01,Abecma (idecabtagene vicleucel; ide-cel),Multiple Myeloma ,BLA Filing,15/03/2024 ET,"AdCom ODAC noted positively (8-3) that Abecma (idecabtagene vicleucel) demonstrated a favorable benefit/risk profile for patients, noted March 15, 2024.",53.23M
Add to portfolio,,,View Clinical Trial Data,,,,,
BMY,Bristol-Myers Squibb Company,50.97,Abecma (idecabtagene vicleucel; ide-cel),Multiple Myeloma ,BLA Filing,15/03/2024 ET,"AdCom ODAC noted positively (8-3) that Abecma (idecabtagene vicleucel) demonstrated a favorable benefit/risk profile for patients, noted March 15, 2024.",2.04B
Add to portfolio,,,View Clinical Trial Data,,,,,
PHVS,Pharvaris N.V.,23.35,Deucrictibant (PHVS416) - (CHAPTER-3),Hereditary angioedema - prophylactic use ,Phase 2,15/03/2024 ET,"Phase 2 full results presented at ITACA reported that treatment significantly reduced the monthly attack rate, noted March 15, 2024.",54.49M
Add to portfolio,,,,,,,,
WHWK,Whitehawk Therapeutics Inc.,—,Nab-sirolimus - (AMPECT),Malignant PEComa (Perivascular epithelioid cell tumour) ,Phase 2,18/03/2024 ET,"Phase 2 data presented at SGO reported that the overall response rate to nab-sirolimus for the subgroup was 37.5% (6/16), noted March 18, 2024.",47.13M
Add to portfolio,,,,,,,,
AZN,AstraZeneca PLC,65.85,Imfinzi (durvalumab) in combination with carboplatin and paclitaxel,Endometrial cancer (EC) ,Phase 3,18/03/2024 ET,"Additional Phase 3 data reported that treatment demonstrated an improvement in multiple key secondary efficacy endpoints, particularly in patients with mismatch repair proficient (pMMR) advanced or recurrent endometrial cancer compared to chemotherapy alone, noted March 18, 2024. read less",3.1B
Add to portfolio,,,,,,,,
ALGS,Aligos Therapeutics Inc.,0.92,ALG-055009 - (HERALD),Metabolic dysfunction-associated steatohepatitis (MASH) ,Phase 2a,18/03/2024 ET,"Phase 2a study initiated, noted March 18, 2024.",6.15M
Add to portfolio,,,,,,,,
IVA,Inventiva S.A.,4.36,Lanifibranor in combination with empagliflozin (Jardiance1) - (LEGEND),"Metabolic dysfunction-associated steatohepatitis (MASH), and type 2 diabetes (T2D) ",Phase 2a,18/03/2024 ET,"Phase 2a achieved its primary efficacy endpoint by significantly lowering HbA1c level in both the lanifibranor arm and in the lanifibranor with empagliflozin arm compared to placebo, noted March 18, 2 … read more",95.66M
Add to portfolio,,,,,,,,
PMVP,PMV Pharmaceuticals Inc.,1.67,Rezatapopt (PC14586) - (PYNNACLE),Solid tumors ,Phase 1/2,18/03/2024 ET,"Phase 1/2 part 1 analysis showed promising efficacy of rezatapopt (PC14586) in heavily pre-treated patients, noted March 18, 2024",52.99M
Add to portfolio,,,FTD,,,,,
MRK,Merck & Company Inc.,120.71,Rezatapopt (PC14586) - (PYNNACLE),Solid tumors ,Phase 1/2,18/03/2024 ET,"Phase 1/2 part 1 analysis showed promising efficacy of rezatapopt (PC14586) in heavily pre-treated patients, noted March 18, 2024",2.5B
Add to portfolio,,,FTD,,,,,
PBM,Psyence Biomedical Ltd.,1.25,Psilocybin,Adjustment Disorder due to a recent cancer diagnosis ,Preclinical,18/03/2024 ET,"Recent study published in the journal Molecular Psychiatry, suggests that nature-derived psilocybin may be demonstrably more therapeutic than its synthetic analog, noted March 18, 2024.",1.87M
Add to portfolio,,,,,,,,
JNJ,Johnson & Johnson,154.94,EDURANT (rilpivirine),HIV in pediatric patients (2-12 years) ,Approved,19/03/2024 ET,"Approved March 19, 2024.",2.41B
Add to portfolio,,,,,,,,
CRNX,Crinetics Pharmaceuticals Inc.,45.18,PALSONIFY (paltusotine),Acromegaly ,Phase 3,19/03/2024 ET,"Phase 3 topline data reported that the trial met its primary endpoint, noted March 19, 2024.",94.18M
Add to portfolio,,,,,,,,
DTIL,Precision BioSciences Inc.,12,PBGENE-PMM,Primary mitochondrial myopathies ,Preclinical,19/03/2024 ET,"Preclinical data presented at Mitochondrial Medicine Therapeutic Development (MMTD) annual conference demonstrated ARCUS' ability to efficiently eliminate mutant mitochondrial DNA without nuclear off-target editing, noted March 19, 2024. read less",11.79M
Add to portfolio,,,,,,,,
AXSM,Axsome Therapeutics Inc.,76.87,Sunosi (Solriamfetol) - (PARADIGM),Major depressive disorder (MDD) ,Phase 3,19/03/2024 ET,"Phase 3 initiated, noted March 19, 2024.",49.9M
Add to portfolio,,,,,,,,
CERS,Cerus Corporation,2.04,INTERCEPT (ReCePI),Patients undergoing complex cardiac surgery procedures ,Phase 3,19/03/2024 ET,"Phase 3 trial met the primary efficacy endpoint demonstrating non-inferiority of the incidence of acute kidney injury, noted March 19, 2024.",191.7M
Add to portfolio,,,View Clinical Trial Data,,,,,
KRBP,Kiromic BioPharma Inc.,2.83,Deltacel-01 - (KB-GDT-01),Stage 4 Metastatic Non-Small Cell Lung Cancer ,Phase 1,19/03/2024 ET,"Phase 1 results reported that stable disease status was confirmed, and the new onset metastatic disease, which completely resolved on repeat MRI imaging performed six weeks from the beginning of treat … read more",1.53M
Add to portfolio,,,FTD,,,,,
SEEL,Seelos Therapeutics Inc.,5.2,SLS-005 (IV trehalose) - (HEALEY ALS Platform Trial),Amyotrophic lateral sclerosis (ALS) ,Phase 2/3,19/03/2024 ET,"Phase 2/3 trial did not meet the primary and secondary endpoint in the Full Analysis Set (FAS), noted March 19, 2024.",435.96K
Add to portfolio,,,ODD,,,,,
,,,FTD,,,,,
,,,View Clinical Trial Data,,,,,
HOTH,Hoth Therapeutics Inc.,1.35,HT-ALZ,Alzheimer's Disease ,Preclinical,19/03/2024 ET,"Preclinical data research presented compelling evidence of HT-ALZ's capacity to improve memory tasks related to the hippocampus and sensorimotor gating, showcasing an important step forward in Alzheim … read more",13.26M
Add to portfolio,,,,,,,,
JSPR,Jasper Therapeutics Inc.,26.24,Subcutaneous briquilimab - (SPOTLIGHT),Chronic inducible urticaria (CIndU) ,Phase 1/2,19/03/2024 ET,"Phase 1b/2a patient enrollment commenced, noted March 19, 2024",16.25M
Add to portfolio,,,,,,,,
ALIM,Alimera Sciences Inc.,4.05,ILUVIEN - (New Day),Visual Acuity Loss due to Radiation Retinopathy ,Phase 1,19/03/2024 ET,"Phase 1 first patient dosed, noted March 19, 2024.",54.38M
Add to portfolio,,,,,,,,
LGND,Ligand Pharmaceuticals Incorporated,72.21,V116 - (STRIDE-6),Pneumococcal Conjugate Vaccine ,Phase 3,19/03/2024 ET,"Phase 3 extensive data reaffirms confidence in the potential clinical value V116 could provide to a range of adult populations, noted March 19, 2024.",19.6M
Add to portfolio,,,,,,,,
MRK,Merck & Company Inc.,121.47,V116 - (STRIDE-6),Pneumococcal Conjugate Vaccine ,Phase 3,19/03/2024 ET,"Phase 3 extensive data reaffirms confidence in the potential clinical value V116 could provide to a range of adult populations, noted March 19, 2024.",2.5B
Add to portfolio,,,,,,,,
CVM,Cel-Sci Corporation,2.03,CEL-4000,Rheumatoid arthritis (RA) ,Preclinical,19/03/2024 ET,"Preclinical data published at the scientific journal Frontiers in Immunology showed that treatment may deliver safe and effective therapy for RA by rebalancing the inflammatory response, without weak … read more",6.88M
Add to portfolio,,,,,,,,
TAK,Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of),14.12,ICLUSIG (ponatinib) - (PhALLCON),Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) ,Approved,19/03/2024 ET,"FDA approved on March 19, 2024.",3.15B
Add to portfolio,,,,,,,,
TSHA,Taysha Gene Therapies Inc.,2.25,TSHA-102 - (REVEAL),Rett syndrome ,Phase 1/2,19/03/2024 ET,Phase 1/2 clinical data from cohort one (low dose) showed that dosing was well-tolerated with no treatment-emergent SAEs as of 35-week assessment. Data from second adult patient showed TSHA-102 (low d … read more,272.79M
Add to portfolio,,,FTD,,,,,
,,,ODD,,,,,
,,,RPDD,,,,,
,,,RMAT,,,,,
,,,BTD,,,,,
AEON,AEON Biopharma Inc. Class A,14.4,ABP-450 (prabotulinumtoxinA),Chronic Migraine (prophylaxis) ,Phase 2,19/03/2024 ET,"FDA and AEON align on the design and endpoints for the proposed pivotal Phase 3 trials for the preventive treatment of both episodic and chronic migraine, noted March 19, 2024.",11.64M
Add to portfolio,,,,,,,,
BMY,Bristol-Myers Squibb Company,50.52,Opdivo (nivolumab) plus Yervoy (ipilimumab) - (CheckMate -9DW),Hepatocellular carcinoma (HCC) ,Phase 3,20/03/2024 ET,"Phase 3 trial met primary endpoint, noted March 20, 2024.",2.04B
Add to portfolio,,,,,,,,
ALMS,Alumis Inc.,—,Subcutaneous lonigutamab - (LONGITUDE),Thyroid eye disease (TED) ,Phase 1/2,20/03/2024 ET,"Phase 1/2 proof of concept data exhibited rapid improvements demonstrated for proptosis, clinical activity scores, and diplopia versus placebo with a favorable safety profile, noted March 20, 2024.",104.06M
Add to portfolio,,,,,,,,
ENTX,Entera Bio Ltd.,1.52,N-Tab (GLP-2 agonist),Short Bowel Syndrome ,Preclinical,20/03/2024 ET,"PK data reported that the trial objective were met, with oral GLP-2 tablets exhibiting significant systemic exposure, noted March 20, 2024.",45.66M
Add to portfolio,,,,,,,,
OPK,Opko Health Inc.,0.89,N-Tab (GLP-2 agonist),Short Bowel Syndrome ,Preclinical,20/03/2024 ET,"PK data reported that the trial objective were met, with oral GLP-2 tablets exhibiting significant systemic exposure, noted March 20, 2024.",793.78M
Add to portfolio,,,,,,,,
TFFP,TFF Pharmaceuticals Inc - Ordinary Shares,7.95,TFF TAC (Tacrolimus Inhalation Powder),Lung transplant (post) ,Phase 2,20/03/2024 ET,"Phase 2 data reported that eight out of eight patients have successfully transitioned from oral Tacrolimus to TFF TAC, with favorable safety results with no mortality or discontinuations due to advers … read more",4.44M
Add to portfolio,,,,,,,,
BNOX,Bionomics Limited,1,BNC210 - (ATTUNE),Post-Traumatic Stress Disorder (PTSD) ,Phase 2b,21/03/2024 ET,Phase 2b results reported that BNC210 led to statistically significant improvement (p<0.05) in the following secondary endpoints: depressive symptoms as measured by the Montgomery-Åsberg Depression Ra … read more,2.36M
Add to portfolio,,,FTD,,,,,
MRK,Merck & Company Inc.,122.88,KEYTRUDA + LYNPARZA - (KEYLYNK-006),Metastatic nonsquamous non-small cell lung cancer (NSCLC) ,Phase 3,21/03/2024 ET,"Phase 3 data reported that the trial did not meet its dual primary endpoints of overall survival (OS) and progression-free survival (PFS), noted March 21, 2024.",2.5B
Add to portfolio,,,,,,,,
PHIO,Phio Pharmaceuticals Corp.,7.56,INTASYL,Hematological malignancies ,Preclinical,21/03/2024 ET,"Preclinical data presented at Immunotherapy of Cancer Conference (ITOC10) reported a consistent silencing of Cbl-b mRNA, which has been shown to limit NK cell activation, noted March 21, 2024.",5.73M
Add to portfolio,,,,,,,,
VRTX,Vertex Pharmaceuticals Incorporated,415.71,VX-407,"Autosomal Dominant Polycystic Kidney Disease (ADPKD), healthy volunteers ",IND-Enabling,21/03/2024 ET,"IND cleared by the FDA, noted March 21, 2024.",256.39M
Add to portfolio,,,,,,,,
ALPN,Alpine Immune Sciences Inc.,41.6,ALPN-303 - (DENALI),Systemic lupus erythematosus (SLE) ,Preclinical,21/03/2024 ET,"Preclinical data presented at SLEuro demonstrated greater reductions in disease activity in a mouse model of lupus compared to WT TACI-Ig or B cell depletion, noted March 21, 2024.",68.6M
Add to portfolio,,,,,,,,
NKTX,Nkarta Inc.,12.98,NKX101,Acute myeloid leukemia / myelodysplastic syndromes ,Phase 1,21/03/2024 ET,"Phase 1 trial update reported that enrollment has been closed, with the aggregate CR/CRi rate (5 of 20 patients) was lower than what had been observed in the first 6 patients in the cohort, noted Marc … read more",71.02M
Add to portfolio,,,ODD,,,,,
ABBV,AbbVie Inc.,175.15,Mirvetuximab - (MIRASOL),Cancer - ovarian cancer and relapsed endometrial cancer ,Approved,22/03/2024 ET,"Approved March 22, 2024.",1.77B
Add to portfolio,,,View Clinical Trial Data,,,,,
OKYO,OKYO Pharma Limited,1.54,urcosimod (OK-101),Dry Eye Disease (DED) ,Phase 2,22/03/2024 ET,"Phase 2 additional efficacy data showed a statistically significant and durable reduction in ocular pain statistically significant improvement in Tear Film Break-Up Time (TFBUT) throughout the study, … read more",33.84M
Add to portfolio,,,,,,,,
SMMT,Summit Therapeutics Inc.,3.37,Ivonescimab plus chemotherapy - (AK112-201),Non-small cell lung cancer (NSCLC) ,Phase 2,22/03/2024 ET,Phase 2 combination data shared at the 2024 European Lung Cancer Congress (ELCC 2024) showed that patients experienced a median PFS of 11.1 months (95% CI: 9.5 – 16.3 months). The frequency of treatme … read more,744.44M
Add to portfolio,,,,,,,,
SMMT,Summit Therapeutics Inc.,3.37,ivonescimab (AK112-202),Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) and Brain Metastases ,Phase 2,22/03/2024 ET,Phase 2 monotherapy data shared at the 2024 European Lung Cancer Congress (ELCC 2024) showed that treatment led to intracranial responses among 34% of patients with brain metastases at baseline – 23% … read more,744.44M
Add to portfolio,,,,,,,,
ABBV,AbbVie Inc.,175.15,ELAHERE (mirvetuximab soravtansine-gynx),Platinum-Resistant Ovarian Cancer ,Approved,22/03/2024 ET,"Full approval announced March 22, 2024.",1.77B
Add to portfolio,,,,,,,,
IVVD,Invivyd Inc.,4.36,PEMGARDA (VYD222 (pemivibart)) - (CANOPY),COVID-19 Prevention ,Approved,22/03/2024 ET,"EUA approval announced March 22, 2024.",120.14M
Add to portfolio,,,,,,,,
IVVD,Invivyd Inc.,4.36,PEMGARDA (VYD222 (pemivibart)) - (CANOPY),COVID-19 Prevention ,Phase 3,22/03/2024 ET,"Additional Phase 3 data reported that only one patient (0.03%) was symptomatic after 90 days, noted March 22, 2024.",120.14M
Add to portfolio,,,,,,,,
ESPR,Esperion Therapeutics Inc.,2.29,NEXLETOL (bempedoic acid) - (CLEAR Outcomes),Cardiovascular Diseases ,Approved,22/03/2024 ET,"Approved March 22, 2024.",201.62M
Add to portfolio,,,View Clinical Trial Data,,,,,
TELO,Telomir Pharmaceuticals Inc.,6.49,Telomir-1,Age-related conditions ,Preclinical,22/03/2024 ET,"Poster presentation delivers pre-clinical results that demonstrate that its lead development product, Telomir-1, elongates telomere caps on human normal embryonic fibroblast cells, noted March 22, 202 … read more",32.28M
Add to portfolio,,,,,,,,
SLRX,Salarius Pharmaceuticals Inc.,4.96,Seclidemstat,Ewing's and other FET-rearranged sarcomas ,Phase 1/2,22/03/2024 ET,"Phase 1/2 trial enrollment resumed, noted March 22, 2024.",509.71K
Add to portfolio,,,FTD,,,,,
,,,ODD,,,,,
ZLAB,Zai Lab Limited,16.18,ZL-1310 (DLL3 ADC),"Solid tumors, relapsed and refractory second-line+ SCLC ",Preclinical,22/03/2024 ET,"Preclinical data presented at ELCC reported strong and specific binding to DLL3 on the cell surface, leading to internalization, cell cycle arrest and the induction of apoptosis in tumor cells, noted … read more",109.96M
Add to portfolio,,,ODD,,,,,
,,,FTD,,,,,
AXSM,Axsome Therapeutics Inc.,77.35,Reboxetine (AXS-12) - (SYMPHONY),Narcolepsy ,Phase 3,25/03/2024 ET,"Phase 3 trial met its primary endpoint, noted March 25, 2024.",49.9M
Add to portfolio,,,View Clinical Trial Data,,,,,
AZN,AstraZeneca PLC,65.46,ULTOMIRIS (ravulizumab-cwvz),Neuromyelitis Optica Spectrum Disorder (NMOSD) ,Approved,25/03/2024 ET,"Approved March 25, 2024.",3.1B
Add to portfolio,,,View Clinical Trial Data,,,,,
AZN,AstraZeneca PLC,65.46,ULTOMIRIS (ravulizumab-cwvz) - (CHAMPION-NMOSD),Neuromyelitis optica spectrum disorder (NMOSD) ,Approved,25/03/2024 ET,"FDA Approved on March 25, 2024.",3.1B
Add to portfolio,,,View Clinical Trial Data,,,,,
ATXS,Astria Therapeutics Inc.,14.75,Navenibart (STAR-0215) - (ALPHA-ORBIT),"Hereditary angioedema (HAE), healthy volunteers ",Phase 1/2,25/03/2024 ET,"Phase 1b/2 proof of concept data reported favorable safety and tolerability profile, mean monthly attack rate reduction of 90-96% for up to 6 months of follow up, noted March 25, 2024.",56.43M
Add to portfolio,,,FTD,,,,,
,,,ODD,,,,,
APGE,Apogee Therapeutics Inc.,65,APG808,"Healthy volunteer, asthma, COPD ",Phase 1,25/03/2024 ET,"Phase 1 dosing commenced and preclinical data demonstrated the potential for improved dosing over other treatment options in development, including the potential for dosing every six- or eight- weeks … read more",59.6M
Add to portfolio,,,,,,,,
MBRX,Moleculin Biotech Inc.,5.25,"Annamycin (MB-106) in combination with Cytarabine - (Ara-C, MIRACLE)",Acute Myeloid Leukemia (AML) ,Phase 1/2,25/03/2024 ET,"Phase 1/2 topline data reported a complete response composite (CRc) rate of 39% in all currently evaluable, intent to treat subjects (n= 18), noted March 25, 2024.",30.29M
Add to portfolio,,,ODD,,,,,
,,,FTD,,,,,
REGN,Regeneron Pharmaceuticals Inc.,961.09,Odronextamab - (OLYMPIA),Non-Hodgkin Lymphoma (NHL) ,CRL,25/03/2024 ET,CRL issued by FDA on March 25 2024.,105.99M
Add to portfolio,,,View Clinical Trial Data,,,,,
ZLAB,Zai Lab Limited,16.25,Odronextamab - (OLYMPIA),Non-Hodgkin Lymphoma (NHL) ,CRL,25/03/2024 ET,CRL issued by FDA on March 25 2024.,109.96M
Add to portfolio,,,View Clinical Trial Data,,,,,
ARWR,Arrowhead Pharmaceuticals Inc.,27.89,Plozasiran (ARO-APOC3-2001) - (SHASTA-2),Hypertriglyceridemia ,Phase 2,25/03/2024 ET,"Phase 2 expanded Access Program (EAP) initiated, noted March 25, 2024.",138.26M
Add to portfolio,,,View Clinical Trial Data,,,,,
RYTM,Rhythm Pharmaceuticals Inc.,39.65,RM-718,Hypothalamic Obesity ,Phase 1,25/03/2024 ET,"Phase 1 trial dosing initiated, noted March 25, 2024.",66.42M
Add to portfolio,,,,,,,,
MRK,Merck & Company Inc.,124.56,Plinabulin with Pembrolizumab plus Etoposide/Platinum (EP),1L Extensive-Stage Small-Cell Lung Cancer (ES-SCLC) ,Phase 2,25/03/2024 ET,"Phase 2 investigator-initiated trial (IIT) dosing initiated, noted March 25, 2024.",2.5B
Add to portfolio,,,,,,,,
BYSI,BeyondSpring Inc.,3.47,Plinabulin with Pembrolizumab plus Etoposide/Platinum (EP),1L Extensive-Stage Small-Cell Lung Cancer (ES-SCLC) ,Phase 2,25/03/2024 ET,"Phase 2 investigator-initiated trial (IIT) dosing initiated, noted March 25, 2024.",40.33M
Add to portfolio,,,,,,,,
SYRS,Syros Pharmaceuticals Inc.,6.4,Tamibarotene (SY-1425) and VIDAZA (azaciditine) - (SELECT-MDS-1),Myelodysplastic Syndrome ,Phase 3,25/03/2024 ET,"Phase 3 enrollment completed, noted March 25, 2024",26.83M
Add to portfolio,,,ODD,,,,,
,,,FTD,,,,,
,,,View Clinical Trial Data,,,,,
MTNB,Matinas Biopharma Holdings Inc.,0.29,Docetaxel,Metastatic and unresectable tumors ,Preclinical,25/03/2024 ET,"Preclinical in vivo data reported that an oral LNC-docetaxel, at a total administered dose of more than 8x greater than IV-docetaxel, showed no evidence of weight loss, compared to an average peak wei … read more",5.09M
Add to portfolio,,,,,,,,
STOK,Stoke Therapeutics Inc.,6.5,Zorevunersen (STK-001) - (EMPEROR),Dravet syndrome ,Phase 1/2,25/03/2024 ET,"Phase 1/2a end of study data of 70mg doses demonstrated substantial and sustained reductions in convulsive seizure frequency on top of the best available anti-seizure medicines, noted March 25, 2024.",54.8M
Add to portfolio,,,,,,,,
NKGN,NKGen Biotech Inc.,2.16,Troculeucel (SNK01),Alzheimer's Disease ,Phase 1,25/03/2024 ET,Phase 1 additional data suggested clinical activity regarding cognitive function in patients with advanced Alzheimer's disease in addition to previously disclosed positive effects on amyloid protein a … read more,124.38M
Add to portfolio,,,FTD,,,,,
AMRX,Amneal Pharmaceuticals Inc.,5.91,ciprofloxacin and dexamethasone otic suspension,"Acute Otitis Externa (AOE) in pediatric (age 6 months and older), adult, and elderly patients due to staphylococcus aureus and pseudomonas aeruginosa. ",Approved,25/03/2024 ET,"ANDA Approval from the FDA, noted March 25, 2024.",314.08M
Add to portfolio,,,,,,,,
REGN,Regeneron Pharmaceuticals Inc.,961.09,Odronextamab,Relapsed/refractory (R/R) follicular lymphoma (FL) or R/R diffuse large B-cell lymphoma (DLBCL) ,CRL,25/03/2024 ET,"CRL issued March 25, 2024.",105.99M
Add to portfolio,,,,,,,,
ZLAB,Zai Lab Limited,16.25,Odronextamab,Relapsed/refractory (R/R) follicular lymphoma (FL) or R/R diffuse large B-cell lymphoma (DLBCL) ,CRL,25/03/2024 ET,"CRL issued March 25, 2024.",109.96M
Add to portfolio,,,,,,,,
PRAX,Praxis Precision Medicines Inc.,62.18,PRAX-628,Photo-Paroxysmal Response (PPR) ,Phase 2,26/03/2024 ET,"Phase 2 data reported a 100% complete response rate in the 45 mg cohort, and in the 15 mg cohort, 80% of patients achieved a complete response and 20% achieved a partial response, noted March 26, 2024 … read more",21.05M
Add to portfolio,,,,,,,,
SLS,SELLAS Life Sciences Group Inc.,1.06,Tambiciclib (SLS009) (GFH009) with venetoclax,"Hematologic malignancies, acute myeloid leukemia (AML), chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL) and lymphoma ",Phase 1/2,26/03/2024 ET,"Phase 1b/2 topline data reported a 10% response rate in the 45 mg QW safety cohort , 20% response rate in the 60 mg QW cohort, and 50% response rate in the 60 mg, 2 x 30 mg BIW cohort, noted March 26, … read more",105.3M
Add to portfolio,,,ODD,,,,,
,,,FTD,,,,,
,,,RPDD,,,,,
TECX,Tectonic Therapeutic Inc.,—,TX45,Group 2 Pulmonary Hypertension ,Phase 1a,26/03/2024 ET,"Phase 1a clinical program advancing on track based on promising initial data, noted March 26, 2024.",18.71M
Add to portfolio,,,,,,,,
VKTX,Viking Therapeutics Inc.,80.83,VK2735,Metabolic and endocrine disorders (GLP-1) ,Phase 1,26/03/2024 ET,Phase 1 data was shown to be safe and well-tolerated in the 28-day study with low rates of GI-related adverse events. Up to 3.3% placebo-adjusted mean weight loss (5.3% from baseline) observed after 2 … read more,113.04M
Add to portfolio,,,,,,,,
CERS,Cerus Corporation,1.74,INTERCEPT,Platelets ,Approved,26/03/2024 ET,"FDA has granted approval of 12-month shelf life for INTERCEPT Platelet Processing Sets, from the date of manufacture, effective immediately, noted March 26, 2024.",191.7M
Add to portfolio,,,,,,,,
LITS,Lite Strategy Inc.,—,Voruciclib plus Venclexta (venetoclax),B-Cell Malignancies or Acute Myeloid Leukemia (AML) ,Phase 1,26/03/2024 ET,"Additional Phase 1 data observed anti-leukemic activity in multiple heavily pretreated patients in the dose escalation cohorts, including responses, anticipated decreases in myeloid leukemia cell diff … read more",35.66M
Add to portfolio,,,,,,,,
MEIP,MEI Pharma Inc.,3.86,Voruciclib plus Venclexta (venetoclax),B-Cell Malignancies or Acute Myeloid Leukemia (AML) ,Phase 1,26/03/2024 ET,"Additional Phase 1 data observed anti-leukemic activity in multiple heavily pretreated patients in the dose escalation cohorts, including responses, anticipated decreases in myeloid leukemia cell diff … read more",6.66M
Add to portfolio,,,,,,,,
STOK,Stoke Therapeutics Inc.,10.29,Zorevunersen (STK-001),Dravet Syndrome ,Phase 1/2,26/03/2024 ET,Phase 1/2 data demonstrated durable reductions in seizures and clinically meaningful improvements in multiple measures of cognition and behavior were maintained over 12 months with continued dosing at … read more,54.8M
Add to portfolio,,,BTD,,,,,
ATNM,Actinium Pharmaceuticals Inc.,8.12,Iomab-ACT,Targeted conditioning prior to CD19 CAR T-cell therapy ,Phase 1,26/03/2024 ET,"Phase 1 trial has commenced enrollment, noted March 26, 2024.",31.2M
Add to portfolio,,,,,,,,
ZVRA,Zevra Therapeutics Inc.,5.72,Serdexmethylphenidate (SDX) - (KP1077),Idiopathic hypersomnia (IH) ,Phase 2,26/03/2024 ET,"Phase 2 topline data demonstrated clinically meaningful impact and encouraging outcomes on both clinical safety and efficacy, noted March 26, 2024.",56.14M
Add to portfolio,,,ODD,,,,,
MRK,Merck & Company Inc.,124.77,WINREVAIR (sotatercept-csrk),Pulmonary arterial hypertension (PAH) ,Approved,26/03/2024 ET,"Approved March 26, 2024.",2.5B
Add to portfolio,,,BTD,,,,,
,,,View Clinical Trial Data,,,,,
ARGX,argenx SE,398.59,Efgartigimod - (RHO),Primary Sjogren's syndrome ,Phase 2,27/03/2024 ET,"Phase 2 trial data reported safety and tolerability profile that was consistent with other clinical trials, and a treatment effect across multiple clinical endpoints, noted March 27, 2024.",60.99M
Add to portfolio,,,,,,,,
MRNA,Moderna Inc.,110.59,mRNA-1283 - (NEXTCove),COVID-19 ,Phase 3,27/03/2024 ET,"Phase 3 data reported a higher immune response against both the Omicron BA.4/BA.5 and original virus strains of SARS-CoV-2 compared to mRNA-1273.222, noted March 27, 2024.",389.08M
Add to portfolio,,,,,,,,
MRNA,Moderna Inc.,110.59,mRNA-1283 - (NEXTCove),COVID-19 ,Phase 3,27/03/2024 ET,"Phase 3 data reported a higher immune response against both the Omicron BA.4/BA.5 and original virus strains of SARS-CoV-2 compared to mRNA-1273.222, noted March 27, 2024.",389.08M
Add to portfolio,,,,,,,,
NVCR,NovoCure Limited,14.64,Tumor Treating Fields (TTFields) - (METIS),Brain Metastases Originating from Non-Small Cell Lung Cancer ,Phase 3,27/03/2024 ET,"Phase 3 final data clinical trial met its primary endpoint, demonstrating a statistically significant improvement in time to intracranial progression for adult patients treated with Tumor Treating Fie … read more",111.8M
Add to portfolio,,,View Clinical Trial Data,,,,,
ZLAB,Zai Lab Limited,16.19,Tumor Treating Fields (TTFields) - (METIS),Brain Metastases Originating from Non-Small Cell Lung Cancer ,Phase 3,27/03/2024 ET,"Phase 3 final data clinical trial met its primary endpoint, demonstrating a statistically significant improvement in time to intracranial progression for adult patients treated with Tumor Treating Fie … read more",109.96M
Add to portfolio,,,View Clinical Trial Data,,,,,
ATAI,ATAI Life Sciences N.V.,1.79,BPL-003,Resistant Depression ,Phase 2a,27/03/2024 ET,"Phase 2a initial results demonstrated that a single 10mg dose of BPL-003 was well-tolerated and resulted in a rapid onset and durable antidepressant effect in patients living with TRD, noted March 27, … read more",214.34M
Add to portfolio,,,BTD,,,,,
ALT,Altimmune Inc.,8.89,Pemvidutide - (MOMENTUM),"Non-alcoholic steatohepatitis (NASH)/ (MASH) - Healthy, Overweight and Obese Volunteers ",Phase 2,27/03/2024 ET,"Phase 2 body composition study showed lean mass preservation, with only 25.5% of weight loss derived from lean mass, noted March 27, 2024.",88.26M
Add to portfolio,,,FTD,,,,,
,,,View Clinical Trial Data,,,,,
ALT,Altimmune Inc.,8.89,HepTCell,Hepatitis B ,Phase 2,27/03/2024 ET,"Phase 2 clinical trial evaluating the efficacy has been completed. The overall response in the trial was deemed to be insufficient to warrant further advancement. As a result, any further development … read more",88.26M
Add to portfolio,,,View Clinical Trial Data,,,,,
AVTX,Avalo Therapeutics Inc.,4.75,AVTX-009 (anti-IL-1β mAb) - (LOTUS),Hidradenitis suppurativa (HS) ,Phase 2,27/03/2024 ET,"Avalo acquires Phase 2-ready anti-IL-1β mAb, AVTX-009, through acquisition of AlmataBio, Inc, noted March 27 , 2024. Phase 2 topline results from trial planned expected in 2026.",13.15M
Add to portfolio,,,,,,,,
TFFP,TFF Pharmaceuticals Inc - Ordinary Shares,6.59,Voriconazole Inhalation Powder - (VORI),Invasive Pulmonary Aspergillosis (IPA) ,Phase 2,27/03/2024 ET,"Phase 2 data continue to demonstrate antifungal activity and a favorable safety and tolerability profile, noted March 27, 2024.",4.44M
Add to portfolio,,,,,,,,
TFFP,TFF Pharmaceuticals Inc - Ordinary Shares,6.59,TFF TAC (Tacrolimus Inhalation Powder),Lung transplant (post) ,Phase 2,27/03/2024 ET,"Phase 2 8/8 patients successfully transitioned from oral tacrolimus to TFF TAC with no sign of acute rejection at reduced systemic exposures, noted March 27, 2024.",4.44M
Add to portfolio,,,,,,,,
GMDA,Gamida Cell Ltd.,0.06,NAM-NK (GDA-201),Follicular and diffuse large B cell lymphomas ,Phase 1,27/03/2024 ET,"Gamida Cell does not plan to conduct further development of GDA-201 at this time, as noted on March 27, 2024.",154.05M
Add to portfolio,,,,,,,,
REGN,Regeneron Pharmaceuticals Inc.,966.3,Pexa-Vec in combination with cemiplimab - (REN026),Metastatic or unresectable renal cell carcinoma (RCC). ,Phase 1/2,27/03/2024 ET,"Phase 1b/2a study demonstrated an acceptable safety profile and encouraging efficacy of the combination therapy of Pexa-Vec, an engineered oncolytic vaccinia virus, and Libtayo (cemiplimab), anti-PD-1 … read more",105.99M
Add to portfolio,,,,,,,,
RARE,Ultragenyx Pharmaceutical Inc.,46.82,Setrusumab (BPS-804) - (ORBIT),Osteogenesis Imperfecta ,Phase 2/3,27/03/2024 ET,Phase 3 enrollment to be completed around the end of 1Q 2024/1H 2024.,96.37M
Add to portfolio,,,,,,,,
MREO,Mereo BioPharma Group plc,3,Setrusumab (BPS-804) - (ORBIT),Osteogenesis Imperfecta ,Phase 2/3,27/03/2024 ET,Phase 3 enrollment to be completed around the end of 1Q 2024/1H 2024.,155.15M
Add to portfolio,,,,,,,,
AKBA,Akebia Therapeutics Inc.,2.24,Vafseo (vadadustat),Anemia due to Chronic Kidney Disease in Adult Patients on Dialysis ,Approved,27/03/2024 ET,"Approved March 28, 2024.",265.15M
Add to portfolio,,,,,,,,
CSLLY,CSL Ltd. ADR,93.88,Vafseo (vadadustat),Anemia due to Chronic Kidney Disease in Adult Patients on Dialysis ,Approved,27/03/2024 ET,"Approved March 28, 2024.",968.41M
Add to portfolio,,,,,,,,
RVPH,Reviva Pharmaceuticals Holdings Inc.,3.9,Brilaroxazine - (RECOVER),Schizophrenia ,Phase 3,27/03/2024 ET,"Phase 3 safety and efficacy shared at ASCPT reported that the 50 mg dose provided a significant decrease in primary (Total PANSS) with a discontinuation rate lower than 6%, noted March 27, 2024.",68M
Add to portfolio,,,,,,,,
PTIX,Protagenic Therapeutics Inc.,1.82,PT00114,Major Depressive Disorder (MDD) / Generalized Anxiety Disorder (GAD) / Post-Traumatic Stress Disorder (PTSD) ,Phase 1,27/03/2024 ET,Phase 1 single-dose results demonstrated safety at a medium dose of 500 micrograms administered subcutaneously in the third of five planned cohorts of subjects in the single dose portion of the Phase … read more,588.96K
Add to portfolio,,,,,,,,
MIST,Milestone Pharmaceuticals Inc.,1.79,CARDAMYST (etripamil) - (RAPID),Paroxysmal supraventricular tachycardia (PSVT) ,NDA Filing,28/03/2024 ET,"NDA resubmitted to FDA, noted March 28, 2024.",84.99M
Add to portfolio,,,View Clinical Trial Data,,,,,
IRWD,Ironwood Pharmaceuticals Inc.,8.71,Apraglutide - (STARGAZE),Acute Graft-Versus-Host Disease ,Phase 2,28/03/2024 ET,"Phase 2 initial data reported that treatment was well-tolerated with an acceptable safety profile, noted March 28, 2024.",162.43M
Add to portfolio,,,ODD,,,,,
LPCN,Lipocine Inc.,5.2,LPCN 1148,"Liver cirrhosis, specifically prevention of OHE recurrence and treatment of sarcopenia ",Phase 2,28/03/2024 ET,"Phase 2 data reported that that participants who received LPCN 1148 during Stage 1 had a significant increase in L3-SMI of 4.1 cm2/m2 (8.8%) at Week 24, noted March 28, 2024.",5.42M
Add to portfolio,,,FTD,,,,,
,,,View Clinical Trial Data,,,,,
GILD,Gilead Sciences Inc.,72.39,Efarindodekin Alfa (XTX301),Solid tumors ,Phase 1,28/03/2024 ET,"Xilio granted Gilead an exclusive global license to develop and commercialize XTX301, Xilio's tumor-activated IL-12, noted March 28, 2024.",1.24B
Add to portfolio,,,,,,,,
XLO,Xilio Therapeutics Inc.,1.08,Efarindodekin Alfa (XTX301),Solid tumors ,Phase 1,28/03/2024 ET,"Xilio granted Gilead an exclusive global license to develop and commercialize XTX301, Xilio's tumor-activated IL-12, noted March 28, 2024.",51.83M
Add to portfolio,,,,,,,,
SNDX,Syndax Pharmaceuticals Inc.,23.8,Revuforj (revumenib) - (AUGMENT-101),Relapsed/refractory (R/R) acute leukemias ,Phase 2,28/03/2024 ET,"Phase 2 enrollment completed, noted March 28, 2024.",86.14M
Add to portfolio,,,FTD,,,,,
,,,BTD,,,,,
OCEA,Ocean Biomedical Inc Com,3.79,VRON-0200,Hepatitis B ,Phase 1b,28/03/2024 ET,"Phase 1b preliminary data reported that VRON-0200 was safe and well tolerated, with no clinical or laboratory changes of concern, noted March 28, 2024.",232.37M
Add to portfolio,,,,,,,,
PPBT,Purple Biotech Ltd.,0.67,NT219 in combination with cetuximab,Recurrent/metastatic squamous cell carcinoma of the head and neck (R/M SCCHN) ,Phase 1/2,28/03/2024 ET,"Phase 1/2 found to suppress cancer stem cells that promote drug resistance to KRASG12C and KRASG12D inhibitors and solid tumor recurrence, noted March 28, 2024.",2.65M
Add to portfolio,,,,,,,,
GRTX,Galera Therapeutics Inc.,0.14,Rucosopasem (GC4711) - (GRECO-1),Non-Small Cell Lung Cancer (NSCLC) ,Phase 1/2,28/03/2024 ET,"Trial discontinued, noted March 28, 2024.",75.46M
Add to portfolio,,,,,,,,
GRTX,Galera Therapeutics Inc.,0.14,Rucosopasem (GC4711) - (GRECO-2),Pancreatic Cancer ,Phase 2b,28/03/2024 ET,"Trial discontinued, noted March 28, 2024.",75.46M
Add to portfolio,,,ODD,,,,,
,,,View Clinical Trial Data,,,,,
APLT,Applied Therapeutics Inc.,6.8,Govorestat (AT-007) - (ACTION-Galactosemia kids),Galactosemia ,PDUFA priority review,28/03/2024 ET,"PDUFA PR date of August 28, 2024. The FDA has set a new PDUFA target action date of November 28, 2024.",144.01M
Add to portfolio,,,FTD,,,,,
,,,View Clinical Trial Data,,,,,
NBIX,Neurocrine Biosciences Inc.,137.92,NBI-1065890,CNS Indications ,Phase 1,28/03/2024 ET,"Phase 1 initiated, noted March 28, 2024.",99.18M
Add to portfolio,,,,,,,,
CADL,Candel Therapeutics Inc.,1.58,CAN-3110,Glioma ,Phase 1b,28/03/2024 ET,"Phase 1b showed that serial procedures were well tolerated without observed dose-limiting toxicity in first cohort, noted March 28, 2024.",54.9M
Add to portfolio,,,FTD,,,,,
,,,ODD,,,,,
BMY,Bristol-Myers Squibb Company,52.81,KRAZATI (adagrasib) and Taxotere (Docetaxel) - (KRYSTAL-12),Non-small cell lung cancer (NSCLC) ,Phase 3,28/03/2024 ET,"Phase 3 trial met its primary endpoints, noted March 28, 2024.",2.04B
Add to portfolio,,,,,,,,
CNTX,Context Therapeutics Inc.,1.38,CTIM-76,Various cancers ,IND-Enabling,28/03/2024 ET,"IND submitted on March 28, 2024.",89.7M
Add to portfolio,,,,,,,,
EQ,Equillium Inc.,2.11,Itolizumab (EQ001) - (EQUALISE),Systemic lupus erythematosus (SLE) and lupus nephritis (LN) ,Phase 1b,01/04/2024 ET,"Phase 1b topline data continues to show clinically meaningful response in highly proteinuric subjects. More than 80% of subjects achieved >50% reduction in urine protein creatinine ratio (UPCR), noted … read more",59.5M
Add to portfolio,,,,,,,,
GRTS,Gritstone bio Inc.,2.35,GRANITE-CRC-1L,1L Microsatellite-Stable Colorectal Cancer (MSS-CRC) ,Phase 2/3,01/04/2024 ET,"Phase 2/3 preliminary data reported that the PFS trends favor GRANITE recipients with hazard ratios of 0.82 in the overall population and 0.52 in a high-risk group, noted April 1, 2024.",118.11M
Add to portfolio,,,,,,,,
NVCR,NovoCure Limited,15.49,Tumor Treating Fields (TTFields) with pembrolizumab and temozolomide - (TIGER),Glioblastoma (GBM) ,Phase 2,01/04/2024 ET,"Phase 2 long-term data presented at ASCO reported that the median OS and PFS were 19.6 months (95% CI, 17.9–22.4) and 10.2 months, noted April 1, 2024.",111.8M
Add to portfolio,,,,,,,,
LQDA,Liquidia Corporation,14.92,YUTREPIA,Interstitial lung disease (PH-ILD) ,PDUFA,01/04/2024 ET,"A District Court set aside the injunction and the FDA is no longer enjoined from issuing final approval of Liquidia's New Drug Application (NDA) for YUTREPIA (treprostinil) inhalation powder, noted Ap … read more",86.09M
Add to portfolio,,,,,,,,
AZN,AstraZeneca PLC,66.84,VOYDEYA (danicopan) add-on to SoC with ULTOMIRIS (ravulizumab-cwvz) or SOLIRIS (eculizumab)- (ALPHA),Paroxysmal nocturnal hemoglobinuria (PNH) and atypical Hemolytic Uremic Syndrome (aHUS) ,Approved,01/04/2024 ET,"FDA Approved on April 1, 2024.",3.1B
Add to portfolio,,,View Clinical Trial Data,,,,,
AXSM,Axsome Therapeutics Inc.,76.99,Sunosi (Solriamfetol) - (ENGAGE),Binge eating disorder ,Phase 3,01/04/2024 ET,"Phase 3 initiated, noted April 1, 2024.",49.9M
Add to portfolio,,,,,,,,
VRTX,Vertex Pharmaceuticals Incorporated,420.48,inaxaplin (VX-147) - (AMPLITUDE),Proteinuric kidney disease with two mutations in the APOL1 gene (AMKD) ,Phase 2/3,01/04/2024 ET,Phase 2/3 trial part 3 dosing initiated with expanded access to include adolescents with AMKD ages 10 to 17 years. An Independent Data Monitoring Committee (IDMC) reviewed Phase 2 safety and efficacy … read more,256.39M
Add to portfolio,,,,,,,,
IRON,Disc Medicine Inc.,34.21,Bitopertin - (APOLLO),Erythropoietic Protoporphyria (EPP) ,Phase 2,01/04/2024 ET,"Phase 2 study met its primary endpoint. Despite improved measures of light tolerance, including the key secondary endpoint, in both 20 mg and 60 mg dose groups, but it did not meet statistical signifi … read more",34.77M
Add to portfolio,,,ODD,,,,,
VTGN,Vistagen Therapeutics Inc.,5.4,PH94B - (PALISADE-3),Social Anxiety Disorder (SAD) ,Phase 3,01/04/2024 ET,"PALISADE-3 initiated, noted April 1, 2024.",30.68M
Add to portfolio,,,View Clinical Trial Data,,,,,
SRZN,Surrozen Inc.,10.1,SZN-043,Severe alcohol associated hepatitis ,Phase 1a,01/04/2024 ET,"Phase 1a demonstrated acceptable safety and tolerability with no reported serious adverse events, noted April 1, 2024.",8.57M
Add to portfolio,,,,,,,,
ATNM,Actinium Pharmaceuticals Inc.,8.56,Iomab-B - (SIERRA),Acute myeloid leukemia (AML) ,Phase 3,01/04/2024 ET,"Phase 3 results demonstrated Iomab-B's ability to overcome the negative impact of a TP53 mutation in patients who otherwise would have limited treatment options and dismal prognosis, noted April 1, 20 … read more",31.2M
Add to portfolio,,,View Clinical Trial Data,,,,,
CORT,Corcept Therapeutics Incorporated,25.74,Relacorilant - (GRADIENT),Cushing’s syndrome ,Phase 3,01/04/2024 ET,"Phase 3 enrollment completed, noted April 1, 2024.",105.37M
Add to portfolio,,,View Clinical Trial Data,,,,,
BMEA,Biomea Fusion Inc.,12.8,Icovamenib (BMF-219) - (COVALENT-112),Type 1 diabetes (T1D) ,Phase 2,02/04/2024 ET,"Phase 2 was initiated, noted January 8, 2024. Phase 2 data reported that in patient one, fasting C-peptide increased by 80% compared to baseline. In patient two, fasting C-peptide increased by 16% com … read more",59.51M
Add to portfolio,,,,,,,,
LLY,Eli Lilly and Company,761.64,VERVE-101 - (Heart-1),Heterozygous familial hypercholesterolemia (HeFH) ,Phase 1b,02/04/2024 ET,Phase 1b clinical trial demonstrated LDL-C reduction of up to 73% at 0.45 mg/kg. Company to pause enrollment in Heart-1 clinical trial following asymptomatic Grade 3 transient ALT elevation and thromb … read more,946.46M
Add to portfolio,,,,,,,,
VERV,Verve Therapeutics Inc.,8.32,VERVE-101 - (Heart-1),Heterozygous familial hypercholesterolemia (HeFH) ,Phase 1b,02/04/2024 ET,Phase 1b clinical trial demonstrated LDL-C reduction of up to 73% at 0.45 mg/kg. Company to pause enrollment in Heart-1 clinical trial following asymptomatic Grade 3 transient ALT elevation and thromb … read more,89.14M
Add to portfolio,,,,,,,,
VTGN,,$5.40 ,PH94B - (PALISADE-3),Social Anxiety Disorder (SAD) ,Phase 3,01/04/2024 ET,"PALISADE-3 initiated, noted April 1, 2024.",30.68M
Add to portfolio,,,View Clinical Trial Data,,,,,
SRZN,,$10.10 ,SZN-043,Severe alcohol associated hepatitis ,Phase 1a,01/04/2024 ET,"Phase 1a demonstrated acceptable safety and tolerability with no reported serious adverse events, noted April 1, 2024.",8.57M
Add to portfolio,,,,,,,,
ATNM,,$8.56 ,Iomab-B - (SIERRA),Acute myeloid leukemia (AML) ,Phase 3,01/04/2024 ET,"Phase 3 results demonstrated Iomab-B's ability to overcome the negative impact of a TP53 mutation in patients who otherwise would have limited treatment options and dismal prognosis, noted April 1, 20 … read more",31.2M
Add to portfolio,,,View Clinical Trial Data,,,,,
CORT,,$25.74 ,Relacorilant - (GRADIENT),Cushing’s syndrome ,Phase 3,01/04/2024 ET,"Phase 3 enrollment completed, noted April 1, 2024.",105.37M
Add to portfolio,,,View Clinical Trial Data,,,,,
BMEA,,$12.80 ,Icovamenib (BMF-219) - (COVALENT-112),Type 1 diabetes (T1D) ,Phase 2,02/04/2024 ET,"Phase 2 was initiated, noted January 8, 2024. Phase 2 data reported that in patient one, fasting C-peptide increased by 80% compared to baseline. In patient two, fasting C-peptide increased by 16% com … read more",59.51M
Add to portfolio,,,,,,,,
LLY,,$761.64 ,VERVE-101 - (Heart-1),Heterozygous familial hypercholesterolemia (HeFH) ,Phase 1b,02/04/2024 ET,Phase 1b clinical trial demonstrated LDL-C reduction of up to 73% at 0.45 mg/kg. Company to pause enrollment in Heart-1 clinical trial following asymptomatic Grade 3 transient ALT elevation and thromb … read more,946.46M
Add to portfolio,,,,,,,,
VERV,,$8.32 ,VERVE-101 - (Heart-1),Heterozygous familial hypercholesterolemia (HeFH) ,Phase 1b,02/04/2024 ET,Phase 1b clinical trial demonstrated LDL-C reduction of up to 73% at 0.45 mg/kg. Company to pause enrollment in Heart-1 clinical trial following asymptomatic Grade 3 transient ALT elevation and thromb … read more,89.14M
Add to portfolio,,,,,,,,
ZLDPF,,$94.49 ,VERVE-101 - (Heart-1),Heterozygous familial hypercholesterolemia (HeFH) ,Phase 1b,02/04/2024 ET,Phase 1b clinical trial demonstrated LDL-C reduction of up to 73% at 0.45 mg/kg. Company to pause enrollment in Heart-1 clinical trial following asymptomatic Grade 3 transient ALT elevation and thromb … read more,70.69M
Add to portfolio,,,,,,,,
ROIV,,$10.92 ,Brepocitinib - (NEPTUNE),Non-infectious uveitis (NIU) ,Phase 2,02/04/2024 ET,"Phase 2 topline data showed the strongest efficacy data in NIU observed to date. The Treatment Failure rate from disease activity (discontinuations censored) was 18% in the brepocitinib 45 mg arm, n … read more",682.88M
Add to portfolio,,,,,,,,
GNPX,,$2.84 ,Oncoprex,Anti-PD1 resistant non-small cell lung cancer (NSCLC) ,Preclinical,02/04/2024 ET,"Preclinical data from mouse model reported that NPRL2 treatment reduced lung metastases significantly, whereas pembrolizumab was ineffective. The antitumor effect was greater in humanized than non-hum … read more",858.11K
Add to portfolio,,,,,,,,
KNSA,,$18.73 ,Abiprubart (KPL-404),Rheumatoid arthritis ,Phase 2,02/04/2024 ET,"Phase 2 cohort 4 data reported a a statistically significant reduction of approximately 40% in Rheumatoid Factor in the abiprubart group, noted April 2, 2024.",74.11M
Add to portfolio,,,,,,,,
KRBP,,$3.00 ,Deltacel-01 - (KB-GDT-01),Stage 4 Metastatic Non-Small Cell Lung Cancer ,Phase 1,02/04/2024 ET,"Phase 1 data from third patient after reviewing safety and efficacy findings from the first cohort, the Safety Monitoring Committee (SMC) recommended not to escalate the cell dose level and instead t … read more",1.53M
Add to portfolio,,,FTD,,,,,
CRBP,,$37.46 ,CRB-701 (SYS6002) with Pembrolizumab,"Solid tumors, Locally advanced or metastatic urothelial carcinoma ",Phase 1,02/04/2024 ET,"Phase 1 US dosing initiated, noted April 2, 2024.",12.26M
Add to portfolio,,,FTD,,,,,
SGHT,,$5.44 ,TearCare - (SAHARA RCT),Dry Eye Disease ,Phase 1,02/04/2024 ET,"Phase 1 clinical results demonstrate long-term efficacy of the OMNI Surgical System for primary open-angle glaucoma and support use of TearCare technology as a primary treatment for dry eye disease, n … read more",52.37M
Add to portfolio,,,,,,,,
VNDA,,$3.91 ,FANAPT (iloperidone),Bipolar Disorder ,Approved,02/04/2024 ET,"Approved April 2, 2024.",59.09M
Add to portfolio,,,,,,,,
FGEN,,$1.47 ,FG-3246 (FOR46) in combination with enzalutamide - (Investigator-sponsored trial),Metastatic castration-resistant prostate cancer (mCRPC) ,Phase 1,03/04/2024 ET,"Phase 1 topline data reported a PSA50 response in 36% of patients, a confirmed radiographic objective response rate of 20%, with a median duration of response of 7.5 months, noted April 3, 2024.",4.04M
Add to portfolio,,,,,,,,
LENZ,,$21.22 ,VIZZ (aceclidine ophthalmic solution),Presbyopia ,Phase 3,03/04/2024 ET,Phase 3 primary endpoint was met with 71% of participants dosed with LNZ100 achieving three-lines or greater improvement at 3 hours. Rapid onset and long duration shown with 71% of participants achiev … read more,28.52M
Add to portfolio,,,,,,,,
MRK,,$129.12 ,"Raludotatug deruxtecan (DS-6000, R-DXd) - (REJOICE-Ovarian01)",Ovarian cancer ,Phase 2/3,03/04/2024 ET,"Phase 2/3 trial portion 2 initiated, noted April 3, 2024.",2.5B
Add to portfolio,,,,,,,,
DSNKY,,$31.22 ,"Raludotatug deruxtecan (DS-6000, R-DXd) - (REJOICE-Ovarian01)",Ovarian cancer ,Phase 2/3,03/04/2024 ET,"Phase 2/3 trial portion 2 initiated, noted April 3, 2024.",1.92B
Add to portfolio,,,,,,,,
PRFX,,$1.77 ,PRF-110,Bunionectomy ,Phase 3,03/04/2024 ET,"Phase 3 enrollment target reached 50%, noted April 2, 2024.",1.89M
Add to portfolio,,,,,,,,
NBTX,,$6.13 ,NBTXR3 - (MD Anderson Study 2020-0123),Non-small cell lung cancer (NSCLC) ,Phase 1,03/04/2024 ET,"Phase 1 dose escalation study completed, noted April 2, 2024.",47.43M
Add to portfolio,,,,,,,,
SPRY,,$9.40 ,Neffy (epinephrine nasal spray),Allergic reactions (type I) including anaphylaxis ,CRL,03/04/2024 ET,The Company submitted its response to the U.S. Food and Drug Administration (FDA) for its New Drug Application (NDA) for neffy® (epinephrine nasal spray) for the treatment of Type I allergic reactions … read more,98.83M
Add to portfolio,,,,,,,,
MRNA,,$101.21 ,mRNA-3927 (Paramount),Propionic Acidemia ,Phase 1/2,03/04/2024 ET,"Phase 1/2 has been well tolerated in participants at the doses administered, with no dose-limiting toxicities observed. Fifteen participants reported treatment-emergent adverse events (TEAEs), while n … read more",389.08M
Add to portfolio,,,,,,,,
MGNX,,$13.67 ,MGC018 - (TAMARACK),Metastatic castration-resistant prostate cancer (mCRPC) ,Phase 2,03/04/2024 ET,"Phase 2 preliminary safety data suggested that reducing the dose and frequency of cobra duo improves its safety and tolerability in men with mCRPC, noted April 3, 2024.",63.21M
Add to portfolio,,,,,,,,
ACHL,,$0.90 ,ATL001 - (CHIRON),Non-Small Cell Lung Cancer (NSCLC) ,Phase 1/2,04/04/2024 ET,"Phase 1/2 data reported that 25% of higher dose (>100M cNeT) patients demonstrated stable disease with some reduction in tumor volume, noted April 4, 2024.",41.08M
Add to portfolio,,,,,,,,
ACHL,,$0.90 ,ATL001 - (THETIS),Melanoma ,Phase 1/2,04/04/2024 ET,"Phase 1/2a data reported that 3 of 12 patients demonstrated stable disease with some reduction in tumor volume, noted April 4, 2024.",41.08M
Add to portfolio,,,,,,,,
CVAC,,$2.96 ,Flu-SV-mRNA,Multivalent seasonal flu vaccine ,Phase 2,04/04/2024 ET,"Phase 2 interim data reported that the vaccine boosted antibody titers against all encoded flu strains and across all age groups and tested dose levels, including the lowest tested dose, noted April 4 … read more",224.34M
Add to portfolio,,,,,,,,
GSK,,$40.15 ,Flu-SV-mRNA,Multivalent seasonal flu vaccine ,Phase 2,04/04/2024 ET,"Phase 2 interim data reported that the vaccine boosted antibody titers against all encoded flu strains and across all age groups and tested dose levels, including the lowest tested dose, noted April 4 … read more",2.03B
Add to portfolio,,,,,,,,
ADCT,,$4.71 ,ZYNLONTA (Loncastuximab Tesirine-Ipyl) - (LOTIS-7),B-cell non-Hodgkin lymphoma ,Phase 1b,04/04/2024 ET,"Phase 1b dose escalation trial completed with no dose-limiting toxicities, no or low-grade cytokine release syndrome and no immune effector cell-associated neurotoxicity syndrome across all patients a … read more",112.5M
Add to portfolio,,,,,,,,
AMLX,,$2.61 ,RELYVRIO (sodium phenylbutyrate and taurursodiol),Amyotrophic lateral sclerosis (ALS) ,Phase 3,04/04/2024 ET,Company has started a process with the FDA and Health Canada to voluntarily discontinue the marketing authorizations for RELYVRIO/ALBRIOZA (sodium phenylbutyrate and taurursodiol [also known as ursodo … read more,89.17M
Add to portfolio,,,,,,,,
AMLX,,$2.61 ,AMX0035 - (A35-004 PHOENIX),Amyotrophic Lateral Sclerosis (AML) ,Phase 3,04/04/2024 ET,"Based on Phase 3 previous results, the company has started a process with the FDA and Health Canada to voluntarily discontinue the marketing authorizations for RELYVRIO/ALBRIOZA (sodium phenylbutyrate … read more",89.17M
Add to portfolio,,,,,,,,
CADL,,$6.40 ,CAN-2409 plus valacyclovir (prodrug),"Non-Metastatic Pancreatic Cancer, Pancreatic ductal adenocarcinoma (PDAC) ",Phase 2,04/04/2024 ET,"Phase 2 interim data reported that at 24 months, survival rate was 71.4% in CAN-2409 treated patients versus only 16.7% in the control group after chemoradiation, noted April 4, 2024.",54.9M
Add to portfolio,,,FTD,,,,,
,,,ODD,,,,,
,,,View Clinical Trial Data,,,,,
EFTR,,$2.96 ,Tomivosertib (MNK1/2) - (KICKSTART),Non-small cell lung cancer (NSCLC) ,Phase 2b,04/04/2024 ET,"Phase 2b study did not meet the pre-specified threshold of p≤0.2. The median PFS was 13.0 weeks in the tomivosertib plus pembrolizumab arm and 11.7 weeks in the placebo plus pembrolizumab arm, respect … read more",4.7M
Add to portfolio,,,,,,,,
GOVX,,$2.01 ,GEO-CM04S1- (COH04S1),COVID-19 in immunocompromised patients ,Preclinical,04/04/2024 ET,"Preclinical data presented at the Annual World Vaccine showed that vaccine-induced immunity protects against infections, serious disease symptoms, and death against the original Wuhan variant as well … read more",25.36M
Add to portfolio,,,View Clinical Trial Data,,,,,
DTIL,,$14.34 ,ECUR-506 - (OTC-HOPE),Ornithine Transcarbamylase (OTC) Deficiency ,IND-Enabling,04/04/2024 ET,"IND Cleared by the FDA, noted April 4, 2024.",11.79M
Add to portfolio,,,FTD,,,,,
CRBU,,$4.54 ,CB-010 - (GALLOP),"Lupus nephritis (LN), extrarenal lupus (ERL) ",IND-Enabling,04/04/2024 ET,"IND Clearance by FDA, noted April 4, 2024. Phase 1 trial planned by year end 2024.",93.12M
Add to portfolio,,,FTD,,,,,
HCM,,$16.36 ,HMPL-295,Solid tumors ,Preclinical,05/04/2024 ET,Preclinical data from AACR reported that HMPL-295 significantly improved the anti-tumor activity of standard-of-care chemotherapy as well as targeted agents in KRAS- or BRAF-mutant tumor models both … read more,174.43M
Add to portfolio,,,,,,,,
HCM,,$16.36 ,HMPL-506,Leukemia ,Preclinical,05/04/2024 ET,Preclinical data from AACR reported that in In vivo studies demonstrated the dose- and exposure- dependent target regulation of MEIS1 and anti-tumor efficacy following HMPL-506 treatment in multiple t … read more,174.43M
Add to portfolio,,,,,,,,
HCM,,$16.36 ,HMPL-A067 (HMA800067),B-cell malignancies ,Preclinical,05/04/2024 ET,"Preclinical data reported that an intravenous injection of HMA800067 at 10 mg/kg single dose induced complete tumor regression in all the animals within 10 days of administration, noted April 5, 2024.",174.43M
Add to portfolio,,,,,,,,
AZN,,$67.04 ,IMFINZI (Durvalumab) - (ADRIATIC),Small cell lung cancer (SCLC) limited disease ,Phase 3,05/04/2024 ET,"Phase 3 trial met the the dual primary endpoints of overall survival (OS) and progression-free survival (PFS), noted April 5, 2024.",3.1B
Add to portfolio,,,View Clinical Trial Data,,,,,
CYTK,,$72.71 ,Aficamten - (FOREST-HCM) (OLE),Non-obstructive hypertrophic cardiomyopathy (HCM) ,Phase 3,05/04/2024 ET,Phase 3 first cohort efficacy and safety datacompleting 1-year follow-up data from ACC.24 reported that treatment with aficamten for 48 weeks resulted in substantial and sustained reductions in averag … read more,119.66M
Add to portfolio,,,,,,,,
OCGN,,$1.83 ,OCU410 - (ArMaDa),Geographic Atrophy (GA) ,Phase 1/2,05/04/2024 ET,"Phase 1/2 Data and Safety Monitoring Board (DSMB) convened and approved to proceed dosing with the medium dose of OCU410 in the dose-escalation phase of the study, noted April 5, 2024.",292.3M
Add to portfolio,,,,,,,,
IGXT,,$0.19 ,Buprenorphine Buccal Film - (Belbuca Biosimilar),Pain ,CRL,05/04/2024 ET,"In an Amendment Acknowledgement received from the FDA by the company, the FDA granted priority review with a Generic Drug User Fee Act (GDUFA) date for review of the Amendment of March 8, 2024, unless … read more",174.66M
Add to portfolio,,,,,,,,
TARA,,$3.63 ,TARA-002 - (ADVANCED-1),Non-muscle invasive bladder cancer (NMIBC) ,Phase 1b,05/04/2024 ET,"Phase 1b data reported a complete response rate of 43% at three months, noted April 5, 2024.",38.58M
Add to portfolio,,,,,,,,
TSVT,,$4.92 ,Abecma (idecabtagene vicleucel; ide-cel),Multiple Myeloma ,Approved,05/04/2024 ET,"Approved April 5, 2024.",53.23M
Add to portfolio,,,View Clinical Trial Data,,,,,
BMY,,$50.56 ,Abecma (idecabtagene vicleucel; ide-cel),Multiple Myeloma ,Approved,05/04/2024 ET,"Approved April 5, 2024.",2.04B
Add to portfolio,,,View Clinical Trial Data,,,,,
CDTX,,$23.20 ,CCR5-001,Colorectal cancer ,Preclinical,05/04/2024 ET,"Preclinical data shared at the AACR conference demonstrated potent efficacy in colorectal cancer mouse model, noted April 5 2024.",25.36M
Add to portfolio,,,,,,,,
CDTX,,$23.20 ,CBO421,Tumor immune evasion prevention ,Preclinical,05/04/2024 ET,"Preclinical data shared at AACR data demonstrated improved efficacy compared to oleclumab in human triple-negative breast cancer cell lines, noted April 5, 2024.",25.36M
Add to portfolio,,,,,,,,
HOWL,,$5.92 ,WTX-518,Solid tumors ,Preclinical,05/04/2024 ET,"Preclinical data presented at AACR reported complete tumor regression in the MC38 mouse tumor model, noted April 5, 2024.",45.73M
Add to portfolio,,,,,,,,
HOWL,,$5.92 ,WTX-712,Solid tumors ,Preclinical,05/04/2024 ET,"Preclinical data presented at AACR reported that treatment demonstrated inducibility and antitumor activity with regressions in the MC38 mouse tumor model, noted April 5, 2024.",45.73M
Add to portfolio,,,,,,,,
JNJ,,$152.39 ,CARVYKTI (ciltacabtagene autoleucel) - (CARTITUDE-4),Multiple Myeloma ,Approved,05/04/2024 ET,"FDA Approval on April 5, 2024.",2.41B
Add to portfolio,,,,,,,,
LEGN,,$54.93 ,CARVYKTI (ciltacabtagene autoleucel) - (CARTITUDE-4),Multiple Myeloma ,Approved,05/04/2024 ET,"FDA Approval on April 5, 2024.",183.65M
Add to portfolio,,,,,,,,
AZN,,$67.04 ,Trastuzumab deruxtecan - (DESTINY-CRC02),HER2-overexpressing/amplified (HER2+) metastatic colorectal cancer (mCRC) ,Phase 2,05/04/2024 ET,"Phase 2 data showed a confirmed ORR of 51.4% and a median DoR range of 19.4 months, noted April 5, 2024.",3.1B
Add to portfolio,,,BTD,,,,,
AMRN,,$1.05 ,VASCEPA (icosapent ethyl) - (REDUCE-IT),Cardiovascular disease ,Phase 1,06/04/2024 ET,Phase 1 data presented at the American College of Cardiology's Annual Scientific Session & Expo show that findings presented on VASCEPA/VAZKEPA utility in REDUCE-IT patient subgroups by baseline High/ … read more,20.68M
Add to portfolio,,,,,,,,
XLO,,$1.47 ,XTX501,Solid Tumors ,Preclinical,07/04/2024 ET,"Preclinical data shared at AACR reported superior PK profile compared to non-masked PD1/IL2 in mice, akin to PD1 antibodies, projected to achieve >95% PD-1 RO with once every 3 weeks (Q3W) dosing, no … read more",51.83M
Add to portfolio,,,,,,,,
REPL,,$7.12 ,RP1 (vusolimogene oderparepvec) - (ARTACUS),Liver and kidney transplant recipients with recurrent Cutaneous squamous cell carcinoma ,Phase 1/2,07/04/2024 ET,"Phase 1/2 open-label data presented at AACR reported an overall response rate (ORR) of 34.8 percent (8 of 23 evaluable patients, including 5 complete responses and 3 partial responses) with most respo … read more",78.06M
Add to portfolio,,,,,,,,
ALNY,,$156.04 ,Zilebesiran - (KARDIA-2),Hypertension ,Phase 2,07/04/2024 ET,"Phase 2 full data shared at the American College of Cardiology Scientific Sessions reported that zilebesiran demonstrated clinically significant and sustained placebo-adjusted, time-adjusted reduction … read more",131.08M
Add to portfolio,,,,,,,,
ARWR,,$25.70 ,Plozasiran (ARO-APOC3-2001) - (SHASTA-2),Hypertriglyceridemia ,Phase 2,07/04/2024 ET,"Phase 2 clinical data presented at ACC.24 reported a dose-dependent placebo-adjusted reductions in triglycerides, with Significant and durable triglyceride and APOC3 reductions to week 48, noted April … read more",138.26M
Add to portfolio,,,View Clinical Trial Data,,,,,
BNTX,,$89.31 ,Cevumeran (BNT122),Resected pancreatic ductal adenocarcinoma (PDAC) ,Phase 1,07/04/2024 ET,"Phase 1 data presented at AACR reported that in 8 of 16 patients, autogene cevumeran elicited high-magnitude T cells specific to the encoded neoantigens. 98% of the T cells targeting individual neoant … read more",239.97M
Add to portfolio,,,View Clinical Trial Data,,,,,
IONS,,$42.24 ,TRYNGOLZA (olezarsen),Familial Chylomicronemia Syndrome (FCS) ,Phase 3,07/04/2024 ET,"Phase 3 trial met her primary endpoint, noted April 7, 2024.",159.39M
Add to portfolio,,,ODD,,,,,
,,,View Clinical Trial Data,,,,,
ITOS,,$12.22 ,EOS-984 - (APT-008),Adenosine on T and B cells ,Preclinical,07/04/2024 ET,"Preclinical data presented at AACR reported a blockade of intracellular adenosine accumulation by EOS-984 enabled proliferation of memory T cells and TILs despite high adenosine concentrations, result … read more",44.21M
Add to portfolio,,,,,,,,
INO,,$11.34 ,GT-30,Cancer Vaccine in advanced hepatocellular carcinoma ,Phase 1/2,07/04/2024 ET,"Phase 1/2 trial has met primary endpoints of safety and immunogenicity and secondary endpoint for efficacy based on response rate, noted April 7, 2024.",53.14M
Add to portfolio,,,,,,,,
EWTX,,$16.88 ,EDG-7500 - (CIRRUS-HCM),Hypertrophic Cardiomyopathy (HCM) ,Preclinical,07/04/2024 ET,Preclinical data presented at ACC blunted the HCM-mediated progressive slowing of LV diastolic relaxation; additionally the candidate preserved myocardial distensibility and maintained cardiac reserve … read more,105.35M
Add to portfolio,,,,,,,,
SNDX,,$22.81 ,Revuforj (revumenib) - (AUGMENT-101),Relapsed/refractory (R/R) acute leukemias ,Phase 2,08/04/2024 ET,"Phase 2 data reported a complete remission (CR) or CR with partial hematological recovery (CRh) rate was 23%, and the overall response rate was 46%, noted April 8, 2024.",86.14M
Add to portfolio,,,FTD,,,,,
,,,BTD,,,,,
ZYME,,$9.62 ,ZW191,"Non-small cell lung cancer, endometrial cancer, and triple-negative breast cancer ",Preclinical,08/04/2024 ET,"Preclinical data reported superior internalization, payload delivery, and spheroid penetration to other FRα-targeted multi-specific antibodies, noted April 8, 2024.",75.17M
Add to portfolio,,,,,,,,
BMRN,,—,BMN 401 (INZ-701) - (adults trial),ENPP1 deficiency ,Phase 1/2,08/04/2024 ET,"Phase 2 topline data showed avorable safety, immunogenicity and clinical outcome data were maintained through 48 weeks in Cohorts 1-3 in ENPP1 Deficiency; Data from Cohort 4 support once weekly dosing … read more",192.01M
Add to portfolio,,,,,,,,
MIST,,$1.82 ,Etripamil - (NODE-303),Paroxysmal supraventricular tachycardia (PSVT) ,Phase 3,08/04/2024 ET,Phase 3 data shared at ACC24 demonstrated that symptom-prompted treatment with etripamil was effective at restoring sinus rhythm as compared to placebo with a median time-to-conversion of 17.0 minutes … read more,84.99M
Add to portfolio,,,View Clinical Trial Data,,,,,
PSTX,,$2.97 ,P-BCMA-ALLO1,Multiple myeloma ,Phase 1,08/04/2024 ET,Phase 1 clinical early update presented at AACR suggests patients with relapsed/refractory multiple myeloma who progressed after prior BCMA-targeted therapy achieved clinical responses with P-BCMA-AL … read more,97.47M
Add to portfolio,,,ODD,,,,,
,,,RMAT,,,,,
KANT,,—,KVA12123 with KEYTRUDA (pembrolizumab) - (VISTA-101),Solid tumors ,Phase 1/2,08/04/2024 ET,"Phase 1/2 data presented at AACR showed a partial response and stable disease reported in combination cohort, and durable stable disease observed in monotherapy cohorts, noted April 8, 2024.",13.54M
Add to portfolio,,,,,,,,
VINC,,$4.78 ,VIP236,Solid tumors ,Phase 1,08/04/2024 ET,"Phase 1 initial data presented at AACR demonstrated positive signs of clinical activity, including tumor reduction, and an improved safety profile in heavily pretreated patients with metastatic solid … read more",5.23M
Add to portfolio,,,,,,,,
CRDF,,$5.88 ,"Onvansertib, FOLFIRI and AVASTIN (bevacizumab) - (ONSEMBLE)",KRAS-Mutated Colorectal Cancer ,Phase 1/2,08/04/2024 ET,Phase 1/2 data presented at AACR showed enhanced clinical efficacy signal in bev naïve patients is consistent with results of randomized ONSEMBLE trial providing two independent data sets in second-li … read more,66.53M
Add to portfolio,,,,,,,,
NUVL,,$68.44 ,Zidesamtinib - (NVL-330) - (HEROEX-1),HER2-mutant tumors ,Preclinical,08/04/2024 ET,"Preclinical data presented at AACR continue to support NVL-330's broad activity against HER2 oncogenic alterations, selectivity over wild-type EGFR, and differentiated brain-penetrant profile , Zidesa … read more",72.1M
Add to portfolio,,,,,,,,
MRUS,,$44.01 ,Zenocutuzumab (Zeno) in combination with Trastuzumab and Vinorelbine,Metastatic breast cancer ,Preclinical,08/04/2024 ET,"Phase 2 data presented at AACR data show that Zeno is effective in tumor cell killing in vitro and in vivo in high NRG1 expressing cancer models representing multiple different tumor types, April 8, 2 … read more",75.63M
Add to portfolio,,,View Clinical Trial Data,,,,,
GMAB,,—,Zenocutuzumab (Zeno) in combination with Trastuzumab and Vinorelbine,Metastatic breast cancer ,Preclinical,08/04/2024 ET,"Phase 2 data presented at AACR data show that Zeno is effective in tumor cell killing in vitro and in vivo in high NRG1 expressing cancer models representing multiple different tumor types, April 8, 2 … read more",661.87M
Add to portfolio,,,View Clinical Trial Data,,,,,
INKT,,$1.32 ,FAP-CAR-IL-15 iNKT (MiNK-215),Non-small cell lung cancer (NSCLC) ,Preclinical,08/04/2024 ET,Preclinical data shared at AACR exhibits potent anti-tumor activity through multiple mechanisms including immune activation and eliminated MSS colorectal cancer liver metastases in human organoid mode … read more,4.52M
Add to portfolio,,,,,,,,
CADL,,$6.43 ,Alpha 201-macro-1 (enLIGHTEN Discovery Platform),"Solid tumors, breast cancer ",Preclinical,08/04/2024 ET,"Preclinical data shared at AACR reported that treatment was shown to induce tertiary lymphoid structure formation, inhibit tumor growth, and improve response to immune checkpoint inhibitor therapy in … read more",54.9M
Add to portfolio,,,,,,,,
COGT,,$6.52 ,CGT4255 - (ErbB2),Solid tumors ,Preclinical,08/04/2024 ET,Preclinical data presented at AACR showed that data further demonstrate Cogent's capability to discover and advance potential best-in-class novel therapies for rare disease populations with high unmet … read more,139.7M
Add to portfolio,,,,,,,,
AGEN,,$9.31 ,BMS-986442 (AGEN1777),Solid tumors ,Preclinical,08/04/2024 ET,"Preclinical data presented at AACR reported that treatment demonstrated superior immune activation as monotherapy and in combination with PD-(L)1 blockade compared to conventional anti-TIGIT mAb, note … read more",31.86M
Add to portfolio,,,,,,,,
ADCT,,$5.09 ,ADCT-601 (mipasetamab uzoptirine),"Soft tissue sarcomas, pancreatic cancer and AXL-expressing non-small cell lung cancer (NSCLC) ",Phase 1b,08/04/2024 ET,"Phase 1b additional data presented at AACR reported that due to the incidence of TEAE judged related to Mipa and the preliminary activity observed, 15mg was selected as the highest dose to be tested i … read more",112.5M
Add to portfolio,,,,,,,,
ALXO,,$12.14 ,ALX148 and Vidaza (azacitidine) - (ASPEN-02),Myelodysplastic syndromes (MDS) ,Phase 1,08/04/2024 ET,"Phase 1 data presented at AACR reported that the combination results in high CR rates in patients with relapsed refractory iNHL, noted April 8, 2024.",53.55M
Add to portfolio,,,,,,,,
PYXS,,$5.58 ,PYX-106,Solid Tumors ,Preclinical,08/04/2024 ET,Additional preclinical data shared at AACR reported that Siglec-15 and PD-L1 mRNA expression are not broadly mutually exclusive across cancer indications and instead expression of each gene varies bro … read more,62.02M
Add to portfolio,,,,,,,,
ELTX,,$8.66 ,ELI-002 (AMPLIFY-201),Solid Tumors ,Phase 1,08/04/2024 ET,Phase 1 trial data presented at AACR reported that a majority of patients who received ELI-002 booster immunizations maintained or increased mKRAS-specific T cell responses relative to baseline. Durab … read more,16.34M
Add to portfolio,,,,,,,,
RIGL,,$12.60 ,REZLIDHIA (olutasidenib) - (CONNECT),High-grade glioma (HGG) harboring an isocitrate dehydrogenase-1 (IDH1) mutation ,Phase 2,08/04/2024 ET,"Phase 2 showed induced durable composite complete remission in 43.8% of patients relapsed or refractory to prior venetoclax-based regimens, noted April 8, 2024.",17.94M
Add to portfolio,,,,,,,,
PTN,,$2.02 ,PL9643 - (MELODY-1),Dry eye disease (DED) ,Phase 3,08/04/2024 ET,Phase 3 results presented at the ASCRS Conference 2024 included co-Primary symptom endpoint of pain met statistical significance and 7 of 11 secondary symptom endpoints met statistical significance (p … read more,46.48M
Add to portfolio,,,View Clinical Trial Data,,,,,
SUPN,,$31.43 ,ONAPGO (apomorphine hydrochloride) injection (SPN-830),Motor fluctuations in Parkinson’s disease (PD) ,CRL,08/04/2024 ET,"CRL announced April 8, 2024.",56.07M
Add to portfolio,,,,,,,,
ORIC,,$10.75 ,ORIC-944,Metastatic castration resistant prostate cancer (mCRPC) ,Preclinical,08/04/2024 ET,"Preclinical data demonstrated that EED and EZH2 inhibitors act through the same mechanism of action, making prostate cancer cells more susceptible to AR inhibition, noted April 8, 2024.",97.12M
Add to portfolio,,,,,,,,
PFE,,$25.84 ,DOVATO (Dolutegravir and lamivudine) - (DANCE),HIV-1 infection in adolescents 12 years + and weighing at least 25 kg with no antiretroviral (ARV) treatment history ,Approved,08/04/2024 ET,"FDA Approved on April 8, 2024.",5.69B
Add to portfolio,,,,,,,,
ENTX,,$1.95 ,EB613,Osteoporosis ,Phase 2,08/04/2024 ET,"Phase 2 publication in the Journal of Bone Mineral Research showed that despite the superior benefits of bone building (anabolic) agents and guidelines supporting their use, these medications are used … read more",45.66M
Add to portfolio,,,View Clinical Trial Data,,,,,
CHRS,,$2.51 ,CHS-1000,Solid Tumors ,Preclinical,08/04/2024 ET,"Preclinical studies showed a high affinity for human ILT4, reverses ILT4-mediated immunosuppressive functions, leading to activation of immune cells and increased cytokine secretion, noted April 8, 20 … read more",116.23M
Add to portfolio,,,,,,,,
NVCT,,$7.81 ,NXP900,Non-small cell lung cancer (NSCLC) ,Phase 1,08/04/2024 ET,"Phase 1 data presented at AACR demonstrated that the combination reverses resistance to osimertinib versus osimertinib alone, noted April 8, 2024.",25.46M
Add to portfolio,,,,,,,,
CCCC,,$7.66 ,CFT1946,Solid tumors ,Preclinical,08/04/2024 ET,"Preclinical data reported that a CFT1946 as a single agent and in combination with cetuximab demonstrates superior activity to the standard of care combination, BRAFi with cetuximab, in all CRC models … read more",71.17M
Add to portfolio,,,,,,,,
CORT,,$24.23 ,Relacorilant plus ABRAXANE (nab-paclitaxel) - (ROSELLA),Ovarian cancer ,Phase 3,08/04/2024 ET,"Phase 3 enrollment completed, noted April 8, 2024.",105.37M
Add to portfolio,,,,,,,,
INMB,,$10.36 ,INB03,MUC4 expressing cancer ,Phase 1,08/04/2024 ET,Trial data reported that the increase in T cell infiltrate did not occur unless both anti-HER2 and INB03 immunotherapy were used in combination. Decreases in T cell and macrophage immune checkpoint p … read more,26.59M
Add to portfolio,,,,,,,,
BMRN,,—,BMN 401 (INZ-701),ABCC6 deficiency ,Phase 1/2,08/04/2024 ET,"Phase 1/2 topline data reported a reduction or stabilization of cIMT was observed across all dose cohorts, and increased choroidal thickness was observed across all dose cohorts, noted April 8, 2024.",192.01M
Add to portfolio,,,ODD,,,,,
,,,FTD,,,,,
MRKR,,$4.71 ,Neldaleucel (MT-601) - (APOLLO),Lymphoma who have failed or are ineligible to receive anti-CD19 CAR T cell treatment ,Phase 1,08/04/2024 ET,"Phase 1 data reported that the initial dose level was well tolerated and demonstrated durable objective responses after MT-601 treatment, noted April 8, 2024.",12.94M
Add to portfolio,,,,,,,,
NVS,,$95.48 ,Leqvio - (V-INITIATE),Low-density lipoprotein cholesterol (LDL-C) in patients with atherosclerotic cardiovascular disease (ASCVD) ,Phase 3,08/04/2024 ET,"Phase 3b data reported significant reductions in LDL-C compared to those receiving usual care (60% vs. 7%), noted April 8, 2024.",1.98B
Add to portfolio,,,,,,,,
NXTC,,$2.05 ,LNCB74,B7-H4 expressing cancers ,Preclinical,08/04/2024 ET,"Preclinical data reported durable tumor regression in multiple CDX and PDX tumor models, suggesting activity comparable or superior to competitor B7-H4 targeting ADCs, noted April 8, 2024.",2.68M
Add to portfolio,,,,,,,,
OCS,,$10.76 ,OCS-01 - (OPTIMIZE-2),Inflammation and pain following ocular surgery ,Phase 3,08/04/2024 ET,"Phase 3 trial data reported that 57.2% of patients treated with OCS-01 were inflammation free (i.e. absence of anterior chamber cells) at Day 15, and 75.5% had absence of ocular pain at Day 4, noted A … read more",43.66M
Add to portfolio,,,,,,,,
CVKD,,$6.13 ,tecarfarin - (ARIES-HM3),Thromboembolism and thrombosis ,Phase 2,09/04/2024 ET,"FDA granted orphan drug designation, noted April 9, 2024.",2.05M
Add to portfolio,,,ODD,,,,,
ATOS,,$1.84 ,(Z)-endoxifen with abemaciclib (VERZENIO) - (EVANGELINE),Pre-menopausal women w/ early-stage estrogen receptor positive and Human Epidermal Growth Factor Receptor 2 negative breast cancer ,Phase 2,09/04/2024 ET,"Phase 2 data shared at AACR showed that a Among the six patients who were treated for a total of 24-weeks, magnetic resonance imaging (MRI) central review demonstrated target lesion decreases in all … read more",129.17M
Add to portfolio,,,,,,,,
LLY,,$754.94 ,(Z)-endoxifen with abemaciclib (VERZENIO) - (EVANGELINE),Pre-menopausal women w/ early-stage estrogen receptor positive and Human Epidermal Growth Factor Receptor 2 negative breast cancer ,Phase 2,09/04/2024 ET,"Phase 2 data shared at AACR showed that a Among the six patients who were treated for a total of 24-weeks, magnetic resonance imaging (MRI) central review demonstrated target lesion decreases in all … read more",946.46M
Add to portfolio,,,,,,,,
IMRX,,$2.19 ,Atebimetinib (IMM-1-104) + mGnP,"Solid tumors, pancreatic cancer, melanoma ",Preclinical,09/04/2024 ET,Preclinical data presented at AACR demonstrated that combining IMM-1-104 with chemotherapies used in the treatment of first-line pancreatic cancer yielded deeper and more durable tumor growth inhibiti … read more,36.32M
Add to portfolio,,,FTD,,,,,
,,,ODD,,,,,
CMPX,,$1.67 ,CTX-009 in combination with paclitaxel,Biliary Tract Cancer (cholangiocarcinoma) ,Preclinical,09/04/2024 ET,Preclinical data presented at AACR suggest that the combination of CTX-009 and CTX-471 could re-establish anti-tumor immunity in patients whose tumors have either downregulated or lost MHC-I expressio … read more,138.28M
Add to portfolio,,,,,,,,
MTEM,,$1.85 ,MT-6402,Solid tumors ,Phase 1,09/04/2024 ET,"Phase 1 interim data presented at AACR showed that drug has been well tolerated with no drug-related Grade 4 or Grade 5 adverse events observed, noted April 9, 2024.",6.58M
Add to portfolio,,,FTD,,,,,
NRIX,,$17.48 ,NX-5948,B-cell malignancies / graft-versus-host disease ,Phase 1a,09/04/2024 ET,Additional data with higher dose levels and longer treatment duration were reported at AACR; The company presented new case studies demonstrating clinical responses in two patients with B cell maligna … read more,76.88M
Add to portfolio,,,FTD,,,,,
IOBT,,$1.61 ,IO102-IO103 - (IOB-032),Squamous cell carcinoma of the head and neck (SCCHN) ,Phase 1/2,09/04/2024 ET,"Phase 1/2 early data presented at AACR demonstrated the mechanism. Based on these results the company hopes to confirm its ongoing Phase 3 pivotal study, noted April 9, 2024.",65.88M
Add to portfolio,,,,,,,,
RAPT,,$8.44 ,tivumecirnon (FLX475) in combination with pembrolizumab,Advanced Cancer ,Phase 2,09/04/2024 ET,"Phase 2 data shared at AACR confirmed an objective response rate (ORR) of 15.6% in all patients regardless of PD-L1 or HPV status, noted April 9, 2024.",16.54M
Add to portfolio,,,,,,,,
FHTX,,$7.48 ,FHD-909 (LY4050784),Non-small cell lung cancer (NSCLC) ,Preclinical,09/04/2024 ET,"Preclinical data presented at AACR demonstrated favorable tolerability and dose-dependent single agent activity in BRG1 mutated cancers preclinically, noted April 9, 2024.",56.53M
Add to portfolio,,,,,,,,
LLY,,$754.94 ,FHD-909 (LY4050784),Non-small cell lung cancer (NSCLC) ,Preclinical,09/04/2024 ET,"Preclinical data presented at AACR demonstrated favorable tolerability and dose-dependent single agent activity in BRG1 mutated cancers preclinically, noted April 9, 2024.",946.46M
Add to portfolio,,,,,,,,
INAB,,$1.09 ,INB-300,Solid Tumors ,Preclinical,09/04/2024 ET,"Preclinical data presented at AACR supports potential for proprietary nsCAR platform to selectively eliminate cancer cells while preserving healthy tissue, noted April 9, 2024.",4.54M
Add to portfolio,,,,,,,,
TPST,,$3.87 ,TPST-1120,renal cell carcinoma (RCC) ,Preclinical,09/04/2024 ET,"Preclinical data shared at AACR showed that TPST-1120 increases infiltrating cytotoxic CD8+ T cells in the tumor microenvironment, consistent with modulation of the tumor microenvironment to a more im … read more",4.44M
Add to portfolio,,,,,,,,
AZN,,$67.99 ,FPI-2265 - (AlphaBreak),Prostate cancer ,Phase 2,09/04/2024 ET,"Phase 2 preliminary data presented at AACR demonstrate that FPI-2265 is active in heavily pretreated patients with progressive metastatic castration-resistant prostate cancer (mCRPC), including those … read more",3.1B
Add to portfolio,,,,,,,,
PRLD,,$4.99 ,PRT7732,lymphoid malignancies ,Preclinical,09/04/2024 ET,"Preclinical data shared at AACR shows robust anti-tumor activity in vivo as monotherapy and in combination with chemotherapy, at well-tolerated doses, noted April 9, 2024.",56.6M
Add to portfolio,,,,,,,,
PRLD,,$4.99 ,PRT2527,Solid tumors and hematological malignancies ,Preclinical,09/04/2024 ET,"Additional preclinical data shared at the AACR provides improved depth and duration of response in combination with BTK/BCL2 inhibition, noted April 9, 2024.",56.6M
Add to portfolio,,,,,,,,
PRLD,,$4.99 ,PRT3645,Cancer ,Preclinical,09/04/2024 ET,"Preclinical data at AACR showed that drug is highly effective in combination with other targeted therapies in preclinical models of breast cancer, CRC and NSCLC, noted April 9, 2024.",56.6M
Add to portfolio,,,,,,,,
CRVS,,$1.63 ,Soquelitinib - (CPI-818),Peripheral T-cell lymphoma (PTCL) ,Phase 3,09/04/2024 ET,"Phase 3 dosing initiated, noted April 9, 2024.",74.51M
Add to portfolio,,,FTD,,,,,
MCRB,,$0.71 ,SER-155,"Gastrointestinal infections, bacteremia and graft versus host disease (GvHD) ",Phase 1b,09/04/2024 ET,"Phase 1b cohort 2 patient enrollment completed, noted April 9, 2024.",8.75M
Add to portfolio,,,FTD,,,,,
,,,BTD,,,,,
QLGN,,$0.40 ,QN-302,"Pancreatic cancer, Prostate cancer and other solid tumors ",Phase 1,09/04/2024 ET,"Phase 1 results demonstrated that for the first five patients (three of whom were PDAC patients), QN-302 is overall well-tolerated (no SAE) and they have reported a ""good"" quality of life during the d … read more",1.7M
Add to portfolio,,,ODD,,,,,
BCTX,,$2.85 ,SV-BR-1-GM,Metastatic breast cancer ,Phase 2,09/04/2024 ET,"Phase 2 efficacy and safety data shared at AACR shows that Bria-IMT provides prolonged progression-free survival and clinical benefits in heavily pre-treated, ADC resistant breast cancer patients comp … read more",1.76M
Add to portfolio,,,,,,,,
BCTX,,$2.85 ,Bria-IMT - (BRIA-ABC),Advanced breast cancer ,Phase 2,09/04/2024 ET,Phase 2 data shared at AACR showed that Bria-IMT's tumor reductions observed in all breast cancer subtypes in patients with intracranial disease underlines its potential clinical effectiveness in mana … read more,1.76M
Add to portfolio,,,,,,,,
IPHA,,$2.60 ,IPH45,Nectin-4 expressing tumors ,Preclinical,09/04/2024 ET,"Preclinical data presented at AACR reported that treatment effectively inhibits Nectin-4 expressing tumor growth both in vitro and in vivo, including in Enfortumab Vedotin (EV) refractory models, note … read more",92.16M
Add to portfolio,,,,,,,,
ALXO,,$12.34 ,ALX148 (evorpacept) + rituximab and lenalidomide,Non-Hodgkin lymphoma (NHL) ,Phase 1,09/04/2024 ET,"Phase 1 trial data presented at AACR reported that the best ORR of 94% and a CRR of 83%, noted April 9, 2024.",53.55M
Add to portfolio,,,,,,,,
GNPX,,$3.07 ,REQORSA (GPX-001) with KEYTRUDA (pembrolizumab) - (Acclaim-2),Non-Small Cell Lung Cancer (NSCLC) ,Preclinical,09/04/2024 ET,"Preclinical data presented at AACR reported that the NPRL2 treatment by itself led to a marked decrease in the size of lung metastases but pembrolizumab had no effect, noted April 9, 2024.",858.11K
Add to portfolio,,,FTD,,,,,
CGEN,,$2.36 ,COM503,Solid tumors ,Preclinical,09/04/2024 ET,"Preclinical data shared at AACR found that COM503's activity is localized to the tumor microenvironment with the additional advantage of a wider therapeutic window than systemic IL-18 delivery, noted … read more",93.51M
Add to portfolio,,,,,,,,
GILD,,$69.12 ,COM503,Solid tumors ,Preclinical,09/04/2024 ET,"Preclinical data shared at AACR found that COM503's activity is localized to the tumor microenvironment with the additional advantage of a wider therapeutic window than systemic IL-18 delivery, noted … read more",1.24B
Add to portfolio,,,,,,,,
NTBL,,$1.41 ,Volasertib,Relapsed/refractory acute myeloid leukemia ,Preclinical,09/04/2024 ET,"Preclinical data presented at AACR suggest a strong correlation between volasertib resistant fractions treated with 31.6 and 100 nM of volasertib and AUCs, which could represent a suitable metric to s … read more",9.66M
Add to portfolio,,,,,,,,
PFE,,$26.03 ,ABRYSVO - (MONeT),Respiratory syncytial virus (RSV)-associated lower respiratory tract disease (LRTD) ,Phase 3,09/04/2024 ET,"Phase 3 trial met its primary endpoint, noted April 9, 2024.",5.69B
Add to portfolio,,,,,,,,
BGNE,,$154.02 ,Tislelizumab (anti-PD1) plus ociperlimab (anti-TIGIT) - (AdvanTIG-204),Small cell lung cancer (SCLC) ,Phase 2,09/04/2024 ET,"Phase 2 data presented at AACR reported that in patients with untreated limited-stage SCLC, tislelizumab + cCRT yielded a trend of improvement in PFS and ORR vs cCRT; addition of ociperlimab did not s … read more",106.62M
Add to portfolio,,,,,,,,
ONC,,—,Tislelizumab (anti-PD1) plus ociperlimab (anti-TIGIT) - (AdvanTIG-204),Small cell lung cancer (SCLC) ,Phase 2,09/04/2024 ET,"Phase 2 data presented at AACR reported that in patients with untreated limited-stage SCLC, tislelizumab + cCRT yielded a trend of improvement in PFS and ORR vs cCRT; addition of ociperlimab did not s … read more",110.03M
Add to portfolio,,,,,,,,
BGNE,,$154.02 ,BGB-10188,Solid tumors ,Phase 1a,09/04/2024 ET,Phase 1a data presented at AACR reported that BGB‑10188 + tislelizumab showed preliminary antitumor activity and was generally safe and tolerable across doses in this heavily pretreated population of … read more,106.62M
Add to portfolio,,,,,,,,
ONC,,—,BGB-10188,Solid tumors ,Phase 1a,09/04/2024 ET,Phase 1a data presented at AACR reported that BGB‑10188 + tislelizumab showed preliminary antitumor activity and was generally safe and tolerable across doses in this heavily pretreated population of … read more,110.03M
Add to portfolio,,,,,,,,
CCCC,,$7.97 ,CFT8634,Synovial sarcoma ,Phase 1,09/04/2024 ET,"Phase 1 data presented at AACR reported that selective targeting of EP300 with targeted protein degradation is a safe and effective treatment strategy for advanced tumors, noted April 9, 2024.",71.17M
Add to portfolio,,,ODD,,,,,
BCYC,,$23.07 ,BT7455,EphA2-expressing cancers ,Preclinical,09/04/2024 ET,"Preclinical data shared at AACR reported that treatment engages EphA2 and CD137 with high affinity, resulting in potent EphA2-dependent activity in vitro and robust anti-tumor activity in vivo with in … read more",69.31M
Add to portfolio,,,,,,,,
APRE,,$6.04 ,ATRN-119,Advanced solid tumors ,Phase 1/2,09/04/2024 ET,Phase 1/2a trial shared at AACR reported that two of 12 patients achieved stable disease (SD): one patient from Dose level 1 (50 mg) who progressed on Day 112 and one patient from Dose level 3 (200 mg … read more,5.83M
Add to portfolio,,,,,,,,
YS,,$0.90 ,PIKA Rabies Vaccine,Rabies ,Phase 3,10/04/2024 ET,"Phase 3 trial met its primary endpoints, noted April 10, 2024.",93.06M
Add to portfolio,,,,,,,,
WHWK,,—,Nab-sirolimus in combination with fulvestrant,Breast Cancer ,Preclinical,10/04/2024 ET,"Preclinical data presented at AACR reported that nab-sirolimus enhanced the cytotoxic effects of fulvestrant in HR+ breast cancer cells and PI3Ki in both HR+ and HR- breast cancer cells, noted April 1 … read more",47.13M
Add to portfolio,,,,,,,,
BTAI,,$2.63 ,Dexmedetomidine (BXCL501) - (TRANQUILITY III),Agitation associated with Alzheimer’s Disease ,Phase 3,10/04/2024 ET,"Phase 3 expanded to In-Care study, trial planned to initiate soon following FDA meeting, noted April 10, 2024.",14.56M
Add to portfolio,,,BTD,,,,,
VSTM,,$11.30 ,GFH375/VS-7375,Cancer KRAS G12D ,Preclinical,10/04/2024 ET,"Preclinical data shared at AACR shown potent efficacy and safety of orally administered GFH375 in animal models, noted April 8, 2024.",61.55M
Add to portfolio,,,,,,,,
GALT,,$3.82 ,GR-MD-02 (belapectin) - (NAVIGATE),Non-alcoholic steatohepatitis (NASH) with cirrhosis ,Phase 2/3,10/04/2024 ET,"5th DSMB recommends the continuation, without modifications, noted April 10, 2024.",64.06M
Add to portfolio,,,FTD,,,,,
,,,View Clinical Trial Data,,,,,
ALKS,,$26.14 ,ALKS 2680 - (Vibrance-1),Narcolepsy ,Phase 1,10/04/2024 ET,Phase 1 demonstrated clinically meaningful and statistically significant improvements from baseline in mean sleep latency compared to placebo at all doses tested in both narcolepsy type 2 and idiopath … read more,165.08M
Add to portfolio,,,,,,,,
ACRV,,$10.39 ,ACR-2316,"Dual WEE1 and PKMYT1 inhibitor, Solid tumors ",Preclinical,10/04/2024 ET,"Preclinical data presented at AACR reported that treatment was highly potent across multiple human tumor cell lines and patient-derived ex vivo tumor models, noted April 10, 2024.",31.46M
Add to portfolio,,,,,,,,
AIM,,$0.56 ,"Ampligen, cisplatin and KEYTRUDA (pembrolizumab)",Ovarian cancer ,Phase 2,10/04/2024 ET,"Phase 2 protocol planned interim results by leading the investigator to concluded that the combination therapy could be far more effective than pembrolizumab alone as a therapy for the disease, noted … read more",2.71M
Add to portfolio,,,View Clinical Trial Data,,,,,
BCTX,,$2.73 ,Bria-Pros+,Prostate cancer ,Preclinical,10/04/2024 ET,"Preclinical data reported that treatment engaged with multiple facets of the adaptive immune response, which may result in lasting anti-cancer effects in patients, noted April 10, 2024.",1.76M
Add to portfolio,,,,,,,,
AMLX,,$2.46 ,AMX0035 - (HELIOS),Wolfram Syndrome ,Phase 2,10/04/2024 ET,"Phase 2 data demonstrated improvements in pancreatic function and glycemic control, as measured by C-peptide and other markers of glucose metabolism, rather than worsening typically expected with dise … read more",89.17M
Add to portfolio,,,ODD,,,,,
REGN,,$936.20 ,BNT116 and Libtayo - (LuCa-MERIT-1),Non-small cell lung cancer (NSCLC) ,Phase 1,10/04/2024 ET,"Phase 1 trial preliminary results presented at AACR reported that BNT116 + DTX shows encouraging antitumor activity, consistent induction of immune responses, a manageable safety profile, and no signs … read more",105.99M
Add to portfolio,,,,,,,,
BNTX,,$88.65 ,BNT116 and Libtayo - (LuCa-MERIT-1),Non-small cell lung cancer (NSCLC) ,Phase 1,10/04/2024 ET,"Phase 1 trial preliminary results presented at AACR reported that BNT116 + DTX shows encouraging antitumor activity, consistent induction of immune responses, a manageable safety profile, and no signs … read more",239.97M
Add to portfolio,,,,,,,,
APVO,,$2.40 ,ALG.APV-527,Solid tumors ,Phase 1,10/04/2024 ET,"Phase 1 Cohort 5 dosing imminent, trial more than 50% enrolled, noted April 10, 2024.",3.29M
Add to portfolio,,,,,,,,
APVO,,$2.40 ,mipletamig (APVO711),Solid tumors ,Preclinical,10/04/2024 ET,"Preclinical studies ongoing, in vivo studies have confirmed that APVO711 reduces the size of PD-L1-expressing tumors, noted April 10, 2024.",3.29M
Add to portfolio,,,,,,,,
CRBU,,$4.35 ,CB-012,Acute Myeloid Leukemia (AML) ,Preclinical,10/04/2024 ET,"Preclinical data presented at AACR reported that in robust tumor control, leading to significant prolongation of survival in AML xenograft models, noted April 10, 2024.",93.12M
Add to portfolio,,,,,,,,
VRTX,,$397.58 ,Povetacicept (ALPN-303) - (RAINIER),"Lupus nephritis, IgA nephropathy ",Phase 2,10/04/2024 ET,"Phase 1b/2a 240mg data presented at the World Congress of Nephrology showed that treatment continues to be well tolerated in IgA nephropathy, with UPCR reductions of greater than 60% observed at 36 we … read more",256.39M
Add to portfolio,,,,,,,,
ALPN,,$47.04 ,Povetacicept (ALPN-303) - (RAINIER),"Lupus nephritis, IgA nephropathy ",Phase 2,10/04/2024 ET,"Phase 1b/2a 240mg data presented at the World Congress of Nephrology showed that treatment continues to be well tolerated in IgA nephropathy, with UPCR reductions of greater than 60% observed at 36 we … read more",68.6M
Add to portfolio,,,,,,,,
KRYS,,$175.70 ,KB707 - (KYANITE-1),Solid Tumors ,Preclinical,10/04/2024 ET,"Preclinical data shared at AACR reported that KB703/KB704 treatment enhanced the frequency of IFNγ-expressing T cells both in the tumor and tumor-draining lymph node, leading to higher levels of circu … read more",28.94M
Add to portfolio,,,FTD,,,,,
,,,RPDD,,,,,
LPCN,,$6.41 ,LPCN 2401,"Obesity, Chronic Weight Management ",Phase 2,11/04/2024 ET,Phase 2 treatment resulted in statistically significant body composition improvement in men Increased lean mass (LM) by 4.4% and decreased fat mass (FM) by 6.7%. Reduced android fat (AF) by 4.1% and i … read more,5.42M
Add to portfolio,,,,,,,,
PRTC,,$27.93 ,LYT-200,"Solid tumors, urothelial and head and neck cancers, acute myeloid leukemia (AML) ",Phase 1/2,11/04/2024 ET,"Fast track designation granted by the FDA, noted April 11, 2024.",24.17M
Add to portfolio,,,FTD,,,,,
,,,ODD,,,,,
CLYM,,—,Budoprutug (TNT119),Systemic lupus erythematosus ,Phase 2,11/04/2024 ET,"Phase 2 ongoing, acquired by Eliem from Tenet Medicines, noted April 11, 2024.",67.76M
Add to portfolio,,,,,,,,
CLYM,,—,Budoprutug (TNT119),Immune thrombocytopenia ,Phase 2,11/04/2024 ET,"Phase 2 ongoing, acquired by Eliem from Tenet Medicines, noted April 11, 2024.",67.76M
Add to portfolio,,,,,,,,
CLYM,,—,Budoprutug (TNT119),Membranous nephropathy ,Phase 1,11/04/2024 ET,"Phase 1 ongoing, acquired by Eliem from Tenet Medicines, noted April 11, 2024.",67.76M
Add to portfolio,,,,,,,,
BOLD,,$11.63 ,BBI-355/BBI-825 - (POTENTIATE),Resistance gene amplifications ,Phase 1/2,11/04/2024 ET,"Phase 1/2 dosing commenced, noted April 11, 2024.",22.39M
Add to portfolio,,,,,,,,
AZN,,$69.02 ,FASENRA (benralizumab) - (TATE),Eosinophilic asthma aged 6 to 11 with an eosinophilic phenotype ,Approved,11/04/2024 ET,"FDA approved on April 11, 2024.",3.1B
Add to portfolio,,,,,,,,
RARE,,$42.87 ,GTX-102 - (Aspire),Angelman Syndrome ,Phase 1/2,15/04/2024 ET,"Phase 1/2 data from expansion cohorts showed rapid, clinically meaningful improvement across multiple domains; improvements consistent or exceeding Dose-escalation Cohorts data at Day 170, noted April … read more",96.37M
Add to portfolio,,,BTD,,,,,
LGND,,$79.77 ,ZTALMY (ganaxolone) - (RAISE),Refractory status epilepticus (RSE) ,Phase 3,15/04/2024 ET,Phase 3 did not meet pre-defined stopping criteria at the interim analysis; Marinus has completed RAISE enrollment at approximately 100 patients with topline results expected summer 2024.,19.6M
Add to portfolio,,,View Clinical Trial Data,,,,,
MRNS,,$1.30 ,ZTALMY (ganaxolone) - (RAISE),Refractory status epilepticus (RSE) ,Phase 3,15/04/2024 ET,Phase 3 did not meet pre-defined stopping criteria at the interim analysis; Marinus has completed RAISE enrollment at approximately 100 patients with topline results expected summer 2024.,55.19M
Add to portfolio,,,View Clinical Trial Data,,,,,
TFFP,,$3.52 ,TFF TAC (Tacrolimus Inhalation Powder),Lung transplant (post) ,Phase 2,15/04/2024 ET,Phase 2 updates data to be presented at the upcoming ISHLT 2024 meeting provided strong biomarker evidence that treatment with TFF TAC results in normalization of rejection-related genes; the treatmen … read more,4.44M
Add to portfolio,,,,,,,,
VIRX,,$0.78 ,Nanatinostat - (NAVAL-1),Epstein Barr Virus-associated cancers ,Phase 2,15/04/2024 ET,Phase 2 Stage 1 data from patients in the Nana-val treatment arm achieved clinically meaningful anti-tumor responses with an overall response rate of 50% and a complete response rate of 20% in the int … read more,39.74M
Add to portfolio,,,,,,,,
RNAZ,,$0.54 ,TTX-MC138,Metastatic solid tumors ,Phase 1/2,15/04/2024 ET,"IND clearance by the FDA, noted April 15, 2024.",833.68K
Add to portfolio,,,ODD,,,,,
ONVO,,$1.35 ,FXR314,MASH & Primary Biliary Cholangitis ,Phase 2,15/04/2024 ET,"Phase 2 16-week details study results demonstrated a statistically significant reduction in liver fat content from baseline in patients receiving FXR314 compared to placebo, noted April 15, 2024.",1.8M
Add to portfolio,,,,,,,,
CORT,,$23.15 ,Dazucorilant (DAZALS),Amyotrophic Lateral Sclerosis (ALS) ,Phase 2,15/04/2024 ET,"Phase 2 enrollment completed, noted April 15, 2024.",105.37M
Add to portfolio,,,,,,,,
EWTX,,$16.48 ,sevasemten (EDG-5506) - (ARCH),Becker muscular dystrophy (BMD) ,Phase 1b,15/04/2024 ET,"Phase 1b 24-months topline data showed that significant decreases were observed in circulating levels of creatine kinase (CK) and fast skeletal muscle troponin I (TNNI2), biomarkers associated with sk … read more",105.35M
Add to portfolio,,,ODD,,,,,
ORIC,,$9.54 ,ORIC-114,"Tumors - EGFR/HER2 Exon 20 Inhibitor, 1L NSCLC ",Phase 1b,15/04/2024 ET,"Phase 1b expansion cohorts initiated, noted April 15, 2024.",97.12M
Add to portfolio,,,,,,,,
TELO,,$8.84 ,Telomir-1,Age-related conditions ,Preclinical,15/04/2024 ET,"Preclinical data confirmed our hypothesis that TELOMIR-1 affects telomere length, promoting its extension in primary cell strains including MRC-5, HUVEC, and MSCs (~40% increase), noted April 15, 2024 … read more",32.28M
Add to portfolio,,,,,,,,
LBPH,,$18.25 ,Bexicaserin (LP352) - (DEEp OCEAN),Adolescent and adult patients with developmental and epileptic encephalopathies (DEEs) ,Phase 1/2,15/04/2024 ET,"Phase 1b/2a data presented at the AAN Annual Meeting reported that treatment with bexicaserin reduced seizures in all participant subgroups, including LGS and DEE Other, noted April 15, 2024.",39.05M
Add to portfolio,,,BTD,,,,,
NVS,,$94.41 ,Fabhalta (iptacopan),IgA nephropathy (IgAN) ,Phase 3,15/04/2024 ET,"Phase 3 data show clinically meaningful and statistically significant proteinuria reduction of 38.3% versus placebo, noted April 15, 2024.",1.98B
Add to portfolio,,,View Clinical Trial Data,,,,,
HALO,,$38.38 ,Efgartigimod - (ADHERE),Chronic inflammatory demyelinating polyneuropathy (CIDP) ,Phase 3,16/04/2024 ET,"Phase 3 data presented at AAN reported that 67% of patients treated with VYVGART Hytrulo demonstrated evidence of clinical improvement (ECI), including 40% who had achieved ECI by the earliest possibl … read more",116.97M
Add to portfolio,,,BTD,,,,,
ARGX,,$370.68 ,Efgartigimod - (ADHERE),Chronic inflammatory demyelinating polyneuropathy (CIDP) ,Phase 3,16/04/2024 ET,"Phase 3 data presented at AAN reported that 67% of patients treated with VYVGART Hytrulo demonstrated evidence of clinical improvement (ECI), including 40% who had achieved ECI by the earliest possibl … read more",60.99M
Add to portfolio,,,BTD,,,,,
ZLAB,,$14.42 ,Efgartigimod - (ADHERE),Chronic inflammatory demyelinating polyneuropathy (CIDP) ,Phase 3,16/04/2024 ET,"Phase 3 data presented at AAN reported that 67% of patients treated with VYVGART Hytrulo demonstrated evidence of clinical improvement (ECI), including 40% who had achieved ECI by the earliest possibl … read more",109.96M
Add to portfolio,,,BTD,,,,,
JNJ,,—,CAPLYTA (lumateperone) - (Study 501),Major depressive disorder (MDD) ,Phase 3,16/04/2024 ET,"Phase 3 topline results for the 42 mg Cohort achieved statistically significant and clinically meaningful results in both the primary and the key secondary endpoints, noted April 16, 2024.",2.41B
Add to portfolio,,,,,,,,
PRTC,,$25.48 ,Deupirfenidone (LYT-100) - (ELEVATE IPF),Idiopathic pulmonary fibrosis (IPF) ,Phase 2,16/04/2024 ET,"Phase 2 enrollment completed, noted April 16, 2024.",24.17M
Add to portfolio,,,,,,,,
CGEM,,$17.32 ,CLN-978,Relapsed/refractory B-cell non-Hodgkin lymphoma ,Phase 1,16/04/2024 ET,"The company has discontinued enrollment in its B-NHL study to focus ongoing development on autoimmune indications, noted April 16, 2024.",59.07M
Add to portfolio,,,,,,,,
PALI,,$5.93 ,PALI-2108,Moderate-to-severe ulcerative colitis (UC) ,Preclinical,16/04/2024 ET,"Preclinical data completion of exvivo analysis, noted April 16, 2024.",9.12M
Add to portfolio,,,,,,,,
CMPX,,$1.57 ,CTX-8371,Solid Tumors ,Phase 1,16/04/2024 ET,"Phase 1 dosing initiated, noted April 16, 2024.",138.28M
Add to portfolio,,,,,,,,
ABOS,,$3.50 ,Sabirnetug (ACU193) - (INTERCEPT-AD),Alzheimer’s disease (AD) ,Phase 1,16/04/2024 ET,"Phase 1 additional data presented at AAN demonstrated a favorable safety and tolerability profile in participants with early AD with a relatively low incidence of ARIA-E, noted April 16, 2024.",60.57M
Add to portfolio,,,FTD,,,,,
LEXX,,$2.31 ,DehydraTECH-GLP-1 - (GLP-1-H24-2),"Healthy volunteers, Diabetes-related control, weight loss ",Preclinical,16/04/2024 ET,"Preclinical approval has been received from an independent third-party ethics review board, for human pilot study #2, noted April 16, 2024.",19.56M
Add to portfolio,,,,,,,,
CLNN,,$6.20 ,CNM-Au8 - (VISIONARY-MS),Multiple Sclerosis ,Phase 2,16/04/2024 ET,"Phase 2 LTE emonstrated significant evidence of repair and remyelination across multiple paraclinical endpoints, noted April 16, 2024.",9.99M
Add to portfolio,,,View Clinical Trial Data,,,,,
PXMD,,$0.66 ,PAX-HAT-301,Stage 1 Trypanosoma Brucei Rhodesiense Human African Trypanosomiasis (Stage 1 TBR HAT) ,NDA Filing,16/04/2024 ET,"NDA Company received an urgent request from the Ministry of Health (MOH) of Malawi, asking for emergency access to IV suramin to avert a potential humanitarian crisis brought on by dwindling supplies … read more",10.88M
Add to portfolio,,,ODD,,,,,
TEVA,,$13.09 ,SELARSDI (ustekinumab-aekn) - (STELARA biosimilar),moderate to severe plaque psoriasis and for active psoriatic arthritis in adults and pediatric patients 6 years and older. ,Approved,16/04/2024 ET,"FDA approved on April 16, 2024.",1.15B
Add to portfolio,,,,,,,,
ALVO,,$12.73 ,SELARSDI (ustekinumab-aekn) - (STELARA biosimilar),moderate to severe plaque psoriasis and for active psoriatic arthritis in adults and pediatric patients 6 years and older. ,Approved,16/04/2024 ET,"FDA approved on April 16, 2024.",301.81M
Add to portfolio,,,,,,,,
SAGE,,$12.57 ,Dalzanemdor (SAGE-718) - (PRECEDENT),Mild cognitive impairment (MCI) ,Phase 2,17/04/2024 ET,"Phase 2 data did not show statistically significant differences versus placebo on the primary endpoint , noted April 17, 2024.",62.78M
Add to portfolio,,,,,,,,
SUPN,,—,Dalzanemdor (SAGE-718) - (PRECEDENT),Mild cognitive impairment (MCI) ,Phase 2,17/04/2024 ET,"Phase 2 data did not show statistically significant differences versus placebo on the primary endpoint , noted April 17, 2024.",56.07M
Add to portfolio,,,,,,,,
LLY,,$748.49 ,Zepbound (Tirzepatide) - (SURMOUNT-OSA),Obstructive Sleep Apnea (OSA) ,Phase 3,17/04/2024 ET,"Phase 3 trial data showed tirzepatide injection (10 mg or 15 mg) significantly reduced the apnea-hypopnea index (AHI) compared to placebo, achieving the primary endpoints, noted April 17, 2024.",946.46M
Add to portfolio,,,FTD,,,,,
GSK,,$38.91 ,Blujepa (Gepotidacin) - (EAGLE 2/3),Uncomplicated urinary tract infection (uUTI) ,Phase 3,17/04/2024 ET,"Phase 3 EAGLE-1 data from ESCMID reported that gepotidacin (oral, two doses of 3,000mg) was non-inferior with 92.6% success rates when compared to 91.2% success rates for intramuscular (IM) ceftriaxon … read more",2.03B
Add to portfolio,,,View Clinical Trial Data,,,,,
RHHBY,,$30.08 ,Ocrevus Zunovo,Multiple sclerosis (MS) or primary progressive MS ,Phase 3,17/04/2024 ET,Phase 3 data reported near-complete suppression of clinical relapses and brain lesions in people with relapsing or primary progressive multiple sclerosis (RMS or PPMS) which reinforce the potential be … read more,6.36B
Add to portfolio,,,,,,,,
HALO,,$38.02 ,Ocrevus Zunovo,Multiple sclerosis (MS) or primary progressive MS ,Phase 3,17/04/2024 ET,Phase 3 data reported near-complete suppression of clinical relapses and brain lesions in people with relapsing or primary progressive multiple sclerosis (RMS or PPMS) which reinforce the potential be … read more,116.97M
Add to portfolio,,,,,,,,
NVS,,$93.08 ,Kesimpta (ofatumumab) - (ALITHIOS),Relapsing Multiple Sclerosis ,Phase 3,17/04/2024 ET,"Additional Phase 3 data reported that significant reductions in ARR (71.3%) and in MRI lesion activity (Gd+ T1: 98.5% reduction; neT2: 93% reduction), and rapid increase in rates of NEDA-3, noted Apri … read more",1.98B
Add to portfolio,,,,,,,,
MTVA,,—,DA-1726,NASH and obesity ,Phase 1a,17/04/2024 ET,"Phase 1a dosing initiated, noted April 17, 2024.",24.2M
Add to portfolio,,,,,,,,
VIGL,,$2.92 ,iluzanebart (VGL101) - (IGNITE),Adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP) ,Phase 2,17/04/2024 ET,"Phase 2 interim results shared at the 2024 American Academy of Neurology (AAN) Annual Meeting demonstrated iluzanebart (VGL101) as potential disease-modifying therapy for ALSP, noted April 17, 2024.",46.67M
Add to portfolio,,,,,,,,
SNY,,—,iluzanebart (VGL101) - (IGNITE),Adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP) ,Phase 2,17/04/2024 ET,"Phase 2 interim results shared at the 2024 American Academy of Neurology (AAN) Annual Meeting demonstrated iluzanebart (VGL101) as potential disease-modifying therapy for ALSP, noted April 17, 2024.",2.46B
Add to portfolio,,,,,,,,
VIGL,,$2.92 ,VGL101 - (ILLUMINATE),Adult-Onset Leukoencephalopathy with Axonal Spheroids and Pigmented Glia (ALSP) ,Phase 2,17/04/2024 ET,"Phase 2 Natural History Study show that MRI and fluid biomarkers are emerging as key measures of ALSP pathophysiology, noted April 17, 2024.",46.67M
Add to portfolio,,,ODD,,,,,
,,,FTD,,,,,
SNY,,—,VGL101 - (ILLUMINATE),Adult-Onset Leukoencephalopathy with Axonal Spheroids and Pigmented Glia (ALSP) ,Phase 2,17/04/2024 ET,"Phase 2 Natural History Study show that MRI and fluid biomarkers are emerging as key measures of ALSP pathophysiology, noted April 17, 2024.",2.46B
Add to portfolio,,,ODD,,,,,
,,,FTD,,,,,
DMAC,,$2.60 ,Rinvecalinase Alfa (DM199) - (ReMEDy2),Acute ischaemic stroke (AIS) ,Phase 2/3,17/04/2024 ET,"Phase 2/3 resumed with dosing of first patient, noted April 17, 2024.",51.69M
Add to portfolio,,,View Clinical Trial Data,,,,,
GLPG,,$29.22 ,GLPG5101 - (ATALANTA-1),Relapsed/refractory Non-Hodgkin Lymphoma (rrNHL) ,Phase 1/2,17/04/2024 ET,"Phase 1/2 preliminary data reported that six patients responded to treatment (ORR 86%), including four CRs (CRR 57%), noted April 17, 2024.",65.9M
Add to portfolio,,,RMAT,,,,,
ATHA,,$2.11 ,ATH-1020,"Healthy volunteers, Neuropsychiatric conditions ",Preclinical,17/04/2024 ET,"Preclinical data presented at AAN reported that significantly enhanced neurite outgrowth, increased synaptic count, and promoted survival in primary neuron cultures, noted April 17, 2024.",3.94M
Add to portfolio,,,,,,,,
GLPG,,$29.22 ,GLPG5201 - (EUPLAGIA-1),"B-cell malignancies, Chronic Lymphocytic Leukemia (CLL) and Small Lymphocytic Lymphoma (SLL) ",Phase 1/2,17/04/2024 ET,"Phase 1/2 data reported an ORR of 93% , noted April 17, 2024.",65.9M
Add to portfolio,,,,,,,,
ABBV,,$163.15 ,Tavapadon - (TEMPO-3),Late Parkinson’s disease ,Phase 3,18/04/2024 ET,"Phase 3 trial met its primary endpoint, noted April 18, 2024.",1.77B
Add to portfolio,,,View Clinical Trial Data,,,,,
OCUL,,$5.86 ,AXPAXLI (OTX-TKI) - (HELIOS),Non-proliferative diabetic retinopathy (NPDR) ,Phase 1,18/04/2024 ET,"Phase 1 interim data showed that demonstrated a 1- or 2-step improvement in the Diabetic Retinopathy Severity Scale (DRSS) at 40 weeks in the AXPAXLI arm, compared to 0% in the control arm. No patient … read more",174M
Add to portfolio,,,,,,,,
BPTH,,$4.20 ,BP1002,Acute Myeloid Leukemia (AML) ,Phase 1b,18/04/2024 ET,"Phase 1/1b second dose cohort completed, noted April 18, 2024.",8.31M
Add to portfolio,,,,,,,,
BNTC,,$6.82 ,BB-301,Oculopharyngeal muscular dystrophy (OPMD) ,Phase 1/2,18/04/2024 ET,"Phase 1b/2a interim safety and efficacy data reported that facilitated improvements across multiple measures of swallowing function in the first subject, as compared to pretreatment assessments conduc … read more",26.25M
Add to portfolio,,,ODD,,,,,
PBLA,,$0.49 ,Lvospemin (SBP-101),Ovarian cancer ,Phase 1,18/04/2024 ET,"Phase 1 data presented at AACR results suggest that SBP-101 in combination with doxorubicin may have a role in the clinical management of ovarian cancer, in particular the difficult to treat platinum- … read more",4.85M
Add to portfolio,,,,,,,,
ATNM,,$6.67 ,Iomab-B - (SIERRA),Acute myeloid leukemia (AML) ,Phase 3,18/04/2024 ET,Phase 3 data presented at the Annual European Bone Marrow Transplant Society Meeting (EBMT) demonstrated that Iomab-B led bone marrow transplant produced high rates of complete remission and durable c … read more,31.2M
Add to portfolio,,,View Clinical Trial Data,,,,,
IMNN,,$1.13 ,IMNN-101 - (IMUNON),SARS-CoV-2 variant XBB.1.5 ,IND-Enabling,18/04/2024 ET,"IND Cleared by the FDA, noted April 18, 2024.",2.52M
Add to portfolio,,,,,,,,
ABBV,,$163.15 ,Upadacitinib (RINVOQ) - (SELECT-GCA),Giant cell arteritis (GCA) ,Phase 3,18/04/2024 ET,"Phase 3 showed that upadacitinib (RINVOQ; 15 mg, once daily) in combination with a 26-week steroid taper regimen achieved its primary endpoint of sustained remissiona from week 12 through week 52, not … read more",1.77B
Add to portfolio,,,,,,,,
NRSN,,$1.52 ,PrimeC - (PARADIGM),Amyotrophic Lateral Sclerosis (ALS) ,Phase 2b,18/04/2024 ET,Phase 2b data presented at AAN reported that PrimeC met safety and tolerability measures as well as statistically significant slowing of disease progression as demonstrated by the ALSFRS-R by 37% (p=0 … read more,23.99M
Add to portfolio,,,,,,,,
PHRRF,,$0.17 ,KETARX (ketamine),Surgical pain management ,CRL,18/04/2024 ET,"CRL issued by FDA, noted April 18, 2024.",91.02M
Add to portfolio,,,FTD,,,,,
RHHBY,,$30.05 ,Alecensa(alectinib),Non-small cell lung cancer (NSCLC) ,Approved,18/04/2024 ET,"FDA approved on April 18, 2024.",6.36B
Add to portfolio,,,View Clinical Trial Data,,,,,
MGTX,,$5.01 ,AAV2-hAQP1 - (AQUAx2),Xerostomia ,Phase 1,18/04/2024 ET,"Phase 1 data presented at AAOM resulted in no treatment-related serious adverse events or dose-limiting toxicities were reported, and all participants completed the study, noted April 18, 2024.",80.45M
Add to portfolio,,,FTD,,,,,
,,,RMAT,,,,,
BRNS,,$2.71 ,VTP-200 - (APOLLO),Human papillomavirus (HPV) ,Phase 1/2,18/04/2024 ET,"Additional Phase 1/2a met its primary endpoint, noted April 18, 2024.",40.72M
Add to portfolio,,,,,,,,
CLYD,,—,VTP-200 - (APOLLO),Human papillomavirus (HPV) ,Phase 1/2,18/04/2024 ET,"Additional Phase 1/2a met its primary endpoint, noted April 18, 2024.",—
Add to portfolio,,,,,,,,
TAK,,$13.16 ,ENTYVIO (vedolizumab),Crohn's Disease ,Approved,18/04/2024 ET,"FDA Approved by the FDA, noted April 18, 2024.",3.15B
Add to portfolio,,,,,,,,
TVGN,,$1.85 ,TVGN 489 - (TCTL Study),Cytotoxic T Lymphocytes for the Treatment of Elderly and High-Risk Patients with Covid-19 ,Phase 1,19/04/2024 ET,"Phase 1 study proof-of-concept clinical trial suggested the ability to target and eliminate a virus in high-risk population with multiple comorbidities, noted April 11, 2024.",196.71M
Add to portfolio,,,,,,,,
OCGN,,$1.32 ,OCU410 - (ArMaDa),Geographic Atrophy (GA) ,Phase 1/2,19/04/2024 ET,"Phase 1/2 Cohort 2 dosing completed, noted April 19, 2024.",292.3M
Add to portfolio,,,,,,,,
CNTA,,$10.00 ,ORX750 - (CRYSTAL-1),Narcolepsy and other sleep-wake disorders ,IND-Enabling,22/04/2024 ET,"IND cleared by the FDA, noted April 22, 2024",134.07M
Add to portfolio,,,,,,,,
KRYS,,$157.25 ,KB707 - (KYANITE-1),Solid Tumors ,Phase 1,22/04/2024 ET,"Phase 1 dosing initiated, noted April 22, 2024.",28.94M
Add to portfolio,,,FTD,,,,,
,,,RPDD,,,,,
ENLV,,$1.27 ,Allocetra - (ENX-CL-05-001),Knee osteoarthritis (OA) ,Phase 2,22/04/2024 ET,"Phase 2 trial initiated, noted April 22, 2024.",23.85M
Add to portfolio,,,,,,,,
CORT,,$22.30 ,Relacorilant - (GRACE),Hypercortisolism (Cushing's Syndrome) ,Phase 3,22/04/2024 ET,"Phase 3 additional results exhibited clinically meaningful and statistically significant improvements in hypertension, hyperglycemia and other key secondary and exploratory endpoints, noted April 22, … read more",105.37M
Add to portfolio,,,,,,,,
ASLN,,$3.64 ,Eblasakimab (ASLAN004) - (TREK-DX),Atopic dermatitis (AD) ,Phase 2b,22/04/2024 ET,Phase 2b data reported that 22 patients shows unprecedented efficacy data compared to prior atopic dermatitis (AD) studies with biologics: 60.0% of dupilumab-experienced AD patients treated with 400mg … read more,2.83M
Add to portfolio,,,,,,,,
PHIO,,$7.47 ,PH-762,Cutaneous Squamous Cell Carcinoma ,Preclinical,22/04/2024 ET,Preclinical studies demonstrated PH-762 is rapidly taken up by cells and robustly silences PD-1 mRNA and protein in lymphocytes within the tumor microenvironment (TME) Intratumoral injection of murine … read more,5.73M
Add to portfolio,,,,,,,,
ABEO,,$7.36 ,ZEVASKYN (prademagene zamikeracel),Recessive dystrophic epidermolysis bullosa (RDEB) ,CRL,22/04/2024 ET,"CRL issued by the FDA, noted April 22, 2024.",51.28M
Add to portfolio,,,View Clinical Trial Data,,,,,
AZTR,,$5.85 ,ATR12-351,Netherton Syndrome ,Preclinical,22/04/2024 ET,"Preclinical data suggests ATR-12 can significantly reduce IL-36g, a pro-inflammatory cytokine that drives Netherton syndrome, noted April 22, 2024.",3.52M
Add to portfolio,,,ODD,,,,,
TOVX,,$10.28 ,VCN-01 (VIRAGE),Metastatic PDAC ,Preclinical,22/04/2024 ET,"Preclinical data demonstrated enhanced anti-tumor effects in a human pancreatic mouse xenograft, noted April 22, 2024.",9.6M
Add to portfolio,,,ODD,,,,,
,,,FTD,,,,,
ACET,,$2.00 ,ADI-270,"Solid tumors CAR T, relapsed/refractory renal cell carcinoma (RCC) ",Preclinical,22/04/2024 ET,"Preclinical findings showed robust anti-tumor activity of ADI-270 in multiple CD70-positive solid and hematological cancer models, noted April 22, 2024",83.25M
Add to portfolio,,,FTD,,,,,
IBRX,,$4.94 ,ANKTIVA,BCG-Unresponsive Non-Muscle Invasive Bladder Cancer ,Approved,22/04/2024 ET,"Approved April 22, 2024.",945.25M
Add to portfolio,,,BTD,,,,,
,,,FTD,,,,,
TOVX,,$9.42 ,VCN-01 (zabilugene almadenorepvec),Retinoblastoma ,Phase 1,23/04/2024 ET,"Phase 1 topline data in collaboration with Sant Joan de Déu-Barcelona Children's Hospital (SJD) determined to have a positive outcome by the study Monitoring Committee, safety and clinical outcomes su … read more",9.6M
Add to portfolio,,,ODD,,,,,
,,,RPDD,,,,,
TLSA,,$0.78 ,Foralumab (Intranasal),Secondary Progressive Multiple Sclerosis (SPMS) ,Phase 2a,23/04/2024 ET,"Phase 2a FDA allowed its intranasal foralumab na-SPMS Expanded Access (EA) Program to expand from 10 patients to a total of 30 patients, noted April 23, 2024.",111.46M
Add to portfolio,,,FTD,,,,,
UBX,,$1.49 ,UBX1325 - (ASPIRE),Diabetic macular edema (DME) ,Phase 2,23/04/2024 ET,"Phase 2 study of UBX1325 has been extended from 24 to 36 weeks to assess potentially greater durability compared to aflibercept. In addition, the study is being upsized from 40 to 50 patients to incre … read more",17.21M
Add to portfolio,,,,,,,,
SILO,,$1.78 ,SPC-15,Post-traumatic stress disorder (PTSD) ,Preclinical,23/04/2024 ET,"Preclinical study of intranasal delivery showed rapid and effective drug exposure for PTSD Therapy, noted April 23, 2024.",9.4M
Add to portfolio,,,,,,,,
NBIX,,$140.09 ,Osavampator (NBI-1065845) - (SAVITRI),Major depressive disorder ,Phase 2,23/04/2024 ET,"Phase 2 study met its primary and key secondary endpoints, demonstrating that once-daily, oral administration of NBI-1065845 produced a statistically significant change from baseline in Montgomery Åsb … read more",99.18M
Add to portfolio,,,,,,,,
TAK,,$13.38 ,Osavampator (NBI-1065845) - (SAVITRI),Major depressive disorder ,Phase 2,23/04/2024 ET,"Phase 2 study met its primary and key secondary endpoints, demonstrating that once-daily, oral administration of NBI-1065845 produced a statistically significant change from baseline in Montgomery Åsb … read more",3.15B
Add to portfolio,,,,,,,,
ANRO,,$13.88 ,ALTO-101,Schizophrenia ,Phase 1,23/04/2024 ET,Phase 1 study in healthy volunteers demonstrated favorable tolerability and improved pharmacokinetics of ALTO-101 when administered via a transdermal delivery system (TDS) compared to oral administrat … read more,27.08M
Add to portfolio,,,FTD,,,,,
HOWL,,$6.44 ,IL-10 Indukine (PREDATOR Platform),Ulcerative Colitis (UC) ,Preclinical,23/04/2024 ET,"Preclinical data in animal models supported unique conditionally active cytokine immunotherapy approach for the potential treatment, noted April 23, 2024.",45.73M
Add to portfolio,,,,,,,,
INMB,,$10.14 ,XPro1595 (pegipanermin) - (XPro),Neuroinflammation caused by Alzheimer’s disease ,Phase 2,23/04/2024 ET,"Phase 3 preparation ongoing after 24-month validation data completed, noted April 23, 2024.",26.59M
Add to portfolio,,,,,,,,
NVS,,$97.28 ,LUTATHERA (lutetium Lu 177) - (NETTER-P),Gastroenteropancreatic neuroendocrine tumors (GEP-NETs) ,Approved,23/04/2024 ET,"FDA approved on April 23, 2024.",1.98B
Add to portfolio,,,,,,,,
DAWN,,$16.64 ,OJEMDA (tovorafenib),Low-grade Glioma ,Approved,23/04/2024 ET,"FDA Approved on April 23, 2024.",102.43M
Add to portfolio,,,ODD,,,,,
,,,View Clinical Trial Data,,,,,
RHHBY,,$30.54 ,HB-700,KRAS-mutated cancers ,IND-Enabling,24/04/2024 ET,"IND cleared by the FDA, noted April 24, 2024.",6.36B
Add to portfolio,,,,,,,,
HOOK,,$8.50 ,HB-700,KRAS-mutated cancers ,IND-Enabling,24/04/2024 ET,"IND cleared by the FDA, noted April 24, 2024.",12.2M
Add to portfolio,,,,,,,,
ALVO,,$13.54 ,AVT05 (biosimilar to golimumab),Rheumatoid Arthritis ,Phase 3,24/04/2024 ET,"Phase 3 trial met its primary endpoint, with results demonstrating therapeutic equivalence between AVT05 and Simponi. Additionally, no clinically meaningful differences in safety were observed through … read more",301.81M
Add to portfolio,,,,,,,,
IMMP,,$2.59 ,Eftilagimod alpha (IMP321) and KEYTRUDA (pembrolizumab) - (TACTI-003),Head and neck squamous cell carcinoma (HNSCC) ,Phase 2b,24/04/2024 ET,"Phase 2b enrollment completed, noted November 9, 2023. Phase 2b data from efti in combination in patients who do not express PD-L1 (TACTI-003, Cohort B) showed a preliminary 26.9% response rate, the p … read more",145.46M
Add to portfolio,,,View Clinical Trial Data,,,,,
ALKS,,$24.65 ,ALKS 2680 - (Vibrance-1),Narcolepsy ,Phase 2,24/04/2024 ET,"Phase 2 initiated, noted April 24, 2024.",165.08M
Add to portfolio,,,,,,,,
ATAI,,$1.87 ,BPL-003,Resistant Depression ,Phase 2a,24/04/2024 ET,"Phase 2a OLE study initiated, noted April 24, 2024.",214.34M
Add to portfolio,,,BTD,,,,,
RDHL,,$10.50 ,RHB-107 (upamostat) - (ACESO PROTECT),Early COVID-19 outpatient treatment ,Phase 2,24/04/2024 ET,"Phase 2 dosing commenced, noted April 24, 2024.",3.33M
Add to portfolio,,,,,,,,
AMRX,,$6.05 ,Naloxone hydrochloride nasal spray - (generic Narcan),Opioid overdose ,Approved,24/04/2024 ET,"FDA Approved, noted April 24, 2024.",314.08M
Add to portfolio,,,,,,,,
CALC,,$5.49 ,Auxora - (CARPO),Acute Pancreatitis ,Phase 2b,24/04/2024 ET,"Phase 2b enrolment completed, noted April 24, 2024.",13.97M
Add to portfolio,,,,,,,,
NVS,,$98.35 ,Coartem (artemether-lumefantrine) - (CALINA),Malaria in babies <5 kg ,Phase 2/3,24/04/2024 ET,"Phase 2/3 data reported that the new formulation has good efficacy and safety, and the data have been submitted for regulatory review, noted April 24, 2024.",1.98B
Add to portfolio,,,,,,,,
GANX,,$3.19 ,"GT-02287, GT-02329",GBA1 and Idiopathic Parkinson's Disease ,Phase 1,24/04/2024 ET,"Phase 1 data reported that treatment was generally well tolerated up to and including the highest planned dose level, and there were no serious adverse events, noted April 24, 2024.",35.95M
Add to portfolio,,,,,,,,
ACRV,,$9.50 ,ACR-368,"Platinum-resistant ovarian,(PROC) endometrial, and urothelial cancers ",Phase 2b,24/04/2024 ET,"Phase 2b initial data demonstrated a 50% confirmed overall response rate observed with ACR-368 in OncoSignature-positive gynecological (ovarian and endometrial) cancers, noted April 24, 2024.",31.46M
Add to portfolio,,,FTD,,,,,
,,,BTD,,,,,
IBRX,,$5.11 ,Anktiva (N-803) + various Checkpoint Inhibitors (QUILT-3.055),"NSCLC, Various tumors ",Phase 2,25/04/2024 ET,"Phase 2 results reported significant prolongation of overall survival, noted April 25, 2024.",945.25M
Add to portfolio,,,View Clinical Trial Data,,,,,
VTGN,,$4.70 ,PH15,Psychomotor impairment caused by mental fatigue ,Phase 2a,25/04/2024 ET,"Phase 2a data reported that treatment demonstrated a statistically significant improvement in reaction time compared to placebo and caffeine in sleep-deprived study participants, noted April 25, 2024.",30.68M
Add to portfolio,,,,,,,,
BLCO,,$14.76 ,LCD supplement capsule,Dry eyes ,Phase 1,25/04/2024 ET,"Trial met both primary endpoints, noted April 25, 2024.",353.87M
Add to portfolio,,,,,,,,
TLSA,,$0.84 ,Foralumab,"Non-active, secondary-progressive multiple sclerosis (na-SPMS) ",Phase 2,25/04/2024 ET,"Phase 2 data quantitative data showing improvement in White Matter Z-scores measured from PET images taken at 3 months in nasal foralumab, noted April 25, 2024.",111.46M
Add to portfolio,,,ODD,,,,,
,,,FTD,,,,,
BIVI,,$4.89 ,Bezisterim (NE3107) - (Biomarker Trial),Alzheimer's disease ,Phase 2,25/04/2024 ET,"Phase 2 data shared at the Annual Alzheimer's & Parkinson's Drug Development Summit shows how bezisterim may be restoring homeostasis via specific genes associated with dementia, metabolism, and infla … read more",7.53M
Add to portfolio,,,,,,,,
ROIV,,$10.88 ,Namilumab - (RESOLVE-Lung),Sarcoidosis ,Phase 2,25/04/2024 ET,"Phase 2 enrollment completed, noted April 25, 2024.",682.88M
Add to portfolio,,,,,,,,
ALGS,,$20.45 ,ALG-097558,COVID-19 ,Phase 1,25/04/2024 ET,"Phase 1 data presented at ECCMID showed that single (up to 2000 mg) and multiple (up to 800 mg Q12 for 7 days) doses of this potent, pan-coronavirus protease inhibitor were well tolerated in healthy v … read more",6.15M
Add to portfolio,,,,,,,,
NKGN,,$1.98 ,Troculeucel (SNK01),Alzheimer's Disease ,Phase 1,25/04/2024 ET,Preclinical data to be presented at the Alzheimer's & Parkinson's Drug Development Summit shows a direct ability to phagocytose and digest amyloid and alpha-synuclein proteins while also secreting imm … read more,124.38M
Add to portfolio,,,FTD,,,,,
PFE,,$24.69 ,BEQVEZ (fidanacogene elaparvovec-dzkt),Hemophilia B ,Approved,26/04/2024 ET,"Approval announced April 26, 2024.",5.69B
Add to portfolio,,,BTD,,,,,
,,,ODD,,,,,
GILD,,$64.06 ,Biktarvy,HIV ,Approved,26/04/2024 ET,"Approved for updated label on (bictegravir 50 mg/emtricitabine 200 mg/tenofovir alafenamide 25 mg tablets, B/F/TAF) to treat pregnant people with HIV-1 (PWH) with suppressed viral loads, noted April 2 … read more",1.24B
Add to portfolio,,,,,,,,
CDTX,,$12.63 ,JNJ-0953 (CD388) - (ANCHOR),Seasonal Influenza ,Phase 2a,26/04/2024 ET,Phase 2a data presented at ESCMID reported that well tolerated and demonstrated statistically significant antiviral effects when administered as a single subcutaneous dose in healthy volunteers challe … read more,25.36M
Add to portfolio,,,FTD,,,,,
,,,BTD,,,,,
JNJ,,$143.86 ,JNJ-0953 (CD388) - (ANCHOR),Seasonal Influenza ,Phase 2a,26/04/2024 ET,Phase 2a data presented at ESCMID reported that well tolerated and demonstrated statistically significant antiviral effects when administered as a single subcutaneous dose in healthy volunteers challe … read more,2.41B
Add to portfolio,,,FTD,,,,,
,,,BTD,,,,,
ENTA,,$12.37 ,EDP-235 - (SPRINT),COVID-19 ,Phase 2,27/04/2024 ET,"Phase 2 data presented at ESCMID reported that the EDP-235 400 mg arm achieved greater mean change in TSS compared with the placebo arm at all time points, noted April 27, 2024.",21.38M
Add to portfolio,,,FTD,,,,,
AZN,,$75.02 ,Enhertu - (DESTINY-Breast06),"HR-positive, HER2-low (IHC 1+ or 2+/ISH-) metastatic breast cancer ",Phase 3,29/04/2024 ET,"Phase 3 data reported statistically significant and clinically meaningful improvement in progression-free survival (PFS) compared to standard-of-care chemotherapy, noted April 29, 2024",3.1B
Add to portfolio,,,BTD,,,,,
DSNKY,,$32.70 ,Enhertu - (DESTINY-Breast06),"HR-positive, HER2-low (IHC 1+ or 2+/ISH-) metastatic breast cancer ",Phase 3,29/04/2024 ET,"Phase 3 data reported statistically significant and clinically meaningful improvement in progression-free survival (PFS) compared to standard-of-care chemotherapy, noted April 29, 2024",1.92B
Add to portfolio,,,BTD,,,,,
AQST,,$3.74 ,Libervant (diazepam) - (pediatric),Acute treatment seizure activity ,Approved,29/04/2024 ET,"FDA Approved on April 29, 2024.",99.72M
Add to portfolio,,,BTD,,,,,
XFOR,,$1.09 ,XOLREMDI (mavorixafor),WHIM syndrome ,Approved,29/04/2024 ET,"Approved April 29, 2024.",11.41M
Add to portfolio,,,View Clinical Trial Data,,,,,
PRME,,$4.86 ,PM359,Chronic Granulomatous Disease (CGD) ,IND-Enabling,29/04/2024 ET,"IND cleared by the FDA, noted April 29, 2024.",134.57M
Add to portfolio,,,RPDD,,,,,
,,,ODD,,,,,
ADXN,,$7.54 ,ADX71149 (mGlu2 PAM) - (JNJ-40411813),Epilepsy ,Phase 2,29/04/2024 ET,"Phase 2 trial did not meet its primary endpoint, noted April 29, 2024.",1.07M
Add to portfolio,,,,,,,,
JNJ,,$144.53 ,ADX71149 (mGlu2 PAM) - (JNJ-40411813),Epilepsy ,Phase 2,29/04/2024 ET,"Phase 2 trial did not meet its primary endpoint, noted April 29, 2024.",2.41B
Add to portfolio,,,,,,,,
ATHE,,$2.20 ,ATH434,Parkinson's Disease ,Preclinical,29/04/2024 ET,"Preclinical data presented at the World Orphan Drug Congress USA 2024 Indicated that ATH434 can function as an iron chaperone to redistribute iron, noted April 29, 2024.",15.35M
Add to portfolio,,,,,,,,
ITRM,,$1.54 ,ORLYNVAH (Oral Sulopenem),Uncomplicated urinary tract infections (uUTI) ,NDA Filing,29/04/2024 ET,"NDA resubmitted to the FDA, noted April 29, 2024.",44.66M
Add to portfolio,,,,,,,,
SLS,,$1.21 ,Galinpepimut-S - (REGAL),Acute Myeloid Leukemia (AML) ,Phase 3,29/04/2024 ET,"IDMC recommended the continuation of the trial, noted April 29, 2024.",105.3M
Add to portfolio,,,RPDD,,,,,
,,,View Clinical Trial Data,,,,,
AZN,,$75.02 ,Ampligen (rintatolimod) with Imfinzi (durvalumab) - (DURIPANC),Pancreatic Cancer ,Phase 1/2,29/04/2024 ET,"Phase 1b/2 first dose level is generally well tolerated, noted April 29, 2024.",3.1B
Add to portfolio,,,,,,,,
AIM,,$0.41 ,Ampligen (rintatolimod) with Imfinzi (durvalumab) - (DURIPANC),Pancreatic Cancer ,Phase 1/2,29/04/2024 ET,"Phase 1b/2 first dose level is generally well tolerated, noted April 29, 2024.",2.71M
Add to portfolio,,,,,,,,
LGND,,$70.46 ,V116 - (STRIDE-10),Pneumococcal vaccine ,Phase 3,29/04/2024 ET,"Phase 3 data presented at ESCMID Global showed that results build on the data supporting the clinical profile of V116 for adults, noted April 29, 2024.",19.6M
Add to portfolio,,,,,,,,
MRK,,$128.50 ,V116 - (STRIDE-10),Pneumococcal vaccine ,Phase 3,29/04/2024 ET,"Phase 3 data presented at ESCMID Global showed that results build on the data supporting the clinical profile of V116 for adults, noted April 29, 2024.",2.5B
Add to portfolio,,,,,,,,
ANVS,,$7.28 ,Buntanetap (ANVS401),Alzheimer’s disease (AD) ,Phase 2/3,29/04/2024 ET,"Phase 2/3 AD study data reported a significantly higher improvement in ADAS-Cog 11 scores in each treatment dose relative to placebo for patients with mild AD (n=90), after unblinding the data to scre … read more",19.49M
Add to portfolio,,,ODD,,,,,
TERN,,$5.10 ,TERN-701 - (CARDINAL),Chronic myeloid leukemia (CML) ,Phase 1,29/04/2024 ET,"Phase 1 interim data showed no clinically significant difference in exposure between fed and fasted dosing, noted April 29, 2024.",87.51M
Add to portfolio,,,ODD,,,,,
TFFP,,$2.71 ,TFF TAC (Tacrolimus Inhalation Powder),Lung transplant (post) ,Phase 2,29/04/2024 ET,"Phase 2 demonstrated that treatment with TFF TAC prevents Lung Transplant Rejection at only one-sixth of the dose of oral Tacrolimus and at Two-thirds of the oral Tacrolimus Systemic Trough Exposures, … read more",4.44M
Add to portfolio,,,,,,,,
PFE,,$24.92 ,TIVDAK (tisotumab vedotin-tftv),Cervical Cancer with disease progression on or after first-line therapy ,Approved,29/04/2024 ET,"Approved April 29, 2024.",5.69B
Add to portfolio,,,View Clinical Trial Data,,,,,
GMAB,,$28.57 ,TIVDAK (tisotumab vedotin-tftv),Cervical Cancer with disease progression on or after first-line therapy ,Approved,29/04/2024 ET,"Approved April 29, 2024.",661.87M
Add to portfolio,,,View Clinical Trial Data,,,,,
MOLN,,$3.70 ,MP0533,Acute myeloid leukemia (AML) ,Preclinical,29/04/2024 ET,"Preclinical data of tetra-specific T cell engager MP0533 demonstrated preferential T cell mediated killing of AML cells, while sparing healthy cells, noted April 29 2024.",40.36M
Add to portfolio,,,,,,,,
VERU,,$1.35 ,Enobosarm with semaglutide (Wegovy) - (PLATEAU),Obesity ,Phase 2b,30/04/2024 ET,"IND cleared February 6, 2024. Phase 2b first patient dosed April 30, 2024.",14.65M
Add to portfolio,,,,,,,,
NBIX,,$137.54 ,TAK-653 / NBI-1065845,Major Depressive Disorder (MDD) ,Phase 2,30/04/2024 ET,"Phase 2 study met its primary and key secondary endpoints, noted April 2024.",99.18M
Add to portfolio,,,,,,,,
TAK,,$13.08 ,TAK-653 / NBI-1065845,Major Depressive Disorder (MDD) ,Phase 2,30/04/2024 ET,"Phase 2 study met its primary and key secondary endpoints, noted April 2024.",3.15B
Add to portfolio,,,,,,,,
AUPH,,$5.09 ,LUPKYNIS (Voclosporin) - (updated label),Lupus Nephritis ,Approved,30/04/2024 ET,"Updated label approved April 30, 2024.",135.1M
Add to portfolio,,,View Clinical Trial Data,,,,,
VRPX,,$2.65 ,Probudur,Pain Relief ,Preclinical,30/04/2024 ET,"MTD data reported that all doses were well-tolerated, noted April 30, 2024.",1.28M
Add to portfolio,,,,,,,,
SNTI,,$3.60 ,SENTI-202,Acute Myeloid Leukemia (AML) ,Preclinical,30/04/2024 ET,"Preclinical data reported that the engineered NK cells killed multiple AML subtypes while protecting primary hematopoietic stem cells (HSCs), noted April 30, 2024.",26.16M
Add to portfolio,,,ODD,,,,,
NRXP,,$2.58 ,NRX-101,Bipolar Depression and Suicidal Ideation ,Phase 2/3,30/04/2024 ET,"Phase 2/3 top line data reported that NRX-101 vs lurasidone demonstrated a promising, though not yet statistically significant 33% reduction in suicidality together with a 70% reduction (P=.076) reduc … read more",19.71M
Add to portfolio,,,BTD,,,,,
,,,FTD,,,,,
,,,View Clinical Trial Data,,,,,
VXRT,,$0.71 ,Norovirus vaccine - (lactating mothers trial),Norovirus ,Phase 1,30/04/2024 ET,"Phase 1 topline data reported no vaccine-related serious adverse events (SAEs) and no dose-limiting pharmacotoxicity, noted April 30, 2024.",228.92M
Add to portfolio,,,,,,,,
INMB,,$11.84 ,XPro1595 (pegipanermin) - (XPro),Neuroinflammation caused by Alzheimer’s disease ,Phase 1b,30/04/2024 ET,"Phase 1b compassionate use data reported that treatment has been well-tolerated throughout the treatment period, with stable cognitive function observed in the patients. Furthermore, the patients expr … read more",26.59M
Add to portfolio,,,,,,,,
GRTS,,$0.80 ,CORAL-CEPI,COVID-19 vaccine ,Phase 1,30/04/2024 ET,"Additional data reported that all doses of the three samRNA vaccine candidates were well tolerated in both HIV-negative participants and PLWH participants irrespective of age, SARS-CoV-2 serostatus, o … read more",118.11M
Add to portfolio,,,,,,,,
SCYX,,$1.69 ,SCY-247,Pulmonary mucormycosis ,Preclinical,30/04/2024 ET,"Preclinical data shared at the ECCMID reported that SCY-247 showed in vitro activity against a broad range of pathogenic fungi, including azole-resistant strains of Candida and Aspergillus species, no … read more",41.92M
Add to portfolio,,,,,,,,
NBIX,,$137.54 ,INGREZZA SPRINKLE (valbenazine) Capsules,Tardive dyskinesia (TD) ,Approved,30/04/2024 ET,"Approved April 30, 2024.",99.18M
Add to portfolio,,,,,,,,
ACXP,,$2.20 ,Ibezapolstat,C. difficile Infection ,Phase 2b,30/04/2024 ET,"Phase 2b data results shared at ESCMID einforced earlier findings related to the anti-recurrence properties, noted April 30, 2024.",1.58M
Add to portfolio,,,FTD,,,,,
,,,View Clinical Trial Data,,,,,
MRK,,$127.20 ,KEYTRUDA (pembrolizumab) in combination with trastuzumab - (KEYNOTE-811),HER2-positive gastric or Gastroesophageal junction (GEJ) adenocarcinoma ,Phase 3,01/05/2024 ET,"Phase 3 trial met its dual primary endpoint of overall survival (OS), noted May 1, 2024.",2.5B
Add to portfolio,,,,,,,,
PALI,,$7.08 ,PALI-2108,Moderate-to-severe ulcerative colitis (UC) ,Preclinical,01/05/2024 ET,"Preclinical successful completion of its analysis to determine the effects of bioactivated PALI-2108 on TNF-α production in a whole blood (WB) assay, noted May 1, 2024.",9.12M
Add to portfolio,,,,,,,,
SLS,,$1.28 ,Tambiciclib (SLS009) (GFH009) with venetoclax,"Hematologic malignancies, acute myeloid leukemia (AML), chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL) and lymphoma ",Phase 2,01/05/2024 ET,"Phase 2 30 mg cohort showed a 100% overall response rate in patients with ASXL1 mutation, treatment exhibited strong anti-leukemic activity in 62% of patients with a favorable safety profile across al … read more",105.3M
Add to portfolio,,,ODD,,,,,
,,,FTD,,,,,
,,,RPDD,,,,,
ALRN,,$4.16 ,LTI-03 - (Caveolin-1),Idiopathic pulmonary fibrosis (IPF) ,Phase 1b,01/05/2024 ET,Phase 1a low dose data showed a reduced expression of multiple profibrotic proteins in both pathological basal-like cells and fibroblasts and increased the expression of a biomarker indicative of epit … read more,21.67M
Add to portfolio,,,,,,,,
COCP,,$1.53 ,CC-42344,Influenza A ,Phase 2a,01/05/2024 ET,"Phase 2a enrollment completed, noted May 1, 2024.",10.26M
Add to portfolio,,,,,,,,
DNLI,,$16.16 ,DNL343 - (HEALEY),Amyotrophic lateral sclerosis (ALS) ,Phase 2/3,01/05/2024 ET,"Phase 2/3 trial enrollment completed noted May 1, 2024.",146.21M
Add to portfolio,,,,,,,,
BCDA,,$5.64 ,CardiAMP (BCDA-02),Chronic Myocardial Ischemia ,Phase 3,01/05/2024 ET,"Phase 3 data reported that 100% of patients responded for the change in Angina Episodes per week, noted May 1, 2024.",5.8M
Add to portfolio,,,View Clinical Trial Data,,,,,
KZIA,,$0.30 ,EVT801,Renal cell carcinoma and soft-tissue sarcoma ,Phase 1,01/05/2024 ET,"Phase 1 trial successful and complete, noted May 1, 2024.",1.36M
Add to portfolio,,,,,,,,
GLTO,,$17.00 ,GB1211 in combination with KEYTRUDA (pembrolizumab),Melanoma and head and neck squamous cell carcinoma (HNSCC) ,Phase 2,01/05/2024 ET,"Phase 2 trial initiated, noted May 1, 2024.",1.32M
Add to portfolio,,,,,,,,
AZN,,$75.34 ,"Calquence (acalabrutinib) with chemoimmunotherapy, bendamustine and rituximab - (ECHO)",Mantle cell lymphoma (MCL) ,Phase 3,02/05/2024 ET,"Phase 3 data reported a statistically significant and clinically meaningful improvement in progression-free survival (PFS) versus standard of care, noted May 2, 2024.",3.1B
Add to portfolio,,,,,,,,
CNTX,,$1.75 ,CTIM-76,Various cancers ,IND-Enabling,02/05/2024 ET,"IND Cleared by the FDA, noted May 2, 2024.",89.7M
Add to portfolio,,,,,,,,
PTN,,$2.05 ,Bremelanotide with Tirzepatide (GLP-1),Obesity ,IND-Enabling,02/05/2024 ET,"IND clearance by the FDA, noted May 2, 2024.",46.48M
Add to portfolio,,,,,,,,
ALLR,,$36.90 ,Stenoparib,Advanced ovarian cancer (AOC) ,Phase 2,02/05/2024 ET,"Phase 2 trial discontinued early due to clear clinical benefit, including tumor shrinkage and long-term disease stability, noted May 2, 2024.",14.62M
Add to portfolio,,,FTD,,,,,
ELAB,,$0.71 ,EL-22 (BLS-M22),GLP-1 Weight Loss Drugs and Age-Related Sarcopenia ,Preclinical,02/05/2024 ET,"Preclinical data reported statistically significant increase in anti-myostatin IgG antibody concentration, where myostatin is a key negative regulator of muscle growth, noted May 2, 2024.",677.07K
Add to portfolio,,,,,,,,
IMMP,,$2.69 ,Eftilagimod alpha with pembrolizumab and radiotherapy - (EFTISARC-NEO),Soft tissue sarcoma ,Phase 2,02/05/2024 ET,"Phase 2 trial is well tolerated and has led to encouraging initial efficacy data. Four of six patients treated have very good, near-complete pathologic responses (primary endpoint of study) that are r … read more",145.46M
Add to portfolio,,,,,,,,
AEON,,$1.70 ,ABP-450 (prabotulinumtoxinA),Chronic Migraine (prophylaxis) ,Phase 2,03/05/2024 ET,"Phase 2 trial did not meet its primary endpoint, noted May 3, 2024.",11.64M
Add to portfolio,,,,,,,,
XOMA,,$24.78 ,Seralutinib (GB002) - (TORREY/PROSERA),Pulmonary arterial hypertension (PAH) ,Phase 2,03/05/2024 ET,Phase 2 data from TPRREY trail published at the Lancet Respiratory Medicine journal confirmed results demonstrating a statistically significant improvement for seralutinib compared to placebo in the p … read more,12.09M
Add to portfolio,,,View Clinical Trial Data,,,,,
GOSS,,$0.74 ,Seralutinib (GB002) - (TORREY/PROSERA),Pulmonary arterial hypertension (PAH) ,Phase 2,03/05/2024 ET,Phase 2 data from TPRREY trail published at the Lancet Respiratory Medicine journal confirmed results demonstrating a statistically significant improvement for seralutinib compared to placebo in the p … read more,227.38M
Add to portfolio,,,View Clinical Trial Data,,,,,
CGON,,$36.27 ,Cretostimogene - (BOND-003),BCG-unresponsive Non-Muscle Invasive Bladder Cancer (NMIBC) with Carcinoma in Situ ,Phase 3,03/05/2024 ET,"Phase 3 data presented at AUA showed sustained, durable complete responses over 12 months with novel investigational oncolytic immunotherapy. Although the median duration of response (DOR) was not rea … read more",76.25M
Add to portfolio,,,BTD,,,,,
,,,FTD,,,,,
URGN,,$14.30 ,UGN-102 - (ATLAS),Non-Muscle-Invasive Bladder Cancer ,Phase 3,04/05/2024 ET,"Data from AUA 2024 reported that DOR at 12 months after achieving CR at 3 months was 87.5% and 69.1% in new and recurrent patients, respectively. Also, patients achieved similar probabilities of DFS r … read more",46.26M
Add to portfolio,,,,,,,,
MNMD,,$10.00 ,MM120 ODT (Lysergide (LSD)) - (Emerge),Major Depressive Disorder (MDD) ,Phase 2,04/05/2024 ET,"Phase 2 data at APA reported clinically and statistically significant efficacy compared to placebo at its primary week 4 and secondary week 12 timepoints, noted May 4, 2024.",75.55M
Add to portfolio,,,,,,,,
IRD,,—,APX3330 Oral Pill - (ZETA-1),Diabetic Retinopathy (DR) / Macular Edema (DME) ,Phase 2,05/05/2024 ET,"Additional data shared at ARVO on May 5, 2024 reported that no participants in the APX3330 group had a ≥ 4-step worsening at week 24 compared to 15.2% in the placebo group, representing a 100% reducti … read more",59.91M
Add to portfolio,,,View Clinical Trial Data,,,,,
VTRS,,$11.57 ,APX3330 Oral Pill - (ZETA-1),Diabetic Retinopathy (DR) / Macular Edema (DME) ,Phase 2,05/05/2024 ET,"Additional data shared at ARVO on May 5, 2024 reported that no participants in the APX3330 group had a ≥ 4-step worsening at week 24 compared to 15.2% in the placebo group, representing a 100% reducti … read more",1.17B
Add to portfolio,,,View Clinical Trial Data,,,,,
NNVC,,$1.40 ,NV-387,"Influenza A viruses, Bird Flu H5N1 ",Preclinical,06/05/2024 ET,"Preclinical data reported that in a lethal animal model of lung infection by Influenza A /H3N2 virus, NV-387 was found to have substantially superior antiviral effects compared to three approved anti- … read more",17.43M
Add to portfolio,,,,,,,,
EYPT,,$11.20 ,DURAVYU ( EYP-1901 vorolanib intravitreal) - (PAVIA),Non-proliferative diabetic retinopathy (NPDR) ,Phase 2,06/05/2024 ET,"Phase 2 trial did not meet the pre-specified primary endpoint, noted May 6, 2024.",68.93M
Add to portfolio,,,,,,,,
GLYC,,$0.32 ,Uproleselan (GMI-1271),Acute myeloid leukemia (AML) newly diagnosed and refractory - cancer ,Phase 3,06/05/2024 ET,"Phase 3 final analysis and topline results did not achieve a statistically significant improvement in overall survival in the intent to treat population versus chemotherapy alone, noted May 6, 2024.",13.89M
Add to portfolio,,,View Clinical Trial Data,,,,,
APLM,,$0.42 ,Uproleselan,Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) ,Phase 3,06/05/2024 ET,"Phase 3 data reported that median overall survival of 13 months, compared to 12.3 months in the placebo arm. Adverse events were consistent with known side effect profiles of chemotherapy used in the … read more",1.1M
Add to portfolio,,,View Clinical Trial Data,,,,,
GLYC,,$0.32 ,Uproleselan,Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) ,Phase 3,06/05/2024 ET,"Phase 3 data reported that median overall survival of 13 months, compared to 12.3 months in the placebo arm. Adverse events were consistent with known side effect profiles of chemotherapy used in the … read more",13.89M
Add to portfolio,,,View Clinical Trial Data,,,,,
ADCT,,$4.45 ,ZYNLONTA (loncastuximab tesirine-lpyl),Relapsed/refractory (r/r) marginal zone lymphoma (MZL) ,Phase 2,06/05/2024 ET,"Phase 2 data reported that treatment was generally well-tolerated and safety was consistent with the known profile, with two patient discontinuations, with both of these patients remain in CR at 10 an … read more",112.5M
Add to portfolio,,,,,,,,
VYNE,,$2.71 ,VYN202,Moderate-to-severe plaque psoriasis ,IND-Enabling,06/05/2024 ET,"IND Cleared by the FDA, noted April 6, 2024.",25.47M
Add to portfolio,,,,,,,,
LYRA,,$0.52 ,LYR-210 - (ENLIGHTEN I),Chronic rhinosinusitis ,Phase 3,06/05/2024 ET,Phase 3 data reported that the trial did not meet its primary endpoint of demonstrating statistically significant improvement compared to sham control in the composite score of the three cardinal symp … read more,1.64M
Add to portfolio,,,View Clinical Trial Data,,,,,
LIAN,,$0.31 ,LYR-210 - (ENLIGHTEN I),Chronic rhinosinusitis ,Phase 3,06/05/2024 ET,Phase 3 data reported that the trial did not meet its primary endpoint of demonstrating statistically significant improvement compared to sham control in the composite score of the three cardinal symp … read more,108.06M
Add to portfolio,,,View Clinical Trial Data,,,,,
BCAB,,$3.17 ,BA3361 (CAB-Nectin-4),Multiple tumor types ,IND-Enabling,06/05/2024 ET,"IND cleared by the FDA, noted May 6 2024.",58.72M
Add to portfolio,,,,,,,,
DRTS,,$2.46 ,Alpha DaRT,Pancreatic Cancer ,Preclinical,06/05/2024 ET,"Preclinical data reported that a statistically significant (FDR adjusted p-value < 0.05) decline in secondary tumor growth rate was found at days 21, 25 and 29 in those mice that received Alpha DaRT … read more",70.38M
Add to portfolio,,,,,,,,
CALT,,$20.13 ,Setanaxib with pembrolizumab,Squamous Cell Carcinoma of the Head and Neck (SCCHN) ,Phase 2,06/05/2024 ET,"Phase 2 final data reported statistically significant improvements in key secondary endpoints, such as progression-free survival, (PFS median 5 months versus 2.9 months; Hazard ratio= 0.58) and statis … read more",26.84M
Add to portfolio,,,,,,,,
BLTE,,$43.30 ,Tinlarebant (LBS-008) - (DRAGON),Adolescent Stargardt disease (STGD1) ,Phase 2/3,06/05/2024 ET,"Phase 2/3 24-month data shared at ARVO 2024 provided further support for the potential of Tinlarebant to slow and potentially halt lesion growth, May 6, 2024.",32.28M
Add to portfolio,,,FTD,,,,,
,,,ODD,,,,,
,,,RPDD,,,,,
,,,BTD,,,,,
NVS,,—,RGSL8429,ADPKD ,Phase 1b,06/05/2024 ET,"Phase 1b Cohort 4 advanced, noted May 6, 2024.",1.98B
Add to portfolio,,,,,,,,
LCTX,,$1.30 ,RG6501 - (OpRegen),Geographic atrophy (GA) ,Phase 1/2,06/05/2024 ET,"Additional Phase 1/2a data suggested that OpRegen may counteract RPE cell dysfunction and cell loss in GA by providing support to remaining retinal cells, with effects observed through at least 2 year … read more",228.36M
Add to portfolio,,,,,,,,
EWTX,,$20.34 ,EDG-7500 - (CIRRUS-HCM),Hypertrophic Cardiomyopathy (HCM) ,Phase 2,06/05/2024 ET,"Phase 2 initiated, noted May 6, 2024.",105.35M
Add to portfolio,,,,,,,,
RYTM,,$43.88 ,IMCIVREE (setmelanotide),"Obesity due to biallelic POMC, PCSK1, LEPR deficiency, or BBS (ages 2-6 years old) ",Phase 3,06/05/2024 ET,"Phase 3 data showcased previously disclosed data that demonstrated that setmelanotide achieved 3.04 mean reduction in BMI-Z score and 18.4 percent mean reduction in BMI in 12 patients, noted May 6, 20 … read more",66.42M
Add to portfolio,,,View Clinical Trial Data,,,,,
MRUS,,$47.34 ,BIZENGRI (zenocutuzumab-zbco),Solid tumors - NRG1+ NSCLC and PDAC cancer ,BLA Filing,06/05/2024 ET,"BLA accepted for priority review by the FDA, noted May 6, 2024.",75.63M
Add to portfolio,,,BTD,,,,,
,,,FTD,,,,,
,,,ODD,,,,,
GMAB,,—,BIZENGRI (zenocutuzumab-zbco),Solid tumors - NRG1+ NSCLC and PDAC cancer ,BLA Filing,06/05/2024 ET,"BLA accepted for priority review by the FDA, noted May 6, 2024.",661.87M
Add to portfolio,,,BTD,,,,,
,,,FTD,,,,,
,,,ODD,,,,,
DTIL,,$10.57 ,ECUR-506 - (OTC-HOPE),Ornithine Transcarbamylase (OTC) Deficiency ,Phase 1/2,07/05/2024 ET,"Fast track designation granted by the FDA, noted May 7, 2024.",11.79M
Add to portfolio,,,FTD,,,,,
ANNX,,$4.73 ,ANX007 - (ARCHER-II),Geographic atrophy ,Phase 2,07/05/2024 ET,"Phase 2 data presented at ARVO demonstrated significant, broad-based protection from vision loss in foveal and non-foveal patients, and in low light settings, noted May 7, 2024.",109.89M
Add to portfolio,,,,,,,,
DNLI,,$16.85 ,DNL788 (SAR443820) - (HIMALAYA),Amyotrophic lateral sclerosis (ALS) ,Phase 2,07/05/2024 ET,"Phase 2 trial did not meet the primary endpoint, noted May 7, 2024.",146.21M
Add to portfolio,,,,,,,,
ELDN,,$2.26 ,Tegoprubart (AT-1501) - (BESTOW),Kidney transplant rejection ,Phase 1b,07/05/2024 ET,"Phase 1b data reported that two subjects completed 12 months on therapy post-transplant and both demonstrated mean eGFRs above 90 mL/min/1.73m2 at one year, noted May 7, 2024.",59.88M
Add to portfolio,,,,,,,,
ASLN,,$3.30 ,Eblasakimab (ASLAN004) - (TREK-DX),Atopic dermatitis (AD) ,Phase 2,07/05/2024 ET,"Additional Phase 2 data reported discontinuation rates were lower for patients treated with eblasakimab (13%, 2/15) compared to those on placebo, noted May 7, 2024.",2.83M
Add to portfolio,,,,,,,,
MBRX,,$5.09 ,"Annamycin (MB-106) in combination with Cytarabine - (Ara-C, MIRACLE)",Acute Myeloid Leukemia (AML) ,Phase 1/2,07/05/2024 ET,"Phase 1/2 topline data reported a CRc rate of 45% and an overall remission rate (ORR) of 55% for all subjects, noted May 7, 2024.",30.29M
Add to portfolio,,,ODD,,,,,
,,,FTD,,,,,
NRSN,,$1.29 ,PrimeC - (PARADIGM),Amyotrophic Lateral Sclerosis (ALS) ,Phase 2b,07/05/2024 ET,"Additional Phase 2b data analysis reported a statistically significant slowing of disease progression in high-risk ALS patients treated with PrimeC by 43% (p=0.02), noted May 7, 2024.",23.99M
Add to portfolio,,,,,,,,
REGN,,$955.76 ,Otoferlin gene therapy (DB-OTO) - (CHORD),Genetic hearing loss ,Phase 1/2,08/05/2024 ET,"Phase 1/2 data presented at ASGCT reported an average 84 dB improvement from baseline and one frequency measure reaching 10 dB in hearing level per PTA. Across all tested frequencies, an average 80 dB … read more",105.99M
Add to portfolio,,,RMAT,,,,,
,,,FTD,,,,,
,,,ODD,,,,,
,,,RPDD,,,,,
VYGR,,$8.57 ,TRACER (GBA1),Parkinson's Disease ,Preclinical,08/05/2024 ET,"Preclinical data reported that showed further enhanced blood-brain barrier (BBB) penetrance, greater liver detargeting, and transduction of 50-75% of cells across diverse brain regions, with upwards o … read more",55.47M
Add to portfolio,,,,,,,,
ALDX,,$4.07 ,Reproxalap (ADX-102) - (TRANQUILITY),Dry eye disease ,Phase 3,08/05/2024 ET,"Phase 3 first patient enrollment, noted May 8, 2024.",59.9M
Add to portfolio,,,,,,,,
CYTK,,$65.27 ,CK-4021586 (CK-586) - (AMBER-HFpEF),Heart failure with preserved ejection fraction (HFpEF) ,Phase 1,08/05/2024 ET,"Phase 1 trial met its primary and secondary objectives, noted May 8, 2024.",119.66M
Add to portfolio,,,,,,,,
TEVA,,$15.74 ,Olanzapine LAI (44749) - (SOLARIS),Schizophrenia ,Phase 3,08/05/2024 ET,"Phase 3 trial data reported that the trial met its primary endpoint as measured by a change in the PANSS total score from baseline after 8 weeks compared to placebo, noted May 8, 2024.",1.15B
Add to portfolio,,,,,,,,
CYTK,,$65.27 ,Aficamten - (CEDAR-HCM),obstructive HCM ,Phase 3,08/05/2024 ET,"Phase 3 initiated, noted May 8, 2024.",119.66M
Add to portfolio,,,,,,,,
PRME,,$5.36 ,PM359,Chronic Granulomatous Disease (CGD) ,Preclinical,08/05/2024 ET,"Preclinical data presented at ASGCT demonstrated the ability of PM359 to correct disease-causing mutation in CGD patient blood stem cells, leading to restored immune function in vivo with no off-targe … read more",134.57M
Add to portfolio,,,RPDD,,,,,
,,,ODD,,,,,
LLY,,$772.64 ,VERVE-102 - (Heart-2),PCSK9 ,Phase 1b,08/05/2024 ET,"Phase 1b dosing initiated, noted May 8, 2024.",946.46M
Add to portfolio,,,FTD,,,,,
VERV,,$6.08 ,VERVE-102 - (Heart-2),PCSK9 ,Phase 1b,08/05/2024 ET,"Phase 1b dosing initiated, noted May 8, 2024.",89.14M
Add to portfolio,,,FTD,,,,,
CVM,,$1.39 ,Multikine - (IT-MATTERS),Head and Neck cancer ,Phase 3,08/05/2024 ET,"Phase 3 Go-Ahead received by the FDA for its study, noted May 8, 2024.",6.88M
Add to portfolio,,,View Clinical Trial Data,,,,,
LEXX,,$3.54 ,DehydraTECH-GLP-1 - (GLP-1-H24-2),"Healthy volunteers, Diabetes-related control, weight loss ",Phase 1,08/05/2024 ET,"Phase 1 dosing initiated, noted May 8, 2024.",19.56M
Add to portfolio,,,,,,,,
PRQR,,$2.00 ,AX-0810,"Healthy volunteers, deficiency of sodium taurocholate cotransporting polypeptide (NTCP), cholestatic diseases ",Preclinical,08/05/2024 ET,"Preclinical data shared at the American Society of Gene & Cell Therapy (ASGCT) confirmed findings in in vitro models and showed translatability across models, noted May 8, 2024",105.21M
Add to portfolio,,,,,,,,
CTMX,,$4.19 ,CX-904,Advanced solid tumors ,Phase 1,08/05/2024 ET,"Phase 1 data demonstrated a favorable safety profile with no cytokine release syndrome (CRS) of any grade observed in step-dosing cohorts and no grade >1 CRS observed overall, noted May 8, 2024.",164.91M
Add to portfolio,,,,,,,,
OCS,,$12.37 ,OCS-05 - (ACUITY),Acute optic neuritis ,Phase 2,08/05/2024 ET,"Phase 2 enrollment completed, noted May 8, 2024.",43.66M
Add to portfolio,,,,,,,,
MRK,,$128.61 ,KEYTRUDA versus chemotherapy - (KEYNOTE-B21),High-Risk Endometrial Cancer ,Phase 3,09/05/2024 ET,"Phase 3 study did not meet the study's pre-specified statistical criteria for DFS compared to placebo plus adjuvant chemotherapy, with or without radiotherapy, noted May 9, 2024.",2.5B
Add to portfolio,,,,,,,,
PRTC,,$27.46 ,SPT-300 (Glyph allopregnanolone; formerly LYT-300),"Healthy volunteers, neurological and neuropsychological conditions ",Phase 2a,09/05/2024 ET,"Phase 2a demonstrated nine times greater allopregnanolone exposure in humans dosed orally than published data for oral allopregnanolone, validating Glyph platform's ability to enhance oral bioavailabi … read more",24.17M
Add to portfolio,,,,,,,,
TCRX,,$7.80 ,TSC-203-A0201 - (PRAME),Targeting PRAME Solid tumors ,Phase 1,09/05/2024 ET,"Phase 1 dosing initiated, noted May 9, 2024.",56.75M
Add to portfolio,,,,,,,,
ANVS,,$6.03 ,Buntanetap,Parkinson's Disease (PD) ,Phase 3,09/05/2024 ET,"The phase 3 study was completed, noted May 9, 2024.",19.49M
Add to portfolio,,,,,,,,
PSTX,,$2.71 ,P-KLKB1-101,Gene Therapy ,Preclinical,09/05/2024 ET,"Preclinical early non-human primate (NHP) data for P-KLKB1-101 demonstrate successful liver gene editing approaching human therapeutic range with a favorable safety and tolerability profile, noted May … read more",97.47M
Add to portfolio,,,,,,,,
PSTX,,$2.71 ,P-FVIII-101,Hemophilia A ,Preclinical,09/05/2024 ET,"Preclinical data highlight sustained Hemophilia A correction following a single dose and support potential for repeat dosing and precise tuning of Factor VIII levels, noted May 9, 2024.",97.47M
Add to portfolio,,,,,,,,
IKT,,$1.36 ,IkT-001Pro,Pulmonary Arterial Hypertension (PAH) ,Preclinical,09/05/2024 ET,Pre-IND meeting with FDA indicated IkT-001Pro can be considered a New Molecular Entity and is eligible for exclusivity designations in Pulmonary Arterial Hypertension. FDA agreed that the 505(b)(2) pa … read more,74.52M
Add to portfolio,,,,,,,,
FATE,,$3.90 ,FT819,B-cell Leukemias and Lymphomas ,Phase 1b,09/05/2024 ET,"Phase 1b translational data presented at ASGCT highlighted the scientific rationale and demonstrate key therapeutic mechanisms of activity for the treatment of B cell-mediated autoimmune disease, note … read more",115.33M
Add to portfolio,,,RMAT,,,,,
FATE,,$3.90 ,FT819,B-cell Leukemias and Lymphomas ,Phase 1b,09/05/2024 ET,"Phase 1b translational data presented at ASGCT highlighted the scientific rationale and demonstrate key therapeutic mechanisms of activity for the treatment of B cell-mediated autoimmune disease, note … read more",115.33M
Add to portfolio,,,RMAT,,,,,
FATE,,$3.90 ,FT522,Lupus ,Preclinical,09/05/2024 ET,"Preclinical data to be presented at ASGCT showed dose-dependent trafficking, infiltration, and residency in secondary and tertiary tissues without cytokine support at human dose equivalency levels of … read more",115.33M
Add to portfolio,,,,,,,,
RAPT,,$4.66 ,Zelnecirnon (RPT193),Asthma ,Phase 2a,09/05/2024 ET,"Trial closed due to clinical hold, noted May 9, 2024.",16.54M
Add to portfolio,,,,,,,,
RAPT,,$4.66 ,Zelnecirnon (RPT193),Atopic dermatitis ,Phase 2a,09/05/2024 ET,"Trial closed due to clinical hold, noted May 9, 2024.",16.54M
Add to portfolio,,,,,,,,
AZN,,$77.13 ,FPI-2265 - (AlphaBreak),Prostate cancer ,Phase 2/3,09/05/2024 ET,"Phase 2/3 trial AlphaBreak initiated, noted May 9, 2024.",3.1B
Add to portfolio,,,,,,,,
ANAB,,$26.23 ,Imsidolimab (ANB019) - (GEMINI-1),Generalized pustular psoriasis ,Phase 3,09/05/2024 ET,Phase 3 data showed that All 8 patients who responded to IV imsidolimab in GEMINI-1 and received monthly SC maintenance dosing in GEMINI-2 maintained clear/almost clear skin through 24 weeks with no f … read more,28M
Add to portfolio,,,,,,,,
PDSB,,$3.83 ,PDS0101 + KEYTRUDA (pembrolizumab) - (VERSATILE-002),HPV16-positive first-line recurrent and/or metastatic head and neck squamous cell cancer with low PD-L1 expression (CPS 1-19) ,Phase 2,09/05/2024 ET,"Phase 2 data presented at a KOL showed a 30-month median overall survival (OS); median OS independent of patient CPS score; ORR 34% (CPS≥1); 48% (CPS≥20, noted May 9, 2024.",46.63M
Add to portfolio,,,View Clinical Trial Data,,,,,
PHIO,,$6.93 ,PH-762,Cutaneous Squamous Cell Carcinoma ,Preclinical,09/05/2024 ET,"Preclinical data presented at ASCGT data demonstrates that intratumoral injection of PH-762 significantly inhibits tumor growth in murine cells and may generate memory-specific T cells, noted May 9, 2 … read more",5.73M
Add to portfolio,,,,,,,,
FDMT,,$25.64 ,4D-175 - (GAZE),Geographic Atrophy ,Preclinical,09/05/2024 ET,Preclinical data presented at ARVO showed that intravitreal administration of 4D-175 to non-human primates (NHP) was safe and well tolerated and resulted in robust transgene expression in the retina a … read more,46.7M
Add to portfolio,,,,,,,,
FDMT,,$25.64 ,4D-150 - (PRISM),Wet age-related macular degeneration (AMD) ,Phase 2,09/05/2024 ET,"Phase 2 interim 24-week landmark data presented at ARVO demonstrated that a high dose of 4D-150 (3E10 vg/eye) resulted in robust reductions in overall treatment burden of 89%, percent of patients with … read more",46.7M
Add to portfolio,,,RMAT,,,,,
FRLN,,—,FLT201 - (GALILEO-1),Gaucher disease ,Phase 1/2,09/05/2024 ET,Phase 1/2 results shared at the ASGCT reported an early lyso-Gb1 data and reduction in BMB and fatigue suggest potential for meaningful improvements in clinical outcomes over existing standard of care … read more,4.34M
Add to portfolio,,,ODD,,,,,
CELU,,$3.05 ,CYNK-201,Solid Tumors ,Preclinical,09/05/2024 ET,Preclinical data presented on at ASGCT reported that PT-CD16VS can be combined with various monoclonal antibodies to engage in anti-tumor antibody-dependent cellular cytotoxicity against diverse cance … read more,26.69M
Add to portfolio,,,,,,,,
INSM,,$26.38 ,Treprostinil Palmitil Inhalation Powder (TPIP),Pulmonary hypertension associated with interstitial lung disease (PH-ILD) ,Phase 2,09/05/2024 ET,"Phase 2 topline results reported that serious adverse events occurred in 20.7% of TPIP-treated patients and 40.0% of placebo-treated patients, noted May 9, 2024.",211.37M
Add to portfolio,,,View Clinical Trial Data,,,,,
EWTX,,$20.00 ,EDG-5506 - (DUNE),Becker muscular dystrophy (BMD) ,Phase 2,09/05/2024 ET,Phase 2 data reported that sevasemten was well tolerated across all 21 participants and significantly reduced biomarkers of muscle damage associated with exercise with a mean post-exercise reduction o … read more,105.35M
Add to portfolio,,,ODD,,,,,
CANF,,$2.14 ,Namodenoson (CF102),Metabolic dysfunction-associated steatohepatitis (MASH) ,IND-Enabling,09/05/2024 ET,"IND cleared by the FDA, noted May 9, 2024.",10.35M
Add to portfolio,,,View Clinical Trial Data,,,,,
MRNA,,$117.31 ,mRESVIA (mRNA-1345) - (ConquerRSV),Respiratory syncytial virus (RSV) vaccine ,PDUFA,10/05/2024 ET,"PDUFA decision due on May 12, 2024. FDA has informed Moderna that due to administrative constraints, the agency will not complete its review of mRNA-1345 by the PDUFA date of May 12, 2024, The FDA has … read more",389.08M
Add to portfolio,,,FTD,,,,,
,,,BTD,,,,,
,,,View Clinical Trial Data,,,,,
IPSC,,$3.13 ,CNTY-101 - (CALiPSO-1),Systemic Lupus Erythematosus ,Preclinical,10/05/2024 ET,"Preclinical data demonstrates the potential utility of using a synthetic ligand targeting CD300a as a universal strategy for preventing NK-mediated rejection in allogeneic cell therapies, as noted on … read more",86.39M
Add to portfolio,,,,,,,,
RCKT,,$22.72 ,RP-L301,Pyruvate Kinase Deficiency (PKD) ,Phase 1,10/05/2024 ET,"Phase 1 data reported robust and sustained efficacy in adults and the first pediatric patient infusion of RP-L301 was well tolerated, with engraftment achieved at day +15, noted May 19, 2023. Phase 1 … read more",107.9M
Add to portfolio,,,RMAT,,,,,
AZTR,,$6.48 ,ATR12-351,Netherton Syndrome ,Preclinical,10/05/2024 ET,Preclinical data presented at ASGCT from In vitro data showed that LEKTI (lympho-epithelial Kazal-type-related inhibitor) protein secreted by ATR-12 has nanomolar inhibition of a key protease that dr … read more,3.52M
Add to portfolio,,,ODD,,,,,
IMMX,,$2.18 ,NXC-201 (HBI10101) - (NEXICART-1),relapsed/refractory multiple myeloma and relapsed/refractory AL amyloidosis ,Phase 1/2,10/05/2024 ET,"Phase 1/2 data presented at ASGCT showed a 92% (12/13) overall response rate (ORR) for relapsed/refractory AL Amyloidosis. Best responder duration of response was 28.0 months with response ongoing, no … read more",28.83M
Add to portfolio,,,ODD,,,,,
PLX,,$1.10 ,PRX-115,Severe Gout ,Phase 1,10/05/2024 ET,"Phase 1 initial data from the seven cohorts, and following the review and acceptance of the safety data from cohort 7 by the safety and monitoring committee for dose escalation for the FIH Study, the … read more",79.73M
Add to portfolio,,,,,,,,
MGNX,,$3.31 ,MGC018 - (TAMARACK),Metastatic castration-resistant prostate cancer (mCRPC) ,Phase 2,10/05/2024 ET,"Phase 2 interim data showed PSA50 responses 43.9%/36.6%, ORR 17.8%/25% confirmed. Unfortunately, 5 deaths were found: 1 unrelated, 2 pneumonitis under investigation., noted May 10, 2024",63.21M
Add to portfolio,,,,,,,,
BMY,,$44.27 ,Opdivo (nivolumab) + Yervoy (ipilimumab) versus CCRT - (CheckMate-73L),Stage III non-small cell lung cancer (NSCLC) ,Phase 3,10/05/2024 ET,"Phase 3 CheckMate -73L trial did not meet its primary endpoint of progression-free survival (PFS), noted May 10, 2024.",2.04B
Add to portfolio,,,,,,,,
ACET,,$1.47 ,ADI-270,"Solid tumors CAR T, relapsed/refractory renal cell carcinoma (RCC) ",Preclinical,10/05/2024 ET,"Preclinical data featured at ASGCT data reported robust efficacy maintained across multiple relevant tumor models of varying stringency, noted May 10, 2024.",83.25M
Add to portfolio,,,FTD,,,,,
MRK,,$127.68 ,KEYTRUDA (KeyVibe-010),Resected high-risk melanoma (Stage IIB-IV) ,Phase 3,13/05/2024 ET,Phase 3 pre-planned analysis data showed that the primary endpoint of recurrence-free survival (RFS) met the pre-specified futility criteria. A higher rate of discontinuation of all adjuvant therapy b … read more,2.5B
Add to portfolio,,,,,,,,
VALN,,$7.61 ,VLA1553-321 - (Adolescents trial),Chikungunya Vaccine for adolecents ,Phase 3,13/05/2024 ET,"Phase 3 day 180 results confirm the initial positive immunogenicity and safety data Valneva reported previously, noted May 13, 2024.",81.26M
Add to portfolio,,,View Clinical Trial Data,,,,,
MRUS,,$45.85 ,Petosemtamab (MCLA-158),"Recurrent/metastatic (r/m) head and neck squamous cell carcinoma (HNSCC), Solid Tumors ",Phase 2,13/05/2024 ET,"FDA Granted Breakthrough Therapy Designation (BTD) on May 13, 2024.",75.63M
Add to portfolio,,,BTD,,,,,
GMAB,,—,Petosemtamab (MCLA-158),"Recurrent/metastatic (r/m) head and neck squamous cell carcinoma (HNSCC), Solid Tumors ",Phase 2,13/05/2024 ET,"FDA Granted Breakthrough Therapy Designation (BTD) on May 13, 2024.",661.87M
Add to portfolio,,,BTD,,,,,
INAB,,$1.02 ,INB-200,Glioblastoma ,Phase 1,13/05/2024 ET,"Phase 1 data presented at ASGCT data provide additional insight into the complex gene-expression changes that occur throughout the manufacturing of our gamma-delta T cell products, which demonstrate a … read more",4.54M
Add to portfolio,,,,,,,,
CYTK,,$57.89 ,Aficamten (CK-274) - (SEQUOIA-HCM),Hypertrophic cardiomyopathy (HCM) ,Phase 3,13/05/2024 ET,"Phase 3 full results due presented at Heart Failure showed that treatment with aficamten for 24 weeks significantly improved exercise capacity compared to placebo, noted May 13, 2024.",119.66M
Add to portfolio,,,BTD,,,,,
,,,View Clinical Trial Data,,,,,
EWTX,,$17.48 ,Sevasemten (EDG-5506) - (CANYON),Becker Muscular Dystrophy (BMD) ,Phase 2,13/05/2024 ET,"Phase 2 trial met primary endpoint, noted May 13, 2024.",105.35M
Add to portfolio,,,ODD,,,,,
PLRX,,$14.14 ,Bexotegrast (PLN-74809) - (INTEGRIS-IPF),Idiopathic pulmonary fibrosis (IFP) ,Phase 2a,14/05/2024 ET,"Phase 2a 12-week post-hoc analysis reported that bexotegrast-treated patients showed a reduction in SUV in the lung compared to an increase seen in placebo, noted May 14, 2024.",61.39M
Add to portfolio,,,View Clinical Trial Data,,,,,
HCM,,$21.40 ,SULANDA (surufatinib),Metastatic pancreatic ductal adenocarcinoma (PDAC) in China ,Phase 2/3,14/05/2024 ET,"Phase 2/3 study initiated in China, noted May 14, 2024.",174.43M
Add to portfolio,,,,,,,,
KOD,,$3.84 ,Tarcocimab tedromer (KSI-301) - (GLOW2),Non-proliferative diabetic retinopathy ,Phase 3,14/05/2024 ET,"Phase GLOW2 dosing initiated, noted May 14, 2024.",52.82M
Add to portfolio,,,,,,,,
HCM,,$21.40 ,HMPL-306 - (RAPHAEL),Relapsed / refractory acute myeloid leukemia (AML) ,Phase 3,14/05/2024 ET,"Phase 3 initiated, noted May 14, 2024.",174.43M
Add to portfolio,,,,,,,,
DVAX,,$11.00 ,HEPLISAV-B,End Stage Renal Disease on Dialysis undergoing hemodialysis ,CRL,14/05/2024 ET,"CRL announced May 14, 2024.",117.27M
Add to portfolio,,,,,,,,
NNVC,,$2.26 ,NV-CoV-2 (NV-387),"RSV (Respiratory Syncytial Virus), Coronavirus, Smallpox/Mpox related Ectromelia virus infection ",Preclinical,14/05/2024 ET,"Preclinical antiviral activity study resulted in full survival of lethally infected animals was achieved, noted May 14, 2024.",17.43M
Add to portfolio,,,,,,,,
NMRA,,$9.58 ,Navacaprant (NMRA-140),Bipolar Depression ,Phase 2,14/05/2024 ET,"Phase 2 initiated, noted May 14, 2024.",161.95M
Add to portfolio,,,,,,,,
EQ,,$1.54 ,Itolizumab - (EQUATOR),1st line Acute graft-versus-host disease (aGVHD) ,Phase 3,14/05/2024 ET,"Phase 3 enrollment target surpassed, noted May 14, 2024.",59.5M
Add to portfolio,,,View Clinical Trial Data,,,,,
ATYR,,$1.82 ,Efzofitimod - (EFZO-FIT),Pulmonary sarcoidosis ,Phase 3,14/05/2024 ET,"Second DSMB recommended that the ongoing Phase 3 study could continue without any modifications after a second pre-planned, interim analysis, noted May 14, 2024.",97.99M
Add to portfolio,,,FTD,,,,,
,,,ODD,,,,,
GNPX,,$2.57 ,REQORSA Immunogene Therapy (quratusugene ozeplasmid) - (Acclaim-3),Extensive-stage small cell lung cancer (ES-SCLC) ,Phase 1/2,14/05/2024 ET,"Phase 1/2 trial dosing initiated, noted May 14, 2024.",858.11K
Add to portfolio,,,ODD,,,,,
,,,FTD,,,,,
CRIS,,$15.69 ,CA-4948 - (TakeAim Lymphoma),Relapsed or Refractory Non-Hodgkin Lymphoma ,Phase 2,14/05/2024 ET,"Phase 2 data reported that 3 of 3 patients who were naïve to FLT3i treatment achieved objective response (2 CR, 1 MLFS), noted May 14, 2024.",12.5M
Add to portfolio,,,,,,,,
KYMR,,$35.09 ,KT-333,Cutaneous T-cell lymphoma (CTCL) ,Phase 1a,14/05/2024 ET,"Phase 1a data reported two complete responses in two cHL patients at DL4, three partial responses in CTCL patients at DL2, 4 and 5, and stable disease in four solid tumor patients at DL3-4, noted May … read more",71.5M
Add to portfolio,,,ODD,,,,,
,,,FTD,,,,,
TFFP,,$2.01 ,TFF TAC (Tacrolimus Inhalation Powder),Lung transplant (post) ,Phase 2,15/05/2024 ET,"Phase 2 additional data showed that patient enrollment has accelerated to now 10 patients, 6/6 who completed 12-week tratemetn chosen to remain on TFF TAC, 1 patient has been treated for over a year a … read more",4.44M
Add to portfolio,,,,,,,,
VNDA,,$5.36 ,Tradipitant - (Motion Serifos),Motion sickness ,Phase 3,15/05/2024 ET,"Phase 3 trial conducted in real-world conditions on boats in U.S. coastal waters, both the 170 mg and 85 mg doses of tradipitant demonstrated superiority over placebo in preventing vomiting, noted May … read more",59.09M
Add to portfolio,,,,,,,,
THRD,,$12.92 ,THB335,Mast cell-mediated inflammatory diseases ,IND-Enabling,15/05/2024 ET,IND was cleared by the FDA during 2Q 2024.,45.13M
Add to portfolio,,,,,,,,
SGMT,,$4.62 ,Denifanstat (PK Study),Metabolic dysfunction-associated steatohepatitis (MASH) ,Phase 1,15/05/2024 ET,"Phase 1 data reported that denifanstat was well-tolerated and no safety signals were reported, noted May 15, 2024.",32.52M
Add to portfolio,,,,,,,,
IMMP,,$2.82 ,Eftilagimod Alpha with weekly paclitaxel - (AIPAC-003),Metastatic breast cancer (MBC) ,Phase 2/3,15/05/2024 ET,"Phase 2/3 data reported an 50% overall response rate, including one complete response and two partial responses, and a 100% disease control rate, with three patients having stable disease as best over … read more",145.46M
Add to portfolio,,,FTD,,,,,
OLMA,,$9.85 ,Palazestrant (OP-1250) and ribociclib - (OPERA-02),Breast Cancer ,Phase 1/2,15/05/2024 ET,Phase 1b/2 data to be shared at ESMO Breast Cancer showed that treatment was well tolerated with no new safety signals or increased toxicity and no clinically meaningful impact on drug exposure of eit … read more,68.63M
Add to portfolio,,,,,,,,
ACXP,,$2.25 ,Ibezapolstat,C. difficile Infection ,Phase 2b,15/05/2024 ET,"Phase 3 agreement with the FDA after EoP2 meeting, noted May 15, 2024.",1.58M
Add to portfolio,,,FTD,,,,,
,,,View Clinical Trial Data,,,,,
BCAB,,$3.00 ,Ozuriftamab Vedotin (BA3021),"Solid Tumors, Non-small cell lung cancer (NSCLC), recurrent or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN) ",Phase 2,15/05/2024 ET,"Phase 2 data reported 11 responses at the combined 2Q3W and Q2W dose regimens (5 confirmed, including 1 complete response), noted May 15, 2024.",58.72M
Add to portfolio,,,FTD,,,,,
,,,View Clinical Trial Data,,,,,
BCDA,,$6.00 ,BCDA-03,Ischemic heart failure ,Phase 1/2,15/05/2024 ET,"Phase 1/2 data reported that treatment-emergent adverse events, arrhythmias, rejection, or allergic response have been observed, noted May 15, 2024.",5.8M
Add to portfolio,,,,,,,,
PHIO,,$7.20 ,PH-762 (direct drug therapy),Melanoma ,Phase 1b,15/05/2024 ET,"Phase 1b dosing of the first cohort of patients was completed and screening for the next dose cohort is on-going, noted May 15, 2024",5.73M
Add to portfolio,,,,,,,,
AXGN,,$5.95 ,Avance Nerve Graf - (RECON),Severed peripheral nerves ,BLA Filing,15/05/2024 ET,"BLA submitted on May 15, 2024.",46.01M
Add to portfolio,,,,,,,,
LLY,,$770.05 ,Insulin efsitora alfa (efsitora) - (QWINT-2 and QWINT-4),Type 2 diabetes ,Phase 3,16/05/2024 ET,"Phase 3 data reported that trials met their primary endpoints, noted May 16, 2024.",946.46M
Add to portfolio,,,,,,,,
PFE,,$28.53 ,ARV-471 with IBRANCE (palbociclib) - (TACTIVE-N),ER+ positive / HER2- negative breast cancer ,Phase 1b,16/05/2024 ET,"Phase 1b data reported a clinical benefit rate (63%), overall response rate (41.9%), median progression-free survival (11.2 months), noted May 16, 2024.",5.69B
Add to portfolio,,,,,,,,
ARVN,,$32.11 ,ARV-471 with IBRANCE (palbociclib) - (TACTIVE-N),ER+ positive / HER2- negative breast cancer ,Phase 1b,16/05/2024 ET,"Phase 1b data reported a clinical benefit rate (63%), overall response rate (41.9%), median progression-free survival (11.2 months), noted May 16, 2024.",73.42M
Add to portfolio,,,,,,,,
AZN,,$76.57 ,Sipavibart (AZD3152) - (SUPERNOVA),COVID‑19 ,Phase 3,16/05/2024 ET,"Phase 3 data reported that the trial met both dual primary endpoints, noted May 16, 2024.",3.1B
Add to portfolio,,,,,,,,
RHHBY,,$32.65 ,CT-388,Obesity and type 2 diabetes ,Phase 1b,16/05/2024 ET,"Phase 1b data reported significant weight loss in healthy adults with obesity compared to placebo, noted May 16, 2024.",6.36B
Add to portfolio,,,,,,,,
BIIB,,$230.04 ,ION582 (BIIB121) - (HALOS),Angelman Syndrome ,Phase 1/2,16/05/2024 ET,"Phase 1b/2 enrollment completed, noted November 2, 2023. Phase 1b datademonstrated consistent improvements across multiple functional domains, noted May 16, 2024.",146.61M
Add to portfolio,,,ODD,,,,,
IONS,,$37.62 ,ION582 (BIIB121) - (HALOS),Angelman Syndrome ,Phase 1/2,16/05/2024 ET,"Phase 1b/2 enrollment completed, noted November 2, 2023. Phase 1b datademonstrated consistent improvements across multiple functional domains, noted May 16, 2024.",159.39M
Add to portfolio,,,ODD,,,,,
TRML,,$15.00 ,TOUR006 - (TRANQUILITY),Atherosclerotic cardiovascular disease (ASCVD) ,Phase 2,16/05/2024 ET,"Phase 2 dosing initiated, noted May 16, 2024.",25.69M
Add to portfolio,,,,,,,,
BIIB,,$230.04 ,BIIB105 (ATXN2 ASO) - (ALSpire),Amyotrophic Lateral Sclerosis (ALS) ,Phase 1/2,16/05/2024 ET,"Phase 1/2 topline data reported that treatment did not result in a reduction in levels of plasma neurofilament light chain (NfL), a marker of neurodegeneration and neuronal damage, noted May 16, 2024.",146.61M
Add to portfolio,,,,,,,,
IONS,,$37.62 ,BIIB105 (ATXN2 ASO) - (ALSpire),Amyotrophic Lateral Sclerosis (ALS) ,Phase 1/2,16/05/2024 ET,"Phase 1/2 topline data reported that treatment did not result in a reduction in levels of plasma neurofilament light chain (NfL), a marker of neurodegeneration and neuronal damage, noted May 16, 2024.",159.39M
Add to portfolio,,,,,,,,
ASND,,$122.80 ,Breyanzi (lisocabtagene maraleucel) - (TRANSCEND FL),Follicular lymphoma ,Approved,16/05/2024 ET,"Approved May 16, 2024.",60.69M
Add to portfolio,,,,,,,,
BMY,,$42.97 ,Breyanzi (lisocabtagene maraleucel) - (TRANSCEND FL),Follicular lymphoma ,Approved,16/05/2024 ET,"Approved May 16, 2024.",2.04B
Add to portfolio,,,,,,,,
PHIO,,$6.59 ,PH-762,Cutaneous Squamous Cell Carcinoma ,Phase 1b,16/05/2024 ET,"Phase 1b data reported that treatment was well tolerated at the maximum administered dose and treatment with mPH-762 provided robust inhibition of tumor growth, noted May 16, 2024.",5.73M
Add to portfolio,,,,,,,,
MLTX,,$40.86 ,Nanobody (sonelokimab) - (VELA),Hidradenitis suppurativa ,Phase 3,16/05/2024 ET,"Phase 3 trial VELA initiated, noted May 16, 2024.",64.23M
Add to portfolio,,,,,,,,
ATXI,,$3.63 ,AJ201,Spinal and bulbar muscular atrophy (SBMA) ,Phase 1/2,16/05/2024 ET,"Phase 1b/2 last patient dosed completed, noted May 16, 2024.",3.18M
Add to portfolio,,,,,,,,
IVA,,$3.65 ,Lanifibranor - (NATiV3),Nonalcoholic steatohepatitis (NASH) ,Phase 3,16/05/2024 ET,"Positive recommendation from DMC on May 16, 2024.",95.66M
Add to portfolio,,,FTD,,,,,
AMGN,,$310.30 ,IMDELLTRA (tarlatamab-dlle),Extensive-stage small cell lung cancer (ES-SCLC) ,Approved,17/05/2024 ET,"Approved May 17, 2024.",538.36M
Add to portfolio,,,,,,,,
MRNS,,$1.33 ,Ganaxolone - (TrustTSC),Tuberous Sclerosis Complex ,Phase 3,17/05/2024 ET,"Phase 3 enrollment completed, noted May 17, 2024.",55.19M
Add to portfolio,,,ODD,,,,,
,,,View Clinical Trial Data,,,,,
AZTR,,$5.46 ,ATR04-484,EGFRi-associated rash ,Preclinical,17/05/2024 ET,"Preclinical data reported that treatment reduced IL-36g, a pro-inflammatory cytokine that drives inflammation in EGFRi-induced toxicity, in human skin model by 75% compared to erlotinib-treated skin, … read more",3.52M
Add to portfolio,,,FTD,,,,,
LEXX,,$3.15 ,DehydraTECH-powered GLP-1 drugs (semaglutide) - (WEIGHT-A24-1),Diabetes ,Preclinical,17/05/2024 ET,"Preclinical trial initiated, noted May 17, 2024.",19.56M
Add to portfolio,,,,,,,,
ARWR,,$24.77 ,Plozasiran (ARO-APOC3) - (CAPITAN),Mixed hyperlipidemia ,Phase 2b,18/05/2024 ET,"Phase 2b data reported that treatment significantly reduced triglycerides and atherogenic triglyceride rich lipoproteins and increased HDL, across all dose levels at Week 24 in patients with mixed dys … read more",138.26M
Add to portfolio,,,View Clinical Trial Data,,,,,
NNVC,,$2.12 ,NV-CoV-2 (NV-387),"RSV (Respiratory Syncytial Virus), Coronavirus, Smallpox/Mpox related Ectromelia virus infection ",Preclinical,20/05/2024 ET,"Preclinical data reported that NV-387 against RSV/A2 is clearly demonstrated by lungs remaining normal and showing no infection-related damage, when treated orally with NV-387, in a lethal lung RSV in … read more",17.43M
Add to portfolio,,,,,,,,
DYN,,$35.38 ,DYNE-101 - (ACHIEVE),Myotonic Dystrophy Type 1 (DM1) ,Phase 1/2,20/05/2024 ET,"Phase 1/2 data reported that patients in the 5.4 mg/kg Q8W cohort had a 27% mean splicing correction from baseline across a broad, 22-gene panel at 3 months, with all participants demonstrating splici … read more",142.26M
Add to portfolio,,,ODD,,,,,
,,,FTD,,,,,
,,,BTD,,,,,
DYN,,$35.38 ,DYNE-251 - (DELIVER),Duchenne muscular dystrophy (DMD) ,Phase 1/2,20/05/2024 ET,"Phase 1/2 data reported that patients treated with 10 mg/kg of DYNE-251 Q4W had a mean absolute dystrophin level of 3.22% of normal and a 2.97% change, noted May 20, 2024.",142.26M
Add to portfolio,,,FTD,,,,,
,,,ODD,,,,,
,,,BTD,,,,,
BCLI,,$8.51 ,NurOwn,Amytrophic lateral sclerosis (ALS) ,Phase 3,20/05/2024 ET,"Phase 3 data reported a 4% decrease from baseline in NfL in Phase 3 and a 27% and 36% decrease from baseline, at the ends of Period 1 and Period 2 of the EAP, respectively, noted May 20, 2024.",10.38M
Add to portfolio,,,View Clinical Trial Data,,,,,
PLUR,,$6.05 ,NurOwn,Amytrophic lateral sclerosis (ALS) ,Phase 3,20/05/2024 ET,"Phase 3 data reported a 4% decrease from baseline in NfL in Phase 3 and a 27% and 36% decrease from baseline, at the ends of Period 1 and Period 2 of the EAP, respectively, noted May 20, 2024.",8.16M
Add to portfolio,,,View Clinical Trial Data,,,,,
ESPR,,$2.48 ,Bempedoic acid - (Japan trial),Hypercholesterolemia ,Phase 3,20/05/2024 ET,"Phase 3 data reported that the percentage change from baseline in LDL-C at Week 12, the primary endpoint, was -25.25%% in the group receiving bempedoic acid placebo group and -3.46% in the placebo gro … read more",201.62M
Add to portfolio,,,,,,,,
ARWR,,$24.82 ,ARO-RAGE-1001,Asthma ,Phase 1/2,20/05/2024 ET,"Phase 1/2a trial data presented at ATS reported that after two doses of ARO-RAGE in patients with mild to moderate asthma, serum sRAGE was reduced up to 88% with a mean maximum reduction up to 77%, no … read more",138.26M
Add to portfolio,,,,,,,,
AMGN,,$312.35 ,TEZSPIRE (tezepelumab-ekko) - (COURSE),Chronic obstructive pulmonary disease (COPD) ,Phase 2,20/05/2024 ET,"Phase 2 data presented at ATS reported that a 17% numerical reduction in the annual rate of moderate or severe COPD exacerbations compared to placebo at week 52, which was not statistically significan … read more",538.36M
Add to portfolio,,,BTD,,,,,
,,,View Clinical Trial Data,,,,,
GILD,,$66.49 ,Livdelzi (Seladelpar) - (ASSURE),Pruritus (itch) in people living with primary biliary cholangitis (PBC) ,Phase 3,20/05/2024 ET,"Phase 3 data reported that 70% of patients achieved the composite response endpoint and 25% experienced ALP normalization, noted May 20, 2024.",1.24B
Add to portfolio,,,,,,,,
SONN,,$13.92 ,SON-1010 with Trabectedin - (SB101),Solid tumors ,Phase 1,20/05/2024 ET,"Additional safety data reported a 10-fold extended half-life for SON-1010 compared with rhIL-12 that induces prolonged and controlled IFNγ responses, with no evidence of cytokine release syndrome at a … read more",6.75M
Add to portfolio,,,,,,,,
RHHBY,,$32.77 ,SON-1010 in combination with atezolizumab - (SB221),Platinum-resistant ovarian cancer ,Phase 1/2,20/05/2024 ET,Phase 1b/2 data reported that one patient in Part 1 of SB221 with uterine sarcomas received 8 cycles of the SON-1010/atezolizumab combination therapy every 3 weeks before progressing; another two have … read more,6.36B
Add to portfolio,,,,,,,,
SONN,,$13.92 ,SON-1010 in combination with atezolizumab - (SB221),Platinum-resistant ovarian cancer ,Phase 1/2,20/05/2024 ET,Phase 1b/2 data reported that one patient in Part 1 of SB221 with uterine sarcomas received 8 cycles of the SON-1010/atezolizumab combination therapy every 3 weeks before progressing; another two have … read more,6.75M
Add to portfolio,,,,,,,,
GRI,,$5.59 ,GRI-0621,Idiopathic pulmonary fibrosis (IPF) ,Preclinical,20/05/2024 ET,"Preclinical data reported that GRI-0621 was shown to reduce the fibrotic score, inhibit the production of TGFβ and VCAM-1 and reduce the immune cell, noted May 20, 2024.",2.52M
Add to portfolio,,,,,,,,
KRRO,,$54.60 ,KRRO-110 - (REWRITE),Alpha-1 Antitrypsin Deficiency (AATD) ,Preclinical,20/05/2024 ET,Preclinical data presented at ATS showed sustained editing efficiency of approximately 60% and increased total alpha-1 antitrypsin (AAT) protein levels to greater than 60uM at week 13 in an in vivo ge … read more,9.39M
Add to portfolio,,,ODD,,,,,
LRMR,,$7.27 ,Nomlabofusp (CTI-1601),Friedreich’s ataxia (FA) ,Phase 2,20/05/2024 ET,"Phase 2 clinical hold removed, noted May 20, 2024.",85.59M
Add to portfolio,,,ODD,,,,,
VTVT,,$28.21 ,Azeliragon,Refractory to first-line treatment of metastatic pancreatic cancer ,Phase 1/2,20/05/2024 ET,"Phase 1/2 Orphan Drug Designation granted by the FDA on May 20, 2024.",3.19M
Add to portfolio,,,ODD,,,,,
ARCT,,$30.50 ,Kostaive (ARCT-154),COVID-19 variant vaccine ,Phase 1/2,20/05/2024 ET,"Phase 1/2 additional results demonstrate that two 5 μg doses of ARCT-154, sa-mRNA vaccine, were well-tolerated, immunogenic and provided significant protection against multiple strains of COVID-19, no … read more",27.15M
Add to portfolio,,,,,,,,
CSLLY,,$92.08 ,Kostaive (ARCT-154),COVID-19 variant vaccine ,Phase 1/2,20/05/2024 ET,"Phase 1/2 additional results demonstrate that two 5 μg doses of ARCT-154, sa-mRNA vaccine, were well-tolerated, immunogenic and provided significant protection against multiple strains of COVID-19, no … read more",968.41M
Add to portfolio,,,,,,,,
GLUE,,$4.30 ,MRT-6160,Autoimmune conditions ,Preclinical,21/05/2024 ET,"Preclinical data reported that MRT-6160-mediated murine (m)VAV1 degradation prevented disease progression by 85% compared to vehicle (P<0.0001), and also reduced the disease activity index (DAI) score … read more",61.76M
Add to portfolio,,,,,,,,
IRWD,,$6.78 ,Apraglutide - (STARS),Short Bowel Syndrome with Intestinal Failure (SBS-IF) ,Phase 3,21/05/2024 ET,"Additional Phase 3 data to be presented at the Digestive Disease Week reported that significantly more apraglutide-patients gained additional days off from PS per week at week 24 versus placebo, noted … read more",162.43M
Add to portfolio,,,View Clinical Trial Data,,,,,
GILD,,$65.89 ,Depemokimab - (SWIFT-1 and SWIFT-2),Severe asthma with type 2 inflammation characterised by blood eosinophil count ,Phase 3,21/05/2024 ET,"Phase 3 data reported that both trials met its primary endpoints, noted May 21, 2024.",1.24B
Add to portfolio,,,,,,,,
CTXR,,$0.73 ,Mino-Lok,Catheter related blood stream infection (CRBSI) ,Phase 3,21/05/2024 ET,"Phase 3 topline data study met its primary endpoint with a statistically significant improvement in the time to failure event, noted May 21, 2024.",17.01M
Add to portfolio,,,View Clinical Trial Data,,,,,
PRTC,,$29.50 ,VE303 - (RESTORATiVE303),Clostridioides difficile infection (CDI) ,Phase 3,21/05/2024 ET,"Phase 3 dosing initiated, noted May 21, 2024.",24.17M
Add to portfolio,,,,,,,,
ASLN,,$3.84 ,eblasakimab versus dupilumab,human tissue model of chronic obstructive pulmonary disease (COPD) ,Preclinical,21/05/2024 ET,"Preclinical data presented at American Thoracic Society results support further investigation of eblasakimab as a potential therapeutic option for COPD, noted May 20, 2024.",2.83M
Add to portfolio,,,,,,,,
ONVO,,$1.03 ,FXR314 with Tofacitinib,Inflammatory Bowel Disease ,Preclinical,21/05/2024 ET,"Preclinical data reported that FXR314 alone improved measures of colon health and colon histopathology similarly to approved IBD therapies tofacitinib and IL-12/23 antagonist, noted May 21, 2024.",1.8M
Add to portfolio,,,,,,,,
PALI,,$5.41 ,PALI-2108,Moderate-to-severe ulcerative colitis (UC) ,Preclinical,21/05/2024 ET,"Preclinical data presented at DDW exhibited a dose-dependent efficacy response in two DSS colitis mouse models, achieving efficacy comparable to doses of apremilast considered intolerable for human us … read more",9.12M
Add to portfolio,,,,,,,,
GRI,,$5.39 ,GRI-0124,Systemic Lupus Erythematosus (SLE) ,Preclinical,21/05/2024 ET,"Preclinical data reported that it inhibited pro-inflammatory cytokines and signaling pathways in NZBWF1 mice, noted May 21, 2024.",2.52M
Add to portfolio,,,,,,,,
GRI,,$5.39 ,GRI-0803,Systemic lupus erythematosus (SLE) ,Preclinical,21/05/2024 ET,"Preclinical data reported favorable solubility profile, and an excellent bioavailability, noted May 21, 2024.",2.52M
Add to portfolio,,,,,,,,
BDRX,,$58.25 ,"eRapa (rapamycin, sirolimus) - (Serenta)",Familial Adenomatous Polyposis (FAP) ,Phase 2,21/05/2024 ET,"Phase 2 results presented at DDW showed an 83% non-progression rate at 6 months and a statistically significant decrease in overall mean polyp burden at 6 months, noted May 21, 2024.",505.06K
Add to portfolio,,,FTD,,,,,
,,,ODD,,,,,
BHC,,—,larsucosterol (DUR-928) - (AHFIRM),Alcoholic hepatitis (AH) ,Phase 2b,21/05/2024 ET,"Breakthrough Therapy designation (BTD) granted by the FDA, noted May 21, 2024.",369.79M
Add to portfolio,,,BTD,,,,,
,,,View Clinical Trial Data,,,,,
LLY,,$802.05 ,Mirikizumab - (VIVID-1),Crohn's disease ,Phase 3,21/05/2024 ET,"Phase 3 data showed that nearly one-half of patients on mirikizumab achieved endoscopic response at 52 weeks; most of these patients were also in clinical remission, noted May 21, 2024.",946.46M
Add to portfolio,,,View Clinical Trial Data,,,,,
XOMA,,$25.90 ,RZ402,Diabetic macular edema (DME) ,Phase 2,21/05/2024 ET,"Phase 2 study met its primary endpoint, noted May 21, 2024.",12.09M
Add to portfolio,,,,,,,,
RZLT,,$3.00 ,RZ402,Diabetic macular edema (DME) ,Phase 2,21/05/2024 ET,"Phase 2 study met its primary endpoint, noted May 21, 2024.",90.81M
Add to portfolio,,,,,,,,
LIPO,,$0.73 ,LP-10 (liposomal tacrolimus),Hemorrhagic cystitis ,Phase 2b,21/05/2024 ET,"Phase 2b type C meeting with the FDA resulted in a preliminary agreement to proceed to Phase 2b expected to initiated in 2H 2024, noted May 21, 2024.",4.62M
Add to portfolio,,,ODD,,,,,
ALGS,,$15.96 ,ALG-055009 - (HERALD),Metabolic dysfunction-associated steatohepatitis (MASH) ,Phase 2a,21/05/2024 ET,"Phase 2a enrollment completed, noted May 21, 2024",6.15M
Add to portfolio,,,,,,,,
SANA,,$8.30 ,SC379,Secondary progressive multiple sclerosis ,Preclinical,21/05/2024 ET,"Preclinical data published in a paper showed that when healthy wild-type (WT), pluripotent stem cell-derived glial progenitor cells (hGPCs) – the cells that give rise to the glial support cells of the … read more",237.81M
Add to portfolio,,,,,,,,
IFRX,,$1.52 ,Gohibic (vilobelimab) - (PANAMO),COVID-19 ,Phase 3,21/05/2024 ET,"Phase 3 data shared at ATS 2024 showed that co-administration of vilobelimab with baricitinib or tocilizumab was not associated with safety concerns, noted May 21, 2024.",59.35M
Add to portfolio,,,FTD,,,,,
,,,ODD,,,,,
,,,View Clinical Trial Data,,,,,
JBIO,,—,AV-101 - (IMPAHCT),Pulmonary arterial hypertension (PAH) ,Phase 2b,21/05/2024 ET,Phase 2b portion of study outcomes shared at the ATS conference showed that baseline characteristics reflect a patient population with significant disease despite treatment with two to three targeted … read more,32.63M
Add to portfolio,,,View Clinical Trial Data,,,,,
RVPH,,$1.31 ,Brilaroxazine,Idiopathic pulmonary fibrosis (IPF) ,Preclinical,21/05/2024 ET,"Preclinical data shared at ATS reported that interactions with multiple 5-HT targets, particularly 5-HT2B/7 receptors, within the pulmonary tissue, provide an underlying basis for this agent's effecti … read more",68M
Add to portfolio,,,ODD,,,,,
LYRA,,$0.36 ,LYR-220 - (BEACON),Chronic rhinosinusitis ,Phase 2,21/05/2024 ET,"Development paused, noted May 21, 2024.",1.64M
Add to portfolio,,,,,,,,
AMPH,,$43.46 ,Albuterol Sulfate Inhalation Aerosol (AMP-008),Bronchospasm ,Approved,22/05/2024 ET,"Approved May 22, 2024.",46.5M
Add to portfolio,,,,,,,,
PLRX,,$14.18 ,Bexotegrast (PLN-74809) - (INTEGRIS-IPF),Idiopathic pulmonary fibrosis (IFP) ,Phase 2a,22/05/2024 ET,Phase 2a data reported that seven previously identified plasma biomarkers of interstitial lung disease (ILD) progression were significantly modulated in participants with IPF receiving bexotegrast ove … read more,61.39M
Add to portfolio,,,View Clinical Trial Data,,,,,
RNAC,,$25.46 ,Descartes-08 - (AURORA),"Generalized myasthenia gravis (MG), Multiple Myeloma and Autoimmune Diseases ",Phase 2b,22/05/2024 ET,"Regenerative Medicine Advanced Therapy (RMAT) granted by the FDA, noted May 22, 2024.",26M
Add to portfolio,,,RMAT,,,,,
,,,ODD,,,,,
INKT,,$1.00 ,AGENT-797,Acute respiratory distress (ARDS) secondary to COVID-19 ,Phase 1/2,22/05/2024 ET,"Phase 1/2 data reported that allogeneic iNKT therapy was safely administered with rapid decrease in IL-18 and other inflammatory cytokines, noted May 22, 2024.",4.52M
Add to portfolio,,,,,,,,
SRRK,,$11.71 ,SRK-439 with apitegromab - (EMBRAZE),Obesity ,Phase 2,22/05/2024 ET,"Phase 2 trial initiated, noted May 22, 2024.",96.13M
Add to portfolio,,,,,,,,
ABUS,,$3.41 ,Imdusiran (AB-729 and VTP-300 with nivolumab) - (IM-PROVE I),Hepatitis B (HBV) ,Phase 2a,22/05/2024 ET,"Phase 2a key findings noting that VTP-300 in combination with nivolumab has been generally well tolerated, with no observed treatment-related serious adverse events, and contributed to declines in hep … read more",191.7M
Add to portfolio,,,,,,,,
BRNS,,$2.30 ,Imdusiran (AB-729 and VTP-300 with nivolumab) - (IM-PROVE I),Hepatitis B (HBV) ,Phase 2a,22/05/2024 ET,"Phase 2a key findings noting that VTP-300 in combination with nivolumab has been generally well tolerated, with no observed treatment-related serious adverse events, and contributed to declines in hep … read more",40.72M
Add to portfolio,,,,,,,,
CLYD,,—,Imdusiran (AB-729 and VTP-300 with nivolumab) - (IM-PROVE I),Hepatitis B (HBV) ,Phase 2a,22/05/2024 ET,"Phase 2a key findings noting that VTP-300 in combination with nivolumab has been generally well tolerated, with no observed treatment-related serious adverse events, and contributed to declines in hep … read more",—
Add to portfolio,,,,,,,,
INDP,,$2.48 ,Decoy 20,Solid tumors ,Phase 1a,22/05/2024 ET,"Phase 1a first-in-human trial confirms ""Pulse-Prime"" hypothesis targeting stimulation of innate and adaptive immune systems, this data to be presented at ASCO 24, noted May 22, 2024.",1.11M
Add to portfolio,,,,,,,,
BIVI,,$4.84 ,Bezisterim (NE3107) - (Biomarker Trial),Alzheimer's disease ,Phase 2a,22/05/2024 ET,Phase 2a full dataset presented at IAPRD suggest patients treated with bezisterim experienced significant improvements in both non-motor symptoms and motor control while placebo-treated patients worse … read more,7.53M
Add to portfolio,,,,,,,,
ANL,,$12.75 ,Palupiprant (AN0025) + Keytruda - (ARTEMIS),"TNBC, NSCLC, bladder cancer, microsatellite stable CRC and cervical cancer ",Phase 2,22/05/2024 ET,"Phase 2 trial initiated, noted May 22, 2024.",36.9M
Add to portfolio,,,,,,,,
PTIX,,$1.80 ,PT00114,Major Depressive Disorder (MDD) / Generalized Anxiety Disorder (GAD) / Post-Traumatic Stress Disorder (PTSD) ,Phase 1/2,22/05/2024 ET,"Phase 1/2a safety data demonstrated no clinically relevant Adverse Events Reported in the single-dose portion, with the multiple-dose portion to commence, noted May 22, 2024.",588.96K
Add to portfolio,,,,,,,,
KYMR,,$35.70 ,KT-621 (STAT6),Type 2 inflammation in allergic diseases ,Preclinical,22/05/2024 ET,"Preclinical data reported that KT-621 was comparable to a saturating dose of the IL-4Rα antibody, dupilumab, in an asthma efficacy model which demonstrated that KT-621 robustly inhibited all the teste … read more",71.5M
Add to portfolio,,,,,,,,
CNTB,,$1.68 ,Rademikibart - (Seabreeze STAT Asthma),Asthma ,Phase 2b,22/05/2024 ET,"Phase 2b data presented at ATS showed that treatment significantly improved lung function at Week 12; improvements were observed as early as Week 1 and sustained through Week 24, noted May 22, 2024.",55.72M
Add to portfolio,,,,,,,,
TNGX,,$7.09 ,TNG348,"BRCA1/2-Mutant and Other HRD+ Cancers, Solid Tumors ",Phase 1/2,23/05/2024 ET,"Phase 1/2 first patient dosed January 3, 2024. Phase 1/2 discontinued due to toxicity observed in the initial study cohorts. No patient had yet received a combination of TNG348 and olaparib., noted Ma … read more",111.26M
Add to portfolio,,,FTD,,,,,
CYTO,,$1.71 ,Bentrio (AM-301) - (NASAR),Seasonal allergic rhinitis (SAR) ,Phase 1,23/05/2024 ET,"Phase 1 data published at in video format showed that the study met its primary efficacy endpoint, showing a statistically significant reduction in the mean daily reflective Total Nasal Symptom Score … read more",4.66M
Add to portfolio,,,,,,,,
NNVC,,$2.23 ,NV-CoV-2 (NV-387),"RSV (Respiratory Syncytial Virus), Coronavirus, Smallpox/Mpox related Ectromelia virus infection ",Phase 1b,23/05/2024 ET,"Phase 1b trial completed, the company also engaged with Aagami, Inc for partnership developments and licensing opportunities, noted May 23, 2024.",17.43M
Add to portfolio,,,,,,,,
EVGN,,$7.20 ,BMC128 with Opdivo,"Non-small cell lung cancer (NSCLC), melanoma or renal cell carcinoma ",Phase 1,23/05/2024 ET,"Phase 1 data from ASCO abstract reported that one patient demonstrated partial response (PR) upon imaging and RECIST v1.1 assessment and remains actively responding to treatment. Additionally, 64% of … read more",6.51M
Add to portfolio,,,,,,,,
BMY,,$40.47 ,BMC128 with Opdivo,"Non-small cell lung cancer (NSCLC), melanoma or renal cell carcinoma ",Phase 1,23/05/2024 ET,"Phase 1 data from ASCO abstract reported that one patient demonstrated partial response (PR) upon imaging and RECIST v1.1 assessment and remains actively responding to treatment. Additionally, 64% of … read more",2.04B
Add to portfolio,,,,,,,,
SUPN,,$27.77 ,SPN-817,Treatment-resisted seizures ,Phase 2,23/05/2024 ET,"Phase 2 interim data reported that 81% of subjects with focal seizures had 30% or more seizure reduction, noted May 23, 2024.",56.07M
Add to portfolio,,,,,,,,
MRUS,,$44.07 ,MCLA-145 with Keytruda (pembrolizumab),Solid tumors ,Phase 1,23/05/2024 ET,"Phase 1 data from abstract reported that 5 partial responses (PRs) were observed with 1 complete response was observed in PD-L1+ NSCLC (treated 6+ mo) and 1 PR in Merkel cell carcinoma, noted May 23, … read more",75.63M
Add to portfolio,,,,,,,,
GMAB,,—,MCLA-145 with Keytruda (pembrolizumab),Solid tumors ,Phase 1,23/05/2024 ET,"Phase 1 data from abstract reported that 5 partial responses (PRs) were observed with 1 complete response was observed in PD-L1+ NSCLC (treated 6+ mo) and 1 PR in Merkel cell carcinoma, noted May 23, … read more",661.87M
Add to portfolio,,,,,,,,
BCYC,,$23.48 ,BT5528 and OPDIVO (nivolumab),Solid tumors ,Phase 1/2,23/05/2024 ET,"Phase 1/2 data from ASCO abstract reported that BT5528-related AEs occurred in 91% of patients, of which 22% were Grade ≥3, noted May 23, 2024.",69.31M
Add to portfolio,,,,,,,,
BCAB,,$2.10 ,Evalstotug (BA3071),Oncology (various) ,Phase 2,23/05/2024 ET,"Phase 2 data from abstract reported two treatment related discontinuations with responses in three of eight patients who received evalstotug 350mg(1 CR, 1 PR, 1 unPR), noted May 23, 2024.",58.72M
Add to portfolio,,,,,,,,
NKGN,,$1.86 ,SNK02,Solid Tumors ,Phase 1,23/05/2024 ET,"Phase 1 data from ASCO abstract reported that the best objective response of stable disease was demonstrated in 100% of patients that completed 8 treatment cycles of SNK02, noted May 23, 2024.",124.38M
Add to portfolio,,,,,,,,
FGEN,,$1.28 ,FG-3246 (FOR46) in combination with enzalutamide - (Investigator-sponsored trial),Metastatic castration-resistant prostate cancer (mCRPC) ,Phase 1/2,23/05/2024 ET,"Phase 1b/2 data from abstract reported a preliminary estimate of median radiographic progression free survival (rPFS) of 10.2 months, noted May 23, 2024.",4.04M
Add to portfolio,,,,,,,,
VSTM,,$12.18 ,VS-6766 and defactinib - (RAMP 205),Metastatic pancreatic cancer ,Phase 1/2,23/05/2024 ET,"Phase 1/2 study as of May 14, 2024, patients receiving the combination of avutometinib and defactinib with gemcitabine and Nab-paclitaxel in dose level 1 cohort achieved a confirmed overall response r … read more",61.55M
Add to portfolio,,,,,,,,
IMAB,,$1.75 ,Ragistomig (ABL503),Solid tumors ,Phase 1,23/05/2024 ET,"Phase 1 data from ASCO abstract reported an overall response rate of 25% at 5 mg/kg, based on 3 partial responses (PR) out of 12 patients with median progression free survival (PFS) of 15.6 weeks, not … read more",81.5M
Add to portfolio,,,,,,,,
CGEM,,$22.65 ,CLN-619 - (MICA) monotherapy and in combination with pembrolizumab,Solid tumors ,Phase 1,23/05/2024 ET,"Phase 1 data from ASCO abstract reported that confirmed partial responses (PR) were observed in 3 patients, noted May 23, 2024.",59.07M
Add to portfolio,,,,,,,,
REGN,,$980.57 ,REGN7075 in combination with cemiplimab,Solid Tumors ,Phase 1/2,23/05/2024 ET,"Phase 1/2 updated data to be presented at ASCO on June 3, 2024. Phase 1/2 data from ASCO abstract reported a 6% (n=3) overall response rate (ORR) and 29% (n=15) disease control rate (DCR), noted May 2 … read more",105.99M
Add to portfolio,,,,,,,,
MURA,,$3.59 ,Nemvaleukin (ALKS 4230) - (ARTISTRY-3),Solid Tumors ,Phase 2,23/05/2024 ET,"Phase 2 data from ASCO abstract reported that all dosing schedules tested in ARTISTRY-3 demonstrated the desired pharmacodynamic effects, including expansion of immune-stimulating NK and CD8+ cells, n … read more",17.32M
Add to portfolio,,,,,,,,
ALKS,,$24.00 ,Nemvaleukin (ALKS 4230) - (ARTISTRY-3),Solid Tumors ,Phase 2,23/05/2024 ET,"Phase 2 data from ASCO abstract reported that all dosing schedules tested in ARTISTRY-3 demonstrated the desired pharmacodynamic effects, including expansion of immune-stimulating NK and CD8+ cells, n … read more",165.08M
Add to portfolio,,,,,,,,
IOVA,,$10.26 ,LN-145 - (IOV-COM-202),Non-small cell lung cancer (NSCLC) ,Phase 2,23/05/2024 ET,"Phase 2 data from ASCO abstract reported a confirmed ORR was 65.2%, including 7 (30.4%) complete responses and 8 (34.8%) partial responses, noted May 23, 2024.",361.85M
Add to portfolio,,,View Clinical Trial Data,,,,,
HOWL,,$5.16 ,WTX-124,Solid Tumors ,Phase 1b,23/05/2024 ET,"Phase 1/1b data from ASCO abstract reported that treatment was well tolerated and clinically active in patients with checkpoint inhibitor therapy relapsed/refractory cancers, noted May 23, 2024.",45.73M
Add to portfolio,,,FTD,,,,,
CMPX,,$1.50 ,CTX-471 (CD137 agonist),Solid tumors ,Phase 1,23/05/2024 ET,"Phase 1 Dose Escalation and Dose Expansion, first-in-human monotherapy study in patients with metastatic or locally advanced malignancies who had progressed on approved PD-1 or PD-L1 inhibitors, noted … read more",138.28M
Add to portfolio,,,,,,,,
INAB,,$1.04 ,INB-200,Glioblastoma ,Phase 1,23/05/2024 ET,"Phase 1 data from ASCO reported no dose-limiting toxicities, cytokine release syndrome, or neurotoxicity, noted May 23, 2024.",4.54M
Add to portfolio,,,,,,,,
EVAX,,$3.88 ,EVX-01 + KEYTRUDA (pembrolizumab) / OPDIVO (nivolumab),Metastatic Melanoma ,Phase 2b,23/05/2024 ET,"Phase 2 data from ASCO abstract reported that EVX-01 vaccine-induced specific and robust immune responses, mediated by both CD4+ and CD8+ T-cells, noted May 23, 2024.",6.32M
Add to portfolio,,,FTD,,,,,
MRK,,$129.46 ,EVX-01 + KEYTRUDA (pembrolizumab) / OPDIVO (nivolumab),Metastatic Melanoma ,Phase 2b,23/05/2024 ET,"Phase 2 data from ASCO abstract reported that EVX-01 vaccine-induced specific and robust immune responses, mediated by both CD4+ and CD8+ T-cells, noted May 23, 2024.",2.5B
Add to portfolio,,,FTD,,,,,
AGEN,,$12.35 ,Botensilimab plus balstilimab,Relapsed/refractory microsatellite stable colorectal cancer with no active liver metastases (r/r MSS CRC NLM) ,Phase 1b,23/05/2024 ET,"Phase 1b data to be presented at ASCO 2024, ASCO abstract released across different NLM sites, overall response rates (ORR) ranged from 18-33%, and disease control rates (DCR) ranged from 67-82%. Over … read more",31.86M
Add to portfolio,,,FTD,,,,,
MRUS,,$44.07 ,Petosemtamab (MCLA-158),"Recurrent/metastatic (r/m) head and neck squamous cell carcinoma (HNSCC), Solid Tumors ",Phase 2,23/05/2024 ET,"Phase 2 data from abstract reported a 60% response rate observed among 10 evaluable patients, noted May 23, 2024.",75.63M
Add to portfolio,,,BTD,,,,,
GMAB,,—,Petosemtamab (MCLA-158),"Recurrent/metastatic (r/m) head and neck squamous cell carcinoma (HNSCC), Solid Tumors ",Phase 2,23/05/2024 ET,"Phase 2 data from abstract reported a 60% response rate observed among 10 evaluable patients, noted May 23, 2024.",661.87M
Add to portfolio,,,BTD,,,,,
AFMD,,$4.71 ,AFM24-102 and TECENTRIQ (atezolizumab),"EGFR Expressing Solid Tumors, Non-small cell lung cancer, and Gastric/gastroesophageal junction (GEJ) cancer ",Phase 2,23/05/2024 ET,"Phase 2 data due to be presented at ASCO on June 1, 2024. Phase 2 ASCO abstract to be presented showed that of the March 18, 2024 data cut-off, the median progression free survival was 5.9 months and … read more",15.23M
Add to portfolio,,,FTD,,,,,
ZNTL,,$11.28 ,Azenosertib and gemcitabine,Relapsed or refractory (R/R) osteosarcoma ,Phase 1,23/05/2024 ET,Phase 1 data from ASCO abstract support further investigation of azenosertib administered in combination with gemcitabine in patients with R/R osteosarcoma in an upcoming investigator-initiated Phase … read more,72.14M
Add to portfolio,,,,,,,,
BPMC,,$102.39 ,BLU-222 - (VELA),(HR+/HER2-) breast cancer. ,Phase 1,23/05/2024 ET,Phase 1 dose escalation data presented at ASCO abstract showed that BLU-222 in combination with ribociclib and fulvestrant was well-tolerated at clinically active dose levels with no dose-limiting tox … read more,64.58M
Add to portfolio,,,,,,,,
SNSE,,$1.45 ,Solnerstotug (formerly SNS-101) with Libtayo - (VISTA),One microsatellite stable (MSS) endometrial cancer ,Phase 1/2,23/05/2024 ET,"Phase 1/2 data demonstrated initial signs of promising clinical activity, noted May 23, 2024.",1.26M
Add to portfolio,,,,,,,,
REGN,,$980.57 ,Solnerstotug (formerly SNS-101) with Libtayo - (VISTA),One microsatellite stable (MSS) endometrial cancer ,Phase 1/2,23/05/2024 ET,"Phase 1/2 data demonstrated initial signs of promising clinical activity, noted May 23, 2024.",105.99M
Add to portfolio,,,,,,,,
COGT,,$7.49 ,Bezuclastinib and SUTENT (sunitinib) - (PEAK),Gastrointestinal Stromal Tumors (GIST) ,Phase 3,23/05/2024 ET,Phase 3 updated data presented at an ASCO abstract showed d that study reached median progression free survival (mPFS) of 19.4-months and 33% ORR in subset of advanced GIST patients with one prior tre … read more,139.7M
Add to portfolio,,,View Clinical Trial Data,,,,,
HOOK,,$10.40 ,Eseba-vec (formerly HB-200) in combination with KEYTRUDA (pembrolizumab),Head and neck squamous cell carcinoma (HNSCC) ,Phase 1/2,23/05/2024 ET,"Phase 2 data due to be presented at ASCO 2024, abstract from updated data showed confirmed objective response rate (ORR) of 53%, complete response (CR) rate of 18%, and disease control rate (DCR) of 8 … read more",12.2M
Add to portfolio,,,FTD,,,,,
CADL,,$10.69 ,CAN-2409 + valacyclovir,Non-small cell lung cancer (NSCLC) ,Phase 2,23/05/2024 ET,"Phase 2 data from ASCO abstract showed that treatment resulted in activation of the systemic immune response after two administrations of CAN-2409, including increased numbers of circulating cytotoxic … read more",54.9M
Add to portfolio,,,FTD,,,,,
,,,View Clinical Trial Data,,,,,
ELTX,,$8.85 ,ELI-002 - (AMPLIFY-7P),mKRAS-driven cancers ,Phase 2,23/05/2024 ET,"Phase 2 ASCO abstract showed that treatment administered as a monotherapy was well tolerated and able to generate a ~100x mKRAS-specific expanded T cell response relative to baseline levels, noted May … read more",16.34M
Add to portfolio,,,,,,,,
PBYI,,$3.99 ,Alisertib - (PUMA-ALI-4201) - (ALISCA-Lung1),Small Cell Lung Cancer (SCLC) ,Phase 1b,23/05/2024 ET,Phase 1/1b data shared at ASCO abstract showed that intermittent dosing of alisertib 30 mg BID in combination with osimertinib 80 mg daily demonstrated no dose-limiting toxicities and was identified a … read more,50.37M
Add to portfolio,,,ODD,,,,,
IPHA,,$2.96 ,IPH6501,Relapsed and/or Refractory CD20-expressing B-cell Non-Hodgkin's Lymphoma (NHL) ,Preclinical,23/05/2024 ET,"Preclinical data from ASCO abstract reported that IPH6501, at well-tolerated doses, significantly boosted peripheral NK cell proliferation, drove their accumulation at tumor locations, and effectively … read more",92.16M
Add to portfolio,,,,,,,,
ALXO,,$14.69 ,Evorpacept w/ cetuximab and pembrolizumab,Colorectal cancer ,Phase 2,23/05/2024 ET,"Phase 2 data from the abstract has ORR was 6.3% (1 ongoing partial response, 95% confidence interval [CI] 0.2-30.2%), disease control rate was 12.5% (95% CI 1.6-38.4%), median progression-free surviva … read more",53.55M
Add to portfolio,,,FTD,,,,,
BNTX,,$99.00 ,BNT327/PM8002,Non-small cell lung cancer (NSCLC) ,Phase 1/2,23/05/2024 ET,"Phase 1b/2 data from ASCO abstract reported a 47% ORR in cohort 6, 19.4% ORR in cohort 7, noted May 23, 2024.",239.97M
Add to portfolio,,,,,,,,
CUE,,$1.74 ,CUE-102,Wilms' Tumor (WT1)-expressing cancers ,Phase 1,23/05/2024 ET,"Phase 1 data from abstract reported that stable disease of ≥ 6 weeks (range 6-36 weeks), as determined by RECIST 1.1, has been observed in 10 of 23 patients (DCR 43.5%), noted May 23, 2024.",76.85M
Add to portfolio,,,,,,,,
CUE,,$1.74 ,CUE-101 and KEYTRUDA (pembrolizumab) - (KEYNOTE-A78),HPV16+ head and neck cancer ,Phase 1,23/05/2024 ET,"Phase 1 data from ASCO abstract reported that of CUE-101 plus pembrolizumab, an ORR of 47% (1 CR, 8 PRs), a Disease Control Rate (ORR + durable SDs) of 74%, and mPFS of 5.8 months, noted May 23, 2024.",76.85M
Add to portfolio,,,FTD,,,,,
MRK,,$129.46 ,Sacituzumab tirumotecan (SKB264/MK-2870) - (OptiTROP-Breast01),Locally recurrent or metastatic triple-negative breast cancer (TNBC) ,Phase 3,23/05/2024 ET,"Phase 3 data from ASCO abstract reported an objective response rate assessed by BICR was 43.8% with SKB264 and 12.8% with chemotherapy, noted May 23, 2024.",2.5B
Add to portfolio,,,BTD,,,,,
PFE,,$28.30 ,PF-07248144,ER+ HER2− breast cancer ,Phase 1,23/05/2024 ET,"Phase 1 data from ASCO abstract reported that for the fulvestrant combination (n=43), with median duration of follow-up of 9.2 mos, the ORR was 30.2% (17.2, 46.1), median DOR was 9.2 mos (7.2, NE), CB … read more",5.69B
Add to portfolio,,,,,,,,
PFE,,$28.30 ,Mevrometostat (PF-06821497),Castration-resistant prostate cancer (CRPC) ,Phase 1,23/05/2024 ET,"Phase 1 data from ASCO abstract reported that the OR rate (95% CI) was 27.3% (10.7, 50.2), including 1 complete and 5 partial responses, noted May 23, 2024.",5.69B
Add to portfolio,,,,,,,,
PFE,,$28.30 ,Elranatamab - (MagnetisMM-9),Multiple Myeloma ,Phase 1/2,23/05/2024 ET,"Phase 1/2 data from ASCO abstract reported that after a median follow-up of 7.4 mo, the most common (>50%) AEs were CRS (63.5%; grade ≥2, 15.3%) and neutropenia (54.1%; all grade ≥2), noted May 23, 20 … read more",5.69B
Add to portfolio,,,,,,,,
PFE,,$28.30 ,Sigvotatug vedotin (SGNB6A-001),Non-small cell lung cancer (NSCLC) ,Phase 1,23/05/2024 ET,"Phase 1 data reported in ASCO abstract reported that the cORR was 19.5% (95% CI, 12.6-28.0) in all pts with NSCLC and 32.5% (95% CI, 18.6-49.1) in pts with non-squamous (non-Sq)/taxane-naive NSCLC. Ad … read more",5.69B
Add to portfolio,,,,,,,,
MOLN,,$3.81 ,MP0317,Solid Tumors ,Phase 1,23/05/2024 ET,"Phase 1 data from ASCO abstract reported that one patient achieved unconfirmed partial response, and stable disease was observed in 11 patients (24%), noted May 23, 2024.",40.36M
Add to portfolio,,,,,,,,
XLO,,$1.07 ,XTX202,Solid Tumors ,Phase 1/2,23/05/2024 ET,"Phase 1/2 data from ASCO abstract reported that the DCR was 62% at the 1.4 mg/kg dose-level and 80% at the 4 mg/kg dose-level, with 19 pts ongoing and awaiting first response assessment, noted May 23, … read more",51.83M
Add to portfolio,,,,,,,,
VSTM,,$4.12 ,AVMAPKI FAKZYNJA CO-PACK,Recurrent low-grade serous ovarian cancer (LGSOC) ,NDA Filing,24/05/2024 ET,"NDA and accelerated approval application submitted May 24, 2024.",61.55M
Add to portfolio,,,ODD,,,,,
IDYA,,$37.71 ,Darovasertib - (neo-adjuvant and adjuvant settings) - (NADOM),Ocular Melanoma ,Phase 2,24/05/2024 ET,Phase 2 clinical efficacy update presented at ASCO abstract showed that monotherapy neoadjuvant treatment was generally well tolerated. Drug-related adverse events (AEs) were predominantly Grade 1 or … read more,87.64M
Add to portfolio,,,ODD,,,,,
BLRX,,$0.69 ,"Motixafortide (BL-8040), gemcitabine, nab-paclitaxel and LIBTAYO (cemiplimab) - (Columbia University trial) - (CheMo4METPANC)",First-line pancreatic ductal adenocarcinoma (PDAC) ,Phase 2,24/05/2024 ET,"Phase 2 data from ASCO reported that 7 of 11 patients in the pilot phase experienced a partial response, with 6 confirmed; 10 of 11 patients experienced disease control , noted May 24, 2024.",3.72M
Add to portfolio,,,View Clinical Trial Data,,,,,
CHRS,,$1.91 ,CHS-114 - (SRF114),Solid tumors ,Phase 1,24/05/2024 ET,Phase 1 preliminary results from dose escalation in an ASCO abstract shown to have an acceptable safety profile with no dose-limiting toxicities (DLTs) in heavily pretreated patients with solid tumors … read more,116.23M
Add to portfolio,,,,,,,,
BCTX,,$1.44 ,Bria-IMT - (BRIA-ABC),Advanced breast cancer ,Phase 2,24/05/2024 ET,"Phase 2 data in an ASCO abstract resulted in an 83% intracranial objective response rate, median progression-free survival of 4.1 months in antibody-drug conjugate (ADC) resistant patients (double his … read more",1.76M
Add to portfolio,,,,,,,,
CGON,,$32.71 ,Cretostimogene in combination with pembrolizumab - (CORE-001),Intermediate-risk NMIBC ,Phase 2,24/05/2024 ET,"Phase 2 final results to be presented at ASCO 2024, abstract released resulted in a ITT CR rate 57% at 12mo, 83% any time. 95% of 12mo CRs maintained CR for 24mo. Median DoR >21mo. 24mo CR rate 69.6%. … read more",76.25M
Add to portfolio,,,BTD,,,,,
MRK,,$127.88 ,Cretostimogene in combination with pembrolizumab - (CORE-001),Intermediate-risk NMIBC ,Phase 2,24/05/2024 ET,"Phase 2 final results to be presented at ASCO 2024, abstract released resulted in a ITT CR rate 57% at 12mo, 83% any time. 95% of 12mo CRs maintained CR for 24mo. Median DoR >21mo. 24mo CR rate 69.6%. … read more",2.5B
Add to portfolio,,,BTD,,,,,
IPHA,,$2.90 ,Lacutamab (IPH4102) - (TELLOMAK),"Mycosis Fungoides, Sézary Syndrome ",Phase 2,24/05/2024 ET,"Phase 2 topline results reported that the ORR was 16.8%, with the median time to response was 1.0 months and median PFS 10.2m, noted May 24, 2024.",92.16M
Add to portfolio,,,BTD,,,,,
,,,View Clinical Trial Data,,,,,
AZN,,$78.06 ,"Imfinzi (durvalumab), Monalizumab, and Oleclumab - (COAST)",Non-small cell lung cancer (NSCLC) ,Phase 2,24/05/2024 ET,"Phase 2 data reported that D+O and D+M increased ORR and prolonged PFS and OS vs D alone, noted May 24, 2024.",3.1B
Add to portfolio,,,View Clinical Trial Data,,,,,
IPHA,,$2.90 ,"Imfinzi (durvalumab), Monalizumab, and Oleclumab - (COAST)",Non-small cell lung cancer (NSCLC) ,Phase 2,24/05/2024 ET,"Phase 2 data reported that D+O and D+M increased ORR and prolonged PFS and OS vs D alone, noted May 24, 2024.",92.16M
Add to portfolio,,,View Clinical Trial Data,,,,,
ANL,,$10.50 ,AN0025 + Keytruda,Solid tumors ,Phase 1b,24/05/2024 ET,"Phase 1b data reported that the disease control rate (DCR) was 92% (11/12). The median progression-free survival (PFS) was not reached, with 6-month and 1-year PFS rates of 91% and 73%, respectively, … read more",36.9M
Add to portfolio,,,,,,,,
HCM,,$18.73 ,Fruquintinib - (FRESCO),Metastatic colorectal cancer (CRC) ,Phase 3,24/05/2024 ET,"Phase 3 data reported improvements in OS and PFS were seen with F vs P regardless of prior tx sequence (Table), with similar magnitudes of benefit for OS and PFS, noted May 24, 2024.",174.43M
Add to portfolio,,,,,,,,
HCM,,$18.73 ,Fruquintinib (HMPL-013) - (FRESCO-2),Metastatic Colorectal Cancer ,Phase 3,24/05/2024 ET,"Phase 3 data reported at ASCO reported improvements in OS and PFS were seen with F vs P regardless of prior tx sequence, with similar magnitudes of benefit for OS (HRs 0.53–0.77) and PFS (HRs 0.25–0.3 … read more",174.43M
Add to portfolio,,,,,,,,
HCM,,$18.73 ,HMPL-295,Solid tumors ,Preclinical,24/05/2024 ET,"Preclinical data from ASCO reported that stable disease with tumor shrinkage was also observed in 2 pts with NSCLC on 50 mg QD and 75 mg QD 2w on/1w off cohort respectively, and 1 pt with pancreatic d … read more",174.43M
Add to portfolio,,,,,,,,
HCM,,$18.73 ,Stereotactic ablative radiotherapy (SABR) + fruquintinib and tislelizumab - (RIFLE),Metastatic colorectal cancer ,Phase 2,24/05/2024 ET,"Phase 2 data from ASCO reported 1 CR, 8 PR, 14 SD and 8 PD, noted May 24, 2024.",174.43M
Add to portfolio,,,,,,,,
INCY,,$57.31 ,INCB099280,Solid Tumors ,Phase 1,24/05/2024 ET,"Phase 1 data to be presented at ASCO on June 1, 2024, with abstract data reporting that 96.6% of pts had ≥1 tx-emergent adverse events, and decreased ctCNA was seen in all complete responders (n=2) an … read more",195.28M
Add to portfolio,,,,,,,,
INCY,,$57.31 ,INCB057643,Myelofibrosis (MF) and Other Advanced Myeloid Neoplasms ,Phase 1,24/05/2024 ET,"Phase 1 data from ASCO abstract reported that SVR35 was achieved by all 3 evaluable pts receiving ≥10 mg monotherapy, and 3/12 achieved a best response of SVR35, noted May 24, 2024.",195.28M
Add to portfolio,,,,,,,,
ALXO,,$13.17 ,Evorpacept with PADCEV (enfortumab vedotin-ejfv) - (ASPEN-07),Urothelial Carcinoma (UC) ,Phase 1a,24/05/2024 ET,"Phase 1a data from abstract reported an overall response rate (ORR) was 63% (1CR, 9PR), noted May 24, 2024.",53.55M
Add to portfolio,,,ODD,,,,,
BNTX,,$96.95 ,YL202/BNT326,Locally advanced or metastatic non-small cell lung cancer and breast cancer ,Phase 1,24/05/2024 ET,"Phase 1 data from ASCO abstract reported an ORR of 42.2% (19/45) and disease control rate (DCR) of 93.3% (42/45), noted May 24, 2024.",239.97M
Add to portfolio,,,,,,,,
GMAB,,$28.00 ,Acasunlimab (GEN1046/BNT311),Non-small cell lung cancer (NSCLC) ,Phase 2,24/05/2024 ET,"Phase 2 data from ASCO abstract reported confirmed ORRs (and mDoR) were 13% (2 mo), 21% (6 mo), and 22% (NR), with 6-mo PFS rates of 0%, 18%, and 33% for arms A, B, and C, respectively, noted May 24, … read more",661.87M
Add to portfolio,,,,,,,,
CGEN,,$2.44 ,"COM701, COM902 and Pembrolizumab","Advanced malignancies, Ovarian cancer ",Phase 1,24/05/2024 ET,"Data from abstract reported an ORR 2/17 (12%); disease control rate [DCR] 5/17 (29%) noted May 24, 2024,",93.51M
Add to portfolio,,,,,,,,
NUVB,,$3.08 ,Taletrectinib - (TRUST-I) (China),ROS1-positive non-small cell lung cancer (NSCLC) ,Phase 2,24/05/2024 ET,"Phase 2 data from ASCO abstract reported that in TKI-pretreated patients, the ORR was 52% (95% CI: 40, 65) and IC-ORR was 75% , noted May 24, 2024.",342.27M
Add to portfolio,,,BTD,,,,,
,,,ODD,,,,,
APLS,,$40.61 ,EMPAVELI (pegcetacoplan) - (VALIANT),C3G and IC-MPGN ,Phase 2,24/05/2024 ET,"Phase 2 data from NOBLE study demonstrated a rreduction in disease activity seen at 12 weeks was sustained at one year, 55% of patients showed zero C3c staining intensity, indicating that C3c deposit … read more",126.29M
Add to portfolio,,,,,,,,
MRK,,$124.52 ,KEYTRUDA (pembrolizumab) - (KEYNOTE-522),Triple negative breast cancer (TNBC) ,Phase 3,28/05/2024 ET,"Phase 3 data reported that trial met its primary endpoint, noted May 28, 2024.",2.5B
Add to portfolio,,,,,,,,
INSM,,$48.06 ,BRINSUPRI (Brensocatib) - (ASPEN),Non-Cystic Fibrosis Bronchiectasis (NCFBE) ,Phase 3,28/05/2024 ET,"Phase 3 topline data reported that the trial met its primary endpoint, noted May 28, 2024.",211.37M
Add to portfolio,,,View Clinical Trial Data,,,,,
ARCT,,$38.41 ,ARCT-032 - (LUNAR-CF),Cystic Fibrosis ,Phase 1b,28/05/2024 ET,"Phase 1b data reported that the first four patients had an average improvement of 4% FEV1 after two administrations, noted May 28, 2024.",27.15M
Add to portfolio,,,RPDD,,,,,
,,,ODD,,,,,
UNCY,,$0.84 ,UNI-494,Acute kidney injury (AKI) ,Preclinical,28/05/2024 ET,"Preclinical model results of hyperphosphatemia demonstrated the relative potency of OLC Compared to tenapanor, noted May 28, 2024.",17.66M
Add to portfolio,,,ODD,,,,,
ALLK,,$1.39 ,AK006 (IV),Chronic spontaneous urticaria (CSU) ,Phase 1,28/05/2024 ET,"Phase 1 trial in CSU initiated, noted May 28, 2024.",90.38M
Add to portfolio,,,,,,,,
MRUS,,$54.87 ,Petosemtamab (MCLA-158),"Recurrent/metastatic (r/m) head and neck squamous cell carcinoma (HNSCC), Solid Tumors ",Phase 1/2,28/05/2024 ET,"Phase 2 data to be presented at ASCO 2024, abstract released on May 23 showed that as of the March 6, 2024 data cutoff, the combination demonstrated a 67% overall response rate across PD-L1 expression … read more",75.63M
Add to portfolio,,,BTD,,,,,
GMAB,,—,Petosemtamab (MCLA-158),"Recurrent/metastatic (r/m) head and neck squamous cell carcinoma (HNSCC), Solid Tumors ",Phase 1/2,28/05/2024 ET,"Phase 2 data to be presented at ASCO 2024, abstract released on May 23 showed that as of the March 6, 2024 data cutoff, the combination demonstrated a 67% overall response rate across PD-L1 expression … read more",661.87M
Add to portfolio,,,BTD,,,,,
VERA,,$37.13 ,Atacicept - (ORIGIN 3),IgA Nephropathy ,Phase 2b,28/05/2024 ET,"Phase 2b 72-week data reported that participants who switched from placebo to atacicept also demonstrated stable eGFR, as well as similar reductions in Gd-IgA1, hematuria, and UPCR, noted May 28, 2024 … read more",63.82M
Add to portfolio,,,BTD,,,,,
,,,View Clinical Trial Data,,,,,
CORT,,$31.61 ,Relacorilant - (GRACE),Hypercortisolism (Cushing's Syndrome) ,Phase 3,28/05/2024 ET,"Phase 3 trial met its primary endpoint, noted May 28, 2024.",105.37M
Add to portfolio,,,,,,,,
ABBV,,$152.69 ,ABBV-400,Colorectal cancer (CRC) ,Phase 1,28/05/2024 ET,"Phase 1 preliminary data derived from ASCO abstract showed that among 122 heavily pre-treated advanced CRC patients, promising antitumor activity was observed at 2.4 and 3.0 mg/kg doses administered o … read more",1.77B
Add to portfolio,,,,,,,,
ABBV,,$152.69 ,ABBV-706,Solid Tumors ,Phase 1,28/05/2024 ET,"Phase 1 data at ASCO abstract demonstrated that among a total of 48 efficacy-evaluable patients (23 SCLC and 25 NEN), the overall confirmed objective response rate was 43.8%. Within the SCLC group, th … read more",1.77B
Add to portfolio,,,,,,,,
AZN,,$76.15 ,DATROWAY (datopotamab deruxtecan-dlnk)- (TROPION-Lung01),Non-small cell lung cancer (NSCLC) ,Phase 3,28/05/2024 ET,Phase 3 trial data reported numerically favored datopotamab deruxtecan (Dato-DXd) compared to docetaxel in the overall trial population of adult patients with locally advanced or metastatic non-small … read more,3.1B
Add to portfolio,,,BTD,,,,,
NVS,,$99.68 ,Vanrafia (atrasentan),Proteinuria reduction in primary IgA nephropathy (IgAN) ,Phase 3,28/05/2024 ET,"Phase 3 data reported a statistically significant 36.1% proteinuria (protein in urine) reduction vs. placebo + supportive care at 36 weeks, noted May 28, 2024.",1.98B
Add to portfolio,,,ODD,,,,,
,,,View Clinical Trial Data,,,,,
NVS,,$99.68 ,Fabhalta (iptacopan),C3 glomerulopathy (C3G) ,Phase 3,28/05/2024 ET,"Phase 3 data reported that patients treated with Fabhalta in addition to supportive care achieved a 35.1% reduction in proteinuria at 6 months when compared to placebo on top of supportive care, noted … read more",1.98B
Add to portfolio,,,View Clinical Trial Data,,,,,
PROK,,$3.71 ,RMCL-002 - (REACT),"Type 2 diabetes, prevent/delay CKD ",Phase 2,28/05/2024 ET,"Phase 2 full results reported that patients s randomized to the deferred treatment arm experienced less decline in kidney function after rilparencel treatment versus standard of care , noted May 28, 2 … read more",294.28M
Add to portfolio,,,,,,,,
VANI,,$1.66 ,OKV-119,Obesity ,Preclinical,28/05/2024 ET,"Preclinical data of proof-of-concept study in felines showed that a single OKV-119 implant effectively delivered therapeutic exenatide levels for the intended 3-month duration, achieving weight loss i … read more",59.24M
Add to portfolio,,,,,,,,
SRRK,,$10.33 ,SRK-181 - (DRAGON),Solid Tumors ,Phase 1,28/05/2024 ET,"Phase 1 data from abstract continued to showed that study continues to be well tolerated in the dose expansion portion of the DRAGON trial (Part B), noted May 28, 2024.",96.13M
Add to portfolio,,,,,,,,
XENE,,$38.61 ,azetukalner (XEN1101) - (X-NOVA),Major depressive disorder (MDD) ,Phase 2,28/05/2024 ET,"Phase 2 data presented at American Epilepsy Society showed azetukalner 20mg achieved clinically meaningful reductions in depression scores on MADRS and HAM-D17 scales, with a 3.04 point difference vs … read more",77.11M
Add to portfolio,,,,,,,,
NRXP,,$3.83 ,NRX-101,Bipolar Depression and Suicidal Ideation ,Phase 2/3,28/05/2024 ET,Phase 2b/3 trial results evaluating NRX-101 versus lurasidone in bipolar depression with suicidal ideation/behavior at ASCP 2024. The data showed NRX-101 achieved similar efficacy to lurasidone on dep … read more,19.71M
Add to portfolio,,,BTD,,,,,
,,,FTD,,,,,
,,,View Clinical Trial Data,,,,,
JAGX,,$4.03 ,Mytesi (crofelemer),Moderate-to-severe diarrhea including Vibrio cholerae ,Phase 1,28/05/2024 ET,Phase 1 nnounced results from an investigator-initiated study showing that crofelemer led to statistically meaningful reductions in abdominal pain/discomfort and improved stool consistency compared to … read more,2.17M
Add to portfolio,,,ODD,,,,,
APRE,,$5.19 ,ATRN-119 - (ABOYA-119),Solid tumors ,Phase 1/2,28/05/2024 ET,Phase 1/2a Safety Review Committee has approved opening enrollment for the 800mg once daily dosing cohort after reviewing favorable safety and pharmacokinetic data from the 550mg cohort. Initial signs … read more,5.83M
Add to portfolio,,,,,,,,
NLSP,,$6.98 ,KO-874,Sleep and wakefulness disorders ,Preclinical,28/05/2024 ET,"Preclinical results results suggested that mazindol may modulate the orexin system through direct or indirect mechanisms. While lower 1 mg/kg doses were not effective, the dose-dependent response and … read more",3.6M
Add to portfolio,,,,,,,,
AZN,,$76.15 ,IK-930,"Solid tumors, non-small cell lung cancer ",Phase 1,28/05/2024 ET,"Phase 1 trial discontinued based on a clinical data review, noted May 28, 2024",3.1B
Add to portfolio,,,FTD,,,,,
IMA,,—,IK-930,"Solid tumors, non-small cell lung cancer ",Phase 1,28/05/2024 ET,"Phase 1 trial discontinued based on a clinical data review, noted May 28, 2024",4.02M
Add to portfolio,,,FTD,,,,,
IKNA,,$1.33 ,IK-930,"Solid tumors, non-small cell lung cancer ",Phase 1,28/05/2024 ET,"Phase 1 trial discontinued based on a clinical data review, noted May 28, 2024",48.26M
Add to portfolio,,,FTD,,,,,
TELO,,$6.23 ,Telomir-1,Age-related conditions ,Preclinical,28/05/2024 ET,"Preclinical canine study dosing initiated, noted May 28, 2024.",32.28M
Add to portfolio,,,,,,,,
VTGN,,$3.96 ,Fasedienol (PH94B) - (PALISADE-2),Social Anxiety Disorder (SAD) ,Phase 3,29/05/2024 ET,Phase 3 results presented at the American Society of Clinical Psychopharmacology Conference reported that a single dose of fasedienol prior to a stressful PSC reduced anxiety levels as measured by SUD … read more,30.68M
Add to portfolio,,,FTD,,,,,
AFMD,,$4.02 ,AFM24-102 and TECENTRIQ (atezolizumab),"EGFR Expressing Solid Tumors, Non-small cell lung cancer, and Gastric/gastroesophageal junction (GEJ) cancer ",Phase 2,29/05/2024 ET,"Fast Track Designation granted May 29, 2024.",15.23M
Add to portfolio,,,FTD,,,,,
KYMR,Kymera Therapeutics Inc.,$32.11 ,KT-253,"AML, Lymphomas, and Uveal melanoma ",Phase 1,01/06/2024 ET,"Phase 1 update from ASCO reported that treatment was was generally well tolerated without hematologic adverse events seen with traditional MDM2 small molecule inhibitors, noted June 1, 2024.",71.5M
Add to portfolio,,,ODD,,,,,
MOLN,Molecular Partners AG,$3.60 ,MP0317,Solid Tumors ,Phase 1,01/06/2024 ET,"Phase 1 full data presented at ASCO reported that one patient achieved an unconfirmed partial response and stable disease was observed in 14 additional patients, noted June 1, 2024.",40.36M
Add to portfolio,,,,,,,,
CRBP,Corbus Pharmaceuticals Holdings Inc.,$42.80 ,CRB-701 (SYS6002) with Pembrolizumab,"Solid tumors, Locally advanced or metastatic urothelial carcinoma ",Phase 1,01/06/2024 ET,"Additional data due presented at ASCO demonstrated 44% ORR and 78% DCR in mUC and 43% ORR and 86% DCR in cervical cancer to date at doses ≥ 1.2mg/Kg, noted June 1, 2024.",12.26M
Add to portfolio,,,FTD,,,,,
CYCC,Cyclacel Pharmaceuticals Inc.,$2.64 ,Fadraciclib (CYC065-101),Advanced cancers ,Phase 1,01/06/2024 ET,"Phase 1 data presented at ASCO reported treatment related adverse events reported were nausea (66.0%), vomiting (46.8%), diarrhea (31.9%) fatigue (25.5%), and hyperglycemia (21.3%), noted June 1, 2024 … read more",2.24M
Add to portfolio,,,,,,,,
EVAX,Evaxion A/S,$3.67 ,EVX-01 + KEYTRUDA (pembrolizumab) / OPDIVO (nivolumab),Metastatic Melanoma ,Phase 2,01/06/2024 ET,"Phase 2 ASCO presentation reported a statistically significant positive correlation between neoantigen quality, as predicted by AI-Immunology™, and vaccine-induced immune response was demonstrated, no … read more",6.32M
Add to portfolio,,,FTD,,,,,
MRK,Merck & Company Inc.,$123.98 ,EVX-01 + KEYTRUDA (pembrolizumab) / OPDIVO (nivolumab),Metastatic Melanoma ,Phase 2,01/06/2024 ET,"Phase 2 ASCO presentation reported a statistically significant positive correlation between neoantigen quality, as predicted by AI-Immunology™, and vaccine-induced immune response was demonstrated, no … read more",2.5B
Add to portfolio,,,FTD,,,,,
INAB,IN8bio Inc.,$1.19 ,INB-200,Glioblastoma ,Phase 1,01/06/2024 ET,"Phase 1 data presented at ASCO reported 92% of evaluable patients treated with INB-200 for GBM exceeded a median PFS of 7 months achieved with the standard-of-care regimen, noted June 1, 2024.",4.54M
Add to portfolio,,,,,,,,
NUVB,Nuvation Bio Inc. Class A,$3.10 ,Taletrectinib - (TRUST-I) (China),ROS1-positive non-small cell lung cancer (NSCLC) ,Phase 2,01/06/2024 ET,"Phase 2 data presented at ASCO 2024 reported that results showed taletrectinib shrank tumors (confirmed objective response rate, cORR, as assessed by an independent review committee, IRC) in 91% of pa … read more",342.27M
Add to portfolio,,,BTD,,,,,
,,,ODD,,,,,
KPTI,Karyopharm Therapeutics Inc.,$0.97 ,XPOVIO (selinexor) - (SIENDO),Endometrial cancer ,Phase 3,01/06/2024 ET,"Phase 3 data presented at ASCO reported that median duration of follow-up of 36.9 months, selinexor-treated patients had a median PFS of 28.4 months compared to 5.2 months for patients receiving place … read more",8.67M
Add to portfolio,,,View Clinical Trial Data,,,,,
AFMD,Affimed N.V.,$4.35 ,AFM24-102 and TECENTRIQ (atezolizumab),"EGFR Expressing Solid Tumors, Non-small cell lung cancer, and Gastric/gastroesophageal junction (GEJ) cancer ",Phase 2,01/06/2024 ET,"Phase 2 data presented at ASCO reported that 4 objective responses; 3 of 4 responses were ongoing for more than 7 months and progression free survival (PFS) was 5.9 months, noted June 1, 2024.",15.23M
Add to portfolio,,,FTD,,,,,
BDTX,Black Diamond Therapeutics Inc.,$4.78 ,BDTX-1535,Glioblastoma multiforme (GBM) and NSCLC ,Phase 1,01/06/2024 ET,"Phase 1 initial results presented at ASCO reported one confirmed partial response was observed and eight patients experienced stable disease, noted June 1, 2024.",56.94M
Add to portfolio,,,FTD,,,,,
HOWL,Werewolf Therapeutics Inc.,$5.17 ,WTX-124,Solid Tumors ,Phase 1b,01/06/2024 ET,"Phase1/1b updated data from ASCO reported that 100% regression of target lesions with responses occurring within the first two cycles of therapy and showing durability at RDE, noted June 1, 2024.",45.73M
Add to portfolio,,,FTD,,,,,
RCUS,Arcus Biosciences Inc.,$15.07 ,"Quemliclustat, domvanalimab, zimberelimab, and chemotherapy (ARC-21) - (STAR-221)","Locally advanced unresectable or metastatic gastric, gastroesophageal junction or esophageal adenocarcinoma ",Phase 2,01/06/2024 ET,"Phase 2 data shared at ASCO reported that 60% of patients in the EDGE-Gastric study achieved progression-free survival at 12 months, noted June 1, 2024.",107.97M
Add to portfolio,,,,,,,,
GILD,Gilead Sciences Inc.,$62.93 ,"Quemliclustat, domvanalimab, zimberelimab, and chemotherapy (ARC-21) - (STAR-221)","Locally advanced unresectable or metastatic gastric, gastroesophageal junction or esophageal adenocarcinoma ",Phase 2,01/06/2024 ET,"Phase 2 data shared at ASCO reported that 60% of patients in the EDGE-Gastric study achieved progression-free survival at 12 months, noted June 1, 2024.",1.24B
Add to portfolio,,,,,,,,
BGNE,BeiGene Ltd.,$148.85 ,BGB‑15025 monotherapy and in combination with tislelizumab (TIS; anti‑PD‑1 antibody),Solid Tumors ,Phase 1a,01/06/2024 ET,"Phase 1a presented at ASCO reported that 5 DLTs were observed with combo tx, no responders and disease control rate (DCR) was 35.0%, noted June 1 2024.",106.62M
Add to portfolio,,,,,,,,
ONC,BeOne Medicines Ltd.,—,BGB‑15025 monotherapy and in combination with tislelizumab (TIS; anti‑PD‑1 antibody),Solid Tumors ,Phase 1a,01/06/2024 ET,"Phase 1a presented at ASCO reported that 5 DLTs were observed with combo tx, no responders and disease control rate (DCR) was 35.0%, noted June 1 2024.",110.03M
Add to portfolio,,,,,,,,
CGEN,Compugen Ltd.,$2.17 ,"COM701, COM902 and Pembrolizumab","Advanced malignancies, Ovarian cancer ",Phase 1,01/06/2024 ET,"Trial data presented at ASCO reported that the objective response rate [ORR] 1/20 [5%] pts; 7 pts with SD, noted June 1, 2024.",93.51M
Add to portfolio,,,,,,,,
CYCC,Cyclacel Pharmaceuticals Inc.,$2.64 ,Fadraciclib (CYC065-102),Hematological Malignancies ,Phase 1,01/06/2024 ET,"Phase 1 safety, pharmacokinetics, and efficacy data presented at ASCO reported two PRs after the first cycle were observed in one patient with CTCL and one with angioimmunoblastic T-Cell Lymphoma (AIT … read more",2.24M
Add to portfolio,,,,,,,,
LLY,Eli Lilly and Company,$819.20 ,ERAS-601 - (FLAGSHP-1),Advanced solid tumors ,Phase 1,01/06/2024 ET,"Phase 1 data presented at ASCO reported to be 1 PR and 8 pts with a best response of SD, noted June 1, 2024.",946.46M
Add to portfolio,,,,,,,,
ERAS,Erasca Inc.,$2.52 ,ERAS-601 - (FLAGSHP-1),Advanced solid tumors ,Phase 1,01/06/2024 ET,"Phase 1 data presented at ASCO reported to be 1 PR and 8 pts with a best response of SD, noted June 1, 2024.",283.67M
Add to portfolio,,,,,,,,
MRK,Merck & Company Inc.,$123.98 ,WTX-124 and KEYTRUDA (pembrolizumab),Solid tumors ,Phase 1b,01/06/2024 ET,"Phase 1/1b initial combination dose escalation data reported that treatment was generally well-tolerated with enhanced immune activation in tumors, noted June 1, 2024.",2.5B
Add to portfolio,,,,,,,,
HOWL,Werewolf Therapeutics Inc.,$5.17 ,WTX-124 and KEYTRUDA (pembrolizumab),Solid tumors ,Phase 1b,01/06/2024 ET,"Phase 1/1b initial combination dose escalation data reported that treatment was generally well-tolerated with enhanced immune activation in tumors, noted June 1, 2024.",45.73M
Add to portfolio,,,,,,,,
NTLA,Intellia Therapeutics Inc.,$23.52 ,"Lonvoguran ziclumeran (lonvo-z, formerly NTLA-2002) - (HAELO)",Hereditary angioedema (HAE) ,Phase 1,02/06/2024 ET,"Phase 1 results presented at EAACI reported that 8 of 10 patients remain completely attack-free following the 16-week primary observation period through the latest follow-up, including patients with t … read more",107.35M
Add to portfolio,,,ODD,,,,,
,,,RMAT,,,,,
CRBU,Caribou Biosciences Inc.,$2.15 ,CB-010 - (ANTLER),B-Cell Non-Hodgkin Lymphoma ,Phase 1,02/06/2024 ET,"Phase 1 initial dose expansion data presented at ASCO reported a median PFS of 14.4 months, noted June 2, 2024.",93.12M
Add to portfolio,,,FTD,,,,,
FLGT,Fulgent Genetics Inc.,$20.87 ,FID-007,Various cancers ,Phase 1,02/06/2024 ET,"Phase 1 efficacy data presented ASCO reported five (45%) had a partial response and three (27%) had stable disease, noted June 2, 2024.",30.61M
Add to portfolio,,,,,,,,
FLGT,Fulgent Genetics Inc.,$20.87 ,FID-007,Various cancers ,Phase 1,02/06/2024 ET,"Phase 1 efficacy data presented ASCO reported five (45%) had a partial response and three (27%) had stable disease, noted June 2, 2024.",30.61M
Add to portfolio,,,,,,,,
AZN,AstraZeneca PLC,$78.51 ,TAGRISSO (osimertinib) - (LAURA),"Unresectable, Stage III epidermal growth factor receptor-mutated (EGFRm) non-small cell lung cancer (NSCLC) ",Phase 3,02/06/2024 ET,Phase 3 data presented at ASCO showed TAGRISSO reduced the risk of disease progression or death by 84% compared to placebo (hazard ratio [HR] 0.16; 95% confidence interval [CI] 0.10-0.24; p<0.001) as … read more,3.1B
Add to portfolio,,,BTD,,,,,
MRUS,Merus N.V.,$52.94 ,MCLA-145 with Keytruda (pembrolizumab),Solid tumors ,Phase 1,02/06/2024 ET,"Phase 1 trial data presented at ASCO reported 1 PR in Merkel cell carcinoma was observed at 25 mg Q3W, 1 complete response was observed in PD-L1+ NSCLC at the RDE 40 mg Q3W, and 3 pts were continuing … read more",75.63M
Add to portfolio,,,,,,,,
GMAB,Genmab A/S,—,MCLA-145 with Keytruda (pembrolizumab),Solid tumors ,Phase 1,02/06/2024 ET,"Phase 1 trial data presented at ASCO reported 1 PR in Merkel cell carcinoma was observed at 25 mg Q3W, 1 complete response was observed in PD-L1+ NSCLC at the RDE 40 mg Q3W, and 3 pts were continuing … read more",661.87M
Add to portfolio,,,,,,,,
MRUS,Merus N.V.,$52.94 ,MCLA-145 with Keytruda (pembrolizumab),Solid tumors ,Phase 1,02/06/2024 ET,"Phase 1 trial data presented at ASCO reported 1 PR in Merkel cell carcinoma was observed at 25 mg Q3W, 1 complete response was observed in PD-L1+ NSCLC at the RDE 40 mg Q3W, and 3 pts were continuing … read more",75.63M
Add to portfolio,,,,,,,,
GMAB,Genmab A/S,—,MCLA-145 with Keytruda (pembrolizumab),Solid tumors ,Phase 1,02/06/2024 ET,"Phase 1 trial data presented at ASCO reported 1 PR in Merkel cell carcinoma was observed at 25 mg Q3W, 1 complete response was observed in PD-L1+ NSCLC at the RDE 40 mg Q3W, and 3 pts were continuing … read more",661.87M
Add to portfolio,,,,,,,,
NBTX,Nanobiotix S.A.,$6.80 ,NBTXR3 - (Study 1100),Advanced Cancers ,Phase 1,02/06/2024 ET,"Phase 1 safety and efficacy data presented at ASCO reported that anti-PD-1 naive patients reported a 48.0% (12/25) overall response rate (""ORR"") as per RECIST 1.1(3 CR; 9 PR), noted June 2, 2024.",47.43M
Add to portfolio,,,,,,,,
AZN,AstraZeneca PLC,$78.51 ,IMFINZI (Durvalumab) - (ADRIATIC),Small cell lung cancer (SCLC) limited disease ,Phase 3,02/06/2024 ET,"Phase 3 data presented at ASCO reported statistically significant and clinically meaningful improvements in the dual primary endpoints of overall survival (OS) and progression-free survival (PFS), not … read more",3.1B
Add to portfolio,,,View Clinical Trial Data,,,,,
AZN,AstraZeneca PLC,$78.51 ,Enhertu - (DESTINY-Breast06),"HR-positive, HER2-low (IHC 1+ or 2+/ISH-) metastatic breast cancer ",Phase 3,02/06/2024 ET,"Phase 3 data presented at ASCO reported a reduced the risk of disease progression or death by 38% by blinded independent central review (BICR) versus chemotherapy in patients with HER2-low expression, … read more",3.1B
Add to portfolio,,,BTD,,,,,
DSNKY,"Daiichi Sankyo Co., Ltd. ADR",$34.73 ,Enhertu - (DESTINY-Breast06),"HR-positive, HER2-low (IHC 1+ or 2+/ISH-) metastatic breast cancer ",Phase 3,02/06/2024 ET,"Phase 3 data presented at ASCO reported a reduced the risk of disease progression or death by 38% by blinded independent central review (BICR) versus chemotherapy in patients with HER2-low expression, … read more",1.92B
Add to portfolio,,,BTD,,,,,
RCUS,Arcus Biosciences Inc.,$15.84 ,Etrumadenant (AB928) and zimberelimab - (ARC-9),Colorectal Cancer ,Phase 1/2,02/06/2024 ET,"Phase 1b/2 data presented at ASCO reported that treatment significantly reduced the risk of death by 63% and risk of disease progression by 73% compared to regorafenib, noted June 2, 2024.",107.97M
Add to portfolio,,,,,,,,
AMGN,Amgen Inc.,$305.28 ,LUMAKRAS (Sotorasib) + Vectibix (panitumumab) - (CodeBreak 101),Colorectal Cancer (CRC) ,Phase 1b,02/06/2024 ET,"Phase 1b data from ASCO reported that in 1L, ORR was 65%, DCR was 100%, median DOR was 9.1 mo, and median PFS was 10.8 mo, noted June 2, 2024.",538.36M
Add to portfolio,,,,,,,,
AMGN,Amgen Inc.,$305.28 ,Tarlatamab (AMG 757) - (DeLLpro-300),Treatment-emergent neuroendocrine prostate cancer ,Phase 1b,02/06/2024 ET,"Phase 1b data presented at ASCO reported that the ORR per Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1) was 10.5% (95% CI, 2.9, 24.8); median progression free survival (mPFS) … read more",538.36M
Add to portfolio,,,,,,,,
AMGN,Amgen Inc.,$305.28 ,Tarlatamab (AMG 757) - (DeLLphi-301),Brain metastasis ,Phase 2,02/06/2024 ET,"Phase 2 trial data presented at ASCO reported that ORR was 45.3% in patients with brain metastases and 32.6% in patients without brain metastases June 2, 2024.",538.36M
Add to portfolio,,,,,,,,
CGEM,Cullinan Therapeutics Inc.,$22.54 ,Zipalertinib (CLN-081/TAS6417) - (REZILIENT1),Non-small cell lung cancer ,Phase 2b,03/06/2024 ET,"Phase 2b data reported a 39% ORR in Modeule C, noted June 3, 2024.",59.07M
Add to portfolio,,,,,,,,
KALV,KalVista Pharmaceuticals Inc.,$12.11 ,EKTERLY (sebetralstat),Hereditary Angioedema (HAE) ,Phase 3,03/06/2024 ET,"Phase 3 data reported that the time to beginning of symptom relief was significantly faster than placebo, with a significantly faster time to a reduction in attack severity from baseline compared to p … read more",50.52M
Add to portfolio,,,View Clinical Trial Data,,,,,
GPCR,Structure Therapeutics Inc.,$52.74 ,GSBR-1290 -(ACCESS and ACCESS II ),"Type 2 Diabetes, obesity ",Phase 2a,03/06/2024 ET,"Phase 2a 12-week data from obesity cohort achieved a statistically significant placebo-adjusted mean weight loss of 6.2%, with 67% of patients achieving ≥6% weight loss. The tablet formulation demonst … read more",57.6M
Add to portfolio,,,,,,,,
CLDI,Calidi Biotherapeutics Inc.,$2.20 ,CLD-400 - (RTNova),Metastatic Solid Tumors & Lung cancer ,Phase 1,03/06/2024 ET,"Phase 1 update highlights enrollment progress, safety and feasibility in delivering up to four weekly doses, noted June 3, 2024.",3.43M
Add to portfolio,,,,,,,,
CLDI,Calidi Biotherapeutics Inc.,$2.20 ,CLD-400 - (RTNova),Metastatic Solid Tumors & Lung cancer ,Preclinical,03/06/2024 ET,"Preclinical data on platform's showcased ability to survive bloodstream and reach all tumors systemically, noted June 03, 2024.",3.43M
Add to portfolio,,,,,,,,
CLDI,Calidi Biotherapeutics Inc.,$2.20 ,CLD-201 - (SuperNova),"Advanced Solid Tumors (TNBC, Melanoma, Head and Neck) ",Preclinical,03/06/2024 ET,"Preclinical trials ongoing. Non-clinical data supporting the upcoming SuperNova (CLD-201) clinical trial presented at ASCO, noted June 3, 2024.",3.43M
Add to portfolio,,,FTD,,,,,
BPTH,Bio-Path Holdings Inc.,$3.23 ,Prexigebersen (BP1001),Acute Myeloid Leukemia (AML) ,Phase 2,03/06/2024 ET,"Phase 2 data presneted at ASCO In the newly diagnosed AML cohort, 75% of evaluable patients achieved complete remission or related responses. In the relapsed/refractory AML cohort, 55% of evaluable pa … read more",8.31M
Add to portfolio,,,,,,,,
NVCR,NovoCure Limited,$23.89 ,Tumor Treating Fields (TTFields) - (METIS),Brain Metastases Originating from Non-Small Cell Lung Cancer ,Phase 3,03/06/2024 ET,Phase 3 data shared at ASCO 2024 demonstrated 21.9 months median time to intracranial progression for patients treated with TTFields therapy and supportive care compared to 11.3 months for patients tr … read more,111.8M
Add to portfolio,,,View Clinical Trial Data,,,,,
ZLAB,Zai Lab Limited,$18.00 ,Tumor Treating Fields (TTFields) - (METIS),Brain Metastases Originating from Non-Small Cell Lung Cancer ,Phase 3,03/06/2024 ET,Phase 3 data shared at ASCO 2024 demonstrated 21.9 months median time to intracranial progression for patients treated with TTFields therapy and supportive care compared to 11.3 months for patients tr … read more,109.96M
Add to portfolio,,,View Clinical Trial Data,,,,,
MTEM,Molecular Templates Inc.,$1.35 ,MT-6402,Solid tumors ,Phase 1,03/06/2024 ET,"Phase 1 has shown monotherapy activity in heavily pre-treated patients who had previously progressed or were refractory to immuno-oncology therapy, noted June 3, 2024.",6.58M
Add to portfolio,,,FTD,,,,,
CLDX,Celldex Therapeutics Inc.,$33.47 ,Barzolvolimab (CDX-0159),Chronic spontaneous urticaria (CSU) ,Phase 2,03/06/2024 ET,"Additional Phase 2 data reported that patients on barzolvolimab experienced a > 8 point improvement in AAS7 (considered a clinically meaningful result) across all doses compared to placebo (p<0.05), n … read more",66.41M
Add to portfolio,,,,,,,,
ENTX,Entera Bio Ltd.,$2.30 ,PTH(1-34) Peptide Tablets (EB612),Hypoparathyroidism ,Phase 1,03/06/2024 ET,"Phase 1 study results from PK/PD study presented at the ENDO showed that significant systemic exposure was reported following both administrations of EB612 tablets, noted June 3, 2024",45.66M
Add to portfolio,,,,,,,,
KTRA,TuHURA Biosciences Inc.,$9.49 ,Immune Fx (IFx-Hu2.0),Cancer vaccine for merkel cell carcinoma (MCC) ,Phase 1b,03/06/2024 ET,"Phase 1b presented at ASCO showed IFx-2.0 was safe and well-tolerated, and demonstrated the ability to overcome resistance to ICI therapy in 63% of patients with advanced MCC, including an 80% durable … read more",55.66M
Add to portfolio,,,,,,,,
GSK,GSK plc American Depositary Shares (Each representing two),$40.50 ,BLENREP (belantamab mafodotin) and POMALYST (Pomalidomide) and Dexamethasone - (DREAMM-8),Multiple Myeloma ,Phase 3,03/06/2024 ET,"Additional data presented at ASCO reported that at the end of one year, 71% (95% CI: 63-78) of patients in the belantamab mafodotin combination group compared to 51% (95% CI: 42-60) in the bortezomib … read more",2.03B
Add to portfolio,,,View Clinical Trial Data,,,,,
BCTX,BriaCell Therapeutics Corp.,$1.53 ,Bria-IMT - (BRIA-ABC),Advanced breast cancer ,Phase 2,03/06/2024 ET,"Phase 2 data presented at ASCO resulted in an 83% intracranial objective response rate, median progression-free survival of 4.1 months in antibody-drug conjugate (ADC) resistant patients (double histo … read more",1.76M
Add to portfolio,,,,,,,,
BMY,Bristol-Myers Squibb Company,$40.69 ,Neoadjuvant Opdivo (nivolumab) and Chemotherapy,Stage IIA to IIIB non-small cell lung cancer (NSCLC) ,Phase 3,03/06/2024 ET,"Phase 3 improved median event-free survival (EFS) regardless of nodal status, including in the N2 subgroup (30.2 vs. 10.0 months; HR, 0.46; 95% CI, 0.30–0.70) and non-N2 subgroup (NR vs. 17.0 months; … read more",2.04B
Add to portfolio,,,,,,,,
BMY,Bristol-Myers Squibb Company,$40.69 ,Neoadjuvant nivolumab (N) + chemotherapy - (CheckMate-816),Non-small cell lung cancer (NSCLC) ,Phase 3,03/06/2024 ET,"Phase 3 overall survival (OS) did not meet statistical significance at this analysis, neoadjuvant Opdivo with chemotherapy continued to show a clinically important OS improvement trend over chemothera … read more",2.04B
Add to portfolio,,,,,,,,
BMY,Bristol-Myers Squibb Company,$40.69 ,Opdivo (nivolumab) plus Yervoy (ipilimumab) - (CheckMate -9LA),Metastatic non-small cell lung cancer (NSCLC) ,Phase 3,03/06/2024 ET,"Phase 3 follow-up of 57.3 months, the dual immunotherapy-based combination continued to improve OS, with 18% of patients treated with Opdivo plus Yervoy with two cycles of chemotherapy alive at five y … read more",2.04B
Add to portfolio,,,,,,,,
CVKD,Cadrenal Therapeutics Inc.,$7.46 ,tecarfarin - (ARIES-HM3),Thromboembolism and thrombosis ,Phase 2/3,03/06/2024 ET,"Phase 2/3 data demonstrated that lower time in therapeutic range, or TTR, translated directly to excessive bleeding events, noted June 3, 2024.",2.05M
Add to portfolio,,,ODD,,,,,
TAK,Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of),$13.36 ,Oveporexton (TAK-861-2001),Narcolepsy type 1 (NT1) ,Phase 2b,03/06/2024 ET,Phase 2b data presented at SLEEP reported statistically significant and clinically meaningful increased sleep latency on the Maintenance of Wakefulness Test (MWT) versus placebo across all doses (LS m … read more,3.15B
Add to portfolio,,,,,,,,
PGEN,Precigen Inc.,$1.56 ,PAPZIMEOS (zopapogene imadenovec-drba),Recurrent Respiratory Papillomatosis (RRP) ,Phase 1/2,03/06/2024 ET,"Phase 1/2 presented art ASCO showed that study met the primary safety and efficacy endpoints, noted June 3, 2024.",297.97M
Add to portfolio,,,BTD,,,,,
,,,ODD,,,,,
AGIO,Agios Pharmaceuticals Inc.,$43.83 ,Mitapivat - (ENERGIZE-T),Transfusion-dependent thalassemia ,Phase 3,03/06/2024 ET,"Phase 3 topline data reported that the trial met its primary endpoint, note June 3, 2024.",58.1M
Add to portfolio,,,,,,,,
IDYA,IDEAYA Biosciences Inc.,$38.89 ,Darovasertib - (neo-adjuvant and adjuvant settings) - (NADOM),Ocular Melanoma ,Phase 2,03/06/2024 ET,Additional data shared at ASCO reported 75% (9 out of 12 enucleation patients) had confirmed Eye Saved and approximately 67% (8 out of 12 enucleation patients) observed greater than 30% tumor shrinkag … read more,87.64M
Add to portfolio,,,ODD,,,,,
MNOV,MediciNova Inc.,$1.47 ,Ibudilast (MN-166),Glioblastoma ,Phase 1/2,03/06/2024 ET,Phase 1b/2a data presented at ASCO reported that treatment was safe and well tolerated. No unexpected adverse effects were observed in both new GBM and recurrent GBM patients. Most reported adverse ev … read more,49.05M
Add to portfolio,,,View Clinical Trial Data,,,,,
GSK,GSK plc American Depositary Shares (Each representing two),$40.50 ,BLENREP (belantamab mafodotin) and POMALYST (Pomalidomide) and Dexamethasone - (DREAMM-8),Multiple Myeloma ,Phase 3,03/06/2024 ET,"Phase 3 data reported was observed but not statistically significant, noted June 3, 2024.",2.03B
Add to portfolio,,,View Clinical Trial Data,,,,,
GMAB,Genmab A/S,$28.83 ,EPCORE (Epcoritamab) - (EPCORE NHL-2),Non-Hodgkin lymphoma (NHL) ,Phase 1/2,03/06/2024 ET,"Phase 1b/2 data with a median follow-up of 21.1 months, additional findings from this arm showed durable responses, with an estimated 89 percent of patients remaining progression free and 93 percent o … read more",661.87M
Add to portfolio,,,,,,,,
PBYI,Puma Biotechnology Inc,$3.79 ,Alisertib (PUMA-ALI-4201) in combination with endocrine treatment - (ALISCA-Breast1),"HER2-negative, hormone receptor-positive metastatic breast cancer ",Phase 3,03/06/2024 ET,"Phase 2 data reported an overall response rate 19.6% vs. 20.0% and median progression-free survival 5.6 months vs. 5.4 months for alisertib vs. alisertib + fulvestrant, respectively, noted June 3, 202 … read more",50.37M
Add to portfolio,,,,,,,,
ALXO,ALX Oncology Holdings Inc.,$8.96 ,Evorpacept with PADCEV (enfortumab vedotin-ejfv) - (ASPEN-07),Urothelial Carcinoma (UC) ,Phase 1a,03/06/2024 ET,"Phase 1a dose escalation results due presented at ASCO unconfirmed overall response rate (""ORR"") of 59% (n=22) with evorpacept plus EV, noted June 3, 2024.",53.55M
Add to portfolio,,,ODD,,,,,
DCPH,Deciphera Pharmaceuticals Inc.,$25.56 ,Vimseltinib (DCC-3014) - (MOTION),Tenosynovial Giant Cell tumor ,Phase 3,03/06/2024 ET,"Phase 3 additional results from Part 1 data demonstrated robust efficacy, clinically meaningful improvements in Quality-of-Life measures, and well-tolerated profile, noted June 3, 2024.",86.48M
Add to portfolio,,,,,,,,
XAIR,Beyond Air Inc.,$1.17 ,Beyond Cancer (UNO),Solid tumors ,Phase 1a,03/06/2024 ET,"Additional Phase 1a data continues to demonstrate proof of concept for the UNO solid tumor platform with observed early tumor responses and clinical resolution of radiation dermatitis, noted June 3, 2 … read more",5.23M
Add to portfolio,,,,,,,,
IPSC,Century Therapeutics Inc.,$2.98 ,CNTY-101 - (ELiPSE-1),Lymphoma or Indolent Lymphoma ,Phase 1,03/06/2024 ET,"Phase 1 additional data shared at ASCO demonstrated a manageable safety profile with no observed DLTs or GvHD and with majority of patients treated in outpatient setting, noted June 3, 2024.",86.39M
Add to portfolio,,,,,,,,
ARWR,Arrowhead Pharmaceuticals Inc.,$24.62 ,Plozasiran (ARO-APOC3-3001) - (PALISADE),"Familial chylomicronemia syndrome (FCS), Hypertriglyceridemia ",Phase 3,03/06/2024 ET,"Phase 3 trial enrollment completed on May 16, 2023 Phase study achieved statistically significant median reductions in triglycerides up to 80% and mean reductions in APOC3 up to 94% at month 10, noted … read more",138.26M
Add to portfolio,,,BTD,,,,,
,,,View Clinical Trial Data,,,,,
BDRX,Biodexa Pharmaceuticals plc,$26.75 ,"eRapa (rapamycin, sirolimus) - (Serenta)",Familial Adenomatous Polyposis (FAP) ,Phase 2,03/06/2024 ET,"Phase 2 results demonstrated a 24% reduction in polyp burden at 6 months and an 83% non-progression rate, showing potential to stall disease progression before polyps turn cancerous, noted June 3, 202 … read more",505.06K
Add to portfolio,,,FTD,,,,,
,,,ODD,,,,,
GMAB,Genmab A/S,$28.83 ,Acasunlimab (GEN1046/BNT311),Non-small cell lung cancer (NSCLC) ,Phase 2,03/06/2024 ET,"Phase 2 trial data presented at ASCO reported that 12-month overall survival (""OS"") rate of 69%, a median overall survival (mOS) of 17.5 months, and a 30% overall response rate (ORR) at the time of da … read more",661.87M
Add to portfolio,,,,,,,,
ALKS,Alkermes plc,$24.06 ,ALKS 2680 - (Vibrance-1),Narcolepsy ,Phase 1,03/06/2024 ET,"Phase 1 data presented at SLEEP 2024 demonstrated clinically meaningful and statistically significant improvements from baseline in mean sleep latency compared to placebo at all doses tested, noted Ju … read more",165.12M
Add to portfolio,,,,,,,,
SPRB,Spruce Biosciences Inc.,$0.71 ,Tildacerfont - (POWER),Polycystic Ovary Syndrome ,Phase 2,03/06/2024 ET,"Phase 2 data presented at ENDO showed a significant reduction in dehydroepiandrosterone sulfate (DHEAS) versus placebo observed in women with elevated DHEAS levels at baseline, noted June 3, 2024.",563.04K
Add to portfolio,,,,,,,,
BGNE,BeiGene Ltd.,$146.24 ,Ziihera (zanidatamab-hrii),HER2-amplified biliary tract cancers ,Phase 2b,03/06/2024 ET,"Phase 2b data reported a confirmed objective response rate (cORR) by independent central review (ICR) was maintained at 41.3%, noted June 3, 2024.",106.62M
Add to portfolio,,,View Clinical Trial Data,,,,,
ONC,BeOne Medicines Ltd.,—,Ziihera (zanidatamab-hrii),HER2-amplified biliary tract cancers ,Phase 2b,03/06/2024 ET,"Phase 2b data reported a confirmed objective response rate (cORR) by independent central review (ICR) was maintained at 41.3%, noted June 3, 2024.",110.03M
Add to portfolio,,,View Clinical Trial Data,,,,,
JAZZ,Jazz Pharmaceuticals plc,$105.74 ,Ziihera (zanidatamab-hrii),HER2-amplified biliary tract cancers ,Phase 2b,03/06/2024 ET,"Phase 2b data reported a confirmed objective response rate (cORR) by independent central review (ICR) was maintained at 41.3%, noted June 3, 2024.",60.66M
Add to portfolio,,,View Clinical Trial Data,,,,,
ZYME,Zymeworks Inc.,$8.43 ,Ziihera (zanidatamab-hrii),HER2-amplified biliary tract cancers ,Phase 2b,03/06/2024 ET,"Phase 2b data reported a confirmed objective response rate (cORR) by independent central review (ICR) was maintained at 41.3%, noted June 3, 2024.",75.17M
Add to portfolio,,,View Clinical Trial Data,,,,,
NGNE,Neurogene Inc.,$37.23 ,NGN-401 - (Embolden),Rett Syndrome ,Phase 1/2,03/06/2024 ET,"Study selected by the FDA for the START program, noted June 3, 2024.",14.27M
Add to portfolio,,,RMAT,,,,,
BMY,Bristol-Myers Squibb Company,$40.69 ,KRAZATI (adagrasib) and Taxotere (Docetaxel) - (KRYSTAL-12),Non-small cell lung cancer (NSCLC) ,Phase 3,03/06/2024 ET,"Phase 3 data reported that the ORR as assessed by BICR was also significantly higher with KRAZATI compared to docetaxel (32% vs 9%; odds ratio, 4.68; P < 0.0001), noted June 3, 2024.",2.04B
Add to portfolio,,,,,,,,
MRNA,Moderna Inc.,$147.82 ,V940-001 (mRNA-4157) with KEYTRUDA (pembrolizumab) - (INTerpath-002),"Personalized cancer vaccine, high-risk melanoma, lung cancer ",Phase 3,03/06/2024 ET,Phase 3 data presented at ASCO showed that at 34.9 months it reduced the risk of recurrence or death by 49% and the risk of distant metastasis or death by 62% compared to KEYTRUDA alone in these patie … read more,389.08M
Add to portfolio,,,BTD,,,,,
MRK,Merck & Company Inc.,$126.82 ,V940-001 (mRNA-4157) with KEYTRUDA (pembrolizumab) - (INTerpath-002),"Personalized cancer vaccine, high-risk melanoma, lung cancer ",Phase 3,03/06/2024 ET,Phase 3 data presented at ASCO showed that at 34.9 months it reduced the risk of recurrence or death by 49% and the risk of distant metastasis or death by 62% compared to KEYTRUDA alone in these patie … read more,2.5B
Add to portfolio,,,BTD,,,,,
REPL,Replimune Group Inc.,$5.44 ,RP1 (vusolimogene oderparepvec) and OPDIVO (nivolumab) - (IGNYTE-3),Non-melanoma (NMSC) / Non-small cell lung cancer (NSCLC) ,Phase 2,03/06/2024 ET,"Phase 2 data presented at ASCO from its 12-month study results demonstrated an overall response rate of 32.7% and duration of response consistent with the previously reported 6-month data, noted June … read more",78.06M
Add to portfolio,,,BTD,,,,,
,,,View Clinical Trial Data,,,,,
LLY,Eli Lilly and Company,$830.10 ,Olomorasib,KRAS G12C-mutant advanced solid tumors ,Phase 1/2,03/06/2024 ET,Phase 1/2 data reported that the median progression free survival (PFS) in all patients with KRAS G12C inhibitor-naive non-CRC solid tumors was 7.1 months and 7.9 months (95% CI: 4.1-NE) in patients w … read more,946.46M
Add to portfolio,,,,,,,,
SMMT,Summit Therapeutics Inc.,$8.84 ,Ivonescimab - (HARMONi-A),Non-squamous non-small cell lung cancer (NSCLC) ,Phase 3,03/06/2024 ET,"Phase 3 data reported that the PFS was significantly improved in the ivonescimab plus chemotherapy arm representing a 54% reduction in the risk of disease progression compared to chemotherapy, noted J … read more",744.44M
Add to portfolio,,,,,,,,
PFE,Pfizer Inc.,$28.92 ,ADCETRIS (brentuximab vedotin) with lenalidomide and rituximab - (ECHELON-3),Relapsed/refractory diffuse large B-cell lymphoma (DLBCL) ,Phase 3,03/06/2024 ET,"Phase 3 full data presented at ASCO reported that the treatment improved the risk-to-benefit profile of the combination treatment, maintaining efficacy with significantly fewer acute and long-lasting … read more",5.69B
Add to portfolio,,,,,,,,
PPBT,Purple Biotech Ltd.,$14.80 ,CM24 and OPDIVO (nivolumab),2L metastatic pancreatic cancer (PDAC) ,Phase 2,03/06/2024 ET,"Phase 2 interim analysis presented at ASCO reported that an ORR (25% vs 7%), disease control rate (DCR) (63% vs 40%), and decrease in CA19-9 level (61% decrease vs. 34% increase), noted June 3, 2024.",2.65M
Add to portfolio,,,,,,,,
DNLI,Denali Therapeutics Inc.,$20.38 ,DNL126,MPS IIIA (Sanfilippo syndrome Type A) ,Phase 1/2,03/06/2024 ET,"Study selected by the FDA for START Program, noted June 3, 2024.",146.21M
Add to portfolio,,,,,,,,
AZN,AstraZeneca PLC,$78.51 ,ENHERTU,Multiple HER2-expressing advanced solid tumors ,Approved,03/06/2024 ET,"Approved April 6, 2024.",3.1B
Add to portfolio,,,BTD,,,,,
DSNKY,"Daiichi Sankyo Co., Ltd. ADR",$34.73 ,ENHERTU,Multiple HER2-expressing advanced solid tumors ,Approved,03/06/2024 ET,"Approved April 6, 2024.",1.92B
Add to portfolio,,,BTD,,,,,
CELU,Celularity Inc.,$3.15 ,PT-CD16VS,HER2-positive cancers ,Preclinical,03/06/2024 ET,Preclinical data presented at ASCO demonstrated the potential of combining Celularity's placental-derived cell therapy platform with currently available antibody therapies to address difficult-to-trea … read more,26.69M
Add to portfolio,,,,,,,,
GMAB,Genmab A/S,$28.83 ,Acasunlimab (DuoBody-PD-L1x4-1BB) with pembrolizumab,Metastatic non-small cell lung cancer (mNSCLC) ,Phase 2,03/06/2024 ET,"Phase 2 data presented at ASCO reported that confirmed ORRs (and mDoR) were 13% (2 mo), 21% (6 mo), and 22% (NR), with 6-mo PFS rates of 0%, 18%, and 33% for arms A, B, and C, respectively, noted June … read more",661.87M
Add to portfolio,,,,,,,,
BTAI,BioXcel Therapeutics Inc.,$1.69 ,BXCL701 and KEYTRUDA (pembrolizumab),Metastatic pancreatic ductal adenocarcinoma (PDAC) ,Phase 2,03/06/2024 ET,"Phase 2 initial data from ASCO reported an objective response rate is 16% and disease control rate is 50%, noted June 3, 2024.",14.56M
Add to portfolio,,,,,,,,
PFE,Pfizer Inc.,$28.92 ,Tisotumab vedotin - (innovaTV 207),Squamous cell carcinoma of the head and neck (SCCHN) ,Phase 2,03/06/2024 ET,"Phase 2 results from innovaTV207 evaluating tisotumab vedotin, showing 32.5% confirmed objective response rate, noted June 3, 2024.",5.69B
Add to portfolio,,,View Clinical Trial Data,,,,,
GMAB,Genmab A/S,$28.83 ,Tisotumab vedotin - (innovaTV 207),Squamous cell carcinoma of the head and neck (SCCHN) ,Phase 2,03/06/2024 ET,"Phase 2 results from innovaTV207 evaluating tisotumab vedotin, showing 32.5% confirmed objective response rate, noted June 3, 2024.",661.87M
Add to portfolio,,,View Clinical Trial Data,,,,,
GILD,Gilead Sciences Inc.,$62.11 ,Brexucabtagene Autoleucel (KTE-X19) - (ZUMA-3),Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia ,Phase 1/2,03/06/2024 ET,"Phase 1/2 study presented at ASCO showed that after more than 4 years of follow-up median overall survival (OS) was 26 months and the OS rate was 40% at 48 months, noted June 3, 2024.",1.24B
Add to portfolio,,,,,,,,
ZVRA,Zevra Therapeutics Inc.,$4.88 ,Serdexmethylphenidate (SDX) - (KP1077),Idiopathic hypersomnia (IH) ,Phase 2,03/06/2024 ET,"Phase 2 full data presented at SLEEP 2024 showed that study was well tolerated and showed meaningful clinical improvements in patient-reported assessments of daytime sleepiness, sleep inertia, and bra … read more",56.14M
Add to portfolio,,,ODD,,,,,
MRUS,Merus N.V.,$52.94 ,MCLA-129 - (ZENO),"Solid Tumors, MET ex14 NSCLC ",Phase 3,03/06/2024 ET,"Phase 3 results published at ASCO showed that as of the cutoff, in 15 evaluable patients, the confirmed partial response rate was 53% (8/15), including 6/8 responses in TKI-naïve and 3/7 in prior MET … read more",75.63M
Add to portfolio,,,,,,,,
GMAB,Genmab A/S,—,MCLA-129 - (ZENO),"Solid Tumors, MET ex14 NSCLC ",Phase 3,03/06/2024 ET,"Phase 3 results published at ASCO showed that as of the cutoff, in 15 evaluable patients, the confirmed partial response rate was 53% (8/15), including 6/8 responses in TKI-naïve and 3/7 in prior MET … read more",661.87M
Add to portfolio,,,,,,,,
FGEN,FibroGen Inc,$1.23 ,FG-3165,Solid Tumors ,IND-Enabling,03/06/2024 ET,"IND cleared by the FDA, noted June 3, 2024.",4.04M
Add to portfolio,,,,,,,,
CRNX,Crinetics Pharmaceuticals Inc.,$46.28 ,Atumelnant (CRN04894) - (TouCAHn),Congenital adrenal hyperplasia (CAH) and Cushing’s disease ,Phase 2,03/06/2024 ET,"Phase 2 trial results presented at ENDO showed that 100% of patients on the 80mg dose maintained normal androstenedione levels through 12 weeks, with >90% reductions in androstenedione and 17-OHP seen … read more",94.18M
Add to portfolio,,,ODD,,,,,
CRNX,Crinetics Pharmaceuticals Inc.,$46.28 ,PALSONIFY (paltusotine),Acromegaly ,Phase 3,03/06/2024 ET,"Phase 3 data presented at ENDO showed rapid and sustained IGF-1 responded in patients treated, noted June 3, 2024.",94.18M
Add to portfolio,,,,,,,,
ADAP,Adaptimmune Therapeutics plc,$1.07 ,Lete-cel - (IGNYTE-ESO),Sarcoma ,Phase 2,03/06/2024 ET,Phase 2 interim results presented at ASCO showed an verall response rate of 40% consistent across sarcoma indications; median duration of response ~11 months with patients still in response at time of … read more,265.05M
Add to portfolio,,,BTD,,,,,
GSK,GSK plc American Depositary Shares (Each representing two),$40.50 ,Lete-cel - (IGNYTE-ESO),Sarcoma ,Phase 2,03/06/2024 ET,Phase 2 interim results presented at ASCO showed an verall response rate of 40% consistent across sarcoma indications; median duration of response ~11 months with patients still in response at time of … read more,2.03B
Add to portfolio,,,BTD,,,,,
PBYI,Puma Biotechnology Inc,$3.79 ,Alisertib - (PUMA-ALI-4201) - (ALISCA-Lung1),Small Cell Lung Cancer (SCLC) ,Phase 2,03/06/2024 ET,"Phase 2 data shared at ASCO study identified alisertib 30mg twice daily as the recommended dose, with a 9.5% overall response rate and 81% disease control rate across 21 evaluable patients, the respon … read more",50.37M
Add to portfolio,,,ODD,,,,,
RYTM,Rhythm Pharmaceuticals Inc.,$37.85 ,Setmelanotide - (DAYBREAK),Variants in one of 31 additional genes with MC4R pathway relevance ,Phase 2,03/06/2024 ET,"Phase 2 data presented at ENDO showed potential setmelanotide efficacy in multiple MC4R pathway variants; stage two data expected in 3Q 2024, noted June 3, 2024.",66.42M
Add to portfolio,,,View Clinical Trial Data,,,,,
SRRK,Scholar Rock Holding Corporation,$9.48 ,SRK-181 - (DRAGON),Solid Tumors ,Phase 1,03/06/2024 ET,"Phase 1 updated safety and efficacy results shared at ASCO showed promising objective response rates (ORR) were observed in multiple tumor types in anti-PD-(L)1 resistant patients, noted June 3, 2024.",96.13M
Add to portfolio,,,,,,,,
ASND,Ascendis Pharma A/S,$135.31 ,TLR7/8 with pembrolizumab - (transcendIT-101),Solid tumors ,Phase 1/2,03/06/2024 ET,"Phase 1/2 showed that 40% of efficacy-evaluable patients (2 out of 5) in the initial cohort of melanoma treated exhibited confirmed clinical responses with no new safety signals, noted June 3, 2024.",60.69M
Add to portfolio,,,,,,,,
ELDN,Eledon Pharmaceuticals Inc.,$2.80 ,Tegoprubart (AT-1501) - (BESTOW),Kidney transplant rejection ,Phase 1b,03/06/2024 ET,"Phase 1b data shared at ATC showed that data from 13 participants continue to support the safety and tolerability profile, noted June 3, 2024.",59.88M
Add to portfolio,,,,,,,,
PHVS,Pharvaris N.V.,$17.71 ,Deucrictibant (PHVS416) - (CHAPTER-3),Hereditary angioedema - prophylactic use ,Phase 2,03/06/2024 ET,"Phase 2 results presented at EAACI showed satisfaction with the effectiveness of deucrictibant is higher to placebo and is in-line with separate observations of high-efficacy injectables, while numeri … read more",54.49M
Add to portfolio,,,,,,,,
LUMO,Lumos Pharma Inc.,$2.30 ,LUM-201 (OraGrowtH212) - (Switch),Pediatric Growth Hormone Deficiency (PGHD) ,Phase 2,03/06/2024 ET,"Phase 2 data presented at ENDO reported that a significant increase over baseline in key parameters was observed for the 1.6 mg/kg/day dose, noted June 3, 2024.",8.65M
Add to portfolio,,,,,,,,
PFE,Pfizer Inc.,$28.92 ,ERAS-007 - (HERKULES-3),Colorectal cancer and gastrointestinal (GI) cancer ,Phase 1b,03/06/2024 ET,"Phase 1b combination expansion data presented at ASCO reported that the ORR was 40% with 3 of the 4 responses confirmed, noted June 3, 2024.",5.69B
Add to portfolio,,,,,,,,
ERAS,Erasca Inc.,$2.58 ,ERAS-007 - (HERKULES-3),Colorectal cancer and gastrointestinal (GI) cancer ,Phase 1b,03/06/2024 ET,"Phase 1b combination expansion data presented at ASCO reported that the ORR was 40% with 3 of the 4 responses confirmed, noted June 3, 2024.",283.67M
Add to portfolio,,,,,,,,
LUMO,Lumos Pharma Inc.,$2.30 ,LUM-201 - (OraGrowtH210),Pediatric Growth Hormone Deficiency (PGHD) ,Phase 2,03/06/2024 ET,"Additional Phase 2 24-month data presented at ENDO reported that LUM-201 stimulates significant increases in GH secretion over 6 months in children with moderate GH deficiency, noted June 3, 2024.",8.65M
Add to portfolio,,,View Clinical Trial Data,,,,,
NVS,Novartis AG,$102.76 ,ARV-766,Metastatic castration-resistant prostate cancer (mCRPC) ,Phase 1/2,03/06/2024 ET,"Phase 1/2 initial results from ASCO reported that pharmacokinetics indicated dose-dependent increases in ARV-766 exposure up to 320 mg QD, with exposure accumulation ranging from ≈5- to 8-fold at stea … read more",1.98B
Add to portfolio,,,,,,,,
ARVN,Arvinas Inc.,$27.89 ,ARV-766,Metastatic castration-resistant prostate cancer (mCRPC) ,Phase 1/2,03/06/2024 ET,"Phase 1/2 initial results from ASCO reported that pharmacokinetics indicated dose-dependent increases in ARV-766 exposure up to 320 mg QD, with exposure accumulation ranging from ≈5- to 8-fold at stea … read more",73.42M
Add to portfolio,,,,,,,,
REGN,Regeneron Pharmaceuticals Inc.,$989.48 ,Ateganosine (THIO-101),Non-small cell lung cancer (NSCLC) ,Phase 2,03/06/2024 ET,"Phase 2 data from ASCO reported that most AEs were G1/2. The most frequent related AEs were AST increase (23%), ALT increase (20%), and nausea (11%), noted June 3, 2024",105.1M
Add to portfolio,,,ODD,,,,,
,,,FTD,,,,,
MAIA,MAIA Biotechnology Inc.,$5.10 ,Ateganosine (THIO-101),Non-small cell lung cancer (NSCLC) ,Phase 2,03/06/2024 ET,"Phase 2 data from ASCO reported that most AEs were G1/2. The most frequent related AEs were AST increase (23%), ALT increase (20%), and nausea (11%), noted June 3, 2024",32.99M
Add to portfolio,,,ODD,,,,,
,,,FTD,,,,,
SWTX,SpringWorks Therapeutics Inc.,$39.27 ,GOMEKLI (mirdametinib) - (ReNeu),Neurofibromas ,Phase 2b,03/06/2024 ET,"Additional Phase 2b data presented at ASCO reported a confirmed ORR of 41% (24/58; P<0.001) in adults and 52% (29/56; P<0.001) in children, noted June 3, 2024.",75.32M
Add to portfolio,,,View Clinical Trial Data,,,,,
YMAB,Y-mAbs Therapeutics Inc.,$12.02 ,DANYELZA (Naxitamab) - (201),High-risk neuroblastoma (HR-NB) commonly ,Preclinical,04/06/2024 ET,"Preclinical data presented at ASCO reported that GD2-SADA binding was significantly improved by a p53-derived domain that drives the self-assembly and disassembly (""SADA"") of GD2-SADA tetramers, noted … read more",45.44M
Add to portfolio,,,,,,,,
ATRA,Atara Biotherapeutics Inc.,$14.20 ,Tabelecleucel (tab-cel),Epstein-Barr Virus Positive Post-Transplant Lymphoproliferative Disease ,Phase 2,04/06/2024 ET,"Phase 2 data presented at ASCO showed an Overall Response Rate (ORR) of 60%, noted June 4, 2022.",7.02M
Add to portfolio,,,BTD,,,,,
ANNX,Annexon Inc.,$5.99 ,Tanruprubart (ANX005),Guillain-Barré Syndrome (GBS) ,Phase 3,04/06/2024 ET,"Phase 3 topline data of its single infusion 30 mg/kg dose met the primary endpoint with a highly statistically significant 2.4-fold improvement in GBS disability score versus placebo at week 8, noted … read more",109.89M
Add to portfolio,,,View Clinical Trial Data,,,,,
VKTX,Viking Therapeutics Inc.,$56.23 ,VK2809 - (VOYAGE),Non-alcoholic steatohepatitis (NASH) and fibrosis ,Phase 2b,04/06/2024 ET,"Phase 2b 52-week biopsy data showed that up to 75% of VK2809-treated patients achieved NASH resolution with no worsening of fibrosis, compared to 29% for placebo. Additionally, up to 57% achieved ≥1- … read more",113.04M
Add to portfolio,,,View Clinical Trial Data,,,,,
LGND,Ligand Pharmaceuticals Incorporated,$80.83 ,VK2809 - (VOYAGE),Non-alcoholic steatohepatitis (NASH) and fibrosis ,Phase 2b,04/06/2024 ET,"Phase 2b 52-week biopsy data showed that up to 75% of VK2809-treated patients achieved NASH resolution with no worsening of fibrosis, compared to 29% for placebo. Additionally, up to 57% achieved ≥1- … read more",19.6M
Add to portfolio,,,View Clinical Trial Data,,,,,
BBIO,BridgeBio Pharma Inc.,$27.13 ,Low-dose infigratinib - (PROPEL3),Achondroplasia ,Phase 2,04/06/2024 ET,"Phase 2 data cohort 5 from PROPEL 2 reported a statistically significant and sustained increase in annualized height velocity (AHV), with a mean change from baseline of +2.51cm/yr at Month 12, and +2. … read more",191.17M
Add to portfolio,,,BTD,,,,,
,,,View Clinical Trial Data,,,,,
AZN,AstraZeneca PLC,$79.53 ,C-CAR301,Solid tumors ,Phase 1,04/06/2024 ET,Phase 1 data presented at ASCO showed that at 9.03-mo median follow up achieves disease control rate (DCR) of 91.3% and objective response rate (ORR) of 56.5% for patients across all dose levels (DLs) … read more,3.1B
Add to portfolio,,,,,,,,
EQ,Equillium Inc.,$1.06 ,EQ101,Alopecia areata ,Phase 2,04/06/2024 ET,Phase 2 top-line data showed that 20% of all patients and 29% of those with moderate to severe disease who completed 24 weeks of treatment achieved a SALT score ≤20 (reduction in hair loss). The mean … read more,59.5M
Add to portfolio,,,,,,,,
CUE,Cue Biopharma Inc.,$1.56 ,CUE-101 and KEYTRUDA (pembrolizumab) - (KEYNOTE-A78),HPV16+ head and neck cancer ,Phase 1,04/06/2024 ET,"Phase 1 dose escalation data presented at ASCO 2024 showed an overall response rate (ORR) of 46% and 12-month overall survival (OS) of 96%, noted June 4, 2024.",76.85M
Add to portfolio,,,FTD,,,,,
CAPR,Capricor Therapeutics Inc.,$5.80 ,Deramiocel (CAP-1002) - (HOPE-2),Duchenne Muscular Dystrophy (DMD) ,Phase 2,04/06/2024 ET,"Phase 2 OLE 3-year safety and efficacy data reported a -4.1 points change from baseline, noted June 4, 2024.",45.72M
Add to portfolio,,,ODD,,,,,
ARTL,Artelo Biosciences Inc.,$1.40 ,ART26.12,Chemotherapy-Induced Pain ,Preclinical,04/06/2024 ET,Preclinical data reported that there was no impact of ART26.12 on body weight or bone density. All CIBP rats had swelling below the knee and above the ankle but no other clinical observations througho … read more,1.32M
Add to portfolio,,,,,,,,
BMY,Bristol-Myers Squibb Company,$40.68 ,Opdivo (nivolumab) plus Yervoy (ipilimumab) - (CheckMate -9DW),Hepatocellular carcinoma (HCC) ,Phase 3,04/06/2024 ET,Phase 3 late-breaking data presented at ASCO demonstrated improved survival benefit compared to lenvatinib or sorafenib in this patient population. ORR was more than double that for lenvatinib or sora … read more,2.04B
Add to portfolio,,,,,,,,
SILO,Silo Pharma Inc.,$2.25 ,SPC-15,Post-traumatic stress disorder (PTSD) ,IND-Enabling,04/06/2024 ET,"Pre -IND submitted, noted June 4, 2024.",9.4M
Add to portfolio,,,,,,,,
RPTX,Repare Therapeutics Inc.,$3.53 ,Lunresertib (RP-6306) + Debio 0123 - (MYTHIC),Solid Tumors ,Phase 1,04/06/2024 ET,"Fast Track designation granted by the FDA, noted June 4, 2024.",42.96M
Add to portfolio,,,FTD,,,,,
ALT,Altimmune Inc.,$7.30 ,Pemvidutide - (MOMENTUM),"Non-alcoholic steatohepatitis (NASH)/ (MASH) - Healthy, Overweight and Obese Volunteers ",Phase 2,05/06/2024 ET,"Phase 2 data presented at EASL International Liver Congress suggests that glucagon receptor agonism could potently affect MASH fibrosis, over and above GLP-1 monotherapy, noted June 5, 2024.",88.26M
Add to portfolio,,,FTD,,,,,
,,,View Clinical Trial Data,,,,,
ALNY,Alnylam Pharmaceuticals Inc.,$152.06 ,Elebsiran (VIR-2218) and tobevibart (VIR-3434) - (SOLSTICE),Hepatitis Delta Virus (HDV) ,Phase 2,05/06/2024 ET,"Additional Phase 2 data presented at EASL reported that 50% (3 of 6) achieved the combined endpoint, noted June 5, 2024.",131.08M
Add to portfolio,,,FTD,,,,,
VIR,Vir Biotechnology Inc.,$12.66 ,Elebsiran (VIR-2218) and tobevibart (VIR-3434) - (SOLSTICE),Hepatitis Delta Virus (HDV) ,Phase 2,05/06/2024 ET,"Additional Phase 2 data presented at EASL reported that 50% (3 of 6) achieved the combined endpoint, noted June 5, 2024.",138.92M
Add to portfolio,,,FTD,,,,,
ABUS,Arbutus Biopharma Corporation,$3.63 ,Imdusiran (AB-729 and VTP-300 with nivolumab) - (IM-PROVE I),Hepatitis B (HBV) ,Phase 2a,05/06/2024 ET,"Phase 2a data presented at EASL reported that all six patients with sustained HBsAg loss have seroconverted with high anti-HBsAg antibody levels, noted June 5, 2024.",191.7M
Add to portfolio,,,,,,,,
BRNS,Barinthus Biotherapeutics plc American Depositary Shares,$1.97 ,Imdusiran (AB-729 and VTP-300 with nivolumab) - (IM-PROVE I),Hepatitis B (HBV) ,Phase 2a,05/06/2024 ET,"Phase 2a data presented at EASL reported that all six patients with sustained HBsAg loss have seroconverted with high anti-HBsAg antibody levels, noted June 5, 2024.",40.72M
Add to portfolio,,,,,,,,
CLYD,Clyde Resources Inc,—,Imdusiran (AB-729 and VTP-300 with nivolumab) - (IM-PROVE I),Hepatitis B (HBV) ,Phase 2a,05/06/2024 ET,"Phase 2a data presented at EASL reported that all six patients with sustained HBsAg loss have seroconverted with high anti-HBsAg antibody levels, noted June 5, 2024.",—
Add to portfolio,,,,,,,,
DTIL,Precision BioSciences Inc.,$13.01 ,PBGENE-HBV - (ELIMINATE-B),Chronic Hepatitis B Virus (HBV) ,Preclinical,05/06/2024 ET,"Preclinical safety data shared at EASL supports the advancement of PBGENE-HBV to clinical trials as a potentially curative, finite treatment, noted June 8, 2024.",11.79M
Add to portfolio,,,FTD,,,,,
GNFT,GENFIT S.A.,$5.32 ,Iqirvo (elafibranor) - (ELATIVE),Primary biliary cholangitis (PBC) ,Phase 3,05/06/2024 ET,"Phase 3 data reported that 70% of patients treated with elafibranor achieved composite endpoint of slowing disease progression measured by biochemical response after 78-weeks, noted June 5, 2024.",50M
Add to portfolio,,,BTD,,,,,
IPSEY,Ipsen ADR,$33.46 ,Iqirvo (elafibranor) - (ELATIVE),Primary biliary cholangitis (PBC) ,Phase 3,05/06/2024 ET,"Phase 3 data reported that 70% of patients treated with elafibranor achieved composite endpoint of slowing disease progression measured by biochemical response after 78-weeks, noted June 5, 2024.",328.12M
Add to portfolio,,,BTD,,,,,
ACET,Adicet Bio Inc.,$1.44 ,ADI-001,Lupus nephritis and Systemic Lupus Erythematosus (SLE) ,Phase 1,05/06/2024 ET,"Fast track designation granted by the FDA, noted June 5, 2024.",83.25M
Add to portfolio,,,FTD,,,,,
GILD,Gilead Sciences Inc.,$62.55 ,Livdelzi (Seladelpar) - (ASSURE),Pruritus (itch) in people living with primary biliary cholangitis (PBC) ,Phase 3,05/06/2024 ET,"Phase 3 interim results presented at EASL reported that 73% achieved the clinically meaningful composite response endpoint, with 42% experiencing ALP normalization, noted June 5, 2024.",1.24B
Add to portfolio,,,,,,,,
AVIR,Atea Pharmaceuticals Inc.,$3.96 ,SVR12 in combination of bemnifosbuvir and ruzasvir,Hepatitis C virus (HCV) ,Phase 2,05/06/2024 ET,"Phase 2 data from the lead-in cohort, presented at EASL, exhibited a 97% SVR12 rate observed with 8 weeks of treatment in the lead-in cohort of HCV-infected patients, noted June 6, 2024.",79.36M
Add to portfolio,,,,,,,,
ASMB,Assembly Biosciences Inc.,$15.30 ,ABI-6250,Chronic hepatitis D virus (HDV) ,Preclinical,05/06/2024 ET,Preclinical data presented at EASL reported that ABI-6250 also effectively inhibited NTCP-mediated bile acid uptake and demonstrated selectivity for the NTCP bile transporter versus other transporters … read more,7.67M
Add to portfolio,,,,,,,,
VYNE,VYNE Therapeutics Inc.,$2.38 ,Repibresib Gel (VYN201),Vitiligo ,Phase 2b,05/06/2024 ET,"Phase 2b initiated, noted June 5, 2024.",25.47M
Add to portfolio,,,,,,,,
HRMY,Harmony Biosciences Holdings Inc.,$29.88 ,WAKIX (pitolisant),Type 1 myotonic dystrophy (DM1) ,Phase 2,05/06/2024 ET,"Phase 2 data reported that the mean improvement on the Daytime Sleepiness Scale (primary endpoint) was greater for pitolisant. Compared with placebo, a dose-response relationship was observed from bas … read more",57.53M
Add to portfolio,,,View Clinical Trial Data,,,,,
GOVX,GeoVax Labs Inc.,$1.80 ,COVID-19 booster with GEO-CM04S1 or Pfizer-BioNTech Bivalent vaccine,"COVID-19 Infection, Chronic Lymphocytic Leukemia ",Phase 2,05/06/2024 ET,"Phase 2 interim data reported that statistically significant increases in neutralizing antibody responses against multiple SARS-CoV-2 variants, ranging from the original Wuhan strain through Delta and … read more",25.36M
Add to portfolio,,,,,,,,
VTYX,Ventyx Biosciences Inc.,$5.28 ,VTX3232,Obesity and cardiometabolic risk factors ,Preclinical,05/06/2024 ET,"Preclinical data reported that treatment decreased body weight and food intake compared to DIO control. Reductions in liver steatosis and triglycerides were also observed, noted June 5, 2025.",71.31M
Add to portfolio,,,,,,,,
IMNN,Imunon Inc.,$1.34 ,IMNN-101 - (IMUNON),SARS-CoV-2 variant XBB.1.5 ,Phase 1,05/06/2024 ET,"Phase 1 initiated, noted June 5, 2024.",2.52M
Add to portfolio,,,,,,,,
AMGN,Amgen Inc.,$305.24 ,UPLIZNA (INEBILIZUMAB-CDON),Immunoglobulin G4-related disease (IgG4-RD) ,Phase 3,05/06/2024 ET,"Phase 3 trial met its primary endpoint, showing a statistically significant 87% reduction in the risk of IgG4-RD flare compared to placebo during the 52-week placebo-controlled period. All key seconda … read more",538.36M
Add to portfolio,,,,,,,,
KALV,KalVista Pharmaceuticals Inc.,$11.85 ,EKTERLY (sebetralstat),Hereditary Angioedema (HAE) ,Phase 3,06/06/2024 ET,"Phase 3 data from US subgroup demonstrated a median time to treatment of 38 minutes and time to beginning of symptom relief 1.3 hours, noted June 6, 2024.",50.52M
Add to portfolio,,,View Clinical Trial Data,,,,,
SGMT,Sagimet Biosciences Inc.,$4.65 ,Denifanstat - (FASCINATE-3),Nonalcoholic steatohepatitis (NASH) ,Phase 2b,06/06/2024 ET,"Phase 2b data reported that treatment statistically significant results on primary and secondary liver biopsy endpoints in the ITT population, noted June 6, 2024.",32.52M
Add to portfolio,,,BTD,,,,,
GILD,Gilead Sciences Inc.,$62.52 ,Hepcludex (Bulevirtide) - (MYR204),Hepatitis delta virus (HDV) ,Phase 2b,06/06/2024 ET,"Phase 2b final results reported that treatment with bulevirtide 10 mg in combination with PegIFN maintained a 46% rate of undetectable HDV RNA at Week 48 after EOT, noted June 6, 2024.",1.24B
Add to portfolio,,,,,,,,
FDMT,4D Molecular Therapeutics Inc.,$22.57 ,4D-710 - (AEROW),Cystic fibrosis ,Phase 1/2,06/06/2024 ET,Phase 1/2 data reported meaningful improvements in ppFEV1 at 12 months observed in 2 of 3 participants with mild to moderate baseline lung function impairment (ppFEV1 50-80%) and >6 months follow up A … read more,46.7M
Add to portfolio,,,RPDD,,,,,
ABBV,AbbVie Inc.,$165.69 ,ABBV-383 - (CERVINO),Multiple myeloma ,Phase 3,06/06/2024 ET,"Phase 3 trial commenced, noted June 6, 2024.",1.77B
Add to portfolio,,,,,,,,
CMMB,Chemomab Therapeutics Ltd.,$1.14 ,nebokitug (CM-101) - (SPRING),Primary Sclerosing Cholangitis ,Phase 2,06/06/2024 ET,"Phase 2 new translational data futher confirmsmodifying activity based on exvivo studies presented at EASL, noted June 6, 2024.",5.19M
Add to portfolio,,,FTD,,,,,
ABBV,AbbVie Inc.,$165.69 ,Mirvetuximab - (PICCOLO),Ovarian cancer ,Phase 2,06/06/2024 ET,"Phase 2 full data reported ORR of 51.9%, noted June 6, 2024.",1.77B
Add to portfolio,,,,,,,,
PLRX,Pliant Therapeutics Inc.,$11.54 ,Bexotegrast (PLN-74809) - (INTEGRIS-PSC),Primary sclerosing cholangitis (PSC) ,Phase 2a,06/06/2024 ET,"Phase 2a data reported that across all doses tested, bexotegrast attenuated increases in enhanced liver fibrosis (ELF) scores and pro-peptide of type III collagen formation (PRO-C3) when compared to p … read more",61.39M
Add to portfolio,,,FTD,,,,,
,,,View Clinical Trial Data,,,,,
MDGL,Madrigal Pharmaceuticals Inc.,$241.35 ,Resmetirom - (MAESTRO-NASH Outcomes),Nonalcoholic Steatohepatitis (NASH) ,Phase 3,06/06/2024 ET,"Phase 3 MAESTRO-NASH data from EASL reported that patients treated with Rezdiffra showed reduction from baseline in these key features compared to placebo, noted June 6, 2024.",22.29M
Add to portfolio,,,,,,,,
TVGN,Tevogen Bio Holdings Inc.,$0.89 ,TVGN 489 - (TCTL Study),Cytotoxic T Lymphocytes for the Treatment of Elderly and High-Risk Patients with Covid-19 ,Phase 1,06/06/2024 ET,"Phase 1 data reported that all patients, regardless of variant, experienced prompt clinical improvement and a reduced amount of virus in their nasal swabs (>99 to 100% in all patients) within 14 days, … read more",196.71M
Add to portfolio,,,,,,,,
BMEA,Biomea Fusion Inc.,$11.27 ,Icovamenib (BMF-219) - (COVALENT-111),"Healthy volunteers, type 2 diabetes ",Phase 1/2,06/06/2024 ET,"Full clinical hold place June 6, 2024.",59.51M
Add to portfolio,,,,,,,,
BMEA,Biomea Fusion Inc.,$11.27 ,Icovamenib (BMF-219) - (COVALENT-112),Type 1 diabetes (T1D) ,Phase 2,06/06/2024 ET,"Full clinical hold announced June 6, 2024.",59.51M
Add to portfolio,,,,,,,,
GERN,Geron Corporation,$3.89 ,RYTELO (imetelstat) - (IMerge),Myelodysplastic syndromes with transfusion-dependent (TD) anemia ,Approved,06/06/2024 ET,"Approved June 6, 2024.",638.02M
Add to portfolio,,,View Clinical Trial Data,,,,,
SNDX,Syndax Pharmaceuticals Inc.,$19.40 ,SNDX-5613,Unresectable metastatic microsatellite stable colorectal cancer. ,Phase 1a,06/06/2024 ET,"Phase 1a received IDMC recommendation to advance based on favorable safety profile observed in Phase 1a portion of trial, noted June 6, 2024.",86.14M
Add to portfolio,,,,,,,,
JNJ,Johnson & Johnson,$145.97 ,Amivantamab - (PALOMA-3),Non-small cell lung cancer (NSCLC) ,BLA Filing,07/06/2024 ET,"BLA submitted June 17, 2024.",2.41B
Add to portfolio,,,,,,,,
YMAB,Y-mAbs Therapeutics Inc.,$11.98 ,GD2-SADA (Basket trial) - (Trial 1001),"Melanoma, sarcoma and small cell lung cancer ",Preclinical,07/06/2024 ET,"Preclinical data presented at SNMMI reinforced the potential clinical utility of GD2-SADA in the diagnosis and treatment of GD2-expressing tumors, and the strength of our radiochemistry program, note … read more",45.44M
Add to portfolio,,,,,,,,
MRNA,Moderna Inc.,$151.01 ,SPIKEVAX (mRNA-1273),COVID-19 vaccine ,Approved,07/06/2024 ET,"Approved vaccine submitted to the FDA for review of its Spikevax 2024-2025 formula, targeting the SARS-CoV-2 variant JN.1., noted June 7, 2024.",389.08M
Add to portfolio,,,,,,,,
ARCT,Arcturus Therapeutics Holdings Inc.,$31.82 ,ARCT-032 - (LUNAR-CF),Cystic Fibrosis ,Phase 1b,07/06/2024 ET,"Phase 1b showed improvements in FEV1 (Forced Expiratory Volume in 1 second) in the four adults with CF after two inhaled administrations, noted June 7, 2024.",27.15M
Add to portfolio,,,RPDD,,,,,
,,,ODD,,,,,
GSK,GSK plc American Depositary Shares (Each representing two),$40.83 ,Arexvy (50-59 at increased risk),"Respiratory syncytial virus (RSV) disease, Vaccine ",Approved,07/06/2024 ET,"Approved June 7, 2024.",2.03B
Add to portfolio,,,,,,,,
RHHBY,Roche Holding AG ADR,—,Pegozafermin - (ENLIVEN),Nonalcoholic Steatohepatitis (NASH) ,Phase 2b,08/06/2024 ET,Phase 2b 48-week data presented at EASL reported statistically significant improvements across key markers of liver health. The benefits observed at week 48 were consistent with the results observed a … read more,6.36B
Add to portfolio,,,BTD,,,,,
ETNB,89bio Inc.,$8.10 ,Pegozafermin - (ENLIVEN),Nonalcoholic Steatohepatitis (NASH) ,Phase 2b,08/06/2024 ET,Phase 2b 48-week data presented at EASL reported statistically significant improvements across key markers of liver health. The benefits observed at week 48 were consistent with the results observed a … read more,148.31M
Add to portfolio,,,BTD,,,,,
MRNA,Moderna Inc.,$148.59 ,mRNA-1083,COVID-19 ,Phase 3,10/06/2024 ET,"Phase 3 data reported that the trial met its primary endpoints, noted June 10, 2024.",389.08M
Add to portfolio,,,FTD,,,,,
PROK,ProKidney Corp.,$3.02 ,Rilparencel - (REGEN-007),Diabetic CKD Stage 3/4 ,Phase 2,10/06/2024 ET,"Phase 2 data reported a sustained eGFR decline of ≥ 20%, and/or an increase in the urine albumin to creatinine ratio (UACR) from baseline of ≥ 30% and ≥ 30 mg/g, noted June 10, 2024.",294.28M
Add to portfolio,,,RMAT,,,,,
OCS,Oculis Holding AG,$12.00 ,Licaminlimab (OCS-02) - (PREDICT-1),Dry eye disease ,Phase 2b,10/06/2024 ET,"Phase 2b data reported a treatment effect favoring licaminlimab was observed in multiple sign endpoints including fluorescein staining in the total cornea, inferior corneal, central corneal and nasal … read more",43.66M
Add to portfolio,,,,,,,,
SKYE,Skye Bioscience Inc.,$9.98 ,SBI-100,Primary open-angle glaucoma (POAG) or Ocular hypertension (OHT) ,Phase 2a,10/06/2024 ET,"Phase 2a study did not meet the primary endpoint for lowering intraocular pressure, leading the company to discontinue the program and associated ophthalmology pipeline, noted June 10, 2024.",30.99M
Add to portfolio,,,,,,,,
CANF,Can-Fite Biopharma Ltd Sponsored ADR (Israel),$2.53 ,Namodenoson - (CF102-222PC),Pancreatic Cancer ,Phase 2a,10/06/2024 ET,"Phase 2a received approval from an Israeli review board to initiate open-label study, noted June 10, 2024.",10.35M
Add to portfolio,,,ODD,,,,,
FDMT,4D Molecular Therapeutics Inc.,$22.57 ,4D-150 - (PRISM),Wet age-related macular degeneration (AMD) ,Phase 2,10/06/2024 ET,Additional subgroup results demonstrated that a single intravitreal dose of 4D-150 without any supplemental anti-VEGF injections resulted in stable mean visual acuity that was equal to or higher than … read more,46.7M
Add to portfolio,,,RMAT,,,,,
RPTX,Repare Therapeutics Inc.,$4.00 ,RP-3500 - (TRESR),Solid tumors ,Phase 2,10/06/2024 ET,"Phase 2 dosing initiated, noted June 10, 2024.",42.96M
Add to portfolio,,,,,,,,
LLY,Eli Lilly and Company,$863.79 ,Tirzepatide - (SYNERGY-NASH),"Nonalcoholic steatohepatitis (NASH), Metabolic dysfunction-associated steatohepatitis (MASH) ",Phase 2,10/06/2024 ET,"Phase 2 data reported that the efficacy estimandi showed 51.8%, 62.8% and 73.3% of participants taking 5 mg, 10 mg and 15 mg, respectively, achieved an absence of MASH with no worsening of fibrosis on … read more",946.46M
Add to portfolio,,,,,,,,
NVO,Novo Nordisk A/S,—,Efruxifermin - (HARMONY),Nonalcoholic Steatohepatitis ,Phase 2b,10/06/2024 ET,"Phase 2b data presented at EASL reported that ≥1-stage improvement in fibrosis with no worsening of MASH after 24 weeks of treatment for both the 50 mg EFX (41%, p<0.05) and 28 mg EFX (39%, p<0.05) do … read more",4.47B
Add to portfolio,,,FTD,,,,,
,,,BTD,,,,,
,,,View Clinical Trial Data,,,,,
AKRO,Akero Therapeutics Inc.,$22.99 ,Efruxifermin - (HARMONY),Nonalcoholic Steatohepatitis ,Phase 2b,10/06/2024 ET,"Phase 2b data presented at EASL reported that ≥1-stage improvement in fibrosis with no worsening of MASH after 24 weeks of treatment for both the 50 mg EFX (41%, p<0.05) and 28 mg EFX (39%, p<0.05) do … read more",79.99M
Add to portfolio,,,FTD,,,,,
,,,BTD,,,,,
,,,View Clinical Trial Data,,,,,
SRZN,Surrozen Inc.,$11.20 ,SZN-043,Severe alcohol associated hepatitis ,Phase 1a,10/06/2024 ET,"Phase 1a data reported that target engagement was confirmed via transient increases in alkaline phosphatase (ALP), noted June 10, 2024.",8.57M
Add to portfolio,,,,,,,,
BDRX,Biodexa Pharmaceuticals plc,$24.51 ,"eRapa (rapamycin, sirolimus) - (Serenta)",Familial Adenomatous Polyposis (FAP) ,Phase 2,10/06/2024 ET,"Phase 2 data reported that 14/18 (78%) patients were non-progressors with 11/18 (61%) of these patients with PR. In the colorectum, 25/29 (86%) patients were non progressors including all with an inta … read more",505.06K
Add to portfolio,,,FTD,,,,,
,,,ODD,,,,,
MNPR,Monopar Therapeutics Inc.,$3.87 ,MNPR-101-Zr (uPAR),Solid tumors ,Phase 1,10/06/2024 ET,"Phase 1 data shared at SNMMI reported durable tumor uptake across multiple cancers with optimization improved biodistribution and stability, noted June 10, 2024.",6.17M
Add to portfolio,,,,,,,,
MIRA,MIRA Pharmaceuticals Inc.,$0.76 ,Ketamir-2,"Treatment-resistant depression (TRD), major depressive disorder with suicidal ideation (MDSI) and post-traumatic stress disorder (PTSD) ",Preclinical,10/06/2024 ET,Preclinical study results highlight the potential as a superior alternative to intravenous ketamine for treating depression and treatment-resistant depression (TRD). The encouraging data support MIRA' … read more,19.07M
Add to portfolio,,,,,,,,
SLS,SELLAS Life Sciences Group Inc.,$1.41 ,Tambiciclib (SLS009) (GFH009) with venetoclax,"Hematologic malignancies, acute myeloid leukemia (AML), chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL) and lymphoma ",Phase 2a,10/06/2024 ET,"Phase 2a enrollment was completed with initial data showing an overall response rate (ORR) of 33% and 50% achieved to date in 60 mg QW and 30 mg BIW cohorts, noted June 10, 2024.",105.3M
Add to portfolio,,,ODD,,,,,
,,,FTD,,,,,
,,,RPDD,,,,,
ATNM,Actinium Pharmaceuticals Inc.,$7.99 ,Iomab-B - (SIERRA),Acute myeloid leukemia (AML) ,Phase 3,10/06/2024 ET,"Phase 3 data presented at SNMMI showed the CD45-targeting antibody radiation conjugate (ARC) improved survival in high-risk relapsed/refractory acute myeloid leukemia (AML) patients, including those w … read more",31.2M
Add to portfolio,,,View Clinical Trial Data,,,,,
NRXP,NRX Pharmaceuticals Inc.,$3.18 ,HTX-100 (NRX-100) (Ketamine Hydrochloride),Acute Suicidal Ideation and Behavior in Bipolar Depression ,Phase 3,10/06/2024 ET,"Phase 3 trial discussed at ASCP meeting suggested intravenous ketamine may have advantages over the intranasal form, noted June 10, 2024.",19.71M
Add to portfolio,,,FTD,,,,,
,,,View Clinical Trial Data,,,,,
LBPH,Longboard Pharmaceuticals Inc.,$18.11 ,Bexicaserin (LP352) - (DEEp OCEAN),Adolescent and adult patients with developmental and epileptic encephalopathies (DEEs) ,Phase 2,10/06/2024 ET,Phase 2 OLE data reported that the overall median seizure reduction of 56.1% in countable motor seizures over an approximate 6-month treatment period; participants randomized to the PACIFIC placebo gr … read more,39.05M
Add to portfolio,,,BTD,,,,,
GNFT,GENFIT S.A.,$5.54 ,Iqirvo (elafibranor) - (ELATIVE),Primary biliary cholangitis (PBC) ,Approved,10/06/2024 ET,"FDA approved on June 10, 2024.",50M
Add to portfolio,,,BTD,,,,,
IPSEY,Ipsen ADR,$33.60 ,Iqirvo (elafibranor) - (ELATIVE),Primary biliary cholangitis (PBC) ,Approved,10/06/2024 ET,"FDA approved on June 10, 2024.",328.12M
Add to portfolio,,,BTD,,,,,
LLY,Eli Lilly and Company,$863.79 ,Kisunla (donanemab) - (TRAILBLAZER-ALZ 2),Alzheimer’s disease ,BLA Filing,10/06/2024 ET,"Advisory committee voted 11-0 (11 Yes; 0 No; 0 Abstain) that the evidence presented showed that donanemab is effective for the treatment of AD, noted June 10, 2024.",946.46M
Add to portfolio,,,BTD,,,,,
,,,View Clinical Trial Data,,,,,
NNVC,NanoViricides Inc.,$3.31 ,NV-387,"Influenza A viruses, Bird Flu H5N1 ",Preclinical,11/06/2024 ET,"Preclinical data reported an ideal flat blood concentration profile for an extended time period upon oral administration in two different animal models, noted June 11, 2024.",17.43M
Add to portfolio,,,,,,,,
SAGE,Sage Therapeutics Inc.,$10.60 ,SAGE-718 - (SURVEYOR),Huntington's disease ,Phase 2,11/06/2024 ET,"Phase 2 topline data reported that the study met its primary endpoint, noted June 11, 2024.",62.78M
Add to portfolio,,,FTD,,,,,
,,,ODD,,,,,
SUPN,Supernus Pharmaceuticals Inc.,—,SAGE-718 - (SURVEYOR),Huntington's disease ,Phase 2,11/06/2024 ET,"Phase 2 topline data reported that the study met its primary endpoint, noted June 11, 2024.",56.07M
Add to portfolio,,,FTD,,,,,
,,,ODD,,,,,
MOLN,Molecular Partners AG,$4.99 ,MP0712,Small-cell lung cancer (SCLC) and other DLL3+ neuroendocrine tumors ,Preclinical,11/06/2024 ET,"Preclinical data reported that treatment showed significant and durable inhibition of tumor growth at clinically-relevant doses, noted June 11, 2024.",40.36M
Add to portfolio,,,,,,,,
THAR,Tharimmune Inc.,$3.43 ,TH104 (AV104),Primary biliary cholangitis (PBC) ,Phase 1,11/06/2024 ET,Phase 1 data reported consistent pharmacokinetic (PK) profiles across buccal and intravenous routes of administration with a comparable safety and tolerability profile between routes of administration … read more,4.64M
Add to portfolio,,,,,,,,
REGN,Regeneron Pharmaceuticals Inc.,"$1,010.54 ",Kevzara (sarilumab),Polyarticular juvenile idiopathic arthritis ,Approved,11/06/2024 ET,"FDA Approved on June 11, 2024.",105.1M
Add to portfolio,,,,,,,,
SNY,Sanofi,$48.51 ,Kevzara (sarilumab),Polyarticular juvenile idiopathic arthritis ,Approved,11/06/2024 ET,"FDA Approved on June 11, 2024.",2.46B
Add to portfolio,,,,,,,,
ANVS,Annovis Bio Inc.,$6.77 ,Buntanetap (ANVS401),Alzheimer’s disease (AD) ,Phase 2/3,11/06/2024 ET,"Additional Phase 2/3 data reported that buntanetap was found to be equally safe in both APOE4 carriers and non-carriers, with no instances of ARIA, noted June 11, 2024.",19.49M
Add to portfolio,,,ODD,,,,,
PCSA,Processa Pharmaceuticals Inc.,$1.80 ,NGC-Capecitabine (PCS6422),Gastrointestinal Cancer ,Phase 1b,11/06/2024 ET,"Phase 1b data showed that 8/12 patients had progression-free survival (PFS) ranging from 5 to 11 months, noted June 11, 2024.",50.35M
Add to portfolio,,,,,,,,
CAPR,Capricor Therapeutics Inc.,$5.55 ,Deramiocel (CAP-1002) - (HOPE-2),Duchenne Muscular Dystrophy (DMD) ,BLA Filing,11/06/2024 ET,"Type-B meeting with the FDA completed, noted June 11, 2024",45.72M
Add to portfolio,,,ODD,,,,,
ATNM,Actinium Pharmaceuticals Inc.,$8.08 ,Actimab-A in combination with CLAG-M,Relapsed or refractory acute myeloid leukemia (AML) ,Phase 1b,11/06/2024 ET,"Phase 1b SNMMI oral presentation highlighted dosimetry results and safety data supporting this novel radiotherapy combination, noted June 11, 2024.",31.2M
Add to portfolio,,,,,,,,
NVO,Novo Nordisk A/S,—,Efruxifermin - (SYMMETRY),Metabolic-associated steatohepatitis (MASH) ,Phase 3,11/06/2024 ET,"Phase 3 initiated, noted June 11, 2024.",4.47B
Add to portfolio,,,View Clinical Trial Data,,,,,
AKRO,Akero Therapeutics Inc.,$23.43 ,Efruxifermin - (SYMMETRY),Metabolic-associated steatohepatitis (MASH) ,Phase 3,11/06/2024 ET,"Phase 3 initiated, noted June 11, 2024.",79.99M
Add to portfolio,,,View Clinical Trial Data,,,,,
ATHA,Athira Pharma Inc.,$2.55 ,ATH-1105,Amyotrophic Lateral Sclerosis (ALS) ,Phase 1,11/06/2024 ET,"Phase 1 first cohort completed, noted June 11, 2024.",3.94M
Add to portfolio,,,,,,,,
INDV,Indivior PLC,$16.87 ,INDV-2000,Opioid Use Disorder (OUD) ,Phase 2,11/06/2024 ET,"Phase 2 POC trial initiated, June 11, 2024",124.77M
Add to portfolio,,,,,,,,
RARE,Ultragenyx Pharmaceutical Inc.,$44.64 ,Setrusumab (BPS-804) - (ORBIT),Osteogenesis Imperfecta ,Phase 2/3,12/06/2024 ET,"Phase 2 data reported that continued, substantial improvements in bone mineral density (BMD) with a mean increase from baseline of 22% (p<0.0001) and a mean improvement in Z-score of +1.25, noted June … read more",96.37M
Add to portfolio,,,,,,,,
MREO,Mereo BioPharma Group plc,$3.83 ,Setrusumab (BPS-804) - (ORBIT),Osteogenesis Imperfecta ,Phase 2/3,12/06/2024 ET,"Phase 2 data reported that continued, substantial improvements in bone mineral density (BMD) with a mean increase from baseline of 22% (p<0.0001) and a mean improvement in Z-score of +1.25, noted June … read more",155.15M
Add to portfolio,,,,,,,,
RNA,Avidity Biosciences Inc.,$38.36 ,Delpacibart braxlosiran (del-brax) - (FORTITUDE),Facioscapulohumeral Muscular Dystrophy (FSHD) ,Phase 1/2,12/06/2024 ET,"Phase 1/2 preliminary data demonstrated greater than 50% mean reduction in DUX4 regulated genes, trends of functional improvement including increased muscle strength and reachable workspace, and posit … read more",128.65M
Add to portfolio,,,ODD,,,,,
,,,FTD,,,,,
PDSB,PDS Biotechnology Corporation,$2.93 ,PDS0101 + KEYTRUDA (pembrolizumab) - (VERSATILE-002),HPV16-positive first-line recurrent and/or metastatic head and neck squamous cell cancer with low PD-L1 expression (CPS 1-19) ,Phase 2,12/06/2024 ET,"Phase 2 data reported that the mOS is 30 months, noted June 12, 2024.",46.63M
Add to portfolio,,,View Clinical Trial Data,,,,,
DNTH,Dianthus Therapeutics Inc.,$25.16 ,DNTH103 - (MoMeNtum),Multifocal Motor Neuropathy (MMN) ,IND-Enabling,12/06/2024 ET,"Phase 2 trial initiated and IND cleared by the FDA, noted June 12, 2024.",32.19M
Add to portfolio,,,,,,,,
NKTR,Nektar Therapeutics,$1.29 ,NKTR-0165,Autoimmune diseases ,Preclinical,12/06/2024 ET,"Preclinical data presented at EULAR demonstrated selective enhancement of Treg Cell function through novel agonistic mechanism, noted June 12, 2024.",19.02M
Add to portfolio,,,,,,,,
AFMD,Affimed N.V.,$6.86 ,AFM13 + AlloNK (AB-101) - (LuminICE-203),"Classical Hodgkin Lymphoma (cHL), relapsed/refractory CD30-positive lymphoma ",Phase 2,12/06/2024 ET,"Phase 2 data reported an 85.7% overall response rate (ORR) (6 of 7 patients); 4 out of 7 patients with complete response (CR), noted June 12, 2024.",15.23M
Add to portfolio,,,RMAT,,,,,
TVRD,Tvardi Therapeutics Inc.,—,Oral KORSUVA (difelikefalin injection) - (KOURAGE 1),Pruritus and Notalgia Paresthetica ,Phase 2,12/06/2024 ET,"Phase 2 dose finding data reported that difelikefalin did not demonstrate a meaningful clinical benefit at any dose compared to placebo, resulting in the Company's decision to discontinue the clinical … read more",9.38M
Add to portfolio,,,,,,,,
AZN,AstraZeneca PLC,$79.58 ,Farxiga,Paediatric type-2 diabetes ,Approved,12/06/2024 ET,"Approved June 12, 2024.",3.1B
Add to portfolio,,,,,,,,
NKGN,NKGen Biotech Inc.,$1.29 ,SNK02,Solid Tumors ,Phase 1,12/06/2024 ET,"Additional Phase 1 data reported that there were 17 Grade 1, 3 Grade 2, and 1 Grade 3 adverse events (""AEs"") related to investigational product, noted June 12, 2024.",124.38M
Add to portfolio,,,,,,,,
PFE,Pfizer Inc.,$27.29 ,Fordadistrogene movaparvovec,Duchenne muscular dystrophy (DMD) ,Phase 3,12/06/2024 ET,"Phase 3 trial did met its primary endpoint, noted June 12, 2024.",5.69B
Add to portfolio,,,,,,,,
PFE,Pfizer Inc.,$27.29 ,PF-06939926 (CIFFREO),Duchenne muscular dystrophy (DMD) ,Phase 3,12/06/2024 ET,"Phase 3 trial did not meet its primary endpoint, noted June 12, 2024.",5.69B
Add to portfolio,,,FTD,,,,,
,,,ODD,,,,,
,,,View Clinical Trial Data,,,,,
CRDL,Cardiol Therapeutics Inc.,$2.97 ,CardiolRx - (MAvERIC-Pilot),Recurrent Pericarditis ,Phase 2,12/06/2024 ET,"Phase 2 topline data reported a mean reduction of 3.7, from 5.8 at baseline for patient-reported pericardial pain, noted June 12, 2024.",83.73M
Add to portfolio,,,ODD,,,,,
MRNA,Moderna Inc.,$145.23 ,mRNA-1283 - (NEXTCove),COVID-19 ,Phase 3,13/06/2024 ET,"Phase 3 met its primary vaccine efficacy endpoint demonstrating non-inferior vaccine efficacy against COVID-19 compared to Spikevax in participants 12 years of age and older, noted June 13, 2024.",389.08M
Add to portfolio,,,,,,,,
URGN,UroGen Pharma Ltd.,$17.50 ,ZUSDURI (VesiGel UGN-102 (mitomycin)) - (ENVISION),Low grade non-muscle invasive bladder cancer (LG-NMIBC) ,Phase 3,13/06/2024 ET,"Phase 3 data reported a 82.3% 12-month duration of response (DOR), noted June 13, 2024.",46.26M
Add to portfolio,,,View Clinical Trial Data,,,,,
OCUL,Ocular Therapeutix Inc.,$5.04 ,AXPAXLI (OTX-TKI) - (HELIOS),Non-proliferative diabetic retinopathy (NPDR) ,Phase 1,13/06/2024 ET,"Phase 1 HELIOS study data reported that 23.1% of patients in AXPAXLI arm experienced ≥2-step DRSS improvement with no patients experiencing worsening of DRSS or vision threatening complications, noted … read more",174M
Add to portfolio,,,,,,,,
SNY,Sanofi,$47.53 ,IPH6101/ SAR443579,Hematological malignancies ,Phase 1/2,13/06/2024 ET,Phase 1/2 data presented at EHA reported that treatment was well tolerated up to doses of 6 mg/kg QW with observed clinical benefit in adult pts with R/R AMLand a maximum response rate seen at a targ … read more,2.46B
Add to portfolio,,,FTD,,,,,
IPHA,Innate Pharma S.A.,$2.37 ,IPH6101/ SAR443579,Hematological malignancies ,Phase 1/2,13/06/2024 ET,Phase 1/2 data presented at EHA reported that treatment was well tolerated up to doses of 6 mg/kg QW with observed clinical benefit in adult pts with R/R AMLand a maximum response rate seen at a targ … read more,92.16M
Add to portfolio,,,FTD,,,,,
TNXP,Tonix Pharmaceuticals Holding Corp.,$1.15 ,Tonmya (TNX-102 SL) - (RELIEF/RESILIENT),Fibromyalgia ,Phase 3,14/06/2024 ET,"Phase 3 data presented at EULAR reported significant improvement on the primary pain endpoint and on all six key secondary endpoints, noted June 14, 2024.",8.77M
Add to portfolio,,,FTD,,,,,
KROS,Keros Therapeutics Inc.,$49.36 ,Elritercept (KER-050),Myelodysplastic syndromes (MDS) ,Phase 2,14/06/2024 ET,"Phase 2 trial data presented at EHA reported that 55.6% of the mITT24 patients achieved an overall erythroid response over the first 24 weeks of treatment, noted June 14, 2024.",40.62M
Add to portfolio,,,FTD,,,,,
,,,View Clinical Trial Data,,,,,
TAK,Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of),$13.10 ,Elritercept (KER-050),Myelodysplastic syndromes (MDS) ,Phase 2,14/06/2024 ET,"Phase 2 trial data presented at EHA reported that 55.6% of the mITT24 patients achieved an overall erythroid response over the first 24 weeks of treatment, noted June 14, 2024.",3.15B
Add to portfolio,,,FTD,,,,,
,,,View Clinical Trial Data,,,,,
HCM,HUTCHMED (China) Limited,$18.12 ,HMPL-523 - (ESLIM-01),Primary immune thrombocytopenia (ITP) ,Phase 3,14/06/2024 ET,"Phase 3 data presented at EHA reported a durable response rate of 48.4% vs. 0% with placebo, noted June 14, 2024.",174.43M
Add to portfolio,,,BTD,,,,,
HCM,HUTCHMED (China) Limited,$18.12 ,HMPL-760,Bruton's Tyrosine Kinase (BTK) Relapsed/Refractory (R/R) Lymphomas ,Phase 1,14/06/2024 ET,"Phase 1 data presented at EHA reported that 3 complete response (CR)(1 DLBCL, 2 MCL), 1 complete remission with incomplete recovery (CRi)(CLL/SLL), 14 partial responses (PR)(8 CLL/SLL, 3 DLBCL, 1 MCL, … read more",174.43M
Add to portfolio,,,,,,,,
IRON,Disc Medicine Inc.,$46.27 ,Bitopertin - (BEACON),Erythropoietic Protoporphyria (EPP) ,Phase 2,14/06/2024 ET,"Phase 2 data shared at EHA reported that the cumulative total time in light observed over 6-month treatment period with bitopertin represents >3x increase relative to historical control, noted June 14 … read more",34.77M
Add to portfolio,,,,,,,,
IRON,Disc Medicine Inc.,$46.27 ,MWTX-003 - (DISC-3405),Polycythemia vera (PV) ,Phase 1,14/06/2024 ET,"Phase 1 initial data in healthy volunteers shared at EHA reported that mean serum iron reduction of more than 50% from baseline was achieved for both 150- and 300-mg doses, noted June 14, 2024.",34.77M
Add to portfolio,,,FTD,,,,,
,,,ODD,,,,,
MOLN,Molecular Partners AG,$6.77 ,MP0621,Acute myeloid leukemia (AML) ,Preclinical,14/06/2024 ET,"Preclinical data reported that MP0621 depleted cKit+ cells in bone marrow of humanized mice without affecting circulating immune cells, noted June 14 2024.",40.36M
Add to portfolio,,,,,,,,
BPTH,Bio-Path Holdings Inc.,$2.16 ,Prexigebersen + DACOGEN (decitabine) + VENCLEXTA (venetoclax),Acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) ,Phase 2,14/06/2024 ET,"Phase 2 presented at EHA continues to be well-tolerated and has now demonstrated compelling efficacy results in two reporting cohorts, noted June 14, 2024.",8.31M
Add to portfolio,,,View Clinical Trial Data,,,,,
KYMR,Kymera Therapeutics Inc.,$33.29 ,KT-333 - (STAT3),Peripheral T-cell Lymphoma (PTCL) ,Phase 1,14/06/2024 ET,"Phase 1 study presented at EHA demonstrated initial clinical proof of concept across multiple hematological malignancies, including complete responses in two patients with Hodgkin's lymphoma, noted Ju … read more",71.5M
Add to portfolio,,,ODD,,,,,
CABA,Cabaletta Bio Inc.,$10.66 ,rese-cel (resecabtagene autoleucel (CABA-201) - (RESET-Myositis),"Active idiopathic inflammatory myopathy (IIM, or myositis) ",Phase 1/2,14/06/2024 ET,"Phase 1/2 trial data reported a decline in creatinine kinase from 617 at infusion to 308 and a total improvement score (TIS) of 30, noted June 14, 2024.",91.47M
Add to portfolio,,,FTD,,,,,
,,,ODD,,,,,
,,,RMAT,,,,,
CABA,Cabaletta Bio Inc.,$10.66 ,CABA-201 - (RESET-SLE),Systemic Lupus Erythematosus ,Phase 1/2,14/06/2024 ET,"Phase 1/2 clinical data demonstrated an improvement in the SLEDAI-2K (systemic lupus erythematosus disease activity index) score from 26 at baseline to 10, noted June 14, 2024.",91.47M
Add to portfolio,,,FTD,,,,,
BEAM,Beam Therapeutics Inc.,$24.87 ,BEAM-101 - (BEACON),Sickle cell disease ,Phase 1/2,14/06/2024 ET,Phase 1/2 manufacturing data presented at EHA reported that reproducibly met the high viability threshold across 14 development runs using healthy and sickle cell trait donor cells and nine GMP clinic … read more,101.16M
Add to portfolio,,,ODD,,,,,
,,,RMAT,,,,,
GILD,Gilead Sciences Inc.,$64.46 ,Axicabtagene Ciloleucel - (ZUMA-24),Relapsed/Refractory Large B-Cell Lymphoma ,Phase 2,14/06/2024 ET,"Phase 2 data presented at EHA reported that data demonstrated that the safety and efficacy of Yescarta was consistent with previous clinical and real-world studies., noted June 14, 2024.",1.24B
Add to portfolio,,,,,,,,
EDIT,Editas Medicine Inc.,$5.06 ,Renizgamglogene autogedtemcel (reni-cel; EDIT-301) - (EdiTHAL),Transfusion-Dependent Beta Thalassemia (TDT) ,Phase 1/2,14/06/2024 ET,Phase 1/2 data presented at EHA reported that treatment was well-tolerated and demonstrated a safety profile consistent with myeloablative conditioning with busulfan and autologous hematopoietic stem … read more,89.92M
Add to portfolio,,,ODD,,,,,
AUTL,Autolus Therapeutics plc,$4.50 ,AUCATZYL (obecabtagene autoleucel) - (FELIX),B-Cell Acute Lymphoblastic Leukemia ,Phase 3,14/06/2024 ET,"Data presented at EHA showed an overall response rate (ORR) (Complete Response/CRi) in all patients who received obe-cel in the FELIX study was 78% (99/127 patients), noted June 14, 2024.",266.14M
Add to portfolio,,,RMAT,,,,,
EDIT,Editas Medicine Inc.,$5.06 ,Renizgamglogene autogedtemcel (reni-cel; EDIT-301) - (RUBY),Sickle Cell Disease ,Phase 1/2,14/06/2024 ET,"Phase 1/2 data presented at EHA reported that mean (SD)Hb levels rapidly increased and were maintained at ≥14.4 (2.5) g/dL from Month 5, noted June 14, 2024.",89.92M
Add to portfolio,,,,,,,,
DYN,Dyne Therapeutics Inc.,$33.07 ,DYNE-302,Facioscapulohumeral Muscular Dystrophy ,Preclinical,14/06/2024 ET,"Preclinical data reported that a single intravenous dose of DYNE-302 resulted in dose-dependent and robust reduction of the DUX4 transcriptome (D4T) that lasted up to three months, with benefit on mus … read more",142.26M
Add to portfolio,,,,,,,,
BMY,Bristol-Myers Squibb Company,$40.14 ,Augtyro (repotrectinib),Solid tumors that have a neurotrophic tyrosine receptor kinase (NTRK) for adults and pediatric patients 12+ ,Approved,14/06/2024 ET,"Approved June 14, 2024.",2.04B
Add to portfolio,,,BTD,,,,,
COGT,Cogent Biosciences Inc.,$8.43 ,Bezuclastinib - (SUMMIT),Non-Advanced Systemic Mastocytosis ,Phase 2,14/06/2024 ET,"Phase 2 data from part 1 presented at EHA showed that patients treated with 100 mg bezuclastinib showed substantial reduction in their most severe symptoms and mast cell reactions, noted June 14, 2024 … read more",139.7M
Add to portfolio,,,BTD,,,,,
,,,View Clinical Trial Data,,,,,
SNDX,Syndax Pharmaceuticals Inc.,$20.11 ,SNDX-5613 - (AUGMENT-102) - (BEAT AML),MLLr or NPM1 acute leukemias ,Phase 1/2,14/06/2024 ET,Phase 1/2 data presented at EHA continue to support revumenib's potential to enhance current standard of care agents. 52% CRc (14 of 27 pts) observed in AUGMENT-102 trial. 96% CRc (23 of 24 pts) obser … read more,86.14M
Add to portfolio,,,,,,,,
BPTH,Bio-Path Holdings Inc.,$2.16 ,Prexigebersen (BP1001),Acute Myeloid Leukemia (AML) ,Phase 2,14/06/2024 ET,"Phase 2 data presented at EHA trial demonstrated compelling efficacy, with 75% of evaluable newly diagnosed AML patients and 55% of evaluable relapsed/refractory AML patients achieving complete or par … read more",8.31M
Add to portfolio,,,,,,,,
IVVD,Invivyd Inc.,$1.58 ,PEMGARDA (VYD222 (pemivibart)) - (CANOPY),COVID-19 Prevention ,Preclinical,14/06/2024 ET,Preclinical new data is broadly concordant with preliminary pseudovirus data showing neutralizing activity of VYD222 against KP.2 FLiRT and KP.3 variants recently publicized by an independent academic … read more,120.14M
Add to portfolio,,,,,,,,
APTO,Aptose Biosciences Inc.,$0.89 ,Tuspetinib - (APTIVATE),Acute myeloid leukemia (AML) ,Preclinical,14/06/2024 ET,"Preclinical data presented at EHA in doublet therapy showed broad clinical activity and strong safety data, noted June 14, 2024.",2.55M
Add to portfolio,,,,,,,,
PTGX,Protagonist Therapeutics Inc.,$33.39 ,Rusfertide - (REVIVE),Polycythemia vera ,Phase 2,14/06/2024 ET,"Phase 2 data presented at EHA reported durable hematocrit (Hct) control (< 45%), decreased phlebotomy use, long-term tolerability, and no new safety signals in patients with polycythemia vera, noted J … read more",62.21M
Add to portfolio,,,,,,,,
IRON,Disc Medicine Inc.,$46.27 ,Bitopertin - (APOLLO),Erythropoietic Protoporphyria (EPP) ,Phase 2,14/06/2024 ET,"Phase 2 additional data shared at EHA demonstrated the clinical activity of bitopertin and highlighted meaningful improvements in light tolerance, phototoxic reactions, and quality of life, noted June … read more",34.77M
Add to portfolio,,,ODD,,,,,
IRON,Disc Medicine Inc.,$46.27 ,DISC-0974,Myelofibrosis (MF) patients with anemia ,Phase 1/2,14/06/2024 ET,"Phase 1b updated data shared at EHA demonstrated durable increases in hemoglobin and reduced transfusion burden in a majority of evaluable patients, noted June 14, 2024.",34.77M
Add to portfolio,,,,,,,,
STTK,Shattuck Labs Inc.,$6.19 ,SL-172154 + Azacitidine (AZA),Acute Myeloid Leukemia (AML) and Higher-Risk Myelodysplastic Syndromes/Neoplasms (HR-MDS) ,Phase 1b,14/06/2024 ET,"Phase 1b data presented at EHA reported a 67% objective Response Rate (ORR) in frontline HR-MDS patients, noted June 14, 2024.",47.9M
Add to portfolio,,,ODD,,,,,
ZURA,Zura Bio Limited,$3.77 ,Tibulizumab (ZB-106),Sjogren's Syndrome ,Phase 1,14/06/2024 ET,"Phase 1 data presented at EULAR reported that treatment was generally well tolerated, with total B cell counts were dose-dependently reduced in all participants, noted June 14, 2024.",65.02M
Add to portfolio,,,,,,,,
MBRX,Moleculin Biotech Inc.,$4.14 ,"Annamycin (MB-106) in combination with Cytarabine - (Ara-C, MIRACLE)",Acute Myeloid Leukemia (AML) ,Phase 1/2,14/06/2024 ET,"Phase 1/2 additional data presented at EHA showed that out of 20 evaluable subjects across all treatment lines, 45% achieved a composite complete remission (CRc), including 89% with poor prognosis cy … read more",30.29M
Add to portfolio,,,ODD,,,,,
,,,FTD,,,,,
GLUE,Monte Rosa Therapeutics Inc.,$3.83 ,MRT-6160,Autoimmune conditions ,Preclinical,14/06/2024 ET,"Preclinical data reported that MRT-6160 inhibited disease progression, pro-inflammatory cytokines and autoantibody production in a model of rheumatoid arthritis, noted June 14, 2024.",61.76M
Add to portfolio,,,,,,,,
AMGN,Amgen Inc.,$296.54 ,BLINCYTO,CD19-positive Philadelphia chromosome-negative B-cell precursor acute lymphoblastic leukemia (B-ALL) ,Approved,14/06/2024 ET,"Approved June 14, 2024.",538.36M
Add to portfolio,,,,,,,,
GLPG,Galapagos NV,$25.44 ,GLPG5101 - (ATALANTA-1),Relapsed/refractory Non-Hodgkin Lymphoma (rrNHL) ,Phase 1/2,14/06/2024 ET,"Phase 1/2 data presented at EHA reported that 14 of 16 efficacy-evaluable patients responded to treatment (objective response rate, ORR 87.5%), with 12 patients achieving a complete response (CR), not … read more",65.9M
Add to portfolio,,,RMAT,,,,,
INAB,IN8bio Inc.,$1.09 ,INB-100,"Allogeneic hematopoietic stem cell transplantation (HSCT), leukemias undergoing haploidentical stem cell transplantation ",Phase 1b,15/06/2024 ET,"Phase 1b data reported that 100% of treated leukemia patients (n=10/10) achieved durable complete remission (CR) at 1-year, noted June 15, 2024.",4.54M
Add to portfolio,,,,,,,,
NRIX,Nurix Therapeutics Inc.,$15.29 ,NX-5948,B-cell malignancies / graft-versus-host disease ,Phase 1b,16/06/2024 ET,Phase 1a/1b data presented at EHA reported that treatment resulted in a robust objective response rate (ORR) of 69.2% across all doses tested with responses observed as early as the first scan (8 week … read more,76.88M
Add to portfolio,,,FTD,,,,,
FBIO,Fortress Biotech Inc.,$1.90 ,MB-106,Waldenstrom macroglobulinemia (WM) ,Phase 1/2,17/06/2024 ET,"Phase 1/2 data reported an overall response rate of 90% in cohort with durable responses observed; one patient remains in complete remission at 31 months, noted June 17, 2024.",29.75M
Add to portfolio,,,,,,,,
MBIO,Mustang Bio Inc.,$0.75 ,MB-106,Waldenstrom macroglobulinemia (WM) ,Phase 1/2,17/06/2024 ET,"Phase 1/2 data reported an overall response rate of 90% in cohort with durable responses observed; one patient remains in complete remission at 31 months, noted June 17, 2024.",7.24M
Add to portfolio,,,,,,,,
JBIO,Jade Biosciences Inc.,—,AV-101 - (IMPAHCT),Pulmonary arterial hypertension (PAH) ,Phase 2b,17/06/2024 ET,"Phase 2b trial did not meet its primary endpoint, noted June 17, 2024.",32.63M
Add to portfolio,,,View Clinical Trial Data,,,,,
EVAX,Evaxion A/S,$2.47 ,EVX-01 + KEYTRUDA (pembrolizumab) / OPDIVO (nivolumab),Metastatic Melanoma ,Phase 2,17/06/2024 ET,"Phase 2 data publication reported that eight out of 12 patients (67%) experienced objective clinical responses (ORR) with six partial and two complete responses, noted June 17, 2024.",6.32M
Add to portfolio,,,FTD,,,,,
MRK,Merck & Company Inc.,$126.67 ,EVX-01 + KEYTRUDA (pembrolizumab) / OPDIVO (nivolumab),Metastatic Melanoma ,Phase 2,17/06/2024 ET,"Phase 2 data publication reported that eight out of 12 patients (67%) experienced objective clinical responses (ORR) with six partial and two complete responses, noted June 17, 2024.",2.5B
Add to portfolio,,,FTD,,,,,
MIRM,Mirum Pharmaceuticals Inc.,$33.00 ,Volixibat - (VANTAGE),Pruritus associated with primary biliary cholangitis ,Phase 2b,17/06/2024 ET,"Phase 2b interim analysis demonstrated a statistically significant (-3.82, p<0.0001) improvement in pruritus for volixibat and a placebo-adjusted difference of -2.32 points in the primary endpoint, p= … read more",50.24M
Add to portfolio,,,,,,,,
ATNM,Actinium Pharmaceuticals Inc.,$7.93 ,Actimab-A with revumenib,Acute myeloid leukemia (AML) ,Preclinical,17/06/2024 ET,"Preclinical data reported potent in vitro AML cell killing activity in both MV-4-11 and MOLM-13 KMT2A mutant cell lines, compared to the non-radio conjugated CD33 antibody lintuzumab, noted June 17, 2 … read more",31.2M
Add to portfolio,,,,,,,,
SLRX,Salarius Pharmaceuticals Inc.,$3.48 ,Seclidemstat,Myelodysplastic Syndromes (MDS) and Chronic Myelomonocytic Leukemia (CMML) ,Phase 1/2,17/06/2024 ET,"Phase 1/2 data presented at EHA reported a 43% overall response rate among 14 predominantly higher risk myelodysplastic syndrome (MDS) and chronic myelomonocytic leukemia (CMML) patients, noted June 1 … read more",509.71K
Add to portfolio,,,,,,,,
ENLV,Enlivex Therapeutics Ltd.,$1.39 ,Allocetra - (ENX-CL-05-001),Knee osteoarthritis (OA) ,Phase 1/2,17/06/2024 ET,"Phase 1/2 data reported a substantial reduction (64%) in average reported pain was observed compared to baseline, with 89% (8/9) of treated patients reporting an improvement in their knee pain compare … read more",23.85M
Add to portfolio,,,,,,,,
AZN,AstraZeneca PLC,$78.82 ,"Calquence (acalabrutinib) with chemoimmunotherapy, bendamustine and rituximab - (ECHO)",Mantle cell lymphoma (MCL) ,Phase 3,17/06/2024 ET,"Phase 3 results reported a reduced the risk of disease progression or death by 27% compared to standard-of-care chemoimmunotherapy, noted June 17, 2024.",3.1B
Add to portfolio,,,,,,,,
RHHBY,Roche Holding AG ADR,$34.58 ,Columvi + GemOx - (STARGLO),2L+ Diffuse Large B-Cell Lymphoma (DLBCL) ,Phase 3,17/06/2024 ET,"Phase 3 data reported a 41% reduction in the risk of death, noted June 17, 2024.",6.36B
Add to portfolio,,,,,,,,
AGIO,Agios Pharmaceuticals Inc.,$42.59 ,PYRUKYND (Mitapivat) - (ENERGIZE),Thalassemia ,Phase 3,17/06/2024 ET,"Phase 3 data presented at EHA reported that 42.3% (n=55/130) of patients in the mitapivat arm achieved a hemoglobin response, compared to 1.6% (n=1/64) of patients in the placebo arm, noted June 17, 2 … read more",58.1M
Add to portfolio,,,View Clinical Trial Data,,,,,
JNJ,Johnson & Johnson,$144.85 ,Nipocalimab - (DAHLIAS),Sjögren's disease (SjD) ,Phase 2,17/06/2024 ET,"Phase 2 data reported that greater than 70 percent relative average improvement on the primary endpoint compared to patients who received placebo, noted June 17, 2024.",2.41B
Add to portfolio,,,BTD,,,,,
MRK,Merck & Company Inc.,$126.67 ,KEYTRUDA (pembrolizumab) Plus Carboplatin and Paclitaxel,Endometrial carcinoma ,Approved,17/06/2024 ET,"Approved June 17, 2024.",2.5B
Add to portfolio,,,,,,,,
OVID,Ovid Therapeutics Inc.,$0.79 ,Soticlestat (TAK-935/OV935)- (Skyline),Dravet Syndrome / Lennox-Gastaut Syndrome ,Phase 3,17/06/2024 ET,"Phase 3 trial did not meet its primary endpoint, noted June 17, 2024.",71.11M
Add to portfolio,,,,,,,,
TAK,Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of),$13.17 ,Soticlestat (TAK-935/OV935)- (Skyline),Dravet Syndrome / Lennox-Gastaut Syndrome ,Phase 3,17/06/2024 ET,"Phase 3 trial did not meet its primary endpoint, noted June 17, 2024.",3.15B
Add to portfolio,,,,,,,,
AZN,AstraZeneca PLC,$78.82 ,Imfinzi (durvalumab) in combination with carboplatin and paclitaxel,Endometrial cancer (EC) ,Approved,17/06/2024 ET,"Approved June 17, 2024.",3.1B
Add to portfolio,,,,,,,,
LGND,Ligand Pharmaceuticals Incorporated,$80.64 ,ZTALMY (ganaxolone) - (RAISE),Refractory status epilepticus (RSE) ,Phase 3,17/06/2024 ET,Phase 3 topline data reported that it met its first co-primary endpoint demonstrating rapid cessation of status epilepticus in a highly refractory patient population but failed to achieve statistical … read more,19.6M
Add to portfolio,,,View Clinical Trial Data,,,,,
MRNS,Marinus Pharmaceuticals Inc.,$1.45 ,ZTALMY (ganaxolone) - (RAISE),Refractory status epilepticus (RSE) ,Phase 3,17/06/2024 ET,Phase 3 topline data reported that it met its first co-primary endpoint demonstrating rapid cessation of status epilepticus in a highly refractory patient population but failed to achieve statistical … read more,55.19M
Add to portfolio,,,View Clinical Trial Data,,,,,
ZNTL,Zentalis Pharmaceuticals Inc.,$4.14 ,Azenosertib (ZN-c3) - (TETON),Uterine serous carcinoma (USC) ,Phase 2,18/06/2024 ET,"Phase 2 placed on clinical hold due to 2 deaths in the DENALI study, noted June 18, 2024.",72.14M
Add to portfolio,,,FTD,,,,,
ZNTL,Zentalis Pharmaceuticals Inc.,$4.14 ,azenosertib (ZN-c3) + ZEJULA (Niraparib) - (DENALI),"Platinum Resistant High-Grade Serous Ovarian, Fallopian Tube or Primary Peritoneal Cancer ",Phase 2,18/06/2024 ET,"Phase 2 study placed in clinical hold after 2 recent deaths presumed sepsis in the study, noted June 18, 2024.",72.14M
Add to portfolio,,,FTD,,,,,
IMCR,Immunocore Holdings plc,$35.94 ,IMC-F106C (PRAME HLA-A02) with nivolumab - (PRISM-MEL-301),First-line advanced cutaneous melanoma trial ,Phase 3,18/06/2024 ET,"Phase 3 trial dosing initiated, noted June 18, 2024.",48.09M
Add to portfolio,,,,,,,,
AZN,AstraZeneca PLC,$77.94 ,Truqap - (CAPItello-290),Metastatic triple-negative breast cancer ,Phase 3,18/06/2024 ET,Phase 3 trial did not meet the dual primary endpoints of improvement in overall survival (OS) versus paclitaxel in combination with placebo in either the overall trial population or in a subgroup of p … read more,3.1B
Add to portfolio,,,,,,,,
PYPD,PolyPid Ltd.,$4.11 ,D-PLEX100 - (SHIELD II),Surgical Site Infection ,Phase 3,18/06/2024 ET,"Phase 3 enrollment update data presented showed that approximately 250/600 have been enrolled at KOL, noted June 18, 2024.",10.19M
Add to portfolio,,,View Clinical Trial Data,,,,,
JNJ,Johnson & Johnson,—,CAPLYTA (lumateperone) - (Study 502),Major depressive disorder (MDD) ,Phase 3,18/06/2024 ET,"Phase 3 topline results reported that the trial met the primary endpoint of change from baseline at Week 6 on the Montgomery-Åsberg Depression Rating Scale (MADRS) total score versus placebo, noted Ju … read more",2.41B
Add to portfolio,,,,,,,,
TSHA,Taysha Gene Therapies Inc.,$2.97 ,TSHA-102 - (REVEAL),Rett syndrome ,Phase 1/2,18/06/2024 ET,Phase 1/2 first cohort data presented at the 2024 IRSF Rett Syndrome Scientific Meeting Presentation reported sustained and new improvements across multiple efficacy measures and clinical domains foll … read more,272.79M
Add to portfolio,,,FTD,,,,,
,,,ODD,,,,,
,,,RPDD,,,,,
,,,RMAT,,,,,
,,,BTD,,,,,
CLNN,Clene Inc.,$7.60 ,CNM-Au8 - (HEALEY ALS),Amyotrophic Lateral Sclerosis (ALS) ,Phase 2/3,18/06/2024 ET,Phase 2 long term urvival analyses with CNM-Au8 30 mg treatment compared to matched PRO-ACT controls demonstrated improved survival up to 3.5 years post-baseline. Average of 28% NfL reduction observed … read more,9.99M
Add to portfolio,,,,,,,,
LGND,Ligand Pharmaceuticals Incorporated,$80.54 ,CAPVAXIVE (Pneumococcal 21-valent Conjugate Vaccine),Pneumococcal conjugate vaccine ,Approved,18/06/2024 ET,"Approved June 18, 2024.",19.6M
Add to portfolio,,,BTD,,,,,
MRK,Merck & Company Inc.,$127.16 ,CAPVAXIVE (Pneumococcal 21-valent Conjugate Vaccine),Pneumococcal conjugate vaccine ,Approved,18/06/2024 ET,"Approved June 18, 2024.",2.5B
Add to portfolio,,,BTD,,,,,
ERAS,Erasca Inc.,$2.04 ,Naporafenib plus trametinib (SEACRAFT-2),NRASm melanoma ,Phase 3,18/06/2024 ET,"Phase 3 trial ongoing with favorable mOS and mPFS demonstrated in pooled analysis of Phase 1b and Phase 2 trials in NRASm melanoma, noted June 18, 2024.",283.67M
Add to portfolio,,,FTD,,,,,
ASMB,Assembly Biosciences Inc.,$14.88 ,ABI-4334,Hepatitis B ,Phase 1b,18/06/2024 ET,"Phase 1b dosing initiated, noted June 18, 2024.",7.67M
Add to portfolio,,,,,,,,
RLMD,Relmada Therapeutics Inc.,$3.03 ,REL-1017 - (RELIANCE I),Major depressive disorder (MDD) ,Phase 3,18/06/2024 ET,"Phase 3 data published at The Journal of Clinical Psychiatry showed that overall results from this trial are clearly consistent with the evidence, produced by the prior phase 2 trial, noted June 18, … read more",33.19M
Add to portfolio,,,View Clinical Trial Data,,,,,
CGON,"CG Oncology, Inc.",$33.89 ,cretostimogene - (PIVOT-006) (EAP),Non-Muscle Invasive Bladder Cancer (NMIBC) ,Phase 3,18/06/2024 ET,"Phase 3 data presented at AUA on May 5, 2024. Phase 3 EAP dosing commenced, noted June 18, 2024.",76.25M
Add to portfolio,,,,,,,,
NGNE,Neurogene Inc.,$30.32 ,NGN-401 - (Embolden),Rett Syndrome ,Phase 1/2,18/06/2024 ET,"Phase 1/2 trial presented at the IRSF ASCEND 2024 Rett Syndrome National Summit showed that high-dose has been well-tolerated, and low-dose continues to show a favorable safety profile, the company al … read more",14.27M
Add to portfolio,,,RMAT,,,,,
XBIT,XBiotech Inc.,$5.26 ,Natrunix (XB2001) - (1-BETTER),Pancreatic Cancer ,Phase 1/2,18/06/2024 ET,"Phase 1/2 data in the 65-subject Phase 2 portion, the Natrunix arm showed fewer overall adverse events, a 28% reduction in serious adverse events, 33% less hospitalization days, and improved symptoms … read more",30.49M
Add to portfolio,,,,,,,,
ABBV,AbbVie Inc.,$168.43 ,SKYRIZI (risankizumab) - (COMMAND),Ulcerative Colitis ,Approved,18/06/2024 ET,"FDA Approval on June 18, 2024.",1.77B
Add to portfolio,,,,,,,,
LXRX,Lexicon Pharmaceuticals Inc.,$1.75 ,LX9211 - (RELIEF-DPN 1),Diabetic Peripheral Neuropathy ,Phase 2,19/06/2024 ET,"Phase 2 data demonstrated clinically significant benefits for people with diabetic peripheral neuropathic pain (DPNP), noted June 19, 2024.",363.4M
Add to portfolio,,,FTD,,,,,
,,,View Clinical Trial Data,,,,,
VSTM,Verastem Inc.,$3.27 ,GFH375/VS-7375,Cancer KRAS G12D ,IND-Enabling,19/06/2024 ET,"IND approved in China, noted June 19, 2024.",61.55M
Add to portfolio,,,,,,,,
RHHBY,Roche Holding AG ADR,$35.22 ,Amezalpat (TPST-1120) with atezolizumab and bevacizumab - (TPST-1120-301),Hepatocellular carcinoma (HCC) ,Phase 1/2,20/06/2024 ET,"Phase 1b/2 study data presented at webcast demonstrated improvements across all efficacy endpoints compared to the standard of care control arm, noted June 20, 2024.",6.36B
Add to portfolio,,,FTD,,,,,
TPST,Tempest Therapeutics Inc.,$2.01 ,Amezalpat (TPST-1120) with atezolizumab and bevacizumab - (TPST-1120-301),Hepatocellular carcinoma (HCC) ,Phase 1/2,20/06/2024 ET,"Phase 1b/2 study data presented at webcast demonstrated improvements across all efficacy endpoints compared to the standard of care control arm, noted June 20, 2024.",4.44M
Add to portfolio,,,FTD,,,,,
ALLO,Allogene Therapeutics Inc.,$2.44 ,Cemacabtagene ansegedleucel (cema-cel) (ALPHA3),Large B-Cell Lymphoma (LBCL) ,Phase 2,20/06/2024 ET,"Phase 2 pivotal trial initiated, noted June 20, 2024.",221.88M
Add to portfolio,,,,,,,,
PTCT,PTC Therapeutics Inc.,$33.29 ,PTC518 - (PIVOT-HD),Huntington's disease ,Phase 2,20/06/2024 ET,"Phase 2 partial hold lifted by the FDA, additionally at Month 12, PTC518 treatment resulted in dose-dependent lowering of mutant huntingtin (mHTT) protein in the blood and cerebrospinal fluid (CSF) in … read more",79.44M
Add to portfolio,,,FTD,,,,,
OCGN,"Ocugen, Inc.",$1.29 ,OCU400-101 - (LiMeliGhT),Retinitis Pigmentosa (RP) ,Phase 3,20/06/2024 ET,"Phase 3 dosing inited, noted June 20, 2024.",292.3M
Add to portfolio,,,ODD,,,,,
,,,RMAT,,,,,
NNVC,NanoViricides Inc.,$2.03 ,NV-387,"Influenza A viruses, Bird Flu H5N1 ",Preclinical,20/06/2024 ET,"Preclinical data presented resulted in significant reduction in lung infiltration and lung cell death, noted June 20, 2024.",17.43M
Add to portfolio,,,,,,,,
ATAI,ATAI Life Sciences N.V.,$1.33 ,ELE-101,Major Depressive Disorder (MDD) ,Phase 1/2,20/06/2024 ET,"Phase 1/2a preliminary data from Phase 1, involving healthy participants, showed ELE-101 was well-tolerated with no serious adverse events, demonstrating a dose-proportional PK profile and inducing sh … read more",214.34M
Add to portfolio,,,,,,,,
TRVN,Trevena Inc.,$6.15 ,TRV045,Epilepsy and other CNS disorders ,Preclinical,20/06/2024 ET,"Preclinical data demonstrated statistically significant, dose-dependent increases in seizure threshold and protection against induced seizures. While not statistically significant, preliminary data pr … read more",863.79K
Add to portfolio,,,,,,,,
TRVN,Trevena Inc.,$6.15 ,TRV045,Diabetic neuropathic pain (DNP) ,Preclinical,20/06/2024 ET,"Preclinical data showed sustained analgesic effects without causing S1P1 receptor desensitization or downregulation, unlike fingolimod, suggesting potential for long-term pain relief without tolerance … read more",863.79K
Add to portfolio,,,,,,,,
KYTX,Kyverna Therapeutics Inc.,$8.03 ,KYV-101 - (KYSA-8),Stiff-person syndrome (SPS) ,IND-Enabling,20/06/2024 ET,"IND cleared by the FDA, noted June 20, 2024.",43.25M
Add to portfolio,,,RMAT,,,,,
GILD,Gilead Sciences Inc.,$67.86 ,Yeztugo (Lenacapavir),HIV PrEP – Pre-exposure prophylaxis ,Phase 3,20/06/2024 ET,"Phase 3 trial indicated that twice-yearly injectable HIV-1 capsid inhibitor, lenacapavir, demonstrated 100% efficacy for the investigational use of HIV prevention in cisgender women, noted June 20, 20 … read more",1.24B
Add to portfolio,,,,,,,,
JNJ,Johnson & Johnson,$146.66 ,TREMFYA (Guselkumab) - (QUASAR),Crohn's disease ,NDA Filing,20/06/2024 ET,"NDA submitted to FDA, noted June 20, 2024.",2.41B
Add to portfolio,,,View Clinical Trial Data,,,,,
NVS,Novartis AG,$105.74 ,TREMFYA (Guselkumab) - (QUASAR),Crohn's disease ,NDA Filing,20/06/2024 ET,"NDA submitted to FDA, noted June 20, 2024.",1.98B
Add to portfolio,,,View Clinical Trial Data,,,,,
MNMD,Mind Medicine (MindMed) Inc.,$7.25 ,MM120 - (Voyage),Generalized Anxiety Disorder (GAD) ,Phase 2,20/06/2024 ET,"EOP2 meeting was supported by results from MindMed's completed Phase 2b clinical trial, MMED008. MM120 met its primary and key secondary endpoints and demonstrated a rapid, clinically meaningful, and … read more",75.55M
Add to portfolio,,,,,,,,
JAZZ,Jazz Pharmaceuticals plc,$107.36 ,Suvecaltamide - (JZP-385),Essential Tremor (ET) ,Phase 2b,20/06/2024 ET,"Phase 2b trial did not meet primary endpoint, noted June 20, 2024.",60.66M
Add to portfolio,,,View Clinical Trial Data,,,,,
RHHBY,Roche Holding AG ADR,$35.59 ,ELEVIDYS (SRP-9001-301) - (EMBARK),Duchenne muscular dystrophy ,Approved,21/06/2024 ET,"FDA Approved on June 21, 2024.",6.36B
Add to portfolio,,,FTD,,,,,
SRPT,Sarepta Therapeutics Inc.,$160.72 ,ELEVIDYS (SRP-9001-301) - (EMBARK),Duchenne muscular dystrophy ,Approved,21/06/2024 ET,"FDA Approved on June 21, 2024.",97.71M
Add to portfolio,,,FTD,,,,,
LXRX,Lexicon Pharmaceuticals Inc.,$1.85 ,Zynquista (sotagliflozin),Type 1 Diabetes and chronic kidney disease (CKD) ,NDA Filing,21/06/2024 ET,"NDA resubmitted to FDA, noted June 21, 2024.",363.4M
Add to portfolio,,,,,,,,
VRTX,Vertex Pharmaceuticals Incorporated,$468.71 ,Zimislecel (VX-880),Type 1 Diabetes ,Phase 1/2,21/06/2024 ET,"Phase 1/2 new data showed that all 12 patients who received the full dose showed islet cell engraftment and insulin production by Day 90, with improved glycemic control and reduced or eliminated insul … read more",256.39M
Add to portfolio,,,,,,,,
LLY,Eli Lilly and Company,$882.65 ,Zepbound (Tirzepatide) - (SURMOUNT-OSA),Obstructive Sleep Apnea (OSA) ,Phase 3,21/06/2024 ET,Phase 3 trial data presented at ADA showed that tirzepatide achieved all primary and key secondary endpoints for both the efficacyi and treatment-regimenii estimands and demonstrated a mean reduction … read more,946.46M
Add to portfolio,,,FTD,,,,,
ARGX,argenx SE,$394.47 ,VYVGART Efgartigimod (ARGX-113) and Enhanze - (ADHERE),Chronic inflammatory demyelinating polyneuropathy ,Approved,21/06/2024 ET,"FDA approved on June 21, 2024.",60.99M
Add to portfolio,,,View Clinical Trial Data,,,,,
BMY,Bristol-Myers Squibb Company,$40.85 ,KRAZATI (adagrasib) - (KRYSTAL-1),Non-Small Cell Lung Cancer / Colorectal Cancer ,Approved,21/06/2024 ET,"FDA approved on June 21, 2024.",2.04B
Add to portfolio,,,BTD,,,,,
CLNN,Clene Inc.,$7.93 ,CNM-Au8,Rett Syndrome ,Preclinical,21/06/2024 ET,"Preclinical data demonstrated neuroprotective effects in an in vitro model of Rett Syndrome, noted June 21, 2024.",9.99M
Add to portfolio,,,,,,,,
ARVN,Arvinas Inc.,$25.22 ,ARV-393,B-cell lymphoma ,Preclinical,21/06/2024 ET,"Preclinical data for ARV-393 presented at the EHA 2024 Annual Congress showed anti-tumor activity in models, noted June 21, 2024.",73.42M
Add to portfolio,,,,,,,,
JNJ,Johnson & Johnson,$147.63 ,PX-128,severe atopic dermatitis (AD) ,Preclinical,21/06/2024 ET,"Preclinical asset acquired by JNJ from Proteologix, noted June 21, 2024.",2.41B
Add to portfolio,,,,,,,,
JNJ,Johnson & Johnson,$147.63 ,PX-130,Asthma ,Preclinical,21/06/2024 ET,"Preclinical asset acquired by JNJ from Proteologix, noted June 21, 2024.",2.41B
Add to portfolio,,,,,,,,
MTVA,MetaVia Inc.,—,DA-1726,NASH and obesity ,Preclinical,22/06/2024 ET,"Preclinical data presented at ADA shown to be superior compared to tirzepatide, noted June 22, 2024.",24.2M
Add to portfolio,,,,,,,,
MNKD,MannKind Corporation,$5.11 ,Afrezza Combined With Insulin Degludec - (INHALE-3),Type 1 Diabetes ,Phase 3,22/06/2024 ET,"Data presented at ADA proves inhaled insulin is as effective as usual care for adults living with T1D meeting the primary endpoint, noted June 22, 2024.",306.83M
Add to portfolio,,,,,,,,
XOMA,XOMA Royalty Corporation,$24.45 ,Mezagitamab (TAK-079) - (TAK-079-1004),Primary Immune Thrombocytopenia ,Phase 2b,22/06/2024 ET,"Phase 2b data presented at ISTH showed rapid and sustained increases in platelet counts that persisted 8 weeks after the last dose through to week 16, noted June 22, 2024.",12.09M
Add to portfolio,,,,,,,,
TAK,Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of),$12.60 ,Mezagitamab (TAK-079) - (TAK-079-1004),Primary Immune Thrombocytopenia ,Phase 2b,22/06/2024 ET,"Phase 2b data presented at ISTH showed rapid and sustained increases in platelet counts that persisted 8 weeks after the last dose through to week 16, noted June 22, 2024.",3.15B
Add to portfolio,,,,,,,,
ALT,Altimmune Inc.,$7.14 ,Pemvidutide - (MOMENTUM),"Non-alcoholic steatohepatitis (NASH)/ (MASH) - Healthy, Overweight and Obese Volunteers ",Phase 2,23/06/2024 ET,"Phase 2 data presented at ADA highlights the impressive lean mass preservation achieved with pemvidutide. Only 21.9% of weight loss is attributable to lean mass, noted June 23, 2024.",88.26M
Add to portfolio,,,FTD,,,,,
,,,View Clinical Trial Data,,,,,
NVO,Novo Nordisk A/S,$141.74 ,Mim8 - (FRONTIER2),Hemophilia A ,Phase 3,23/06/2024 ET,"Phase 3 data presented at ISTH 2024 showed that up to 95% of people, who had no prior prophylaxis treatment, experienced zero treated bleeds while on Mim8, noted JUne 23, 2024.",4.47B
Add to portfolio,,,,,,,,
GUTS,"Fractyl Health, Inc.",$4.77 ,Rejuva (RJVA-001),Obesity and type 2 diabetes (T2D) ,Preclinical,23/06/2024 ET,Preclinical data presented at ADA showed that a single administration of Rejuva reduced fat mass and improved glycemia in the well-validated diet-induced obesity (DIO) mouse model. Rejuva also prevent … read more,50.29M
Add to portfolio,,,,,,,,
TERN,Terns Pharmaceuticals Inc.,$7.52 ,TERN-501 + semaglutide,Obesity ,Preclinical,23/06/2024 ET,"Preclinical study presented at ADA showed that in mice fed a high fat diet for 24 weeks prior to study start. Obese mice were treated once daily with vehicle, TERN-501, semaglutide, TERN-501+semagluti … read more",87.51M
Add to portfolio,,,,,,,,
NVS,Novartis AG,—,Farabursen (RGLS8429) (MAD),Autosomal Dominant Polycystic Kidney Disease (ADPKD) ,Phase 1b,24/06/2024 ET,"Phase 1b data from cohort 3 in the 3 mg/kg dose showed a continued mechanistic dose response, with statistically significant increases in urinary PC1 and PC2 compared to placebo, noted June 24, 2024.",1.98B
Add to portfolio,,,ODD,,,,,
BNTX,BioNTech SE,$86.61 ,BNT324/DB-1311,Solid tumors ,Phase 1/2,24/06/2024 ET,"Phase 1/2 trial ongoing. Fast track designation granted by the FDA on June 24, 2024.",239.97M
Add to portfolio,,,FTD,,,,,
ALNY,Alnylam Pharmaceuticals Inc.,$222.90 ,AMVUTTRA (vutrisiran),ATTR Amyloidosis with Cardiomyopathy (ATTR-CM) ,Phase 3,24/06/2024 ET,"Phase 3 topline data reported that study met the main goal in a late-stage study testing it as a treatment for a type of heart disease, noted June 24, 2024.",131.08M
Add to portfolio,,,View Clinical Trial Data,,,,,
DYN,Dyne Therapeutics Inc.,$35.63 ,FORCE platform,Pompe Disease ,Preclinical,24/06/2024 ET,Preclinical data presented at the New Directions in Biology and Disease of Skeletal Muscle Conference showed that for the first time the ability of FORCE to deliver enzymes to skeletal and cardiac mu … read more,142.26M
Add to portfolio,,,,,,,,
RGNX,REGENXBIO Inc.,$12.79 ,RGX-202 - (AFFINITY DUCHENNE),Duchenne Muscular Dystrophy (DMD) ,Phase 1/2,24/06/2024 ET,"The phase 1/2 expansion trial was initiated, noted June 24, 2024",50.51M
Add to portfolio,,,ODD,,,,,
,,,FTD,,,,,
PBLA,Panbela Therapeutics Inc.,$0.39 ,SBP-101 in combination with Gemcitabine and Nab-Paclitaxel - (ASPIRE),Pancreatic Ductal Adenocarcinoma (PDA) ,Phase 2/3,24/06/2024 ET,"Phase 2/3 DSMB recommended to proceed without modification affirms support for ivospemin's safety profile, noted June 24, 2024.",4.85M
Add to portfolio,,,,,,,,
FDMT,4D Molecular Therapeutics Inc.,$23.25 ,4D-175 - (GAZE),Geographic Atrophy ,IND-Enabling,24/06/2024 ET,"The IND cleared by the FDA on June 24, 2024",46.7M
Add to portfolio,,,,,,,,
REVB,Revelation Biosciences Inc.,$2.40 ,RVL-HV02 - (Gemini),Healthy volunteers ,Phase 1,24/06/2024 ET,"Phase 1 top-line data of gemini administration induced statistically significant, dose dependent changes in key biomarkers of activity, noted June 24, 2024.",1.7M
Add to portfolio,,,,,,,,
MTNB,Matinas Biopharma Holdings Inc.,$8.21 ,Oral amphotericin b (MAT2203) - (EnACT),Cryptococcal meningitis ,Phase 3,24/06/2024 ET,"Phase 3 reported the successful treatment of a 22-year-old male with polymicrobial necrotizing fasciitis using MAT2203, their oral formulation of amphotericin B. The patient was discharged after six w … read more",5.09M
Add to portfolio,,,,,,,,
VERU,Veru Inc.,$0.85 ,Enobosarm with semaglutide (Wegovy) - (PLATEAU),Obesity ,Phase 2b,24/06/2024 ET,"Phase 2b showed it was well-tolerated across 1,027 patients, with an adverse event profile comparable to placebo, noted June 24, 2024.",14.65M
Add to portfolio,,,,,,,,
BDRX,Biodexa Pharmaceuticals plc,$22.36 ,"eRapa (rapamycin, sirolimus) - (Serenta)",Familial Adenomatous Polyposis (FAP) ,Phase 2,24/06/2024 ET,Phase 2 data presented at Bi-Annual In-SIGHT ppeared safe and well-tolerated with a median 17% reduction in the total polyp burden at 12 months compared with baseline and an overall 75% non-progressio … read more,505.06K
Add to portfolio,,,FTD,,,,,
,,,ODD,,,,,
MIRA,MIRA Pharmaceuticals Inc.,$0.71 ,Ketamir-2,"Treatment-resistant depression (TRD), major depressive disorder with suicidal ideation (MDSI) and post-traumatic stress disorder (PTSD) ",Preclinical,24/06/2024 ET,"Additional preclinical studies suggest that, unlike traditional ketamine, MIRA's oral ketamine analog Ketamir-2 does not induce hyper-locomotor activity, indicative of psychotic symptoms, offering the … read more",19.07M
Add to portfolio,,,,,,,,
FBIO,Fortress Biotech Inc.,$1.70 ,UNLOXCYT (cosibelimab-ipdl),Cutaneous squamous cell carcinoma (CSCC) ,BLA Filing,24/06/2024 ET,"The company reached alignment with FDA for BLA resubmission, noted June 24, 2024.",29.75M
Add to portfolio,,,,,,,,
CKPT,Checkpoint Therapeutics Inc.,$2.08 ,UNLOXCYT (cosibelimab-ipdl),Cutaneous squamous cell carcinoma (CSCC) ,BLA Filing,24/06/2024 ET,"The company reached alignment with FDA for BLA resubmission, noted June 24, 2024.",87.02M
Add to portfolio,,,,,,,,
HRMY,Harmony Biosciences Holdings Inc.,$30.10 ,WAKIX (pitolisant),Excessive daytime sleepiness (EDS) or cataplexy in pediatric patients 6 years of age and older with narcolepsy ,Approved,24/06/2024 ET,"FDA Approved on June 24, 2024.",57.53M
Add to portfolio,,,,,,,,
CANF,Can-Fite Biopharma Ltd Sponsored ADR (Israel),$2.87 ,Namodenoson (CF102),"Advanced liver cancer, hepatocellular carcinoma ",Phase 3,24/06/2024 ET,"Additional data showed that the anti-cancer and protective effects in the liver are conferred via the signaling protein adiponectin, noted June 24, 2024.",10.35M
Add to portfolio,,,FTD,,,,,
,,,ODD,,,,,
ACET,Adicet Bio Inc.,$1.50 ,ADI-270,"Solid tumors CAR T, relapsed/refractory renal cell carcinoma (RCC) ",IND-Enabling,24/06/2024 ET,"IND cleared by the FDA, noted June 24, 2024.",83.25M
Add to portfolio,,,FTD,,,,,
NNVC,NanoViricides Inc.,$1.92 ,NV-387,"Influenza A viruses, Bird Flu H5N1 ",Preclinical,24/06/2024 ET,"Preclinical data recently found that its host-mimetic clinical drug candidate NV-387 was substantially superior to the three approved drugs against influenza, noted June 24, 2024.",17.43M
Add to portfolio,,,,,,,,
DARE,Dare Bioscience Inc.,$5.32 ,"Sildenafil Cream, 3.6% - (RESPOND)",Female Sexual Arousal Disorder (FSAD) ,Phase 2b,24/06/2024 ET,"Phase 2b study demonstrated topical Sildenafil Cream, 3.6% improved outcomes among women with female sexual arousal disorder (FSAD), particularly in an exploratory subset of women with FSAD with or wi … read more",13.48M
Add to portfolio,,,,,,,,
SRRK,Scholar Rock Holding Corporation,$8.41 ,SRK-439 with apitegromab - (EMBRAZE),Obesity ,Preclinical,24/06/2024 ET,"Preclinical data presented at ADA support the potential of SRK-439 to increase lean mass and contribute to a favorable body composition following withdrawal from GLP-1 RA treatment, noted June 24, 202 … read more",96.13M
Add to portfolio,,,,,,,,
KURA,Kura Oncology Inc.,$21.08 ,Ziftomenib,Type 2 diabetes ,Preclinical,24/06/2024 ET,"Preclinical data presented at ADA showed that treatment induces insulin production, improves insulin sensitivity and reduces insulin resistance in preclinical model of type 2 diabetes, noted June 24, … read more",86.8M
Add to portfolio,,,,,,,,
ANIX,Anixa Biosciences Inc.,$2.50 ,Chimeric endocrine receptor T-cell (CER-T),Ovarian Cancer ,Phase 1,24/06/2024 ET,"Phase 1 trial six patient treated, this patient is expected to be the final patient in the second dosage cohort of the trial, noted June 24, 2024.",32.92M
Add to portfolio,,,,,,,,
ARWR,Arrowhead Pharmaceuticals Inc.,$27.24 ,ARO-INHBE,Obesity ,Preclinical,24/06/2024 ET,"Preclinical results demonstrate that ARO-INHBE substantially silenced hepatic expression of the INHBE gene, which has been identified through large genetic studies as a promising target for next gener … read more",138.26M
Add to portfolio,,,,,,,,
ASND,Ascendis Pharma A/S,$129.39 ,TransCon CNP - (ACcomplisH),Achondroplasia ,Phase 2,24/06/2024 ET,Phase 2 data based on children 2 to 10 years old showed that patients treated for one year at the pivotal 100μg/kg/week dose demonstrated significant improvements in well-being and physical functionin … read more,60.69M
Add to portfolio,,,,,,,,
SGMO,Sangamo Therapeutics Inc.,—,Civaparvovec (ST-920) - (STAAR),Fabry disease ,Phase 1/2,24/06/2024 ET,"Phase 1/2 data announced that following a single dose of isaralgagene civoparvovec, a positive mean annualized eGFR slope of 1.965 mL/min/1.73m2/year (95% confidence interval (CI): -0.153, 4.083) at 5 … read more",301.71M
Add to portfolio,,,FTD,,,,,
,,,ODD,,,,,
AZN,AstraZeneca PLC,$79.26 ,Imfinzi (durvalumab) - (ADJUVANT BR.31),Early-stage (IB-IIIA) non-small cell lung cancer (NSCLC) ,Phase 3,25/06/2024 ET,"Phase 3 trial did not meet statistical significance for the primary endpoint of disease-free survival (DFS) versus placebo, noted June 25, 2024.",3.1B
Add to portfolio,,,,,,,,
AZN,AstraZeneca PLC,$79.26 ,IMFINZI (durvalumab),Muscle-invasive bladder cancer (MIBC) ,Phase 3,25/06/2024 ET,"Phase 3 trial demonstrated a statistically significant and clinically meaningful improvement in the primary endpoint, noted June 25, 2024.",3.1B
Add to portfolio,,,,,,,,
QNCX,Quince Therapeutics Inc.,$0.69 ,EryDex - (NEAT),Ataxia-Telangiectasia (A-T) ,Phase 3,25/06/2024 ET,"Phase 3 dosing initiated, noted June 25, 2024.",53.71M
Add to portfolio,,,FTD,,,,,
HOWL,Werewolf Therapeutics Inc.,$2.34 ,WTX-330,Solid tumors ,Phase 1,25/06/2024 ET,"Phase 1 preliminary dose-escalation data showed improved tolerability over historical IL-12 treatments, with early signs of efficacy including a partial response in a melanoma patient and stable disea … read more",45.73M
Add to portfolio,,,,,,,,
SNGX,Soligenix Inc.,$2.65 ,HyBryte vs Valchlor,Cutaneous T-cell lymphoma (CTCL) ,Phase 3,25/06/2024 ET,"Phase 3 data reported that treatment resulted in 60% of patients achieving a 50% or better improvement in their mCAILS score versus 20% of Valchlor, noted June 25, 2024.",4.29M
Add to portfolio,,,,,,,,
UNCY,Unicycive Therapeutics Inc.,$0.50 ,Oxylanthanum Carbonate (OLC),Kidney disease ,Phase 3,25/06/2024 ET,"Pivotal trial data reported that there was only 1 discontinuation due to a treatment-related AE in the Evaluable Population (n=71), a rate of 1.4%. In the full Safety Population, a total of 3 patients … read more",17.66M
Add to portfolio,,,,,,,,
WVE,Wave Life Sciences Ltd.,$4.77 ,WVE-003 - (SELECT-HD),Huntington’s disease ,Phase 1/2,25/06/2024 ET,"Phase 1b/2a data reported a 46% mean reduction in CSF mutant huntingtin (mHTT) protein compared to placebo, preservation of wild-type huntingtin (wtHTT) protein, and generally safe and well-tolerated … read more",159.14M
Add to portfolio,,,,,,,,
BTAI,BioXcel Therapeutics Inc.,$1.18 ,Dexmedetomidine (BXCL501) - (TRANQUILITY III),Agitation associated with Alzheimer’s Disease ,Phase 3,25/06/2024 ET,"Phase 3 data showed no evidence of tachyphylaxis, tolerance, or withdrawal with the 180 mcg dose over seven days of as-needed treatment. Efficacy measures indicated reduced agitation across episodes, … read more",14.56M
Add to portfolio,,,BTD,,,,,
IONS,Ionis Pharmaceuticals Inc.,$47.00 ,TRYNGOLZA (olezarsen),Familial Chylomicronemia Syndrome (FCS) ,Phase 3,25/06/2024 ET,"PDUFA PR date set for December 19, 2024",159.39M
Add to portfolio,,,ODD,,,,,
,,,View Clinical Trial Data,,,,,
ALLR,Allarity Therapeutics Inc.,$6.24 ,Stenoparib,Advanced ovarian cancer (AOC) ,Phase 2,25/06/2024 ET,"Additional Phase 2 data reported that multiple patients have now exceeded 30 weeks on treatment, noted June 25, 2024.",14.62M
Add to portfolio,,,FTD,,,,,
ABBV,AbbVie Inc.,$167.83 ,VYALEV (foscarbidopa and foslevodopa),Parkinson's disease ,CRL,25/06/2024 ET,"CRL issued June 25, 2024.",1.77B
Add to portfolio,,,,,,,,
AQST,Aquestive Therapeutics Inc.,$2.31 ,Anaphylm (AQST-109) - (EPIPHAST II),Allergic reactions (anaphylaxis) ,Phase 2,25/06/2024 ET,"PK data reported that results were unaffected by oral cavity exposure to liquids of different temperatures and pH, noted June 25, 2024.",99.72M
Add to portfolio,,,FTD,,,,,
LPCN,Lipocine Inc.,$8.15 ,LPCN 1154,Postpartum Depression ,Phase 3,25/06/2024 ET,"Pivotal trial topline results reported that the trial met its standard bioequivalence (BE) criteria, noted June 25, 2024.",5.42M
Add to portfolio,,,,,,,,
TVGN,Tevogen Bio Holdings Inc.,$0.70 ,TVGN 489 - (TCTL Study),Cytotoxic T Lymphocytes for the Treatment of Elderly and High-Risk Patients with Covid-19 ,Phase 1,25/06/2024 ET,"Phase 1 data treatment was well-tolerated, with rapid viral elimination and no disease progression observed. Notably, donor-derived cells persisted for 6 months post-treatment, noted JUne 25, 2024.",196.71M
Add to portfolio,,,,,,,,
REGN,Regeneron Pharmaceuticals Inc.,"$1,071.19 ","Nexiguran ziclumeran (nex-z, NTLA-2001) - (MAGNITUDE)",Transthyretin amyloidosis (ATTR) ,Phase 1,25/06/2024 ET,"Phase 1 data presented at the Peripheral Nerve Society Annual Meeting showed that patients who initially received a low dose were given a follow-on 55 mg dose, resulting in a 90% median reduction in s … read more",105.1M
Add to portfolio,,,ODD,,,,,
,,,RMAT,,,,,
NTLA,Intellia Therapeutics Inc.,$24.00 ,"Nexiguran ziclumeran (nex-z, NTLA-2001) - (MAGNITUDE)",Transthyretin amyloidosis (ATTR) ,Phase 1,25/06/2024 ET,"Phase 1 data presented at the Peripheral Nerve Society Annual Meeting showed that patients who initially received a low dose were given a follow-on 55 mg dose, resulting in a 90% median reduction in s … read more",107.35M
Add to portfolio,,,ODD,,,,,
,,,RMAT,,,,,
ALLK,Allakos Inc.,$1.18 ,AK006 (IV),Chronic spontaneous urticaria (CSU) ,Phase 1,25/06/2024 ET,"Phase 1 data showed that intravenous AK006 was well-tolerated up to 720 mg doses, with no serious adverse events or discontinuations. The drug demonstrated dose-linear exposure, a 21-day half-life at … read more",90.38M
Add to portfolio,,,,,,,,
ARGX,argenx SE,$451.55 ,Empasiprubart (ARGX-117) - (ARDA),Multifocal motor neuropathy (MMN) ,Phase 2,25/06/2024 ET,"Phase 2 new data presented at PNS showed the potential for empasiprubart to drive functional improvement and reduce the risk of relapse for multifocal motor neuropathy (MMN) patients, as noted on June … read more",60.99M
Add to portfolio,,,,,,,,
ANNX,Annexon Inc.,$4.58 ,Tanruprubart (ANX005),Guillain-Barré Syndrome (GBS) ,Phase 3,25/06/2024 ET,"Phase 3 demonstrated faster and more complete recovery from week 1 through week 26 compared to placebo, with 2.5 times more ANX005-treated patients returning to a normal state by week 26. ANX005 show … read more",109.89M
Add to portfolio,,,View Clinical Trial Data,,,,,
SVRA,Savara Inc.,$3.84 ,MOLBREEVI (Molgradex) - (IMPALA-2),Autoimmune pulmonary alveolar proteinosis (aPAP) ,Phase 3,26/06/2024 ET,"Phase 3 data reported that the trial met its primary endpoint, noted June 26, 2024.",172.84M
Add to portfolio,,,View Clinical Trial Data,,,,,
LYEL,Lyell Immunopharma Inc.,$1.31 ,LYL797,Solid Tumors ,Preclinical,26/06/2024 ET,"Preclinical dose-dependent antitumor clinical activity in ROR1+ resulted in a 40% objective response rate and 60% clinical benefit rate at the highest dose cleared to date, IND submission completed, n … read more",19.21M
Add to portfolio,,,,,,,,
TLSA,Tiziana Life Sciences Ltd,$0.93 ,Foralumab (Intranasal),Alzheimer’s Disease ,Phase 1,26/06/2024 ET,"FDA has allowed intranasal foralumab to be used under an Expanded Access (EA) IND in its first patient with moderate Alzheimer's disease, noted June 26, 2024.",111.46M
Add to portfolio,,,,,,,,
NVO,Novo Nordisk A/S,$143.12 ,Ocedurenone - (CLARION-CKD),Chronic kidney disease ,Phase 3,26/06/2024 ET,"Phase 3 trial did not meet its primary endpoint, noted June 26, 2024.",4.47B
Add to portfolio,,,,,,,,
RPTX,Repare Therapeutics Inc.,$3.37 ,Lunresertib (RP-6306) w/ FOLFIRI - (MINOTAUR),Molecularly advanced solid tumors ,Phase 1,26/06/2024 ET,"Phase 1 data presented at ESMO GI reported an overall response (OR) across tumor types was 18.2% (n=33), including four confirmed and two unconfirmed partial responses (PR), noted June 26, 2024.",42.96M
Add to portfolio,,,,,,,,
LGND,Ligand Pharmaceuticals Incorporated,$77.82 ,Ohtuvayre (ensifentrine),Chronic obstructive pulmonary disease (COPD) ,Approved,26/06/2024 ET,"Approved June 26, 2024.",19.6M
Add to portfolio,,,View Clinical Trial Data,,,,,
MRK,Merck & Company Inc.,—,Ohtuvayre (ensifentrine),Chronic obstructive pulmonary disease (COPD) ,Approved,26/06/2024 ET,"Approved June 26, 2024.",2.5B
Add to portfolio,,,View Clinical Trial Data,,,,,
MRK,Merck & Company Inc.,$128.98 ,MK-1022 (patritumab deruxtecan) - (HERTHENA-Lung02),EGFR-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC) ,CRL,27/06/2024 ET,"CRL announced June 27, 2024.",2.5B
Add to portfolio,,,BTD,,,,,
DSNKY,"Daiichi Sankyo Co., Ltd. ADR",$34.26 ,MK-1022 (patritumab deruxtecan) - (HERTHENA-Lung02),EGFR-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC) ,CRL,27/06/2024 ET,"CRL announced June 27, 2024.",1.92B
Add to portfolio,,,BTD,,,,,
ABBV,AbbVie Inc.,$166.10 ,EPKINLY (epcoritamab-bysp),Follicular lymphoma (FL) ,Approved,27/06/2024 ET,"Approved June 27, 2024.",1.77B
Add to portfolio,,,BTD,,,,,
GMAB,Genmab A/S,$25.58 ,EPKINLY (epcoritamab-bysp),Follicular lymphoma (FL) ,Approved,27/06/2024 ET,"Approved June 27, 2024.",661.87M
Add to portfolio,,,BTD,,,,,
XFOR,X4 Pharmaceuticals Inc.,$0.67 ,Mavorixafor (X4P-001),Severe Congenital Neutropenia (SCN) ,Phase 2,27/06/2024 ET,"Phase 2 data reported that 100% (6/6) of evaluable participants who had completed the six-month study achieved target ANC increase, noted June 27, 2024.",11.41M
Add to portfolio,,,,,,,,
ONCY,Oncolytics Biotech Inc.,$1.01 ,"Pelareorep, (Taxol) paclitaxel and BAVENCIO (avelumab) - (BRACELET-1)",HR+ / HER2- breast cancer ,Phase 2,27/06/2024 ET,"Company received productive feedback from its Type C meeting with FDA, supporting the planned potential registration-enabling trial for pelareorep, noted June 27, 2024.",100.36M
Add to portfolio,,,View Clinical Trial Data,,,,,
GLUE,Monte Rosa Therapeutics Inc.,$3.38 ,MRT-2359,MYC-driven solid tumors ,Phase 1/2,27/06/2024 ET,"Phase 1/2 demonstrates favorable safety and pharmacodynamic profile dosing 0.5 mg using a 21/7 schedule; currently assessing 0.75 mg dose level, noted June 27, 2024.",61.76M
Add to portfolio,,,ODD,,,,,
,,,FTD,,,,,
SLN,Silence Therapeutics Plc,$19.00 ,Divesiran (SLN124) - (SANRECO),Polycythemia Vera ,Phase 1,27/06/2024 ET,"Phase 1 data reported that of the 16 patients, 8 patients are considered well-controlled and 8 patients have HCT levels over 45% at baseline, noted June 27, 2024.",46.8M
Add to portfolio,,,FTD,,,,,
,,,ODD,,,,,
GLUE,Monte Rosa Therapeutics Inc.,$3.38 ,MRT-6160,Autoimmune conditions ,IND-Enabling,27/06/2024 ET,"IND submitted to FDA, noted June 27 2024.",61.76M
Add to portfolio,,,,,,,,
PPBT,Purple Biotech Ltd.,$8.75 ,CM24 and OPDIVO (nivolumab),2L metastatic pancreatic cancer (PDAC) ,Phase 2,27/06/2024 ET,"Phase 2 data reported serum MPO levels below the mean MPO and is associated with OS improvement of 3.6 months in median OS of 8.1 months vs. 4.5 month, noted June 27, 2024.",2.65M
Add to portfolio,,,,,,,,
PRFX,PainReform Ltd.,$2.99 ,PRF-110,Bunionectomy ,Phase 3,27/06/2024 ET,"Second part of Phase 3 trial enrollment completed, noted June 27, 2024",1.89M
Add to portfolio,,,,,,,,
CALC,CalciMedica Inc.,$3.15 ,Auxora - (CARPO),Acute Pancreatitis ,Phase 2b,27/06/2024 ET,Phase 2b data reported that the trial met with statistically significant dose response with up to 43.6% relative reduction (2.1 day improvement) in median time to solid food tolerance versus placebo i … read more,13.97M
Add to portfolio,,,,,,,,
NLSP,NLS Pharmaceutics Ltd.,$9.60 ,AEX-231,Parkinson's Disease ,Preclinical,27/06/2024 ET,"A preclinical study is planned after three compounds (AEX-23, AEX-19, and AEX-24) demonstrated potential benefits in improving neuronal connectivity, offering neuroprotection, and enhancing alpha-synu … read more",3.6M
Add to portfolio,,,,,,,,
NLSP,NLS Pharmaceutics Ltd.,$9.60 ,AEX-230,Parkinson's Disease ,Preclinical,27/06/2024 ET,"A preclinical study is planned after three compounds (AEX-23, AEX-19, and AEX-24) demonstrated potential benefits in improving neuronal connectivity, offering neuroprotection, and enhancing alpha-synu … read more",3.6M
Add to portfolio,,,,,,,,
GANX,Gain Therapeutics Inc.,$1.25 ,"GT-02287, GT-02329",GBA1 and Idiopathic Parkinson's Disease ,Preclinical,27/06/2024 ET,"Preclinical data to be shared at the FENS Forum 2024 showed that study focused on a mouse model of GBA1-Parkinson's disease, demonstrated improvements in cognitive performance and daily living activi … read more",35.95M
Add to portfolio,,,,,,,,
ELTX,Elicio Therapeutics Inc.,$6.89 ,ELI-002 - (AMPLIFY-7P),mKRAS-driven cancers ,Phase 1a,27/06/2024 ET,"Phase 1a data reported that the median disease-free survival (""mDFS"") has not been reached in patients receiving the 4.9mg AMP-peptide dose (n=8) vs. 12.6 weeks for patients receiving the 1.4mg AMP-pe … read more",16.34M
Add to portfolio,,,,,,,,
IMMP,Immutep Limited,$1.87 ,Eftilagimod alpha (IMP321) and KEYTRUDA (pembrolizumab) - (TACTI-003),Head and neck squamous cell carcinoma (HNSCC) ,Phase 2b,27/06/2024 ET,"Phase 2b data reported that combination with KEYTRUDA led to higher overall response rates in evaluable patients, noted June 27, 2024.",147.19M
Add to portfolio,,,View Clinical Trial Data,,,,,
RCKT,Rocket Pharmaceuticals Inc.,$21.53 ,KRESLADI (marnetegragene autotemcel),Leukocyte Adhesion Deficiency-I (LAD-I) ,CRL,28/06/2024 ET,"CRL issued June 28, 2024.",107.9M
Add to portfolio,,,,,,,,
MIRM,Mirum Pharmaceuticals Inc.,$34.19 ,Volixibat - (VISTAS),Primary sclerosing cholangitis ,Phase 2b,28/06/2024 ET,"Phase 2b interim analysis reported a 3.8 point reduction from baseline and 2.3 point placebo-adjusted (p=0.0026) reduction in primary endpoint of pruritus, noted June 28, 2024.",50.24M
Add to portfolio,,,BTD,,,,,
,,,View Clinical Trial Data,,,,,
AGEN,Agenus Inc.,$16.75 ,Neoadjuvant botensilimab plus balstilimab - (NEST-1),Colorectal cancer ,Phase 2,28/06/2024 ET,"Phase 2 data reported that in the NEST-2 cohort, 78% (7/9) of MSS patients achieved pathologic responses of at least 50% tumor regression, with 56% (5/9) reaching complete pathologic responses, noted … read more",31.86M
Add to portfolio,,,,,,,,
JNJ,Johnson & Johnson,$145.06 ,IMAAVY (Nipocalimab) - (Vivacity-MG3),Generalized myasthenia gravis (gMG) ,Phase 3,28/06/2024 ET,"Phase 3 data reported that patients receiving nipocalimab plus SOC improved by 4.70 points on the MG-ADL, significantly more than the 3.25 point improvement from baseline observed with placebo plus SO … read more",2.41B
Add to portfolio,,,,,,,,
OVID,Ovid Therapeutics Inc.,$0.86 ,OV888/GV101,Cerebral cavernous malformations (CCM) ,Phase 1,01/07/2024 ET,"Phase 1 data reported that the trial met its objective, demonstrating a favorable safety and tolerability profile with no serious adverse events, noted July 1, 2024.",71.11M
Add to portfolio,,,,,,,,
BIOR,Biora Therapeutics Inc.,$6.30 ,BT-600 + NaviCap Platform,Ulcerative Colitis (UC) ,Phase 1,01/07/2024 ET,"Phase 1 trial reported that treatment was well tolerated and met all trial objectives, noted July 1, 2024.",4.52M
Add to portfolio,,,,,,,,
NRSN,NeuroSense Therapeutics Ltd.,$1.08 ,PrimeC - (PARADIGM),Amyotrophic Lateral Sclerosis (ALS) ,Phase 2b,01/07/2024 ET,"Phase 2b 12-month clinical data showed a 36% slowing of disease progression in participants who received PrimeC for 12 months compared to those initially on placebo, as measured by the ALS Functional … read more",23.99M
Add to portfolio,,,,,,,,
TCON,TRACON Pharmaceuticals Inc.,$1.11 ,Envafolimab - (ENVASARC),Sarcomas ,Phase 3,01/07/2024 ET,Phase 3 study showed that the objective response rate by blinded independent central review in the fully enrolled ENVASARC pivotal trial in the 82 evaluable patients is 5% (four responders) and did no … read more,3.41M
Add to portfolio,,,ODD,,,,,
,,,FTD,,,,,
,,,View Clinical Trial Data,,,,,
LBPH,Longboard Pharmaceuticals Inc.,$30.92 ,Bexicaserin (LP352) - (DEEp OCEAN),Adolescent and adult patients with developmental and epileptic encephalopathies (DEEs) ,Phase 3,01/07/2024 ET,"Breakthrough Therapy designation granted by the FDA, noted July 1, 2024.",39.05M
Add to portfolio,,,BTD,,,,,
ARCT,Arcturus Therapeutics Holdings Inc.,$23.66 ,ARCT-810 - (LUNAR-OTC),Ornithine Transcarbamylase (OTC) deficiency ,Phase 2,01/07/2024 ET,"Phase 2 enrollment completed for the study in Europe at 0.3 mg/kg dose level, with data expected later this year. Expanding the Phase 2 program in the U.S. to include patients with more severe disease … read more",27.15M
Add to portfolio,,,,,,,,
ARCT,Arcturus Therapeutics Holdings Inc.,$23.66 ,ARCT-032 - (LUNAR-CF),Cystic Fibrosis ,Phase 1b,01/07/2024 ET,"Phase IND for multiple ascending dose study to be submitted in the next 60 days, noted July 1, 2024.",27.15M
Add to portfolio,,,RPDD,,,,,
,,,ODD,,,,,
GILD,Gilead Sciences Inc.,$68.01 ,HB-500,HIV ,Phase 1b,01/07/2024 ET,"Phase 1b study dosing initiated, noted July 1, 2024.",1.24B
Add to portfolio,,,,,,,,
HOOK,HOOKIPA Pharma Inc.,$6.28 ,HB-500,HIV ,Phase 1b,01/07/2024 ET,"Phase 1b study dosing initiated, noted July 1, 2024.",12.2M
Add to portfolio,,,,,,,,
RNAC,Cartesian Therapeutics Inc.,$15.77 ,Descartes-08 - (AURORA),"Generalized myasthenia gravis (MG), Multiple Myeloma and Autoimmune Diseases ",Phase 2b,02/07/2024 ET,"Phase 2b trial met primary endpoint with statistical significance, noted July 2, 2024.",26M
Add to portfolio,,,RMAT,,,,,
,,,ODD,,,,,
FBIO,Fortress Biotech Inc.,$1.67 ,UNLOXCYT (cosibelimab-ipdl),Cutaneous squamous cell carcinoma (CSCC) ,BLA Filing,02/07/2024 ET,"BLA Resubmission to FDA, noted July 2, 2024.",29.75M
Add to portfolio,,,,,,,,
CKPT,Checkpoint Therapeutics Inc.,$2.13 ,UNLOXCYT (cosibelimab-ipdl),Cutaneous squamous cell carcinoma (CSCC) ,BLA Filing,02/07/2024 ET,"BLA Resubmission to FDA, noted July 2, 2024.",87.02M
Add to portfolio,,,,,,,,
ANIP,ANI Pharmaceuticals Inc.,$62.64 ,"Naproxen Delayed-Release Tablets, USP.",Pain ,Approved,02/07/2024 ET,"FDA approval for ANDA, noted July 2, 2024.",21.7M
Add to portfolio,,,,,,,,
ANVS,Annovis Bio Inc.,$9.28 ,Buntanetap,Parkinson's Disease (PD) ,Phase 3,02/07/2024 ET,Phase 3 update showed dose-dependent and statistically significant improvements in cognition in the overall enrolled PD population. Buntanetap's activity resulted in statistically significant improvem … read more,19.49M
Add to portfolio,,,,,,,,
BMRN,BioMarin Pharmaceutical Inc.,—,BMN 401 (INZ-701),ABCC6 deficiency ,Phase 1/2,02/07/2024 ET,"Fast track designation, granted by the FDA, noted July 2, 2024.",192.11M
Add to portfolio,,,ODD,,,,,
,,,FTD,,,,,
BDRX,Biodexa Pharmaceuticals plc,$22.42 ,MTX110 - (PNOC015),Diffuse Midline Glioma (DMG) ,Phase 1,02/07/2024 ET,"Phase 1 data reported that median progression free survival (PFS) was 10 months (range 8 to 20 months) and overall survival (OS) of patients in the study was 16.5 months, noted July 2, 2024.",505.06K
Add to portfolio,,,,,,,,
BDRX,Biodexa Pharmaceuticals plc,$22.42 ,MTX110,Children with Newly Diagnosed Diffuse Midline Gliomas (DMGs) ,Phase 1,02/07/2024 ET,"Phase 1 data presented at ISPNO 2024 showed that overall, the treatment was well tolerated by patients. There was one Grade 4 adverse event assessed by the investigators as unrelated to the drug but r … read more",505.06K
Add to portfolio,,,,,,,,
ALVO,Alvotech,$12.24 ,"AVT03-GL-P01 (denosumab) - (PROLIA Biosimilar, Xgeva Biosimilar)",Osteoporosis in postmenopausal women and for bone loss in adult men and women ,Phase 1,02/07/2024 ET,"Confirmatory trial demonstrate clinical similarity between AVT03 and Prolia, noted July 2, 2024.",301.81M
Add to portfolio,,,,,,,,
ARTL,Artelo Biosciences Inc.,$1.32 ,ART26.12,Chemotherapy-Induced Pain ,Preclinical,02/07/2024 ET,"Preclinical data reported a direct anti-tumoral effect of oral treatment with ART26.12, noted July 2, 2024.",1.32M
Add to portfolio,,,,,,,,
LLY,Eli Lilly and Company,$903.87 ,Kisunla (donanemab-azbt),Early symptomatic Alzheimer's disease (AD) ,Approved,02/07/2024 ET,"Approved July 2, 2024.",946.46M
Add to portfolio,,,BTD,,,,,
,,,View Clinical Trial Data,,,,,
ARTL,Artelo Biosciences Inc.,$1.36 ,ART12.11,Anxiety ,Preclinical,03/07/2024 ET,"Preclinical data reported increased plasma levels of CBD and its metabolites compared to CBD in the same formulation, noted July 3, 2024.",1.32M
Add to portfolio,,,,,,,,
IGXT,IntelGenx Technologies Corp,$0.17 ,Montelukast VersaFilm - (BUENA),Alzheimer's Disease ,Phase 2a,03/07/2024 ET,"Phase 2a data reported that no benefit to general cognition was observed when compared to change under placebo, noted July 3, 2024",174.66M
Add to portfolio,,,,,,,,
INSM,Insmed Incorporated,$62.00 ,BRINSUPRI (Brensocatib) - (ASPEN),Non-Cystic Fibrosis Bronchiectasis (NCFBE) ,Phase 3,03/07/2024 ET,"Phase 3 additional results from study presented at the 7th World Bronchiectasis Conference confirmed that the study met its primary endpoint, with both 10 mg and 25 mg doses significantly reducing the … read more",211.37M
Add to portfolio,,,View Clinical Trial Data,,,,,
NAVB,Navidea Biopharmaceuticals Inc.,$0.00 ,NAV3-33,Rheumatoid Arthritis (RA) ,Phase 3,03/07/2024 ET,"Phase 3 trial data reported an overall accuracy of early treatment response was on average consistently below 70%, noted July 3, 2024.",100.08M
Add to portfolio,,,,,,,,
RHHBY,Roche Holding AG ADR,$34.11 ,Tiragolumab - (SKYSCRAPER-06),1L Non-Squamous Non-Small Cell Lung Cancer ,Phase 2/3,04/07/2024 ET,"Phase 2 trial did not meet its primary endpoint, noted July 4, 2024.",6.36B
Add to portfolio,,,,,,,,
RHHBY,Roche Holding AG ADR,$34.03 ,Vabysmo Prefilled Syringe (PFS),"Wet, or neovascular, age-related macular degeneration (AMD), diabetic macular edema (DME) and macular edema following retinal vein occlusion (RVO) ",Approved,05/07/2024 ET,"Approved July 5, 2024.",6.36B
Add to portfolio,,,,,,,,
IVA,Inventiva S.A.,$2.95 ,Lanifibranor - (NATiV3),Nonalcoholic steatohepatitis (NASH) ,Phase 3,05/07/2024 ET,Phase 3 update resulted in over 80% enrollment in the main cohort and 100% in the exploratory cohort; patient characteristics similar to the Phase 2b trial; blinded analysis suggests weight gain plate … read more,95.66M
Add to portfolio,,,FTD,,,,,
IDYA,IDEAYA Biosciences Inc.,$39.51 ,IDE397 and Trodelvy,Solid Tumors ,Phase 2,08/07/2024 ET,"Phase 2 data update reported a 39% Overall Response Rate (ORR). One (1) complete response and six (6) partial responses, noted July 8, 2024.",87.64M
Add to portfolio,,,,,,,,
BCDA,BioCardia Inc.,$2.91 ,ProtheraCytes - (EXCELLENT),Acute myocardial infarction ,Phase 2,08/07/2024 ET,"Phase 2 trial data reported significant improvement of the viability of segments from baseline to six months, noted July 8, 2024.",5.8M
Add to portfolio,,,,,,,,
ACET,Adicet Bio Inc.,$1.17 ,ADI-270,"Solid tumors CAR T, relapsed/refractory renal cell carcinoma (RCC) ",IND-Enabling,08/07/2024 ET,"Fast track designation granted by the FDA, noted July 8, 2024.",83.25M
Add to portfolio,,,FTD,,,,,
XOMA,XOMA Royalty Corporation,—,HIL-214 - (NEST-IN1),Prevention of Norovirus-Related Acute Gastroenteritis in Infants ,Phase 2b,08/07/2024 ET,"Phase 2b topline data reported that the trial did not meet its primary endpoint of efficacy against moderate or severe acute gastroenteritis (AGE) events due to GI.1 or GII.4 norovirus genotypes, note … read more",12.09M
Add to portfolio,,,,,,,,
JBIO,Jade Biosciences Inc.,—,AV-101 - (IMPAHCT),Pulmonary arterial hypertension (PAH) ,Phase 3,08/07/2024 ET,"Phase 3 enrollment halted and shutdown, company looking for strategic alternatives, noted July 8, 2024.",32.63M
Add to portfolio,,,View Clinical Trial Data,,,,,
MRUS,Merus N.V.,$55.71 ,Petosemtamab (MCLA-158),"Recurrent/metastatic (r/m) head and neck squamous cell carcinoma (HNSCC), Solid Tumors ",Phase 2,08/07/2024 ET,"Phase 2 trial initiated in 2L metastatic colorectal cancer (mCRC) cohort, noted July 8, 2024.",75.63M
Add to portfolio,,,BTD,,,,,
GMAB,Genmab A/S,—,Petosemtamab (MCLA-158),"Recurrent/metastatic (r/m) head and neck squamous cell carcinoma (HNSCC), Solid Tumors ",Phase 2,08/07/2024 ET,"Phase 2 trial initiated in 2L metastatic colorectal cancer (mCRC) cohort, noted July 8, 2024.",661.87M
Add to portfolio,,,BTD,,,,,
PHIO,Phio Pharmaceuticals Corp.,$5.72 ,PH-762 (direct drug therapy),Melanoma ,Phase 1b,08/07/2024 ET,"Phase 1b additional site opened, noted July 8, 2024.",5.73M
Add to portfolio,,,,,,,,
RHHBY,Roche Holding AG ADR,$33.89 ,Susvimo (ranibizumab injection),Neovascular Age-Related Macular Degeneration ,Approved,08/07/2024 ET,"FDA supplemental approval on for patients with wet, or neovascular, age-related macular degeneration (AMD), following the end of a voluntary recall, noted July 8, 2024.",6.36B
Add to portfolio,,,,,,,,
KYMR,Kymera Therapeutics Inc.,$31.96 ,KT-474 (SAR444656) - (ADVANTA),Hidradenitis suppurativa / atopic dermatitis ,Phase 2,08/07/2024 ET,Sanofi plans to expand the ongoing Phase 2 trials of KT-474 in Hidradenitis Suppurativa (HS) and Atopic Dermatitis (AD). This decision follows a review of preliminary safety and efficacy data by an In … read more,71.5M
Add to portfolio,,,,,,,,
SNY,Sanofi,$50.24 ,KT-474 (SAR444656) - (ADVANTA),Hidradenitis suppurativa / atopic dermatitis ,Phase 2,08/07/2024 ET,Sanofi plans to expand the ongoing Phase 2 trials of KT-474 in Hidradenitis Suppurativa (HS) and Atopic Dermatitis (AD). This decision follows a review of preliminary safety and efficacy data by an In … read more,2.46B
Add to portfolio,,,,,,,,
SXTP,60 Degrees Pharmaceuticals Inc.,$2.92 ,ARAKODA (tafenoquine),Babesiosis ,Phase 2,09/07/2024 ET,"Phase 2 trial ethic approval announced July 9, 2024.",4.1M
Add to portfolio,,,ODD,,,,,
MESO,Mesoblast Limited,$7.60 ,RYONCIL (remestemcel-L),"Pediatric participants with acute graft versus host disease (aGVHD), following allogeneic hematopoietic stem cell transplant (HSCT) ",BLA Filing,09/07/2024 ET,"BLA resubmitted on July 9, 2024.",128.12M
Add to portfolio,,,,,,,,
PLUR,Pluri Inc.,$5.80 ,RYONCIL (remestemcel-L),"Pediatric participants with acute graft versus host disease (aGVHD), following allogeneic hematopoietic stem cell transplant (HSCT) ",BLA Filing,09/07/2024 ET,"BLA resubmitted on July 9, 2024.",8.16M
Add to portfolio,,,,,,,,
AVTX,Avalo Therapeutics Inc.,$12.86 ,AVTX-009 (anti-IL-1β mAb) - (LOTUS),Hidradenitis suppurativa (HS) ,Phase 2,09/07/2024 ET,"Phase 2 allowed to commence after IND active, noted July 9, 2024.",13.15M
Add to portfolio,,,,,,,,
MNPR,Monopar Therapeutics Inc.,$3.71 ,MNPR-101-Zr (uPAR),Solid tumors ,Phase 1,09/07/2024 ET,"Phase 1 dosing commenced, noted July 9, 2024.",6.17M
Add to portfolio,,,,,,,,
GANX,Gain Therapeutics Inc.,$1.18 ,"GT-02287, GT-02329",GBA1 and Idiopathic Parkinson's Disease ,Phase 1,09/07/2024 ET,"Phase 1 dosing completed the highest planned dose levels. No discontinuations or serious adverse events were reported, noted July 9, 2024.",35.95M
Add to portfolio,,,,,,,,
SNGX,Soligenix Inc.,$7.42 ,HyBryte (SGX301/hypericin sodium) - (FLASH),Cutaneous T-Cell Lymphoma (CTCL) cancer ,Phase 3,09/07/2024 ET,"Additional Phase 3 data reported that 75% (3 of the 4 subjects who have completed at least 12 weeks of therapy) already achieving ""Treatment Success,"" noted July 9, 2024.",4.29M
Add to portfolio,,,ODD,,,,,
QURE,uniQure N.V.,$6.67 ,AMT-130,Huntington's disease ,Phase 1/2,09/07/2024 ET,Additional Phase 1/2 data reported an 80% slowing of disease progression in the composite Unified Huntington's Disease Rating Scale (cUHDRS) at 24 months compared to a propensity score-weighted extern … read more,54.87M
Add to portfolio,,,RMAT,,,,,
,,,BTD,,,,,
,,,FTD,,,,,
,,,ODD,,,,,
QURE,uniQure N.V.,$6.67 ,AMT-130 - (Europe Trial),Huntington’s disease ,Phase 1/2,09/07/2024 ET,Additional Phase 1/2 data reported an 80% slowing of disease progression in the composite Unified Huntington's Disease Rating Scale (cUHDRS) at 24 months compared to a propensity score-weighted extern … read more,54.87M
Add to portfolio,,,,,,,,
KNSA,Kiniksa Pharmaceuticals Ltd.,$20.23 ,Abiprubart,Sjogren's Disease ,Phase 2b,09/07/2024 ET,"Phase 2b study enrollment commenced, noted July 9, 2024.",75.8M
Add to portfolio,,,,,,,,
ARQT,Arcutis Biotherapeutics Inc.,$10.02 ,"ZORYVE (roflumilast) cream, 0.15%",Atopic dermatitis ,PDUFA priority review,09/07/2024 ET,"PDUFA Date on July 7, 2024. PDUFA date PASSED, although the FDA has not requested additional information or extended the PDUFA goal date of July 7, 2024, suggesting a complete submission, noted July 9 … read more",122.49M
Add to portfolio,,,,,,,,
NRSN,NeuroSense Therapeutics Ltd.,$0.93 ,PrimeC - (PARADIGM),Amyotrophic Lateral Sclerosis (ALS) ,Phase 2b,09/07/2024 ET,"Phase 2b 12-month study showed a 57% difference in complication-free survival favoring PrimeC over placebo in the Intent to Treat population, and a 73% difference in the Per Protocol Population. Prim … read more",23.99M
Add to portfolio,,,,,,,,
ARQT,Arcutis Biotherapeutics Inc.,$10.02 ,"ZORYVE (roflumilast) cream, 0.15%",Atopic dermatitis ,Approved,09/07/2024 ET,"FDA Approved on July 9, 2024.",122.49M
Add to portfolio,,,,,,,,
LSTA,Lisata Therapeutics Inc.,$3.36 ,Certepetide (LSTA1),Intrahepatic Cholangiocarcinoma ,Preclinical,09/07/2024 ET,"Preclinical data reported that certepetide combined with standard-of-care chemotherapy and immunotherapy improved survival in mice with intrahepatic cholangiocarcinoma, noted July 10, 2024.",8.76M
Add to portfolio,,,,,,,,
VRPX,Virpax Pharmaceuticals Inc.,$1.70 ,Probudur,Pain Relief ,Preclinical,10/07/2024 ET,"Swine Model data reported that treatment was well-tolerated by all of the pigs and demonstrated a long-term, slow-release profile, noted July 10, 2024.",1.28M
Add to portfolio,,,,,,,,
OKYO,OKYO Pharma Limited,$1.17 ,urcosimod (OK-101),Dry Eye Disease (DED) ,Phase 2,10/07/2024 ET,"Data reported a 68% improvement in responder rate results from patients who achieved both the conjunctival staining ""sign"" and ocular pain ""symptom"" endpoints, noted July 10, 2024.",33.84M
Add to portfolio,,,,,,,,
KZIA,Kazia Therapeutics Limited,$6.68 ,Paxalisib (GDC-0084) - (GBM AGILE),Glioblastoma multiforme ,Phase 2/3,10/07/2024 ET,"Phase 2/3 study demonstrated a 3.8-month improvement in overall survival compared to standard care, with a median overall survival of 15.54 months versus 11.89 months. These results align with previou … read more",1.36M
Add to portfolio,,,View Clinical Trial Data,,,,,
CRGX,CARGO Therapeutics Inc.,$16.60 ,Firicabtagene autoleucel (firi-cel) - (FIRCE-1),Relapsed or refractory (R/R) large B-cell lymphoma (LBCL) ,Phase 1,10/07/2024 ET,"Phase 1 data showed notable patient subset analyses show the durability of Complete Response (CR), underscoring promising efficacy in a high-risk, heavily pretreated population with advanced disease, … read more",48.36M
Add to portfolio,,,,,,,,
MBRX,Moleculin Biotech Inc.,$3.39 ,"Annamycin (MB-106) in combination with Cytarabine - (Ara-C, MIRACLE)",Acute Myeloid Leukemia (AML) ,Phase 1/2,10/07/2024 ET,"Phase 1b/2 was completed with its EoP2 meeting with the FDA, noted July 10, 2024.",30.29M
Add to portfolio,,,ODD,,,,,
,,,FTD,,,,,
OGEN,Oragenics Inc.,$1.18 ,ONP-002,Moderate-to-severe concussion in the acute through subacute phases ,Phase 2,10/07/2024 ET,"Phase 2 in preparation with NCE designed and formulation, noted July 10, 2024.",4.13M
Add to portfolio,,,,,,,,
PFE,Pfizer Inc.,$27.84 ,Danuglipron (PF-06882961) - (PK Study),Obesity ,Phase 1,11/07/2024 ET,"PK trial data reported encouraging pharmacokinetic data for several candidates with one showing the most favorable profile, noted July 11, 2024.",5.69B
Add to portfolio,,,,,,,,
NVO,Novo Nordisk A/S,$139.26 ,Insulin icodec,"Diabetes mellitus, Type 1 diabetes ",CRL,11/07/2024 ET,"CRL announced July 10, 2024.",4.47B
Add to portfolio,,,,,,,,
BDRX,Biodexa Pharmaceuticals plc,$27.00 ,"eRapa (rapamycin, sirolimus) - (Serenta)",Familial Adenomatous Polyposis (FAP) ,Phase 2,11/07/2024 ET,"Phase 2 12-month data complementing recent data presented at the 2024 InSIGHT meeting, showed a 17% median decrease in polyp burden and a 75% non-progression rate. For Cohort 2, 89% were non-progresso … read more",505.06K
Add to portfolio,,,FTD,,,,,
,,,ODD,,,,,
ARMP,Armata Pharmaceuticals Inc.,$3.00 ,AP-PA02 - (Tailwind),Non-cystic fibrosis bronchiectasis (NCFB) ,Phase 2,11/07/2024 ET,"Phase 2 trial enrollment completed, noted July 11, 2024.",36.23M
Add to portfolio,,,,,,,,
CANF,Can-Fite Biopharma Ltd Sponsored ADR (Israel),$3.26 ,Namodenoson - (CF102-222PC),Pancreatic Cancer ,Phase 2a,11/07/2024 ET,"Fast Track designation application submitted to the FDA, noted July 11, 2024.",10.35M
Add to portfolio,,,ODD,,,,,
IMMP,Immutep Limited,$2.01 ,Eftilagimod alpha (IMP321) and KEYTRUDA (pembrolizumab) - (TACTI-003),Head and neck squamous cell carcinoma (HNSCC) ,Phase 2b,11/07/2024 ET,"Phase 2b data presented at the ESMO Virtual Plenary session reported a 35.5% response rate in evaluable patients, noted July 11, 2024.",147.19M
Add to portfolio,,,View Clinical Trial Data,,,,,
VSTM,Verastem Inc.,$3.36 ,GFH375/VS-7375,Cancer KRAS G12D ,Phase 1/2,12/07/2024 ET,"Phase 1/2 dosing initiated in China, noted July 12, 2024.",61.55M
Add to portfolio,,,,,,,,
ABBV,AbbVie Inc.,$167.37 ,Upadacitinib (RINVOQ) - (SELECT-GCA),Giant cell arteritis (GCA) ,NDA Filing,12/07/2024 ET,"NDA submitted July 12, 2024.",1.77B
Add to portfolio,,,,,,,,
BNTC,Benitec Biopharma Inc.,$10.20 ,BB-301,Oculopharyngeal muscular dystrophy (OPMD) ,Phase 1/2,15/07/2024 ET,"Additional interim safety data and efficacy data reported that for three of the four food types evaluated during the radiographic swallowing study assessments for Subject 1, the post-dose average Tota … read more",26.25M
Add to portfolio,,,ODD,,,,,
LXEO,"Lexeo Therapeutics, Inc.",$13.01 ,LX2006 - (SUNRISE-FA),Cardiac Friedreich’s Ataxia ,Phase 1/2,15/07/2024 ET,"Phase 1/2 interim update reported a mean reduction in left ventricular mass index (LVMI) of 11.4% at 12 months and 18.3% at 18 months, noted July 15, 2024.",54M
Add to portfolio,,,ODD,,,,,
,,,RPDD,,,,,
,,,FTD,,,,,
,,,BTD,,,,,
LXEO,"Lexeo Therapeutics, Inc.",$13.01 ,LX2006 - (Weill Cornell Medicine),Cardiomyopathy associated with Friedreich's ataxia (FA) ,Phase 1a,15/07/2024 ET,"Phase 1a data reported that treatment was well tolerated with no treatment-related serious adverse events, noted July 15, 2024.",54M
Add to portfolio,,,BTD,,,,,
SCNI,Scinai Immunotherapeutics Ltd.,$5.89 ,Nanosized VHH antibodies (nanoAbs),Plaque psoriasis ,Preclinical,15/07/2024 ET,"Preclinical results showed that Scinai's NanoAb had similar effects on inflammatory markers as the comparator drugs, demonstrating its potential to reduce psoriatic lesion severity and improve skin in … read more",999.92K
Add to portfolio,,,,,,,,
MIRA,MIRA Pharmaceuticals Inc.,$0.74 ,MIRA-55,Neurological and neuropsychiatric disorders ,Preclinical,15/07/2024 ET,"Preclinical new data confirms MIRA's earlier beliefs regarding MIRA-55's pharmacological profile and potential for potency and efficacy, noted July 15, 2024.",19.07M
Add to portfolio,,,,,,,,
ADXN,Addex Therapeutics Ltd,$8.32 ,GABAB PAM (Compound A),Chronic cough ,Preclinical,15/07/2024 ET,"Preclinical data reported a significantly and dose-dependently reduced citric acid-induced cough frequency (minimal efficacious dose 1 mg/kg), increased cough latency and showed no signs of tolerance … read more",1.07M
Add to portfolio,,,,,,,,
ANIP,ANI Pharmaceuticals Inc.,$63.22 ,L-Glutamine Oral Powder (Endari),Biosimilar ,Approved,15/07/2024 ET,"FDA ANDA Approval on July 15, 2024.",21.7M
Add to portfolio,,,,,,,,
PLRX,Pliant Therapeutics Inc.,$13.23 ,Bexotegrast (PLN-74809) - (INTEGRIS-PSC),Primary sclerosing cholangitis (PSC) ,Phase 2a,15/07/2024 ET,"Phase 2a final 320mg data of the cohort met its primary endpoint of safety, demonstrating that bexotegrast was well tolerated up to 40 weeks of treatment, noted July 15, 2024.",61.39M
Add to portfolio,,,FTD,,,,,
,,,View Clinical Trial Data,,,,,
ARTL,Artelo Biosciences Inc.,$1.33 ,ART26.12,Chemotherapy-Induced Pain ,IND-Enabling,15/07/2024 ET,"IND Cleared by the FDA, noted July 15, 2024.",1.32M
Add to portfolio,,,,,,,,
KYTX,Kyverna Therapeutics Inc.,$9.91 ,KYV-101 - (KYSA-8),Stiff-person syndrome (SPS) ,Phase 2,15/07/2024 ET,"FDA granted Regenerative Medicine Advanced Therapies (RMAT) designation, noted July 15, 2024.",43.25M
Add to portfolio,,,RMAT,,,,,
SLS,SELLAS Life Sciences Group Inc.,$1.14 ,Tambiciclib (SLS009) (GFH009) with venetoclax,"Hematologic malignancies, acute myeloid leukemia (AML), chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL) and lymphoma ",Phase 2,16/07/2024 ET,"Rare Pediatric Disease Designation (RPDD) granted by the FDA, noted July 16, 2024.",105.3M
Add to portfolio,,,ODD,,,,,
,,,FTD,,,,,
,,,RPDD,,,,,
PASG,Passage Bio Inc.,$0.95 ,PBFT02 - (upliFT-D),Frontotemporal dementia ,Phase 1/2,16/07/2024 ET,"Phase 1/2 study to be expanded in FTD patients with C9orf72 gene mutations after FDA feedback from Type C meeting, noted July 16, 2024.",3.18M
Add to portfolio,,,FTD,,,,,
,,,ODD,,,,,
ANVS,Annovis Bio Inc.,$12.51 ,Buntanetap (ANVS401),Alzheimer’s disease (AD) ,Phase 2/3,16/07/2024 ET,Company received FDA approval to use a new crystalline form of their drug buntanetap in future clinical trials for neurodegenerative disorders following June's 2024 patent filings for the new crystal … read more,19.49M
Add to portfolio,,,ODD,,,,,
CLDX,Celldex Therapeutics Inc.,$39.98 ,Barzolvolimab (CDX-0159) - (EMBARQ-CSU1),Chronic Spontaneous Urticaria (CSU) ,Phase 3,16/07/2024 ET,"Phase 3 trial enrollment commenced, noted July 16, 2024.",66.41M
Add to portfolio,,,,,,,,
CLDX,Celldex Therapeutics Inc.,$39.98 ,Barzolvolimab (CDX-0159) - (EMBARQ-CSU2),Chronic Spontaneous Urticaria (CSU) ,Phase 3,16/07/2024 ET,"Phase 3 trial enrollment commenced, noted July 16, 2024.",66.41M
Add to portfolio,,,,,,,,
LSTA,Lisata Therapeutics Inc.,$3.70 ,Certepetide (LSTA1) - (BOLSTER),Intrahepatic Cholangiocarcinoma ,Phase 2a,16/07/2024 ET,"Phase 2a trial enrollment completed, noted July 16, 2024.",8.76M
Add to portfolio,,,ODD,,,,,
CMND,Clearmind Medicine Inc.,$1.83 ,CMND-100,Alcohol use disorder (AUD) ,Phase 1/2,16/07/2024 ET,"IND Cleared by the FDA, noted July 16, 2024.",5.38M
Add to portfolio,,,,,,,,
FDMT,4D Molecular Therapeutics Inc.,$18.20 ,4D-150 - (PRISM),Wet age-related macular degeneration (AMD) ,Phase 2,17/07/2024 ET,Phase 2 24-week data reported reduction in anti-VEGF injection treatment burden through Week 24 achieved in 30 patients at planned Phase 3 dose (3E10 vg/eye) with 89% reduction in annualized injection … read more,46.7M
Add to portfolio,,,RMAT,,,,,
ADVM,Adverum Biotechnologies Inc.,$8.78 ,"Ixo-vec (ixoberogene soroparvovec, ADVM-022) - (ARTEMIS)",Wet age-related macular degeneration (AMD) ,Phase 2,17/07/2024 ET,"Additional LUNA data reported that 76% of 6E10 patients were injection free, with maintained visual acuity and fluid control, noted July 17, 2024.",20.98M
Add to portfolio,,,FTD,,,,,
,,,RMAT,,,,,
RHHBY,Roche Holding AG ADR,$39.00 ,CT-996,Type 2 diabetes and obesity ,Phase 1,17/07/2024 ET,"Phase 1 data reported a clinically meaningful placebo-adjusted mean weight loss of -6.1% within four weeks, noted July 17, 2024.",6.36B
Add to portfolio,,,,,,,,
ATHE,Alterity Therapeutics Limited,$2.14 ,ATH434-202 - (biomarker data),Multiple System Atrophy (MSA) ,Phase 2,17/07/2024 ET,"Phase 2 data demonstrated that after 6 months of treatment, 43% of participants showed improved daily living activities, and 29% had stable or improved neurological symptoms. Clinical responders showe … read more",15.35M
Add to portfolio,,,ODD,,,,,
,,,FTD,,,,,
IMMP,Immutep Limited,$2.00 ,IMP761,Autoimmune diseases ,Phase 1,17/07/2024 ET,"Phase 1 regulatory clearance in the Netherlands to initiate the first-in-human Phase 1 study, noted July 17, 2024.",147.19M
Add to portfolio,,,,,,,,
NVCR,NovoCure Limited,$19.11 ,Optune Lua is (Tumor Treating Fields (TTFields)) - (LUNAR),Non-small cell lung cancer (NSCLC) ,Phase 3,17/07/2024 ET,"Additional Phase 3 data shared at ASRS reported a ≥ 90% reduction in annualized anti-VEGF injections at both doses, noted July 17, 2024.",111.8M
Add to portfolio,,,View Clinical Trial Data,,,,,
ZLAB,Zai Lab Limited,$18.74 ,Optune Lua is (Tumor Treating Fields (TTFields)) - (LUNAR),Non-small cell lung cancer (NSCLC) ,Phase 3,17/07/2024 ET,"Additional Phase 3 data shared at ASRS reported a ≥ 90% reduction in annualized anti-VEGF injections at both doses, noted July 17, 2024.",109.96M
Add to portfolio,,,View Clinical Trial Data,,,,,
NEUP,Neuphoria Therapeutics Inc.,—,BNC210 - (AFFIRM-1),Social Anxiety Disorder (SAD) ,Phase 3,18/07/2024 ET,"Phase 3 trial patient screening initiated July 18, 2024.",2.36M
Add to portfolio,,,FTD,,,,,
IONS,Ionis Pharmaceuticals Inc.,$47.33 ,Zilganersen (ION373),Alexander disease ,Phase 3,18/07/2024 ET,"Phase 3 enrollment completed, noted July 18, 2024",159.39M
Add to portfolio,,,FTD,,,,,
,,,View Clinical Trial Data,,,,,
VIGL,Vigil Neuroscience Inc.,$3.77 ,iluzanebart (VGL101) - (IGNITE),Adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP) ,Phase 2,18/07/2024 ET,"Phase 2 study update following a Type C Meeting with the FDA which stated that it was open to considering the accelerated approval pathway, noted July 18, 2024.",46.67M
Add to portfolio,,,,,,,,
SNY,Sanofi,—,iluzanebart (VGL101) - (IGNITE),Adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP) ,Phase 2,18/07/2024 ET,"Phase 2 study update following a Type C Meeting with the FDA which stated that it was open to considering the accelerated approval pathway, noted July 18, 2024.",2.46B
Add to portfolio,,,,,,,,
AGEN,Agenus Inc.,$7.30 ,Botensilimab plus balstilimab,Relapsed/refractory microsatellite stable colorectal cancer with no active liver metastases (r/r MSS CRC NLM) ,Phase 2,18/07/2024 ET,"Phase 2 preliminary data showed a 19.4% overall response rate and 90% 6-month survival rate, and FDA advice against seeking Accelerated Approval. noted July 18, 2024.",31.86M
Add to portfolio,,,FTD,,,,,
RHHBY,Roche Holding AG ADR,$39.34 ,Susvimo (ranibizumab injection) 100 mg/mL - (Pagoda and Pavilion),Diabetic macular edema (DME) and diabetic retinopathy (DR) ,Phase 3,18/07/2024 ET,"hase 3 2 year data reported that 80% of Susvimo participants achieved a two-step or greater improvement on the DRSS from pre-implant baseline, and participants who received Susvimo from week 64 either … read more",6.36B
Add to portfolio,,,,,,,,
RHHBY,Roche Holding AG ADR,$39.34 ,Susvimo (ranibizumab injection) 100 mg/mL - (Pagoda and Pavilion),Diabetic macular edema (DME) and diabetic retinopathy (DR) ,BLA Filing,18/07/2024 ET,"sBLA submitted July 18, 2024.",6.36B
Add to portfolio,,,,,,,,
BCTX,BriaCell Therapeutics Corp.,$0.76 ,Bria-IMT + check point inhibitor (CPI) - (investigator-initiated trial),Metastatic breast cancer ,Phase 2,18/07/2024 ET,"Phase 2 study of the Bria-IMT regimen for metastatic breast cancer. A top responder patient achieved 9.1 months of progression-free survival, quadrupling the PFS of patients in similar studies. This h … read more",1.76M
Add to portfolio,,,,,,,,
PHAT,Phathom Pharmaceuticals Inc.,$11.18 ,VOQUEZNA (vonoprazan) - (PHALCON-NERD-301),Heartburn associated with Non-Erosive gastroesophageal reflux disease (GERD) ,Approved,18/07/2024 ET,"FDA Approved on July 18, 2024.",70.94M
Add to portfolio,,,,,,,,
COCP,Cocrystal Pharma Inc.,$2.35 ,CDI-988,"Healthy volunteers, Pandemic Norovirus and Coronavirus ",Phase 1,18/07/2024 ET,"Phase 1 SAD data reported no serious adverse events or severe treatment-emergent adverse events, noted July 18, 2024.",10.26M
Add to portfolio,,,,,,,,
BIOR,Biora Therapeutics Inc.,$7.01 ,BT-600 + NaviCap Platform,Ulcerative Colitis (UC) ,Phase 1,18/07/2024 ET,"Phase 1 results clinical trial demonstrated a pharmacokinetic (PK) profile consistent with drug delivery and absorption in the colon for both single and multiple ascending dose (SAD/MAD) cohorts, note … read more",4.52M
Add to portfolio,,,,,,,,
TEVA,Teva Pharmaceutical Industries Limited American Depositary Shares,$16.34 ,AJOVY (fremanezumab-vfrm),Episodic migraine in children and adolescent patients aged 6-17 years who weigh 45 kilograms (99 pounds) or more ,Phase 3,18/07/2024 ET,"Phase 3 trial met its primary end point, noted July 18, 2024.",1.15B
Add to portfolio,,,,,,,,
OCUL,Ocular Therapeutix Inc.,$7.75 ,AXPAXLI (OTX-TKI) - (HELIOS),Non-proliferative diabetic retinopathy (NPDR) ,Phase 1,18/07/2024 ET,"Phase 1 additional data presented at ASRS reported that 23.1% of patients in the OTX-TKI arm demonstrated a ≥2-step DRSS improvement, and 46.2% of patients demonstrated a 1- or ≥2-step DRSS improvemen … read more",174M
Add to portfolio,,,,,,,,
EDAP,EDAP TMS S.A.,$5.10 ,Transrectal High-intensity focused ultrasound (TR-HIFU),Rectal Deep Infiltrating Endometriosis ,Phase 3,19/07/2024 ET,"Phase 3 did not meet the primary endpoint of reduced acute pelvic pain compared to the Sham treatment at three months post-procedure. However, both arms showed significant pain reduction from baseline … read more",37.39M
Add to portfolio,,,,,,,,
ADXN,Addex Therapeutics Ltd,$8.06 ,ADX71149 (mGlu2 PAM) - (JNJ-40411813),Epilepsy ,Phase 2,22/07/2024 ET,"Phase 2 study was discontinued after disappointing results on April, noted July 22, 2024.",1.07M
Add to portfolio,,,,,,,,
JNJ,Johnson & Johnson,$151.86 ,ADX71149 (mGlu2 PAM) - (JNJ-40411813),Epilepsy ,Phase 2,22/07/2024 ET,"Phase 2 study was discontinued after disappointing results on April, noted July 22, 2024.",2.41B
Add to portfolio,,,,,,,,
ZYME,Zymeworks Inc.,$10.26 ,ZW191,"Non-small cell lung cancer, endometrial cancer, and triple-negative breast cancer ",IND-Enabling,22/07/2024 ET,"IND Cleared by the FDA, noted July 22, 2024",75.17M
Add to portfolio,,,,,,,,
MESO,Mesoblast Limited,$7.55 ,Rexlemestrocel-L (MPC-06-ID),Chronic low back pain ,Phase 3,22/07/2024 ET,"Phase 3 second trial enrollment initiated, noted July 22, 2024",128.12M
Add to portfolio,,,BTD,,,,,
,,,FTD,,,,,
,,,RMAT,,,,,
,,,View Clinical Trial Data,,,,,
NUVL,Nuvalent Inc.,$81.14 ,Zidesamtinib - (NVL-330) - (HEROEX-1),HER2-mutant tumors ,Phase 1,22/07/2024 ET,"Phase 1a/1b initiated, noted July 22, 2024.",72.1M
Add to portfolio,,,,,,,,
JNJ,Johnson & Johnson,$151.86 ,SPRAVATO (esketamine) monotherapy,Treatment Resistant Depression (TRD4005) ,sNDA Filing,22/07/2024 ET,"Supplemental New Drug Application (sNDA) submitted to FDA, noted July 22, 2024.",2.41B
Add to portfolio,,,,,,,,
MIRA,MIRA Pharmaceuticals Inc.,$5.01 ,Ketamir-2,"Treatment-resistant depression (TRD), major depressive disorder with suicidal ideation (MDSI) and post-traumatic stress disorder (PTSD) ",Preclinical,22/07/2024 ET,Preclinical study results showed that the drug has potential for treating various neurological and neuropsychiatric disorders. It has high oral bioavailability and better brain penetration than tradit … read more,19.07M
Add to portfolio,,,,,,,,
BIIB,Biogen Inc.,$226.63 ,ION582 (BIIB121) - (HALOS),Angelman Syndrome ,Phase 1/2,22/07/2024 ET,"Phase 1/2a data showed robust and consistent benefits in communication, cognition, and motor function in a broad patient population evaluated with a comprehensive set of assessment tools that collect … read more",146.61M
Add to portfolio,,,ODD,,,,,
IONS,Ionis Pharmaceuticals Inc.,$50.61 ,ION582 (BIIB121) - (HALOS),Angelman Syndrome ,Phase 1/2,22/07/2024 ET,"Phase 1/2a data showed robust and consistent benefits in communication, cognition, and motor function in a broad patient population evaluated with a comprehensive set of assessment tools that collect … read more",159.39M
Add to portfolio,,,ODD,,,,,
IMMP,Immutep Limited,$1.90 ,Eftilagimod alpha (efti) - (TACTI-004),1L Non-small cell lung cancer (NSCLC) ,Phase 3,22/07/2024 ET,"Phase 3 Type-C meeting FDA feedback resulted in successful preparatory regulatory interactions for the design of this registrational trial, noted July 22, 2024.",147.19M
Add to portfolio,,,,,,,,
TCBP,TC BioPharm (Holdings) plc,$8.10 ,OmnImmune (TCB008) - (ACHIEVE),Acute Myeloid Leukemia ,Phase 2b,22/07/2024 ET,"Phase 2b sixth patient dosed, 5 patients treated in ""safety cohort"" showed no drug related Serious Adverse Events, noted July 22, 2024.",2.1M
Add to portfolio,,,,,,,,
ATOS,Atossa Therapeutics Inc.,$1.48 ,(Z)-endoxifen with abemaciclib (VERZENIO) - (EVANGELINE),Pre-menopausal women w/ early-stage estrogen receptor positive and Human Epidermal Growth Factor Receptor 2 negative breast cancer ,Phase 2,22/07/2024 ET,"Phase 2 Run-in cohort enrollment completed, noted July 22, 2024.",129.17M
Add to portfolio,,,,,,,,
LLY,Eli Lilly and Company,$863.26 ,(Z)-endoxifen with abemaciclib (VERZENIO) - (EVANGELINE),Pre-menopausal women w/ early-stage estrogen receptor positive and Human Epidermal Growth Factor Receptor 2 negative breast cancer ,Phase 2,22/07/2024 ET,"Phase 2 Run-in cohort enrollment completed, noted July 22, 2024.",946.46M
Add to portfolio,,,,,,,,
JAGX,Jaguar Health Inc.,$1.76 ,Mytesi (crofelemer) - (OnTarget),Cancer Therapy-Related Diarrhea ,Phase 3,23/07/2024 ET,"Phase 3 study did not meet its primary endpoint, noted July 23, 2023.",2.17M
Add to portfolio,,,View Clinical Trial Data,,,,,
ADIL,Adial Pharmaceuticals Inc,$1.31 ,AD04 - (ONWARD),Alcohol use disorder ,Phase 3,23/07/2024 ET,"Phase 3 study advanced to its second cohort after completing the first, noted July 23, 2024.",21.83M
Add to portfolio,,,View Clinical Trial Data,,,,,
RYTM,Rhythm Pharmaceuticals Inc.,$49.80 ,Bivamelagon (LB54640),Healthy overweight adults ,Phase 2,23/07/2024 ET,"Phase 2 dosing initiated, noted July 23, 2024.",66.42M
Add to portfolio,,,ODD,,,,,
MRK,Merck & Company Inc.,$123.57 ,ENFLONSIA (Clesrovimab) (MK-1654-004) - (CLEVER),Respiratory syncytial virus (RSV) infants ,Phase 2/3,23/07/2024 ET,"Phase 2b/3 study met its primary safety and efficacy endpoints, including reducing medically attended lower respiratory infections (MALRI) caused by RSV through Day 150, noted July 23, 2024.",2.5B
Add to portfolio,,,,,,,,
ANIX,Anixa Biosciences Inc.,$2.89 ,Chimeric endocrine receptor T-cell (CER-T),Ovarian Cancer ,IND-Enabling,23/07/2024 ET,"IND cleared by the FDA for collaborator Moffitt Cancer Center, noted July 23, 2024.",32.92M
Add to portfolio,,,,,,,,
VIRI,Dogwood Therapeutics Inc.,$6.09 ,IMC-2 with Valacyclovir and Celecoxib - (Bateman Horne Center trial),Long COVID-19 ,Phase 2,23/07/2024 ET,"Phase 2 enrollment completed, noted July 23, 2024.",27.76M
Add to portfolio,,,,,,,,
CLRB,Cellectar Biosciences Inc.,$2.46 ,Iopofosine (CLR 131) - (CLOVER-WaM),Waldenstrom’s macroglobulinemia ,Phase 2b,23/07/2024 ET,"Phase 2b study showed an 80% overall response rate and a 56.4% major response rate, exceeding the primary endpoint. The treatment was effective across various patient subgroups, including those resist … read more",3.19M
Add to portfolio,,,BTD,,,,,
,,,View Clinical Trial Data,,,,,
MESO,Mesoblast Limited,$8.27 ,RYONCIL (remestemcel-L),"Pediatric participants with acute graft versus host disease (aGVHD), following allogeneic hematopoietic stem cell transplant (HSCT) ",PDUFA,23/07/2024 ET,"The FDA accepted BLA resubmission, noted on July 23, 2024.",128.12M
Add to portfolio,,,,,,,,
PLUR,Pluri Inc.,$5.70 ,RYONCIL (remestemcel-L),"Pediatric participants with acute graft versus host disease (aGVHD), following allogeneic hematopoietic stem cell transplant (HSCT) ",PDUFA,23/07/2024 ET,"The FDA accepted BLA resubmission, noted on July 23, 2024.",8.16M
Add to portfolio,,,,,,,,
REGN,Regeneron Pharmaceuticals Inc.,"$1,055.57 ",Ateganosine (THIO-101),Non-small cell lung cancer (NSCLC) ,Phase 2,23/07/2024 ET,"Phase 2 clinical trial treatment has shown good tolerability with lower toxicity compared to standard care. Notably, six patients have been on the trial regimen for over 12 months, completing up to 21 … read more",105.1M
Add to portfolio,,,ODD,,,,,
,,,FTD,,,,,
MAIA,MAIA Biotechnology Inc.,$3.70 ,Ateganosine (THIO-101),Non-small cell lung cancer (NSCLC) ,Phase 2,23/07/2024 ET,"Phase 2 clinical trial treatment has shown good tolerability with lower toxicity compared to standard care. Notably, six patients have been on the trial regimen for over 12 months, completing up to 21 … read more",32.99M
Add to portfolio,,,ODD,,,,,
,,,FTD,,,,,
ARQT,Arcutis Biotherapeutics Inc.,$10.20 ,ZORYVE (roflumilast),Scalp psoriasis ,sNDA Filing,23/07/2024 ET,"sNDA submitted to the FDA, noted July 23, 2024.",122.49M
Add to portfolio,,,View Clinical Trial Data,,,,,
BCAB,BioAtla Inc.,$1.75 ,Ozuriftamab Vedotin (BA3021),"Solid Tumors, Non-small cell lung cancer (NSCLC), recurrent or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN) ",Phase 2,23/07/2024 ET,"Fast Track Designation (FTD) granted by the FDA, noted July 23, 2024.",58.72M
Add to portfolio,,,FTD,,,,,
,,,View Clinical Trial Data,,,,,
KRON,Kronos Bio Inc.,$1.32 ,KB-0742,Solid tumors ,Phase 2,24/07/2024 ET,"Phase 2 80mg expansion cohort dosing initiated, noted July 24, 2024.",60.97M
Add to portfolio,,,,,,,,
GILD,Gilead Sciences Inc.,$72.82 ,Yeztugo (Lenacapavir),HIV PrEP – Pre-exposure prophylaxis ,Phase 3,24/07/2024 ET,"Phase 3 trial ata showed zero Infections and 100% Efficacy and Superiority of lenacapavir to background HIV incidence and daily Truvada for PrEP, noted July 24, 2024.",1.24B
Add to portfolio,,,,,,,,
SGMO,Sangamo Therapeutics Inc.,$0.56 ,Giroctocogene fitelparvovec (SB-525) - (AFFINE),Hemophilia A ,Phase 3,24/07/2024 ET,"Phase 3 data met its primary and key secondary objectives of superiority compared to prophylaxis, noted on July 24, 2024.",301.71M
Add to portfolio,,,,,,,,
TLSA,Tiziana Life Sciences Ltd,$1.00 ,Foralumab (Intranasal),Secondary Progressive Multiple Sclerosis (SPMS) ,Phase 2a,24/07/2024 ET,"Fast track designation granted by the FDA, noted July 24, 2024.",111.46M
Add to portfolio,,,FTD,,,,,
MRUS,Merus N.V.,$54.70 ,Petosemtamab (MCLA-158) - (LiGeR-HN2),Recurrent/metastatic head and neck squamous cell carcinoma (r/m HNSCC) ,Phase 3,24/07/2024 ET,"Phase 3 study dosing initiated, noted July 24, 2024.",75.63M
Add to portfolio,,,BTD,,,,,
GMAB,Genmab A/S,—,Petosemtamab (MCLA-158) - (LiGeR-HN2),Recurrent/metastatic head and neck squamous cell carcinoma (r/m HNSCC) ,Phase 3,24/07/2024 ET,"Phase 3 study dosing initiated, noted July 24, 2024.",661.87M
Add to portfolio,,,BTD,,,,,
SAGE,Sage Therapeutics Inc.,$10.38 ,SAGE-324 (BIIB124) - (KINETIC 2),Essential tremor ,Phase 2b,24/07/2024 ET,"Phase 2b topline data did not demonstrate a statistically significant dose-response relationship on the primary endpoint in participants with essential tremor, noted July 24, 2025.",62.78M
Add to portfolio,,,View Clinical Trial Data,,,,,
BIIB,Biogen Inc.,$226.03 ,SAGE-324 (BIIB124) - (KINETIC 2),Essential tremor ,Phase 2b,24/07/2024 ET,"Phase 2b topline data did not demonstrate a statistically significant dose-response relationship on the primary endpoint in participants with essential tremor, noted July 24, 2025.",146.61M
Add to portfolio,,,View Clinical Trial Data,,,,,
VIGL,Vigil Neuroscience Inc.,$4.25 ,VG-3927,Alzheimer's disease ,Phase 1,24/07/2024 ET,"Phase 1 interim data on healthy volunteers showed that VG-3927 had a significant impact on sTREM2, a key biomarker in AD, and supports treatment as a potent molecule that functionally engages TREM2 re … read more",46.67M
Add to portfolio,,,,,,,,
SNY,Sanofi,—,VG-3927,Alzheimer's disease ,Phase 1,24/07/2024 ET,"Phase 1 interim data on healthy volunteers showed that VG-3927 had a significant impact on sTREM2, a key biomarker in AD, and supports treatment as a potent molecule that functionally engages TREM2 re … read more",2.46B
Add to portfolio,,,,,,,,
SONN,Sonnet BioTherapeutics Holdings Inc.,$6.95 ,SON-080 - (SB211),Chemotherapy Induced Peripheral Neuropathy (CIPN) ,Phase 1/2,24/07/2024 ET,"Phase 1b/2a unblinded safety data indicated that SON-080 was well-tolerated at both doses, with no evidence of a pro-inflammatory cytokine response, noted July 24, 2024.",6.75M
Add to portfolio,,,,,,,,
NTBL,Notable Labs Ltd.,$0.62 ,Volasertib,Relapsed/refractory acute myeloid leukemia ,Phase 2,24/07/2024 ET,"Phase 2 ""Clearance to Proceed"" receipt issued by the FDA, noted July 24, 2024.",9.66M
Add to portfolio,,,,,,,,
OSTX,OS Therapies Incorporated,$2.51 ,OST-HER2,Solid tumors in breast cancer ,Preclinical,24/07/2024 ET,"Preclinical breast cancer efficacy models showed positive data to prevent breast cancer metastases to the brain, reduce tumor growth by over 90% in combination with HER2-targeted antibodies, and preve … read more",31.89M
Add to portfolio,,,FTD,,,,,
,,,ODD,,,,,
,,,RPDD,,,,,
BMRN,BioMarin Pharmaceutical Inc.,$84.63 ,BRINEURA (cerliponase alfa) - (Study 190-203),CLN2 Batten Disease Children of All Ages ,Approved,24/07/2024 ET,"FDA supplemental Approval on July 24, 2024.",192.11M
Add to portfolio,,,,,,,,
RARE,Ultragenyx Pharmaceutical Inc.,$45.11 ,GTX-102 - (Aspire),Angelman Syndrome ,Phase 1/2,24/07/2024 ET,"Phase 1/2 previously disclosed results presented at ASF Presentation on July 24, 2024.",96.37M
Add to portfolio,,,BTD,,,,,
SNY,Sanofi,$53.10 ,Duvakitug (TEV-'574/SAR447189) - (RELIEVE UCCD),Moderate-to-severe inflammatory bowel disease (IBD); this includes ulcerative colitis (UC) and Crohn's disease (CD) ,Phase 2b,25/07/2024 ET,"Phase 2b trial completed early, noted July 25, 2024.",2.46B
Add to portfolio,,,,,,,,
TEVA,Teva Pharmaceutical Industries Limited American Depositary Shares,$16.80 ,Duvakitug (TEV-'574/SAR447189) - (RELIEVE UCCD),Moderate-to-severe inflammatory bowel disease (IBD); this includes ulcerative colitis (UC) and Crohn's disease (CD) ,Phase 2b,25/07/2024 ET,"Phase 2b trial completed early, noted July 25, 2024.",1.15B
Add to portfolio,,,,,,,,
OCGN,"Ocugen, Inc.",$1.63 ,OCU410 - (ArMaDa),Geographic Atrophy (GA) ,Phase 1/2,25/07/2024 ET,"Phase 1/2 third cohort dosing completed and Phase 2 initiated, noted July 25, 2024.",292.3M
Add to portfolio,,,,,,,,
ACIU,AC Immune SA,$3.91 ,JNJ-2056 (ACI-35.030) - (ReTain),Alzheimer’s Disease ,Preclinical,25/07/2024 ET,"Fast Track designation granted by the FDA, noted July 25, 2024.",100.41M
Add to portfolio,,,FTD,,,,,
JNJ,Johnson & Johnson,$157.17 ,JNJ-2056 (ACI-35.030) - (ReTain),Alzheimer’s Disease ,Preclinical,25/07/2024 ET,"Fast Track designation granted by the FDA, noted July 25, 2024.",2.41B
Add to portfolio,,,FTD,,,,,
MIRM,Mirum Pharmaceuticals Inc.,$40.37 ,LIVMARLI (maralixibat),Progressive Familial Intrahepatic Cholestasis (PFIC) ,Approved,25/07/2024 ET,"FDA Approval of label expansion on patients 12 months and older, noted July 25, 2024.",50.24M
Add to portfolio,,,View Clinical Trial Data,,,,,
CMMB,Chemomab Therapeutics Ltd.,$1.19 ,nebokitug (CM-101) - (SPRING),Primary Sclerosing Cholangitis ,Phase 2,25/07/2024 ET,"Phase 2 topline 15-week data met its primary safety and tolerability endpoint and demonstrated anti-fibrotic, anti-inflammatory, and anti-cholestatic effects across multiple disease-related secondary … read more",5.19M
Add to portfolio,,,FTD,,,,,
BCDA,BioCardia Inc.,$2.95 ,CardiAMP (BCDA-01),Ischemic Heart Failure ,Phase 3,25/07/2024 ET,"Phase 3 enrollment in the US commenced, noted July 25, 2024.",5.8M
Add to portfolio,,,BTD,,,,,
,,,View Clinical Trial Data,,,,,
ENVB,Enveric Biosciences Inc.,$0.47 ,EB-003 (EVM301 series),Mental health disorders ,Preclinical,25/07/2024 ET,"Preclinical results indicate the potential for the drug candidate to be delivered via oral administration with significant brain exposure in rodent models at potential therapeutic doses, noted July 25 … read more",518.3K
Add to portfolio,,,,,,,,
ALT,Altimmune Inc.,$6.69 ,Pemvidutide - (IMPACT),Metabolic dysfunction-associated steatohepatitis (MASH) ,Phase 2b,25/07/2024 ET,"Phase 2b intiatl data showed that weekly subcutaneous doses of pemvidutide resulted in up to 68.5% relative reduction in liver fat content (LFC), with up to 55.6% of subjects achieving LFC normalizati … read more",88.26M
Add to portfolio,,,FTD,,,,,
VRDN,Viridian Therapeutics Inc.,$16.34 ,Veligrotug (VRDN-001) - (THRIVE-2),Thyroid Eye Disease (TED) ,Phase 1/2,25/07/2024 ET,"Phase 1/2 exceeded its enrollment target due to patient demand; 188 patients enrolled with approximately 40% from US sites, noted July 25, 2024.",81.66M
Add to portfolio,,,BTD,,,,,
ATNM,Actinium Pharmaceuticals Inc.,$7.90 ,Iomab-ACT,Sickle cell disease ,IND-Enabling,25/07/2024 ET,"IND cleared by the FDA, noted July 25, 2024.",31.2M
Add to portfolio,,,,,,,,
ZVSA,ZyVersa Therapeutics Inc.,$3.85 ,IC 100 (AIM2 and NLRP3 inflammasome),Obesity and Type 1 diabetes ,Preclinical,25/07/2024 ET,"Preclinical program near completion, selected as lead drug for obesity and IND submission planned on 4Q 2024, noted July 25, 2024.",8.1M
Add to portfolio,,,,,,,,
AQST,Aquestive Therapeutics Inc.,$3.45 ,Anaphylm (AQ-109)- (103),Anaphylaxis ,Phase 3,25/07/2024 ET,"Phase 3 data met all primary and secondary pharmacokinetic endpoints, study expected to be completed by late 3Q / early 4Q 2024. NDA filing expected 4Q 2024/ early 1Q 2025, noted July 25, 2024.",99.72M
Add to portfolio,,,,,,,,
CRVS,Corvus Pharmaceuticals Inc.,$2.31 ,Soquelitinib - (CPI-818),Peripheral T-cell lymphoma (PTCL) ,Preclinical,25/07/2024 ET,"Preclinical data demonstrated in vitro and in vivo ITK inhibition with soquelitinib induced switching of proinflammatory Th17 cells into anti-inflammatory Treg cells, noted July 25, 2024.",74.51M
Add to portfolio,,,FTD,,,,,
WINT,Windtree Therapeutics Inc.,$3.29 ,Istaroxime - (SEISMiC C),Cardiogenic Shock in severe acute heart failure ,Phase 2,25/07/2024 ET,Phase 2 extension study in SCAI Stage B enrollment to be completed by the end of 3Q 2024.,29.33M
Add to portfolio,,,View Clinical Trial Data,,,,,
GLYC,GlycoMimetics Inc.,$0.24 ,Uproleselan (GMI-1271) - NCI-sponsored,Acute myeloid leukemia (AML) ,Phase 2/3,25/07/2024 ET,"Phase 2/3 additional trial required after meeting with FDA, noted July 25, 2024.",13.89M
Add to portfolio,,,View Clinical Trial Data,,,,,
AZN,AstraZeneca PLC,$78.04 ,IMFINZI (durvalumab),Non-Small Cell Lung Cancer (before and after surgery) ,PDUFA,25/07/2024 ET,"FDA Oncologic Drugs Advisory Committee (ODAC) acknowledged that treatment met the primary endpoint of event-free survival (EFS), noted July 25, 2024.",3.1B
Add to portfolio,,,,,,,,
CLLS,Cellectis S.A.,$2.05 ,UCART22 - (BALLI-01),Relapsed/refractory B-cell acute lymphoblastic leukemia (B-ALL) ,Phase 1/2,25/07/2024 ET,"Phase 1/2 trial FDA granted Orphan drug designation and Rare Pediatric Disease Designation, noted July 25, 2024.",72.09M
Add to portfolio,,,ODD,,,,,
,,,RPDD,,,,,
PMN,ProMIS Neurosciences Inc.,$1.60 ,PMN310 - (PRECISE-AD),Alzheimer's disease (AD) ,Phase 1a,26/07/2024 ET,Phase 1a topline data demonstrated a favorable safety profile and tolerability across four ascending dose levels in healthy volunteers and showed dose dependent levels of PMN310 antibody in Cerebrospi … read more,53.81M
Add to portfolio,,,FTD,,,,,
CVM,Cel-Sci Corporation,$1.31 ,Multikine - (IT-MATTERS),Head and Neck cancer ,Phase 3,26/07/2024 ET,"Phase 3 bias analysis analysis found no bias or confounding factors between the treatment and control groups, supporting the validity of the study's efficacy results. In the target population, Multiki … read more",6.88M
Add to portfolio,,,View Clinical Trial Data,,,,,
CALT,Calliditas Therapeutics AB,$38.19 ,Setanaxib - (TRANSFORM),Primary biliary cholangitis (PBC) ,Phase 2b,26/07/2024 ET,"Phase 2b topline data met its primary endpoint, showing statistically significant improvement in ALP (Alkaline Phosphatase) for both doses tested versus placebo, noted July 26, 2024.",26.84M
Add to portfolio,,,View Clinical Trial Data,,,,,
VTVT,vTv Therapeutics Inc.,$21.20 ,Cadisegliatin (TTP399),Type 1 Diabetes ,Phase 3,26/07/2024 ET,"Phase 3 FDA placed a clinical hold based on the discovery of a chromatographic signal in a recent human absorption, distribution, metabolism, and excretion (ADME) study of cadisegliatin that could not … read more",3.19M
Add to portfolio,,,View Clinical Trial Data,,,,,
CERO,CERo Therapeutics Holdings Inc.,$0.26 ,CER-1236 - (CertainT-1),"Acute myeloid leukemia (AML), Hematologic malignancies ",IND-Enabling,26/07/2024 ET,"IND placed on clinical hold, noted July 26, 2024.",1.21M
Add to portfolio,,,ODD,,,,,
,,,FTD,,,,,
LGVN,Longeveron Inc.,$3.47 ,Laromestrocel (lomecel-B) - (CLEAR MIND),Alzheimer's Disease ,Phase 2a,28/07/2024 ET,"Phase 2a results from AAIC reported that treatment demonstrated in MRI biomarker results showing 49% reduction in brain volume loss and improvement in inflammation, noted July 28, 2024.",15.18M
Add to portfolio,,,RMAT,,,,,
,,,FTD,,,,,
ABOS,Acumen Pharmaceuticals Inc.,$3.29 ,Sabirnetug (ACU193) - (INTERCEPT-AD),Alzheimer’s disease (AD) ,Phase 1,28/07/2024 ET,"Phase 1 data from AAIC reported that three administrations of sabirnetug significantly lowered CSF levels of both pre- and post-synaptic proteins, noted July 28, 2024.",60.57M
Add to portfolio,,,FTD,,,,,
SNDX,Syndax Pharmaceuticals Inc.,$21.99 ,Revuforj (revumenib),Adult and pediatric relapsed or refractory (R/R) KMT2A-rearranged (KMT2Ar) acute leukemia ,PDUFA,29/07/2024 ET,"PDUFA action was extended by 3 months to December 26, 2024.",86.14M
Add to portfolio,,,,,,,,
CGTX,Cognition Therapeutics Inc.,$1.33 ,Zervimesine (CT1812) - (SHINE),Mild-to-Moderate Alzheimer's Disease ,Phase 2,29/07/2024 ET,"Phase 2 data presented at AAIC showed a consistent trend in cognitive improvement compared to placebo across multiple measures, with participants treated for six months demonstrating a 39% slowing of … read more",73.47M
Add to portfolio,,,View Clinical Trial Data,,,,,
AVXL,Anavex Life Sciences Corp.,$7.04 ,Blarcamesine (ANAVEX2-73-AD-004) - (ATTENTION-AD),Mild to moderate Alzheimer’s disease ,Phase 2/3,29/07/2024 ET,"Phase 2b/3 results reported that Blarcamesine significantly slowed clinical progression by 38.5% and 34.6% at 48 weeks in 50 mg and 30 mg groups vs. placebo, respectively, on the prespecified primary … read more",85.89M
Add to portfolio,,,View Clinical Trial Data,,,,,
ZVSA,ZyVersa Therapeutics Inc.,$3.60 ,IC100,Parkinson's disease ,Preclinical,29/07/2024 ET,Preclinical data presented at the International Journal of Molecular Sciences demonstrating that plasma levels of inflammasome ASC show promise as a biomarker of early cognitive decline in older adult … read more,8.1M
Add to portfolio,,,,,,,,
VTYX,Ventyx Biosciences Inc.,$2.28 ,VTX958,Crohn's disease ,Phase 2,29/07/2024 ET,"Phase 2 trial did not meet its primary endpoint of change from baseline in mean CDAI score in either VTX958 dose group, noted July 29, 2024.",71.31M
Add to portfolio,,,,,,,,
HALO,Halozyme Therapeutics Inc.,$55.47 ,Sabirnetug (ACU193) with ENHANZE,Alzheimer's disease (AD) ,Phase 1,29/07/2024 ET,"Phase 1 dosing initiated, noted July 29, 2024.",116.97M
Add to portfolio,,,,,,,,
ABOS,Acumen Pharmaceuticals Inc.,$3.29 ,Sabirnetug (ACU193) with ENHANZE,Alzheimer's disease (AD) ,Phase 1,29/07/2024 ET,"Phase 1 dosing initiated, noted July 29, 2024.",60.57M
Add to portfolio,,,,,,,,
CGEN,Compugen Ltd.,$1.71 ,COM503,Solid tumors ,IND-Enabling,29/07/2024 ET,"IND cleared by the FDA, noted July 29, 2024.",93.51M
Add to portfolio,,,,,,,,
GILD,Gilead Sciences Inc.,$76.37 ,COM503,Solid tumors ,IND-Enabling,29/07/2024 ET,"IND cleared by the FDA, noted July 29, 2024.",1.24B
Add to portfolio,,,,,,,,
PALI,Palisade Bio Inc.,$3.75 ,PALI-2108,Moderate-to-severe ulcerative colitis (UC) ,Preclinical,29/07/2024 ET,"Preclinical findings demonstrate that the microbiome and enzymes are sufficient in mouse, dog, and Normal Healthy Volunteers (NHV) and Ulcerative Colitis (UC) patients, noted July 29, 2024.",9.12M
Add to portfolio,,,,,,,,
CRVO,CervoMed Inc.,$14.41 ,Neflamapimod - (AscenD-LB),Dementia with Lewy bodies (DLB) ,Phase 2a,29/07/2024 ET,"Phase 2a data presented at AAIC reported that there was a mean 14.1 pg/mL increase in the placebo treatment group (N=13) vs. mean 10.6 pg/mL reduction with neflamapimod treatment, noted July 29, 2024.",9.25M
Add to portfolio,,,,,,,,
AZN,AstraZeneca PLC,$77.88 ,Calquence (acalabrutinib) - (AMPLIFY),Chronic lymphocytic leukaemia (CLL) ,Phase 3,29/07/2024 ET,"Phase 3 data reported a a statistically significant and clinically meaningful improvement in progression-free survival (PFS) compared to standard-of-care chemoimmunotherapy, noted July 29, 2024.",3.1B
Add to portfolio,,,,,,,,
CLDX,Celldex Therapeutics Inc.,$41.99 ,Barzolvolimab - (CindU),"Chronic inducible urticaria (CIndU), cold urticaria (ColdU) and symptomatic dermographism (SD), Chronic Spontaneous Urticaria (CSU) ",Phase 2,29/07/2024 ET,"Phase 2 study met its primary endpoint, showing statistically significant and clinically meaningful complete response rates in both dose groups compared to placebo.",66.41M
Add to portfolio,,,,,,,,
VSTM,Verastem Inc.,$2.74 ,VS-6766 and defactinib - (RAMP 205),Metastatic pancreatic cancer ,Phase 1/2,29/07/2024 ET,"Phase 1/2 study granted Orphan Drug Designation (ODD) by the FDA, noted July 29, 2024.",61.55M
Add to portfolio,,,,,,,,
AMRX,Amneal Pharmaceuticals Inc.,$7.34 ,Potassium Phosphates in 0.9% Injection IV RTU bags,Hyperphosphatemia ,Approved,29/07/2024 ET,"FDA approved via 505(b)(2) pathway, noted July 29, 2024.",314.08M
Add to portfolio,,,,,,,,
ACOG,Alpha Cognition Inc.,—,ZUNVEYL (benzgalantamine),Mild-to-moderate Alzheimer's disease ,Approved,29/07/2024 ET,"FDA approved on July 29, 2024.",16.16M
Add to portfolio,,,,,,,,
REGN,Regeneron Pharmaceuticals Inc.,"$1,077.80 ","SAR4442454, BNT111 and LIBTAYO (cemiplimab)",Melanoma ,Phase 2,30/07/2024 ET,"Phase 2 trial met its primary endpoint, noted July 30, 2024.",105.1M
Add to portfolio,,,FTD,,,,,
,,,View Clinical Trial Data,,,,,
SNY,Sanofi,$51.69 ,"SAR4442454, BNT111 and LIBTAYO (cemiplimab)",Melanoma ,Phase 2,30/07/2024 ET,"Phase 2 trial met its primary endpoint, noted July 30, 2024.",2.46B
Add to portfolio,,,FTD,,,,,
,,,View Clinical Trial Data,,,,,
BNTX,BioNTech SE,$86.74 ,"SAR4442454, BNT111 and LIBTAYO (cemiplimab)",Melanoma ,Phase 2,30/07/2024 ET,"Phase 2 trial met its primary endpoint, noted July 30, 2024.",239.97M
Add to portfolio,,,FTD,,,,,
,,,View Clinical Trial Data,,,,,
AVXL,Anavex Life Sciences Corp.,$6.31 ,ANAVEX 2-73,Fragile X Syndrome ,Preclinical,30/07/2024 ET,"Preclinical data reported positive results in directly to humans' translatable electroencephalogram (EEG) biomarkers present in both individuals with FXS and animal models of FXS, noted July 30, 2024.",85.89M
Add to portfolio,,,ODD,,,,,
INCY,Incyte Corporation,$67.79 ,INCA33989 (mCALR),Myelofibrosis (MF) ,Phase 1/2,30/07/2024 ET,Phase 1 ongoing .,196.32M
Add to portfolio,,,,,,,,
IMNN,Imunon Inc.,$3.32 ,IMNN-001 - (OVATION 2),Ovarian cancer ,Phase 3,30/07/2024 ET,"Phase 2 data reported an 11.1 month increase in median OS, and three-month improvement in PFS, noted July 30, 2024.",2.52M
Add to portfolio,,,,,,,,
PTCT,PTC Therapeutics Inc.,$33.03 ,SEPHIENCE (Sepiapterin (PTC923)) - (APHENITY),Phenylketonuria (PKU) ,NDA Filing,30/07/2024 ET,"NDA submitted to FDA, noted July 30, 2024.",79.44M
Add to portfolio,,,ODD,,,,,
NKGN,NKGen Biotech Inc.,$1.07 ,Troculeucel (SNK01),Alzheimer's Disease ,Preclinical,30/07/2024 ET,"Preclinical new biomarker data to be presented at AAIC showed the ability to reduce α-synuclein levels in cerebrospinal fluid. Notably, 60% of patients exhibited decreased α-synuclein levels, and 90% … read more",124.38M
Add to portfolio,,,FTD,,,,,
PMN,ProMIS Neurosciences Inc.,$1.37 ,PMN310 - (PRECISE-AD),Alzheimer's disease (AD) ,Preclinical,30/07/2024 ET,"Preclinical data reported a strong antibody responses with no measurable pro-inflammatory T cell responses against AßO and support novel approach for potential Alzheimer's disease vaccine, noted July … read more",53.81M
Add to portfolio,,,FTD,,,,,
NAMS,NewAmsterdam Pharma Company N.V.,$16.18 ,Obicetrapib - (BROOKLYN),Heterozygous familial hypercholesterolemia (HeFH) ,Phase 3,30/07/2024 ET,"Phase 3 data reported that ldl-c reduction applied to prevail baseline data continues to suggest hypothetical 20%+ mace benefit, noted July 30, 2024.",112.63M
Add to portfolio,,,,,,,,
FGEN,FibroGen Inc,$1.03 ,"SM-88, Gemcitabine, nab-paclitaxel, and pamrevlumab - (PanCAN_Precision Promise)",Metastatic pancreatic ductal adenocarcinoma (mPDAC) ,Phase 2/3,30/07/2024 ET,"Phase 2/3 data did not meet the primary endpoint of overall survival as determined by the protocol pre-specified Bayesian statistical analysis, noted July 30, 2024.",4.04M
Add to portfolio,,,View Clinical Trial Data,,,,,
FGEN,FibroGen Inc,$1.03 ,Pamrevlumab (LAPIS),Pancreatic cancer ,Phase 3,30/07/2024 ET,"Phase 3 trial did not meet the primary endpoint of overall survival, noted July 30, 2024.",4.04M
Add to portfolio,,,View Clinical Trial Data,,,,,
PEPG,PepGen Inc.,$16.98 ,PGN-EDO51 - (CONNECT1),Duchenne muscular dystrophy (DMD) ,Phase 1,30/07/2024 ET,Phase 1 Proof of concept data from the first dose cohort (5 mg/kg) of PGN-EDO51 demonstrated higher exon skipping levels than previously reported studies with similar oligonucleotide therapies. After … read more,32.8M
Add to portfolio,,,ODD,,,,,
,,,RPDD,,,,,
JNJ,Johnson & Johnson,$155.41 ,DARZALEX FASPRO (daratumumab and hyaluronidase-fihj),Frontline multiple myeloma transplant eligible ,Approved,31/07/2024 ET,"Approved July 31, 2024.",2.41B
Add to portfolio,,,,,,,,
HUMA,Humacyte Inc.,$9.46 ,ATEV - (V007),Acellular tissue engineered vessel (ATEV) in arteriovenous access for patients with end-stage renal disease. ,Phase 3,31/07/2024 ET,"Phase 3 data demonstrated superiority at six and 12 months (co-primary endpoints) compared to autogenous fistula, the current standard of care for hemodialysis, noted July 31, 2024.",158.37M
Add to portfolio,,,,,,,,
ACHV,Achieve Life Sciences Inc.,$4.98 ,Cytisinicline - (ORCA-V1),E-cigarette & vape cessation ,Phase 2,31/07/2024 ET,"Breakthrough Therapy Designation granted by the FDA, noted July 31, 2024.",51.1M
Add to portfolio,,,BTD,,,,,
VCNX,Vaccinex Inc.,$5.10 ,Pepinemab - (SIGNAL-AD),Alzheimer’s Disease (AD) ,Phase 1/2,31/07/2024 ET,"Phase 1/2 trial met primary endpoint, noted July 31, 2024.",2.68M
Add to portfolio,,,,,,,,
ALXO,ALX Oncology Holdings Inc.,$4.80 ,ALX148 + HERCEPTIN (Trastuzumab) + CYRAMZA (ramucirumab) and TAXOL (paclitaxel) - (ASPEN-06),2nd line or greater gastric/gastroesophageal junction cancer ,Phase 2,31/07/2024 ET,"Phase 2 final analysis reported an ORR of 40.3%, noted July 31, 2024.",53.55M
Add to portfolio,,,View Clinical Trial Data,,,,,
HCM,HUTCHMED (China) Limited,$19.44 ,Savolitinib + TAGRISSO (osimertinib) - (SAVANNAH),Non-small cell lung cancer (NSCLC) ,Phase 2,31/07/2024 ET,"Phase 2 enrollment completed, noted July 31, 2024.",174.43M
Add to portfolio,,,FTD,,,,,
,,,View Clinical Trial Data,,,,,
HCM,HUTCHMED (China) Limited,$19.44 ,IMG-004,Immunological diseases ,Phase 1,31/07/2024 ET,"Phase 1 topline results indicated a once-daily dosing potential. It was well tolerated, without reports of liver enzyme elevation or bleeding events, across once daily doses ranges for 10 days. Prelim … read more",174.43M
Add to portfolio,,,,,,,,
HCM,HUTCHMED (China) Limited,$19.44 ,IMG-007,Atopic dermatitis and other immunological diseases ,Phase 2a,31/07/2024 ET,"Phase 2a teatment led to rapid, marked, and durable improvement of skin signs in patients with atopic dermatitis, noted July 31, 2024.",174.43M
Add to portfolio,,,,,,,,
AGIO,Agios Pharmaceuticals Inc.,$44.50 ,Mitapivat (AG-348) - (ACTIVATE kids-T study),Pediatric PK Deficiency ,Phase 3,01/08/2024 ET,"Phase 3 data reported that 28.1% of patients in the mitapivat arm achieved the primary endpoint of transfusion reduction response, compared to 11.8% of patients in the placebo arm, noted August 1, 202 … read more",58.1M
Add to portfolio,,,,,,,,
LLY,Eli Lilly and Company,$829.83 ,Tirzepatide - (SUMMIT),Heart failure with preserved ejection fraction (HFpEF) and obesity ,Phase 3,01/08/2024 ET,"Phase 3 data reported a statistically significant improvements in both primary endpoints, noted August 1, 2024.",946.46M
Add to portfolio,,,,,,,,
RDHL,Redhill Biopharma Ltd.,$19.00 ,RHB-104 MAP,Crohn’s disease ,Phase 3,01/08/2024 ET,"Phase 3 data is 64% more effective than the standard of care alone. It achieved a statistically significant higher clinical remission rate at week 26 compared to the placebo, noted on August 1, 2024.",3.33M
Add to portfolio,,,View Clinical Trial Data,,,,,
NRSN,NeuroSense Therapeutics Ltd.,$0.68 ,PrimeC - (PARADIGM),Amyotrophic Lateral Sclerosis (ALS) ,Phase 2b,01/08/2024 ET,"Phase 2b demonstrated regulation of iron levels, which aligns with improved ALS survival and disease mitigation, noted August 1, 2024.",23.99M
Add to portfolio,,,,,,,,
GSK,GSK plc American Depositary Shares (Each representing two),$38.82 ,Jemperli (dostarlimab-gxly) plus chemotherapy,Primary advanced or recurrent endometrial cancer ,Approved,01/08/2024 ET,"Approved August 1, 2024.",2.03B
Add to portfolio,,,,,,,,
SUPN,Supernus Pharmaceuticals Inc.,$29.57 ,ONAPGO (apomorphine hydrochloride) injection (SPN-830),Motor fluctuations in Parkinson’s disease (PD) ,NDA Filing,01/08/2024 ET,"NDA resubmitted August 1, 2024.",56.07M
Add to portfolio,,,,,,,,
RGNX,REGENXBIO Inc.,$13.31 ,RGX-314 - (AAVIATE),Wet AMD using suprachoroidal delivery ,Phase 2,01/08/2024 ET,"Phase 2 update reported that treatment was well tolerated with no drug-related SAEs and no cases of intraocular inflammation, noted August 1, 2024.",50.51M
Add to portfolio,,,View Clinical Trial Data,,,,,
CLSD,Clearside Biomedical Inc.,$1.13 ,RGX-314 - (AAVIATE),Wet AMD using suprachoroidal delivery ,Phase 2,01/08/2024 ET,"Phase 2 update reported that treatment was well tolerated with no drug-related SAEs and no cases of intraocular inflammation, noted August 1, 2024.",5.23M
Add to portfolio,,,View Clinical Trial Data,,,,,
ADAP,Adaptimmune Therapeutics plc,$1.27 ,TECELRA (afamitresgene autoleucel),Unresectable or metastatic synovial sarcoma ,Approved,01/08/2024 ET,"Approved August 1, 2024.",265.05M
Add to portfolio,,,,,,,,
LBPH,Longboard Pharmaceuticals Inc.,$32.92 ,LP659,Multiple neurological diseases ,Phase 1,01/08/2024 ET,"Phase 1 SAD data reported that LP659 was generally safe and well tolerated, noted August 1, 2024.",39.05M
Add to portfolio,,,,,,,,
MRK,Merck & Company Inc.,$112.17 ,Ifinatamab deruxtecan (DS-7300) - (IDeate-Lung02 ),Extensive-stage small cell lung cancer (SCLC) ,Phase 3,01/08/2024 ET,"Phase 3 trial initiated, noted August 1, 2024.",2.5B
Add to portfolio,,,,,,,,
PDSB,PDS Biotechnology Corporation,$3.23 ,PDS0101 in combination with KEYTRUDA - (VERSATILE-003),Human papillomavirus (HPV) 16-positive head and neck squamous cell carcinoma (HNSCC) ,Phase 3,01/08/2024 ET,"Phase 3 trial to be initiated in 4Q 2024 after FDA meeting, noted August 1, 2024.",46.63M
Add to portfolio,,,,,,,,
RHHBY,Roche Holding AG ADR,$40.72 ,IONIS-FB-LRx - (GOLDEN),Geographic atrophy due to age-related macular degeneration (AMD) ,Phase 3,01/08/2024 ET,"Phase 3 trial discontinued development, noted August 1, 2024.",6.36B
Add to portfolio,,,,,,,,
IONS,Ionis Pharmaceuticals Inc.,$51.32 ,IONIS-FB-LRx - (GOLDEN),Geographic atrophy due to age-related macular degeneration (AMD) ,Phase 3,01/08/2024 ET,"Phase 3 trial discontinued development, noted August 1, 2024.",159.39M
Add to portfolio,,,,,,,,
RGNX,REGENXBIO Inc.,$13.31 ,RGX-202 - (AFFINITY DUCHENNE),Duchenne Muscular Dystrophy (DMD) ,Phase 1/2,01/08/2024 ET,"Phase 1/2 data in the pivotal dose group, patients aged 5.8 and 8.5 years showed microdystrophin expression levels of 77.2% and 46.5% of control, respectively, at three months post-treatment. The ther … read more",50.51M
Add to portfolio,,,ODD,,,,,
,,,FTD,,,,,
JAGX,Jaguar Health Inc.,$1.19 ,Mytesi (crofelemer),Inflammatory bowel disease (IBS-D) ,Phase 2,01/08/2024 ET,"Phase 2 showed a benefit in patients with chronic refractory diarrhea noted August 1, 2024.",2.17M
Add to portfolio,,,ODD,,,,,
XOMA,XOMA Royalty Corporation,$24.89 ,MIPLYFFA (MY-PLY-FAH) (arimoclomol),Niemann-Pick disease Type C (NPC) ,PDUFA,02/08/2024 ET,"FDA Advisory Committee votes resulted in 11 voting Yes, 5 voting no , none abstained, noted August 2, 2024.",12.09M
Add to portfolio,,,,,,,,
ZVRA,Zevra Therapeutics Inc.,$6.30 ,MIPLYFFA (MY-PLY-FAH) (arimoclomol),Niemann-Pick disease Type C (NPC) ,PDUFA,02/08/2024 ET,"FDA Advisory Committee votes resulted in 11 voting Yes, 5 voting no , none abstained, noted August 2, 2024.",56.14M
Add to portfolio,,,,,,,,
PSTX,Poseida Therapeutics Inc.,$3.02 ,P-BCMA-101 - (PRIME),Multiple myeloma ,Phase 2,04/08/2024 ET,"Phase 2 data reported that a repeat stringent complete response (sCR) more than 3 years after original CAR-T therapy, noted September 4, 2024.",97.47M
Add to portfolio,,,,,,,,
ATNM,Actinium Pharmaceuticals Inc.,$2.48 ,Iomab-B - (SIERRA),Acute myeloid leukemia (AML) ,Phase 3,05/08/2024 ET,"Phase 3 study determined by the FDA that the trial is not adequate to support a BLA filing for Iomab-B despite its statistically significant primary endpoint, noted August 5, 2024.",31.2M
Add to portfolio,,,View Clinical Trial Data,,,,,
IXHL,Incannex Healthcare Inc.,$2.04 ,PSX-001 (Psilocybin treatment) - (PsiGAD2),Generalized anxiety disorder (GAD) ,Phase 2b,05/08/2024 ET,"IND for Phase 2b (PsiGAD2) trial completed August 5, 2024.",347.71M
Add to portfolio,,,,,,,,
XOMA,XOMA Royalty Corporation,$23.54 ,RZ358,Hypoglycemia in patients with tumor hyperinsulinism (HI) ,Phase 3,05/08/2024 ET,"Phase 3 IND cleared August 5, 2024.",12.09M
Add to portfolio,,,ODD,,,,,
,,,BTD,,,,,
RZLT,Rezolute Inc.,$4.40 ,RZ358,Hypoglycemia in patients with tumor hyperinsulinism (HI) ,Phase 3,05/08/2024 ET,"Phase 3 IND cleared August 5, 2024.",90.81M
Add to portfolio,,,ODD,,,,,
,,,BTD,,,,,
ANNX,Annexon Inc.,$5.41 ,ANX007 - (ARCHER-II),Geographic atrophy ,Phase 3,05/08/2024 ET,"Additional data demonstrated both significant vision protection in standard and low light conditions, and significant structural protection in regions of the eye Important for visual acuity. Phase 3 p … read more",109.89M
Add to portfolio,,,,,,,,
LTRN,Lantern Pharma Inc.,$3.52 ,LP-300 - (Harmonic),Non-small cell lung cancer (NSCLC) ,Phase 2,05/08/2024 ET,"Phase 2 data reported that 3 patients showed partial responses with an average tumor size reduction of 51% and 3 patients have stable disease with an average tumor size reduction of 13%, noted August … read more",10.8M
Add to portfolio,,,,,,,,
ELEV,Elevation Oncology Inc.,$0.78 ,EO-3021 (SYSA1801) with ramucirumab + dostarlimab,Advanced Unresectable or Metastatic Solid Tumors Likely to Express Claudin 18.2 ,Phase 1,06/08/2024 ET,"Phase 1 update reported a 42.8% confirmed ORR observed in Claudin 18.2-enriched subset of gastric and GEJ cancer, noted August 6, 2024.",59.22M
Add to portfolio,,,FTD,,,,,
TFFP,TFF Pharmaceuticals Inc - Ordinary Shares,$1.65 ,TFF TAC (Tacrolimus Inhalation Powder),Lung transplant (post) ,Phase 2,06/08/2024 ET,"Phase 2 additional data reported a 6.5-fold reduction in the number of abnormally expressed rejection-related gene sets after treatment with TFF TAC, noted August 6, 2024.",4.44M
Add to portfolio,,,,,,,,
ADTX,Aditxt Inc.,—,ATI-1701,Francisella tularensis vaccine ,Preclinical,06/08/2024 ET,"Preclinical data reported a 100% survival in rats challenged with aerosolized SCHU S4 up to one-year post-vaccination, even at challenge doses >10,000x the median lethal dose (LD50), noted August 6, 2 … read more",4.98M
Add to portfolio,,,,,,,,
APLIF,Appili Therapeutics Inc,—,ATI-1701,Francisella tularensis vaccine ,Preclinical,06/08/2024 ET,"Preclinical data reported a 100% survival in rats challenged with aerosolized SCHU S4 up to one-year post-vaccination, even at challenge doses >10,000x the median lethal dose (LD50), noted August 6, 2 … read more",121.27M
Add to portfolio,,,,,,,,
EQ,Equillium Inc.,$0.73 ,Itolizumab - (EQUATOR),1st line Acute graft-versus-host disease (aGVHD) ,Phase 3,06/08/2024 ET,"Phase 3 IDMC issued a positive recommendation based on the interim data, noted August 6, 2024.",59.5M
Add to portfolio,,,View Clinical Trial Data,,,,,
CLNN,Clene Inc.,$5.88 ,CNM-Au8 - (RESCUE-ALS),Amyotrophic Lateral Sclerosis ,Phase 2,06/08/2024 ET,"Additional Phase 2 data reported that it demonstrated a 28% mean reduction in NfL levels compared to baseline, noted August 6, 2024.",9.99M
Add to portfolio,,,View Clinical Trial Data,,,,,
ANVS,Annovis Bio Inc.,$8.35 ,Buntanetap (ANVS401),Alzheimer’s disease (AD) ,Preclinical,06/08/2024 ET,"Preclinical data reported that buntanetap significantly amplifies the effects of dulaglutide on memory and learning, with a 6- to 10-fold increase in efficacy, noted August 6, 2024.",19.49M
Add to portfolio,,,ODD,,,,,
AGIO,Agios Pharmaceuticals Inc.,$42.57 ,VORANIGO (vorasidenib),Grade 2 IDH-mutant Glioma ,Approved,07/08/2024 ET,"Approved August 6, 2024.",58.1M
Add to portfolio,,,,,,,,
EYPT,EyePoint Pharmaceuticals Inc.,$8.65 ,DURAVYU ( EYP-1901 vorolanib intravitreal) - (PAVIA),Non-proliferative diabetic retinopathy (NPDR) ,Phase 2,07/08/2024 ET,"Phase 2 data demonstrated stable or improved diabetic retinopathy severity scores (DRSS) and a favorable safety profile at nine-months., noted August 7, 2024.",68.93M
Add to portfolio,,,,,,,,
PRFX,PainReform Ltd.,$7.40 ,PRF-110,Bunionectomy ,Phase 3,07/08/2024 ET,"Phase 3 data reported a promising safety profile, with maximum blood levels (Cmax) recorded at approximately 10% of the FDA-established safety threshold, noting August 7, 2024.",1.89M
Add to portfolio,,,,,,,,
AMRX,Amneal Pharmaceuticals Inc.,$6.81 ,CREXONT (Carbidopa and Levodopa),Parkinson's disease ,Approved,07/08/2024 ET,"Approved August 7, 2024.",314.08M
Add to portfolio,,,,,,,,
NVS,Novartis AG,$111.02 ,Fabhalta (iptacopan),IgA nephropathy (IgAN) ,Approved,08/08/2024 ET,"Approved August 8, 2024.",1.98B
Add to portfolio,,,View Clinical Trial Data,,,,,
APLS,Apellis Pharmaceuticals Inc.,$37.66 ,EMPAVELI (pegcetacoplan) - (VALIANT),C3G and IC-MPGN ,Phase 3,08/08/2024 ET,"Phase 3 top-line data reported that the trial met its primary endpoint, noted August 8, 2024.",126.29M
Add to portfolio,,,,,,,,
ALDX,Aldeyra Therapeutics Inc.,$4.19 ,Reproxalap (ADX-102) - (TRANQUILITY),Dry eye disease ,Phase 3,08/08/2024 ET,"Phase 3 trial met primary endpoint, noted August 8, 2024.",59.9M
Add to portfolio,,,,,,,,
CTXR,Citius Pharmaceuticals Inc.,$22.25 ,LYMPHIR (denileukin diftitox-cxdl),CTCL non-Hodgkin lymphoma ,Approved,08/08/2024 ET,"Approved August 8, 2024.",17.01M
Add to portfolio,,,View Clinical Trial Data,,,,,
OGEN,Oragenics Inc.,$1.08 ,ONP-002,Moderate-to-severe concussion in the acute through subacute phases ,Phase 2,08/08/2024 ET,"Cleared FDA-required cardiotoxicity testing, noted August 8, 2024.",4.13M
Add to portfolio,,,,,,,,
CARM,Carisma Therapeutics Inc.,$0.90 ,CT-0508 with pembrolizumab,HER2+ solid tumors ,Phase 1,08/08/2024 ET,"Phase 1 trial met primary endpoint, noted August 8, 2024.",41.79M
Add to portfolio,,,,,,,,
NTLA,Intellia Therapeutics Inc.,$22.38 ,"Lonvoguran ziclumeran (lonvo-z, formerly NTLA-2002) - (HAELO)",Hereditary angioedema (HAE) ,Phase 2,08/08/2024 ET,"Phase 2 trial met its primary endpoint, noted August 8, 2024.",107.35M
Add to portfolio,,,ODD,,,,,
,,,RMAT,,,,,
ANTX,AN2 Therapeutics Inc.,$2.64 ,EBO-301,Treatment-Refractory MAC Lung Disease ,Phase 2/3,08/08/2024 ET,"Phase 2/3 data reported higher PRO-based clinical response rate in the epetraborole + OBR arm (39.5%) vs. placebo + OBR (25.0%; treatment difference 13.9%, p=0.19), noted August 8, 2024.",27.33M
Add to portfolio,,,,,,,,
RNA,Avidity Biosciences Inc.,$46.95 ,Delpacibart zotadirsen (del-zota) - (EXPLORE44),Duchenne Muscular Dystrophy (DMD) Mutations Amenable to Exon 44 Skipping ,Phase 1/2,09/08/2024 ET,"Phase 1/2 5 mg/kg cohort data reported a statistically significant 37% increase in exon 44 skipping and up to 66% skipping with delpacibart zotadirsen 5 mg/kg at four months, noted August 9, 2024.",128.65M
Add to portfolio,,,FTD,,,,,
,,,ODD,,,,,
,,,RPDD,,,,,
,,,BTD,,,,,
KRBP,Kiromic BioPharma Inc.,$1.38 ,Deltacel-01 - (KB-GDT-01),Stage 4 Metastatic Non-Small Cell Lung Cancer ,Phase 1,09/08/2024 ET,"Phase 1 interim data reported a PFS ranging from 2 to 8 months, with an average of 4.8 months, noted August 9, 2024.",1.53M
Add to portfolio,,,FTD,,,,,
SPRY,ARS Pharmaceuticals Inc.,$10.88 ,Neffy (epinephrine nasal spray),Allergic reactions (type I) including anaphylaxis ,Approved,09/08/2024 ET,"Approved August 9, 2024.",98.83M
Add to portfolio,,,,,,,,
PSTV,PLUS THERAPEUTICS Inc.,$1.45 ,REYOBIQ (rhenium Re186 obisbemeda) - (ReSPECT-LM),Leptomeningeal metastases (LM) ,Phase 1,09/08/2024 ET,"Phase 1 dose escalation data from SNO/ASCO reported continued feasibility and safety of up to 44 mCi of intrathecal Rhenium (186Re) Obisbemeda, noted August 9, 2024.",99.26M
Add to portfolio,,,FTD,,,,,
,,,ODD,,,,,
HUMA,Humacyte Inc.,$7.91 ,SYMVESS (acellular tissue engineered vessel-tyod),Extremity Vascular Trauma ,PDUFA priority review,09/08/2024 ET,"PDUFA date was expected for August 10, 2024, however the FDA to require additional time for review, noted August 9, 2024.",158.37M
Add to portfolio,,,,,,,,
PFE,Pfizer Inc.,$28.01 ,ABRYSVO - (MONeT),Respiratory syncytial virus (RSV)-associated lower respiratory tract disease (LRTD) ,Phase 3,12/08/2024 ET,"Phase 3 data reported that ABRYSVO was well-tolerated and generated strong neutralizing responses after a single dose in adults ≥ 18 years of age, noted August 12, 2024.",5.69B
Add to portfolio,,,,,,,,
SCPH,scPharmaceuticals Inc.,$4.43 ,FUROSCIX,Heart Failure ,Approved,12/08/2024 ET,"Approved August 12, 2024.",53.3M
Add to portfolio,,,View Clinical Trial Data,,,,,
SCPH,scPharmaceuticals Inc.,$4.43 ,FUROSCIX (Autoinjector),Healthy volunteers ,Phase 1,12/08/2024 ET,"PK data reported a bioavailability of 107.3% (90% CI: 103.9 - 110.8), achieving the 90% confidence interval limit of 80 to 125 percent, noted August 12, 2024.",53.3M
Add to portfolio,,,,,,,,
NVS,Novartis AG,$111.42 ,Enzeevu (aflibercept-abzv),Neovascular age-related macular degeneration (nAMD) ,Approved,12/08/2024 ET,"Approved August 12, 2024.",1.98B
Add to portfolio,,,,,,,,
ASND,Ascendis Pharma A/S,$128.48 ,YORVIPATH (Palopegteriparatide),Hypoparathyroidism ,Approved,12/08/2024 ET,"Approved August 12, 2024.",60.69M
Add to portfolio,,,ODD,,,,,
TNXP,Tonix Pharmaceuticals Holding Corp.,$0.51 ,Tonmya (TNX-102 SL) - (RELIEF/RESILIENT),Fibromyalgia ,Phase 3,12/08/2024 ET,"Phase 3 results presented at IASP showed correlations between improvements in pain and sleep quality at Week 14, noted August 12, 2024.",8.77M
Add to portfolio,,,FTD,,,,,
OGEN,Oragenics Inc.,$2.08 ,ONP-002,Moderate-to-severe concussion in the acute through subacute phases ,Preclinical,12/08/2024 ET,"Animal data reported no cancer-causing DNA damage, noted August 12, 2024.",4.13M
Add to portfolio,,,,,,,,
AMLX,Amylyx Pharmaceuticals Inc.,$1.98 ,AMX0035 - (PEGASUS),Alzheimer's Disease ,Phase 2,12/08/2024 ET,"Phase 2 data reported that AMX0035 reduced levels of p-tau181 and total tau. AMX0035 treatment also reduced levels of synaptic and neuronal degeneration biomarkers in the CSF, specifically neurogranin … read more",89.17M
Add to portfolio,,,,,,,,
CMPX,Compass Therapeutics Inc.,$1.13 ,CTX-009 - (COMPANION-003),Colorectal cancer (CRC) ,Phase 2,12/08/2024 ET,"Phase 2 data reported an objective response rate (ORR) of 5% (2 out of 41 patients), median progression free survival (PFS) of 3.9 months, disease control rate (DCR) of 71%, noted August 12, 2024.",138.28M
Add to portfolio,,,,,,,,
SYRS,Syros Pharmaceuticals Inc.,$5.01 ,Tamibarotene (SY-1425) with VENCLEXTA (venetoclax) and VIDAZA (azacitidine) - (SELECT-AML-1),Acute myeloid leukemia (AML) ,Phase 2,12/08/2024 ET,"Phase 2 probability for success of the SELECT-AML-1 study to demonstrate superiority at the final analysis in 80 randomized patients was considered low, enrollment discontinued, noted August 12, 2024.",26.83M
Add to portfolio,,,FTD,,,,,
,,,View Clinical Trial Data,,,,,
CATX,Isoray. (DE),$12.09 ,[212Pb]VMT-α-NET,Neuroendocrine tumors (NETs) ,Phase 1,12/08/2024 ET,"Phase 1 preliminary data reported that the average renal doses for the three patients who received amino acids was 0.46±0.20 Gy/mCi, as compared to 0.56±0.16 Gy/mCi for the seven patients who did not … read more",74.26M
Add to portfolio,,,,,,,,
VCNX,Vaccinex Inc.,—,Pepinemab - (SIGNAL-AD),Alzheimer’s Disease (AD) ,Phase 1/2,12/08/2024 ET,"Phase 1/2a trial changes in the levels of GFAP and pTau-217 biomarkers in blood correlated over 12-months of treatment, with a positive relationship between the two measures (correlation coefficient > … read more",2.68M
Add to portfolio,,,,,,,,
ATAI,ATAI Life Sciences N.V.,$1.22 ,VLS-01 - (Elumina),Treatment Resistant Depression ,Phase 1b,13/08/2024 ET,"Phase 1b topline data reported that treatment demonstrated a favorable safety profile and was well tolerated, with all adverse events classified as either mild or moderate, and most resolving on the d … read more",214.34M
Add to portfolio,,,,,,,,
PSTV,PLUS THERAPEUTICS Inc.,$1.49 ,CNSide - (FORESEE),Breast or Non-Small Cell Lung Cancer (NSCLC) who have suspicious or confirmed Leptomeningeal Metastases (LM) ,Phase 1,13/08/2024 ET,"Trial data reported that the trial achieved its primary endpoint, demonstrating that CNSide influenced treatment decisions in over 90% of cases, surpassing the 20% primary endpoint target, noted Augus … read more",99.26M
Add to portfolio,,,,,,,,
ALMS,Alumis Inc.,$12.54 ,Izokibep,Hidradenitis Suppurativa (HS) ,Phase 3,13/08/2024 ET,"Phase 3 data reported statistically signiﬁcant responses across multiple eﬃcacy endpoints at 12 weeks, including 33% of patients receiving izokibep 160mg weekly (QW) achieving HiSCR75, compared to 21% … read more",104.06M
Add to portfolio,,,,,,,,
SLS,SELLAS Life Sciences Group Inc.,$1.19 ,Tambiciclib (SLS009) (GFH009) with venetoclax,"Hematologic malignancies, acute myeloid leukemia (AML), chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL) and lymphoma ",Phase 2a,13/08/2024 ET,"Phase 2a data reported that except for one, all patients in this Phase 2a trial had adverse risk AML (97%), noted August 13, 2024.",105.3M
Add to portfolio,,,ODD,,,,,
,,,FTD,,,,,
,,,RPDD,,,,,
KZR,Kezar Life Sciences Inc.,$5.80 ,KZR-261 (101),Solid Tumors ,Phase 1,13/08/2024 ET,"Phase 1 data reported no objective responses have been observed to date, noted August 13, 2024.",7.32M
Add to portfolio,,,,,,,,
ANTX,AN2 Therapeutics Inc.,$1.09 ,Epetraborole - (EBO-103),"Mycobacterium avium complex (MAC) lung disease, Chronic non-tuberculous mycobacterial (NTM) lung disease ",Phase 2,13/08/2024 ET,"Phase 2 topline data reported that trial met primary endpoint, noted August 13, 2024.",27.33M
Add to portfolio,,,,,,,,
VRCA,Verrica Pharmaceuticals Inc.,$3.12 ,VP-315 (LTX-315),Basal cell carcinoma ,Phase 2,14/08/2024 ET,"Phase 2 topline data reported an overall reduction in tumor size of all lesions treated in Part 2 of approximately 86%, noted August 14, 2024.",9.45M
Add to portfolio,,,,,,,,
VIRX,Viracta Therapeutics Inc.,$0.38 ,Nanatinostat - (NAVAL-1),Epstein Barr Virus-associated cancers ,Phase 2,14/08/2024 ET,Phase 2 additional data reported that the overall response rate (ORR) was 33% and the complete response rate (CRR) was 19% in the intent-to-treat (ITT) population (N=21); the ORR was 41% and the CRR w … read more,39.74M
Add to portfolio,,,,,,,,
GILD,Gilead Sciences Inc.,$72.85 ,Livdelzi (Seladelpar),Primary biliary cholangitis (PBC) ,Approved,14/08/2024 ET,"Approved August 14, 2024.",1.24B
Add to portfolio,,,BTD,,,,,
,,,View Clinical Trial Data,,,,,
TSBX,Turnstone Biologics Corp.,$2.18 ,TIDAL-01 / TBio-4101 (TIL) and Pembrolizumab - (STARLING),"Solid tumors in Breast Cancer, Colorectal Cancer, Uveal Melanoma ",Phase 1,14/08/2024 ET,"Phase 1 initial data reported an ORR of 25% and 50% disease control rate (""DCR"") observed in first four evaluable patients treated with TIDAL-01 with advanced CRC, noted August 14, 2024.",23.14M
Add to portfolio,,,,,,,,
SNDX,Syndax Pharmaceuticals Inc.,$19.58 ,Niktimvo (axatilimab-csfr),Chronic Graft versus host disease (cGvHD) ,Approved,14/08/2024 ET,"Approved August 14, 2024.",86.14M
Add to portfolio,,,,,,,,
INCY,Incyte Corporation,$61.18 ,Niktimvo (axatilimab-csfr),Chronic Graft versus host disease (cGvHD) ,Approved,14/08/2024 ET,"Approved August 14, 2024.",196.32M
Add to portfolio,,,,,,,,
LYRA,Lyra Therapeutics Inc.,$0.29 ,LYR-210 - (ENLIGHTEN I),Chronic rhinosinusitis ,Phase 3,14/08/2024 ET,"Phase 3 data reported that treatment resulted in a mean (standard error; SE) improvement in the 3CS score of 3.21 (0.436) points, compared to 0.96 (0.619) points in sham control for a difference of 2 … read more",1.64M
Add to portfolio,,,View Clinical Trial Data,,,,,
LIAN,LianBio,$0.31 ,LYR-210 - (ENLIGHTEN I),Chronic rhinosinusitis ,Phase 3,14/08/2024 ET,"Phase 3 data reported that treatment resulted in a mean (standard error; SE) improvement in the 3CS score of 3.21 (0.436) points, compared to 0.96 (0.619) points in sham control for a difference of 2 … read more",108.06M
Add to portfolio,,,View Clinical Trial Data,,,,,
SIGA,SIGA Technologies Inc.,$9.62 ,PALM 007 (Tecovirimat for Treatment of Monkeypox Virus),Monkeypox (mpox) ,Phase 2,15/08/2024 ET,"Phase 2 data reported that the study did not reach statistical significance on its primary endpoint of tecovirimat being superior to placebo in lesion resolution for all patients, noted August 15, 202 … read more",71.61M
Add to portfolio,,,,,,,,
VCEL,Vericel Corporation,$46.14 ,NexoBrid (CIDS),Severe burns - pediatric ,Approved,15/08/2024 ET,"Approved 15, 2024.",50.46M
Add to portfolio,,,,,,,,
MDWD,MediWound Ltd.,$18.17 ,NexoBrid (CIDS),Severe burns - pediatric ,Approved,15/08/2024 ET,"Approved 15, 2024.",11.25M
Add to portfolio,,,,,,,,
XNCR,Xencor Inc.,$16.03 ,MONJUVI (tafasitamab) with REVLIMID (lenalidomide) and RITUXAN (rituximab),Follicular lymphoma (FL) / marginal zone lymphoma (MZL) ,Phase 3,15/08/2024 ET,"Phase 3 data reported that that it met its primary endpoint of progression free survival (PFS) in relapsed or refractory follicular lymphoma (FL), noted August 15, 2024.",71.32M
Add to portfolio,,,View Clinical Trial Data,,,,,
NVS,Novartis AG,$113.31 ,MONJUVI (tafasitamab) with REVLIMID (lenalidomide) and RITUXAN (rituximab),Follicular lymphoma (FL) / marginal zone lymphoma (MZL) ,Phase 3,15/08/2024 ET,"Phase 3 data reported that that it met its primary endpoint of progression free survival (PFS) in relapsed or refractory follicular lymphoma (FL), noted August 15, 2024.",1.98B
Add to portfolio,,,View Clinical Trial Data,,,,,
INCY,Incyte Corporation,$61.68 ,MONJUVI (tafasitamab) with REVLIMID (lenalidomide) and RITUXAN (rituximab),Follicular lymphoma (FL) / marginal zone lymphoma (MZL) ,Phase 3,15/08/2024 ET,"Phase 3 data reported that that it met its primary endpoint of progression free survival (PFS) in relapsed or refractory follicular lymphoma (FL), noted August 15, 2024.",196.32M
Add to portfolio,,,View Clinical Trial Data,,,,,
AZN,AstraZeneca PLC,$84.41 ,IMFINZI (durvalumab),Non-Small Cell Lung Cancer (before and after surgery) ,Approved,16/08/2024 ET,"Approved August 16, 2024.",3.1B
Add to portfolio,,,,,,,,
PFE,Pfizer Inc.,$27.86 ,Modified RNA (modRNA) vaccine,Influenza ,Phase 2,16/08/2024 ET,"Phase 2 data reported that the primary endpoints for this qIRV first-generation candidate were not met in adults aged 65 and older, as statistical non-inferior relative vaccine efficacy (""rVE"") compar … read more",5.69B
Add to portfolio,,,,,,,,
LQDA,Liquidia Corporation,$9.79 ,YUTREPIA,Interstitial lung disease (PH-ILD) ,Approved,19/08/2024 ET,"Tentative approval announced August 19, 2024.",86.09M
Add to portfolio,,,,,,,,
APGE,Apogee Therapeutics Inc.,$50.04 ,APG777 + APG990,Atopic dermatitis (AD) ,Phase 1,19/08/2024 ET,"Phase 1 initiated in healthy volunteers, noted August 19, 2024.",59.6M
Add to portfolio,,,,,,,,
RDHL,Redhill Biopharma Ltd.,$8.03 ,Opaganib (ABC294640),Obesity ,Preclinical,19/08/2024 ET,"Invivo study done by RedHill's partner, Apogee Biotechnology Corporation has shown the impact of opaganib on weight gain and glucose tolerance in a high fat diet (HFD) model, supporting the potential … read more",3.33M
Add to portfolio,,,,,,,,
GLUE,Monte Rosa Therapeutics Inc.,$4.84 ,MRT-6160,Autoimmune conditions ,Phase 1,19/08/2024 ET,"Phase 1 dosing initiated, noted August 19, 2024.",61.76M
Add to portfolio,,,,,,,,
PCSA,Processa Pharmaceuticals Inc.,$1.52 ,SN-38,Cancer ,Preclinical,19/08/2024 ET,"Preclinical data reported that accumulation of SN-38 in the tumor compared with other tissues, such as muscle, was greater after NGC-Iri administration than after irinotecan or Onivyde administration, … read more",50.35M
Add to portfolio,,,,,,,,
SONN,Sonnet BioTherapeutics Holdings Inc.,$5.37 ,SON-1210,Solid Tumors ,Preclinical,19/08/2024 ET,"Preclinical data has demonstrated the potential of SON-1210, the first albumin-binding bifunctional IL-12/IL-15 fusion protein, for solid tumor immunotherapy. IIOC, led by Oncology experts funded by t … read more",6.75M
Add to portfolio,,,,,,,,
LLY,Eli Lilly and Company,$948.32 ,Tirzepatide - (SURMOUNT-1),Pre-diabetes and obesity or overweight ,Phase 3,20/08/2024 ET,"Phase 3 176-week data reported that treatment significantly reduced the risk of progression to type 2 diabetes by 94% ii among adults with pre-diabetes and obesity or overweight compared to placebo, n … read more",946.46M
Add to portfolio,,,,,,,,
JNJ,Johnson & Johnson,$157.69 ,RYBREVANT (amivantamab-vmjw) plus LAZCLUZE - (MARIPOSA),1L locally advanced or metastatic non-small cell lung cancer (NSCLC) ,Approved,20/08/2024 ET,"FDA approved on August 20, 2024.",2.41B
Add to portfolio,,,,,,,,
TNXP,Tonix Pharmaceuticals Holding Corp.,$0.38 ,TNX-1300 - (CATALYST),Drug overdose ,Phase 2,20/08/2024 ET,"Phase 2 dosing commenced, noted August 20, 2024.",8.77M
Add to portfolio,,,BTD,,,,,
INM,InMed Pharmaceuticals Inc.,$8.62 ,INM-901,Alzheimer’s disease ,Preclinical,20/08/2024 ET,"Preclinical studies confirmed that INM-901 as an oral formulation that will be utilized in its development programs for Alzheimer’s disease, noted August 20, 2024.",1.21M
Add to portfolio,,,,,,,,
AMRX,Amneal Pharmaceuticals Inc.,$8.10 ,Propofol emulsion (Diprivan generic),Anesthetic and sedation ,Approved,20/08/2024 ET,"FDA approved under ANDA approval on August 20, 2024.",314.08M
Add to portfolio,,,,,,,,
SPRC,SciSparc Ltd.,$0.43 ,SCI-210,Autism Spectrum Disorder ,Phase 1,20/08/2024 ET,"First 5 patients enrolled, noted August 20, 2024.",534.56K
Add to portfolio,,,,,,,,
PRFX,PainReform Ltd.,$6.32 ,PRF-110,Bunionectomy ,Phase 3,20/08/2024 ET,"Phase 3 safety data revealed a low incidence of adverse events, averaging just one per subject, noted August 20, 2024.",1.89M
Add to portfolio,,,,,,,,
AZTR,Azitra Inc,$0.64 ,ATR12-351,Netherton Syndrome ,Phase 1b,20/08/2024 ET,"Phase 1b first patient successfully screened, noted August 20, 2024.",3.52M
Add to portfolio,,,ODD,,,,,
WHWK,Whitehawk Therapeutics Inc.,—,FYARRO - (PRECISION 1),Solid tumors ,Phase 2,20/08/2024 ET,"Phase 2 analysis by the IDMC demonstrated that the study was unlikely to exceed an efficacy threshold necessary to support an accelerated approval, to preserve cash the company is halting the registra … read more",47.13M
Add to portfolio,,,View Clinical Trial Data,,,,,
REGN,Regeneron Pharmaceuticals Inc.,"$1,192.23 ",Lynozyfic (linvoseltamab-gcpt),Multiple myeloma ,CRL,20/08/2024 ET,"CRL announced August 20, 2024.",105.1M
Add to portfolio,,,FTD,,,,,
BPTH,Bio-Path Holdings Inc.,$1.50 ,Prexigebersen (BP1001),Acute Myeloid Leukemia (AML) ,Phase 2,21/08/2024 ET,"Additional Phase 2 interim data reported that the first patient received 16 cycles of treatment over 21 months and continues in complete remission, whole a second patient is completing their twelfth c … read more",8.31M
Add to portfolio,,,,,,,,
CGTX,Cognition Therapeutics Inc.,$0.76 ,CT1812 - (SEQUEL),Mild-to-Moderate Alzheimer's Disease ,Phase 2,22/08/2024 ET,Phase 2 study published in the Journal of Prevention of Alzheimer's Disease exhibited consistent trends of improvement across all prespecified electroencephalography (EEG) parameters with several reac … read more,73.47M
Add to portfolio,,,,,,,,
ALKS,Alkermes plc,$27.99 ,alixorexton (ALKS 2680) - (Vibrance-2),Narcolepsy and excessive daytime sleepiness ,Phase 2,22/08/2024 ET,"Phase 2 initiated, noted August 22, 2024.",165.12M
Add to portfolio,,,,,,,,
SKYE,Skye Bioscience Inc.,$5.28 ,Nimacimab - (CBeyond),Obesity ,Phase 2,22/08/2024 ET,"Phase 2 dosing initiated, noted August 22, 2024.",30.99M
Add to portfolio,,,,,,,,
MRNA,Moderna Inc.,$81.04 ,Spikevax (2024-2025 formula),COVID-19 Vaccine ,Approved,22/08/2024 ET,"Approved August 22, 2024.",389.08M
Add to portfolio,,,,,,,,
JAZZ,Jazz Pharmaceuticals plc,$114.55 ,Cannabidiol oral solution (GWP42003-P),Treatment-Resistant Epilepsies ,Phase 3,22/08/2024 ET,"Phase 3 trial did not meet its primary endpoint, noted August 22, 2024.",60.66M
Add to portfolio,,,,,,,,
PFE,Pfizer Inc.,$28.33 ,COMIRNATY,Omicron KP.2-adapted COVID-19 Vaccine ,Approved,22/08/2024 ET,"Approved August 22, 2024.",5.69B
Add to portfolio,,,,,,,,
BNTX,BioNTech SE,$87.23 ,COMIRNATY,Omicron KP.2-adapted COVID-19 Vaccine ,Approved,22/08/2024 ET,"Approved August 22, 2024.",239.97M
Add to portfolio,,,,,,,,
VTRS,Viatris Inc.,$11.66 ,Cenerimod (ACT-333441) - (CARE),Moderate to severe systemic lupus erythematosus (SLE) in Japanese patients ,Phase 2,23/08/2024 ET,"Phase 2 data showed a clinically meaningful improvement in disease activity consistent with results from other global Phase 2 studies, noted August 23, 2024.",1.17B
Add to portfolio,,,,,,,,
RDHL,Redhill Biopharma Ltd.,$8.43 ,Opaganib (ABC294640),Neuroblastoma ,Phase 2,26/08/2024 ET,"Phase 2 is ongoing with orphan drug designation granted by the FDA, noted August 26, 2024.",3.33M
Add to portfolio,,,ODD,,,,,
ELAB,PMGC Holdings Inc.,$64.00 ,Elevai Enfinity Topical Exosome Serum,Facial appearance ,Phase 1,26/08/2024 ET,"Trial data reported that treatment was safe and tolerable with significant improvement noted across many aspects of skin appearance, noted August 26, 2024.",677.07K
Add to portfolio,,,,,,,,
VCEL,Vericel Corporation,$49.94 ,MACI Arthro,Arthroscopic Administration ,Approved,26/08/2024 ET,"FDA approved on August 26, 2024.",50.46M
Add to portfolio,,,,,,,,
MIRA,MIRA Pharmaceuticals Inc.,$2.11 ,Ketamir-2 (Topical),"Neuropathic pain and chemo-induced depression, as well as neuropathic pain and PTSD ",Preclinical,26/08/2024 ET,"Preclinical data reported that low oral doses of Ketamir-2 led to a significant reversal of pain for 14 and 22 days following the operation. At higher oral dose, Ketamir-2 achieved complete normalizat … read more",19.07M
Add to portfolio,,,,,,,,
DARE,Dare Bioscience Inc.,$3.55 ,"Sildenafil Cream, 3.6% - (RESPOND)",Female Sexual Arousal Disorder (FSAD) ,Phase 2b,26/08/2024 ET,"Phase 2b data published at the Journal of sexual medicine showed that topical Sildenafil Cream, 3.6% was safe and well tolerated by women and their partners across 1,357 sexual experiences. Use of top … read more",13.48M
Add to portfolio,,,,,,,,
CSCI,COSCIENS Biopharma Inc.,$3.96 ,MACRILEN (Macimorelin Acetate) - (DETECT AEZS-130-P02),Pediatric patients with suspected growth hormone deficiency (GHD) ,Phase 3,27/08/2024 ET,"Phase 3 topline data reported that the trial did not meet its primary endpoint, noted August 27, 2024.",3.18M
Add to portfolio,,,View Clinical Trial Data,,,,,
CLSD,Clearside Biomedical Inc.,$1.01 ,CLS-AX - (ODYSSEY),Neovascular age-related macular degeneration (wet AMD) ,Phase 2b,27/08/2024 ET,"Phase 2b trial completed, noted August 27, 2024.",5.23M
Add to portfolio,,,,,,,,
IVVD,Invivyd Inc.,$0.92 ,PEMGARDA (VYD222 (pemivibart)) - (CANOPY),COVID-19 Prevention ,Phase 3,27/08/2024 ET,"Phase 3 data in Cohort B showed showed a relative risk reduction of 84% with pemivibart compared to placebo in the likelihood of trial participants contracting confirmed symptomatic COVID-19, with no … read more",120.14M
Add to portfolio,,,,,,,,
HUMA,Humacyte Inc.,$6.66 ,SYMVESS (acellular tissue engineered vessel-tyod),Extremity Vascular Trauma ,BLA Filing,27/08/2024 ET,Phase 3 results presented at the Department of Defense's Military Health System Research Symposium (MHSRS) showed that in real-world military setting the ATEV was observed to have 12-month patency of … read more,158.37M
Add to portfolio,,,,,,,,
ENSC,Ensysce Biosciences Inc.,$9.67 ,PF614-MPAR-102 - (MPAR),Overdose Protection ,Phase 1,27/08/2024 ET,"IRB has approved a single and multiple doser study, noted August 27, 2024.",2.97M
Add to portfolio,,,BTD,,,,,
NBIX,Neurocrine Biosciences Inc.,$123.76 ,NBI-1117568 (NBI-'568),Schizophrenia ,Phase 2,28/08/2024 ET,"Phase 2 met the primary endpoint, showing significant improvement in PANSS scores versus placebo, and was well-tolerated. Secondary endpoints were also met, noted August 28, 2024.",99.71M
Add to portfolio,,,,,,,,
VXRT,Vaxart Inc.,$0.85 ,Mucosal Vaccine,HPV-Related Cervical Dysplasia ,Preclinical,28/08/2024 ET,"Preclinical data reported that the vaccine constructs stimulate specific T cell immune responses, reduce tumor size, and increase survival in an animal model of human papillomavirus (HPV)-related tumo … read more",228.92M
Add to portfolio,,,,,,,,
NVS,Novartis AG,$119.98 ,Leqvio - (V-Mono),CVRR (Primary prevention) ,Phase 3,28/08/2024 ET,"Phase 3 data reported that the trial met its primary endpoints, demonstrating superiority of Leqvio (inclisiran) monotherapy vs both placebo and ezetimibe in LDL-C reduction, noted August 28, 2024.",1.98B
Add to portfolio,,,,,,,,
TNXP,Tonix Pharmaceuticals Holding Corp.,$0.30 ,Tonmya (TNX-102 SL) - (RELIEF/RESILIENT),Fibromyalgia ,Phase 3,28/08/2024 ET,Phase 3 data presented at MHSRS highlighted results from confirmatory Phase 3 RESILIENT study of TNX-102 SL (sublingual cyclobenzaprine HCl) treatment demonstrating statistically significant improveme … read more,8.77M
Add to portfolio,,,FTD,,,,,
KRYS,Krystal Biotech Inc.,$203.91 ,KB301 - (PEARL-1),Wrinkles and acne scars ,Phase 1,28/08/2024 ET,"Phase 1 cohort 3 & 4 data showed meaningful improvements in both décolleté and lateral canthal regions. In the décolleté cohort, 94% of subjects showed improvement at 2 months post-treatment. For late … read more",28.94M
Add to portfolio,,,,,,,,
AZTR,Azitra Inc,$0.68 ,ATR12-351,Netherton Syndrome ,Phase 1b,28/08/2024 ET,"Phase 1b dosing iniutiated, noted August 28, 2024.",3.52M
Add to portfolio,,,ODD,,,,,
GANX,Gain Therapeutics Inc.,$1.07 ,"GT-02287, GT-02329",GBA1 and Idiopathic Parkinson's Disease ,Phase 1,29/08/2024 ET,"Phase 1 data reported that single and multiple doses of GT-02287 were safe and generally well tolerated up to and including the highest planned dose levels across all age groups, with no discontinuati … read more",35.95M
Add to portfolio,,,,,,,,
JNJ,Johnson & Johnson,$162.92 ,IMAAVY (Nipocalimab) - (Vivacity-MG3),Generalized myasthenia gravis (gMG) ,BLA Filing,29/08/2024 ET,"BLA submitted August 29, 2024.",2.41B
Add to portfolio,,,,,,,,
SCLX,Scilex Holding Company,$1.11 ,GLOPERBA (colchicine),Acute and chronic pain ,Approved,29/08/2024 ET,"FDA final approval on August 29, 2024.",6.96M
Add to portfolio,,,,,,,,
LEXX,Lexaria Bioscience Corp.,$3.23 ,DehydraTECH-GLP-1 - (GLP-1-H24-2),"Healthy volunteers, Diabetes-related control, weight loss ",Phase 1,29/08/2024 ET,"Phase 1 PK data reported that 13 or 81%, experienced mild or moderate side effects with the Rybelsus tablet and only 7 people, or 44%, experienced only mild side effects with the Rybelsus that was pro … read more",19.56M
Add to portfolio,,,,,,,,
NCNA,NuCana plc,$7.73 ,NUC-3373 (NuTide: 323),2L Colorectal cancer ,Phase 2,29/08/2024 ET,"Phase 2 trial discontinued, noted August 29, 2024.",1.91M
Add to portfolio,,,,,,,,
ALNY,Alnylam Pharmaceuticals Inc.,$262.69 ,AMVUTTRA (vutrisiran),ATTR Amyloidosis with Cardiomyopathy (ATTR-CM) ,Phase 3,30/08/2024 ET,"Phase 3 data presented at ESC reported a a lack of statistical significance in ACM with vutrisiran monotherapy group for all-cause mortality up to month 36, with a hazard ratio (HR) of 0.706 (p = 0.11 … read more",131.08M
Add to portfolio,,,View Clinical Trial Data,,,,,
EBS,Emergent BioSolutions Inc.,$8.31 ,ACAM2000,Smallpox and Mpox (Vaccinia) Vaccine ,Approved,30/08/2024 ET,"Approved August 30, 2024.",53.35M
Add to portfolio,,,,,,,,
IOBT,IO Biotech Inc.,$1.50 ,"Cylembio (imsapepimut and etimupepimut, adjuvanted (IO102-IO103)) w/ pembrolizumab (KEYTRUDA) - (IOB-013/KN-D18)",Advanced melanoma ,Phase 3,30/08/2024 ET,"Phase 3 interim analysis by IDMC concluded with the recommendation to continue without modifications with primary endpoint data due in 1H 2025, noted August 30, 2024.",65.88M
Add to portfolio,,,,,,,,
AMRN,Amarin Corporation plc,$0.63 ,VASCEPA (icosapent ethyl) - (REDUCE-IT),Cardiovascular disease ,Phase 1,30/08/2024 ET,Phase 1 subgroup data shared at the ESC reported that Icosapent ethyl reduced the rate of the primary outcome compared with placebo (17.2% vs 22.0%; hazard ratio,20.68M
Add to portfolio,,,,,,,,
CYTK,Cytokinetics Incorporated,$57.08 ,Aficamten (CK-274) - (SEQUOIA-HCM),Hypertrophic cardiomyopathy (HCM) ,Phase 3,01/09/2024 ET,"Phase3 additional data reported treatment with aficamten significantly improved LVMI (-15.4 g/m2, p=0.001) and resulted in favorable cardiac remodeling as demonstrated by reductions in left ventricula … read more",119.66M
Add to portfolio,,,BTD,,,,,
,,,View Clinical Trial Data,,,,,
ARWR,Arrowhead Pharmaceuticals Inc.,$22.91 ,Plozasiran (ARO-APOC3-3001) - (PALISADE),"Familial chylomicronemia syndrome (FCS), Hypertriglyceridemia ",Phase 3,02/09/2024 ET,"Phase 3 data from ESC reported that plozasiran reduced triglycerides by 80% from baseline and reduced the risk of developing acute pancreatitis by 83%, noted September 2, 2024.",138.26M
Add to portfolio,,,BTD,,,,,
,,,View Clinical Trial Data,,,,,
PFE,Pfizer Inc.,$27.41 ,VLA15-221,Lyme disease ,Phase 2,03/09/2024 ET,Additional Phase 2 data reported a significant anamnestic antibody response across all six serotypes covered by the vaccine candidate in pediatric (5 to 11 years of age) and adolescent (12 to 17 years … read more,5.69B
Add to portfolio,,,View Clinical Trial Data,,,,,
VALN,Valneva SE,$7.27 ,VLA15-221,Lyme disease ,Phase 2,03/09/2024 ET,Additional Phase 2 data reported a significant anamnestic antibody response across all six serotypes covered by the vaccine candidate in pediatric (5 to 11 years of age) and adolescent (12 to 17 years … read more,81.26M
Add to portfolio,,,View Clinical Trial Data,,,,,
UNCY,Unicycive Therapeutics Inc.,$0.32 ,Oxylanthanum Carbonate (OLC),Kidney disease ,NDA Filing,03/09/2024 ET,"NDA submitted to the FDA under 505(b)(2) pathway, noted September 3, 2024",17.66M
Add to portfolio,,,,,,,,
PRAX,Praxis Precision Medicines Inc.,$55.38 ,PRAX-562 - (EMBOLD),Developmental epileptic encephalopathies (DEEs) ,Phase 2,03/09/2024 ET,"Phase 2 topline results reported placebo-adjusted monthly motor seizure reduction of 46% during double-blind period, noted September 3, 2024.",21.05M
Add to portfolio,,,ODD,,,,,
,,,BTD,,,,,
ELAB,PMGC Holdings Inc.,$64.00 ,Exosomes,Hairloss ,Phase 2,03/09/2024 ET,"Trial data reported ceased crown inflammation, reversal of miniaturized hairs and recovered hair from the dormant phase, among other benefits, noted September 3, 2024.",677.07K
Add to portfolio,,,,,,,,
IFRX,InflaRx N.V.,$1.61 ,INF904,Chronic Autoimmune and Inflammatory Diseases ,Preclinical,03/09/2024 ET,"Preclinical data presented at EMCHD demonstrated INF904's efficacy in reducing neutrophil activation and inflammation in various disease models, with potentially fewer drug interactions due to minimal … read more",59.35M
Add to portfolio,,,,,,,,
PCVX,Vaxcyte Inc.,$110.15 ,VAX-31,Invasive Pneumococcal Disease (IPD) ,Phase 1/2,03/09/2024 ET,"Phase 1/2 topline data reported that at the high and middle doses, VAX-31 met or exceeded the regulatory immunogenicity criteria for all 31 serotypes and, at the low dose, for 29 of 31 serotypes, note … read more",129.82M
Add to portfolio,,,,,,,,
DYN,Dyne Therapeutics Inc.,$31.94 ,DYNE-251 - (DELIVER),Duchenne muscular dystrophy (DMD) ,Phase 1/2,03/09/2024 ET,"Phase 1/2 update reported increased dystrophin expression and functional improvements across multiple patient cohorts, noted September 3, 2024.",142.26M
Add to portfolio,,,FTD,,,,,
,,,ODD,,,,,
,,,BTD,,,,,
CRBU,Caribou Biosciences Inc.,$1.98 ,CB-010 - (GALLOP),"Lupus nephritis (LN), extrarenal lupus (ERL) ",Phase 1,03/09/2024 ET,"Fast Track Designation granted by the FDA, noted September 3, 2024.",93.12M
Add to portfolio,,,FTD,,,,,
KROS,Keros Therapeutics Inc.,$47.79 ,Cibotercept (KER-012) - (TROPOS),Pulmonary arterial hypertension (PAH) and disorders associated with bone loss ,Phase 2,03/09/2024 ET,"Phase 2 screening closed, noted September 3, 2024.",40.62M
Add to portfolio,,,,,,,,
DNLI,Denali Therapeutics Inc.,$25.12 ,Tividenofusp alfa (DNL310) - (COMPASS),Hunter syndrome MPS II ,Phase 1/2,03/09/2024 ET,"Phase 1/2 data from SSIEM reported a 90% mean reduction in CSF HS from baseline at Week 24, noted September 3, 2024.",146.21M
Add to portfolio,,,BTD,,,,,
RXRX,Recursion Pharmaceuticals Inc.,$6.07 ,REC-994 - (SYCAMORE),Cerebral Cavernous Malformation (CCM) ,Phase 2,03/09/2024 ET,"Phase 2 trial met its primary endpoint, noted September 3, 2024.",434.15M
Add to portfolio,,,,,,,,
RGNX,REGENXBIO Inc.,$11.34 ,clemidsogene lanparvovec (RGX-121) - (CAMPSIITE),MPS II (Hunter Syndrome) ,Phase 3,03/09/2024 ET,"Phase 1/2/3 additional interim data presented at SSIEM 2024 demonstrated an 85% median reduction of cerebrospinal fluid (CSF) levels of heparan sulfate (HS) D2S6, a key biomarker of brain disease acti … read more",50.51M
Add to portfolio,,,RMAT,,,,,
,,,RPDD,,,,,
,,,FTD,,,,,
,,,ODD,,,,,
ATHA,Athira Pharma Inc.,$2.83 ,Fosgonimeton (ATH-1017) - (LIFT-AD),Alzheimer’s disease ,Phase 2/3,03/09/2024 ET,"Phase 2/3 topline data did not meet primary endpoint of GST and key secondary endpoints of cognition (ADAS-Cog11) and function (ADCS-ADL23), noted September 3, 2024.",3.94M
Add to portfolio,,,View Clinical Trial Data,,,,,
RNAC,Cartesian Therapeutics Inc.,$13.12 ,Descartes-15,Solid tumors ,Phase 1,03/09/2024 ET,"Preclinical data observed to achieve an approximately ten-fold increase relative to Descartes-08 in CAR expression and selective target-specific killing. Phase 1 data to dosing initiated, noted Septem … read more",26M
Add to portfolio,,,,,,,,
INDV,Indivior PLC,$12.14 ,AEF0117,Cannabis-Related Disorders (CrD) ,Phase 2b,04/09/2024 ET,"Phase 2b trial did not meet its primary or secondary endpoints, noted September 4, 2024.",124.77M
Add to portfolio,,,,,,,,
BIIB,Biogen Inc.,$204.95 ,SPINRAZA (Nusinersen) - (DEVOTE),Spinal muscular atrophy (SMA) ,Phase 2/3,04/09/2024 ET,"Phase 2/3 data reported statistically significant improvement compared to a prespecified matched sham control group, noted September 4, 2024.",146.61M
Add to portfolio,,,View Clinical Trial Data,,,,,
IONS,Ionis Pharmaceuticals Inc.,$47.65 ,SPINRAZA (Nusinersen) - (DEVOTE),Spinal muscular atrophy (SMA) ,Phase 2/3,04/09/2024 ET,"Phase 2/3 data reported statistically significant improvement compared to a prespecified matched sham control group, noted September 4, 2024.",159.39M
Add to portfolio,,,View Clinical Trial Data,,,,,
WINT,Windtree Therapeutics Inc.,$3.32 ,Istaroxime - (SEISMiC C),Cardiogenic Shock in severe acute heart failure ,Phase 2b,04/09/2024 ET,"Phase 2 extension study in SCAI Stage B enrollment to be completed, noted September 4, 2024.",29.33M
Add to portfolio,,,View Clinical Trial Data,,,,,
PHRRF,PharmaTher Holdings Ltd,$0.16 ,KETARX (ketamine),Surgical pain management ,PDUFA,04/09/2024 ET,"FDA communicated with the Company that the review is ongoing and no additional information is needed, but is subject to change, noted September 4, 2024.",91.02M
Add to portfolio,,,FTD,,,,,
IVVD,Invivyd Inc.,$0.85 ,VYD2311 - (DECLARATION),COVID-19 ,Phase 1,04/09/2024 ET,"Phase 1 initiated, noted September 4, 2024.",120.14M
Add to portfolio,,,,,,,,
ALXO,ALX Oncology Holdings Inc.,$2.06 ,evorpacept in combination with SARCLISA (isatuximab-irfc) - (UMBRELLA),Multiple myeloma (MM) ,Phase 1/2,04/09/2024 ET,"Phase 1/2 initiated, noted September 4, 2024.",53.55M
Add to portfolio,,,,,,,,
SNY,Sanofi,$58.53 ,evorpacept in combination with SARCLISA (isatuximab-irfc) - (UMBRELLA),Multiple myeloma (MM) ,Phase 1/2,04/09/2024 ET,"Phase 1/2 initiated, noted September 4, 2024.",2.46B
Add to portfolio,,,,,,,,
ELDN,Eledon Pharmaceuticals Inc.,$2.58 ,Tegoprubart (AT-1501) - (BESTOW),Kidney transplant rejection ,Phase 2,04/09/2024 ET,"Phase 2 study enrollment completed, noted September 4, 2024.",59.88M
Add to portfolio,,,,,,,,
CYTH,Cyclo Therapeutics Inc.,$0.68 ,Trappsol Cyclo - (TransportNPC),Niemann-Pick Disease Type C ,Phase 3,05/09/2024 ET,"Phase 3 data to be presented at the SSIEM Annual Symposium 2024 showed that study was well tolerated, noted September 5, 2024.",28.77M
Add to portfolio,,,ODD,,,,,
,,,View Clinical Trial Data,,,,,
RFL,Rafael Holdings Inc. Class B,—,Trappsol Cyclo - (TransportNPC),Niemann-Pick Disease Type C ,Phase 3,05/09/2024 ET,"Phase 3 data to be presented at the SSIEM Annual Symposium 2024 showed that study was well tolerated, noted September 5, 2024.",35.09M
Add to portfolio,,,ODD,,,,,
,,,View Clinical Trial Data,,,,,
ARQT,Arcutis Biotherapeutics Inc.,$10.83 ,ARQ-255,Alopecia Areata ,Phase 1b,05/09/2024 ET,"Phase 1b enrollment completed, noted September 5, 2024.",122.49M
Add to portfolio,,,,,,,,
CATX,Isoray. (DE),$15.44 ,212Pb-VMT01,MC1R-positive metastatic melanoma ,Phase 1/2,05/09/2024 ET,"Phase 1/2 FDA granted Fast Track designation, noted September 5, 2024",74.26M
Add to portfolio,,,FTD,,,,,
LLY,Eli Lilly and Company,$911.16 ,Insulin efsitora alfa (efsitora) - (QWINT-1),Type 2 diabetes ,Phase 3,05/09/2024 ET,"Phase 3 topline data reported that the trial met its primary endpoint of non-inferior A1C reduction with efsitora compared to insulin glargine at week 52, noted September 5, 2024.",946.46M
Add to portfolio,,,,,,,,
LLY,Eli Lilly and Company,$911.16 ,Insulin efsitora alfa (efsitora) - (QWINT-3),Type 2 diabetes ,Phase 3,05/09/2024 ET,"Phase 3 topline data reported that the trial met its primary endpoint of non-inferior A1C reduction with efsitora compared to insulin degludec at week 26, noted September 5, 2024.",946.46M
Add to portfolio,,,,,,,,
LSTA,Lisata Therapeutics Inc.,$3.27 ,Certepetide (LSTA1) - (BOLSTER),Intrahepatic Cholangiocarcinoma ,Phase 2a,05/09/2024 ET,"FDA granted orphan drug designation, noted September 5, 2024.",8.76M
Add to portfolio,,,ODD,,,,,
HOTH,Hoth Therapeutics Inc.,$1.26 ,HT-001 - (CLEER-001),EGFRI-induced skin toxicity ,Phase 2a,05/09/2024 ET,"Phase 2a data from study showed that during this first-of-its-kind human patient case, the patient was able to cease treatment after just one week due to the rapid and successful resolution of symptom … read more",13.26M
Add to portfolio,,,,,,,,
BTAI,BioXcel Therapeutics Inc.,$0.59 ,BXCL501 - (SERENITY III),Agitation associated with bipolar I or II disorder or schizophrenia ,Phase 3,05/09/2024 ET,"Phase 3 at-home trial initiated, noted September 5, 2024.",14.56M
Add to portfolio,,,,,,,,
VOR,Vor Biopharma Inc.,$0.83 ,Trem-cel + Mylotarg (VBP101),Acute myeloid leukemia (AML) ,Phase 1/2,05/09/2024 ET,"Phase 1/2 data reported reliable engraftment, shielding from Mylotarg on-target toxicity, a broadened Mylotarg therapeutic window, and early evidence of patient benefit, noted September 5, 2024.",6.84M
Add to portfolio,,,,,,,,
TVTX,Travere Therapeutics Inc.,$9.93 ,FILSPARI (sparsentan),IgA nephropathy (IgAN) ,Approved,05/09/2024 ET,"Approved September 5, 2024.",89.14M
Add to portfolio,,,,,,,,
LGND,Ligand Pharmaceuticals Incorporated,$103.15 ,FILSPARI (sparsentan),IgA nephropathy (IgAN) ,Approved,05/09/2024 ET,"Approved September 5, 2024.",19.6M
Add to portfolio,,,,,,,,
RIGL,Rigel Pharmaceuticals Inc.,$13.41 ,REZLIDHIA (olutasidenib) in combination with decitabine and venetoclax,Acute myeloid leukemia ,Phase 1/2,05/09/2024 ET,"Phase 1b/2 triplet therapy initiated, noted September 5, 2024.",17.94M
Add to portfolio,,,,,,,,
VTYX,Ventyx Biosciences Inc.,$2.17 ,VTX3232,Parkinson's disease ,Phase 2a,06/09/2024 ET,"Phase 2a initiated, noted September 6, 2024.",71.31M
Add to portfolio,,,,,,,,
KALV,KalVista Pharmaceuticals Inc.,$12.34 ,Sebetralstat - (KONFIDENT-S),Hereditary angioedema (HAE) ,Phase 3,06/09/2024 ET,Data presentation from Bradykinin Symposium reported a median time to treatment was 9 minutes for all attacks and 8 minutes for laryngeal attacks; the median time to beginning of symptom relief was 1. … read more,50.52M
Add to portfolio,,,,,,,,
GSK,GSK plc American Depositary Shares (Each representing two),$43.17 ,Nucala (mepolizumab),Chronic obstructive pulmonary disease (COPD) ,Phase 3,06/09/2024 ET,"Phase 3 data reported that it met its primary endpoint with the addition of Nucala to inhaled maintenance therapy, noted September 6, 2024.",2.03B
Add to portfolio,,,,,,,,
AXGN,Axogen Inc.,$13.02 ,Avance Nerve Graf - (RECON),Severed peripheral nerves ,BLA Filing,06/09/2024 ET,"BLA submission completed, noted September 6, 2024.",46.01M
Add to portfolio,,,,,,,,
YMAB,Y-mAbs Therapeutics Inc.,$13.82 ,DANYELZA (Naxitamab) - (201),High-risk neuroblastoma (HR-NB) commonly ,Phase 2,06/09/2024 ET,"Phase 2 AACR data reported that the trial achieved a disease control rate of 63%, note September 6, 2024.",45.44M
Add to portfolio,,,,,,,,
ZVRA,Zevra Therapeutics Inc.,$7.32 ,Arimoclomol (EAP),Niemann-Pick disease type C (NPC) ,Phase 3,06/09/2024 ET,"Phase 3 new clinical efficacy and safety data demonstrated clinically meaningful reduction in disease progression, noted September 6, 2024.",56.14M
Add to portfolio,,,,,,,,
CYTK,Cytokinetics Incorporated,$55.83 ,CK-4021586 (CK-586) - (AMBER-HFpEF),Heart failure with preserved ejection fraction (HFpEF) ,Phase 1,08/09/2024 ET,"Phase 1 data presented at ACCP reported dose-linearity without a change in half-life over a wide range of exposures, with steady state appearing evident within seven days of dosing, noted September 8, … read more",119.66M
Add to portfolio,,,,,,,,
LBPH,Longboard Pharmaceuticals Inc.,$34.51 ,Bexicaserin (LP352) - (DEEp OCEAN),Adolescent and adult patients with developmental and epileptic encephalopathies (DEEs) ,Phase 1/2,08/09/2024 ET,"Phase 1b/2a OLE data presented at the ILAE reported an overall median seizure reduction of 57.7% in countable motor seizures over an approximate 9-month treatment period, noted September 8, 2024.",39.05M
Add to portfolio,,,BTD,,,,,
SVRA,Savara Inc.,$4.26 ,MOLBREEVI (Molgradex) - (IMPALA-2),Autoimmune pulmonary alveolar proteinosis (aPAP) ,Phase 3,08/09/2024 ET,Phase 3 results presented at ERS reported statistical significance in change from baseline in hemoglobin-adjusted percent predicted diffusing capacity of the lungs for carbon monoxide (DLCO%) through … read more,172.84M
Add to portfolio,,,View Clinical Trial Data,,,,,
SMMT,Summit Therapeutics Inc.,$19.14 ,Ivonescimab (SMT112) with chemotherapy - (HARMONi-2),"Epidermal growth factor receptor (EGFR)-mutated, locally advanced or metastatic non-squamous NSCLC ",Phase 3,08/09/2024 ET,"Additional Phase 3 data presented at WCLC reported a hazard ratio (HR) of 0.51, and a clinically meaningful benefit was demonstrated across clinical subgroups, noted September 8, 2024.",744.44M
Add to portfolio,,,,,,,,
AZN,AstraZeneca PLC,$80.89 ,DATROWAY (datopotamab deruxtecan-dlnk)- (TROPION-Lung01),Non-small cell lung cancer (NSCLC) ,Phase 3,08/09/2024 ET,"Phase 3 data reported a meaningfully greater magnitude of progression-free survival benefit in patients with this biomarker, noted September 8, 2024.",3.1B
Add to portfolio,,,BTD,,,,,
JNJ,Johnson & Johnson,$165.28 ,Amivantamab and Lazertinib - (MARIPOSA),GFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer ,Phase 3,08/09/2024 ET,"Phase 3 longer-term data from the MARIPOSA study confirm superior outcomes of chemotherapy-free RYBREVANT® plus LAZCLUZE™ regimen compared to osimertinib monotherapy as first-line therapy, noted Septe … read more",2.41B
Add to portfolio,,,,,,,,
NUVL,Nuvalent Inc.,$89.24 ,Zidesamtinib (NVL-520) - (ARROS-1),ROS1 Non-small cell lung cancer (NSCLC) ,Phase 1,09/09/2024 ET,"Phase 1 data demonstrated encouraging efficacy and durability in patients with pretreated ROS1-positive NSCLC, noted September 9, 2024. This data is to be presented at ESMO on September 14, 2024.",72.1M
Add to portfolio,,,BTD,,,,,
AGEN,Agenus Inc.,$5.13 ,Botensilimab plus balstilimab,Relapsed/refractory microsatellite stable colorectal cancer with no active liver metastases (r/r MSS CRC NLM) ,Phase 1,09/09/2024 ET,"Phase 1 data from ESMO reported that in EE pts (n=50), ORR was 23%, DCR 66%, and median DOR 8.3 mos with 64% responses ongoing at 6-mos and longest ongoing response at 20.8+ mos, noted September 9, 2 … read more",31.86M
Add to portfolio,,,FTD,,,,,
EVAX,Evaxion A/S,$16.25 ,EVX-01 + KEYTRUDA (pembrolizumab) / OPDIVO (nivolumab),Metastatic Melanoma ,Phase 2,09/09/2024 ET,"Phase 2 data from a one-year interim analysis of the ongoing phase 2 trial show that 11 out of 16 patients had objective clinical responses, equaling a 69% Overall Response Rate to be presented, noted … read more",6.32M
Add to portfolio,,,FTD,,,,,
MRK,Merck & Company Inc.,$113.74 ,EVX-01 + KEYTRUDA (pembrolizumab) / OPDIVO (nivolumab),Metastatic Melanoma ,Phase 2,09/09/2024 ET,"Phase 2 data from a one-year interim analysis of the ongoing phase 2 trial show that 11 out of 16 patients had objective clinical responses, equaling a 69% Overall Response Rate to be presented, noted … read more",2.5B
Add to portfolio,,,FTD,,,,,
MBRX,Moleculin Biotech Inc.,$2.36 ,WP1066,Glioblastoma (NU 21C06) ,Phase 2,09/09/2024 ET,"Phase 2 patient dosing initiated, noted September 9, 2024.",30.29M
Add to portfolio,,,ODD,,,,,
,,,RPDD,,,,,
PDSB,PDS Biotechnology Corporation,$3.01 ,PDS0101 + KEYTRUDA (pembrolizumab) - (VERSATILE-002),HPV16-positive first-line recurrent and/or metastatic head and neck squamous cell cancer with low PD-L1 expression (CPS 1-19) ,Phase 2,09/09/2024 ET,"Phase 2 full data presented at ESMO reported that the median OS was 30 months (95% CI 18.4, NE) and the 12-month OS rate was 80%, noted September 9, 2024.",46.63M
Add to portfolio,,,View Clinical Trial Data,,,,,
ACTU,Actuate Therapeutics Inc.,$8.27 ,Elraglusib (9-ING-41) - (Actuate-1902),Ewing Sarcoma (Pediatric) ,Phase 1,09/09/2024 ET,"Phase 1 update reported that two patients with recurrent /refractory EWS are experiencing ongoing complete responses (CR), two patients achieved stable disease (SD), and two patients withdrew from the … read more",20.75M
Add to portfolio,,,RPDD,,,,,
PRLD,Prelude Therapeutics Incorporated,$4.96 ,PRT3789 with KEYTRUDA (pembrolizumab) - (SMARCA2/BRM),"SMARCA4-deleted cancers, solid tumors ",Phase 1,09/09/2024 ET,"Phase 1 data presented at ESMO reported partial responses, tumor shrinkage and prolonged stable disease, noted September 9, 2024.",56.6M
Add to portfolio,,,,,,,,
MRK,Merck & Company Inc.,$113.74 ,PRT3789 with KEYTRUDA (pembrolizumab) - (SMARCA2/BRM),"SMARCA4-deleted cancers, solid tumors ",Phase 1,09/09/2024 ET,"Phase 1 data presented at ESMO reported partial responses, tumor shrinkage and prolonged stable disease, noted September 9, 2024.",2.5B
Add to portfolio,,,,,,,,
REGN,Regeneron Pharmaceuticals Inc.,"$1,144.77 ",Libtayo (cemiplimab) combined with Fianlimab,Melanoma ,Phase 1,09/09/2024 ET,"Phase 1 data from ESMO reported that the median PFS was 24 months (85% CI: 12 months to NE) and median OS was not reached, noted September 9, 2024.",105.1M
Add to portfolio,,,,,,,,
EVAX,Evaxion A/S,$16.25 ,EVX-B2,Gonorrhea vaccine ,Preclinical,09/09/2024 ET,"Preclinical data reported that the vaccine triggers a targeted immune response, noted September 9, 2024.",6.32M
Add to portfolio,,,,,,,,
IBRX,ImmunityBio Inc.,$3.55 ,Anktiva (N-803) + various Checkpoint Inhibitors (QUILT-3.055),"NSCLC, Various tumors ",Phase 2b,09/09/2024 ET,"Phase 2b study showed long-term overall survival of 57 percent (49/86) and 34 percent (29/86) at 12 and 18 months respectively, exceeding the current standard of care, noted September 9, 2024.",945.25M
Add to portfolio,,,View Clinical Trial Data,,,,,
CTMX,CytomX Therapeutics Inc.,$1.25 ,Conditionally Activated Interferon Alpha-2b (CX-801),Solid tumors ,Phase 1,09/09/2024 ET,"Phase 1 dosing initiated, noted September 9, 2024.",164.91M
Add to portfolio,,,,,,,,
REPL,Replimune Group Inc.,$10.53 ,RP1 (vusolimogene oderparepvec) and OPDIVO (nivolumab) - (IGNYTE-3),Non-melanoma (NMSC) / Non-small cell lung cancer (NSCLC) ,Phase 3,09/09/2024 ET,"Phase 3 pre BLA review successfully completed, noted September 9, 2024.",78.06M
Add to portfolio,,,BTD,,,,,
,,,View Clinical Trial Data,,,,,
TCBP,TC BioPharm (Holdings) plc,$2.89 ,TCB008,Monkeypox (Mpox) ,Preclinical,09/09/2024 ET,"Preclinical proof of concept study intended, noted September 9, 2024.",2.1M
Add to portfolio,,,,,,,,
AMGN,Amgen Inc.,$323.31 ,Tarlatamab (AMG 757) - (DeLLphi-303),Small cell lung cancer (SCLC) ,Phase 1b,09/09/2024 ET,"Phase 1b trial presented at the WCLC demonstrated sustained disease control, with a 9-month overall survival rate of up to 91.8%, noted September 9, 2024.",538.36M
Add to portfolio,,,,,,,,
AMGN,Amgen Inc.,$323.31 ,Tarlatamab (AMG 757) - (DeLLphi-301),Brain metastasis ,Phase 2,09/09/2024 ET,"Phase 2 presented at the WCLC showed a long-term follow-up confirmed sustained efficacy and safety in previously treated ES-SCLC patients, with a 40% objective response rate and a median overall survi … read more",538.36M
Add to portfolio,,,,,,,,
AVBP,ArriVent BioPharma Inc.,$27.73 ,Firmonertinib monotherapy - (FURTHER),Non-small cell lung cancer (NSCLC) harboring EGFR PACC mutations ,Phase 1b,09/09/2024 ET,"Phase 1b data presented at WCLC showed an 81.8% ORR by BICR and 63.6% confirmed ORR by BICR at the 240 mg dose; 46.2% confirmed ORR in CNS Metastases, noted September 9, 2024.",40.57M
Add to portfolio,,,,,,,,
SPRY,ARS Pharmaceuticals Inc.,$11.71 ,Neffy 1 mg (epinephrine nasal spray),Anaphylaxis ,sNDA Filing,09/09/2024 ET,"sNDA submission to the FDA, noted September 9, 2024.",98.83M
Add to portfolio,,,,,,,,
ITRM,Iterum Therapeutics plc,$1.08 ,ORLYNVAH (Oral Sulopenem),Uncomplicated urinary tract infections (uUTI) ,PDUFA,09/09/2024 ET,"FDA's AdCom reviewed the drug's benefits and risks and considerations for its appropriate use but did not vote on the matter, noted September 9, 2024.",44.66M
Add to portfolio,,,,,,,,
PLRX,Pliant Therapeutics Inc.,$12.88 ,Bexotegrast (PLN-74809) - (INTEGRIS-PSC),Primary sclerosing cholangitis (PSC) ,Phase 2a,09/09/2024 ET,"Phase 2a safety and tolerability data presented at the European Respiratory Society (ERS) reported that integrin beta-6, were reduced in participants receiving bexotegrast at the 320 mg dose versus p … read more",61.39M
Add to portfolio,,,FTD,,,,,
,,,View Clinical Trial Data,,,,,
PHGE,BiomX Inc.,$1.13 ,BX004,P. aeruginosa in patients with Cystic Fibrosis (CF) ,Phase 1/2,09/09/2024 ET,"Phase 1b/2a study data presented at the European Respiratory Society (ERS) Congress reported that treatment was well tolerated and no adverse events of special interest, noted September 9, 2024.",26.53M
Add to portfolio,,,FTD,,,,,
,,,ODD,,,,,
LLY,Eli Lilly and Company,$906.69 ,Insulin efsitora alfa (efsitora) - (QWINT-2 and QWINT-4),Type 2 diabetes ,Phase 3,09/09/2024 ET,"Phase 3 QWINT-2 data presented at EASD helped adults naïve to insulin therapy currently using and not using GLP-1 receptor agonists achieve an A1C below 7% , noted May 16, 2024.",946.46M
Add to portfolio,,,,,,,,
LLY,Eli Lilly and Company,$906.69 ,Insulin efsitora alfa (efsitora) - (QWINT-5),Type 2 diabetes ,Phase 3,09/09/2024 ET,"Phase 3 data presented at EASD efsitora met the primary endpoint of non-inferior A1C reduction at week 26, noted September 9, 2024.",946.46M
Add to portfolio,,,,,,,,
MRK,Merck & Company Inc.,$113.74 ,Ifinatamab deruxtecan (DS-7300) - (IDeate-Lung02 ),Extensive-stage small cell lung cancer (SCLC) ,Phase 2,09/09/2024 ET,Phase 2 IDeate-Lung01 data reported that a confirmed objective response rate (ORR) of 54.8% (95% CI: 38.7-70.2) and 26.1% (95% CI: 14.3-41.1) were observed in patients with ES-SCLC receiving ifinatama … read more,2.5B
Add to portfolio,,,,,,,,
CCCC,C4 Therapeutics Inc.,$5.73 ,CFT1946,Solid tumors ,Phase 1,09/09/2024 ET,"Phase 1 dose escalation data presented at ESMO reported that 1 pt had an unconfirmed partial response (uPR) and 7/14 (50%) efficacy evaluable pts had a best response of stable disease or better, noted … read more",71.17M
Add to portfolio,,,,,,,,
IPHA,Innate Pharma S.A.,$2.25 ,Monalizuma - (NeoCOAST-2),Early-stage non-small cell lung cancer (NSCLC) ,Phase 2,09/09/2024 ET,"Phase 2 data reported a pathological complete response rate of 26.7% and a major pathological response rate of 53.3%, noted September 9, 2024.",92.16M
Add to portfolio,,,,,,,,
TNXP,Tonix Pharmaceuticals Holding Corp.,$0.17 ,TNX-801 - (Kenya study),"Monkeypox, horse pox and smallpox infection ",Phase 1/2,09/09/2024 ET,"Phase 1/2 vaccination demonstrated efficacy in protecting animals from lethal challenge with clade I monkeypox and is in development as an mpox vaccine, new data show improved tolerability in immunoco … read more",8.77M
Add to portfolio,,,,,,,,
OABI,OmniAb Inc.,$4.11 ,Batoclimab,Graves' Disease ,Phase 2,09/09/2024 ET,"Phase 2 additional results reported a 76% response rate in patients uncontrolled on antithyroid drugs (ATDs) at week 12, noted September 9, 2024.",122.7M
Add to portfolio,,,,,,,,
IMVT,Immunovant Inc.,$31.44 ,Batoclimab,Graves' Disease ,Phase 2,09/09/2024 ET,"Phase 2 additional results reported a 76% response rate in patients uncontrolled on antithyroid drugs (ATDs) at week 12, noted September 9, 2024.",174.32M
Add to portfolio,,,,,,,,
CVAC,CureVac N.V.,$2.92 ,CVGBM,Glioblastoma ,Phase 1,09/09/2024 ET,"Phase 1 data presented at ESMO reported that 7 pts had 9 ≥ Gr 3 AEs assessed as potentially related to CVGBM, noted September 9, 2024.",224.34M
Add to portfolio,,,,,,,,
TERN,Terns Pharmaceuticals Inc.,$9.12 ,TERN-601 - (FALCON),Obesity ,Phase 1,09/09/2024 ET,"Phase 1 data reported a statistically significant mean weight loss up to 5.5% over 28 days, noted September 9, 2024.",87.51M
Add to portfolio,,,,,,,,
RLAY,Relay Therapeutics Inc.,$9.51 ,RLY-2608 + fulvestrant + ribociclib triplet combination - (ReDiscover),"PIK3CA (PI3Kα) mutant tumors, including HR+/HER2- breast cancer ",Phase 1,09/09/2024 ET,"Phase 1 data resulted on 9.2-month median PFS in heavily pre-treated patients, 33% ORR across all patients & 53% ORR in patients with kinase mutations at RP2D. Data support planned initiation of 2L pi … read more",172.41M
Add to portfolio,,,,,,,,
NVO,Novo Nordisk A/S,—,Efruxifermin - (SYMMETRY),Metabolic-associated steatohepatitis (MASH) ,Phase 3,09/09/2024 ET,"Phase 3 Outcomes study dosing initiated, noted September 9, 2024.",4.47B
Add to portfolio,,,View Clinical Trial Data,,,,,
AKRO,Akero Therapeutics Inc.,$26.30 ,Efruxifermin - (SYMMETRY),Metabolic-associated steatohepatitis (MASH) ,Phase 3,09/09/2024 ET,"Phase 3 Outcomes study dosing initiated, noted September 9, 2024.",79.99M
Add to portfolio,,,View Clinical Trial Data,,,,,
XNCR,Xencor Inc.,$19.89 ,XmAb819,Renal Cell Carcinoma (RCC) ,Phase 1,09/09/2024 ET,"Phase 1 update reported evidence of anti-tumor activity has been observed in recent dose-escalation cohorts, noted September 9, 2024.",71.32M
Add to portfolio,,,,,,,,
XNCR,Xencor Inc.,$19.89 ,XmAb808 + pembrolizumab,Solid tumors ,Phase 1,09/09/2024 ET,"Phase 1 trial update reported prostate specific antigen (PSA) declines have been observed during the four-week monotherapy safety run-in period, noted September 9, 2024.",71.32M
Add to portfolio,,,,,,,,
NUVL,Nuvalent Inc.,$89.24 ,Neladalkib (NVL-655) - (ALKove-1),ALK non-small cell lung cancer (NSCLC) ,Phase 1,09/09/2024 ET,"Additional Phase 1 data demonstrated encouraging efficacy and durability in heavily pretreated ALK-positive NSCLC patients, noted September 9, 2024. This data is expected to be presented at ESMO Septe … read more",72.1M
Add to portfolio,,,BTD,,,,,
REGN,Regeneron Pharmaceuticals Inc.,"$1,136.35 ",Ateganosine (THIO-101),Non-small cell lung cancer (NSCLC) ,Phase 2,10/09/2024 ET,"Phase 2 update reported that 16 patients surpassed 12-month survival follow-up, with a median survival follow-up in third line of 10.6 months, noted September 10, 2024.",105.1M
Add to portfolio,,,ODD,,,,,
,,,FTD,,,,,
MAIA,MAIA Biotechnology Inc.,$3.28 ,Ateganosine (THIO-101),Non-small cell lung cancer (NSCLC) ,Phase 2,10/09/2024 ET,"Phase 2 update reported that 16 patients surpassed 12-month survival follow-up, with a median survival follow-up in third line of 10.6 months, noted September 10, 2024.",32.99M
Add to portfolio,,,ODD,,,,,
,,,FTD,,,,,
BYSI,BeyondSpring Inc.,$2.09 ,Plinabulin (Trial 103) - (DUBLIN-3),Non small cell lung cancer ,Phase 3,10/09/2024 ET,"Phase 3 study presented data at the 2024 WCLC showing that its combination with docetaxel, significantly improved overall survival (OS), progression-free survival (PFS), and objective response rate (O … read more",40.33M
Add to portfolio,,,,,,,,
VRDN,Viridian Therapeutics Inc.,$18.75 ,VRDN-001 - (THRIVE),Active Thyroid Eye Disease (TED) ,Phase 3,10/09/2024 ET,"Phase 3 data presented at Webcast achieved all primary and secondary endpoints, noted September 10, 2024.",81.66M
Add to portfolio,,,,,,,,
ALT,Altimmune Inc.,$6.96 ,Pemvidutide - (IMPACT),Metabolic dysfunction-associated steatohepatitis (MASH) ,Phase 2,10/09/2024 ET,"Phase 2 data presented at the Annual Meeting of the European Association for the Study of Diabetes reported that the lean loss ratio, defined as the change in lean mass compared to the change in total … read more",88.26M
Add to portfolio,,,FTD,,,,,
CNTA,Centessa Pharmaceuticals plc,$14.58 ,ORX750 - (CRYSTAL-1),Narcolepsy and other sleep-wake disorders ,Phase 1,10/09/2024 ET,"Phase 1 study showed a favorable safety profile with no on-target adverse events commonly associated with other OX2R agonists, such as hepatotoxicity or visual disturbances. Based on these results, Ce … read more",134.07M
Add to portfolio,,,,,,,,
LXRX,Lexicon Pharmaceuticals Inc.,$1.67 ,Sotagliflozin - (SOTA-INS CGM),Basal Insulin-Treated Type 2 Diabetes ,Phase 3,10/09/2024 ET,"Phase 3 data reported that 200 mg and 400 mg once daily TIR (15.3 and 15.9 hours, respectively) approached the ADA target, with modest reductions in time-above-range (TAR) and mild increases in time-b … read more",363.4M
Add to portfolio,,,,,,,,
RNAZ,TransCode Therapeutics Inc.,$8.46 ,TTX-MC138,Metastatic solid tumors ,Preclinical,10/09/2024 ET,"Study published the journal Oncotarget showed that stem-like breast cancer cells increase expression of miR-10b, noted September 10, 2024.",833.68K
Add to portfolio,,,ODD,,,,,
TFFP,TFF Pharmaceuticals Inc - Ordinary Shares,$1.95 ,TFF-dry powder hemagglutinin (HA) antigen,Influenza Vaccine ,Preclinical,10/09/2024 ET,"Preclinical data for its TFF-dry powder hemagglutinin (HA) antigen vaccine candidates showing induced neutralizing antibody titers in ferrets against H1 and H3 influenza strains, noted September 10, 2 … read more",4.44M
Add to portfolio,,,,,,,,
BBIO,BridgeBio Pharma Inc.,$29.99 ,BBP-812 - (CANaspire),Canavan Disease ,Phase 1/2,10/09/2024 ET,"FDA Granted RMAT designation, noted September 10, 2024.",191.17M
Add to portfolio,,,RMAT,,,,,
BBIO,BridgeBio Pharma Inc.,$29.99 ,BBP-631 - (ADventure),Congenital adrenal hyperplasia (CAH) ,Phase 1/2,10/09/2024 ET,Phase 1/2 trial topline data showed increased endogenous cortisol production in all patients at higher dose levels—a first for CAH. The therapy was well-tolerated with no treatment-related serious adv … read more,191.17M
Add to portfolio,,,FTD,,,,,
IMAB,I-MAB,$1.09 ,Uliledlimab (TJ004309),Solid tumors ,Phase 1,10/09/2024 ET,"Phase 1 PK/PD data showed a positive correlation between uliledlimab concentration and overall response rate, supporting dose selection for future trials. A Phase 2 study combining uliledlimab with pe … read more",81.5M
Add to portfolio,,,,,,,,
NUVB,Nuvation Bio Inc. Class A,$2.94 ,Taletrectinib - (TRUST-I) (China),ROS1-positive non-small cell lung cancer (NSCLC) ,Phase 2,10/09/2024 ET,Phase 2 data from ESMO reported that tumors shrank in 89% of taletrectinib-treated patients with advanced ROS1-positive (ROS1+) non-small cell lung cancer (NSCLC) who were tyrosine kinase inhibitor (T … read more,342.27M
Add to portfolio,,,BTD,,,,,
,,,ODD,,,,,
NUVB,Nuvation Bio Inc. Class A,$2.94 ,IBTROZI (taletrectinib),ROS1+ Non–Small Cell Lung Cancer ,Phase 2,10/09/2024 ET,Phase 2 data from ESMO demonstrated durable responses and prolonged progression-free survival (PFS) with long-term follow up; median duration of response (DOR) and median PFS in TKI-naïve patients wer … read more,342.27M
Add to portfolio,,,ODD,,,,,
AGIO,Agios Pharmaceuticals Inc.,$44.31 ,AG-946,Myelodysplastic syndrome (MDS) ,Phase 2a,11/09/2024 ET,"Phase 2a FDA granted Orphan drug designation, noted Septemeber 11, 2024.",58.1M
Add to portfolio,,,ODD,,,,,
MRK,Merck & Company Inc.,$113.05 ,GARDASIL9 (V503-064 ),Human Papillomavirus (HPV) vaccine ,Phase 3,11/09/2024 ET,"Phase 3 met its primary and secondary endpoints, noted September 11, 2024.",2.5B
Add to portfolio,,,,,,,,
GSK,GSK plc American Depositary Shares (Each representing two),$43.27 ,GSK3943104 - (TH HSV REC-003),Herpes simplex virus (HSV) vaccine ,Phase 1/2,11/09/2024 ET,"Phase 1/2 trial did not meet the study's primary efficacy objective, noted September 11, 2024.",2.03B
Add to portfolio,,,,,,,,
REGN,Regeneron Pharmaceuticals Inc.,"$1,141.45 ",Dupixent (dupilumab),Chronic spontaneous urticaria (CSU) ,Phase 3,11/09/2024 ET,"Phase 3 met its primary and key secondary endpoints, noted September 11, 2024.",105.1M
Add to portfolio,,,,,,,,
SNY,Sanofi,$57.46 ,Dupixent (dupilumab),Chronic spontaneous urticaria (CSU) ,Phase 3,11/09/2024 ET,"Phase 3 met its primary and key secondary endpoints, noted September 11, 2024.",2.46B
Add to portfolio,,,,,,,,
REGN,Regeneron Pharmaceuticals Inc.,"$1,141.45 ",DUPIXENT (dupilumab),Bullous pemphigoid (BP) ,Phase 3,11/09/2024 ET,"Phase 3 trial met its primary and key secondary endpoints, noted September 11, 2024.",105.1M
Add to portfolio,,,,,,,,
SNY,Sanofi,$57.46 ,DUPIXENT (dupilumab),Bullous pemphigoid (BP) ,Phase 3,11/09/2024 ET,"Phase 3 trial met its primary and key secondary endpoints, noted September 11, 2024.",2.46B
Add to portfolio,,,,,,,,
BCTX,BriaCell Therapeutics Corp.,$9.60 ,Bria-IMT + check point inhibitor (CPI) - (investigator-initiated trial),Metastatic breast cancer ,Phase 2,11/09/2024 ET,"Phase 2 data reported a median overall survival of 15.6 months and OS of 15.6 months, noted September 11, 2024.",1.76M
Add to portfolio,,,,,,,,
OSTX,OS Therapies Incorporated,$3.51 ,OST-tADC-FRA-H,Ovarian Cancer ,Preclinical,11/09/2024 ET,"Preclinical data reported an average tumor volume of 10mm3 as compared with 1000 mm3 for the untreated animals, noted September 11, 2024.",31.89M
Add to portfolio,,,,,,,,
AIM,AIM ImmunoTech Inc.,$0.31 ,Ampligen (AMP-518),Post-COVID conditions ,Phase 2,11/09/2024 ET,"Phase 2 further analysis showed that patients with Long COVID were, on average, able to walk farther in a Six-Minute Walk Test (6MWT) when compared to subjects who received a placebo, noted September … read more",2.71M
Add to portfolio,,,,,,,,
KTRA,TuHURA Biosciences Inc.,$6.05 ,REM-001,Cutaneous Metastatic Breast Cancer (CMBC) ,Phase 3,11/09/2024 ET,"Kintara warns that without the merger, it may lack the financial resources to continue the REM-001 study or operate and may need to consider bankruptcy, noted September 11, 2024.",55.66M
Add to portfolio,,,FTD,,,,,
JNJ,Johnson & Johnson,$163.51 ,TREMFYA (Guselkumab),Ulcerative colitis ,Approved,11/09/2024 ET,"Approved September 11, 2024.",2.41B
Add to portfolio,,,View Clinical Trial Data,,,,,
NVS,Novartis AG,$115.28 ,TREMFYA (Guselkumab),Ulcerative colitis ,Approved,11/09/2024 ET,"Approved September 11, 2024.",1.98B
Add to portfolio,,,View Clinical Trial Data,,,,,
AMRN,Amarin Corporation plc,$0.59 ,VASCEPA (icosapent ethyl) - (REDUCE-IT),Cardiovascular disease ,Phase 1,11/09/2024 ET,"Phase 1 trial data presented at EASD reported that absolute risk reduction was 7.9% and 9.4% in first events with a number needed to treat of 13 and 11 for the primary and key secondary endpoints, not … read more",20.68M
Add to portfolio,,,,,,,,
AURA,Aura Biosciences Inc.,$9.79 ,AU-011 (belzupacap sarotalocan) (IVT administration) - (CoMpass),Uveal melanoma including choroidal melanoma ,Phase 2,12/09/2024 ET,"Phase 2 final results reported an 80% Tumor Control Rate, and 90% Visual Acuity Preservation, noted September 12, 2024.",62.12M
Add to portfolio,,,ODD,,,,,
SNY,Sanofi,$56.75 ,Losmapimod - (REACH),Facioscapulohumeral muscular dystrophy (FSHD) ,Phase 3,12/09/2024 ET,"Phase 3 trial study failed to show an improvement in relative surface area (RSA), a measure of reachable workspace (RWS), versus placebo at week 48, study did not meet primary endpoint. Fulcrum to sus … read more",2.46B
Add to portfolio,,,FTD,,,,,
FULC,Fulcrum Therapeutics Inc.,$3.44 ,Losmapimod - (REACH),Facioscapulohumeral muscular dystrophy (FSHD) ,Phase 3,12/09/2024 ET,"Phase 3 trial study failed to show an improvement in relative surface area (RSA), a measure of reachable workspace (RWS), versus placebo at week 48, study did not meet primary endpoint. Fulcrum to sus … read more",54.09M
Add to portfolio,,,FTD,,,,,
CVAC,CureVac N.V.,$3.09 ,Multivalent seasonal influenza vaccine,Influenza B strain ,Phase 2,12/09/2024 ET,"Phase 2 data suggest the vaccine candidates have an acceptable safety and reactogenicity profile for all mRNA formulations tested, noted September 12, 2024.",224.34M
Add to portfolio,,,,,,,,
GSK,GSK plc American Depositary Shares (Each representing two),$42.61 ,Multivalent seasonal influenza vaccine,Influenza B strain ,Phase 2,12/09/2024 ET,"Phase 2 data suggest the vaccine candidates have an acceptable safety and reactogenicity profile for all mRNA formulations tested, noted September 12, 2024.",2.03B
Add to portfolio,,,,,,,,
PMN,ProMIS Neurosciences Inc.,$1.25 ,PMN310 - (PRECISE-AD),Alzheimer's disease (AD) ,Preclinical,12/09/2024 ET,"Preclinical data showed little interaction with non-toxic species and did not bind to amyloid plaques, potentially reducing the risk of amyloid-related imaging abnormalities, noted September 12, 2024.",53.81M
Add to portfolio,,,FTD,,,,,
MCRB,Seres Therapeutics Inc.,$0.96 ,SER-155,"Gastrointestinal infections, bacteremia and graft versus host disease (GvHD) ",Phase 1b,12/09/2024 ET,"Phase 1b placebo-controlled Cohort 2 data readout significantly reduced bacterial bloodstream infections (BSIs) and systemic antibiotic exposure, with fewer cases of febrile neutropenia compared to pl … read more",8.75M
Add to portfolio,,,FTD,,,,,
,,,BTD,,,,,
MNPR,Monopar Therapeutics Inc.,$3.95 ,MNPR-101-Zr (uPAR),Solid tumors ,Phase 1,12/09/2024 ET,"Phase 1 Initial results showed high specificity and durable uptake of MNPR-101-Zr in metastatic tumors compared to normal tissue, aligning with conventional PET imaging, noted September 12, 2024.",6.17M
Add to portfolio,,,,,,,,
NKGN,NKGen Biotech Inc.,$0.87 ,Troculeucel (SNK01),Alzheimer's Disease ,Phase 1,12/09/2024 ET,"Phase 1 data from two of the first three patients in the cohort, treated with the highest dose of 6 billion cells, showed cognitive improvement from moderate to mild AD after three months, noted Septe … read more",124.38M
Add to portfolio,,,FTD,,,,,
DRUG,Bright Minds Biosciences Inc.,$1.25 ,BMB-101 - (BREAKTHROUGH),Dravet Syndrome ,Phase 2,12/09/2024 ET,"Phase 2 study initiated, noted September 12, 2024.",7.08M
Add to portfolio,,,,,,,,
VYNE,VYNE Therapeutics Inc.,$1.79 ,VYN202,Moderate-to-severe plaque psoriasis ,Phase 1a,12/09/2024 ET,"Phase 1a pharmacokinetic results demonstrated dose-dependent exposure of VYN202 in blood, study was generally well tolerated with no drug-related adverse events, noted September 12, 2024.",25.47M
Add to portfolio,,,,,,,,
VERA,Vera Therapeutics Inc.,$35.66 ,Atacicept - (ORIGIN 3),IgA Nephropathy ,Phase 3,12/09/2024 ET,"Phase 3 enrollment completed, noted September 12, 2024.",63.82M
Add to portfolio,,,BTD,,,,,
,,,View Clinical Trial Data,,,,,
IPHA,Innate Pharma S.A.,$2.28 ,IPH5301 - (CHANCES),Solid tumors ,Phase 1,12/09/2024 ET,"Phase 1 data from ESMO noted that treatment was safe and well-tolerated with preliminary signals of monotherapy antitumor activity, noted September 12, 2024.",92.16M
Add to portfolio,,,,,,,,
NBIX,Neurocrine Biosciences Inc.,$121.28 ,Luvadaxistat (NBI-1065844),Cognitive Impairment Associated with Schizophrenia (CIAS) ,Phase 2,12/09/2024 ET,"Phase 2 trial failed to meet its primary endpoint, noted September 12, 2024.",99.71M
Add to portfolio,,,,,,,,
IMRX,Immuneering Corporation,$1.43 ,Atebimetinib (IMM-1-104) + mGnP,"Solid tumors, pancreatic cancer, melanoma ",Phase 2a,12/09/2024 ET,"Phase 2a data reported a complete or partial responses have been observed in the first two patients (2/5) to date, for an initial response rate of 40% and an initial disease control rate of 80%, with … read more",36.32M
Add to portfolio,,,FTD,,,,,
,,,ODD,,,,,
RHHBY,Roche Holding AG ADR,$38.71 ,Tecentriq Hybreza (atezolizumab and hyaluronidase-tqjs) with ENHANZE,"Lung, liver, skin and soft tissue cancer ",Approved,12/09/2024 ET,"Approved September 12, 2024.",6.36B
Add to portfolio,,,,,,,,
HALO,Halozyme Therapeutics Inc.,$60.54 ,Tecentriq Hybreza (atezolizumab and hyaluronidase-tqjs) with ENHANZE,"Lung, liver, skin and soft tissue cancer ",Approved,12/09/2024 ET,"Approved September 12, 2024.",116.97M
Add to portfolio,,,,,,,,
CVAC,CureVac N.V.,$3.44 ,CVGBM,Glioblastoma ,Phase 1,13/09/2024 ET,"Phase 1 data from ESMO reported the induction of cancer antigen-specific T-cell responses in 77% of evaluable patients following CVGBM monotherapy, noted September 13, 2024.",224.34M
Add to portfolio,,,,,,,,
PRLD,Prelude Therapeutics Incorporated,$2.77 ,PRT3789 with KEYTRUDA (pembrolizumab) - (SMARCA2/BRM),"SMARCA4-deleted cancers, solid tumors ",Phase 1,13/09/2024 ET,"Phase 1 data presented at ESMO showed signs of anti-tumor activity, including partial responses in 3 of 26 patients with heavily pre-treated NSCLC or esophageal cancer, and additional patients with pr … read more",56.6M
Add to portfolio,,,,,,,,
MRK,Merck & Company Inc.,$114.18 ,PRT3789 with KEYTRUDA (pembrolizumab) - (SMARCA2/BRM),"SMARCA4-deleted cancers, solid tumors ",Phase 1,13/09/2024 ET,"Phase 1 data presented at ESMO showed signs of anti-tumor activity, including partial responses in 3 of 26 patients with heavily pre-treated NSCLC or esophageal cancer, and additional patients with pr … read more",2.5B
Add to portfolio,,,,,,,,
RHHBY,Roche Holding AG ADR,$39.11 ,Ocrevus Zunovo,Multiple sclerosis (MS) or primary progressive MS ,Approved,13/09/2024 ET,"FDA approval on September 13, 2024.",6.36B
Add to portfolio,,,,,,,,
HALO,Halozyme Therapeutics Inc.,$62.30 ,Ocrevus Zunovo,Multiple sclerosis (MS) or primary progressive MS ,Approved,13/09/2024 ET,"FDA approval on September 13, 2024.",116.97M
Add to portfolio,,,,,,,,
REGN,Regeneron Pharmaceuticals Inc.,"$1,153.35 ",Dupixent (dupilumab),Chronic rhinosinusitis with nasal polyposis (CRSwNP) in adolescents aged 12 to 17 years ,Approved,13/09/2024 ET,"FDA approved on September 13, 2024.",105.1M
Add to portfolio,,,,,,,,
LLY,Eli Lilly and Company,$922.10 ,EBGLYSS (lebrikizumab-lbkz),Atopic Dermatitis ,Approved,13/09/2024 ET,"Approved September 13, 2024.",946.46M
Add to portfolio,,,View Clinical Trial Data,,,,,
CCCC,C4 Therapeutics Inc.,$6.44 ,CFT1946,Solid tumors ,Phase 1,13/09/2024 ET,"Phase 1 dose escalation data presented at ESMO showed it was well-tolerated across all doses with no dose-limiting toxicities and achieved dose-proportional pharmacokinetics, noted September 13, 2024.",71.17M
Add to portfolio,,,,,,,,
PFE,Pfizer Inc.,$28.35 ,SGN-PDL1V,Non-small cell lung cancer (NSCLC) and head and neck squamous cell carcinomas (HNSCC) ,Phase 1,13/09/2024 ET,"Phase 1 data presented at ESMO reported that treatment was generally well tolerated with no unexpected adverse events, and encouraging antitumor activity, noted September 13, 2023.",5.69B
Add to portfolio,,,,,,,,
BNTX,BioNTech SE,$123.40 ,BNT211,Solid tumors ,Phase 1/2,13/09/2024 ET,"Additional Phase 1/2 data from ESMO reported an objective response rate (ORR) was 38%, noted September 13, 2024.",239.97M
Add to portfolio,,,,,,,,
IMCR,Immunocore Holdings plc,$33.55 ,Brenetafusp (IMC-F106C) - (PRAME-A02),Solid tumors ,Phase 1,14/09/2024 ET,"Phase 1 ovarian data from ESMO reported that the median progression-free survival (PFS) was 3.3 months, and the overall survival (OS), while still maturing, was 73% at 6 months, noted September 14, 20 … read more",48.09M
Add to portfolio,,,,,,,,
ACRV,Acrivon Therapeutics Inc.,$8.91 ,ACR-368,"Platinum-resistant ovarian,(PROC) endometrial, and urothelial cancers ",Phase 2,14/09/2024 ET,"Phase 2 update from ESMO reported a overall response rate (ORR) = 62.5% observed in prospectively-selected ACR-368 OncoSignature-positive (BM+) patients with endometrial cancer, noted September 14, 20 … read more",31.46M
Add to portfolio,,,FTD,,,,,
,,,BTD,,,,,
PFE,Pfizer Inc.,$28.35 ,Ponsegromab,Cancer-associated cachexia ,Phase 2,14/09/2024 ET,"Phase 2 data from ESMO reported a significant and robust increases in body weight after 12 weeks across all doses: 2.02% (95% confidence interval (CI), -0.97 to 5.01%) in the 100 mg treatment group, 3 … read more",5.69B
Add to portfolio,,,,,,,,
INCY,Incyte Corporation,$63.56 ,INCB123667,"Late-stage cancers, ovarian cancer ",Phase 1,14/09/2024 ET,"Phase 1 safety and efficacy data from ESMO reported that the highest OR rate of 31.3% (5 responders, including 2 CRs) was found in the 50mg BID cohort, noted September 14, 2024.",196.32M
Add to portfolio,,,,,,,,
APVO,Aptevo Therapeutics Inc.,$13.13 ,ALG.APV-527,Solid tumors ,Phase 1,14/09/2024 ET,"Phase 1 interim data from ESMO report nine of 15 efficacy evaluable patients (60%) have a best overall response to date of stable disease (SD), noted September 14, 2024.",3.29M
Add to portfolio,,,,,,,,
ALMS,Alumis Inc.,$11.59 ,Subcutaneous lonigutamab - (LONGITUDE),Thyroid eye disease (TED) ,Phase 1/2,14/09/2024 ET,"Phase 1/2 preliminary safety, efficacy, and quality of life outcomes at ESOPRS reported that patients in cohort 1 (40 mg Q3W) achieved early clinical responses across manifestations of disease, noted … read more",104.06M
Add to portfolio,,,,,,,,
PFE,Pfizer Inc.,$28.35 ,Atirmociclib (PF-07220060) + PF-07104091,HR+/HER2- breast cancer ,Phase 1/2,14/09/2024 ET,"Phase 1b/2 data from ESMO showed a manageable safety profile and encouraging efficacy in patients with heavily pretreated HR+/HER2- breast cancer, noted September 14, 2024.",5.69B
Add to portfolio,,,,,,,,
BCYC,Bicycle Therapeutics plc,$27.02 ,BT5528 and OPDIVO (nivolumab),Solid tumors ,Phase 1/2,14/09/2024 ET,"Phase 1/2 data from ESMO reported that the ORR was 43% (6/14) (unconfirmed & confirmed) among patients who were EphA2+, compared with 20% (2/10) among patients who were EphA2, noted September 14, 202 … read more",69.31M
Add to portfolio,,,,,,,,
RPTX,Repare Therapeutics Inc.,$3.53 ,Camonsertib (RP-3500)/ RG6526)- (TRESR),Solid Tumors ,Phase 1/2,14/09/2024 ET,"Phase 1/2 data from ESMO reported that the overall response was 15% (7/46); 21% (7/33) excluding pts with confirmed non-biallelic LoF, noted September 14, 2024.",42.96M
Add to portfolio,,,,,,,,
ZLAB,Zai Lab Limited,$20.51 ,ZL-1218,Solid tumors ,Phase 1,14/09/2024 ET,"Phase 1 trial data from ESMO demonstrated reductions of more than 60% in CCR8+ cells and increased of CD8+ T cells, noted September 14, 2024.",109.96M
Add to portfolio,,,,,,,,
BCAB,BioAtla Inc.,$1.81 ,Ozuriftamab Vedotin (BA3021),"Solid Tumors, Non-small cell lung cancer (NSCLC), recurrent or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN) ",Phase 2,14/09/2024 ET,"Phase 2 data from ESMO reported that treatment with ozuriftamab vedotin achieved durable responses and promising tumor control among a patient population with a median of 3 prior lines of therapy, not … read more",58.72M
Add to portfolio,,,FTD,,,,,
,,,View Clinical Trial Data,,,,,
INCY,Incyte Corporation,$63.56 ,Zynyz (retifanlimab-dlwr),Advanced Anal Cancer Patients ,Phase 3,14/09/2024 ET,"Phase 3 data reported that the median PFS was significantly higher in the R vs P arm (9.30 vs 7.39 mo) noted September 14, 2024.",196.32M
Add to portfolio,,,,,,,,
BNTX,BioNTech SE,$123.40 ,BNT113 and KEYTRUDA (pembrolizumab),Head and Neck Cancer / HPV ,Phase 2,14/09/2024 ET,"Phase 2 preliminary data from ESMO reported that 70% of patients mounted cellular immune responses against E6/7 as measured ex vivo by IFNγ ELISpot, noted September 14, 2024.",239.97M
Add to portfolio,,,View Clinical Trial Data,,,,,
MGNX,MacroGenics Inc.,$3.43 ,MGC018 - (TAMARACK),Metastatic castration-resistant prostate cancer (mCRPC) ,Phase 2,15/09/2024 ET,"Phase 2 data from ESMO reported a confirmed objective response rate (ORR) was 20.0% (n=9) and the unconfirmed ORR was 26.7%, noted September 15, 2024.",63.21M
Add to portfolio,,,,,,,,
LLY,Eli Lilly and Company,$921.93 ,177Lu-PNT2002 - (SPLASH),Metastatic Castration-Resistant Prostate Cancer ,Phase 3,15/09/2024 ET,"Phase 3 data from ESMO reported that the Overall Response Rate was 38.1% vs. 12.0% for the ARPI switch arm, including 9.3% Complete Responses, noted September 15, 2024.",946.46M
Add to portfolio,,,FTD,,,,,
LNTH,Lantheus Holdings Inc.,$107.51 ,177Lu-PNT2002 - (SPLASH),Metastatic Castration-Resistant Prostate Cancer ,Phase 3,15/09/2024 ET,"Phase 3 data from ESMO reported that the Overall Response Rate was 38.1% vs. 12.0% for the ARPI switch arm, including 9.3% Complete Responses, noted September 15, 2024.",67.99M
Add to portfolio,,,FTD,,,,,
REPL,Replimune Group Inc.,$10.46 ,RP1 (vusolimogene oderparepvec) and OPDIVO (nivolumab) - (IGNYTE-3),Non-melanoma (NMSC) / Non-small cell lung cancer (NSCLC) ,Phase 3,15/09/2024 ET,"Phase 3 data from ESMO reported a primary analysis shows clinically meaningful activity across all subgroups, including those who had received prior anti-PD1 and anti-CTLA-4 or had primary resistance … read more",78.06M
Add to portfolio,,,BTD,,,,,
,,,View Clinical Trial Data,,,,,
AZN,AstraZeneca PLC,$79.04 ,IMFINZI (durvalumab),Muscle-invasive bladder cancer (MIBC) ,Phase 3,15/09/2024 ET,"Phase 3 data from ESMO reported a 32% reduction in the risk of disease progression, recurrence, not undergoing surgery, or death versus the comparator arm , notedSeptember 15, 2024.",3.1B
Add to portfolio,,,,,,,,
AMGN,Amgen Inc.,$332.58 ,LUMAKRAS (Sotorasib) + Vectibix (panitumumab) - (CodeBreak 101),Colorectal Cancer (CRC) ,Phase 1b,15/09/2024 ET,"Phase 1b data presented at ESMO reported that 30 pts had confirmed partial responses, with an overall response rate of 75%, noted September 15, 2024.",538.36M
Add to portfolio,,,,,,,,
ZNTL,Zentalis Pharmaceuticals Inc.,$3.68 ,Azenosertib Combination with Topoisomerase I,HER2+ breast cancer ,Preclinical,15/09/2024 ET,"Preclinical data from ESMO reported that 50% of animals showing complete tumor regression (CR) noted September 15, 2024.",72.14M
Add to portfolio,,,,,,,,
IMMP,Immutep Limited,$2.31 ,Eftilagimod alpha (IMP321) and KEYTRUDA (pembrolizumab) - (TACTI-003),Head and neck squamous cell carcinoma (HNSCC) ,Phase 2b,15/09/2024 ET,"Additional Phase 2b data presented at ESMO reported that E+P resulted in numerically higher ORR & DCR compared to P only in CPS ≥1 pts noted September 15, 2024.",147.19M
Add to portfolio,,,View Clinical Trial Data,,,,,
EPIX,ESSA Pharma Inc.,$7.00 ,Masofaniten (EPI-7386),Castrate resistant prostate cancer ,Phase 1b,16/09/2024 ET,"Phase 1/2 data reported that across all dose cohorts, 88% of patients (14 of 16) achieved PSA50, 88% of patients (14 of 16) achieved PSA90, 69% of patients (11 of 16) achieved PSA90 in less than 90 da … read more",47.31M
Add to portfolio,,,,,,,,
ITOS,iTeos Therapeutics Inc.,$12.10 ,Belrestotug (EOS-448/GSK4428859A) - (GALAXIES Lung-201),1L non-small cell lung cancer (NSCLC) ,Phase 2,16/09/2024 ET,"Phase 2 interim data from ESMO reported an objective response rate (ORR) of 63.3-76.7% observed with belrestotug + dostarlimab combinations, with confirmed ORR (cORR) at ~60% for every dose, noted Sep … read more",44.21M
Add to portfolio,,,,,,,,
GSK,GSK plc American Depositary Shares (Each representing two),$43.05 ,Belrestotug (EOS-448/GSK4428859A) - (GALAXIES Lung-201),1L non-small cell lung cancer (NSCLC) ,Phase 2,16/09/2024 ET,"Phase 2 interim data from ESMO reported an objective response rate (ORR) of 63.3-76.7% observed with belrestotug + dostarlimab combinations, with confirmed ORR (cORR) at ~60% for every dose, noted Sep … read more",2.03B
Add to portfolio,,,,,,,,
ZNTL,Zentalis Pharmaceuticals Inc.,$3.68 ,azenosertib (ZN-c3) + ZEJULA (Niraparib) - (DENALI),"Platinum Resistant High-Grade Serous Ovarian, Fallopian Tube or Primary Peritoneal Cancer ",Phase 2,16/09/2024 ET,"Phase 2 clinical hold lifted by the FDA, noted September 16, 2024.",72.14M
Add to portfolio,,,FTD,,,,,
IOBT,IO Biotech Inc.,$0.78 ,IO102-IO103 - (IOB-032),Squamous cell carcinoma of the head and neck (SCCHN) ,Phase 2,16/09/2024 ET,"Phase 2 data from ESMO confirmed 44.4% overall response rate (ORR) in a PD-L1 high population of patients with SCCHN irrespective of HPV status, noted September 16, 2024.",65.88M
Add to portfolio,,,,,,,,
ZNTL,Zentalis Pharmaceuticals Inc.,$3.68 ,Azenosertib (ZN-c3) - (TETON),Uterine serous carcinoma (USC) ,Phase 2,16/09/2024 ET,"Phase 2 clinical hold lifted by the FDA, noted September 16, 2024.",72.14M
Add to portfolio,,,FTD,,,,,
TNXP,Tonix Pharmaceuticals Holding Corp.,$14.75 ,TNX-801 - (Kenya study),"Monkeypox, horse pox and smallpox infection ",Phase 1/2,16/09/2024 ET,"Phase 1/2 vaccine candidate, aligns closely with the World Health Organization's (WHO) preferred target product profile (TPP) for mpox vaccines, noted Septemeber 16, 2024.",8.77M
Add to portfolio,,,,,,,,
BCYC,Bicycle Therapeutics plc,$24.97 ,Bicycle Toxin Conjugates zelenectide pevedotin (BT8009) - (Duravelo-2),Solid tumors ,Phase 1/2,16/09/2024 ET,"Phase 1/2 data from ESMO reported a 45% overall response rate (ORR), 11.1 months median duration of response and a generally well-tolerated safety profile, noted September 16, 2024.",69.31M
Add to portfolio,,,FTD,,,,,
NCNA,NuCana plc,$6.37 ,NUC-7738 (NuTide:701) in combination with pembrolizumab,Melanoma ,Phase 1/2,16/09/2024 ET,"Phase 1/2 data from ESMO reported that 75% of patients achieved disease control, including two patients who achieved Partial Responses, noted September 16, 2024.",1.91M
Add to portfolio,,,,,,,,
EVAX,Evaxion A/S,$16.25 ,EVX-01 + KEYTRUDA (pembrolizumab) / OPDIVO (nivolumab),Metastatic Melanoma ,Phase 2,16/09/2024 ET,"Phase 2 data presented at ESMO 24 showed a 69% overall response rate (ORR), with tumor reductions in 15 out of 16 patients and a 79% rate of targeted immune responses to the vaccine's neoantigens, not … read more",6.32M
Add to portfolio,,,FTD,,,,,
MRK,Merck & Company Inc.,$117.01 ,EVX-01 + KEYTRUDA (pembrolizumab) / OPDIVO (nivolumab),Metastatic Melanoma ,Phase 2,16/09/2024 ET,"Phase 2 data presented at ESMO 24 showed a 69% overall response rate (ORR), with tumor reductions in 15 out of 16 patients and a 79% rate of targeted immune responses to the vaccine's neoantigens, not … read more",2.5B
Add to portfolio,,,FTD,,,,,
JNJ,Johnson & Johnson,$165.66 ,TAR-200 with Cetrelimab - (SunRISe-4),High-Risk Non-Muscle Invasive Bladder Cancer (NMIBC) ,Phase 2b,16/09/2024 ET,"Phase 2b data reported that the overall efficacy with a centrally confirmed pathologic complete response (pCR, [T0]) rate of 42 percent compared to 23% with CET alone in patients with histologically p … read more",2.41B
Add to portfolio,,,,,,,,
PASG,Passage Bio Inc.,$0.73 ,PBFT02 - (upliFT-D),Frontotemporal dementia ,Phase 1/2,16/09/2024 ET,"Phase 1/2 data to be presented at ISFTD showed sustained increases in cerebrospinal fluid (CSF) progranulin levels in all treated patients for up to 12 months, with no serious adverse events observed … read more",3.18M
Add to portfolio,,,FTD,,,,,
,,,ODD,,,,,
CGEM,Cullinan Therapeutics Inc.,$16.93 ,Zipalertinib (CLN-081/TAS6417) - (REZILIENT1),Non-small cell lung cancer ,Phase 2b,16/09/2024 ET,"Phase 2b data reported an objective response rate of 40% , noted September 16, 2024.",59.07M
Add to portfolio,,,,,,,,
ASND,Ascendis Pharma A/S,$139.57 ,TransCon IL-2 β/γ - (IL-βelieγe),Solid tumors ,Phase 1/2,16/09/2024 ET,"Phase 1/2 initial clinical results presented at ESMO 2024 showed anti-tumor responses in 29% (4/14) of efficacy-evaluable, heavily pre-treated patients with platinum-resistant ovarian cancer (PROC) wh … read more",60.69M
Add to portfolio,,,,,,,,
ASND,Ascendis Pharma A/S,$139.57 ,TransCon CNP - (ApproaCH),Achondroplasia ,Phase 3,16/09/2024 ET,"Phase 3 topline data presented at ESMO demonstrated a significant increase in annualized growth velocity (AGV) compared to placebo, with an LS mean treatment difference of 1.49 cm/year at Week 52. Sub … read more",60.69M
Add to portfolio,,,,,,,,
CGEM,Cullinan Therapeutics Inc.,$16.93 ,CLN-978,Systemic Lupus Erythematosus (SLE) ,IND-Enabling,16/09/2024 ET,"IND submitted to the FDA, noted September 16, 2024.",59.07M
Add to portfolio,,,,,,,,
JNJ,Johnson & Johnson,$165.66 ,INLEXZO (gemcitabine intravesical system) (TAR-200) - (SunRISe-1),"Bacillus Calmette-Guérin (BCG)-unresponsive, high-risk non-muscle-invasive bladder cancer (HR-NMIBC) ",Phase 2b,16/09/2024 ET,"Phase 2b reported a 46.4% centrally-confirmed CR, noted September 16, 2024.",2.41B
Add to portfolio,,,,,,,,
BYSI,BeyondSpring Inc.,$2.18 ,Plinabulin (Trial 103) - (DUBLIN-3),Non small cell lung cancer ,Phase 3,16/09/2024 ET,"Phase 3 study presented data shared at ESMO demonstrated a substantial reduction in Grade 4 neutropenia (over 80% reduction) and a favorable safety profile, with fewer serious adverse events and impro … read more",40.33M
Add to portfolio,,,,,,,,
MRK,Merck & Company Inc.,$117.01 ,KEYTRUDA plus LENVIMA with TACE - (LEAP-012),"Unresectable, non-metastatic hepatocellular carcinoma ",Phase 3,16/09/2024 ET,"Phase 3 results from ESMO reported a reduced the risk of disease progression or death by 34% compared to TACE alone, noted September 16, 2024.",2.5B
Add to portfolio,,,,,,,,
MRK,Merck & Company Inc.,$117.01 ,KEYTRUDA (pembrolizumab) + plinabulin / docetaxel - (KeyPelms-004 / 303 Study) (TROPION Lung-01),2L/3L Non-small cell lung cancer (NSCLC) ,Phase 2,16/09/2024 ET,"Phase 2 data from the 303 Study at ESMO 2024 showed that among 19 evaluable patients, the combination achieved a 21.1% overall response rate (ORR), a median progression-free survival (PFS) of 8.63 mon … read more",2.5B
Add to portfolio,,,,,,,,
BYSI,BeyondSpring Inc.,$2.18 ,KEYTRUDA (pembrolizumab) + plinabulin / docetaxel - (KeyPelms-004 / 303 Study) (TROPION Lung-01),2L/3L Non-small cell lung cancer (NSCLC) ,Phase 2,16/09/2024 ET,"Phase 2 data from the 303 Study at ESMO 2024 showed that among 19 evaluable patients, the combination achieved a 21.1% overall response rate (ORR), a median progression-free survival (PFS) of 8.63 mon … read more",40.33M
Add to portfolio,,,,,,,,
PSTX,Poseida Therapeutics Inc.,$3.00 ,P-BCMA-ALLO1,Multiple myeloma ,Phase 1,16/09/2024 ET,"RMAT designation granted by the FDA, noted September 16, 2024.",97.47M
Add to portfolio,,,ODD,,,,,
,,,RMAT,,,,,
EXEL,Exelixis Inc.,$27.47 ,CABOMETYX (cabozantinib) and TECENTRIQ (atezolizumab) - (CONTACT-02),Castration-Resistant Prostate Cancer ,Phase 3,16/09/2024 ET,"Phase 3 final analysis of OS showed a numerical but not statistically significant improvement favoring cabozantinib in combination with atezolizumab, noted September 16, 2024.",269.2M
Add to portfolio,,,View Clinical Trial Data,,,,,
IPSEY,Ipsen ADR,$30.02 ,CABOMETYX (cabozantinib) and TECENTRIQ (atezolizumab) - (CONTACT-02),Castration-Resistant Prostate Cancer ,Phase 3,16/09/2024 ET,"Phase 3 final analysis of OS showed a numerical but not statistically significant improvement favoring cabozantinib in combination with atezolizumab, noted September 16, 2024.",328.12M
Add to portfolio,,,View Clinical Trial Data,,,,,
MRK,Merck & Company Inc.,$117.01 ,KEYTRUDA (pembrolizumab) vs Ipilimumab - (KEYNOTE-006),Advanced Melanoma ,Phase 3,16/09/2024 ET,"Phase 3 data reported that KEYTRUDA demonstrated a sustained OS benefit, reducing the risk of death by 29%, noted September 16, 2024.",2.5B
Add to portfolio,,,,,,,,
GMAB,Genmab A/S,$26.58 ,Rinatabart sesutecan (Rina-S) - (RAINFOL),"Ovarian cancer, Endometrial Cancers, Solid tumors ",Phase 1/2,16/09/2024 ET,"Phase 1/2 data demonstrated a confirmed objective response rate (ORR) of 50.0% (95% CI) in ovarian cancer patients treated with Rina-S 120 mg/m2 once every 3 weeks (Q3W), regardless of FRα expression … read more",661.87M
Add to portfolio,,,FTD,,,,,
,,,BTD,,,,,
ADAG,Adagene Inc.,$2.75 ,muzastotug (ADG126) combined with KEYTRUDA (pembrolizumab) - (ADG126-P001/KEYNOTE-C98),Solid tumors ,Phase 1/2,16/09/2024 ET,"Phase 1/2 data from ESMO reported a confirmed partial responses (PRs) doubled to four since ASCO GI in MSS CRC patients without liver and peritoneal metastases for overall response rate (ORR) of 24%, … read more",47.11M
Add to portfolio,,,,,,,,
NVS,Novartis AG,$116.95 ,Kisqali (ribociclib) - (NATALEE),Adjuvant breast cancer ,Phase 3,16/09/2024 ET,"Phase 3 data showed a deepening benefit beyond the three-year treatment period, reducing the risk of recurrence by 28.5% (HR=0.715; 95% CI 0.609–0.840; P<0.0001), compared to ET alone, noted September … read more",1.98B
Add to portfolio,,,View Clinical Trial Data,,,,,
IMTX,Immatics N.V.,$12.73 ,TCER IMA401 (MAGEA4/8),Solid tumors ,Phase 1,16/09/2024 ET,"Phase 1 data from ESMO reported a 29% ORR, noted September 16, 2024.",121.55M
Add to portfolio,,,,,,,,
SMMT,Summit Therapeutics Inc.,$29.48 ,AK112-206,Metastatic microsatellite-stable (MSS) colorectal cancer (CRC) ,Phase 2,16/09/2024 ET,"Phase 2 data reported that an 81.8% in ORR in group A with an ORR of 88.2% in group B, noted September 16, 2024.",744.44M
Add to portfolio,,,,,,,,
SMMT,Summit Therapeutics Inc.,$29.48 ,AK117-203,Triple-negative breast cancer (TNBC) ,Phase 2,16/09/2024 ET,"Phase 2 data reported an ORR of 72.4%, noted September 16, 2024.",744.44M
Add to portfolio,,,,,,,,
SMMT,Summit Therapeutics Inc.,$29.48 ,AK117-201,Recurrent / metastatic head and neck squamous cell carcinoma (HNSCC) ,Phase 2,16/09/2024 ET,"Phase 2 data reported an ORR of 30.0% in the monotherapy, and of 60% in the combo, noted September 16, 2024.",744.44M
Add to portfolio,,,,,,,,
COYA,Coya Therapeutics Inc.,$6.28 ,COYA 302,Parkinson's disease (PD) ,Preclinical,16/09/2024 ET,"Preclinical data reported that COYA 302 significantly reduced inflammation and microglial activation in nigrostriatal brain regions responsible for motor control, noted September 16, 2024.",16.73M
Add to portfolio,,,,,,,,
MRK,Merck & Company Inc.,$117.01 ,WELIREG - (LITESPARK-005),Advanced renal cell carcinoma (RCC) ,Phase 3,16/09/2024 ET,"Phase 3 data from ESMO reported that the median OS was 21.4 mo with belzutifan vs 18.2 mo with everolimus, noted September 16, 2024.",2.5B
Add to portfolio,,,,,,,,
PDSB,PDS Biotechnology Corporation,$3.06 ,PDS0101 + KEYTRUDA (pembrolizumab) - (VERSATILE-002),HPV16-positive first-line recurrent and/or metastatic head and neck squamous cell cancer with low PD-L1 expression (CPS 1-19) ,Phase 2,16/09/2024 ET,"Phase 2 full data presented at ESMO reported that the median OS was 30 months (95% CI 18.4, NE), ORR of 36% and the 12-month OS rate was 77%, noted September 16, 2024.",46.63M
Add to portfolio,,,View Clinical Trial Data,,,,,
NXTC,NextCure Inc.,$1.33 ,NC410 in combination w/ pembrolizumab - (LAIR-2),Solid Tumors ,Phase 1/2,16/09/2024 ET,"Phase 1b/2 data presented at ESMO showed clinical activity in hard-to-treat cancers, including ovarian cancer and immune checkpoint inhibitor (ICI)-naïve and refractory microsatellite stable (MSS)/mic … read more",2.68M
Add to portfolio,,,,,,,,
IMAB,I-MAB,$1.06 ,Givastomig (TJ033721 / ABL111),"First-line metastatic gastric cancers, solid tumors ",Phase 1,16/09/2024 ET,"Phase 1 study determined the recommended Phase 2 dose to be 8-12 mg/kg, with givastomig being well-tolerated up to the highest study doses. In 43 patients with advanced gastroesophageal carcinoma, the … read more",81.5M
Add to portfolio,,,ODD,,,,,
MRK,Merck & Company Inc.,$117.01 ,KEYTRUDA (pembrolizumab) in combination with trastuzumab - (KEYNOTE-811),HER2-positive gastric or Gastroesophageal junction (GEJ) adenocarcinoma ,Phase 3,16/09/2024 ET,"Phase 3 data presented at ESMO reported that ORR was 72.6% vs 60.1% with pembro + SOC vs pbo + SOC, noted September 16, 2024.",2.5B
Add to portfolio,,,,,,,,
ZYME,Zymeworks Inc.,$12.51 ,Zanidatamab (ZW25) - (mGEA),"HER2-expressing Gastrointestinal Cancers (Gastroesophageal Adenocarcinoma, Biliary Tract Cancer, and Colorectal Cancer) ",Phase 2,16/09/2024 ET,"Phase 2 data presented at ESMO showed a confirmed objective response rate (cORR) of 84%, a median duration of response (DoR) of 18.7 months, a median progression-free survival (mPFS) of 15.2 months, a … read more",75.17M
Add to portfolio,,,View Clinical Trial Data,,,,,
MRK,Merck & Company Inc.,$117.34 ,MK-1022 (patritumab deruxtecan) - (HERTHENA-Lung02),EGFR-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC) ,Phase 3,17/09/2024 ET,Phase 3 data reported a statistically significant progression-free survival improvement in this EGFR-mutated non-small cell lung cancer population with high unmet need following prior EGFR TKI treatme … read more,2.5B
Add to portfolio,,,BTD,,,,,
DSNKY,"Daiichi Sankyo Co., Ltd. ADR",$35.11 ,MK-1022 (patritumab deruxtecan) - (HERTHENA-Lung02),EGFR-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC) ,Phase 3,17/09/2024 ET,Phase 3 data reported a statistically significant progression-free survival improvement in this EGFR-mutated non-small cell lung cancer population with high unmet need following prior EGFR TKI treatme … read more,1.92B
Add to portfolio,,,BTD,,,,,
VIGL,Vigil Neuroscience Inc.,$3.50 ,VG-3927,Alzheimer's disease ,Phase 1,17/09/2024 ET,"Phase 1 partial clinical hold removed by the FDA, noted September 17, 2024.",46.67M
Add to portfolio,,,,,,,,
SNY,Sanofi,—,VG-3927,Alzheimer's disease ,Phase 1,17/09/2024 ET,"Phase 1 partial clinical hold removed by the FDA, noted September 17, 2024.",2.46B
Add to portfolio,,,,,,,,
ACRS,Aclaris Therapeutics Inc.,$1.17 ,ATI-2138,Atopic dermatitis (AD) ,Phase 2a,17/09/2024 ET,"Phase 2a initiated, noted September 17, 2024.",108.33M
Add to portfolio,,,,,,,,
RCKT,Rocket Pharmaceuticals Inc.,$21.80 ,RP-A501,Danon disease ,Phase 2,17/09/2024 ET,"Phase 2 enrollment completed, noted September 17, 2024",107.9M
Add to portfolio,,,BTD,,,,,
RNAZ,TransCode Therapeutics Inc.,$9.57 ,TTX-MC138,Metastatic solid tumors ,Phase 1,17/09/2024 ET,"Phase 1 dosing initiated September 17, 2024.",833.68K
Add to portfolio,,,ODD,,,,,
HOTH,Hoth Therapeutics Inc.,$1.07 ,HT-ALZ,Alzheimer's Disease ,Preclinical,17/09/2024 ET,"Preclinical data reported significant reductions in astrocyte activity were observed in key areas of the brain, suggesting a potential link between reduced reactive astrocytes, and improved cognitive … read more",13.26M
Add to portfolio,,,,,,,,
LSTA,Lisata Therapeutics Inc.,$3.10 ,Certepetide (LSTA1) - (BOLSTER),Intrahepatic Cholangiocarcinoma ,Phase 2a,17/09/2024 ET,"Phase 2a trial dosing initiated, noted September 17, 2024.",8.76M
Add to portfolio,,,ODD,,,,,
ALLR,Allarity Therapeutics Inc.,$2.99 ,Stenoparib,Advanced ovarian cancer (AOC) ,Phase 2,17/09/2024 ET,"Phase 2 study showed that two heavily pre-treated ovarian cancer patients have surpassed one year on therapy, highlighting the drug's potential for durable clinical benefit, noted September 17, 2024.",14.62M
Add to portfolio,,,FTD,,,,,
INMB,INmune Bio Inc.,$5.55 ,AD02,Alzheimer's Disease (AD) ,Phase 2,17/09/2024 ET,"Phase 2 data reported a highly significant correlation (p<0.001) between baseline scores on EMACC and CDR-SB, noted September 17, 2024.",26.59M
Add to portfolio,,,,,,,,
NVS,Novartis AG,$115.70 ,Kisqali (ribociclib) - (NATALEE),Adjuvant breast cancer ,Approved,17/09/2024 ET,"FDA Approved on September 17, 2024.",1.98B
Add to portfolio,,,View Clinical Trial Data,,,,,
PPBT,Purple Biotech Ltd.,$7.37 ,CM24 and OPDIVO (nivolumab),2L metastatic pancreatic cancer (PDAC) ,Phase 2,17/09/2024 ET,"Phase 2 data reported a potential 62% reduction in risk of death (HR=0.38) for CM24+nivolumab+Nal-IRI/5FU/LV therapy in PDAC patients, and prolongation of 3.3 months in median OS, noted September 17, … read more",2.65M
Add to portfolio,,,,,,,,
IMUX,Immunic Inc.,$1.79 ,IMU-838 - (CALLIPER),Progressive Multiple Sclerosis ,Phase 2,18/09/2024 ET,Phase 2 data reported a 10% decrease in NfL versus a 20% increase for placebo among those with an Expanded Disability Status Scale (EDSS) score ≤ 5.5; and a 2% decrease for vidofludimus calcium versus … read more,98.65M
Add to portfolio,,,View Clinical Trial Data,,,,,
AZN,AstraZeneca PLC,$78.58 ,FASENRA (benralizumab) - (MANDARA),Eosinophilic granulomatosis with polyangiitis (EGPA) ,Approved,18/09/2024 ET,"FDA Approved on September 18, 2024.",3.1B
Add to portfolio,,,,,,,,
TGTX,TG Therapeutics Inc.,$25.25 ,BRIUMVI (ublituximab-xiiy) - (ENHANCE),Relapsing forms of Multiple Sclerosis (RMS) ,Phase 3,18/09/2024 ET,"Phase 3b additional data presented at ECTRIMS showed that 30-minute BRIUMVI infusions were well-tolerated, with only mild (Grade 1) infusion-related reactions, and patients switching from prior anti- … read more",158.67M
Add to portfolio,,,View Clinical Trial Data,,,,,
BCTX,BriaCell Therapeutics Corp.,$7.85 ,Bria-OTS,Advanced breast cancer ,Phase 1/2,18/09/2024 ET,"FDA granted Expanded Access Policy (EAP), noted September 18, 2024.",1.76M
Add to portfolio,,,,,,,,
FDMT,4D Molecular Therapeutics Inc.,$16.82 ,4D-150 - (PRISM),Wet age-related macular degeneration (AMD) ,Phase 1/2,18/09/2024 ET,"Phase 1/2 data reported a 83% overall reduction in annualized injections through 52 weeks, noted September 18, 2024.",46.7M
Add to portfolio,,,RMAT,,,,,
RHHBY,Roche Holding AG ADR,$39.61 ,Xofluza (baloxavir marboxil) - (CENTERSTONE),Influenza viruses ,Phase 3,18/09/2024 ET,"Phase 3 trial met its primary endpoint, noted September 19, 2024.",6.36B
Add to portfolio,,,,,,,,
VNDA,Vanda Pharmaceuticals Inc.,$4.65 ,Tradipitant - (VP-VLY-686-3303),Gastroparesis ,CRL,19/09/2024 ET,"CRL issued by the FDA on September 18, 2024.",59.09M
Add to portfolio,,,View Clinical Trial Data,,,,,
EWTX,Edgewise Therapeutics Inc.,$29.50 ,EDG-7500 - (CIRRUS-HCM),Hypertrophic Cardiomyopathy (HCM) ,Phase 2,19/09/2024 ET,Phase 2 data showed that a single dose significantly reduced left ventricular outflow tract gradients without reducing LVEF. The company has initiated a 28-day trial and expects to report data in ear … read more,105.35M
Add to portfolio,,,,,,,,
AZN,AstraZeneca PLC,$78.90 ,Ampligen (rintatolimod) with Imfinzi (durvalumab) - (DURIPANC),Pancreatic Cancer ,Phase 1/2,19/09/2024 ET,"Phase 1b/2 data reported stable disease in two out of three patients at 6 months in the first subject cohort, noted September 19, 2024.",3.1B
Add to portfolio,,,,,,,,
AIM,AIM ImmunoTech Inc.,$0.29 ,Ampligen (rintatolimod) with Imfinzi (durvalumab) - (DURIPANC),Pancreatic Cancer ,Phase 1/2,19/09/2024 ET,"Phase 1b/2 data reported stable disease in two out of three patients at 6 months in the first subject cohort, noted September 19, 2024.",2.71M
Add to portfolio,,,,,,,,
ALGS,Aligos Therapeutics Inc.,$10.18 ,ALG-055009 - (HERALD),Metabolic dysfunction-associated steatohepatitis (MASH) ,Phase 2a,19/09/2024 ET,"Phase 2a topline data reported that the trial met the primary endpoint with statistically significant reductions in liver fat at Week 12 as measured by MRI-PDFF, noted September 19, 2024.",6.15M
Add to portfolio,,,,,,,,
KRBP,Kiromic BioPharma Inc.,$1.58 ,Deltacel-01 - (KB-GDT-01),Stage 4 Metastatic Non-Small Cell Lung Cancer ,Phase 1,19/09/2024 ET,"Phase 1 SMC has unanimously voted in favor of proceeding with the expansion phase of trial, noted September 19, 2024.",1.53M
Add to portfolio,,,FTD,,,,,
JNJ,Johnson & Johnson,$163.51 ,RYBREVANT (amivantamab-vmjw),Second-line EGFR-mutated advanced lung cancer ,Approved,19/09/2024 ET,"Approved September 19, 2024.",2.41B
Add to portfolio,,,,,,,,
JNJ,Johnson & Johnson,$162.85 ,Amivantamab and Lazertinib - (MARIPOSA),GFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer ,Approved,20/09/2024 ET,"Approved September 20, 2024.",2.41B
Add to portfolio,,,,,,,,
NVO,Novo Nordisk A/S,$127.51 ,Monlunabant (INV-202),Obesity ,Phase 2a,20/09/2024 ET,"Phase 2a trial data reported that all doses of monlunabant achieved a statistically significant weight loss compared to placebo, noted September 20, 2024.",4.47B
Add to portfolio,,,,,,,,
AZN,AstraZeneca PLC,$78.38 ,"FLUMIST QUADRIVALENT (Influenza Vaccine Live, Intranasal)","Influenza Vaccine Live, Intranasal ",Approved,20/09/2024 ET,"Approved September 20, 2024.",3.1B
Add to portfolio,,,,,,,,
SNY,Sanofi,$57.63 ,"SARCLISA (isatuximab) with bortezomib, lenalidomide and dexamethasone (VRd)",Transplant-ineligible newly diagnosed multiple myeloma (NDMM) ,Approved,20/09/2024 ET,"Approval announced September 20, 2024.",2.46B
Add to portfolio,,,,,,,,
TEVA,Teva Pharmaceutical Industries Limited American Depositary Shares,$17.72 ,Olanzapine LAI (44749) - (SOLARIS),Schizophrenia ,Phase 3,23/09/2024 ET,"Additional Phase 3 data reported that statistically significant mean differences in the change in PANSS total scores from baseline to week 8 of -9.71 points, -11.25 points, and -9.69 points versus pla … read more",1.15B
Add to portfolio,,,,,,,,
IDYA,IDEAYA Biosciences Inc.,$33.73 ,Darovasertib - (IDE196-009),Uveal Melanoma ,Phase 2,23/09/2024 ET,"Phase 2 efficacy data reported that 49% of patients with >30% tumor shrinkage by product of diameters, and 61% eye preservation rate for enucleation patients noted September 23, 2024.",87.64M
Add to portfolio,,,BTD,,,,,
BDTX,Black Diamond Therapeutics Inc.,$4.50 ,BDTX-1535,Glioblastoma multiforme (GBM) and NSCLC ,Phase 2,23/09/2024 ET,"Phase 2 results showed that a 200 mg daily dose was selected for pivotal development, demonstrating a favorable safety profile and a 42% objective response rate (ORR) in 19 evaluable patients, noted S … read more",56.94M
Add to portfolio,,,FTD,,,,,
RPTX,Repare Therapeutics Inc.,$3.38 ,Lunresertib (RP-6306) + Debio 0123 - (MYTHIC),Solid Tumors ,Phase 1,23/09/2024 ET,"Phase 1 data preesented at AACR Ovarian Cancer Research Symposium showing that ovarian and endometrial cancers with CCNE1 amplifications, FBXW7, or PPP2R1A mutations carry a significantly poor prognos … read more",42.96M
Add to portfolio,,,FTD,,,,,
AZN,AstraZeneca PLC,$77.14 ,Datopotamab Deruxtecan - (TROPION-Breast01),"HR Positive, HER2 Negative Breast Cancer ",Phase 3,23/09/2024 ET,"Phase 3 trial did not meet its primary endpoint, noted September 23, 2024.",3.1B
Add to portfolio,,,View Clinical Trial Data,,,,,
IVVD,Invivyd Inc.,$1.20 ,PEMGARDA (VYD222 (pemivibart)) - (CANOPY),COVID-19 Prevention ,Phase 3,23/09/2024 ET,"Additional data continues to demonstrate stable neutralization potency against contemporary SARS-CoV-2 variants, including KP.3.1.1 and LB.1. Structural analysis of the spike protein shows minimal mut … read more",120.14M
Add to portfolio,,,,,,,,
ELEV,Elevation Oncology Inc.,$0.58 ,EO-3021 (SYSA1801) with ramucirumab + dostarlimab,Advanced Unresectable or Metastatic Solid Tumors Likely to Express Claudin 18.2 ,Phase 1,23/09/2024 ET,"Fast Track designation (FTD) granted by the FDA, noted September 23, 2024.",59.22M
Add to portfolio,,,FTD,,,,,
BHVN,Biohaven Ltd.,$45.94 ,Troriluzole (BHV4157-206-RWE),Spinocerebellar Ataxia ,Phase 3,23/09/2024 ET,"Phase 3 study achieved the primary endpoint and showed statistically significant improvements on the f-SARA at years 1 and 2 , noted September 23, 2024.",105.79M
Add to portfolio,,,,,,,,
QURE,uniQure N.V.,$5.05 ,AMT-191,Fabry disease ,Phase 1/2,23/09/2024 ET,"Orphan Drug Designation granted by the FDA, noted September 23, 2024.",54.87M
Add to portfolio,,,ODD,,,,,
KZIA,Kazia Therapeutics Limited,$3.34 ,EVT801,Renal cell carcinoma and soft-tissue sarcoma ,Phase 1,23/09/2024 ET,"Phase 1 data one patient had a partial response (-39% decrease) after 2 cycles of EVT801 therapy, noted September 23, 2024.",1.36M
Add to portfolio,,,,,,,,
ASMB,Assembly Biosciences Inc.,$16.26 ,ABI-5366,HSV-2 ,Phase 1a,23/09/2024 ET,"Phase 1a interim data reported that treatment was well-tolerated, with a favorable safety profile observed with exposure of up to 70 days, noted September 23, 2024.",7.67M
Add to portfolio,,,,,,,,
KRON,Kronos Bio Inc.,$1.00 ,KB-0742,Solid tumors ,Preclinical,23/09/2024 ET,"Preclinical data reported that istisociclib given at 80mg on a 4 days on/3 days off schedule resulted in sustained downregulation of CDK9-dependent genes in peripheral blood mononuclear cells (PBMCs), … read more",60.97M
Add to portfolio,,,,,,,,
ALRN,Rein Therapeutics Inc Com (New),$3.71 ,LTI-03 - (Caveolin-1),Idiopathic pulmonary fibrosis (IPF) ,Phase 1b,23/09/2024 ET,"Phase 1b cohort 1 data demonstrated trends in seven of the eight biomarkers evaluated, suggesting a potential therapeutic effect, noted September 23, 2024.",21.67M
Add to portfolio,,,,,,,,
SPRC,SciSparc Ltd.,$0.26 ,SCI-110,Tourette Syndrome ,Phase 1/2,23/09/2024 ET,"IND Cleared by the FDA, noted September 23, 2024. Phase 1/2 planned.",534.56K
Add to portfolio,,,,,,,,
BIIB,Biogen Inc.,$194.12 ,Dapirolizumab pegol (anti-CD40L),Systemic lupus erythematosus ,Phase 3,24/09/2024 ET,"Phase 3 trial met its primary endpoint, noted September 24, 2024.",146.61M
Add to portfolio,,,View Clinical Trial Data,,,,,
RHHBY,Roche Holding AG ADR,$39.95 ,HB-700,KRAS-mutated cancers ,Preclinical,24/09/2024 ET,"Preclinical data presented Annual RAS-Targeted Drug Development Summit demonstrated safety, induction of target-specific CD8+ T-cells, and target cell killing in several different animal and translati … read more",6.36B
Add to portfolio,,,,,,,,
HOOK,HOOKIPA Pharma Inc.,$4.50 ,HB-700,KRAS-mutated cancers ,Preclinical,24/09/2024 ET,"Preclinical data presented Annual RAS-Targeted Drug Development Summit demonstrated safety, induction of target-specific CD8+ T-cells, and target cell killing in several different animal and translati … read more",12.2M
Add to portfolio,,,,,,,,
LIPO,Lipella Pharmaceuticals Inc.,$3.62 ,LP-310,Oral Lichen Planus (OLP) ,Phase 2a,24/09/2024 ET,"Phase 2a initial results reported that three participants have completed the four-week treatment with LP-310, an oral rinse, with encouraging findings: The treatment was well tolerated and had no unpl … read more",4.62M
Add to portfolio,,,,,,,,
CYDY,Cytodyn Inc,$0.17 ,Leronlimab,Metabolic dysfunction associated steatohepatitis (MASH) ,Preclinical,24/09/2024 ET,"Preclinical data showed that monotherapy (700 mg) demonstrated statistically significant fibrosis reversal compared to an isotype IgG4 control arm, noted September 24, 2024.",1.26B
Add to portfolio,,,,,,,,
WVE,Wave Life Sciences Ltd.,$8.19 ,WVE-N531 - (FORWARD-53),Duchenne muscular dystrophy (DMD) in boys ,Phase 1/2,24/09/2024 ET,"Phase 1b/2 data reported that mean muscle content-adjusted dystrophin expression of 9.0% and unadjusted dystrophin of 5.5%, with high consistency across participants, noted September 24, 2024.",159.14M
Add to portfolio,,,RPDD,,,,,
TECX,Tectonic Therapeutic Inc.,$24.24 ,RXFP1 Agonist (TX45 – Fc-relaxin),Heart Failure with Preserved Ejection Fraction (HFpEF) ,Phase 1a,24/09/2024 ET,"Phase 1a was well-tolerated with no observed immunogenicity, and demonstrated a favorable PK/PD relationship, noted September 24, 2024.",18.71M
Add to portfolio,,,,,,,,
ENLV,Enlivex Therapeutics Ltd.,$1.48 ,Allocetra - (ENX-CL-05-001),Knee osteoarthritis (OA) ,Phase 1/2,24/09/2024 ET,"Phase 1/2 completed independent DSMB completed confirming that the safety profile of Allocetra allows the Company to move forward to the Phase 2 stage of the Phase 1/2 trial, noted September 24, 2024.",23.85M
Add to portfolio,,,,,,,,
SAVA,Cassava Sciences Inc.,$29.58 ,Simufilam (PTI-125) - (RETHINK-ALZ),Alzheimer’s disease ,Phase 3,24/09/2024 ET,"Phase 3 independent DSMB recommended studies to continue without modification, noted September 24, 2024.",48.31M
Add to portfolio,,,View Clinical Trial Data,,,,,
ACXP,Acurx Pharmaceuticals Inc.,$1.83 ,Ibezapolstat,C. difficile Infection ,Phase 2b,24/09/2024 ET,"Phase 2b results feature high-resolution elucidation of interaction of ibezapolstat with its molecular target, noted September 24, 2024.",1.58M
Add to portfolio,,,FTD,,,,,
,,,View Clinical Trial Data,,,,,
CAPR,Capricor Therapeutics Inc.,$9.10 ,CAP-1002 - (HOPE-3),Duchenne Muscular Dystrophy (DMD) ,Phase 3,24/09/2024 ET,"Phase 3 HOPE-3 clinical trial to combine Cohorts A and B, study planned to serve as a post-approval study and does not intend to unblind Cohort A at this time, which was expected to occur in the 4Q 20 … read more",45.72M
Add to portfolio,,,,,,,,
MRK,Merck & Company Inc.,$113.81 ,Favezelimab and Pembrolizumab - (KEYFORM-007),PD-L1 positive microsatellite stable (MSS) metastatic colorectal cancer (mCRC) ,Phase 3,25/09/2024 ET,"Phase 3 trial did not meet its primary endpoint, noted September 25, 2024.",2.5B
Add to portfolio,,,,,,,,
ARQT,Arcutis Biotherapeutics Inc.,$9.10 ,ZORYVE (roflumilast) Cream 0.05%,Atopic Dermatitis - ages of 2-5 years old ,Phase 3,25/09/2024 ET,"Phase 3 data from EADV reported consistent efficacy in disease clearance and reduction in itch for individuals with atopic dermatitis (AD) regardless of race, ethnicity, and Fitzpatrick skin type, not … read more",122.49M
Add to portfolio,,,,,,,,
ORKA,Oruka Therapeutics Inc.,$23.84 ,ORKA-001 - (EVERLAST-A),Moderate-to-severe plaque psoriasis ,Preclinical,25/09/2024 ET,"Preclinical data reported a half-life in non-human primates (NHP) of 30.3 days after subcutaneous (SQ) administration and 33.8 days after intravenous (IV) administration, noted September 25, 2024.",37.45M
Add to portfolio,,,,,,,,
KYMR,Kymera Therapeutics Inc.,$51.93 ,KT-621 (STAT6),Type 2 inflammation in allergic diseases ,Preclinical,25/09/2024 ET,Preclinical data presented at EADV demonstrated strong degradation of STAT6 in human sensory neurons resulting in inhibition of IL-13-induced itch- and pain-related gene transcripts with the potential … read more,71.5M
Add to portfolio,,,,,,,,
HRTX,Heron Therapeutics Inc.,$1.89 ,ZYNRELEF (bupivacaine and meloxicam) extended-release solution,Pain relief following surgery ,Approved,25/09/2024 ET,"Approved September 25, 2024.",153.29M
Add to portfolio,,,,,,,,
WINT,Windtree Therapeutics Inc.,$2.90 ,Istaroxime - (SEISMiC C),Cardiogenic Shock in severe acute heart failure ,Phase 2b,25/09/2024 ET,Phase 2b data reported that treatment significantly improved primary endpoint of the systolic blood pressure profile over six hours and showed significant improvements in many secondary endpoint asses … read more,29.33M
Add to portfolio,,,View Clinical Trial Data,,,,,
CERO,CERo Therapeutics Holdings Inc.,$10.00 ,CER-1236 - (CertainT-1),"Acute myeloid leukemia (AML), Hematologic malignancies ",IND-Enabling,25/09/2024 ET,"Type A Meeting requested to FDA regarding clinical hold after new financing, noted September 25, 2024.",1.21M
Add to portfolio,,,ODD,,,,,
,,,FTD,,,,,
CLDX,Celldex Therapeutics Inc.,$36.02 ,Barzolvolimab (CDX-0159),Chronic spontaneous urticaria (CSU) ,Phase 2,25/09/2024 ET,"Phase 2 52-week results from EADV reported that 71% of patients (150 mg Q4W) achieved complete response at Week 52, noted September 25, 2024.",66.41M
Add to portfolio,,,,,,,,
ABVX,Abivax SA,$11.16 ,Obefazimod with etrasimod,Inflammatory Bowel Disease (IBD) ,Preclinical,25/09/2024 ET,"Preclinical data reported a synergistic and statistically significant reduction of several cytokines (TNF-alpha, IL-17, IL-6, IFN-gamma) in the blood compared to each treatment alone, noted September … read more",77.7M
Add to portfolio,,,,,,,,
CDTX,Cidara Therapeutics Inc.,$10.82 ,JNJ-0953 (CD388) - (ANCHOR),Seasonal Influenza ,Phase 1/2,25/09/2024 ET,"Phase 1 and Phase 2a data reported that there was no dose-, route- or repeat-dose-related treatment-emergent adverse events (TEAEs), noted September 25, 2024.",25.36M
Add to portfolio,,,FTD,,,,,
,,,BTD,,,,,
JNJ,Johnson & Johnson,$158.06 ,JNJ-0953 (CD388) - (ANCHOR),Seasonal Influenza ,Phase 1/2,25/09/2024 ET,"Phase 1 and Phase 2a data reported that there was no dose-, route- or repeat-dose-related treatment-emergent adverse events (TEAEs), noted September 25, 2024.",2.41B
Add to portfolio,,,FTD,,,,,
,,,BTD,,,,,
ANIP,ANI Pharmaceuticals Inc.,$58.30 ,"Ketoconazole Shampoo, 2%",Fungus ,Approved,26/09/2024 ET,"Approved September 26, 2024.",21.7M
Add to portfolio,,,,,,,,
AZN,AstraZeneca PLC,$78.18 ,TAGRISSO (osimertinib) - (LAURA),"Unresectable, Stage III epidermal growth factor receptor-mutated (EGFRm) non-small cell lung cancer (NSCLC) ",Approved,26/09/2024 ET,"FDA Approved on September 26, 2024.",3.1B
Add to portfolio,,,BTD,,,,,
ENGN,enGene Holdings Inc.,$5.50 ,Detalimogene voraplasmid (EG-70) - (LEGEND),BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) ,Phase 1/2,26/09/2024 ET,"Phase 1/2 preliminary data reported that the Complete Response (CR) rate at any time was 71%, the CR rate at three months was 67% and the CR rate at six months was 47%, noted September 26, 2024.",51.11M
Add to portfolio,,,RMAT,,,,,
CNTA,Centessa Pharmaceuticals plc,$15.67 ,ORX142,Excessive daytime sleepiness (EDS) ,Preclinical,26/09/2024 ET,"Preclinical data shared at the European Sleep Research Society reported that the oral administration of ORX142 showed significant activity at the lowest dose tested, which was 0.03 mg/kg, noted Septem … read more",134.07M
Add to portfolio,,,,,,,,
ENTA,Enanta Pharmaceuticals Inc.,$10.47 ,Zelicapavir (EDP-323) - (RSVPED),Respiratory Syncytial Virus RSV-A and RSV-B ,Phase 2a,26/09/2024 ET,"Phase 2a topline data reported that trial met its primary and secondary endpoints, noted September 26, 2024.",21.38M
Add to portfolio,,,FTD,,,,,
RHHBY,Roche Holding AG ADR,$40.16 ,Gazyva/Gazyvaro,Lupus Nephritis ,Phase 3,26/09/2024 ET,"Phase 3 data reported that the trial met its primary endpoint, noted September 26, 2024.",6.36B
Add to portfolio,,,,,,,,
OVID,Ovid Therapeutics Inc.,$1.12 ,OV329,Drug-resistant epilepsies (DREs) ,Preclinical,26/09/2024 ET,"Preclinical study found showed cleared and remained undetectable in the retina, eye, and brain tissues of mice unlike vigabatrin which has repeatedly shown to preferentially accumulate in mouse retina … read more",71.11M
Add to portfolio,,,,,,,,
ABBV,AbbVie Inc.,$188.56 ,Tavapadon - (TEMPO-1),Early Parkinson’s disease ,Phase 3,26/09/2024 ET,"Phase 3 trial data reported that trial met its primary endpoint, noted September 26, 2024.",1.77B
Add to portfolio,,,View Clinical Trial Data,,,,,
INMB,INmune Bio Inc.,$4.96 ,INKmune - (CaRe PC),Metastatic castration-resistant prostate cancer (mCRPC) ,Phase 1/2,26/09/2024 ET,"Phase 1/2 data reported that one patient showed a transient 21% decrease in PSA associated with the increase in NK cell activity and function, noted September 26, 2024.",26.59M
Add to portfolio,,,,,,,,
BMEA,Biomea Fusion Inc.,$9.57 ,Icovamenib (BMF-219) - (COVALENT-111),"Healthy volunteers, type 2 diabetes ",Phase 1/2,26/09/2024 ET,"Clinical hold lifted September 26, 2024.",59.51M
Add to portfolio,,,,,,,,
BMEA,Biomea Fusion Inc.,$9.57 ,Icovamenib (BMF-219) - (COVALENT-112),Type 1 diabetes (T1D) ,Phase 2,26/09/2024 ET,"Clinical hold lifted September 26, 2024",59.51M
Add to portfolio,,,,,,,,
BMY,Bristol-Myers Squibb Company,$49.80 ,"COBENFY (KarXT, xanomeline and trospium chloride)",Schizophrenia ,Approved,27/09/2024 ET,"Approved September 27, 2024.",2.04B
Add to portfolio,,,View Clinical Trial Data,,,,,
PRTC,PureTech Health plc,$21.25 ,"COBENFY (KarXT, xanomeline and trospium chloride)",Schizophrenia ,Approved,27/09/2024 ET,"Approved September 27, 2024.",24.17M
Add to portfolio,,,View Clinical Trial Data,,,,,
BGNE,BeiGene Ltd.,$218.42 ,TEVIMBRA (tislelizumab-jsgr) - (RATIONALE 305),Gastric or gastroesophageal junction (G/GEJ) adenocarcinoma ,BLA Filing,27/09/2024 ET,"Advisory committee voted 10 to 2 in favor of a favorable benefit-risk profile, noted September 27, 2024.",106.62M
Add to portfolio,,,View Clinical Trial Data,,,,,
ONC,BeOne Medicines Ltd.,—,TEVIMBRA (tislelizumab-jsgr) - (RATIONALE 305),Gastric or gastroesophageal junction (G/GEJ) adenocarcinoma ,BLA Filing,27/09/2024 ET,"Advisory committee voted 10 to 2 in favor of a favorable benefit-risk profile, noted September 27, 2024.",110.03M
Add to portfolio,,,View Clinical Trial Data,,,,,
ALMS,Alumis Inc.,$11.16 ,ESK-001 - (ONWARD3),Moderate-to-severe plaque psoriasis ,Phase 2,27/09/2024 ET,"Phase 2 28-week data presented at EADV 2024 show ESK-001 was generally well tolerated, and most patients treated with the top dose of 40 mg twice daily achieved PASI 75, noted September 27, 2024.",104.06M
Add to portfolio,,,,,,,,
SVRA,Savara Inc.,$4.24 ,MOLBREEVI (Molgradex) - (IMPALA-2),Autoimmune pulmonary alveolar proteinosis (aPAP) ,Phase 3,27/09/2024 ET,"FDA granted Expanded Access Program (EAP), noted September 27, 2024.",172.84M
Add to portfolio,,,View Clinical Trial Data,,,,,
REGN,Regeneron Pharmaceuticals Inc.,"$1,041.37 ",Dupixent (dupilumab) - (NOTUS),Chronic obstructive pulmonary disease (COPD) ,Approved,27/09/2024 ET,"Approved September 27, 2024.",105.1M
Add to portfolio,,,,,,,,
ESLA,Estrella Immunopharma Inc.,$1.19 ,EB103 (CD19) - (STARLIGHT-1),"Diffuse large B cell lymphoma (DLBCL), Follicular Lymphoma (FL), and other types of B-cell Lymphoma ",Phase 1/2,27/09/2024 ET,"Phase 1/2 first patient achieved a complete response (CR) one month after receiving dose, noted September 27, 2024.",37.07M
Add to portfolio,,,,,,,,
JNJ,Johnson & Johnson,$158.84 ,TALVEY (talquetamab-tgvs) and TECVAYLI (teclistamab-cqyv) - (RedirecTT-1 ),Multiple Myeloma ,Phase 1b,27/09/2024 ET,"Phase 1b data demonstrated a safety profile consistent to TALVEY and TECVAYLI monotherapies, noted September 27, 2024.",2.41B
Add to portfolio,,,,,,,,
JNJ,Johnson & Johnson,$158.84 ,TALVEY (talquetamab-tgvs) with DARZALEX FASPRO (daratumumab and hyaluronidase-fihj) and pomalidomide - (TRIMM-2),Multiple Myeloma ,Phase 1b,27/09/2024 ET,"Phase 1b updated data show 100 percent overall response rate with 56 percent of patients achieving complete response or better with weekly dosing, supporting the combinability of the GPRC5D bispecific … read more",2.41B
Add to portfolio,,,,,,,,
ABBV,AbbVie Inc.,$191.40 ,telisotuzumab-vedotin (Teliso-V),Advanced/metastatic nonsquamous non-small cell lung cancer (NSCLC) ,BLA Filing,27/09/2024 ET,"BLA submitted to the FDA, and it was noted on September 27, 2024.",1.77B
Add to portfolio,,,,,,,,
GEHC,GE HealthCare Technologies Inc.,$91.92 ,flurpiridaz F 18,Coronary artery disease (CAD) ,Approved,27/09/2024 ET,"FDA Approved on September 27, 2024.",456.56M
Add to portfolio,,,View Clinical Trial Data,,,,,
LNTH,Lantheus Holdings Inc.,$107.36 ,flurpiridaz F 18,Coronary artery disease (CAD) ,Approved,27/09/2024 ET,"FDA Approved on September 27, 2024.",67.99M
Add to portfolio,,,View Clinical Trial Data,,,,,
PSTX,Poseida Therapeutics Inc.,$2.90 ,P-BCMA-ALLO1,Multiple myeloma ,Phase 1,27/09/2024 ET,"Phase 1 study presented at IMS showed a 91% ORR with P-BCMA-ALLO1 in an optimized lymphodepletion arm, including a 100% ORR in BCMA-naïve patients, and an 86% ORR in those who had received at least on … read more",97.47M
Add to portfolio,,,ODD,,,,,
,,,RMAT,,,,,
ELVN,Enliven Therapeutics Inc.,$24.13 ,ELVN-001 - (ENABLE),Chronic Myeloid Leukemia (CML) ,Phase 1,28/09/2024 ET,"Data form ESH-iCMLf reported a cumulative MMR rate of 44% (8/18) by 24 weeks, with stable or deepening responses between weeks 12 and 24, which continues to compare favorably to precedent Phase 1 tria … read more",59.24M
Add to portfolio,,,,,,,,
RDHL,Redhill Biopharma Ltd.,$8.74 ,YELIVA (Opaganib),COVID-19 ,Phase 2/3,30/09/2024 ET,"Phase 2/3 post-hoc data showed that patients with ≤60% FiO2 levels had better outcomes after 14 days' opaganib treatment (n=117) compared to placebo (n=134), including: increased number of patients no … read more",3.33M
Add to portfolio,,,View Clinical Trial Data,,,,,
GANX,Gain Therapeutics Inc.,$1.78 ,"GT-02287, GT-02329",GBA1 and Idiopathic Parkinson's Disease ,Preclinical,30/09/2024 ET,"Preclinical data to be shared at a webinar showed CNS exposure, supporting its potential as a disease-modifying treatment for Parkinson’s disease. The drug was well tolerated with no serious adverse e … read more",35.95M
Add to portfolio,,,,,,,,
MNKD,MannKind Corporation,$6.29 ,Afrezza Combined With Insulin Degludec - (INHALE-3),Type 1 Diabetes ,Phase 3,30/09/2024 ET,"Phase 4 data reported that switching from usual care to Afrezza (plus degludec) at week-17 allowed more than double the subjects to achieve A1c <7% at week-30, compared to the number at goal at week-1 … read more",306.83M
Add to portfolio,,,,,,,,
BGNE,BeiGene Ltd.,$224.51 ,DKN-01 with bevacizumab - (DeFianCe),Colorectal cancer ,Phase 2,30/09/2024 ET,"Phase 2 enrollment completed, noted September 30, 2024.",106.62M
Add to portfolio,,,,,,,,
ONC,BeOne Medicines Ltd.,—,DKN-01 with bevacizumab - (DeFianCe),Colorectal cancer ,Phase 2,30/09/2024 ET,"Phase 2 enrollment completed, noted September 30, 2024.",110.03M
Add to portfolio,,,,,,,,
LPTX,Leap Therapeutics Inc.,$2.57 ,DKN-01 with bevacizumab - (DeFianCe),Colorectal cancer ,Phase 2,30/09/2024 ET,"Phase 2 enrollment completed, noted September 30, 2024.",41.44M
Add to portfolio,,,,,,,,
NRXP,NRX Pharmaceuticals Inc.,$1.69 ,HTX-100 (NRX-100) (Ketamine Hydrochloride),Acute Suicidal Ideation and Behavior in Bipolar Depression ,Phase 3,30/09/2024 ET,"Phase 3 reported that twelve-month real-time stability on the first manufactured lot, noted September 30, 2024.",19.71M
Add to portfolio,,,FTD,,,,,
,,,View Clinical Trial Data,,,,,
MRNA,Moderna Inc.,$66.83 ,Trivalent (mRNA-1403) - (Nova 301),Norovirus ,Phase 3,30/09/2024 ET,"Phase 3 study dosing initiated, noted September 30, 2024.",389.08M
Add to portfolio,,,,,,,,
ALNY,Alnylam Pharmaceuticals Inc.,$275.03 ,AMVUTTRA (vutrisiran),ATTR Amyloidosis with Cardiomyopathy (ATTR-CM) ,Phase 3,30/09/2024 ET,"Phase 3 data reported that at month 30, the relative reduction in the fold change in NT-proBNP in patients treated with vutrisiran compared to placebo was 32% in the overall population and 43% in the … read more",131.08M
Add to portfolio,,,View Clinical Trial Data,,,,,
MRUS,Merus N.V.,$49.96 ,Petosemtamab (MCLA-158) - (LiGeR-HN1),PD-L1+ recurrent/metastatic head and neck squamous cell carcinoma (r/m HNSCC) ,Phase 3,30/09/2024 ET,"Phase 3 study dosing initiated, noted September 30, 2024.",75.63M
Add to portfolio,,,BTD,,,,,
GMAB,Genmab A/S,—,Petosemtamab (MCLA-158) - (LiGeR-HN1),PD-L1+ recurrent/metastatic head and neck squamous cell carcinoma (r/m HNSCC) ,Phase 3,30/09/2024 ET,"Phase 3 study dosing initiated, noted September 30, 2024.",661.87M
Add to portfolio,,,BTD,,,,,
MDGL,Madrigal Pharmaceuticals Inc.,$212.22 ,Resmetirom - (MAESTRO-NASH Outcomes),Nonalcoholic Steatohepatitis (NASH) ,Phase 3,30/09/2024 ET,"Phase 3 results improved health-related quality of life (HRQL) in patients with NASH with moderate to advanced fibrosis, noted September 30, 2024.",22.29M
Add to portfolio,,,,,,,,
WINT,Windtree Therapeutics Inc.,$119.50 ,Istaroxime - (SEISMiC C),Cardiogenic Shock in severe acute heart failure ,Phase 2b,30/09/2024 ET,"Phase 2b data reported that treatment significantly improved systolic blood pressure as well as cardiac output and renal function without increasing heart rate or clinically significant arrhythmias, n … read more",29.33M
Add to portfolio,,,View Clinical Trial Data,,,,,
ARCT,Arcturus Therapeutics Holdings Inc.,$23.21 ,Kostaive (ARCT-154),COVID-19 variant vaccine ,Phase 3,30/09/2024 ET,"Phase 3 data reported that the vaccine maintained superior immunogenicity compared to the conventional mRNA vaccine Comirnaty for up to one year against Wuhan-Hu-1, Omicron BA.4-5 and certain other va … read more",27.15M
Add to portfolio,,,,,,,,
CSLLY,CSL Ltd. ADR,$98.79 ,Kostaive (ARCT-154),COVID-19 variant vaccine ,Phase 3,30/09/2024 ET,"Phase 3 data reported that the vaccine maintained superior immunogenicity compared to the conventional mRNA vaccine Comirnaty for up to one year against Wuhan-Hu-1, Omicron BA.4-5 and certain other va … read more",968.41M
Add to portfolio,,,,,,,,
CYTK,Cytokinetics Incorporated,$52.80 ,Aficamten (CK-274) - (SEQUOIA-HCM),Hypertrophic cardiomyopathy (HCM) ,Phase 3,30/09/2024 ET,"Phase 3 data reported an improvement in maximal wall thickness by ≥1.5 mm (n = 282; 47.9% vs 30.7%; p=0.003), noted September 30, 2024.",119.66M
Add to portfolio,,,BTD,,,,,
,,,View Clinical Trial Data,,,,,
AQST,Aquestive Therapeutics Inc.,$4.98 ,AQST-108 (epinephrine) Topical Gel,Alopecia areata (AA) ,Preclinical,30/09/2024 ET,"Preclinical data reported that the treatment demonstrated immunomodulation across multiple cytokines monitored in the PCA model, noted September 30, 2024.",99.72M
Add to portfolio,,,,,,,,
RPTX,Repare Therapeutics Inc.,$3.44 ,Camonsertib (RP-3500)/ RG6526)- (ATTACC),Solid Tumors ,Phase 1/2,30/09/2024 ET,"Phase 1 data showed notable efficacy in those with pathogenic ATM mutations, with a 2-month response rate of 2 complete responses (CR), 5 partial responses (PR), and 4 stable disease (SD). At 6 months … read more",42.96M
Add to portfolio,,,,,,,,
GRTS,Gritstone bio Inc.,$0.58 ,GRANITE-CRC-1L,1L Microsatellite-Stable Colorectal Cancer (MSS-CRC) ,Phase 2/3,30/09/2024 ET,Phase 2/3 mature PFS data showed a 21% relative risk reduction in progression or death for all treated patients (HR=0.79) and a 38% risk reduction in patients with low baseline ctDNA (HR=0.62). GRANIT … read more,118.11M
Add to portfolio,,,,,,,,
JNJ,Johnson & Johnson,$159.49 ,"DARZALEX FASPRO (daratumumab and hyaluronidase-fihj) in combination with bortezomib, lenalidomide and dexamethasone (D-VRd) - (CEPHEUS)",Newly diagnosed multiple myeloma (NDMM) ,BLA Filing,30/09/2024 ET,"sBLA submitted to the FDA, noted September 30, 2024.",2.41B
Add to portfolio,,,,,,,,
IRWD,Ironwood Pharmaceuticals Inc.,$4.12 ,CNP-104,Primary Biliary Cholangitis (PBC) ,Phase 2,30/09/2024 ET,"Phase 2 data topline data resulted in the decision by the company to not to exercise the option to acquire an exclusive license to CNP-104, noted September 30, 2024.",162.43M
Add to portfolio,,,,,,,,
IONS,Ionis Pharmaceuticals Inc.,$39.07 ,Zilganersen (ION373),Alexander disease ,Phase 1,01/10/2024 ET,"Fast track designation granted by FDA, noted October 1, 2024.",159.39M
Add to portfolio,,,FTD,,,,,
,,,View Clinical Trial Data,,,,,
SGMT,Sagimet Biosciences Inc.,$3.12 ,Denifanstat - (FASCINATE-3),Nonalcoholic steatohepatitis (NASH) ,Phase 2b,01/10/2024 ET,"FDA granted Breakthrough Therapy designation, noted October 1, 2024.",32.52M
Add to portfolio,,,BTD,,,,,
PSTV,PLUS THERAPEUTICS Inc.,$1.31 ,REYOBIQ (rhenium Re186 obisbemeda) - (ReSPECT-GBM),Glioma ,Phase 2b,01/10/2024 ET,"Phase 2b data from CNS reported a statistically significant reduction in tumor volume rate change was seen in tumors receiving > 100 Gy absorbed dose, noted October 1, 2024.",99.26M
Add to portfolio,,,,,,,,
BCTX,BriaCell Therapeutics Corp.,$12.15 ,Bria-IMT - (BRIA-ABC),Advanced breast cancer ,Phase 2,01/10/2024 ET,"Phase 2 data showed a complete 100% resolution of brain metastasis in the right temporal lobe after 8 and 11 months of treatment. The patient, who also experienced marked reduction of an orbital tumor … read more",1.76M
Add to portfolio,,,,,,,,
JAGX,Jaguar Health Inc.,$1.23 ,Mytesi (crofelemer) - (OnTarget),Cancer Therapy-Related Diarrhea ,Phase 3,01/10/2024 ET,"Phase 3 OnTarget trial showed statistical significance for crofelemer in a prespecified subgroup of breast cancer patients for the prophylaxis of cancer therapy-related diarrhea, noted October 1, 2024 … read more",2.17M
Add to portfolio,,,View Clinical Trial Data,,,,,
ATHE,Alterity Therapeutics Limited,$1.43 ,ATH434-202 - (biomarker data),Multiple System Atrophy (MSA) ,Phase 2,02/10/2024 ET,"Phase 2 interim data from MDS reported that at 6 months all participants exhibited brain volume declines consistent with MSA progression; however, the clinical responders maintained stable brain volum … read more",15.35M
Add to portfolio,,,ODD,,,,,
,,,FTD,,,,,
PDSB,PDS Biotechnology Corporation,$4.11 ,PDS0101 and chemoradiotherapy - (IMMUNOCERV),Cervical cancer ,Phase 2,02/10/2024 ET,"Phase 2 data presented at ASTRO showed 100% 36-month overall survival (OS) and progression-free survival (PFS) rates in fully treated patients. Notably, 88% of patients achieved a complete metabolic r … read more",46.63M
Add to portfolio,,,View Clinical Trial Data,,,,,
RXRX,Recursion Pharmaceuticals Inc.,$6.11 ,REC-1245 - (DAHLIA),Solid tumors ,IND-Enabling,02/10/2024 ET,"IND cleared by the FDA, noted October 2, 2024.",434.15M
Add to portfolio,,,,,,,,
ATYR,aTyr Pharma Inc.,$1.78 ,Efzofitimod - (EFZO-FIT),Pulmonary sarcoidosis ,Phase 1/2,02/10/2024 ET,Additional Phase 1b/2a data from post hoc analysis emonstrated statistically significant difference in time-to-first-relapse for corticosteroid use in therapeutic (3.0 and 5.0 mg/kg efzofitimod) vs su … read more,97.99M
Add to portfolio,,,FTD,,,,,
,,,ODD,,,,,
URGN,UroGen Pharma Ltd.,$12.58 ,UGN-103 - (UTOPIA),Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer ,Phase 3,02/10/2024 ET,"Phase 3 trial dosing initiated, noted October 2, 2024.",46.26M
Add to portfolio,,,,,,,,
KZIA,Kazia Therapeutics Limited,$4.36 ,Paxalisib (GDC-0084) with radiotherapy,Brain Metastases ,Phase 1,02/10/2024 ET,"Phase 1 data at the 2024 ASTRO Annual Meeting showed a 67% partial response (PR) in patients treated with 45mg paxalisib combined with radiotherapy, noted October 2, 2024.",1.36M
Add to portfolio,,,FTD,,,,,
IMMX,Immix Biopharma Inc.,$1.46 ,NXC-201 (HBI10101) - (NEXICART-2),Relapsed/refractory AL Amyloidosis ,Phase 1/2,02/10/2024 ET,Phase 1b/2 data presented at ASGCT showed that study is now dosing at dose expansion level of 450 million NXC-201 CAR+T cells. First cohort at 150 million CAR+T cells already successfully completed.Th … read more,28.83M
Add to portfolio,,,ODD,,,,,
,,,RMAT,,,,,
BMY,Bristol-Myers Squibb Company,$53.02 ,Opdivo (nivolumab) - (CheckMate -77T),Non-metastatic non-small cell lung cancer ,Approved,03/10/2024 ET,"Approved October 3, 2024.",2.04B
Add to portfolio,,,,,,,,
ABVX,Abivax SA,$10.29 ,Obefazimod,Ulcerative Colitis ,Phase 2b,03/10/2024 ET,"Phase 2b OLM data reported clinical remission and a safety profile consistent with prior studies of oral, once-daily obefazimod when administered at a reduced dose of 25mg for up to an additional two … read more",77.7M
Add to portfolio,,,,,,,,
RNA,Avidity Biosciences Inc.,$47.05 ,del-desiran (AOC 1001) - (HARBOR),Myotonic dystrophy type 1 (DM1) ,Phase 3,03/10/2024 ET,"Phase 3 partial clinical hold removed by the FDA, noted October 3, 2024.",128.65M
Add to portfolio,,,BTD,,,,,
PHVS,Pharvaris N.V.,$17.89 ,Bradykinin B2 receptor - (CHAPTER-1),Hereditary angioedema (HAE) attacks ,Phase 2,03/10/2024 ET,"Phase 2 OLE long term safety data to be presented on October 5, 2024.",54.49M
Add to portfolio,,,,,,,,
IONS,Ionis Pharmaceuticals Inc.,$37.81 ,DAWNZERA (Donidalorsen),Hereditary Angioedema (HAE) ,Phase 2,03/10/2024 ET,Phase 2 new 3 year OLE data that continues to demonstrate donidalorsen potential to deliver significant and sustained reductions in HAE attacks up to three years with monthly or every two-month dosing … read more,159.39M
Add to portfolio,,,View Clinical Trial Data,,,,,
TOVX,"Theriva Biologics, Inc.",$1.79 ,SYN-004 (Ribaxamase),Allogeneic hematopoietic cell transplantation (HCT) for the prevention of acute graft-versus-host-disease (aGVHD) ,Phase 1/2,03/10/2024 ET,"Phase 1b/2 DSMC positive review with 15 SAEs were reported among 10 patients, with the most common SAE being infections and infestations, including sepsis, noted October 3, 2024.",9.6M
Add to portfolio,,,,,,,,
IMRN,Immuron Limited,$2.69 ,"CampETEC HBC product, ProMilk 85, C. jejuni CG8421 Challenge strain","Campylobacter and Enterotoxigenic Escherichia coli (ETEC), Healthy Volunteers ",Phase 2,04/10/2024 ET,"Phase 2 data reported a 10.4% protective efficacy against moderate to severe campylobacteriosis following challenge with Campylobacter compared to the placebo group, noted October 4, 2024.",6.71M
Add to portfolio,,,,,,,,
RLFTF,RELIEF THERAPEUTICS HLDG AG,$3.10 ,RLF-OD032,Phenylketonuria (PKU) ,Phase 1,04/10/2024 ET,"Topline data showed that RLF-OD032 administered under fed conditions, with or without water intake, achieved peak and total exposure of sapropterin dihydrochloride similar to those achieved by KUVAN ® … read more",12.58M
Add to portfolio,,,,,,,,
BMY,Bristol-Myers Squibb Company,$53.38 ,Neoadjuvant Opdivo (nivolumab) and Chemotherapy,Stage IIA to IIIB non-small cell lung cancer (NSCLC) ,Approved,04/10/2024 ET,"Approved October 4, 2024.",2.04B
Add to portfolio,,,,,,,,
RARE,Ultragenyx Pharmaceutical Inc.,$53.79 ,UX701 - (Cyprus2+),Wilson Disease ,Phase 1/2,04/10/2024 ET,"Phase 1/2/3 data reported that six of the patients have completely tapered off of standard-of-care treatment with chelators and/or zinc therapy, and a seventh patient has begun to taper as of the data … read more",96.37M
Add to portfolio,,,,,,,,
BDRX,Biodexa Pharmaceuticals plc,$5.55 ,MTX110 - (MAGIC-G1),Recurrent Glioblastoma (GBM) ,Phase 1,04/10/2024 ET,"Phase 1 open label data reported that Patients #1 and #2 have deceased with overall survival (OS) since start of treatment of 12 months and 13 months, respectively, noted October 4, 2024.",505.06K
Add to portfolio,,,FTD,,,,,
KZR,Kezar Life Sciences Inc.,$7.98 ,Zetomipzomib - (PALIZADE),Lupus nephritis ,Phase 2b,04/10/2024 ET,"Phase 2b IND placed on clinical hold, noted October 4, 2024.",7.32M
Add to portfolio,,,,,,,,
PHVS,Pharvaris N.V.,$18.20 ,Bradykinin B2 receptor - (CHAPTER-1),Hereditary angioedema (HAE) attacks ,Phase 2,05/10/2024 ET,Phase 2 OLE long term safety data reported that the attack rate remained low through >1.5 years. An early-onset reduction of attack rate in participants switching from placebo to deucrictibant 40 mg/d … read more,54.49M
Add to portfolio,,,,,,,,
SRRK,Scholar Rock Holding Corporation,$34.28 ,Apitegromab - (SAPPHIRE),Type 2 and Type 3 Spinal Muscular Atrophy (SMA) ,Phase 3,07/10/2024 ET,"Phase 3 study met its primary endpoint, demonstrating a statistically significant and clinically meaningful improvement in motor function, as measured by the Hammersmith Functional Motor Scale Expande … read more",96.13M
Add to portfolio,,,View Clinical Trial Data,,,,,
RARE,Ultragenyx Pharmaceutical Inc.,$52.43 ,UX143 (setrusumab) - (Orbit),Osteogenesis Imperfecta ,Phase 2/3,07/10/2024 ET,"Breakthrough Therapy Designation granted by the FDA, noted October 7, 2024.",96.37M
Add to portfolio,,,BTD,,,,,
GANX,Gain Therapeutics Inc.,$2.14 ,"GT-02287, GT-02329",GBA1 and Idiopathic Parkinson's Disease ,Preclinical,07/10/2024 ET,"Preclinical data demonstrated improvements in motor and cognitive function, which persisted even after the treatment was discontinued, suggesting a lasting neuroprotective effect, noted October 7, 202 … read more",35.95M
Add to portfolio,,,,,,,,
BFRI,Biofrontera Inc.,$0.87 ,Ameluz (aminolevulinic acid HCI) Topical Gel - (3 tubes),Actinic keratosis (AK) ,Approved,07/10/2024 ET,"Approved October 7, 2024.",10.67M
Add to portfolio,,,,,,,,
VINC,Vincerx Pharma Inc.,$13.96 ,VIP943 (anti-CD123),Hematologic malignancies ,Phase 1,07/10/2024 ET,"Phase 1 data demonstrated a favorable safety profile with no dose-limiting toxicities, noted October 7, 2024.",5.23M
Add to portfolio,,,,,,,,
BDTX,Black Diamond Therapeutics Inc.,$3.66 ,BDTX-4933,Brain tumors harboring all-class BRAF or RAS mutations ,Phase 1,07/10/2024 ET,"Phase 1 deprioritized, looking for a partnership to continue program, noted October 7, 2024.",56.94M
Add to portfolio,,,,,,,,
KRRO,Korro Bio Inc.,$35.86 ,KRRO-110 - (REWRITE),Alpha-1 Antitrypsin Deficiency (AATD) ,Preclinical,07/10/2024 ET,"Preclinical data from the Oligonucleotide Therapeutics Society reported that treatment achieved AAT levels between MM and MZ in rodents as early as Week 1, noted October 7, 2024.",9.39M
Add to portfolio,,,ODD,,,,,
AZN,AstraZeneca PLC,$75.80 ,Airsupra (albuterol/budesonide) - (BATURA),Severe exacerbations in patients with intermittent or mild persistent asthma ,Phase 3,07/10/2024 ET,"Phase 3 trial met primary endpoint, noted October 7, 2024.",3.1B
Add to portfolio,,,,,,,,
MRK,Merck & Company Inc.,$107.65 ,KEYTRUDA (pembrolizumab) - (KEYNOTE-689),Head and Neck Squamous Cell Carcinoma ,Phase 3,08/10/2024 ET,"Phase 3 trial met its primary endpoint, noted October 8, 2024.",2.5B
Add to portfolio,,,,,,,,
SAGE,Sage Therapeutics Inc.,$6.43 ,Dalzanemdor (SAGE-718) - (LIGHTWAVE),Mild cognitive impairment and mild dementia due to AD ,Phase 2,08/10/2024 ET,"Phase 2 topline data reported that the trial did not demonstrate a statistically significant difference from baseline in participants treated with dalzanemdor versus placebo on the primary endpoint, n … read more",62.78M
Add to portfolio,,,,,,,,
SUPN,Supernus Pharmaceuticals Inc.,—,Dalzanemdor (SAGE-718) - (LIGHTWAVE),Mild cognitive impairment and mild dementia due to AD ,Phase 2,08/10/2024 ET,"Phase 2 topline data reported that the trial did not demonstrate a statistically significant difference from baseline in participants treated with dalzanemdor versus placebo on the primary endpoint, n … read more",56.07M
Add to portfolio,,,,,,,,
RLFTF,RELIEF THERAPEUTICS HLDG AG,$4.91 ,RLF-TD011,Epidermolysis bullosa (EB) ,Phase 1,08/10/2024 ET,"Preliminary results reported a statistically significant reduction in Staphylococcus aureus and an increase in beneficial bacteria in EB wounds, accompanied by a marked improvement in alpha microbiome … read more",12.58M
Add to portfolio,,,RPDD,,,,,
,,,QID,,,,,
AVTX,Avalo Therapeutics Inc.,$9.63 ,AVTX-009 (anti-IL-1β mAb) - (LOTUS),Hidradenitis suppurativa (HS) ,Phase 2,08/10/2024 ET,"Phase 2 patient dosing commenced, noted October 8, 2024",13.15M
Add to portfolio,,,,,,,,
BIIB,Biogen Inc.,$182.30 ,SPINRAZA (Nusinersen) - (DEVOTE),Spinal muscular atrophy (SMA) ,Phase 2/3,08/10/2024 ET,"Phase 2/3 results reported clinical benefits of a higher dose regimen of nusinersen (50/28 mg) in both individuals previously treated and treatment-naïve to nusinersen, noted October 8, 2024.",146.61M
Add to portfolio,,,View Clinical Trial Data,,,,,
IONS,Ionis Pharmaceuticals Inc.,$37.80 ,SPINRAZA (Nusinersen) - (DEVOTE),Spinal muscular atrophy (SMA) ,Phase 2/3,08/10/2024 ET,"Phase 2/3 results reported clinical benefits of a higher dose regimen of nusinersen (50/28 mg) in both individuals previously treated and treatment-naïve to nusinersen, noted October 8, 2024.",159.39M
Add to portfolio,,,View Clinical Trial Data,,,,,
BPTH,Bio-Path Holdings Inc.,$1.19 ,BP1001-A (Prexigebersen-A),Obesity in Type 2 diabetes patients ,Phase 1,08/10/2024 ET,"Phase 1 initiated, noted October 8, 2024.",8.31M
Add to portfolio,,,,,,,,
OGEN,Oragenics Inc.,$0.36 ,ONP-002,Moderate-to-severe concussion in the acute through subacute phases ,Phase 2,08/10/2024 ET,"Phase 2 data reported that the drug spreads well in the areas of the nose where it can be quickly absorbed into the brain, noted October 8, 2024.",4.13M
Add to portfolio,,,,,,,,
PHIO,Phio Pharmaceuticals Corp.,$2.81 ,INTASYL,Hematological malignancies ,Preclinical,08/10/2024 ET,"Preclinical data shared at the Oligonucleotide Therapeutics Society (OTS) Meeting showed that compounds also improve the functionality and outcomes of adoptive cell therapies such as NK, TIL and CAR- … read more",5.73M
Add to portfolio,,,,,,,,
PTCT,PTC Therapeutics Inc.,$40.77 ,Vatiquinone - (MOVE-FA),Friedreich ataxia ,Phase 3,08/10/2024 ET,"Phase 3 trial met pre-specified endpoint for two different FA long-term extension studie with highly statistically significant evidence of durable treatment benefit on disease progression, noted Octob … read more",79.44M
Add to portfolio,,,View Clinical Trial Data,,,,,
TVGN,Tevogen Bio Holdings Inc.,$0.31 ,TVGN 489 - (TCTL Study),Cytotoxic T Lymphocytes for the Treatment of Elderly and High-Risk Patients with Covid-19 ,Phase 1,08/10/2024 ET,"Phase 1 data published at the Blood Advances Journal showed that all patients treated with TVGN 489 returned to baseline health within 14 days, with no evidence of reinfection or Long COVID during a s … read more",196.71M
Add to portfolio,,,,,,,,
INSM,Insmed Incorporated,$71.37 ,BRINSUPRI (Brensocatib) - (ASPEN),Non-Cystic Fibrosis Bronchiectasis (NCFBE) ,Phase 3,08/10/2024 ET,"Phase 3 additional data presented at CHEST 2024 showed that treatment was well-tolerated, noted October 8, 2024.",211.37M
Add to portfolio,,,View Clinical Trial Data,,,,,
TEVA,Teva Pharmaceutical Industries Limited American Depositary Shares,$17.53 ,Prolia (denosumab) biosimilar - (TVB-009P),Osteoporosis ,Approved,08/10/2024 ET,"FDA biosimilar approved on October 8, 2024.",1.15B
Add to portfolio,,,,,,,,
GSK,GSK plc American Depositary Shares (Each representing two),$37.18 ,Arexvy (60+ at increased risk) - (AReSVi-006),"Respiratory Syncytial Virus Vaccine, Adjuvanted ",Phase 3,08/10/2024 ET,"Phase 3 data presented at CHEST showed that trial met primary endpoint, noted October 8, 2024.",2.03B
Add to portfolio,,,,,,,,
CLSD,Clearside Biomedical Inc.,$1.31 ,CLS-AX - (ODYSSEY),Neovascular age-related macular degeneration (wet AMD) ,Phase 2b,09/10/2024 ET,"Phase 2b with topline data reported that the trial achieved both its primary and secondary outcomes. noted October 9, 2024.",5.23M
Add to portfolio,,,,,,,,
OCGN,"Ocugen, Inc.",$0.95 ,OCU200,Diabetic macular edema (DME) ,IND-Enabling,09/10/2024 ET,"Clinical hold lifted October 9, 2024.",292.3M
Add to portfolio,,,,,,,,
KYMR,Kymera Therapeutics Inc.,$43.34 ,KT-621 (STAT6),Type 2 inflammation in allergic diseases ,Phase 1,09/10/2024 ET,"IND cleared by the FDA, noted October 9, 2024.",71.5M
Add to portfolio,,,,,,,,
VKTX,Viking Therapeutics Inc.,$62.64 ,VK0214,X-linked adrenoleukodystrophy (X-ALD) ,Phase 1b,09/10/2024 ET,"Phase 1b results after 28 days of once-daily dosing, treatment shown to be safe and well-tolerated, with significant reductions in very long-chain fatty acids (VLCFAs), key biomarkers of X-ALD, noted … read more",113.04M
Add to portfolio,,,,,,,,
ALNY,Alnylam Pharmaceuticals Inc.,$270.90 ,AMVUTTRA (vutrisiran),ATTR Amyloidosis with Cardiomyopathy (ATTR-CM) ,sNDA Filing,09/10/2024 ET,"sNDA submitted to the FDA, noted October 9, 2024. Priority review voucher utilized to accelerate review period",131.08M
Add to portfolio,,,View Clinical Trial Data,,,,,
CANF,Can-Fite Biopharma Ltd Sponsored ADR (Israel),$2.35 ,Namodenoson - (CF102-222PC),Pancreatic Cancer ,Phase 1,09/10/2024 ET,"Orphan Drug Designation granted by the FDA, noted October 9, 2024.",10.35M
Add to portfolio,,,ODD,,,,,
BIIB,Biogen Inc.,$185.76 ,Felzartamab - (TRANSCEND),Antibody-mediated rejection (AMR) in kidney transplant recipients ,Phase 3,09/10/2024 ET,"Breakthrough Therapy Designation granted by the FDA, noted October 9, 2024.",146.61M
Add to portfolio,,,ODD,,,,,
,,,BTD,,,,,
DYN,Dyne Therapeutics Inc.,$32.02 ,DYNE-101 - (ACHIEVE),Myotonic Dystrophy Type 1 (DM1) ,Phase 1/2,09/10/2024 ET,"Phase 1/2 update presented at the World Muscle Society demonstrated robust muscle delivery and dose-dependent, consistent splicing correction while also showing improvement in myotonia, muscle strengt … read more",142.26M
Add to portfolio,,,ODD,,,,,
,,,FTD,,,,,
,,,BTD,,,,,
DYN,Dyne Therapeutics Inc.,$32.02 ,DYNE-251 - (DELIVER),Duchenne muscular dystrophy (DMD) ,Phase 1/2,09/10/2024 ET,"Phase 1/2 update demonstrated dose dependent exon skipping and dystrophin expression and improvement in multiple functional endpoints in both cohorts, noted October 9, 2024.",142.26M
Add to portfolio,,,FTD,,,,,
,,,ODD,,,,,
,,,BTD,,,,,
VTRS,Viatris Inc.,$11.31 ,EFFEXOR (venlafaxine) - (B2411367),Generalized anxiety disorder (GAD) ,Phase 3,09/10/2024 ET,"Phase 3 study met primary and all secondary efficacy endpoints, noted October 9, 2024.",1.17B
Add to portfolio,,,,,,,,
TRDA,Entrada Therapeutics Inc.,$16.17 ,ENTR-601-44,Duchenne Muscular Dystrophy (DMD) ,Phase 1,09/10/2024 ET,"Phase 1 interim data presented at the World Muscle Society reinforced its safety profile and supports the planned 4Q 2024 global regulatory filings for a Phase 2 clinical trial, noted October 9, 2024 … read more",38.04M
Add to portfolio,,,,,,,,
UNCY,Unicycive Therapeutics Inc.,$0.36 ,UNI-494,Acute kidney injury (AKI) ,Phase 1,09/10/2024 ET,"Phase 1 study completed, noted October 9, 2024.",17.66M
Add to portfolio,,,ODD,,,,,
ZLDPF,Zealand Pharma A/S.,$115.00 ,Dasiglucagon - (17103),"Congenital hyperinsulinism (CHI), (Pediatric) ",CRL,09/10/2024 ET,"CRL issued October 9, 2024.",70.69M
Add to portfolio,,,,,,,,
PEPG,PepGen Inc.,$9.52 ,PGN-EDO51 - (CONNECT1),Duchenne muscular dystrophy (DMD) ,Phase 2,09/10/2024 ET,"Phase 2 OLE 12-week data from WMS reported that all participants at 5 mg/kg demonstrated increased dystrophin production and exon skipping at just 3 months and after 4 doses, noted October 9, 2024.",32.8M
Add to portfolio,,,ODD,,,,,
,,,RPDD,,,,,
IMTX,Immatics N.V.,$9.35 ,"Anzu-cel (anzutresgene autoleucel, IMA203) (ACTengine) - (SUPRAME)",Melanoma ,Phase 1b,10/10/2024 ET,"Phase 1b cohorts data reported an cORR of 54% in both all melanoma patients and in cutaneous melanoma patients, noted October 10, 2024.",121.55M
Add to portfolio,,,RMAT,,,,,
RNAZ,TransCode Therapeutics Inc.,$24.07 ,TTX-MC138,Metastatic solid tumors ,Phase 1,10/10/2024 ET,"Phase 1 initial dosing completed, noted October 10, 2024.",833.68K
Add to portfolio,,,ODD,,,,,
JNJ,Johnson & Johnson,$157.97 ,TREMFYA (Guselkumab) - (QUASAR),Crohn's disease ,Approved,10/10/2024 ET,"FDA Approved on October 10, 2024.",2.41B
Add to portfolio,,,View Clinical Trial Data,,,,,
NVS,Novartis AG,$114.81 ,TREMFYA (Guselkumab) - (QUASAR),Crohn's disease ,Approved,10/10/2024 ET,"FDA Approved on October 10, 2024.",1.98B
Add to portfolio,,,View Clinical Trial Data,,,,,
ALLK,Allakos Inc.,$0.66 ,AK006 (IV),Chronic spontaneous urticaria (CSU) ,Phase 1,10/10/2024 ET,"Phase 1 topline data reported that the 720 mg dose of AK006 showed 98% receptor occupancy at day 113 suggesting the potential for infrequent dosing, noted October 10, 2024.",90.38M
Add to portfolio,,,,,,,,
ALLK,Allakos Inc.,$0.66 ,AK006 (subcutaneous),Healthy volunteers ,Phase 1,10/10/2024 ET,"Phase 1 topline data reported that the 720 mg dose of AK006 showed 98% receptor occupancy at day 113 suggesting the potential for infrequent dosing, noted October 10, 2024.",90.38M
Add to portfolio,,,,,,,,
RHHBY,Roche Holding AG ADR,$38.87 ,Itovebi (inavolisib) with palbociclib (Ibrance) and fulvestrant,"HER2-negative, endocrine-resistant, locally advanced or metastatic breast cancer ",Approved,10/10/2024 ET,"Approved October 10, 2024.",6.36B
Add to portfolio,,,BTD,,,,,
FHTX,Foghorn Therapeutics Inc.,$7.06 ,FHD-909 (LY4050784),Non-small cell lung cancer (NSCLC) ,Phase 1,10/10/2024 ET,"Phase 1 trial initiated, noted October 10, 2024.",56.53M
Add to portfolio,,,,,,,,
LLY,Eli Lilly and Company,$907.49 ,FHD-909 (LY4050784),Non-small cell lung cancer (NSCLC) ,Phase 1,10/10/2024 ET,"Phase 1 trial initiated, noted October 10, 2024.",946.46M
Add to portfolio,,,,,,,,
PFE,Pfizer Inc.,$28.42 ,CRDF-004,Metastatic colorectal cancer (mCRC) ,Phase 2,10/10/2024 ET,"Phase 2 data reported a 64% ORR in the 30mg onvansertib dose arm versus 33% ORR in the control arm, noted December 10, 2024.",5.69B
Add to portfolio,,,,,,,,
CRDF,Cardiff Oncology Inc.,$2.52 ,CRDF-004,Metastatic colorectal cancer (mCRC) ,Phase 2,10/10/2024 ET,"Phase 2 data reported a 64% ORR in the 30mg onvansertib dose arm versus 33% ORR in the control arm, noted December 10, 2024.",66.53M
Add to portfolio,,,,,,,,
SGMT,Sagimet Biosciences Inc.,$4.31 ,Denifanstat - (FASCINATE-3),Nonalcoholic steatohepatitis (NASH) ,Phase 2b,11/10/2024 ET,"Phase 2b study showed 36% of patients on denifanstat achieved MASH resolution without worsening fibrosis, and 52% had a ≥2-point NAS reduction. With secondary endpoints and a favorable safety profile, … read more",32.52M
Add to portfolio,,,BTD,,,,,
CATX,Isoray. (DE),$12.66 ,212Pb-VMT01,MC1R-positive metastatic melanoma ,Phase 1/2,11/10/2024 ET,"Phase 1/2 safety and efficacy update reported that one patient experiencing a RECIST version 1.1 objective response after completion of treatment, and two patients experiencing stable disease at 9 and … read more",74.26M
Add to portfolio,,,FTD,,,,,
CAPR,Capricor Therapeutics Inc.,$17.77 ,Deramiocel (CAP-1002) - (HOPE-2),Duchenne Muscular Dystrophy (DMD) ,BLA Filing,11/10/2024 ET,"Phase 3 OLE data presented at the 29th Annual Congress of the World Muscle Society, demonstrated sustained improvements in cardiac and skeletal muscle function over three years. Key outcomes included … read more",45.72M
Add to portfolio,,,ODD,,,,,
BCAB,BioAtla Inc.,$2.07 ,Evalstotug (BA3071),Oncology (various) ,Phase 2,11/10/2024 ET,"Phase 2 data presented at SMR reported 1 cCR (cervical cancer) and 2 cPRs (melanoma and gastric), noted October 11, 2024.",58.72M
Add to portfolio,,,,,,,,
PFE,Pfizer Inc.,$28.24 ,Hympavzi (marstacimab-hncq),Hemophilia A or B ,Approved,11/10/2024 ET,"Approved October 11, 2024.",5.69B
Add to portfolio,,,View Clinical Trial Data,,,,,
BNTC,Benitec Biopharma Inc.,$10.86 ,BB-301,Oculopharyngeal muscular dystrophy (OPMD) ,Phase 1/2,12/10/2024 ET,"Phase 1b/2a data from the Annual Congress of the World Muscle Society reported that Subject 1 and Subject 2 experienced durable, clinically meaningful improvements in swallowing at 9-months and 6-mont … read more",26.25M
Add to portfolio,,,ODD,,,,,
LLY,Eli Lilly and Company,$926.25 ,Mirikizumab - (VIVID-1),Crohn's disease ,Phase 3,14/10/2024 ET,"Phase 3 1-year data reported that a greater number of patients that achieved histologic response were observed with mirikizumab at Week 52 in the overall population (58.2% versus 48.8%; p=0.0075), not … read more",946.46M
Add to portfolio,,,View Clinical Trial Data,,,,,
GSK,GSK plc American Depositary Shares (Each representing two),$38.26 ,Depemokimab - (ANCHOR 1/2),Chronic rhinosinusitis with nasal polyps ,Phase 3,14/10/2024 ET,"Phase 3 data reported that trial met primary endpoint, noted October 14, 2024.",2.03B
Add to portfolio,,,,,,,,
RHHBY,Roche Holding AG ADR,$39.17 ,Evrysdi (risdiplam) - (RAINBOWFISH),Babies with pre-symptomatic spinal muscular atrophy (SMA) ,Phase 3,14/10/2024 ET,"Phase 3 2-year data reported that all of the children treated with Evrysdi who had three or more SMN2 copies (n=18), achieved standing and walking (100%) milestones as assessed by Bayley Scales of Inf … read more",6.36B
Add to portfolio,,,,,,,,
RPTX,Repare Therapeutics Inc.,$3.39 ,RP-3467 - (POLAR),Solid tumors ,Phase 1,14/10/2024 ET,"Phase 1 dosing commenced, noted October 14, 2024.",42.96M
Add to portfolio,,,,,,,,
CMND,Clearmind Medicine Inc.,$1.41 ,CMND-100,Alcohol use disorder (AUD) ,Phase 1/2,14/10/2024 ET,"IRB approval on US clinical sites for part A of Phase 1/2a, noted October 14, 2024.",5.38M
Add to portfolio,,,,,,,,
ENVB,Enveric Biosciences Inc.,$6.35 ,EB-003 (EVM301 series),Mental health disorders ,Preclinical,15/10/2024 ET,"In vitro data showed no meaningful activity against hERG or 5-HT2B, targets related to cardiovascular adverse drug reactions (ADRs), noted October 15, 2024.",518.3K
Add to portfolio,,,,,,,,
AMGN,Amgen Inc.,$319.87 ,UPLIZNA (Inebilizumab) - (MINT),Myasthenia gravis ,Phase 3,15/10/2024 ET,"Phase 3 trial met its primary endpoint, noted October 15, 2024.",538.36M
Add to portfolio,,,View Clinical Trial Data,,,,,
ANVS,Annovis Bio Inc.,$7.98 ,Buntanetap (ANVS401),Alzheimer’s disease (AD) ,Phase 2/3,15/10/2024 ET,"Phase 2 EoP2 meeting. During the meeting, the FDA granted clearance to proceed with pivotal Phase 3 studies, based on the Company's Phase 2/3 clinical data showing symptomatic improvement in early AD … read more",19.49M
Add to portfolio,,,ODD,,,,,
JNJ,Johnson & Johnson,$161.50 ,Nipocalimab - (Vibrance-MG),Generalized myasthenia gravis ,Phase 2/3,15/10/2024 ET,"Phase 2/3 data reported sustained disease control over 24 weeks in antibody positive adolescents aged 12 – 17 years, noted October 15, 2024.",2.41B
Add to portfolio,,,,,,,,
VTYX,Ventyx Biosciences Inc.,$2.41 ,Tamuzimod (VTX002),Ulcerative Colitis (UC) ,Phase 2,15/10/2024 ET,"Phase 2 data reported that endoscopic remission occurred in 43.8% (14/32) and 46.4% (13/28) of patients who received tamuzimod 30 mg and 60 mg, respectively, compared to 18.2% (4/22) of patients who r … read more",71.31M
Add to portfolio,,,,,,,,
MGTX,MeiraGTx Holdings plc,$5.33 ,AAV-GAD,Parkinson's Disease ,Phase 1,15/10/2024 ET,"Phase 1 met its primary endpoint, noted October 15, 2024.",80.45M
Add to portfolio,,,RMAT,,,,,
NVCR,NovoCure Limited,$17.78 ,Optune Lua is (Tumor Treating Fields (TTFields)) - (LUNAR),Non-small cell lung cancer (NSCLC) ,Approved,15/10/2024 ET,"FDA approved by the FDA, noted October 15, 2024.",111.8M
Add to portfolio,,,View Clinical Trial Data,,,,,
ZLAB,Zai Lab Limited,$24.79 ,Optune Lua is (Tumor Treating Fields (TTFields)) - (LUNAR),Non-small cell lung cancer (NSCLC) ,Approved,15/10/2024 ET,"FDA approved by the FDA, noted October 15, 2024.",109.96M
Add to portfolio,,,View Clinical Trial Data,,,,,
GNPX,Genprex Inc.,$0.34 ,REQORSA Immunogene Therapy (quratusugene ozeplasmid) - (Acclaim-3),Extensive-stage small cell lung cancer (ES-SCLC) ,Phase 1,15/10/2024 ET,"Phase 1 portion to continue following review from safety review committee approval to advance to highest dose, noted October 15, 2024.",858.11K
Add to portfolio,,,ODD,,,,,
,,,FTD,,,,,
RHHBY,Roche Holding AG ADR,—,Zepzelca (lurbinectedin) and Atezolizumab (Tecentriq),"First-line, Small Cell Lung Cancer (SCLC) ",Phase 3,15/10/2024 ET,"Phase 3 topline data demonstrated a statistically significant improvement in the primary endpoints of overall survival (OS) and progression-free survival (PFS), as assessed by an independent review f … read more",6.36B
Add to portfolio,,,View Clinical Trial Data,,,,,
JAZZ,Jazz Pharmaceuticals plc,$117.28 ,Zepzelca (lurbinectedin) and Atezolizumab (Tecentriq),"First-line, Small Cell Lung Cancer (SCLC) ",Phase 3,15/10/2024 ET,"Phase 3 topline data demonstrated a statistically significant improvement in the primary endpoints of overall survival (OS) and progression-free survival (PFS), as assessed by an independent review f … read more",60.66M
Add to portfolio,,,View Clinical Trial Data,,,,,
LYRA,Lyra Therapeutics Inc.,$0.23 ,LYR-210 - (ENLIGHTEN II),Chronic rhinosinusitis ,Phase 3,15/10/2024 ET,"Phase 3 enrollment to be completed, noted Ocrtober 15, 2024",1.64M
Add to portfolio,,,,,,,,
QURE,uniQure N.V.,$5.64 ,AMT-162,SOD1-ALS ,Phase 1/2,15/10/2024 ET,"Phase 1/2 dosing commenced, noted October 15, 2024.",54.87M
Add to portfolio,,,,,,,,
HCM,HUTCHMED (China) Limited,$19.81 ,Savolitinib + TAGRISSO (osimertinib) - (SAVANNAH),Non-small cell lung cancer (NSCLC) ,Phase 2,16/10/2024 ET,"Phase 2 data demonstrated a high, clinically meaningful and durable objective response rate (ORR) for patients with epidermal growth factor receptor-mutated (EGFRm) non-small cell lung cancer (NSCLC) … read more",174.43M
Add to portfolio,,,FTD,,,,,
,,,View Clinical Trial Data,,,,,
AZN,AstraZeneca PLC,$77.22 ,IVX-A12,RSV/human Metapneumovirus (hMPV) ,Phase 2,16/10/2024 ET,"Phase 2 interim data from ID week reported that treatment was well-tolerated and immunogenic against both RSV and hMPV in older adults 60 to 85 years of age, noted October 16, 2024.",3.1B
Add to portfolio,,,FTD,,,,,
ACET,Adicet Bio Inc.,$1.49 ,ADI-001,Idiopathic inflammatory myopathy (IIM) and stiff person syndrome (SPS) ,IND-Enabling,16/10/2024 ET,"IND Clearance by the FDA, noted October 16, 2024.",83.25M
Add to portfolio,,,,,,,,
CGEM,Cullinan Therapeutics Inc.,$17.61 ,CLN-978,Systemic Lupus Erythematosus (SLE) ,IND-Enabling,16/10/2024 ET,"IND Cleared by the FDA, noted October 16, 2024.",59.07M
Add to portfolio,,,,,,,,
NVAX,Novavax Inc.,$10.15 ,NVX-CoV2373 - (COVID-19-Influenza Combination),"COVID-19, COVID-19 vaccine, Influenza ",Phase 2,16/10/2024 ET,"Phase 2 IND placed on hold October 16, 2024.",162.42M
Add to portfolio,,,,,,,,
WVE,Wave Life Sciences Ltd.,$14.90 ,WVE-006 - (RestorAATion-2),"Healthy volunteers, AATD who have the homozygous PiZZ mutation ",Phase 1/2,16/10/2024 ET,"Phase 1b/2a data resulted in mean plasma total AAT levels of ~11 micromolar, with mean wild-type M-AAT representing more than 60% of total AAT; durable editing with M-AAT protein observed through 57 d … read more",159.14M
Add to portfolio,,,,,,,,
GRI,GRI Bio Inc.,$7.89 ,GRI-0621,Idiopathic pulmonary fibrosis (IPF) ,Preclinical,16/10/2024 ET,"Preclinical data reported an increase in IFN-γ producing NKT cells in IPF, compared to controls and confirmed iNKT cell phenotype in a second cohort, using an antibody against Vα24-Jα18 of the iNKT TC … read more",2.52M
Add to portfolio,,,,,,,,
DRUG,Bright Minds Biosciences Inc.,$28.80 ,BMB-201,Pain ,Preclinical,16/10/2024 ET,"Preclinical data reported dose-dependent efficacy with similar efficacy to morphin, noted October 16, 2024.",7.08M
Add to portfolio,,,,,,,,
GKOS,Glaukos Corporation,$128.20 ,Epioxa (Epi-on),Progressive keratoconus ,Phase 3,16/10/2024 ET,"Second Phase 3 trial met primary endpoint, noted October 16, 2024.",57.35M
Add to portfolio,,,,,,,,
PHIO,Phio Pharmaceuticals Corp.,$3.25 ,INTASYL(PH-894),Solid tumors ,Preclinical,16/10/2024 ET,"Preclinical data shared at ASGCT 2024 showed that treatment leads to potent and specific silencing of BRD4 in NK cells, without affecting cell viability., noted October 16, 2024.",5.73M
Add to portfolio,,,,,,,,
VSTM,Verastem Inc.,$2.66 ,AVMAPKI FAKZYNJA CO-PACK,Recurrent low-grade serous ovarian cancer (LGSOC) ,Phase 3,17/10/2024 ET,"Phase 3 data reported overall response rates observed (31% overall, 44% in KRAS mutant, 17% in KRAS wild-type) in patients whose cancer had progressed despite prior treatment with chemotherapy and/or … read more",61.55M
Add to portfolio,,,ODD,,,,,
LGND,Ligand Pharmaceuticals Incorporated,$105.89 ,ZTALMY (ganaxolone) - (RAISE),Refractory status epilepticus (RSE) ,Phase 3,17/10/2024 ET,"Phase 3 data at the NCS showed that the trial met one of its two co-primary endpoints, with 80% of patients achieving SE cessation within 30 minutes. IV ganaxolone also showed faster SE cessation. How … read more",19.6M
Add to portfolio,,,View Clinical Trial Data,,,,,
MRNS,Marinus Pharmaceuticals Inc.,$1.74 ,ZTALMY (ganaxolone) - (RAISE),Refractory status epilepticus (RSE) ,Phase 3,17/10/2024 ET,"Phase 3 data at the NCS showed that the trial met one of its two co-primary endpoints, with 80% of patients achieving SE cessation within 30 minutes. IV ganaxolone also showed faster SE cessation. How … read more",55.19M
Add to portfolio,,,View Clinical Trial Data,,,,,
,,,,,,,,
BDRX,Biodexa Pharmaceuticals plc,$5.87 ,MTX110 - (MAGIC-G1),Recurrent Glioblastoma (GBM) ,Phase 1,17/10/2024 ET,"Phase 1 data reported that patient #3 has achieved 13 months OS to date, with six months progression free survival (PFS). Patient #4 has not progressed and achieved 12 months PFS and 12 months OS to d … read more",505.06K
Add to portfolio,,,FTD,,,,,
AVXL,Anavex Life Sciences Corp.,$5.51 ,ANAVEX 3-71 (AF710B),Schizophrenia ,Phase 2,17/10/2024 ET,"Phase 2 data reported that ANAVEX3-71 demonstrates a dose-dependent pharmacodynamic effect on objective EEG biomarkers of schizophrenia, noted October 17, 2024.",85.89M
Add to portfolio,,,,,,,,
ADTX,Aditxt Inc.,$1.08 ,ATI-1701,Francisella tularensis vaccine ,Preclinical,17/10/2024 ET,"Preclinical data presented at IDweek reported full protection against lethal tularemia in animal models after one year, noted October 17, 2024.",4.98M
Add to portfolio,,,,,,,,
APLIF,Appili Therapeutics Inc,$0.03 ,ATI-1701,Francisella tularensis vaccine ,Preclinical,17/10/2024 ET,"Preclinical data presented at IDweek reported full protection against lethal tularemia in animal models after one year, noted October 17, 2024.",121.27M
Add to portfolio,,,,,,,,
KZR,Kezar Life Sciences Inc.,$8.16 ,Zetomipzomib (KZR-616-208) - (PORTOLA),Autoimmune Hepatitis (AIH) ,Phase 2a,17/10/2024 ET,"Phase 2a IDMC ecommended that the trial may proceed without modification following its third scheduled meeting., noted October 17, 2024.",7.32M
Add to portfolio,,,,,,,,
AMLX,Amylyx Pharmaceuticals Inc.,$3.92 ,AMX0035 - (HELIOS),Wolfram Syndrome ,Phase 2,17/10/2024 ET,"Phase 2 topline data from ISPAD reported improvement in pancreatic function, as measured by C-peptide response after 24 weeks of treatment with AMX0035, the study's primary efficacy endpoint, noted Oc … read more",89.17M
Add to portfolio,,,ODD,,,,,
AVDL,Avadel Pharmaceuticals plc,$13.92 ,LUMRYZ (sodium oxybate) Extended-Release Oral Suspension (CIII),Pediatric narcolepsy ,Approved,17/10/2024 ET,"Approved October 17, 2024.",97.1M
Add to portfolio,,,,,,,,
AURA,Aura Biosciences Inc.,$10.29 ,Belzupacap sarotalocan (AU-011),Non-muscular invasive bladder cancer (NMIBC) ,Phase 1,17/10/2024 ET,Phase 1 updated data reported that 4 out of 5 patients with low grade disease demonstrated a clinical complete response with no tumor cells remaining on histopathological evaluation and 2 out of 3 pat … read more,62.12M
Add to portfolio,,,FTD,,,,,
SUPN,Supernus Pharmaceuticals Inc.,$33.84 ,SPN-820,Treatment-resistant depression ,Phase 2a,17/10/2024 ET,"Phase 2a open label data reported a rapid and substantial decrease in depressive symptoms, noted October 17, 2024.",56.07M
Add to portfolio,,,View Clinical Trial Data,,,,,
RANI,Rani Therapeutics Holdings Inc.,$2.63 ,RT-114,Obesity ,Preclinical,17/10/2024 ET,"Preclinical pharmacokinetic data provided further evidence of the RaniPill platform's potential to enable oral delivery of multiple obesity treatments, noted October 17, 2024.",71.87M
Add to portfolio,,,,,,,,
ABBV,AbbVie Inc.,$186.78 ,VYALEV (foscarbidopa and foslevodopa),Parkinson's disease ,Approved,17/10/2024 ET,"Approved October 17, 2024.",1.77B
Add to portfolio,,,,,,,,
ALPMY,Astellas Pharma Inc. ADR,$11.73 ,Zolbetuximab,HER2-negative gastric or gastroesophageal junction (GEJ) adenocarcinoma whose tumors are CLDN18.2-positive ,Approved,18/10/2024 ET,"Approved October 18, 2024.",1.79B
Add to portfolio,,,,,,,,
KZR,Kezar Life Sciences Inc.,$8.24 ,Zetomipzomib - (PALIZADE),Lupus nephritis ,Phase 2b,18/10/2024 ET,"Phase 2b IND placed on clinical hold, noted October 4, 2024. Phase 2b will be discontinued after clinical hold following the recommendation of the IDMC after its assessment of four Grade 5 (fatal), no … read more",7.32M
Add to portfolio,,,,,,,,
MRK,Merck & Company Inc.,$107.83 ,ENFLONSIA (Clesrovimab) (MK-1654-004) - (CLEVER),Respiratory syncytial virus (RSV) infants ,Phase 2/3,18/10/2024 ET,Phase 2b/3 data presented at IDweek reported that treatment reduced RSV-associated hospitalizations (secondary endpoint) and RSV-associated lower respiratory infection hospitalizations (tertiary endpo … read more,2.5B
Add to portfolio,,,,,,,,
PFE,Pfizer Inc.,$28.30 ,VYLOY (zolbetuximab-clzb),Advanced Gastric and GEJ Cancer ,Approved,18/10/2024 ET,"Approved October 18, 2024.",5.69B
Add to portfolio,,,,,,,,
ALPMY,Astellas Pharma Inc. ADR,$11.73 ,VYLOY (zolbetuximab-clzb),Advanced Gastric and GEJ Cancer ,Approved,18/10/2024 ET,"Approved October 18, 2024.",1.79B
Add to portfolio,,,,,,,,
RHHBY,Roche Holding AG ADR,$39.40 ,Vabysmo (faricimab-svoa) - (ELEVATUM),Diabetic macular edema (DME) ,Phase 3,21/10/2024 ET,"Phase 4 trial data showed clinically meaningful improvement in vision and reduction in retinal fluid in people with DME treated with Vabysmo who identify as African American, Black, Hispanic and Latin … read more",6.36B
Add to portfolio,,,,,,,,
REGN,Regeneron Pharmaceuticals Inc.,$967.28 ,EYLEA HD (aflibercept) - (PHOTON ext),Diabetic macular edema (DME) ,Phase 3,21/10/2024 ET,"Phase 3 extension data reported that 88% of EYLEA HD patients had a last assigned dosing interval of ≥12 weeks at week 156, while sustaining visual and anatomic improvements achieved in the first 96 w … read more",105.1M
Add to portfolio,,,,,,,,
ACXP,Acurx Pharmaceuticals Inc.,$1.96 ,Ibezapolstat,C. difficile Infection ,Phase 2b,21/10/2024 ET,"Phase 2b microbiome analysis presented at ID Week indicate a favorable gut bile acid profile which may contribute to ibezapostat's beneficial anti-recurrence effect in patients, noted October 21, 2024 … read more",1.58M
Add to portfolio,,,FTD,,,,,
,,,View Clinical Trial Data,,,,,
ABBV,AbbVie Inc.,$184.77 ,BOTOX (OnabotulinumtoxinA),Platysma prominence associated with platysma muscle activity (M21-310) ,Approved,21/10/2024 ET,"Approved October 21, 2024.",1.77B
Add to portfolio,,,,,,,,
NRIX,Nurix Therapeutics Inc.,$25.48 ,Bexobrutideg (NX-5948),Relapsed/Refractory Waldenstrom's Macroglobulinemia ,Phase 1/2,21/10/2024 ET,"Phase 1a/1b data reported an objective responses observed in 7 of 9 (77.8%), noted October 21, 2024.",76.88M
Add to portfolio,,,FTD,,,,,
,,,ODD,,,,,
PYPD,PolyPid Ltd.,$3.30 ,D-PLEX100 - (SHIELD I),Abdominal (soft tissue) sternal surgical site infections ,Phase 3,21/10/2024 ET,"Phase 3 data published at the Journal of Surgery trial showed that despite study did not meet its primary endpoint due to COVID-19-related impacts, pre-specified and post-hoc analyses indicated poten … read more",10.19M
Add to portfolio,,,View Clinical Trial Data,,,,,
ELAB,PMGC Holdings Inc.,$19.80 ,EL-32,Obesity ,Preclinical,21/10/2024 ET,"Preclinical data reported statistically significant increases in grip strength, motor function and body composition in aged C57BL/6J mouse model, noted October 21, 2024.",677.07K
Add to portfolio,,,,,,,,
RGNX,REGENXBIO Inc.,$10.37 ,ABBV-RGX-314,Wet age-related macular degeneration (wet AMD) ,Phase 2,21/10/2024 ET,"Phase 2 data reported a 97% reduction in treatment burden at nine months after treatment, noted October 21, 2024.",50.51M
Add to portfolio,,,,,,,,
MIRA,MIRA Pharmaceuticals Inc.,$1.05 ,Ketamir-2 (Topical),"Neuropathic pain and chemo-induced depression, as well as neuropathic pain and PTSD ",Preclinical,21/10/2024 ET,"Preclinical data has shown greater pain relief compared to FDA-approved treatments Gabapentin (Neurontin) and Pregabalin (Lyrica), noted October 21, 2024.",19.07M
Add to portfolio,,,,,,,,
NVO,Novo Nordisk A/S,$117.33 ,Semaglutide - (SOUL),Major adverse cardiovascular events (MACE) ,Phase 3,21/10/2024 ET,"Trial data reported that trial met its primary endpoint, noted October 21, 2024.",4.47B
Add to portfolio,,,,,,,,
GILD,Gilead Sciences Inc.,$85.57 ,Islatravir (MK-8591D) and Lenacapavir - (ISLEND),Human immunodeficiency virus (HIV) ,Phase 2,21/10/2024 ET,"Phase 2 data reported that the combination maintained a high rate (n=49; 94.2%) of viral suppression (HIV-1 RNA <50 copies/mL) in virologically suppressed adults, a secondary endpoint of the study, no … read more",1.24B
Add to portfolio,,,View Clinical Trial Data,,,,,
MRK,Merck & Company Inc.,$105.49 ,Islatravir (MK-8591D) and Lenacapavir - (ISLEND),Human immunodeficiency virus (HIV) ,Phase 2,21/10/2024 ET,"Phase 2 data reported that the combination maintained a high rate (n=49; 94.2%) of viral suppression (HIV-1 RNA <50 copies/mL) in virologically suppressed adults, a secondary endpoint of the study, no … read more",2.5B
Add to portfolio,,,View Clinical Trial Data,,,,,
TARA,Protara Therapeutics Inc.,$2.01 ,IV choline chloride - (THRIVE-3),Parenteral nutrition (PN) ,Phase 3,21/10/2024 ET,"Fast Track Designation graned by the FDA, noted October 21, 2024.",38.58M
Add to portfolio,,,FTD,,,,,
AMRX,Amneal Pharmaceuticals Inc.,$8.47 ,Pyridostigmine Bromide Extended-Release (PB ER) Tablets USP 105 mg,Lethal effects of soman nerve agent poisoning ,Approved,21/10/2024 ET,"NDA Approved by the FDA, noted October 21, 2024.",314.08M
Add to portfolio,,,,,,,,
MDGL,Madrigal Pharmaceuticals Inc.,$208.89 ,Resmetirom - (MAESTRO-NASH Outcomes),Nonalcoholic Steatohepatitis (NASH) ,Phase 3,21/10/2024 ET,"Phase 3 enrollment completed, noted October 21, 2024.",22.29M
Add to portfolio,,,,,,,,
RGNX,REGENXBIO Inc.,$10.37 ,RGX-314 - (ALTITUDE),Diabetic retinopathy ,Phase 1/2,21/10/2024 ET,"Phase 1/2a long-term results reported that treatment was well-tolerated with 78% of patiences injection-free and 97% reduction in anti-VEGF treatment burden, noted October 21, 2024.",50.51M
Add to portfolio,,,View Clinical Trial Data,,,,,
CLSD,Clearside Biomedical Inc.,$1.32 ,RGX-314 - (ALTITUDE),Diabetic retinopathy ,Phase 1/2,21/10/2024 ET,"Phase 1/2a long-term results reported that treatment was well-tolerated with 78% of patiences injection-free and 97% reduction in anti-VEGF treatment burden, noted October 21, 2024.",5.23M
Add to portfolio,,,View Clinical Trial Data,,,,,
ABBV,AbbVie Inc.,$184.77 ,RGX-314 - (ALTITUDE),Diabetic retinopathy ,Phase 1/2,21/10/2024 ET,"Phase 1/2a long-term results reported that treatment was well-tolerated with 78% of patiences injection-free and 97% reduction in anti-VEGF treatment burden, noted October 21, 2024.",1.77B
Add to portfolio,,,View Clinical Trial Data,,,,,
RVMD,Revolution Medicines Inc - Ordinary Shares,$47.75 ,Daraxonrasib (RMC-6236) - (RASolute 302),Metastatic pancreatic ductal adenocarcinoma (PDAC) ,Phase 3,21/10/2024 ET,"Phase 3 dosing commenced, noted October 21, 2024.",186.93M
Add to portfolio,,,BTD,,,,,
,,,ODD,,,,,
OCGN,"Ocugen, Inc.",$0.94 ,OCU410ST - (GARDian),"Stargardt, Retinitis Pigmentosa 19 (RP19), and Cone-rod dystrophy 3 (CORD3) diseases ",Phase 1/2,21/10/2024 ET,"Phase 1/2 DSMB convened and approved enrollment for the second phase, noted October 21, 2024.",292.3M
Add to portfolio,,,RPDD,,,,,
IMRN,Immuron Limited,$2.00 ,Travelan - (CHIM),Enterotoxigenic Escherichia coli (ETEC) ,Phase 2,22/10/2024 ET,"Phase 2 final results reported no SAEs and that all subjects challenged had ETEC negative stool at discharge, noted October 22, 2024.",6.71M
Add to portfolio,,,,,,,,
TEVA,Teva Pharmaceutical Industries Limited American Depositary Shares,$18.38 ,SELARSDI (ustekinumab-aekn) 130 mg/26 mL - (STELARA Biosimilar),Crohn's disease ,Approved,22/10/2024 ET,"FDA Biosimilar approval on October 22, 2024.",1.15B
Add to portfolio,,,,,,,,
ALVO,Alvotech,$12.40 ,SELARSDI (ustekinumab-aekn) 130 mg/26 mL - (STELARA Biosimilar),Crohn's disease ,Approved,22/10/2024 ET,"FDA Biosimilar approval on October 22, 2024.",301.81M
Add to portfolio,,,,,,,,
IMUX,Immunic Inc.,$1.40 ,Vidofludimus Calcium - (ENSURE),Progressive Multiple Sclerosis ,Phase 3,22/10/2024 ET,"Phase 3 trial had positive outcome of the non-binding, interim futility analysis, noted October 22, 2024.",98.65M
Add to portfolio,,,,,,,,
MOLN,Molecular Partners AG,$6.57 ,MP0712,Small-cell lung cancer (SCLC) and other DLL3+ neuroendocrine tumors ,Preclinical,22/10/2024 ET,"Preclinical data presented at EANM led to strong and dose-dependent efficacy in mice bearing established tumors with clinically-relevant levels of DLL3 expression and at a clinically-relevant dose, as … read more",40.36M
Add to portfolio,,,,,,,,
ANNX,Annexon Inc.,$7.57 ,ANX007 - (ARCHER-II),Geographic atrophy ,Phase 2,22/10/2024 ET,"Phase 2 data from AAO reported that 0% (0/56) ANX007 monthly-treated patients with less advanced disease lost 15 letters, or three lines on an eye chart, vs. 17% (10/59) sham patients, and 6% (5/89) A … read more",109.89M
Add to portfolio,,,,,,,,
BCTX,BriaCell Therapeutics Corp.,$13.08 ,Bria-IMT - (BRIA-ABC),Advanced breast cancer ,Phase 2,22/10/2024 ET,"Phase 2 new survival data showing a 55% one-year survival rate with the Bria-IMT regimen, surpassing current SoC, noted October 22, 2024.",1.76M
Add to portfolio,,,,,,,,
MNPR,Monopar Therapeutics Inc.,$5.25 ,MNPR-101-Zr (uPAR),Solid tumors ,Phase 1,22/10/2024 ET,"Phase 1 data presented at EANM reported favorable biodistribution, tumor uptake, and low off-target binding, noted October 22, 2024.",6.17M
Add to portfolio,,,,,,,,
GNLX,Genelux Corporation,$2.60 ,Olvimulogene Nanivacirepvec (Olvi-Vec) - (VIRO-25),Malignant pleural effusion (MPE) due to non-small cell lung cancer (NSCLC) or breast cancer ,Phase 2,22/10/2024 ET,"Phase 2 dosing commenced, noted October 22, 2024.",37.77M
Add to portfolio,,,,,,,,
PFE,Pfizer Inc.,$27.93 ,ABRYSVO - (MONeT),Respiratory syncytial virus (RSV)-associated lower respiratory tract disease (LRTD) ,Approved,22/10/2024 ET,"FDA Approved on October 22, 2024.",5.69B
Add to portfolio,,,,,,,,
ANRO,Alto Neuroscience Inc.,$14.53 ,ALTO-100,Major depressive disorder ,Phase 2b,22/10/2024 ET,"Phase 2b study did not demonstrate improvement in depressive symptoms compared to placebo in patients with a memory-based cognitive biomarker, noted October 22, 2024.",27.08M
Add to portfolio,,,,,,,,
RXRX,Recursion Pharmaceuticals Inc.,$6.61 ,REC-3964,Difficile Colitis ,Phase 2,22/10/2024 ET,"Phase 2 dosing initiated, noted October 22, 2024.",434.15M
Add to portfolio,,,,,,,,
GYRE,Gyre Therapeutics Inc.,$13.99 ,Hydronidone (F351),Chronic hepatitis B (CHB)-associated liver fibrosis in the PRC ,Phase 3,22/10/2024 ET,"Phase 3 last patient completed, noted October 22, 2024.",96.31M
Add to portfolio,,,BTD,,,,,
OKYO,OKYO Pharma Limited,$1.23 ,Urcosimod (OK-101),Neuropathic corneal pain (NCP) ,Phase 2,23/10/2024 ET,"Phase 2 initiated, noted October 23, 2024.",33.84M
Add to portfolio,,,FTD,,,,,
GLUE,Monte Rosa Therapeutics Inc.,$4.87 ,MRT-50969,CCNE1-amplified solid tumors ,Preclinical,23/10/2024 ET,"Preclinical data from EORTC-NCI-AACR reported that treatment induced robust tumor growth suppression and regression, noted October 23, 2024.",61.76M
Add to portfolio,,,,,,,,
RPTX,Repare Therapeutics Inc.,$3.43 ,Lunresertib (RP-6306) + Debio 0123 - (MYTHIC),Solid Tumors ,Phase 1,23/10/2024 ET,"Phase 1 data reported that after 9 weeks on therapy, there was no observed impact on Progression Free Survival (PFS) in patients who started on or switched to the schedule of 2 weeks on / 1 week off o … read more",42.96M
Add to portfolio,,,FTD,,,,,
SDGR,Schrodinger Inc.,$18.12 ,SGR-3515,Solid tumors ,Preclinical,23/10/2024 ET,"Preclinical data presented at EORTC-NCI-AACR reported superior anti-tumor activity of SGR-3515 compared to inhibitors of Wee1 or Myt1 alone due to strong target engagement of both Wee1 and Myt1, noted … read more",73.61M
Add to portfolio,,,,,,,,
RVMD,Revolution Medicines Inc - Ordinary Shares,$48.51 ,Daraxonrasib (RMC-6236),Advanced Solid Tumors ,Phase 1,23/10/2024 ET,"Updated Phase 1 data from AACR-NCI-EORTC reported progression-free survival (PFS) and overall survival (OS) at daily doses ranging from 160 mg to 300 mg, noted October 23, 2024.",186.93M
Add to portfolio,,,,,,,,
GANX,Gain Therapeutics Inc.,$2.68 ,GT-03842,Oncology ,Preclinical,23/10/2024 ET,"Presentation at ENA reported that GT-03842 and its analogues were found to inhibit DDR2 phosphorylation in a dose-dependent manner, noted October 23, 2024.",35.95M
Add to portfolio,,,,,,,,
COGT,Cogent Biosciences Inc.,$12.30 ,CGT6297,Solid tumors ,Preclinical,23/10/2024 ET,"Preclinical data presented at EORTC-NCI-AACR 2024 demonstrated robust inhibition of downstream signaling and efficacy, noted October 23, 2024.",139.7M
Add to portfolio,,,,,,,,
OLMA,Olema Pharmaceuticals Inc.,$11.91 ,OP-3136,Breast Cancer ,Preclinical,23/10/2024 ET,"Preclinical data presented at the EORTC-NCI-AACR demonstrated robust anti-tumor activity as a single agent, as well as synergy and enhanced anti-tumor activity in combination with palazestrant; IND su … read more",68.63M
Add to portfolio,,,,,,,,
ORIC,Oric Pharmaceuticals Inc.,$8.82 ,ORIC-114,"Tumors - EGFR/HER2 Exon 20 Inhibitor, 1L NSCLC ",Preclinical,23/10/2024 ET,"Preclinical data presented at the EORTC-NCI-AACR 2024 demonstrated systemic and intracranial clinical responses in heavily pre-treated patients with EGFR and HER2 exon 20 insertion mutations, noted Oc … read more",97.12M
Add to portfolio,,,,,,,,
APRE,Aprea Therapeutics Inc.,$3.90 ,APR-1051 - (ACESOT-1051),Solid tumors ,Phase 1,23/10/2024 ET,"Phase 1 clinical efficacy and safety from EORTC-NCI-AACR reported that one patient had disease progression at 49 days, a second withdrew following 36 days of treatment and dosing is ongoing in the thi … read more",5.83M
Add to portfolio,,,,,,,,
CATX,Isoray. (DE),$11.69 ,[203/212Pb]Pb-PSV359,Solid Tumors ,Preclinical,23/10/2024 ET,"Preclinical findings presented at EANM demonstrated that drug exhibits strong binding affinity and selectivity for hFAP, noted October 23, 2024.",74.26M
Add to portfolio,,,,,,,,
PHRRF,PharmaTher Holdings Ltd,$0.15 ,KETARX (ketamine),Surgical pain management ,CRL,23/10/2024 ET,"CRL announced October 23, 2024.",91.02M
Add to portfolio,,,FTD,,,,,
CYCC,Cyclacel Pharmaceuticals Inc.,$1.06 ,Fadraciclib (CYC065-101),Advanced cancers ,Phase 1,23/10/2024 ET,Phase 1 initial data reported that two patients achieved stable disease: a melanoma patient whose treatment duration was 125 days and a squamous cell CUP patient who achieved 11% tumor shrinkage in th … read more,2.24M
Add to portfolio,,,,,,,,
MAIA,MAIA Biotechnology Inc.,$2.66 ,MAIA-2021-020,Solid Tumors ,Preclinical,23/10/2024 ET,"Preclinical data shared at EORTC-NCI-AACR Symposium reported that MAIA-2022-12 and MAIA-2021-20 resulted in tumor growth inhibition in preclinical models of lung cancer, colorectal carcinoma, melanoma … read more",32.99M
Add to portfolio,,,,,,,,
RNAZ,TransCode Therapeutics Inc.,$22.21 ,TTX-MC138,Metastatic solid tumors ,Preclinical,23/10/2024 ET,"Phase 1 progressed to Cohort 2. The Safety Review Committee approved the move after a favorable safety assessment of Cohort 1, with no significant safety issues or dose-limiting toxicities observed, n … read more",833.68K
Add to portfolio,,,ODD,,,,,
ZLAB,Zai Lab Limited,$33.18 ,ZL-1310 (DLL3 ADC),"Solid tumors, relapsed and refractory second-line+ SCLC ",Phase 1b,24/10/2024 ET,"Phase 1a/1b trial preliminary data shared at the EORTC-NCI-AACR Symposium reported an objective response rate (ORR) of 74% across all tested dose levels, noted October 24, 2024.",109.96M
Add to portfolio,,,ODD,,,,,
,,,FTD,,,,,
PTN,Palatin Technologies Inc.,$1.10 ,PL9643 - (MELODY-1),Dry eye disease (DED) ,Phase 3,24/10/2024 ET,"Phase 3 data presentation reported that PL9643 has a positive effect across multiple regions of the eye in patients with moderate and severe dry eye disease (DED), with an excellent ocular safety/tole … read more",46.48M
Add to portfolio,,,View Clinical Trial Data,,,,,
PTN,Palatin Technologies Inc.,$1.10 ,PL9654,Retinal diseases ,Preclinical,24/10/2024 ET,"Preclinical data reported that PL9654 0.05 mg/kg causes a reduction in microglia and negative enrichment of genes associated with immune-related pathways, noted October 24, 2024.",46.48M
Add to portfolio,,,,,,,,
BBIO,BridgeBio Pharma Inc.,$24.17 ,BBP-812 - (CANaspire),Canavan Disease ,Phase 1/2,24/10/2024 ET,"Phase 1/2 preliminary data showed significant and sustained reductions in N-acetylaspartate (NAA) levels in urine, cerebrospinal fluid (CSF), and brain in all participants who received low dose, noted … read more",191.17M
Add to portfolio,,,RMAT,,,,,
KURA,Kura Oncology Inc.,$17.78 ,Ziftomenib and imatinib - (KOMET-015),Gastrointestinal Stromal Tumors (GIST) ,Preclinical,24/10/2024 ET,"Preclinical data showed robust and durable antitumor activity in imatinib-sensitive (1L) and imatinib-resistant (2L/3L) GIST models, noted October 24, 2024.",86.8M
Add to portfolio,,,,,,,,
RCUS,Arcus Biosciences Inc.,$17.83 ,Casdatifan (AB521) + volrustomig,Clear cell renal cell carcinoma (ccRCC) ,Phase 2,24/10/2024 ET,"Phase 2 first clinical data presented at EORTC-NCI-AACR reported an objective response rate of 34%, noted October 24, 2024.",107.97M
Add to portfolio,,,,,,,,
PRLD,Prelude Therapeutics Incorporated,$1.55 ,PRT3789 with KEYTRUDA (pembrolizumab) - (SMARCA2/BRM),"SMARCA4-deleted cancers, solid tumors ",Phase 1,24/10/2024 ET,"Phase 1 data update shared at the EORTC-NCI-AACR reported confirmed partial responses (PRs) were observed in 4 patients (2 esophageal, 2 NSCLC), including 2 of 9 NSCLC patients with confirmed PRs at d … read more",56.6M
Add to portfolio,,,,,,,,
MRK,Merck & Company Inc.,$105.03 ,PRT3789 with KEYTRUDA (pembrolizumab) - (SMARCA2/BRM),"SMARCA4-deleted cancers, solid tumors ",Phase 1,24/10/2024 ET,"Phase 1 data update shared at the EORTC-NCI-AACR reported confirmed partial responses (PRs) were observed in 4 patients (2 esophageal, 2 NSCLC), including 2 of 9 NSCLC patients with confirmed PRs at d … read more",2.5B
Add to portfolio,,,,,,,,
VRCA,Verrica Pharmaceuticals Inc.,$1.50 ,VP-315 (LTX-315),Basal cell carcinoma ,Phase 2,24/10/2024 ET,Phase 2 presented data at the Fall Clinical Dermatology Conference highlighting that approximately 51% of tumors treated in Part 2 achieved complete histological clearance and patients with residual t … read more,9.45M
Add to portfolio,,,,,,,,
NRSN,NeuroSense Therapeutics Ltd.,$1.21 ,PrimeC - (PARADIGM),Amyotrophic Lateral Sclerosis (ALS) ,Phase 2b,24/10/2024 ET,"Phase 2b data presented at the NEALS meeting reported a 2-fold reduction of several miRNAs following PrimeC treatment, noted October 24, 2024.",23.99M
Add to portfolio,,,,,,,,
LEXX,Lexaria Bioscience Corp.,$2.73 ,DehydraTECH-powered GLP-1 drugs (semaglutide) - (WEIGHT-A24-1),Diabetes ,Preclinical,24/10/2024 ET,"Preclinical data reported that of the eight Study groups reported on today, DehydraTECH-CBD group B and the sole DehydraTECH-liraglutide group H were both successful in reducing blood sugar levels, wh … read more",19.56M
Add to portfolio,,,,,,,,
ERAS,Erasca Inc.,$2.58 ,Naporafenib plus trametinib - (SEACRAFT-1),RAS Q61X solid tumors ,Phase 1b,24/10/2024 ET,"Phase 1b data from EORTC-NCI-AACR reported that 40% (4/10) response rate observed in the melanoma cohort, including three confirmed partial responses (cPR) and one unconfirmed partial response (uPR), … read more",283.67M
Add to portfolio,,,,,,,,
APGE,Apogee Therapeutics Inc.,$51.95 ,APG777 - (APEX),"Healthy volunteers, Atopic dermatitis (AD) ",Phase 1,24/10/2024 ET,"Phase 1 9 month data reported that MAD cohorts showed similar inhibition of pSTAT6 through available follow-up. Single doses of APG777 suppressed TARC, an inflammatory mediator and the most strongly c … read more",59.6M
Add to portfolio,,,,,,,,
REGN,Regeneron Pharmaceuticals Inc.,$927.73 ,Dupixent (dupilumab),Chronic spontaneous urticaria (CSU) ,Phase 3,24/10/2024 ET,"Phase 3 data reported that dupixent significantly reduced itch and hive activity from baseline; 41% of patients achieved well-controlled disease status, noted October 24, 2024.",105.1M
Add to portfolio,,,,,,,,
SNY,Sanofi,$52.05 ,Dupixent (dupilumab),Chronic spontaneous urticaria (CSU) ,Phase 3,24/10/2024 ET,"Phase 3 data reported that dupixent significantly reduced itch and hive activity from baseline; 41% of patients achieved well-controlled disease status, noted October 24, 2024.",2.46B
Add to portfolio,,,,,,,,
GSK,GSK plc American Depositary Shares (Each representing two),$36.90 ,Arexvy (60+ at increased risk) - (AReSVi-006),"Respiratory Syncytial Virus Vaccine, Adjuvanted ",Phase 3,24/10/2024 ET,"Additional Phase 3 data reported that a single dose of vaccine elicited robust immune response with acceptable safety profile in adults aged 18-49 at increased risk for RSV-LRTD. noted October 24, 202 … read more",2.03B
Add to portfolio,,,,,,,,
PFE,Pfizer Inc.,$27.74 ,"PREVNAR 20 + seasonal influenza vaccine (SIIV, Fluad Quadrivalent)",Pneumonia and influenza for >65 yrs ,NDA Filing,24/10/2024 ET,"ACIP voted to expand the recommendation, noted October 24, 2024.",5.69B
Add to portfolio,,,View Clinical Trial Data,,,,,
MRNS,Marinus Pharmaceuticals Inc.,$0.30 ,Ganaxolone - (TrustTSC),Tuberous Sclerosis Complex ,Phase 3,24/10/2024 ET,"Phase 3 study did not meet the primary endpoint of percent change in 28-day TSC-associated seizure frequency, noted October 24, 2024.",55.19M
Add to portfolio,,,ODD,,,,,
,,,View Clinical Trial Data,,,,,
LYEL,Lyell Immunopharma Inc.,$1.09 ,LYL845,Solid Tumors ,Phase 1,24/10/2024 ET,"Program discontinued, noted October 24, 2024.",19.21M
Add to portfolio,,,ODD,,,,,
INVO,NAYA Biosciences Inc Com Par $0.0001 (New),$0.88 ,NY-303 FLEX-NK + ONKT105,Hepatocellular carcinoma ,Phase 1/2,24/10/2024 ET,"Phase 1/2a initiated, noted October 24, 2024.",3.91M
Add to portfolio,,,,,,,,
NTLA,Intellia Therapeutics Inc.,$15.85 ,"Lonvoguran ziclumeran (lonvo-z, formerly NTLA-2002) - (HAELO)",Hereditary angioedema (HAE) ,Phase 2,24/10/2024 ET,Phase 2 data presentation at ACAAI showed that deep attack rate reductions achieved in both dose levels tested; a single 50 mg dose resulted in a mean monthly attack rate reduction of 77% and 81% comp … read more,107.35M
Add to portfolio,,,ODD,,,,,
,,,RMAT,,,,,
PHVS,Pharvaris N.V.,$21.33 ,Deucrictibant (PHVS416) - (CHAPTER-3),Hereditary angioedema - prophylactic use ,Phase 2,24/10/2024 ET,"Phase 2 data presented at ACAAI provided further evidence on the long-term safety and efficacy of deucrictibant for prevention of HAE attacks , noted October 24, 2024.",54.49M
Add to portfolio,,,,,,,,
DTIL,Precision BioSciences Inc.,$8.48 ,PBGENE-PMM,Primary mitochondrial myopathies ,Preclinical,24/10/2024 ET,"Preclinical data reported that targeted gene insertion can be achieved using ARCUS in greater than 85% of T cells and 39% of non-dividing primary human hepatocytes, noted October 24, 2024.",11.79M
Add to portfolio,,,,,,,,
PROK,ProKidney Corp.,$1.73 ,RMCL-002 - (REACT),"Type 2 diabetes, prevent/delay CKD ",Phase 2,24/10/2024 ET,Phase 2 interim results presented at Kidney Week reported that six SAEs in 51 patients were related to the kidney biopsy procedure and one SAE was related to the injection procedure. No product relate … read more,294.28M
Add to portfolio,,,,,,,,
EYPT,EyePoint Pharmaceuticals Inc.,$9.56 ,DURAVYU (EYP-1901) - (LUGANO),Wet age-related macular degeneration (AMD) ,Phase 3,24/10/2024 ET,"Phase 3 trial dosing was initiated based on DAVIO-2 study results, noted October 24, 2024.",68.93M
Add to portfolio,,,,,,,,
RXRX,Recursion Pharmaceuticals Inc.,$6.36 ,EXS73565 (‘565),Haematological cancers ,Preclinical,24/10/2024 ET,"Preclinical data from the EORTC-NCI-AACR (ENA) reported that combining ‘565 with zanu in models of B-cell malignancies provided deeper, more durable efficacy than either agent alone, including in ABC- … read more",434.15M
Add to portfolio,,,,,,,,
EXAI,Exscientia Plc,$4.80 ,EXS73565 (‘565),Haematological cancers ,Preclinical,24/10/2024 ET,"Preclinical data from the EORTC-NCI-AACR (ENA) reported that combining ‘565 with zanu in models of B-cell malignancies provided deeper, more durable efficacy than either agent alone, including in ABC- … read more",125.7M
Add to portfolio,,,,,,,,
GILD,Gilead Sciences Inc.,$88.26 ,IDE397 + Trodelvy (sacituzumab-govitecan-hziy),MTAP-Deletion Bladder Cancer ,Phase 1,25/10/2024 ET,"Phase 1 trial presentation at EORTC-NCI-AACR reported an 33% ORR by RECIST 1.1: 1 CR + 8 PRs out of 27 evaluable heavily pre-treated (median 2-3 prior lines, ranging from 1-7) MTAP-deletion UC and NSC … read more",1.24B
Add to portfolio,,,,,,,,
IDYA,IDEAYA Biosciences Inc.,$29.30 ,IDE397 + Trodelvy (sacituzumab-govitecan-hziy),MTAP-Deletion Bladder Cancer ,Phase 1,25/10/2024 ET,"Phase 1 trial presentation at EORTC-NCI-AACR reported an 33% ORR by RECIST 1.1: 1 CR + 8 PRs out of 27 evaluable heavily pre-treated (median 2-3 prior lines, ranging from 1-7) MTAP-deletion UC and NSC … read more",87.64M
Add to portfolio,,,,,,,,
ZYME,Zymeworks Inc.,$12.93 ,ZW220,"NSCLC, ovarian and uterine cancer ",Preclinical,25/10/2024 ET,"Preclinical data presented at EORTC-NCI-AACR reported a strong anti-tumor activity across a wide range of hepatocellular carcinoma (HCC) models, including those with lower and heterogenous GPC3 expres … read more",75.17M
Add to portfolio,,,,,,,,
RLFTF,RELIEF THERAPEUTICS HLDG AG,$7.10 ,RLF-OD032,Phenylketonuria (PKU) ,Phase 1,25/10/2024 ET,Additional data that RLF-OD032 in a fasted state without water resulted in greater absorption of sapropterin dihydrochloride compared to the reference product administered under fed conditions with wa … read more,12.58M
Add to portfolio,,,,,,,,
TYRA,Tyra Biosciences Inc.,$21.93 ,TYRA-300 - (SURF301),Bladder and solid tumors ,Phase 1/2,25/10/2024 ET,"Phase 1/2 trial dosing initiated, noted November 29, 2022. Phase 1/2 data presented at EORTC-NCI-AACR reported that 6 out of 11 (54.5%) patients with FGFR3+ mUC achieved a confirmed partial response … read more",53.3M
Add to portfolio,,,,,,,,
PPBT,Purple Biotech Ltd.,$4.10 ,IM1240 - (CAPTN-3),Cancer ,Preclinical,25/10/2024 ET,Preclinical data presented at EORTC-NCI-AACR reported sustained tumor regression in a triple negative breast cancer in-vivo model; A dose dependent activity and a synergistic effect of the engager arm … read more,2.65M
Add to portfolio,,,,,,,,
ANIP,ANI Pharmaceuticals Inc.,$58.32 ,"Estradiol Gel, 0.06% - (generic version of EstroGel Gel, 0.06%)",Hot flashes and to treat moderate to severe menopausal changes ,Approved,25/10/2024 ET,"Approved October 25, 2025.",21.7M
Add to portfolio,,,,,,,,
AQST,Aquestive Therapeutics Inc.,$5.49 ,Anaphylm (AQST-109) - (EPIPHAST II),Allergic reactions (anaphylaxis) ,Phase 2,25/10/2024 ET,"Trial PK and PD data reported that 87.5% of subjects showing no change in film location between 1.5 to 3 minutes after administration of Anaphylm, noted October 25, 2024.",99.72M
Add to portfolio,,,FTD,,,,,
JNJ,Johnson & Johnson,$158.33 ,TREMFYA (guselkumab) - (SPECTREM),Plaque psoriasis (PsO) ,Phase 3,25/10/2024 ET,"Phase 3b data reported statistical significance across all primary and secondary endpoints in low body surface area psoriasis with special site involvement, noted October 25, 2024.",2.41B
Add to portfolio,,,,,,,,
ITRM,Iterum Therapeutics plc,$1.88 ,ORLYNVAH (Oral Sulopenem),Uncomplicated urinary tract infections (uUTI) ,Approved,25/10/2024 ET,"Approved October 25, 2024.",44.66M
Add to portfolio,,,,,,,,
VRTX,Vertex Pharmaceuticals Incorporated,$477.70 ,Povetacicept (ALPN-303) - (RAINIER),"Lupus nephritis, IgA nephropathy ",Phase 1/2,25/10/2024 ET,"Phase 1b/2a new data on 80 mg SC Q4 weeks in IgA nephropathy showed mean UPCR reduction from baseline of 66% observed at 48 weeks, associated with stable renal function (eGFR) and 63% achieving clinic … read more",256.39M
Add to portfolio,,,,,,,,
ALPN,Alpine Immune Sciences Inc.,—,Povetacicept (ALPN-303) - (RAINIER),"Lupus nephritis, IgA nephropathy ",Phase 1/2,25/10/2024 ET,"Phase 1b/2a new data on 80 mg SC Q4 weeks in IgA nephropathy showed mean UPCR reduction from baseline of 66% observed at 48 weeks, associated with stable renal function (eGFR) and 63% achieving clinic … read more",68.6M
Add to portfolio,,,,,,,,
IRON,Disc Medicine Inc.,$46.01 ,DISC-0974,Patients with non-dialysis dependent chronic kidney disease (NDD-CKD) and anemia ,Phase 1/2,25/10/2024 ET,"Phase 1b/2 data presented at ASN demonstrated that a single dose results in sustained suppression of hepcidin and mobilization of iron, and increased erythropoiesis and levels of hemoglobin in NDD-CKD … read more",34.77M
Add to portfolio,,,FTD,,,,,
KALV,KalVista Pharmaceuticals Inc.,$11.68 ,Sebetralstat - (KONFIDENT-S),Hereditary angioedema (HAE) ,Phase 3,25/10/2024 ET,"Phase 3 data presented at ACAAI reported that patients treated with sebetralstat 300mg (n=49, P=0.002) and sebetralstat 600mg (n=52, P=0.034) achieved a faster reduction in substantial symptom burden … read more",50.52M
Add to portfolio,,,,,,,,
NVCT,Nuvectis Pharma Inc.,$8.76 ,NXP900,Non-small cell lung cancer (NSCLC) ,Phase 1,25/10/2024 ET,"Data reported at AACR-NCI-EORT noted that NXP900 as a single agent potently inhibits cell proliferation of ALK fusion driven cell lines that are resistant to crizotinib, alectinib and lorlatinib, note … read more",25.46M
Add to portfolio,,,,,,,,
ATXS,Astria Therapeutics Inc.,$11.47 ,Navenibart (STAR-0215) - (ALPHA-ORBIT),"Hereditary angioedema (HAE), healthy volunteers ",Phase 1/2,25/10/2024 ET,Phase 1b/2 data presented at the ACAAI reported rapid inhibition of plasma kallikrein was associated with reductions in HAE attacks and with a favorable safety profile during the first 28 days of the … read more,56.43M
Add to portfolio,,,FTD,,,,,
,,,ODD,,,,,
RVMD,Revolution Medicines Inc - Ordinary Shares,$46.42 ,RMC-9805,"Pancreatic cancer, non-small cell lung cancer (NSCLC), and colorectal cancer. ",Phase 1,25/10/2024 ET,"Phase 1 preliminary safety data presented at AACR-NCI-EORTC reported acceptable tolerability and encouraging initial antitumor activity, with durability assessment pending longer follow-up, noted Octo … read more",186.93M
Add to portfolio,,,,,,,,
KURA,Kura Oncology Inc.,$17.51 ,KO-2806 - (FIT-001),Solid Tumors ,Preclinical,25/10/2024 ET,"Preclinical and clinical data presented at EORTC-NCI-AACR showed improved tumor growth inhibition compared to the combinations with a SHP2 or SOS1 inhibitors, noted October 25, 2024.",86.8M
Add to portfolio,,,,,,,,
ZYME,Zymeworks Inc.,$12.93 ,ZW251,Hepatocellular carcinoma ,Preclinical,25/10/2024 ET,"Preclinical data presented at EORTC-NCI-AACR reported a strong anti-tumor activity in models with a breadth of NaPi2b expression, noted October 25, 2024.",75.17M
Add to portfolio,,,,,,,,
NKGN,NKGen Biotech Inc.,$0.40 ,Troculeucel (SNK01),Alzheimer's Disease ,Phase 1/2,25/10/2024 ET,"Phase 1/2a data from WSC 2024 reported that treatment appears to cross the BBB to reduce neuroinflammation noted October 25, 2024.",124.38M
Add to portfolio,,,FTD,,,,,
VERA,Vera Therapeutics Inc.,$41.09 ,Atacicept - (ORIGIN 3),IgA Nephropathy ,Phase 2b,26/10/2024 ET,"Phase 2b 96-week data presented at Kidney Week reported that -66% reduction in galactose-deficient IgA1 (Gd-IgA1), resolution of hematuria in 75% of participants, a -52% reduction in proteinuria, and … read more",63.82M
Add to portfolio,,,BTD,,,,,
,,,View Clinical Trial Data,,,,,
BIIB,Biogen Inc.,$181.69 ,Felzartamab - (PREVAIL),IgA nephropathy (IgAN) ,Phase 2,26/10/2024 ET,"Phase 2 trial final results presented at ASN reported that patients maintained a mean reduction of approximately 50% in the UPCR through month 24, which was more than 18 months after the last dose was … read more",146.61M
Add to portfolio,,,,,,,,
CLDX,Celldex Therapeutics Inc.,$26.95 ,Barzolvolimab - (CindU),"Chronic inducible urticaria (CIndU), cold urticaria (ColdU) and symptomatic dermographism (SD), Chronic Spontaneous Urticaria (CSU) ",Phase 2,26/10/2024 ET,"Phase 2 efficacy and safety data from ACAAI reported that trial met all primary end secondary endpoints, noted October 26, 2024.",66.41M
Add to portfolio,,,,,,,,
APLS,Apellis Pharmaceuticals Inc.,$26.68 ,EMPAVELI (pegcetacoplan) - (VALIANT),C3G and IC-MPGN ,Phase 3,26/10/2024 ET,"Phase 3 study results presented at ASN Kidney Week reported a statistically significant 68% (p<0.0001) proteinuria reduction compared to placebo, with reduction observed as early as Week 4, noted Octo … read more",126.29M
Add to portfolio,,,,,,,,
LGVN,Longeveron Inc.,$2.18 ,Laromestrocel (lomecel-B) - (ELPIS II),Hypoplastic Left Heart Syndrome ,Phase 2b,27/10/2024 ET,Phase 2b long term survival data shared at the Congenital Heart Surgeons' Society (CHSS) reported a 5-year survival after stage 2 Glenn surgery of 100% with none requiring heart transplant; this comp … read more,15.18M
Add to portfolio,,,FTD,,,,,
,,,ODD,,,,,
,,,View Clinical Trial Data,,,,,
HUMA,Humacyte Inc.,$5.42 ,ATEV - (V007),Acellular tissue engineered vessel (ATEV) in arteriovenous access for patients with end-stage renal disease. ,Phase 3,28/10/2024 ET,"Phase 3 detailed results presented at ASN showed superior patency and function over the standard autogenous fistula at six and 12 months, noted October 28, 2024.",158.37M
Add to portfolio,,,,,,,,
UNCY,Unicycive Therapeutics Inc.,$0.50 ,UNI-494,Acute kidney injury (AKI) ,Preclinical,28/10/2024 ET,"Preclinical data and Phase 1 presented at the American Society of Nephrology (ASN) Kidney Week indicated therapeutic administration of UNI-494 slows down and may even halt or reverse AKI progression, … read more",17.66M
Add to portfolio,,,ODD,,,,,
EYPT,EyePoint Pharmaceuticals Inc.,$12.12 ,EYP-1901 - (VERONA),Diabetic macular edema (DME) ,Phase 2,28/10/2024 ET,"Phase 2 interim data demonstrated that the 2.7mg dose showed a +8.9-letter improvement in best-corrected visual acuity (BCVA) and a 68-micron reduction in CST, outperforming the aflibercept control. T … read more",68.93M
Add to portfolio,,,,,,,,
BCLI,Brainstorm Cell Therapeutics Inc.,$2.02 ,NurOwn,Amytrophic lateral sclerosis (ALS) ,Phase 3,28/10/2024 ET,"Phase 3 expanded access data reported a statistically significant difference in favor of debamestrocel (LRT, p= 0.0379) with a median survival time of 46.6 months for the debamestrocel group compared … read more",10.38M
Add to portfolio,,,View Clinical Trial Data,,,,,
PLUR,Pluri Inc.,$4.32 ,NurOwn,Amytrophic lateral sclerosis (ALS) ,Phase 3,28/10/2024 ET,"Phase 3 expanded access data reported a statistically significant difference in favor of debamestrocel (LRT, p= 0.0379) with a median survival time of 46.6 months for the debamestrocel group compared … read more",8.16M
Add to portfolio,,,View Clinical Trial Data,,,,,
IRWD,Ironwood Pharmaceuticals Inc.,$4.15 ,Apraglutide - (STARS),Short Bowel Syndrome with Intestinal Failure (SBS-IF) ,Phase 3,28/10/2024 ET,"New Phase 3 data demonstrated a steady treatment effect across patient demographics and SBS characteristics. Safety results showed high treatment compliance and low rates of adverse events, noted Octo … read more",162.43M
Add to portfolio,,,View Clinical Trial Data,,,,,
TYRA,Tyra Biosciences Inc.,$19.89 ,TYRA-300 - (BEACH301),Achondroplasia ,IND-Enabling,28/10/2024 ET,"IND cleared by the FDA, noted October 28, 2024.",53.3M
Add to portfolio,,,ODD,,,,,
,,,RPDD,,,,,
MIRA,MIRA Pharmaceuticals Inc.,$1.57 ,Ketamir-2 (Topical),"Neuropathic pain and chemo-induced depression, as well as neuropathic pain and PTSD ",Preclinical,28/10/2024 ET,"Preclinical data reported that on Day 9, at the optimal dose of 300 mg/kg, Ketamir-2 led to near-complete normalization of pain sensitivity, outperforming FDA-approved gabapentin by 60%, which provide … read more",19.07M
Add to portfolio,,,,,,,,
AGIO,Agios Pharmaceuticals Inc.,$46.08 ,Mitapivat (AG-348) - (RISE UP),Sickle cell disease ,Phase 3,28/10/2024 ET,"Phase 3 portion of the study enrollment completed, noted October 23, 2024.",58.1M
Add to portfolio,,,,,,,,
CADL,Candel Therapeutics Inc.,$5.51 ,CAN-3110,Glioma ,Phase 1b,28/10/2024 ET,"Phase 1b data presented at IOVC showed improved survival and immune activation, with 3 out of 6 patients surviving over a year post-treatment, noted October 28, 2024.",54.9M
Add to portfolio,,,FTD,,,,,
,,,ODD,,,,,
JNJ,Johnson & Johnson,$159.04 ,TREMFYA (guselkumab),Ulcerative Colitis Subcutaneous Induction (ASTRO) Crohn's Disease Subcutaneous Induction ,Phase 3,28/10/2024 ET,Phase 3 results reported that a greater number of patients treated with subcutaneous TREMFYA induction and maintenance achieved clinical and endoscopic remission at 48 weeks in the Phase 3 GRAVITI stu … read more,2.41B
Add to portfolio,,,,,,,,
LLY,Eli Lilly and Company,$892.45 ,Mirikizumab - (LUCENT-3),Ulcerative colitis (UC) ,Phase 3,28/10/2024 ET,"Phase 3 data reported that 81% of patients maintained long-term clinical remission and 82% achieved long-term endoscopic remission, noted October 28, 2024.",946.46M
Add to portfolio,,,,,,,,
LLY,Eli Lilly and Company,$892.45 ,Mirikizumab - (VIVID-2),Crohn's disease ,Phase 2,28/10/2024 ET,"Phase 2 data reported that 96% of patients had clinical response as measured by the Crohn's Disease Activity Index (CDAI) and 87% were in clinical remission as measured by CDAI, noted October 28, 2024 … read more",946.46M
Add to portfolio,,,,,,,,
NVS,Novartis AG,$115.63 ,Fabhalta (iptacopan),C3 glomerulopathy (C3G) ,Phase 3,28/10/2024 ET,"Phase 3 data reported that Fabhalta sustained proteinuria reduction at 12 months, noted October 28, 2024.",1.98B
Add to portfolio,,,View Clinical Trial Data,,,,,
SHPH,Shuttle Pharmaceuticals Holdings Inc.,$1.33 ,Ropidoxuridine,Glioblastoma ,Phase 2,28/10/2024 ET,"Phase 2 study engaged all six of the planned clinical trial site locations to administer the clinical trial, noted October 28, 2024.",1.07M
Add to portfolio,,,ODD,,,,,
GNPX,Genprex Inc.,$2.74 ,REQORSA (GPX-001) with KEYTRUDA (pembrolizumab) - (Acclaim-2),Non-Small Cell Lung Cancer (NSCLC) ,Preclinical,28/10/2024 ET,"Preclinical data presented at EORTC-NCI-AACR demonstrated Reqorsa’s potential effectiveness across these challenging cancer types, expanding its applicability beyond KRAS G12C mutant lung cancer, not … read more",858.11K
Add to portfolio,,,FTD,,,,,
THAR,Tharimmune Inc.,$1.98 ,TH104 (AV104),Primary biliary cholangitis (PBC) ,Phase 1,28/10/2024 ET,"Phase 1 results presented at ACG Meeting showed no opioid withdrawal effects, reinforcing safety profile, noted October 28, 2024.",4.64M
Add to portfolio,,,,,,,,
BCDA,BioCardia Inc.,$2.63 ,CardiAMP (Heart Failure II),Ischemic heart failure of reduced ejection fraction (HFrEF) ,Phase 3,28/10/2024 ET,"Phase 3 completed, noted October 28, 2024.",5.8M
Add to portfolio,,,,,,,,
COYA,Coya Therapeutics Inc.,$7.37 ,Low Dose Interleukin-2 (LD IL-2) - (COYA 301),Alzheimer’s Disease (AD) ,Phase 2,29/10/2024 ET,"Phase 2 trial met primary and secondary endpoints, noted October 29, 2024.",16.73M
Add to portfolio,,,,,,,,
GLYC,GlycoMimetics Inc.,$0.49 ,Uproleselan (GMI-1271) - NCI-sponsored,Acute myeloid leukemia (AML) ,Phase 2,29/10/2024 ET,"Phase 2 trial did not meet primary endpoint, noted October 29, 2024.",13.89M
Add to portfolio,,,View Clinical Trial Data,,,,,
ZLAB,Zai Lab Limited,$31.43 ,Xanomeline-Trospium (KarXT) (ZL-2701-001) - (China Bridging Trial),Schizophrenia ,Phase 3,29/10/2024 ET,"Phase 3 trial demonstrated a statistically significant 9.2-point reduction in PANSS Total score from baseline at Week 5 compared to placebo, noted October 29, 2024.",109.96M
Add to portfolio,,,,,,,,
ABEO,Abeona Therapeutics Inc.,$6.57 ,ZEVASKYN (prademagene zamikeracel),Recessive dystrophic epidermolysis bullosa (RDEB) ,BLA Filing,29/10/2024 ET,"BLA resubmitted on October 29, 2024.",51.28M
Add to portfolio,,,View Clinical Trial Data,,,,,
SGMT,Sagimet Biosciences Inc.,$5.83 ,Denifanstat - (FASCINATE-3),Nonalcoholic steatohepatitis (NASH) ,Phase 2b,29/10/2024 ET,"Phase 2b completed and Phase 3 expected to commenced by year end 2024, noted October 29, 2024.",32.52M
Add to portfolio,,,BTD,,,,,
IVVD,Invivyd Inc.,$0.91 ,PEMGARDA (VYD222 (pemivibart)) - (CANOPY),COVID-19 Prevention ,Phase 3,29/10/2024 ET,"Phase 3 study following strong protection (84% relative risk reduction versus placebo) demonstrated through month 6 with pemivibart, CANOPY clinical trial participants were followed for an additional … read more",120.14M
Add to portfolio,,,,,,,,
NKGN,NKGen Biotech Inc.,$0.31 ,Troculeucel (SNK01),Alzheimer's Disease ,Phase 1/2,29/10/2024 ET,Phase 1/2a study Six-month interim data shared at the 17th Annual Clinical Trials on Alzheimer's Disease Conference (CTAD) newly analyzed biomarker data from the initial dose-escalation Phase 1 AD tri … read more,124.38M
Add to portfolio,,,FTD,,,,,
IMNM,Immunome Inc.,$12.20 ,IM-1021,Advanced B-cell lymphomas and advanced solid tumors ,Preclinical,29/10/2024 ET,"Preclinical data reported that IM-1021 showed superior efficacy compared to zilovertamab vedotin in both the Jeko-1 mantle cell lymphoma model and the MDA-MB-468 triple negative breast cancer model, n … read more",87.05M
Add to portfolio,,,,,,,,
LGVN,Longeveron Inc.,$2.19 ,Laromestrocel (lomecel-B) - (CLEAR MIND),Alzheimer's Disease ,Phase 2a,29/10/2024 ET,Phase 2a data presented at CTAD in late breaking presentation showed that that Lomecel-B's ability to inhibit MMP14 activity correlates with improved clinical and biomarker outcomes in Alzheimer's pat … read more,15.18M
Add to portfolio,,,RMAT,,,,,
,,,FTD,,,,,
JAGX,Jaguar Health Inc.,$1.08 ,Mytesi (crofelemer) - (OnTarget),Cancer Therapy-Related Diarrhea ,Phase 3,29/10/2024 ET,"Additional data from pilot study on functional diarrhea, crofelemer significantly improved stool consistency and reduced abdominal pain without causing constipation, marking it as a potentially effect … read more",2.17M
Add to portfolio,,,View Clinical Trial Data,,,,,
NVS,Novartis AG,$110.53 ,Scemblix - (ASC4FIRST),1L Chronic myeloid leukemia (CML) ,Approved,29/10/2024 ET,"FDA Approved on October 29, 2024.",1.98B
Add to portfolio,,,BTD,,,,,
CGTX,Cognition Therapeutics Inc.,$0.57 ,Zervimesine (CT1812) - (SHINE),Mild-to-Moderate Alzheimer's Disease ,Phase 2,29/10/2024 ET,"Phase 2 results presented at CTAD showed a significant slowdown in cognitive decline, particularly in participants with lower plasma p-tau217 levels, an Alzheimer’s biomarker, noted October 29, 2024.",73.47M
Add to portfolio,,,View Clinical Trial Data,,,,,
SPRO,Spero Therapeutics Inc.,$1.31 ,SPR720,Nontuberculous mycobacterial (NTM) pulmonary disease (PD) ,Phase 2,29/10/2024 ET,"Phase 2 study did not meet its primary endpoint, based on the planned interim analysis of 16 patients; current development was suspended, noted on October 29, 2024.",56.28M
Add to portfolio,,,View Clinical Trial Data,,,,,
CALC,CalciMedica Inc.,$4.80 ,Auxora - (CARPO),Acute Pancreatitis ,Phase 2b,30/10/2024 ET,Phase 2 full results presented at ACG showed high and medium doses of Auxora led to a 100% reduction in severe respiratory failure and a 64.2% reduction in persistent respiratory failure compared to l … read more,13.97M
Add to portfolio,,,,,,,,
LXEO,"Lexeo Therapeutics, Inc.",$8.28 ,LX1001 - (LEAD),Alzheimer’s disease ,Phase 1/2,30/10/2024 ET,"Phase 1/2 interim data from CTAD reported a dose-dependent increase in neuroprotective APOE2 expression in all participants with ongoing durability at 12 months, noted October 30, 2024.",54M
Add to portfolio,,,FTD,,,,,
PMN,ProMIS Neurosciences Inc.,$1.09 ,PMN310 - (PRECISE-AD),Alzheimer's disease (AD) ,Phase 1a,30/10/2024 ET,"Phase 1a topline data from 5 cohorts reported that generally well tolerated and achieved concentrations in the cerebrospinal fluid indicating its potential for target engagement in AD patients, noted … read more",53.81M
Add to portfolio,,,FTD,,,,,
MLYS,Mineralys Therapeutics Inc.,$13.78 ,Lorundrostat - (Launch-HTN),Uncontrolled hypertension (uHTN) or resistant hypertension (rHTN). ,Phase 3,30/10/2024 ET,"Phase 3 enrollment completed, noted October 30, 2024.",66.3M
Add to portfolio,,,,,,,,
TLSA,Tiziana Life Sciences Ltd,$1.18 ,Foralumab + Ozempic (semaglutide),Obesity ,Preclinical,30/10/2024 ET,"Preclinical data reported that nasal anti-CD3 in combination with semaglutide demonstrated synergistic effects in promoting liver homeostasis in preclinical models of diet-induced obesity, noted Octob … read more",111.46M
Add to portfolio,,,,,,,,
NVO,Novo Nordisk A/S,$113.24 ,Foralumab + Ozempic (semaglutide),Obesity ,Preclinical,30/10/2024 ET,"Preclinical data reported that nasal anti-CD3 in combination with semaglutide demonstrated synergistic effects in promoting liver homeostasis in preclinical models of diet-induced obesity, noted Octob … read more",4.47B
Add to portfolio,,,,,,,,
BMEA,Biomea Fusion Inc.,$10.34 ,Icovamenib (BMF-219) with a GLP-1-Based Therapy - (COVALENT-211),Diabetes and obesity ,Preclinical,30/10/2024 ET,"Preclinical data reported that pretreatment improved insulin secretion, approximately doubling the effect-size depending on the dose, noted October 30, 2024.",59.51M
Add to portfolio,,,,,,,,
BMEA,Biomea Fusion Inc.,$10.34 ,BMF-650,Obesity ,Preclinical,30/10/2024 ET,"Preclinical data reported a higher bioavailability and a less variable pharmacokinetic profile, with significant improvements in glucose stimulated insulin secretion, noted October 30, 2024.",59.51M
Add to portfolio,,,,,,,,
CORT,Corcept Therapeutics Incorporated,$46.89 ,Relacorilant - (GRADIENT),Cushing’s syndrome ,Phase 3,30/10/2024 ET,"Phase 3 data reported statistically significant improvements in mean SBP at 22 weeks, noted October 30, 2024.",105.37M
Add to portfolio,,,View Clinical Trial Data,,,,,
NRIX,Nurix Therapeutics Inc.,$24.07 ,NX-5948,B-cell malignancies / graft-versus-host disease ,Preclinical,30/10/2024 ET,"Preclinical data reported that clinical activity in patients with CLL with 69.2% ORR and all responses ongoing as of April 17, 2024:, noted October 30, 2024.",76.88M
Add to portfolio,,,FTD,,,,,
VINC,Vincerx Pharma Inc.,$6.98 ,VIP236,Solid tumors ,Phase 1,31/10/2024 ET,"Phase 1 data reported a 45% disease control rate, noted October 2024.",5.23M
Add to portfolio,,,,,,,,
MTNB,Matinas Biopharma Holdings Inc.,$0.62 ,MAT2203 - (ORALTO),Invasive aspergillosis ,Phase 3,31/10/2024 ET,"Trial development ceased as company non-bidding term-sheet terminated following notification from the prospective partner, company looking for potential asset sale to avoid wind-down or dissolution, n … read more",5.09M
Add to portfolio,,,,,,,,
MTNB,Matinas Biopharma Holdings Inc.,$0.62 ,Oral amphotericin b (MAT2203) - (EnACT),Cryptococcal meningitis ,Phase 3,31/10/2024 ET,"Trial development ceased as company non-bidding term-sheet terminated following notification from the prospective partner, company looking for potential asset sale to avoid wind-down or dissolution, n … read more",5.09M
Add to portfolio,,,,,,,,
KYMR,Kymera Therapeutics Inc.,$46.17 ,KT-621 (STAT6),Type 2 inflammation in allergic diseases ,Phase 1,31/10/2024 ET,"Phase 1 clinical trial initiated, noted October 31, 2024.",71.5M
Add to portfolio,,,,,,,,
AVXL,Anavex Life Sciences Corp.,$6.62 ,Blarcamesine (ANAVEX2-73-AD-004) - (ATTENTION-AD),Mild to moderate Alzheimer’s disease ,Phase 2/3,31/10/2024 ET,"Phase 2b/3 data confirmed the mechanism of action (MoA) by pre-specified SIGMAR1 gene analysis, noted October 31, 2024.",85.89M
Add to portfolio,,,View Clinical Trial Data,,,,,
SILO,Silo Pharma Inc.,$1.13 ,SPC-15,Post-traumatic stress disorder (PTSD) ,Phase 1,31/10/2024 ET,"Additional data reported a sustained 80%+ drug release over a 7-day period and minimal variation in key physical properties, noted October 31, 2024.",9.4M
Add to portfolio,,,,,,,,
ABOS,Acumen Pharmaceuticals Inc.,$2.88 ,ACU193 - (ALTITUDE-AD),Early Alzheimer's disease ,Phase 2,31/10/2024 ET,Phase 2 data at CTAD highlighted the pTau217 assay as an effective and efficient tool to screen participants for ALTITUDE-AD that reduces unnecessary amyloid PET scans and lumbar puncture procedures f … read more,60.57M
Add to portfolio,,,,,,,,
ATOS,Atossa Therapeutics Inc.,$1.38 ,(Z)-Endoxifen - (I-SPY 2),Locally advanced breast cancer ,Phase 2,31/10/2024 ET,"Phase 2 study met the primary endpoint at 10mg once daily, noted October 31, 2024.",129.17M
Add to portfolio,,,,,,,,
PALI,Palisade Bio Inc.,$2.72 ,PALI-2108,Moderate-to-severe ulcerative colitis (UC) ,Preclinical,31/10/2024 ET,"Preclinical data reported a high conversion rate of 90.1% at 24 hours with significant inhibition of TNFα production in human whole blood, with an IC50 of 0.022 μM, indicating strong potency, noted Oc … read more",9.12M
Add to portfolio,,,,,,,,
INTS,Intensity Therapeutics Inc.,$3.25 ,INT230-6 - (INVINCIBLE-4),Triple Negative Breast Cancer ,Phase 2,31/10/2024 ET,"Phase 2 trial dosing intiated, noted October 31, 2024",47.06M
Add to portfolio,,,,,,,,
BFRI,Biofrontera Inc.,$1.23 ,Ameluz (BF-200 ALA),Basal cell carcinoma ,Phase 3,31/10/2024 ET,"Phase 3 data reported primary and secondary endpoints were all highly statistically significant, noted October 31, 2024.",10.67M
Add to portfolio,,,,,,,,
VCNX,Vaccinex Inc.,$2.79 ,Pepinemab - (SIGNAL-AD),Alzheimer’s Disease (AD) ,Phase 1/2,31/10/2024 ET,"Phase 1/2 data presented at CTAD reported that the expression of plasma GFAP and p-tau 217 biomarkers appears to increase predominantly during MCI and that this is inhibited by pepinemab treatment, no … read more",2.68M
Add to portfolio,,,,,,,,
SUPN,Supernus Pharmaceuticals Inc.,$34.07 ,SPN-820,Treatment-resistant depression ,Phase 2a,31/10/2024 ET,"Phase 2a data reported that suicidal ideation decreased by 80%, noted October 31, 2024.",56.07M
Add to portfolio,,,View Clinical Trial Data,,,,,
EPIX,ESSA Pharma Inc.,$1.40 ,Masofaniten (EPI-7386),Castrate resistant prostate cancer ,Phase 1/2,01/11/2024 ET,Phase 1/2 trial terminated after data showed a much higher rate of PSA90 response in patients treated with enzalutamide monotherapy (which is standard of care for this patient population) than were ex … read more,47.31M
Add to portfolio,,,,,,,,
LXRX,Lexicon Pharmaceuticals Inc.,$1.22 ,Zynquista (sotagliflozin),Type 1 Diabetes and chronic kidney disease (CKD) ,NDA Filing,01/11/2024 ET,"Advisory Committee voted 11 to 3 that the benefits of Zynquista do not outweigh the risks in adults with T1D and CKD, noted November 1, 2024.",363.4M
Add to portfolio,,,,,,,,
TNXP,Tonix Pharmaceuticals Holding Corp.,$13.93 ,TNX-801 - (Kenya study),"Monkeypox, horse pox and smallpox infection ",Preclinical,01/11/2024 ET,"Preclinical data showed tolerability and no evidence of spreading to blood or tissues, noted November 1, 2024.",8.77M
Add to portfolio,,,,,,,,
NVO,Novo Nordisk A/S,$111.94 ,Wegovy (semaglutide) injection - (ESSENCE),Metabolic dysfunction-associated steatohepatitis (MASH) ,Phase 3,01/11/2024 ET,"Phase 3 trial met its primary endpoint, noted November 1, 2024.",4.47B
Add to portfolio,,,,,,,,
TEVA,Teva Pharmaceutical Industries Limited American Depositary Shares,$18.45 ,Olanzapine LAI (44749) - (SOLARIS),Schizophrenia ,Phase 3,01/11/2024 ET,"Phase 3 data reported no occurrence of Post-Injection Delirium/Sedation Syndrome (PDSS) events to date, noted November 1, 2024.",1.15B
Add to portfolio,,,,,,,,
VKTX,Viking Therapeutics Inc.,$63.14 ,VK2735 - (VENTURE),Obesity ,Phase 2a,03/11/2024 ET,"Phase 2a 13 week data presented at Obesity week demonstrated reductions in mean body weight relative to placebo, ranging up to 6.8%, noted November 3, 2024.",113.04M
Add to portfolio,,,,,,,,
SUPN,Supernus Pharmaceuticals Inc.,$34.70 ,SPN-817,Treatment-resisted seizures ,Phase 2,04/11/2024 ET,Phase 2 data reported that treatment was safe and had acceptable tolerability with 2 subjects discontinuing because of treatment related adverse events out of the 26 subjects who entered the maintenan … read more,56.07M
Add to portfolio,,,,,,,,
FBIO,Fortress Biotech Inc.,$1.73 ,"Emrosi (Minocycline Hydrochloride ER Capsules, 40 mg) (DFD-29) - (MVOR-2)",Papulopustular Rosacea ,Approved,04/11/2024 ET,"FDA approved on November 4, 2024.",29.75M
Add to portfolio,,,,,,,,
DERM,Journey Medical Corporation,$5.32 ,"Emrosi (Minocycline Hydrochloride ER Capsules, 40 mg) (DFD-29) - (MVOR-2)",Papulopustular Rosacea ,Approved,04/11/2024 ET,"FDA approved on November 4, 2024.",24.38M
Add to portfolio,,,,,,,,
CRBP,Corbus Pharmaceuticals Holdings Inc.,$18.31 ,CRB-913,Obesity ,Preclinical,04/11/2024 ET,"Preclinical results presented at Obesity Week suggest CRB-913's clinical potential as a standalone therapy, in combination with incretin analogs, or as a maintenance therapy , noted November 4, 2024.",12.26M
Add to portfolio,,,,,,,,
XNCR,Xencor Inc.,$21.52 ,XmAb942 - (XENITH-UC),Inflammatory bowel diseases (IBD) ,Phase 1,04/11/2024 ET,"Phase 1 dosing commenced, noted November 4, 2024. Phase",71.32M
Add to portfolio,,,,,,,,
PTN,Palatin Technologies Inc.,$1.19 ,PL7737,Obesity Due to Leptin Receptor Deficiency ,Preclinical,04/11/2024 ET,"Preclinical data reported that L7737 significantly decreased food intake and body weight in DIO mice, but not in MC4R-KO mice, noted November 4, 2024.",46.48M
Add to portfolio,,,ODD,,,,,
PPBT,Purple Biotech Ltd.,$2.97 ,CM24 and OPDIVO (nivolumab),2L metastatic pancreatic cancer (PDAC) ,Phase 2,04/11/2024 ET,Phase 2 additional new data demonstrated significant improvements in both progression-free survival (PFS) and overall survival (OS) when treated with CM24 in combination with nivolumab and chemotherap … read more,2.65M
Add to portfolio,,,,,,,,
IRON,Disc Medicine Inc.,$58.25 ,Bitopertin - (APOLLO),Erythropoietic Protoporphyria (EPP) ,Phase 2,04/11/2024 ET,End of Phase 2 meeting with the FDA resulted in positive feedback to initiate its Phase 3 APOLLO trial by mid-2025.,34.77M
Add to portfolio,,,ODD,,,,,
CRVO,CervoMed Inc.,$12.47 ,Neflamapimod - (AscenD-LB),Dementia with Lewy bodies (DLB) ,Phase 2a,04/11/2024 ET,Phase 2a data presented at CTAD confirmed recent scientific literature indicating that plasma glial fibrillary acid protein (GFAP) is a robust measure of neurodegenerative disease activity in DLB. Nef … read more,9.25M
Add to portfolio,,,,,,,,
SKYE,Skye Bioscience Inc.,$5.44 ,Nimacimab - (CBeyond),Obesity ,Preclinical,04/11/2024 ET,"Preclinical preliminary data from a diet-induced obesity (DIO) model in mice, achieved significant dose-dependent weight loss of up to 16% compared to vehicle, highlighting a novel peripherally-driven … read more",30.99M
Add to portfolio,,,,,,,,
SRRK,Scholar Rock Holding Corporation,$27.67 ,SRK-439 with apitegromab - (EMBRAZE),Obesity ,Preclinical,04/11/2024 ET,"Preclinical data show that SRK-439 increased lean mass and lowered fat mass gain in mice receiving metformin, noted November 4, 2024.",96.13M
Add to portfolio,,,,,,,,
CYDY,Cytodyn Inc,$0.12 ,Leronlimab with trifluridine plus tipiracil (TAS-102) and bevacizumab,"CCR5+, microsatellite stable (MSS), relapsed or refractory metastatic colorectal cancer (mCRC) ",Phase 2,04/11/2024 ET,"The FDA cleared the Phase 2 trial, noted on November 4, 2024.",1.26B
Add to portfolio,,,,,,,,
ATOS,Atossa Therapeutics Inc.,$1.41 ,Z-Endoxifen - (Karisma),"Mammographic breast density (MBD), breast cancer ",Phase 2,04/11/2024 ET,"Phase 2 data reported that the relative significant density change was -19.3 percent and -26.5 percent for the 1 and 2 mg arms, respectively, using the placebo arm as a reference. No significant diffe … read more",129.17M
Add to portfolio,,,,,,,,
GUTS,"Fractyl Health, Inc.",$2.56 ,Revita - (REVITALIZE-1),Type 2 Diabetes ,Phase 1,04/11/2024 ET,"Phase 1 data showed that a single Revita procedure led to sustained, clinically meaningful weight loss in the majority of patients with T2D, noted November 4, 2024.",50.29M
Add to portfolio,,,,,,,,
GPCR,Structure Therapeutics Inc.,$39.74 ,GSBR-1290 -(ACCESS and ACCESS II ),"Type 2 Diabetes, obesity ",Phase 2a,04/11/2024 ET,"Poster presented at Obesity week reported a 6.8% placebo-adjusted weight loss at 60 and 120 mg, respectively, with QD dosing at 12 weeks, noted November 4, 2024.",57.6M
Add to portfolio,,,,,,,,
GUTS,"Fractyl Health, Inc.",$2.40 ,Rejuva (RJVA-001),Obesity and type 2 diabetes (T2D) ,Preclinical,05/11/2024 ET,"Preclinical study 13-week follow-up represents the longest data to-date demonstrating durable efficacy of RJVA-001 on weight and blood sugar in the diet-induced obesity (DIO) mouse model, noted Novemb … read more",50.29M
Add to portfolio,,,,,,,,
RCUS,Arcus Biosciences Inc.,$15.29 ,Domvanalimab + zimberelimab vs. zimberelimab vs. chemotherapy - (ARC-10),Non Small Cell Lung Cancer (NSCLC) ,Phase 3,05/11/2024 ET,"Phase 3 data presented reported results from Part 1 of its ARC-10 study, showing that treatment led to greater PFS, overall survival, and objective response rates compared to zimberelimab alone or che … read more",107.97M
Add to portfolio,,,View Clinical Trial Data,,,,,
NXTC,NextCure Inc.,$1.31 ,LNCB74,B7-H4 expressing cancers ,Preclinical,05/11/2024 ET,Preclinical data presented at SITC demonstrated strong anti-tumor activity in multiple CDX and PDX tumor models. A single dose of 3 mg/kg resulted in durable tumor regression in multiple tumor models … read more,2.68M
Add to portfolio,,,,,,,,
RYTM,Rhythm Pharmaceuticals Inc.,$56.25 ,Setmelanotide - (DAYBREAK),Variants in one of 31 additional genes with MC4R pathway relevance ,Phase 2,05/11/2024 ET,"Phase 2 trial showed that patients with acquired hypothalamic obesity who were on therapy for more than one year achieved a mean overall percent reduction in fat mass of 29.6%, versus a reduction in l … read more",66.42M
Add to portfolio,,,View Clinical Trial Data,,,,,
JNJ,Johnson & Johnson,—,CAPLYTA (Lumateperone) 42mg - (Study 304),Prevention of relapse in schizophrenia ,Phase 3,05/11/2024 ET,"Phase 3 study demonstrated a statistically significant (p=0.0002) longer time to relapse in schizophrenia patients treated with lumateperone compared to placebo, noted November 5, 2024.",2.41B
Add to portfolio,,,,,,,,
SANA,Sana Biotechnology Inc.,$3.39 ,SC291 - (ARDENT),"Solid tumors, B-cell lymphomas and leukemias ",Phase 1,05/11/2024 ET,"Sana is halting enrollment and further internal investment in the Phase 1 ARDENT trial. It is actively seeking a licensing partner to support advancement, noted November 2024.",237.81M
Add to portfolio,,,,,,,,
NXTC,NextCure Inc.,$1.31 ,NC410 in combination w/ pembrolizumab - (LAIR-2),Solid Tumors ,Phase 1/2,06/11/2024 ET,"Phase 1/2 data presented at SITC reported a disease control rates were 86% and 47% for the 200 mg and 100 mg NC410 doses, respectively, noted November 6, 2024.",2.68M
Add to portfolio,,,,,,,,
HCM,HUTCHMED (China) Limited,$18.33 ,HMPL-523 - (ESLIM-01),Primary immune thrombocytopenia (ITP) ,Phase 3,06/11/2024 ET,"Phase 3 data presented at ESMO Asia with an overall response was achieved by 81%, noted November 6, 2024.",174.43M
Add to portfolio,,,BTD,,,,,
TNGX,Tango Therapeutics Inc.,$3.24 ,TNG462 with daraxonrasib or zoldonrasib,Solid Tumors ,Phase 1/2,06/11/2024 ET,"Phase 1/2 data demonstrated durable clinical activity across multiple tumor types, noted November 6, 2024.",111.26M
Add to portfolio,,,FTD,,,,,
,,,ODD,,,,,
TNGX,Tango Therapeutics Inc.,$3.24 ,TNG908,MTAP-deleted tumors ,Phase 1/2,06/11/2024 ET,"TNG908 enrollment being stopped to fully resource TNG462 and TNG456, noted November 6, 2024.",111.26M
Add to portfolio,,,ODD,,,,,
CCCC,C4 Therapeutics Inc.,$5.97 ,CFT8919,Non-Small Cell Lung Cancer (NSCLC) ,Phase 1,06/11/2024 ET,"Phase 1 dosing commenced, noted November 6, 2024.",71.17M
Add to portfolio,,,,,,,,
IONS,Ionis Pharmaceuticals Inc.,$39.04 ,ION582 - (REVEAL),Angelman Syndrome ,Phase 3,06/11/2024 ET,"Phase 2 EoP2 discussion with FDA went well, including alignment on Phase 3 design, noted November 6, 2024.",159.39M
Add to portfolio,,,ODD,,,,,
,,,BTD,,,,,
VINC,Vincerx Pharma Inc.,$6.54 ,OQY-3258 (ESG401),Unresectable recurrent or metastatic triple-negative breast cancer ,Phase 3,06/11/2024 ET,"Phase 3 garnered Breakthrough Designation from China's National Medical Products Administration (NMPA) on November 6, 2024.",5.23M
Add to portfolio,,,BTD,,,,,
YS,LakeShore Biopharma Co. Ltd Ord,$2.30 ,PIKA Rabies Vaccine,Rabies ,BLA Filing,07/11/2024 ET,"BLA initiated November 7, 2024.",93.06M
Add to portfolio,,,,,,,,
DVAX,Dynavax Technologies Corporation,$12.02 ,CpG 1018 adjuvant with rF1V vaccine - (DoD Trial),Recombinant plague vaccine ,Phase 2,07/11/2024 ET,"Based on the results from a randomized, active-controlled Phase 2 clinical trial of the two-dose plague vaccine adjuvanted with CpG 1018, Dynavax has submitted a proposal to the DoD regarding addition … read more",117.27M
Add to portfolio,,,,,,,,
HOWL,Werewolf Therapeutics Inc.,$2.24 ,WTX-330,Solid tumors ,Phase 1,07/11/2024 ET,"Phase 1 data presented at SITC revealed the clinical potential of the tumor-activated IL-12 prodrug WTX-330, with favorable tolerability profile and encouraging efficacy signal, noted November 7, 2024 … read more",45.73M
Add to portfolio,,,,,,,,
INDP,Indaptus Therapeutics Inc.,$1.19 ,Decoy-20 - (INDP-D101),Advanced/metastatic solid tumors ,Phase 1,07/11/2024 ET,"Phase 1 data from SITC reported that confirmed that Decoy20 quickly disappeared from the bloodstream after administration, supporting the Company's ""pulse"" approach, noted November 7, 2024.",1.11M
Add to portfolio,,,,,,,,
INKT,MiNK Therapeutics Inc.,$7.35 ,AGENT-797,Solid Tumors ,Preclinical,07/11/2024 ET,"Preclinical data presented at SITC reported durable disease control in majority of heavily pretreated patients, noted November 7, 2024.",4.52M
Add to portfolio,,,,,,,,
IOBT,IO Biotech Inc.,$1.23 ,IO102-IO103 in combination with pembrolizumab - (IOB-022),Non-small cell lung cancer (NSCLC) ,Phase 2,07/11/2024 ET,"Phase 2 data presented at SITC reported an overall response rate of 55% unconfirmed/48% confirmed, disease control rate of 81%, and approximately 50% of patients without disease progression at 12 mont … read more",65.88M
Add to portfolio,,,,,,,,
BOLT,Bolt Biotherapeutics Inc.,$0.65 ,BDC-4182,"gastric/gastroesophageal junction cancer, pancreatic cancer ",Preclinical,07/11/2024 ET,"Preclinical data from SITC reported that treatment demonstrated anti-tumor activity in a wide range of tumor models and elicits immunological memory, noted November 7, 2024.",1.92M
Add to portfolio,,,,,,,,
BOLT,Bolt Biotherapeutics Inc.,$0.65 ,Trastuzumab imbotolimod (BDC-1001) with Opdivo,"HER2-Expressing Solid Tumors, gastric cancer, including gastroesophageal junction cancer ",Phase 1,07/11/2024 ET,"Phase 1 data reported pharmacodynamic changes were observed in HER2 IHC3+ and HER2 IHC2+, with both the greatest increase and statistical significance in patients with HER2 IHC 3+ tumors, noted Novemb … read more",1.92M
Add to portfolio,,,ODD,,,,,
ALLO,Allogene Therapeutics Inc.,$3.19 ,ALLO-316 - (TRAVERSE),Clear cell renal cell carcinoma (ccRCC) ,Phase 1,07/11/2024 ET,"Phase 1 update presented at SITC reported an Overall Response Rate of 50% and Confirmed Response Rate of 33% in Patients with CD70 Tumor Proportion Score (TPS) of Greater than 50%, noted November 7, 2 … read more",221.88M
Add to portfolio,,,FTD,,,,,
,,,RMAT,,,,,
CLLS,Cellectis S.A.,$1.75 ,ALLO-316 - (TRAVERSE),Clear cell renal cell carcinoma (ccRCC) ,Phase 1,07/11/2024 ET,"Phase 1 update presented at SITC reported an Overall Response Rate of 50% and Confirmed Response Rate of 33% in Patients with CD70 Tumor Proportion Score (TPS) of Greater than 50%, noted November 7, 2 … read more",72.09M
Add to portfolio,,,FTD,,,,,
,,,RMAT,,,,,
NKTR,Nektar Therapeutics,$1.37 ,NKTR-255,Locally advanced non-small cell lung cancer (NSCLC) ,Phase 2,07/11/2024 ET,Phase 2 data reported at SITC demonstrated statistically significant superiority of the eight-week absolute lymphocyte count with NKTR-255 post chemoradiation and in combination with durvalumab versus … read more,19.02M
Add to portfolio,,,,,,,,
PALI,Palisade Bio Inc.,$2.54 ,PALI-2108,Moderate-to-severe ulcerative colitis (UC) ,Phase 1,07/11/2024 ET,"Phase 1 clinical study commenced, noted November 7, 2024.",9.12M
Add to portfolio,,,,,,,,
NKTX,Nkarta Inc.,$3.27 ,NKX019,Non-Hodgkin lymphoma (NHL) ,Phase 1,07/11/2024 ET,"No further NKX019 development in lymphoma planned, noted November 7, 2024.",71.02M
Add to portfolio,,,,,,,,
MOLN,Molecular Partners AG,$6.03 ,MP0317,Solid Tumors ,Preclinical,07/11/2024 ET,"Preclnical PoC data presented at SITC supports the potential of CD3 Switch-DARPin platform to activate and boost T cells in the presence of tumor targets only, November 7, 2024.",40.36M
Add to portfolio,,,,,,,,
AVIR,Atea Pharmaceuticals Inc.,$3.44 ,Bemnifosbuvir (AT-527) - (SUNRISE-3),COVID-19 ,Phase 3,07/11/2024 ET,"Phase 3 trial did not meet primary endpoint, noted November 7, 2024.",79.36M
Add to portfolio,,,FTD,,,,,
,,,View Clinical Trial Data,,,,,
IMNN,Imunon Inc.,$0.80 ,IMNN-001 - (OVATION 2),Ovarian cancer ,Phase 2,08/11/2024 ET,"Phase 2 data presented at SITC reported a 35% improvement in overall survival and 25% improvement in progression-free survival versus standard-of-care alone, noted November 8, 2024.",2.52M
Add to portfolio,,,,,,,,
MURA,Mural Oncology plc,$3.52 ,Nemvaleukin (ALKS 4230) - (ARTISTRY-3),Solid Tumors ,Phase 1/2,08/11/2024 ET,"Phase 1/2 microenvironment pharmacodynamic data shared at SITC demonstrated tumor-site-specific pharmacodynamic activity and immune activation, noted November 8, 2024.",17.32M
Add to portfolio,,,,,,,,
ALKS,Alkermes plc,$28.86 ,Nemvaleukin (ALKS 4230) - (ARTISTRY-3),Solid Tumors ,Phase 1/2,08/11/2024 ET,"Phase 1/2 microenvironment pharmacodynamic data shared at SITC demonstrated tumor-site-specific pharmacodynamic activity and immune activation, noted November 8, 2024.",165.12M
Add to portfolio,,,,,,,,
ELTX,Elicio Therapeutics Inc.,$5.08 ,ELI-002 - (AMPLIFY-7P),mKRAS-driven cancers ,Phase 1a,08/11/2024 ET,"Phase 1a data presented at SITC reported that the highest three quartiles of T cell responders have not yet reached mDFS, whereas the lowest quartile achieved a mDFS of 3.1 months, noted November 8, 2 … read more",16.34M
Add to portfolio,,,,,,,,
AMGN,Amgen Inc.,—,TEZSPIRE (tezepelumab-ekko),Chronic Rhinosinusitis with Nasal Polyps (CRwNP) ,Phase 3,08/11/2024 ET,"Phase 3 data reported a statistically significant and clinically meaningful reduction in nasal polyp size and reduced nasal congestion compared to placebo, noted November 8, 2024.",538.36M
Add to portfolio,,,,,,,,
AZN,AstraZeneca PLC,$63.59 ,TEZSPIRE (tezepelumab-ekko),Chronic Rhinosinusitis with Nasal Polyps (CRwNP) ,Phase 3,08/11/2024 ET,"Phase 3 data reported a statistically significant and clinically meaningful reduction in nasal polyp size and reduced nasal congestion compared to placebo, noted November 8, 2024.",3.1B
Add to portfolio,,,,,,,,
AMGN,Amgen Inc.,$320.06 ,Tezepelumab - (WAYPOINT),Chronic Rhinosinusitis With Nasal Polyps ,Phase 3,08/11/2024 ET,"Phase 3 trial had a statistically significant and clinically meaningful reduction in the size of nasal polyps and reduced nasal congestion compared to placebo, noted November 8, 2024.",538.36M
Add to portfolio,,,View Clinical Trial Data,,,,,
IPHA,Innate Pharma S.A.,$1.84 ,IPH6501,Relapsed and/or Refractory CD20-expressing B-cell Non-Hodgkin's Lymphoma (NHL) ,Preclinical,08/11/2024 ET,"Preclinical data reported that IPH6501 targets on NK cells and show effective IPH6501-induced killing of CD20+ B-NHL target cells, noted November 8, 2024.",92.16M
Add to portfolio,,,,,,,,
IOVA,Iovance Biotherapeutics Inc.,$10.59 ,LN-145 and KEYTRUDA (pembrolizumab) - (IOV-COM-202),Solid Tumors ,Phase 2,08/11/2024 ET,"Phase 2 updated cohort 1a data at ASCO noted that 30% confirmed complete response rate, noted November 8, 2024",361.85M
Add to portfolio,,,View Clinical Trial Data,,,,,
CARM,Carisma Therapeutics Inc.,$1.01 ,CAR-M therapy,Hepatocellular carcinoma (HCC) ,Preclinical,08/11/2024 ET,"Preclinical data reported the treatment produced pro-inflammatory cytokines and adopted an inflammatory, activated macrophage phenotype upon antigen engagement, noted November 8, 2024.",41.79M
Add to portfolio,,,,,,,,
MRNA,Moderna Inc.,$46.83 ,CAR-M therapy,Hepatocellular carcinoma (HCC) ,Preclinical,08/11/2024 ET,"Preclinical data reported the treatment produced pro-inflammatory cytokines and adopted an inflammatory, activated macrophage phenotype upon antigen engagement, noted November 8, 2024.",389.08M
Add to portfolio,,,,,,,,
VTYX,Ventyx Biosciences Inc.,$2.20 ,VTX958,Crohn's disease ,Phase 2,08/11/2024 ET,"The company does not plan to commit significant internal resources to further development of VTX958, noted November 8, 2024.",71.31M
Add to portfolio,,,,,,,,
CMPX,Compass Therapeutics Inc.,$1.80 ,CTX-471 (CD137 agonist),Solid tumors ,Phase 1,08/11/2024 ET,Phase 1 new data presented at SITC showed a correlation between the levels of neural cell adhesion molecule (NCAM or CD56) expression and response and disease control in patients treated with CTX-471 … read more,138.28M
Add to portfolio,,,,,,,,
ANIX,Anixa Biosciences Inc.,$3.44 ,α-lactalbumin,Breast cancer vaccine ,Phase 1a,08/11/2024 ET,"Phase 1a additional data presented at SITC showed that vaccine was safe and well tolerated by participants in all 3 cohorts, noted November 8, 2024.",32.92M
Add to portfolio,,,,,,,,
CUE,Cue Biopharma Inc.,$1.72 ,CUE-101 and KEYTRUDA (pembrolizumab) - (KEYNOTE-A78),HPV16+ head and neck cancer ,Phase 1,08/11/2024 ET,"Phase 1 presented at SITC showed an objective response rate (ORR) of 46%, 12-month overall survival (OS) of 91.3% and a median overall survival (mOS) of 21.8 months, noted November 8, 2024.",76.85M
Add to portfolio,,,FTD,,,,,
AUTL,Autolus Therapeutics plc,$3.73 ,AUCATZYL (obecabtagene autoleucel) - (FELIX),B-Cell Acute Lymphoblastic Leukemia ,Approved,08/11/2024 ET,"FDA Approved on November 8, 2024.",266.14M
Add to portfolio,,,RMAT,,,,,
CADL,Candel Therapeutics Inc.,$4.83 ,CAN-3110,Melanoma ,Preclinical,08/11/2024 ET,"Data presented in a poster at SITC reported that CAN-3110 demonstrated potent antitumor activity both in vitro and in vivo, highlighting its potential as a promising therapeutic agent for treating me … read more",54.9M
Add to portfolio,,,,,,,,
REGN,Regeneron Pharmaceuticals Inc.,$827.37 ,Ateganosine (THIO-101),Non-small cell lung cancer (NSCLC) ,Phase 2,08/11/2024 ET,"Phase 2 update presented at SITC reported an ORR in the 3L setting with the 180 mg dose is 38% (3/8), noted November 8, 2024.",105.1M
Add to portfolio,,,ODD,,,,,
,,,FTD,,,,,
MAIA,MAIA Biotechnology Inc.,$2.91 ,Ateganosine (THIO-101),Non-small cell lung cancer (NSCLC) ,Phase 2,08/11/2024 ET,"Phase 2 update presented at SITC reported an ORR in the 3L setting with the 180 mg dose is 38% (3/8), noted November 8, 2024.",32.99M
Add to portfolio,,,ODD,,,,,
,,,FTD,,,,,
CGEN,Compugen Ltd.,$1.78 ,"COM701, COM902 and Pembrolizumab","Advanced malignancies, Ovarian cancer ",Phase 1,08/11/2024 ET,"Report initial findings at SITC reported a Confirmed ORR of 17.4%, noted November 8, 2024.",93.51M
Add to portfolio,,,,,,,,
SILO,Silo Pharma Inc.,$1.28 ,SPC-15,Post-traumatic stress disorder (PTSD) ,Preclinical,08/11/2024 ET,"Preclinical data reported that the combined treatment demonstrated significant improvement in behavioral outcomes related to severe stress-induced conditions as compared to using either agent alone, n … read more",9.4M
Add to portfolio,,,,,,,,
ADAG,Adagene Inc.,$2.64 ,muzastotug (ADG126) combined with KEYTRUDA (pembrolizumab) - (ADG126-P001/KEYNOTE-C98),Solid tumors ,Phase 1/2,09/11/2024 ET,"Phase 1/2 data presented at SITC showed a three-fold increased active (e.g., cleaved) drug exposure in homogenized tumor tissue samples at 10 mg/kg versus a single dose of ipilimumab at 1 mg/kg while … read more",47.11M
Add to portfolio,,,,,,,,
PHIO,Phio Pharmaceuticals Corp.,$2.95 ,PH-762,Cutaneous Squamous Cell Carcinoma ,Phase 1b,09/11/2024 ET,"Phase 1b additional data shared at SITC reported one complete response and one partial response, noted November 9, 2024.",5.73M
Add to portfolio,,,,,,,,
REPL,Replimune Group Inc.,$12.44 ,RP1 (vusolimogene oderparepvec) and OPDIVO (nivolumab) - (IGNYTE-3),Non-melanoma (NMSC) / Non-small cell lung cancer (NSCLC) ,Phase 3,09/11/2024 ET,"Phase 3 data presented at SITC reported that the median overall survival for the trial has not been reached, however, one-, two-, and three-year survival rates were 75.3%, 63.3%, and 54.8%, respective … read more",78.06M
Add to portfolio,,,BTD,,,,,
,,,View Clinical Trial Data,,,,,
SRRK,Scholar Rock Holding Corporation,$29.08 ,SRK-181 - (DRAGON),Solid Tumors ,Phase 1,09/11/2024 ET,"Phase 1 data presented at SITC demonstrated durable antitumor activity in heavily pretreated patients with anti–PD-1–resistant cancer across multiple cancer types , noted November 9, 2024.",96.13M
Add to portfolio,,,,,,,,
CUE,Cue Biopharma Inc.,$1.72 ,CUE-102,Wilms' Tumor (WT1)-expressing cancers ,Phase 1,09/11/2024 ET,Phase 1 trial presentation SITC reported that patients with HPV16+ R/M HNSCC refractory to platinum-based treatments and checkpoint inhibitors (2L+) receiving CUE-101 4 mg/kg monotherapy exhibit an … read more,76.85M
Add to portfolio,,,,,,,,
IMAB,I-MAB,$1.10 ,Givastomig (TJ033721 / ABL111),"First-line metastatic gastric cancers, solid tumors ",Phase 1,09/11/2024 ET,"Phase 1 data presented at SITC 2024 reported that a dose range between 8-12 mg/kg Q2W was identified as the preferred dose range for heavily pre-treated GEC patients., noted November 9, 2024.",81.5M
Add to portfolio,,,ODD,,,,,
RCUS,Arcus Biosciences Inc.,$17.85 ,Etrumadenant (AB928) and zimberelimab - (ARC-9),Colorectal Cancer ,Phase 1/2,09/11/2024 ET,"Phase 1b/2 data presented at SITC reported that OS was greater with zim than with chemo, noted November 9, 2024.",107.97M
Add to portfolio,,,,,,,,
RLFTF,RELIEF THERAPEUTICS HLDG AG,$7.15 ,RLF-TD011,Epidermolysis bullosa (EB) ,Phase 1,11/11/2024 ET,"Final results reported that RLF-TD011 led to a 24% decrease in S. aureus relative abundance (p=0.01), which correlated strongly (rho=0.64) with wound size reduction. Overall, 78% of treated wounds clo … read more",12.58M
Add to portfolio,,,RPDD,,,,,
,,,QID,,,,,
XAIR,Beyond Air Inc.,$0.51 ,Beyond Cancer (UNO),Solid tumors ,Preclinical,11/11/2024 ET,"Preclinical efficacy data from Low Volume UNO (LV UNO, < 100 mL) presented at SITC showed that LV UNO in combination with anti-rPD-L1 resulted in prolonged survival and doubled the tumor growth inhibi … read more",5.23M
Add to portfolio,,,,,,,,
CANF,Can-Fite Biopharma Ltd Sponsored ADR (Israel),$2.11 ,Namodenoson - (CF102-222PC),Pancreatic Cancer ,Phase 2a,11/11/2024 ET,"Phase 2a dosing initiated, noted November 11, 2024.",10.35M
Add to portfolio,,,ODD,,,,,
NCNA,NuCana plc,$1.56 ,NUC-3373 in Combination with Pembrolizumab or Docetaxel - NuTide: 303),Non Small Cell Lung Cancer (NSCLC) ,Phase 1/2,11/11/2024 ET,"Phase 1b/2 commenced, noted October 26, 2022. Phase 1b/2 initial data showed that among patients who had exhausted all other treatment options, including prior PD-(L)1 therapy, a 22% objective respons … read more",1.91M
Add to portfolio,,,,,,,,
MRK,Merck & Company Inc.,$99.92 ,KEYTRUDA (pembrolizumab) + plinabulin / docetaxel - (KeyPelms-004 / 303 Study) (TROPION Lung-01),2L/3L Non-small cell lung cancer (NSCLC) ,Phase 2,11/11/2024 ET,"Phase 2 data reported an overall response rate (ORR) of 12.8% and median PFS (mPFS) of 3.7 months, noted November 11, 2024.",2.5B
Add to portfolio,,,,,,,,
BYSI,BeyondSpring Inc.,$1.98 ,KEYTRUDA (pembrolizumab) + plinabulin / docetaxel - (KeyPelms-004 / 303 Study) (TROPION Lung-01),2L/3L Non-small cell lung cancer (NSCLC) ,Phase 2,11/11/2024 ET,"Phase 2 data reported an overall response rate (ORR) of 12.8% and median PFS (mPFS) of 3.7 months, noted November 11, 2024.",40.33M
Add to portfolio,,,,,,,,
CERO,CERo Therapeutics Holdings Inc.,$19.60 ,CER-1236,"Solid tumors, non-small cell lung cancer (NSCLC) and ovarian cancer ",Preclinical,11/11/2024 ET,"Preclinical study presented ar SITC highlighted CER-1236's ability to increase TIM-4-L expression in ovarian cancer cells, resulting in tumor cell death while sparing healthy cells, noted November 11, … read more",1.21M
Add to portfolio,,,,,,,,
NVAX,Novavax Inc.,$9.01 ,NVX-CoV2373 - (COVID-19-Influenza Combination),"COVID-19, COVID-19 vaccine, Influenza ",Phase 2,11/11/2024 ET,"Phase 2 hold removed, FDA cleared study to begin enrolling in planned Phase 3 trial, noted November 11, 2024.",162.42M
Add to portfolio,,,,,,,,
CTXR,Citius Pharmaceuticals Inc.,$11.23 ,LYMPHIR (denileukin diftitox),B-cell lymphomas ,Phase 1,11/11/2024 ET,"Phase 1 preliminary efficacy results strongly suggests that LYMPHIR may have the ability to improve and prolong the anti-tumor activity of immune checkpoint inhibitors. To date, this unique regimen ha … read more",17.01M
Add to portfolio,,,,,,,,
ABBV,AbbVie Inc.,$172.78 ,Emraclidine (CVL-231) - (EMPOWER-1),Schizophrenia ,Phase 2,11/11/2024 ET,"Phase 2 trial did not meet their primary endpoint, noted November 11, 2024.",1.77B
Add to portfolio,,,View Clinical Trial Data,,,,,
APVO,Aptevo Therapeutics Inc.,$10.66 ,ALG.APV-527,Solid tumors ,Phase 1,11/11/2024 ET,"Phase 1 data presented at SITC indicated that trial endpoints of adequate exposure, safety, tolerability and biological activity were met, noted November 11, 2024.",3.29M
Add to portfolio,,,,,,,,
AIMD,Ainos Inc.,$0.50 ,VELDONA,Sjögren's syndrome ,Phase 3,11/11/2024 ET,"IRB approval on track as scheduled, company plans new phase of treatment evaluation expected 1Q 2025, noted November 11, 2024.",4.66M
Add to portfolio,,,,,,,,
CRVS,Corvus Pharmaceuticals Inc.,$9.56 ,Ciforadenant,Metastatic castration resistant prostate cancer (mCRPC) ,Phase 1/2,11/11/2024 ET,"Phase 1/2 data reported that 5 of 24 (21%) receiving combination therapy had PSA partial responses defined as PSA reductions >30%, compared to 1 of 11 (9%) receiving monotherapy, noted November 11, 20 … read more",74.51M
Add to portfolio,,,,,,,,
FATE,Fate Therapeutics Inc.,$2.56 ,FT825/ONO-8250,Solid Tumors ,Phase 1,11/11/2024 ET,"Phase 1 data reported that treatment was well-tolerated with no DLTs and no events of any grade of CRS, ICANS, or GvHD, noted November 11, 2024.",115.33M
Add to portfolio,,,,,,,,
RARE,Ultragenyx Pharmaceutical Inc.,$50.73 ,GTX-102 - (Aspire),Angelman Syndrome ,Phase 1/2,11/11/2024 ET,"Phase 1/2 data reported statistically significant separation between the GTX-102 and sham arms, noted November 11, 2024.",96.37M
Add to portfolio,,,BTD,,,,,
IMTX,Immatics N.V.,$9.04 ,"Anzu-cel (anzutresgene autoleucel, IMA203) (ACTengine) - (SUPRAME)",Melanoma ,Phase 1b,11/11/2024 ET,"Phase 1b data reported a 54% cORR, 12.1 months mDOR and 6 months mPFS in heavily pretreated metastatic melanoma patients and >1-year mPFS in patients with deep responses, noted November 11, 2024.",121.55M
Add to portfolio,,,RMAT,,,,,
FATE,Fate Therapeutics Inc.,$2.56 ,FT836,Solid Tumors ,Preclinical,11/11/2024 ET,"Preclinical data presented at SITC showed robust antigen-mediated expansion, functional persistence, and durable anti-tumor activity in the presence of alloreactive T cells, noted November 11, 2024.",115.33
Add to portfolio,,,,,,,,
NGNE,Neurogene Inc.,$71.53 ,NGN-101,CLN5 Batten Disease ,Phase 1/2,11/11/2024 ET,"Phase 1/2 was discontinued due to RMAT application denial by the FDA, noted November 11, 2024.",14.27M
Add to portfolio,,,,,,,,
NGNE,Neurogene Inc.,$71.53 ,NGN-401 - (Embolden),Rett Syndrome ,Phase 1/2,11/11/2024 ET,"Phase 1/2 data showed that all four participants in the low-dose cohort showed consistent and durable improvements across key clinical domains, including hand function, language, and ambulation, with … read more",14.27M
Add to portfolio,,,RMAT,,,,,
ZVRA,Zevra Therapeutics Inc.,$8.96 ,Arimoclomol (EAP),Niemann-Pick disease type C (NPC) ,Phase 3,11/11/2024 ET,Additional data presented at the 53rd Child Neurology Society Annual Meeting showed that the NPCCSS swallow score reflects the patient's level of dysfunction. Study indicates that a change in score re … read more,56.14M
Add to portfolio,,,,,,,,
ARCT,Arcturus Therapeutics Holdings Inc.,$20.37 ,"ARCT-2304 - (LUNAR-H5N1, BARDA)",Influenza disease caused by H5N1 virus ,IND-Enabling,11/11/2024 ET,"IND cleared after receiving ""Study May Proceed"" notification by the FDA, noted November 11, 2024",27.15M
Add to portfolio,,,FTD,,,,,
SNDX,Syndax Pharmaceuticals Inc.,$16.21 ,Revuforj (revumenib) - (AUGMENT-101),Relapsed/refractory (R/R) acute leukemias ,Phase 2,12/11/2024 ET,"Phase 2 topline results showed that the trial met its primary endpoint. Revumenib demonstrated a favorable safety profile with only 5% treatment-related discontinuation, noted November 12, 2024.",86.14M
Add to portfolio,,,FTD,,,,,
,,,BTD,,,,,
IVVD,Invivyd Inc.,$1.00 ,PEMGARDA (VYD222 (pemivibart)) - (CANOPY),COVID-19 Prevention ,Phase 3,12/11/2024 ET,"Phase 3 data from long-term follow-up from months 7-12 after cessation of drug noted a 64% relative risk reduction in symptomatic disease versus placebo, noted November 12, 2024.",120.14M
Add to portfolio,,,,,,,,
EQ,Equillium Inc.,$0.85 ,EQ302 - (IL-15 and IL-21),Solid Tumors ,Preclinical,12/11/2024 ET,Preclinical data shared at SITC reported a modest effect on reversing the phenotype and function of terminally exhausted CD8+ T cells as shown by the increase in the percentage of TCF-1 positive cells … read more,59.5M
Add to portfolio,,,,,,,,
AZN,AstraZeneca PLC,$64.28 ,KOSELUGO (selumetinib) - (KOMET),Neurofibromatosis Type 1-Plexiform Neurofibromas (NF1-PN) in Adults ,Phase 3,12/11/2024 ET,"Phase 3 results showed reduction in tumor volume, building on the established safety and efficacy profile of KOSELUGO in certain children and has the potential to support expanded use in certain adult … read more",3.1B
Add to portfolio,,,,,,,,
EVAX,Evaxion A/S,$11.90 ,EVX-V1,Cytomegalovirus (CMV) vaccine ,Preclinical,12/11/2024 ET,"Preclinical data reported successfully induced a specific immune response comparable to that of the conventional gB antigen, noted November 12, 2024.",6.32M
Add to portfolio,,,,,,,,
AZN,AstraZeneca PLC,$64.28 ,DATROWAY (datopotamab deruxtecan-dlnk)- (TROPION-Lung01),Non-small cell lung cancer (NSCLC) ,BLA Filing,12/11/2024 ET,"Voluntarily withdrawn November 12, 2024.",3.1B
Add to portfolio,,,BTD,,,,,
AZN,AstraZeneca PLC,$64.28 ,Datopotamab deruxtecan - (TROPION-Lung05),EGFR non-small cell lung cancer (NSCLC) ,BLA Filing,12/11/2024 ET,"BLA submitted November 12, 2024.",3.1B
Add to portfolio,,,BTD,,,,,
DSNKY,"Daiichi Sankyo Co., Ltd. ADR",$31.20 ,Datopotamab deruxtecan - (TROPION-Lung05),EGFR non-small cell lung cancer (NSCLC) ,BLA Filing,12/11/2024 ET,"BLA submitted November 12, 2024.",1.92B
Add to portfolio,,,BTD,,,,,
RVPH,Reviva Pharmaceuticals Holdings Inc.,$1.32 ,Brilaroxazine - (RECOVER),Schizophrenia ,Phase 3,12/11/2024 ET,"108 patients have completed 1-year of treatment which is generally well tolerated to date in patients with acute and stable schizophrenia, noted November 12, 2024.",68M
Add to portfolio,,,,,,,,
XBIO,Xenetic Biosciences Inc.,$4.13 ,DNase,Pancreatic carcinoma ,Phase 1,12/11/2024 ET,"Phase 1 data reported that treatment demonstrated beneficial effects of targeting NETs with systemic DNase I in models of primary tumor and metastatic CRC, improving the efficacy of CTLA-4 immune chec … read more",1.54M
Add to portfolio,,,,,,,,
SYRE,Spyre Therapeutics Inc.,$35.82 ,SPY001,Inflammatory Bowel Disease (IBD) ,Phase 1,12/11/2024 ET,"Phase 1 interim data showed a favorable safety profile and strong pharmacokinetics with a half-life over 90 days—four times longer than vedolizumab, noted November 12, 2024.",60.4M
Add to portfolio,,,,,,,,
GILD,Gilead Sciences Inc.,$91.86 ,Lenacapavir - (PURPOSE 2),HIV PreP ,Phase 3,13/11/2024 ET,"Phase 3 data reported that results demonstrated superiority of twice-yearly lenacapavir over bHIV, with 96% relative risk reduction, noted November 13, 2024.",1.24B
Add to portfolio,,,,,,,,
AMGN,Amgen Inc.,$296.60 ,AMG 133 (maridebart cafraglutide) - (MariTide),Obesity and without diabetes ,Phase 1,13/11/2024 ET,"Phase 1 data reported that the company did not see an association between the administration of MariTide and bone mineral density changes, noted November 13, 2024.",538.36M
Add to portfolio,,,,,,,,
LYRA,Lyra Therapeutics Inc.,$0.20 ,LYR-210 - (ENLIGHTEN I),Chronic rhinosinusitis ,Phase 3,13/11/2024 ET,"Phase 3 52 week extension data indicated that LYR-210 was generally well tolerated over the extended treatment period, including among patients who received repeat dosing for a total of 12 months. No … read more",1.64M
Add to portfolio,,,View Clinical Trial Data,,,,,
LIAN,LianBio,$0.30 ,LYR-210 - (ENLIGHTEN I),Chronic rhinosinusitis ,Phase 3,13/11/2024 ET,"Phase 3 52 week extension data indicated that LYR-210 was generally well tolerated over the extended treatment period, including among patients who received repeat dosing for a total of 12 months. No … read more",108.06M
Add to portfolio,,,View Clinical Trial Data,,,,,
ALRN,Rein Therapeutics Inc Com (New),$3.57 ,LTI-03 - (Caveolin-1),Idiopathic pulmonary fibrosis (IPF) ,Phase 1b,13/11/2024 ET,"Phase 1b topline data from cohort 2 demonstrated that the high-dose treatment (5 mg BID) showed significant reductions in profibrotic proteins and a 5% decrease in surfactant protein D (SPD), a bioma … read more",21.67M
Add to portfolio,,,,,,,,
INO,Inovio Pharmaceuticals Inc.,$4.95 ,INO-3107,HPV 6 and HPV 11-associated Recurrent respiratory papillomatosis ,Phase 1/2,13/11/2024 ET,"New immunology on Phase 1/2 data shows INO-3107 induced an expansion of new clonal T cells in blood that were not detectable prior to treatment, noted November 13, 2024.",53.14M
Add to portfolio,,,BTD,,,,,
,,,View Clinical Trial Data,,,,,
BRTX,BioRestorative Therapies Inc,$1.54 ,BRTX-100,Chronic lumbar disc disease ,Phase 2,13/11/2024 ET,"Phase 2 blinded preliminary data presented demonstrate a positive trend and clear signal in Primary and Secondary endpoints November 13, 2024.",7.98M
Add to portfolio,,,FTD,,,,,
ADAP,Adaptimmune Therapeutics plc,$0.77 ,Lete-cel - (IGNYTE-ESO),Sarcoma ,Phase 2,13/11/2024 ET,"Phase 2 data reported six complete responses (6/64); twenty-one partial responses (21/64) noted November 13, 2024.",265.05M
Add to portfolio,,,BTD,,,,,
GSK,GSK plc American Depositary Shares (Each representing two),$34.33 ,Lete-cel - (IGNYTE-ESO),Sarcoma ,Phase 2,13/11/2024 ET,"Phase 2 data reported six complete responses (6/64); twenty-one partial responses (21/64) noted November 13, 2024.",2.03B
Add to portfolio,,,BTD,,,,,
RNA,Avidity Biosciences Inc.,$52.50 ,AOC1086,PLN Cardiomyopathy ,Preclinical,13/11/2024 ET,"Preclinical data demonstrated robust siRNA delivery to the heart and targeted knockdown with potent reduction of approximately 80% in cardiac PLN mRNA, noted November 13, 2024.",128.65M
Add to portfolio,,,,,,,,
GILD,Gilead Sciences Inc.,$91.86 ,Biktarvy - (ALLIANCE),HIV/HBV Coinfection ,Phase 3,13/11/2024 ET,"Phase 3 data reported that after 3 years of treatment, Biktarvy maintained high rates of HIV-1 and HBV virologic suppression, defined as HIV RNA <50 copies/ mL and HBV RNA <29 IU/ mL, respectively, no … read more",1.24B
Add to portfolio,,,,,,,,
GILD,Gilead Sciences Inc.,$91.86 ,Bictegravir and Lenacapavir - (ARTISTRY-1),HIV ,Phase 2/3,13/11/2024 ET,"Phase 2/3 data reported that at Week 48, fasting lipid parameters generally improved from baseline in both BIC+LEN groups (BIC 75 mg +LEN 25 mg and BIC 75 mg +LEN 50 mg) versus the complex antiretrovi … read more",1.24B
Add to portfolio,,,,,,,,
GILD,Gilead Sciences Inc.,$91.86 ,Lenacapavir (GS-6207),HIV ,Phase 1b,13/11/2024 ET,"Phase 1b data reported that at Week 26, 21% (n=3) of participants who received LEN + TAB and the low dose of ZAB and 0% (n=0) participants who received LEN +TAB and the high dose of ZAB had an HIV vir … read more",1.24B
Add to portfolio,,,,,,,,
CLPT,"ClearPoint Neuro, Inc.",$10.95 ,Upstaza (PTC-AADC),AADC deficiency ,Approved,13/11/2024 ET,"Approved November 13, 2024.",28.43M
Add to portfolio,,,,,,,,
PTCT,PTC Therapeutics Inc.,$44.03 ,Upstaza (PTC-AADC),AADC deficiency ,Approved,13/11/2024 ET,"Approved November 13, 2024.",79.44M
Add to portfolio,,,,,,,,
GSK,GSK plc American Depositary Shares (Each representing two),$33.63 ,Blenrep,Multiple myeloma ,Phase 3,14/11/2024 ET,"Additional Phase 3 data reported that the trial met the key secondary endpoint of overall survival (OS), noted November 14, 2024.",2.03B
Add to portfolio,,,,,,,,
ACIU,AC Immune SA,$3.55 ,ACI-7104.056 - (VacSYn),Parkinson's disease (PD) ,Phase 2,14/11/2024 ET,"Phase 2 interim safety and immunogenicity data reported that 100% of patients receiving ACI-7104.056 responded against the target antigen, noted November 14, 2024.",100.41M
Add to portfolio,,,,,,,,
LLY,Eli Lilly and Company,$783.47 ,Tirzepatide - (SURMOUNT-1),Pre-diabetes and obesity or overweight ,Phase 3,14/11/2024 ET,"Phase 3 data reported a 94% reduction in risk of progression to type 2 diabetes across all pooled doses of tirzepatide compared to placebo over three years, noted November 14, 2024.",946.46M
Add to portfolio,,,,,,,,
IMMP,Immutep Limited,$2.09 ,Eftilagimod alpha with pembrolizumab and radiotherapy - (EFTISARC-NEO),Soft tissue sarcoma ,Phase 2,14/11/2024 ET,"Phase 2 data presented at CTOS demonstrated a greater than three-fold increase in tumor hyalinization/fibrosis (median 50%), compared to the historical median of 15% with radiotherapy alone, November … read more",147.19M
Add to portfolio,,,,,,,,
IMMP,Immutep Limited,$2.09 ,Eftilagimod alpha + chemo+ anti-PD-1 - (INSIGHT-003),Solid tumors ,Phase 1,14/11/2024 ET,"Phase 1 data update data in patients with a minimum follow-up of 22 months with a median overall survival is 32.9 months, with median progression free survival reaching 12.7 months, and a 24-month ove … read more",147.19M
Add to portfolio,,,,,,,,
ADIL,Adial Pharmaceuticals Inc,$1.14 ,AD04 - (ONWARD),Alcohol use disorder ,Phase 3,14/11/2024 ET,Phase 3 topline results demonstrated that AD04 delivers lower ondansetron PK exposure compared to the marketed 4mg ondansetron tablet and can be taken in both fed and fasted states. Adial plans to eng … read more,21.83M
Add to portfolio,,,View Clinical Trial Data,,,,,
MBRX,Moleculin Biotech Inc.,$3.09 ,"Annamycin (MB-106) in combination with Cytarabine - (Ara-C, MIRACLE)",Acute Myeloid Leukemia (AML) ,Phase 3,14/11/2024 ET,"Phase 3 protocol amended with preliminary data now expected on 2H 2025, noted November 14, 2024.",30.29M
Add to portfolio,,,ODD,,,,,
,,,FTD,,,,,
ANTX,AN2 Therapeutics Inc.,$1.00 ,Epetraborole - (EBO-103),"Mycobacterium avium complex (MAC) lung disease, Chronic non-tuberculous mycobacterial (NTM) lung disease ",Phase 2,14/11/2024 ET,"Phase 2 data reported nominally statistically significant improvements in MACrO2 measured from baseline to month 6 in post-hoc analysis, noted November 14, 2024.",27.33M
Add to portfolio,,,,,,,,
CRVS,Corvus Pharmaceuticals Inc.,$8.52 ,Soquelitinib - (CPI-818),Systemic sclerosis ,Preclinical,14/11/2024 ET,"Preclinical findings showed a reduced Th2 helper T cell infiltration and pulmonary fibrosis. These data support the broader application of ITK inhibitors in immune-mediated fibrotic diseases, noted No … read more",74.51M
Add to portfolio,,,,,,,,
KRON,Kronos Bio Inc.,$0.85 ,KB-7898,Sjögren's disease ,Preclinical,15/11/2024 ET,"Preclinical data reported the ability of p300 KAT inhibition to modulate multiple pro-inflammatory signaling pathways, including antibodies and cytokine production, in ex vivo and in vivo models at we … read more",60.97M
Add to portfolio,,,,,,,,
DTIL,Precision BioSciences Inc.,$7.62 ,PBGENE-HBV - (ELIMINATE-B),Chronic Hepatitis B Virus (HBV) ,Preclinical,15/11/2024 ET,"Preclinical data reinforced safety profile and potential to deliver a functional cure for chronic hepatitis B, supporting advancement into first-in-human clinical study, noted November 15, 2024.",11.79M
Add to portfolio,,,FTD,,,,,
RHHBY,Roche Holding AG ADR,—,Pegozafermin - (ENLIVEN),Nonalcoholic Steatohepatitis (NASH) ,Phase 2b,15/11/2024 ET,"Phase 2b data presented at AASLD reported that treatment improved patients' FAST scores but also achieved both MASH resolution and fibrosis improvement, noted November 15, 2024.",6.36B
Add to portfolio,,,BTD,,,,,
ETNB,89bio Inc.,$7.93 ,Pegozafermin - (ENLIVEN),Nonalcoholic Steatohepatitis (NASH) ,Phase 2b,15/11/2024 ET,"Phase 2b data presented at AASLD reported that treatment improved patients' FAST scores but also achieved both MASH resolution and fibrosis improvement, noted November 15, 2024.",148.31M
Add to portfolio,,,BTD,,,,,
CERO,CERo Therapeutics Holdings Inc.,$28.53 ,CER-1236 - (CertainT-1),"Acute myeloid leukemia (AML), Hematologic malignancies ",IND-Enabling,15/11/2024 ET,"IND cleared by the FDA, noted November 15, 2024.",1.21M
Add to portfolio,,,ODD,,,,,
,,,FTD,,,,,
ABUS,Arbutus Biopharma Corporation,$3.64 ,Imdusiran (AB-729 w/ NA therapy and Peginterferon alfa-2a) - (IM-PROVE II),Chronic Hepatitis B ,Phase 2a,15/11/2024 ET,"Phase 2a data presented at AASLD reported that 50% of patients who had baseline HBsAg levels less than 1000 IU/mL achieved functional cure in Cohort A1, noted November 15, 2024.",191.7M
Add to portfolio,,,,,,,,
GILD,Gilead Sciences Inc.,$87.67 ,Livdelzi (Seladelpar) - (ASSURE),Pruritus (itch) in people living with primary biliary cholangitis (PBC) ,Phase 3,15/11/2024 ET,"Phase 3 data reported that 81% (30 out of 37) of participants with primary biliary cholangitis (PBC) treated with Livdelzi® (seladelpar) achieved a composite biochemical response, noted November 15, 2 … read more",1.24B
Add to portfolio,,,,,,,,
AVIR,Atea Pharmaceuticals Inc.,$3.22 ,Bemnifosbuvir and ruzasvir (RZR) - (C-FORWARD),Hepatitis C Virus (HCV) ,Phase 2,15/11/2024 ET,"Phase 2 results from AASLD reported a SVR12 rate of 97%, noted November 15, 2024.",79.36M
Add to portfolio,,,,,,,,
ALT,Altimmune Inc.,$7.61 ,Pemvidutide - (IMPACT),Metabolic dysfunction-associated steatohepatitis (MASH) ,Phase 1b,15/11/2024 ET,"Phase 1b data presented at AASLD reported that treatment reduced LFC relative to baseline by up to 68.5% and decreased total cholesterol and triglycerides by up to 12.2% and 44.6%, respectively, after … read more",88.26M
Add to portfolio,,,FTD,,,,,
ALNY,Alnylam Pharmaceuticals Inc.,$235.56 ,ALN-HBV02 (VIR-2218) and VIR-3434 - (MARCH),Hepatitis B ,Phase 2,15/11/2024 ET,"Phase 2 data reported that 39% of participants with low baseline Hepatitis B surface antigen (HBsAg) achieved HBsAg loss with tobevibart + elebsiran, and 46% with tobevibart + elebsiran + pegylated in … read more",131.08M
Add to portfolio,,,View Clinical Trial Data,,,,,
VIR,Vir Biotechnology Inc.,$8.01 ,ALN-HBV02 (VIR-2218) and VIR-3434 - (MARCH),Hepatitis B ,Phase 2,15/11/2024 ET,"Phase 2 data reported that 39% of participants with low baseline Hepatitis B surface antigen (HBsAg) achieved HBsAg loss with tobevibart + elebsiran, and 46% with tobevibart + elebsiran + pegylated in … read more",138.92M
Add to portfolio,,,View Clinical Trial Data,,,,,
SNDX,Syndax Pharmaceuticals Inc.,$15.83 ,Revuforj (revumenib),Adult and pediatric relapsed or refractory (R/R) KMT2A-rearranged (KMT2Ar) acute leukemia ,Approved,15/11/2024 ET,"FDA approved on November 15, 2024.",86.14M
Add to portfolio,,,,,,,,
AMGN,Amgen Inc.,$279.06 ,UPLIZNA (INEBILIZUMAB-CDON),Immunoglobulin G4-related disease (IgG4-RD) ,Phase 3,15/11/2024 ET,"Phase 3 data presented at ACR Convergence with statistically significant 87% reduction in the risk of IgG4-RD flare compared to placebo, noted November 15, 2024.",538.36M
Add to portfolio,,,,,,,,
REGN,Regeneron Pharmaceuticals Inc.,$755.85 ,"Nexiguran ziclumeran (nex-z, NTLA-2001) - (MAGNITUDE)",Transthyretin amyloidosis (ATTR) ,Phase 1,16/11/2024 ET,"Phase 1 interim data presented at AHA reported that a ll patients with NYHA Class III at baseline (n=18) showed improvement or no change in their NYHA Class at month 12, noted November 16, 2024.",105.1M
Add to portfolio,,,ODD,,,,,
,,,RMAT,,,,,
NTLA,Intellia Therapeutics Inc.,$13.97 ,"Nexiguran ziclumeran (nex-z, NTLA-2001) - (MAGNITUDE)",Transthyretin amyloidosis (ATTR) ,Phase 1,16/11/2024 ET,"Phase 1 interim data presented at AHA reported that a ll patients with NYHA Class III at baseline (n=18) showed improvement or no change in their NYHA Class at month 12, noted November 16, 2024.",107.35M
Add to portfolio,,,ODD,,,,,
,,,RMAT,,,,,
NVO,Novo Nordisk A/S,—,Efruxifermin - (HARMONY),Nonalcoholic Steatohepatitis ,Phase 2b,17/11/2024 ET,"Phase 2b additional 96-Week data presented at AASLD reported an over 40% of participants treated with EFX 50mg for 96 weeks, compared with 0% for placebo, showed regression of liver fibrosis by all of … read more",4.47B
Add to portfolio,,,FTD,,,,,
,,,BTD,,,,,
,,,View Clinical Trial Data,,,,,
AKRO,Akero Therapeutics Inc.,$29.56 ,Efruxifermin - (HARMONY),Nonalcoholic Steatohepatitis ,Phase 2b,17/11/2024 ET,"Phase 2b additional 96-Week data presented at AASLD reported an over 40% of participants treated with EFX 50mg for 96 weeks, compared with 0% for placebo, showed regression of liver fibrosis by all of … read more",79.99M
Add to portfolio,,,FTD,,,,,
,,,BTD,,,,,
,,,View Clinical Trial Data,,,,,
SGMT,Sagimet Biosciences Inc.,$4.36 ,Denifanstat - (FASCINATE-3),Nonalcoholic steatohepatitis (NASH) ,Phase 2b,17/11/2024 ET,"Additional data shared at AASLD reported that denifanstat treatment improved fibrosis by ≥ 1 stage in more than 50% of F3 patients as follows, noted November 17, 2024.",32.52M
Add to portfolio,,,BTD,,,,,
ALNY,Alnylam Pharmaceuticals Inc.,$232.27 ,Nucresiran (ALN-TTRsc04) - (TRITON-CM),ATTR amyloidosis ,Phase 1,17/11/2024 ET,"Phase 1 additional data from AHA reported mean reductions of greater than 90% from baseline achieved at Day 15 and sustained through at least Day 180, noted November 17, 2024.",131.08M
Add to portfolio,,,ODD,,,,,
CYTK,Cytokinetics Incorporated,$51.94 ,Aficamten (CK-274) - (SEQUOIA-HCM),Hypertrophic cardiomyopathy (HCM) ,Phase 3,17/11/2024 ET,"Phase 3 data shared at AHA reported shortened times for VO2Rec to decline by 12.5% (VO2Rec T12.5%), 25% (VO2Rec T25%) and 50% (VO2Rec T50%) of peak VO2, corresponding to absolute reductions relative t … read more",119.66M
Add to portfolio,,,BTD,,,,,
,,,View Clinical Trial Data,,,,,
CYTK,Cytokinetics Incorporated,$51.94 ,Aficamten - (FOREST-HCM) (OLE),Non-obstructive hypertrophic cardiomyopathy (HCM) ,Phase 3,17/11/2024 ET,"Phase 3 data shared at AHA reported that treatment rapidly improved the symptom and LVOT gradient criteria used to define guidelineeligibility in 97% of patients, noted November 17, 2024.",119.66M
Add to portfolio,,,,,,,,
IVA,Inventiva S.A.,$2.73 ,Lanifibranor in combination with empagliflozin (Jardiance1) - (LEGEND),"Metabolic dysfunction-associated steatohepatitis (MASH), and type 2 diabetes (T2D) ",Phase 2a,18/11/2024 ET,"Phase 2a data presented at AASLD reported that 50% percent of patients saw their HbA1c levels below 6.5% at week 24 following treatment with lanifibranor alone or in combination with empagliflozin, no … read more",95.66M
Add to portfolio,,,,,,,,
NGNE,Neurogene Inc.,$19.82 ,NGN-401 - (Embolden),Rett Syndrome ,Phase 1/2,18/11/2024 ET,"Phase 1/2 discontinuation of 3E15 vg dose announced November 18, 2024.",14.27M
Add to portfolio,,,RMAT,,,,,
ACET,Adicet Bio Inc.,$0.97 ,ADI-001,Lupus nephritis and Systemic Lupus Erythematosus (SLE) ,Phase 1,18/11/2024 ET,"Phase 1 clinical trial initiated, noted November 18, 2024.",83.25M
Add to portfolio,,,FTD,,,,,
ADVM,Adverum Biotechnologies Inc.,$6.85 ,"Ixo-vec (ixoberogene soroparvovec, ADVM-022) - (ARTEMIS)",Wet age-related macular degeneration (AMD) ,Phase 2,18/11/2024 ET,"Phase 2 52-week data combined with follow-up from OPTIC at 4 years continue to support long-term potential best-in-class product profile of Ixo-vec, The therapy reduced injection burden by 80%-90%, ac … read more",20.98M
Add to portfolio,,,FTD,,,,,
,,,RMAT,,,,,
TNXP,Tonix Pharmaceuticals Holding Corp.,$13.30 ,Tonmya (TNX-102 SL) - (RELIEF/RESILIENT),Fibromyalgia ,Phase 3,18/11/2024 ET,"Phase 3 data presented at ACR Convergence demonstrated statistically significant improvement in the primary endpoint of fibromyalgia neoplastic pain and in all six key secondary endpoints, including s … read more",8.77M
Add to portfolio,,,FTD,,,,,
RGNX,REGENXBIO Inc.,$10.15 ,RGX-202 - (AFFINITY DUCHENNE),Duchenne Muscular Dystrophy (DMD) ,Phase 1/2,18/11/2024 ET,"Phase 1/2 data showed functional improvements in all patients, with dose-dependent performance exceeding natural history benchmarks. Biomarker data confirmed robust microdystrophin expression, and th … read more",50.51M
Add to portfolio,,,ODD,,,,,
,,,FTD,,,,,
IMTX,Immatics N.V.,$7.82 ,IMA402,Solid Tumors ,Phase 1/2,18/11/2024 ET,"Phase 1/2 initial clinical data demonstrated a favorable tolerability profile and signs of dose-dependent and PRAME expression-dependent clinical activity, including first objective responses in melan … read more",121.55M
Add to portfolio,,,,,,,,
CYBN,Cybin Inc.,$10.60 ,CYB003 - (EXTEND and EMBRACE),Major Depressive Disorder (MDD) and Alcohol use disorder (AUD) ,Phase 2,18/11/2024 ET,"Phase 2 12-month data showed that 100% of participants were responsive to treatment and 71% of participants were in remission at 12 months after just two 16 mg doses, noted November 18, 2024.",23.59M
Add to portfolio,,,BTD,,,,,
LRMR,Larimar Therapeutics Inc.,$6.16 ,Nomlabofusp (CTI-1601),Friedreich’s ataxia (FA) ,Phase 2,18/11/2024 ET,"Phase 2 data presented at ICAR demonstrated alignment between FXN levels and disease progression, reinforcing the drug's potential efficacy, noted November 18, 2024.",85.59M
Add to portfolio,,,ODD,,,,,
CABA,Cabaletta Bio Inc.,$2.70 ,CABA-201 - (RESET-SLE),Systemic Lupus Erythematosus ,Phase 1/2,18/11/2024 ET,"Phase 1/2 additional data to presented at ACR showed that demonstrated compelling efficacy, including 100% B cell depletion within one month and early naïve B cell repopulation, indicating potential i … read more",91.47M
Add to portfolio,,,FTD,,,,,
CABA,Cabaletta Bio Inc.,$2.70 ,rese-cel (resecabtagene autoleucel (CABA-201) - (RESET-Myositis),"Active idiopathic inflammatory myopathy (IIM, or myositis) ",Phase 1/2,18/11/2024 ET,"Phase 1/2 data presented at ACR showed a safety profile was favorable, with low-grade CRS in three patients and no additional ICANS events reported, noted November 18, 2024.",91.47M
Add to portfolio,,,FTD,,,,,
,,,ODD,,,,,
,,,RMAT,,,,,
CABA,Cabaletta Bio Inc.,$2.70 ,CABA-201 - (RESET-SSc),Systemic sclerosis (SSc) ,Phase 1/2,18/11/2024 ET,"Phase 1/2 initial data presented at ACR showed that first SSc patient demonstrated an emerging, drug-free clinical response, noted November 18, 2024.",91.47M
Add to portfolio,,,ODD,,,,,
THAR,Tharimmune Inc.,$2.37 ,TH104 (AV104),Primary biliary cholangitis (PBC) ,Phase 1,18/11/2024 ET,"Phase 1 results at AASLD demonstrated a significant correlation between blood levels of TH104 and reductions in pruritus, measured by the Worst-Itch Numerical Rating Scale (WI-NRS). Patients experienc … read more",4.64M
Add to portfolio,,,,,,,,
CTNM,Contineum Therapeutics Inc.,$15.83 ,PIPE-791,Osteoarthritis and low back pain ,IND-Enabling,18/11/2024 ET,"IND cleared by the FDA, noted November 18, 2024.",28.04M
Add to portfolio,,,,,,,,
MBRX,Moleculin Biotech Inc.,$2.52 ,Annamycin and Ara-C,Acute myeloid leukemia (AML) ,Phase 1/2,18/11/2024 ET,"Phase 1/2 data demonstrated median overall survival (""OS"") of 9.1 months for subjects with a wide range of (0-6) prior lines of therapy (n=22) and 11.6 months (n=10) for subjects with 1 prior line of … read more",30.29M
Add to portfolio,,,FTD,,,,,
INTS,Intensity Therapeutics Inc.,$3.14 ,INT230-6 (VINblastine CIsplatin) - (INVINCIBLE-3),Early-stage presurgical breast cancer ,Phase 3,18/11/2024 ET,"Phase 3 data reported a median overall survival (""mOS"") of 21.3 months versus a synthetic control of 6.7 months, noted November 18, 2024.",47.06M
Add to portfolio,,,,,,,,
CLDI,Calidi Biotherapeutics Inc.,$2.35 ,CLD-400 - (RTNova),Metastatic Solid Tumors & Lung cancer ,Phase 1,18/11/2024 ET,"Phase 1 data reported that treatment successfully kills and transforms tumor microenvironments and can additionally induce expression of engineered payloads in the tumor cells, noted November 18, 2024 … read more",3.43M
Add to portfolio,,,,,,,,
ALLR,Allarity Therapeutics Inc.,$1.21 ,Stenoparib,Advanced ovarian cancer (AOC) ,Phase 2,18/11/2024 ET,"Phase 2 update reported that two patients exceed 14 months on treatment, noted November 18, 2024.",14.62M
Add to portfolio,,,FTD,,,,,
BMEA,Biomea Fusion Inc.,$6.43 ,Icovamenib (BMF-219) - (COVALENT-111),"Healthy volunteers, type 2 diabetes ",Phase 2,18/11/2024 ET,"Phase 2 trial data presented at ATTD-ASIA reported that 83% of patients with insulin deficiency responded to icovamenib, and showed a greater mean HbA1c reduction at Week 26 compared to baseline, than … read more",59.51M
Add to portfolio,,,,,,,,
ARWR,Arrowhead Pharmaceuticals Inc.,$19.02 ,Plozasiran (ARO-APOC3-3001) - (PALISADE),"Familial chylomicronemia syndrome (FCS), Hypertriglyceridemia ",NDA Filing,18/11/2024 ET,"NDA submitted November 18, 2024.",138.26M
Add to portfolio,,,BTD,,,,,
,,,View Clinical Trial Data,,,,,
ARWR,Arrowhead Pharmaceuticals Inc.,$19.02 ,Plozasiran (ARO-APOC3-2001) - (SHASTA-2),Hypertriglyceridemia ,Phase 2b,18/11/2024 ET,"Additional Phase 2b data reported that 10, 25, or 50 mg of plozasiran in the blinded portion of the studies produced mean reductions up to -74% at 24 weeks, noted November 18, 2024.",138.26M
Add to portfolio,,,View Clinical Trial Data,,,,,
LLY,Eli Lilly and Company,$725.91 ,Tirzepatide - (SUMMIT),Heart failure with preserved ejection fraction (HFpEF) and obesity ,Phase 3,18/11/2024 ET,"Phase 3 data showed a 38% reduction in the risk of heart failure outcomes, noted November 18, 2024.",946.46M
Add to portfolio,,,,,,,,
CYTK,Cytokinetics Incorporated,$51.94 ,Omecamtiv mecarbil - (GALACTIC-HF),Heart failure with reduced ejection fraction (HFrEF) ,Phase 3,18/11/2024 ET,"Phase 3 data shared at AHA reported that there was a significantly higher risk of the primary endpoint of cardiovascular death or heart failure events and all-cause mortality, noted November 18, 2024.",119.66M
Add to portfolio,,,View Clinical Trial Data,,,,,
AMGN,Amgen Inc.,$276.50 ,Omecamtiv mecarbil - (GALACTIC-HF),Heart failure with reduced ejection fraction (HFrEF) ,Phase 3,18/11/2024 ET,"Phase 3 data shared at AHA reported that there was a significantly higher risk of the primary endpoint of cardiovascular death or heart failure events and all-cause mortality, noted November 18, 2024.",538.36M
Add to portfolio,,,View Clinical Trial Data,,,,,
ACET,Adicet Bio Inc.,$0.97 ,ADI-001,Non-Hodgkin’s lymphoma ,Phase 1,18/11/2024 ET,"Phase 1 clinical update presented at ACR reported tissue trafficking and activation, complete depletion of CD19+ B cells within analyzed lymph node tissue was also observed, noted November 18, 2024.",83.25M
Add to portfolio,,,FTD,,,,,
ALGS,Aligos Therapeutics Inc.,$20.12 ,Pevifoscorvir (ALG-000184) - (CAM-2),HBeAg-positive chronic hepatitis B (CHB) ,Phase 1b,18/11/2024 ET,Phase 1a/1b data presented at the Liver Meeting reported that treatment decreased serum total cholesterol in young healthy dogs maintained on a normal diet in the 2-week study at ≥50 µg/kg/day (up to … read more,6.15M
Add to portfolio,,,,,,,,
NAMS,NewAmsterdam Pharma Company N.V.,$24.66 ,Obicetrapib - (BROOKLYN),Heterozygous familial hypercholesterolemia (HeFH) ,Phase 3,18/11/2024 ET,"Phase 3 data presented at AHA showed that the trial met its primary endpoint with an LDL-C mean reduction versus placebo of 36.3% at day 84 and 41.5% at day 365, noted November 18, 2024.",112.63M
Add to portfolio,,,,,,,,
NKTR,Nektar Therapeutics,$1.03 ,NKTR-422,Autoimmune diseases ,Preclinical,18/11/2024 ET,"Preclinical study presented at ACR 2024 demonstrated inflammation resolution and tissue repair in multiple preclinical models of chronic inflammatory conditions, noted November 18, 2024.",19.02M
Add to portfolio,,,,,,,,
JNJ,Johnson & Johnson,$152.32 ,Icotrokinra (JNJ-2113) - (ICONIC-LEAD),Moderate-to-severe psoriasis ,Phase 3,18/11/2024 ET,"Phase 3 study met its co-primary endpoints in patients with moderate to severe plaque psoriasis, noted November 18, 2024.",2.41B
Add to portfolio,,,,,,,,
PTGX,Protagonist Therapeutics Inc.,$40.39 ,Icotrokinra (JNJ-2113) - (ICONIC-LEAD),Moderate-to-severe psoriasis ,Phase 3,18/11/2024 ET,"Phase 3 study met its co-primary endpoints in patients with moderate to severe plaque psoriasis, noted November 18, 2024.",62.21M
Add to portfolio,,,,,,,,
JNJ,Johnson & Johnson,$152.32 ,Icotrokinra (JNJ-2113) - (ICONIC-TOTAL),Moderate-to-severe psoriasis ,Phase 3,18/11/2024 ET,"Phase 3 study showed once daily icotrokinra met the primary endpoint of IGA of 0/1 at week 16 compared to placebo, noted November 18, 2024.",2.41B
Add to portfolio,,,,,,,,
PTGX,Protagonist Therapeutics Inc.,$40.39 ,Icotrokinra (JNJ-2113) - (ICONIC-TOTAL),Moderate-to-severe psoriasis ,Phase 3,18/11/2024 ET,"Phase 3 study showed once daily icotrokinra met the primary endpoint of IGA of 0/1 at week 16 compared to placebo, noted November 18, 2024.",62.21M
Add to portfolio,,,,,,,,
INCY,Incyte Corporation,$76.97 ,MRGPRX2 (INCB000262),Spontaneous urticaria (CSU) ,Phase 2,18/11/2024 ET,"Phase 2 enrollment paused, noted November 18, 2024.",196.32M
Add to portfolio,,,,,,,,
INCY,Incyte Corporation,$76.97 ,MRGPRX4 (INCB000547),Cholestatic pruritus (CP) ,Phase 2,18/11/2024 ET,"Phase 2 study data does not support further development, noted November 18, 2024.",196.32M
Add to portfolio,,,,,,,,
SLN,Silence Therapeutics Plc,$11.02 ,Zerlasiran (formerly SLN360) - (ALPACAR-360),Cardiovascular diseases and Polycythemia vera ,Phase 2,18/11/2024 ET,"Phase 2 data presented at AHA showed significant time-averaged Lp(a) reductions, with effects persisting 60 weeks following the first dose, noted November 18, 2024.",46.8M
Add to portfolio,,,,,,,,
PLRX,Pliant Therapeutics Inc.,$12.32 ,Bexotegrast (PLN-74809) - (INTEGRIS-PSC),Primary sclerosing cholangitis (PSC) ,Phase 2a,18/11/2024 ET,"Phase 2a data presented at AASLD reported a stable ELF score from Week 12 to Week 24, with a reduction in participants with an ELF score of >9.8 at baseline, noted November 18, 2024.",61.39M
Add to portfolio,,,FTD,,,,,
,,,View Clinical Trial Data,,,,,
ALLO,Allogene Therapeutics Inc.,$2.15 ,ALLO-329 - (RESOLUTION),Autoimmune Disease (AID) ,Preclinical,18/11/2024 ET,"Preclinical data shared at ACR demonstrated that ALLO-329 could be effective in treating autoimmune diseases with reduced or no lymphodepleting chemotherapy, noted November 18, 2024.",221.88M
Add to portfolio,,,FTD,,,,,
ALNY,Alnylam Pharmaceuticals Inc.,$232.27 ,Elebsiran (VIR-2218) and tobevibart (VIR-3434) - (SOLSTICE),Hepatitis Delta Virus (HDV) ,Phase 2,18/11/2024 ET,"Phase 2, 24-week data from AASLD reported 100% virologic suppression, noted November 18, 2024.",131.08M
Add to portfolio,,,FTD,,,,,
VIR,Vir Biotechnology Inc.,$7.03 ,Elebsiran (VIR-2218) and tobevibart (VIR-3434) - (SOLSTICE),Hepatitis Delta Virus (HDV) ,Phase 2,18/11/2024 ET,"Phase 2, 24-week data from AASLD reported 100% virologic suppression, noted November 18, 2024.",138.92M
Add to portfolio,,,FTD,,,,,
MIRM,Mirum Pharmaceuticals Inc.,$41.42 ,Volixibat - (VANTAGE),Pruritus associated with primary biliary cholangitis ,Phase 2b,18/11/2024 ET,"Phase 2b data presented at AASLD reported rapid and statistically significant reductions in cholestatic pruritus were observed after treatment, noted November 18, 2024.",50.24M
Add to portfolio,,,,,,,,
ADVM,Adverum Biotechnologies Inc.,$6.85 ,"Lxo-vec (ixoberogene soroparvovec, ADVM-022) - (OPTIC)",Wet age-related macular degeneration (Wet-AMD) ,Phase 2,18/11/2024 ET,"Phase 2 long term data reported that 78% of patients who were injection free through year 1 remained injection free through year 4, noted November 18, 2024.",20.98M
Add to portfolio,,,,,,,,
LUMO,Lumos Pharma Inc.,$4.32 ,LUM-201 - (OraGrowtH212),Pediatric Growth Hormone Deficiency (PGHD) ,Phase 2,18/11/2024 ET,"Phase 2 data presented at ESPE reported that The 1.6 mg/kg dose showed the highest AHV, with a normalized IGF-1 which persisted at 12 months, noted November 18, 2024.",8.65M
Add to portfolio,,,View Clinical Trial Data,,,,,
LLY,Eli Lilly and Company,$725.91 ,Muvalaplin,Heart disease ,Phase 2,18/11/2024 ET,"Phase 2 study met at the 12-week its primary endpoint, noted November 18, 2024.",946.46M
Add to portfolio,,,,,,,,
RCKT,Rocket Pharmaceuticals Inc.,$13.66 ,RP-A501,Danon disease ,Phase 2,18/11/2024 ET,Phase 2 demonstrated safety and meaningful efficacy; all evaluable patients show cardiac LAMP2 expression and ≥10% reduction in LV mass index at 12 months and sustained through most recent follow up ( … read more,107.9M
Add to portfolio,,,BTD,,,,,
FATE,Fate Therapeutics Inc.,$2.27 ,FT819,B-cell Leukemias and Lymphomas ,Phase 1b,18/11/2024 ET,"Phase 1b data presenteed at ACR showed patient treated with fludarabine-free conditioning and single-dose FT819; favorable safety profile with no grade ≥3 adverse events and no events of CRS, ICANS, o … read more",115.33M
Add to portfolio,,,RMAT,,,,,
FATE,Fate Therapeutics Inc.,$2.27 ,FT522,Lupus ,Phase 1,18/11/2024 ET,"Phase 1 initial data showed a favorable safety profile, complete responses, and persistence of FT522 live cells, noted November 18, 2024.",115.33M
Add to portfolio,,,,,,,,
CMMB,Chemomab Therapeutics Ltd.,$1.62 ,nebokitug (CM-101) - (SPRING),Primary Sclerosing Cholangitis ,Phase 2,19/11/2024 ET,"Phase 2 data presented at AASLD met the trial's primary endpoint, demonstrating a favorable safety profile over the 15-week treatment period on November 19, 2024.",5.19M
Add to portfolio,,,FTD,,,,,
MRK,Merck & Company Inc.,$95.76 ,KEYTRUDA QLEX (pembrolizumab and berahyaluronidase alfa-pmph),Solid tumors ,Phase 3,19/11/2024 ET,"Phase 3 data reported that the trial met its primary endpoint, noted November 19, 2024.",2.5B
Add to portfolio,,,,,,,,
PHIO,Phio Pharmaceuticals Corp.,$2.55 ,PH-762,Cutaneous Squamous Cell Carcinoma ,Phase 1b,19/11/2024 ET,"Phase 1b 2nd cohort completion, noted November 19, 2024.",5.73M
Add to portfolio,,,,,,,,
GSK,GSK plc American Depositary Shares (Each representing two),$33.10 ,Linerixibat - (GLISTEN),Primary biliary cholangitis (PBC) ,Phase 3,19/11/2024 ET,"Phase 3 trial met primary endpoint, noted November 19, 2024.",2.03B
Add to portfolio,,,,,,,,
BIIB,Biogen Inc.,$155.43 ,Dapirolizumab pegol (anti-CD40L),Systemic lupus erythematosus ,Phase 3,19/11/2024 ET,Phase 3 data reported that a greater response was observed across multiple clinical endpoints among participants treated with DZP including 50% less severe disease flares compared to participants on s … read more,146.61M
Add to portfolio,,,View Clinical Trial Data,,,,,
ALGS,Aligos Therapeutics Inc.,$18.50 ,Pevifoscorvir (ALG-000184) - (CAM-2),HBeAg-positive chronic hepatitis B (CHB) ,Phase 1b,19/11/2024 ET,"Phase 1a/1b data presented at AALSD from ≤84 weeks demonstrated sustained HBV DNA suppression in 7/7 (100%) HBeAg-positive CHB subjects, noted November 19, 2024.",6.15M
Add to portfolio,,,,,,,,
NVO,Novo Nordisk A/S,$102.63 ,Icosema - (COMBINE 3),Type 2 diabetes ,Phase 3,19/11/2024 ET,"Phase 3a data reported that treatment had safe and well-tolerated profile, noted November 19, 2024.",4.47B
Add to portfolio,,,,,,,,
GOVX,GeoVax Labs Inc.,$2.91 ,COVID-19 booster with GEO-CM04S1 or Pfizer-BioNTech Bivalent vaccine,"COVID-19 Infection, Chronic Lymphocytic Leukemia ",Phase 2,19/11/2024 ET,"Phase 2 DSMB review of interim data completed, the DSMB determined that, while the mRNA control arm of the study failed to meet the predetermined primary endpoint, the study should continue enrollment … read more",25.36M
Add to portfolio,,,,,,,,
PHRRF,PharmaTher Holdings Ltd,$0.15 ,KETARX (ketamine),Surgical pain management ,CRL,19/11/2024 ET,"The FDA granted the Meeting scheduled for December 2, 2024. Company initiated activities to address the deficiencies cited in the CRL, noted November 19, 2024.",91.02M
Add to portfolio,,,FTD,,,,,
NXTC,NextCure Inc.,$1.31 ,NC605,Osteogenesis Imperfecta (OI) ,Preclinical,19/11/2024 ET,"Preclinical data demonstrating that treatment with NC605, a novel anti-Siglec-15 (S15) antibody, resulted in enhanced generation of quality bone with better mechanical properties, noted November 19, … read more",2.68M
Add to portfolio,,,,,,,,
LTRN,Lantern Pharma Inc.,$3.08 ,LP-300 - (Harmonic),Non-small cell lung cancer (NSCLC) ,Phase 2,19/11/2024 ET,"Phase 2 additional expansion cohort dosing initiated, noted November 19, 2024.",10.8M
Add to portfolio,,,,,,,,
OCGN,"Ocugen, Inc.",$0.87 ,OCU410 - (ArMaDa),Geographic Atrophy (GA) ,Phase 1/2,19/11/2024 ET,"Phase 1/2 preliminary data showed an considerably slower lesion growth (21.4%) from baseline in treated vs. untreated fellow eyes that followed the natural history of the disease, noted November 19, 2 … read more",292.3M
Add to portfolio,,,,,,,,
SGMO,Sangamo Therapeutics Inc.,$1.96 ,ST-503,Chronic neuropathic pain ,Phase 1/2,19/11/2024 ET,"IND Clearance by the FDA, noted November 19, 2024.",301.71M
Add to portfolio,,,,,,,,
VKTX,Viking Therapeutics Inc.,$51.51 ,VK2809 - (VOYAGE),Non-alcoholic steatohepatitis (NASH) and fibrosis ,Phase 2b,19/11/2024 ET,"Phase 2b 52 week data presented at AASLD summarized results including successful achievement of study's primary and secondary endpoints, noted November 19, 2024.",113.04M
Add to portfolio,,,View Clinical Trial Data,,,,,
LGND,Ligand Pharmaceuticals Incorporated,$111.80 ,VK2809 - (VOYAGE),Non-alcoholic steatohepatitis (NASH) and fibrosis ,Phase 2b,19/11/2024 ET,"Phase 2b 52 week data presented at AASLD summarized results including successful achievement of study's primary and secondary endpoints, noted November 19, 2024.",19.6M
Add to portfolio,,,View Clinical Trial Data,,,,,
CRDL,Cardiol Therapeutics Inc.,$1.65 ,CardiolRx - (MAvERIC-Pilot),Recurrent Pericarditis ,Phase 2,19/11/2024 ET,"The phase 2 study marked rapid reductions in pericarditis pain and inflammation throughout the 26-week study. Episodes of pericarditis per year substantially reduced, noted November 18, 2024.",83.73M
Add to portfolio,,,ODD,,,,,
SAGE,Sage Therapeutics Inc.,$4.91 ,Dalzanemdor (SAGE-718) - (DIMENSION),Huntington's disease (HD) ,Phase 2,20/11/2024 ET,"Phase 2 topline data reported that the trial did not meet its primary endpoint, noted November 20, 2024.",62.78M
Add to portfolio,,,,,,,,
SUPN,Supernus Pharmaceuticals Inc.,—,Dalzanemdor (SAGE-718) - (DIMENSION),Huntington's disease (HD) ,Phase 2,20/11/2024 ET,"Phase 2 topline data reported that the trial did not meet its primary endpoint, noted November 20, 2024.",56.07M
Add to portfolio,,,,,,,,
ARGX,argenx SE,$591.82 ,Efgartigimod - (ALKIVIA),"Myositis subsets (Immune-mediated necrotizing myopathy (IMNM), anti-synthetase syndrome (ASyS), and dermatomyositis (DM)) ",Phase 2/3,20/11/2024 ET,"Phase 2/3 data reported that the trial met its primary endpoint, noted November 20, 2024.",60.99M
Add to portfolio,,,,,,,,
CLDX,Celldex Therapeutics Inc.,$26.40 ,CDX-622,Chronic inflammation ,Phase 1a,20/11/2024 ET,"Phase 1a dosing commenced, noted November 20, 2024.",66.41M
Add to portfolio,,,,,,,,
PRFX,PainReform Ltd.,$4.16 ,PRF-110,Bunionectomy ,Phase 3,20/11/2024 ET,"Phase 3 partial topline data indicated that PRF-110 demonstrated statistically significant superiority over placebo in reducing pain during the first 48 hours following surgery, noted November 20, 202 … read more",1.89M
Add to portfolio,,,,,,,,
ONVO,Organovo Holdings Inc.,$0.35 ,FXR314 with Tofacitinib,Inflammatory Bowel Disease ,Preclinical,20/11/2024 ET,"Preclinical data reported results with encouraging data in liver fat but did not demonstrate the expected toxicities of this class, noted November 20, 2024.",1.8M
Add to portfolio,,,,,,,,
VYGR,Voyager Therapeutics Inc.,$5.36 ,VY1706,Alzheimer's disease ,Preclinical,20/11/2024 ET,"Preclinical candidate VY1706 demonstrated significant reductions of tau at low doses in NHP study, noted November 20, 2024. I",55.47M
Add to portfolio,,,,,,,,
NAMS,NewAmsterdam Pharma Company N.V.,$20.01 ,Obicetrapib & ezetimibe - (TANDEM),Cardiovascular disease ,Phase 3,20/11/2024 ET,"Phase 3 study achieved all co-primary endpoints of LS mean reduction in LDL-C on top of maximally tolerated lipid-modifying therapies versus each of placebo, ezetimibe 10 mg, and obicetrapib 10 mg mon … read more",112.63M
Add to portfolio,,,,,,,,
VRTX,Vertex Pharmaceuticals Incorporated,$451.23 ,Povetacicept (ALPN-303) - (RAINIER),"Lupus nephritis, IgA nephropathy ",Phase 1/2,20/11/2024 ET,"Phase 1b/2a study achieved a 90% reduction in leukemic blasts within the first 30 days of treatment, continuing the overall efficacy trend seen in prior studies, noted November 20, 2024.",256.39M
Add to portfolio,,,,,,,,
ALPN,Alpine Immune Sciences Inc.,—,Povetacicept (ALPN-303) - (RAINIER),"Lupus nephritis, IgA nephropathy ",Phase 1/2,20/11/2024 ET,"Phase 1b/2a study achieved a 90% reduction in leukemic blasts within the first 30 days of treatment, continuing the overall efficacy trend seen in prior studies, noted November 20, 2024.",68.6M
Add to portfolio,,,,,,,,
PBYI,Puma Biotechnology Inc,$2.84 ,PUMA-ALI-1201 - (ALISCA-Breast1),HER-2 Recurrent or metastatic breast cancer ,Phase 2,20/11/2024 ET,"Phase 2 was initiated, noted November 20, 2024.",50.37M
Add to portfolio,,,,,,,,
RXRX,Recursion Pharmaceuticals Inc.,$6.04 ,REC-4881,AXIN1 or APC Mutant Cancers ,Phase 2,20/11/2024 ET,"Phase 2 was deprioritized as part of a disciplined strategic portfolio prioritization, noted November 20, 2024.",434.15M
Add to portfolio,,,ODD,,,,,
PYXS,Pyxis Oncology Inc.,$3.82 ,PYX-201-101,Pancreatic Cancer ,Phase 1,20/11/2024 ET,"Phase 1 preliminary clinical data achieved a confirmed 50% objective response rate (ORR) based on RECIST 1.1 criteria, including one complete response and a disease control rate (DCR) of 100% in six h … read more",62.02M
Add to portfolio,,,ODD,,,,,
,,,FTD,,,,,
KTTA,Pasithea Therapeutics Corp.,$3.19 ,PAS-004,Neurofibromatosis Type 1 (NF1) and solid tumors ,Phase 1,20/11/2024 ET,"Phase 1 external Safety Review Committee recommended proceeding to cohort 4, 15mg capsule, without modifications. This recommendation was based on the absence of any dose limiting toxicities (DLT's), … read more",7.44M
Add to portfolio,,,,,,,,
PALI,Palisade Bio Inc.,$2.44 ,PALI-2108,Moderate-to-severe ulcerative colitis (UC) ,Preclinical,21/11/2024 ET,"Preclinical data reported that treatment reduced key intracellular markers of inflammation and fibrosis in the colon, including PDE4B expression, while increasing cAMP levels, noted November 21, 2024.",9.12M
Add to portfolio,,,,,,,,
XBIO,Xenetic Biosciences Inc.,$4.01 ,DNase I,Melanoma Lung Metastasis ,Preclinical,21/11/2024 ET,"Preclinical data demonstrated to significantly suppress metastatic tumor burden, decreases the number of metastatic foci, and substantially prolongs survival compared to the CAR T cell monotherapy gro … read more",1.54M
Add to portfolio,,,,,,,,
TELO,Telomir Pharmaceuticals Inc.,$4.47 ,Telomir-1,Age-related conditions ,Preclinical,21/11/2024 ET,"Preclinical results confirmed the efficacy of Telomir-1 to turn back the biological clock and support longevity effectively, noted November 21, 2024.",32.28M
Add to portfolio,,,,,,,,
QURE,uniQure N.V.,$5.85 ,AMT-260 - (GenTLE),Refractory Temporal Lobe Epilepsy (rTLE) ,Phase 1/2,21/11/2024 ET,"Phase 1/2a trial dosing commenced, noted November 21, 2024.",54.87M
Add to portfolio,,,,,,,,
LUMO,Lumos Pharma Inc.,$4.33 ,LUM-201 - (OraGrowtH210),Pediatric Growth Hormone Deficiency (PGHD) ,Phase 2,21/11/2024 ET,"Phase 2 data reported a significant increase over baseline in Annualized Height Velocity (AHV) was observed for the combined 1.6 and 3.2 mg/kg/day doses. At baseline, AHV was 4.6 cm/yr for 37 subjects … read more",8.65M
Add to portfolio,,,View Clinical Trial Data,,,,,
BGNE,BeiGene Ltd.,$194.56 ,Ziihera (zanidatamab-hrii),HER2-amplified biliary tract cancers ,Approved,21/11/2024 ET,"Approved November 21, 2024.",106.62M
Add to portfolio,,,View Clinical Trial Data,,,,,
ONC,BeOne Medicines Ltd.,—,Ziihera (zanidatamab-hrii),HER2-amplified biliary tract cancers ,Approved,21/11/2024 ET,"Approved November 21, 2024.",110.03M
Add to portfolio,,,View Clinical Trial Data,,,,,
JAZZ,Jazz Pharmaceuticals plc,$125.10 ,Ziihera (zanidatamab-hrii),HER2-amplified biliary tract cancers ,Approved,21/11/2024 ET,"Approved November 21, 2024.",60.66M
Add to portfolio,,,View Clinical Trial Data,,,,,
ZYME,Zymeworks Inc.,$13.68 ,Ziihera (zanidatamab-hrii),HER2-amplified biliary tract cancers ,Approved,21/11/2024 ET,"Approved November 21, 2024.",75.17M
Add to portfolio,,,View Clinical Trial Data,,,,,
AMRX,Amneal Pharmaceuticals Inc.,$8.32 ,Brekiya (dihydroergotamine mesylate) injection,Migraine with or without aura and cluster headache in adults ,NDA Filing,21/11/2024 ET,"Resubmitted NDA November 21, 2024.",314.08M
Add to portfolio,,,,,,,,
CATX,Isoray. (DE),$3.47 ,[212Pb]VMT-α-NET,Neuroendocrine tumors (NETs) ,Phase 1,22/11/2024 ET,"Phase 1 data reported that eight of nine patients had durable control of disease, noted November 22, 2024.",74.26M
Add to portfolio,,,,,,,,
PSTV,PLUS THERAPEUTICS Inc.,$1.18 ,CNSide - (FORESEE),Breast or Non-Small Cell Lung Cancer (NSCLC) who have suspicious or confirmed Leptomeningeal Metastases (LM) ,Phase 2,22/11/2024 ET,"Additional trial data demonstrated enhanced sensitivity in detecting tumor cells (80%) vs. CSF cytology (29%) in patients with LM, noted November 22, 2024.",99.26M
Add to portfolio,,,,,,,,
VRPX,Virpax Pharmaceuticals Inc.,$0.57 ,Probudur,Pain Relief ,Preclinical,22/11/2024 ET,"Preclinical data results from a minipig Dose Range Finding (DRF) study for Probudur demonstrated positive tolerance to it, and no adverse effects were reported, noted November 22, 2024.",1.28M
Add to portfolio,,,,,,,,
AZN,AstraZeneca PLC,$64.71 ,Attruby (Acoramidis) - (ATTRibute-CM),Amyloid cardiomyopathy (ATTR-CM) ,Approved,22/11/2024 ET,"FDA approved on November 22, 2024.",3.1B
Add to portfolio,,,View Clinical Trial Data,,,,,
BBIO,BridgeBio Pharma Inc.,$23.42 ,Attruby (Acoramidis) - (ATTRibute-CM),Amyloid cardiomyopathy (ATTR-CM) ,Approved,22/11/2024 ET,"FDA approved on November 22, 2024.",191.17M
Add to portfolio,,,View Clinical Trial Data,,,,,
CNSP,CNS Pharmaceuticals Inc.,$6.22 ,Berubicin,Glioblastoma (GBM) (adult) ,Phase 2,22/11/2024 ET,"Phase 2 update reported a slightly greater percentage of patients with all grades or Grades 3-5 with anaemia, headache, and decrease in neutrophil counts were shown in patients receiving Berubicin, wh … read more",574.58K
Add to portfolio,,,FTD,,,,,
,,,ODD,,,,,
,,,View Clinical Trial Data,,,,,
PSTV,PLUS THERAPEUTICS Inc.,$1.18 ,REYOBIQ (rhenium Re186 obisbemeda) - (ReSPECT-LM),Leptomeningeal metastases (LM) ,Phase 1,22/11/2024 ET,"Phase 1 data presented at SNO reported 86% (12/14 patients), with 2 responses and 10 stable cases, noted on November 22, 2024.",99.26M
Add to portfolio,,,FTD,,,,,
,,,ODD,,,,,
MRK,Merck & Company Inc.,$100.35 ,WINREVAIR (sotatercept-csrk) - (ZENITH),"Pulmonary arterial hypertension (PAH, WHO* Group 1) ",Phase 3,25/11/2024 ET,"Phase 3 trial met primary endpoint, noted November 25, 2024.",2.5B
Add to portfolio,,,,,,,,
AZN,AstraZeneca PLC,$65.47 ,Truqap - (CAPItello-281),Dephosphorylated Phosphatase and Tensin Homolog (dPTEN) Hormone-Sensitive Prostate Cancer (HSPC) ,Phase 3,25/11/2024 ET,"Phase 3 trial data demonstrated a statistically significant and clinically meaningful improvement in the primary endpoint of radiographic progression-free survival (rPFS), noted November 25, 2024.",3.1B
Add to portfolio,,,,,,,,
INAB,IN8bio Inc.,$0.30 ,INB-200,Glioblastoma ,Phase 1,25/11/2024 ET,Phase 1 study presented at SNO reported that 50% of patients who received repeated doses (n=10) remained alive and in remission beyond the expected median OS from standard-of-care Stupp regimen while … read more,4.54M
Add to portfolio,,,,,,,,
CGTX,Cognition Therapeutics Inc.,$0.41 ,Zervimesine (CT1812) - (SHINE),Mild-to-Moderate Alzheimer's Disease ,Phase 2,25/11/2024 ET,"Phase 2 additional analysis demonstrated that individuals who entered the study with plasma p-tau217 below the median experienced a normalization of several key indicators, such as the neuroinflammato … read more",73.47M
Add to portfolio,,,View Clinical Trial Data,,,,,
SAVA,Cassava Sciences Inc.,$4.30 ,Simufilam (PTI-125) - (RETHINK-ALZ),Alzheimer’s disease ,Phase 3,25/11/2024 ET,"Phase 3 trial did not meet primary endpoint, noted November 25, 2024.",48.31M
Add to portfolio,,,View Clinical Trial Data,,,,,
CTXR,Citius Pharmaceuticals Inc.,$3.34 ,Mino-Lok,Catheter related blood stream infection (CRBSI) ,Phase 3,25/11/2024 ET,"Phase 3 EoP Type C Meeting with the FDA resulted in clear, constructive, and actionable guidance underscoring a pathway to support a future NDA submission, noted November 25, 2024.",17.01M
Add to portfolio,,,View Clinical Trial Data,,,,,
BMY,Bristol-Myers Squibb Company,$58.14 ,Taldefgrobep - (RESILIENT),Spinal Muscular Atrophy (SMA) ,Phase 3,25/11/2024 ET,Phase 3 topline results reported clinically meaningful improvements in motor function at all timepoints on the Motor Function Measurement-32 scale (MFM-32) but the treatment arm did not statistically … read more,2.04B
Add to portfolio,,,FTD,,,,,
,,,ODD,,,,,
PFE,Pfizer Inc.,$25.75 ,Taldefgrobep - (RESILIENT),Spinal Muscular Atrophy (SMA) ,Phase 3,25/11/2024 ET,Phase 3 topline results reported clinically meaningful improvements in motor function at all timepoints on the Motor Function Measurement-32 scale (MFM-32) but the treatment arm did not statistically … read more,5.69B
Add to portfolio,,,FTD,,,,,
,,,ODD,,,,,
BHVN,Biohaven Ltd.,$45.23 ,Taldefgrobep - (RESILIENT),Spinal Muscular Atrophy (SMA) ,Phase 3,25/11/2024 ET,Phase 3 topline results reported clinically meaningful improvements in motor function at all timepoints on the Motor Function Measurement-32 scale (MFM-32) but the treatment arm did not statistically … read more,105.79M
Add to portfolio,,,FTD,,,,,
,,,ODD,,,,,
TNYA,Tenaya Therapeutics Inc.,$2.96 ,TN-401 - (RIDGE-1),Arrhythmogenic Right Ventricular Cardiomyopathy ,Phase 1b,25/11/2024 ET,"Phase 1b dosing commenced, noted on November 25, 2024.",162.98M
Add to portfolio,,,ODD,,,,,
ABBV,AbbVie Inc.,$175.38 ,AL002 - (INVOKE-2),Alzheimer’s disease ,Phase 2,25/11/2024 ET,"Phase 2 failed to meet primary and secondary endpoints. Based upon the results, Alector is stopping the long-term extension study, noted November 25, 2024.",1.77B
Add to portfolio,,,View Clinical Trial Data,,,,,
ALEC,Alector Inc.,$3.96 ,AL002 - (INVOKE-2),Alzheimer’s disease ,Phase 2,25/11/2024 ET,"Phase 2 failed to meet primary and secondary endpoints. Based upon the results, Alector is stopping the long-term extension study, noted November 25, 2024.",101.21M
Add to portfolio,,,View Clinical Trial Data,,,,,
ALEC,Alector Inc.,$3.96 ,AL101/GSK4527226 - (PROGRESS-AD),Early Alzheimer's disease (AD) ,Phase 2,25/11/2024 ET,"Phase 2 study reached a third of target enrollment, noted November 25, 2024.",101.21M
Add to portfolio,,,,,,,,
GSK,GSK plc American Depositary Shares (Each representing two),$33.78 ,AL101/GSK4527226 - (PROGRESS-AD),Early Alzheimer's disease (AD) ,Phase 2,25/11/2024 ET,"Phase 2 study reached a third of target enrollment, noted November 25, 2024.",2.03B
Add to portfolio,,,,,,,,
AMGN,Amgen Inc.,$277.74 ,AMG 133 (maridebart cafraglutide) - (MariTide),Obesity and without diabetes ,Phase 2,26/11/2024 ET,"Phase 2 52-week data demonstrated up to ~20% average weight loss at week 52 without a weight loss plateau, indicating the potential for further weight loss beyond 52 weeks, noted November 26, 2024.",538.36M
Add to portfolio,,,,,,,,
PTCT,PTC Therapeutics Inc.,$46.01 ,PTC857 - (CardinALS),Amyotrophic Lateral Sclerosis (ALS) ,Phase 2,26/11/2024 ET,"Phase 2 study failed to meet primary and secondary efficacy endpoints. Due to the lack of efficacy and biomarker signal, further development is not planned at this time, noted November 26, 2024.",79.44M
Add to portfolio,,,,,,,,
PRTG,Portage Biotech Inc.,$4.87 ,PORT-6 - (ADPORT-601),A2A & A2B High Solid Tumors ,Phase 1a,26/11/2024 ET,"The Phase 1a trial was paused for further patient accrual pending additional financial resources and data analysis, as noted on November 26, 2024.",2.28M
Add to portfolio,,,,,,,,
VALN,Valneva SE,$4.00 ,IXCHIQ (VLA1553-303),Chikungunya vaccine ,BLA Filing,26/11/2024 ET,"BLA submitted, noted November 26, 2024.",81.26M
Add to portfolio,,,,,,,,
LTRN,Lantern Pharma Inc.,$3.07 ,LP-184 (STAR-001),Solid tumors ,Preclinical,26/11/2024 ET,"Preclinical data, including previously published research by Lantern Pharma, demonstrate an up to 6-fold increase in GBM cell sensitivity when LP-184 is combined with spironolactone, noted November 26 … read more",10.8M
Add to portfolio,,,FTD,,,,,
LXRX,Lexicon Pharmaceuticals Inc.,$0.82 ,Pilavapadin (LX9211) - (PROGRESS),Diabetic Peripheral Neuropathic Pain (DPNP) ,Phase 2b,26/11/2024 ET,"Phase 2b enrollment completed, noted November 26, 2024.",363.4M
Add to portfolio,,,FTD,,,,,
OTLK,Outlook Therapeutics Inc.,$1.70 ,ONS-5010 / LYTENAVA (bevacizumab-vikg) - (NORSE EIGHT),Wet age-related macular degeneration (wet AMD) ,Phase 3,27/11/2024 ET,"NORSE EIGHT trial did not meet the SPA primary endpoint, noted November 27, 2024.",44.42M
Add to portfolio,,,BTD,,,,,
CRVO,CervoMed Inc.,$9.16 ,Neflamapimod - (RewinD-LB),Dementia with Lewy bodies (DLB) ,Phase 2b,27/11/2024 ET,"Phase 2b Orphan Drug Designation granted on November 27, 2024.",9.25M
Add to portfolio,,,ODD,,,,,
SLS,SELLAS Life Sciences Group Inc.,$1.17 ,Tambiciclib (SLS009) (GFH009) with venetoclax,"Hematologic malignancies, acute myeloid leukemia (AML), chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL) and lymphoma ",Preclinical,27/11/2024 ET,"Preclinical data reported CRC MSI-H, ASXL1 mutations were observed in 7/12 (58%) of PDCs, aligning with predicted frequency of ~55%, noted November 27, 2024.",105.3M
Add to portfolio,,,ODD,,,,,
,,,FTD,,,,,
,,,RPDD,,,,,
APLT,Applied Therapeutics Inc.,$8.57 ,Govorestat (AT-007) - (ACTION-Galactosemia kids),Galactosemia ,CRL,27/11/2024 ET,"CRL announced November 27, 2024.",144.01M
Add to portfolio,,,FTD,,,,,
,,,View Clinical Trial Data,,,,,
MRUS,Merus N.V.,$48.53 ,Petosemtamab (MCLA-158),"Recurrent/metastatic (r/m) head and neck squamous cell carcinoma (HNSCC), Solid Tumors ",Phase 2,02/12/2024 ET,"Phase 2 additional data from ESMO Asia Congress reported 1 complete response, 3 PRs, and 1 unconfirmed PR, noted December 2, 2024.",75.63M
Add to portfolio,,,BTD,,,,,
GMAB,Genmab A/S,—,Petosemtamab (MCLA-158),"Recurrent/metastatic (r/m) head and neck squamous cell carcinoma (HNSCC), Solid Tumors ",Phase 2,02/12/2024 ET,"Phase 2 additional data from ESMO Asia Congress reported 1 complete response, 3 PRs, and 1 unconfirmed PR, noted December 2, 2024.",661.87M
Add to portfolio,,,BTD,,,,,
APGE,Apogee Therapeutics Inc.,$46.14 ,APG808,"Healthy volunteer, asthma, COPD ",Phase 1,02/12/2024 ET,"Phase 1 PK data reported that treatment was well-tolerated with half-life of approximately 55 days, supporting potential for 2- to 3- month dosing and demonstrating deep and sustained inhibition of bi … read more",59.6M
Add to portfolio,,,,,,,,
SNTI,Senti Biosciences Inc.,$10.00 ,SENTI-202,Acute Myeloid Leukemia (AML) ,Phase 1,02/12/2024 ET,"Phase 1 initial data reported that 2 of 3 patients achieved MRD negative CR in the first dose level evaluated in the trial with a generally well-tolerated preliminary safety profile, noted December 2, … read more",26.16M
Add to portfolio,,,ODD,,,,,
NVCR,NovoCure Limited,$29.85 ,Tumor Treating Fields (TTFields) - (PANOVA-3),Pancreatic cancer ,Phase 3,02/12/2024 ET,"Phase 3 final data showed that study met its primary endpoint with a statistically significant improvement in overall survival for patients, noted December 2, 2024.",111.8M
Add to portfolio,,,View Clinical Trial Data,,,,,
PPBT,Purple Biotech Ltd.,$8.40 ,CM24 and OPDIVO (nivolumab),2L metastatic pancreatic cancer (PDAC) ,Phase 2,02/12/2024 ET,"Phase 2 Final data demonstrated that combination showed clear and consistent improvement across all efficacy endpoints, noted December 2, 2024.",2.65M
Add to portfolio,,,,,,,,
SNGX,Soligenix Inc.,$3.32 ,HyBryte (synthetic hypericin) - (HPN-CTCL-04),Cutaneous T-Cell Lymphoma ,Phase 1,02/12/2024 ET,"Trial data reported a statistically significantly improved compared to the Valchlor treated plaques (63%, [10/16] treatment success with HyBryte™ vs. 17%, [2/12] with Valchlor, p=0.02), noted December … read more",4.29M
Add to portfolio,,,,,,,,
RVMD,Revolution Medicines Inc - Ordinary Shares,$51.80 ,Daraxonrasib (RMC-6236) - (RASolute 302),Metastatic pancreatic ductal adenocarcinoma (PDAC) ,Phase 1,02/12/2024 ET,"Phase 1 data reported an objective response rate (ORR) of 36% and 27% in patients with PDAC harboring a KRAS G12X mutation and patients with PDAC harboring any RAS mutation, respectively, noted Decemb … read more",186.93M
Add to portfolio,,,BTD,,,,,
,,,ODD,,,,,
RVMD,Revolution Medicines Inc - Ordinary Shares,$51.80 ,Elironrasib (RMC-6291),Solid Tumors ,Phase 1b,02/12/2024 ET,"Phase 1b data reported an ORR of 25%, in the cohort of RMC-6291 in combination RMC-6236, noted December 2, 2024.",186.93M
Add to portfolio,,,BTD,,,,,
RIGL,Rigel Pharmaceuticals Inc.,$27.05 ,R289,Myeloid dysplastic syndrome (MDS) ,Phase 1/2,02/12/2024 ET,"FDA Fast track designation granted by the FDA, noted December 2, 2024.",17.94M
Add to portfolio,,,FTD,,,,,
,,,ODD,,,,,
JNJ,Johnson & Johnson,$153.57 ,TREMFYA (guselkumab),Pediatric Juvenile Psoriatic Arthritis ,BLA Filing,02/12/2024 ET,"BLA submission on December 2, 2024.",2.41B
Add to portfolio,,,,,,,,
JANX,Janux Therapeutics Inc.,$40.18 ,PSMA-TRACTr (JANX007) - (ENGAGER-PSMA-01),Metastatic castration-resistant prostate cancer (mCPRC) ,Phase 1,02/12/2024 ET,"Phase 1a interim update achieved 100% PSA50 declines, 63% PSA90 declines, and 31% PSA99 declines, with durable responses observed at ≥12 weeks. Anti-tumor activity showed a 50% objective response rat … read more",60.09M
Add to portfolio,,,,,,,,
JSPR,Jasper Therapeutics Inc.,$23.97 ,Briquilimab - (ETESIAN),Asthma ,Phase 1/2,02/12/2024 ET,"Phase 1b/2a dosing initiated, noted December 2, 2024.",16.25M
Add to portfolio,,,,,,,,
BCTX,BriaCell Therapeutics Corp.,$16.65 ,Bria-IMT - (BRIA-ABC),Advanced breast cancer ,Phase 2,02/12/2024 ET,"Phase 3 DSMB recommended continuation of the study, noted December 3, 2024.",1.76M
Add to portfolio,,,,,,,,
SYRE,Spyre Therapeutics Inc.,$27.65 ,SPY002,Inflammatory Bowel Disease (IBD) ,Phase 1,02/12/2024 ET,"Phase 1 dosing initiated, noted December 2, 2024.",60.4M
Add to portfolio,,,,,,,,
JNJ,Johnson & Johnson,—,CAPLYTA (lumateperone) - (Study 502),Major depressive disorder (MDD) ,sNDA Filing,03/12/2024 ET,"sNDA submitted December 3, 2024.",2.41B
Add to portfolio,,,,,,,,
TELO,Telomir Pharmaceuticals Inc.,$4.88 ,Telomir-1,Age-related conditions ,Preclinical,03/12/2024 ET,"Preclinical results reported success demonstrating age reversal, longevity, and increased healthspan, noted December 3, 2024.",32.28M
Add to portfolio,,,,,,,,
CRBP,Corbus Pharmaceuticals Holdings Inc.,$16.75 ,CRB-701 (SYS6002) with Pembrolizumab,"Solid tumors, Locally advanced or metastatic urothelial carcinoma ",Phase 1,03/12/2024 ET,"Fast Track Designation granted by the FDA, noted December 3, 2024.",12.26M
Add to portfolio,,,FTD,,,,,
TERN,Terns Pharmaceuticals Inc.,$6.36 ,TERN-701 - (CARDINAL),Chronic myeloid leukemia (CML) ,Phase 1,03/12/2024 ET,"Phase 1 study showed a safety profile with no dose-limiting toxicities, adverse event-related treatment discontinuations, or dose reductions across three dose escalation cohorts, noted December 3, 202 … read more",87.51M
Add to portfolio,,,ODD,,,,,
ROIV,Roivant Sciences Ltd.,$12.12 ,Namilumab - (RESOLVE-Lung),Sarcoidosis ,Phase 2,03/12/2024 ET,"Phase 2 data did not meet its primary endpoints. Further development of namilumab for the treatment of sarcoidosis will be discontinued, as noted on December 3, 2024.",682.88M
Add to portfolio,,,,,,,,
PALI,Palisade Bio Inc.,$2.28 ,PALI-2108,Moderate-to-severe ulcerative colitis (UC) ,Phase 1,03/12/2024 ET,"Phase 1 data reported no treatment related adverse events, noted December 3, 2024.",9.12M
Add to portfolio,,,,,,,,
TRVI,Trevi Therapeutics Inc.,$2.78 ,Haduvio - (Human Abuse Potential trial),Abuse Potential study ,Phase 1,03/12/2024 ET,"The phase 1 study showed statistically significant lower ""Drug Liking"" scores for clinical doses of oral nalbuphine (81mg and 162mg) compared to IV butorphanol (6mg), supporting its low abuse potentia … read more",121.78M
Add to portfolio,,,,,,,,
LTRN,Lantern Pharma Inc.,$3.19 ,LP-184,Triple Negative Breast Cancer (TNBC) ,Phase 1a,03/12/2024 ET,"FDA granted Fast Track Designation on December 3, 2024.",10.8M
Add to portfolio,,,FTD,,,,,
ENLV,Enlivex Therapeutics Ltd.,$1.30 ,Allocetra - (ENX-CL-05-001),Knee osteoarthritis (OA) ,Phase 1/2,03/12/2024 ET,"Phase 1/2 treatment showed significant improvements in pain (50% reduction, p<0.0007), functionality (42%, p<0.0008), and stiffness (37%, p<0.003) at three months, with no serious adverse reactions, n … read more",23.85M
Add to portfolio,,,,,,,,
RXRX,Recursion Pharmaceuticals Inc.,$7.09 ,REC-1245 - (DAHLIA),Solid tumors ,Phase 1,03/12/2024 ET,"Phase 1 dosing initiated, noted December 3, 2024.",434.15M
Add to portfolio,,,,,,,,
ELTX,Elicio Therapeutics Inc.,$5.00 ,ELI-002 - (AMPLIFY-7P),mKRAS-driven cancers ,Phase 2,03/12/2024 ET,"Phase 2 enrollment completed, noted December 3, 2024",16.34M
Add to portfolio,,,,,,,,
TEVA,Teva Pharmaceutical Industries Limited American Depositary Shares,$17.80 ,AJOVY (fremanezumab-vfrm),Episodic migraine in children and adolescent patients aged 6-17 years who weigh 45 kilograms (99 pounds) or more ,Phase 3,04/12/2024 ET,"Phase 3 data reported a significant reduction in monthly migraine & headaches days (MMD) vs placebo, noted December 4, 2024.",1.15B
Add to portfolio,,,,,,,,
LLY,Eli Lilly and Company,$828.37 ,Zepbound (tirzepatide) - (SURMOUNT-5),Obesity ,Phase 3,04/12/2024 ET,"Phase 3 data reported that participants using Zepbound lost 50.3 lbs (22.8 kg) and participants on Wegovy lost 33.1 lbs (15.0 kg), noted December 4, 2024.",946.46M
Add to portfolio,,,,,,,,
AVIR,Atea Pharmaceuticals Inc.,$3.12 ,SVR12 in combination of bemnifosbuvir and ruzasvir,Hepatitis C virus (HCV) ,Phase 2,04/12/2024 ET,"Phase 2 data met its primary endpoints of safety and sustained virologic response at 12 weeks post-treatment (SVR12), noted December 4, 2024.",79.36M
Add to portfolio,,,,,,,,
RLMD,Relmada Therapeutics Inc.,$0.63 ,REL-1017 - (RELIANCE II),Major depressive disorder (MDD) ,Phase 3,04/12/2024 ET,"Phase 3 pre-planned interim analysis conducted by IDMC indicated that the Reliance II Phase 3 study is futile and is unlikely to meet the primary efficacy endpoint with statistical significance, note … read more",33.19M
Add to portfolio,,,FTD,,,,,
APVO,Aptevo Therapeutics Inc.,$10.00 ,APVO442 (PSMA x CD3),PSMA-expressing prostate tumor cells ,Preclinical,04/12/2024 ET,"Preclinical study showed that the molecule readily localizes to solid tumors by avoiding unwanted binding to immune cells circulating in the bloodstream, noted December 4, 2024.",3.29M
Add to portfolio,,,,,,,,
NRSN,NeuroSense Therapeutics Ltd.,$1.07 ,PrimeC - (PARADIGM),Amyotrophic Lateral Sclerosis (ALS) ,Phase 2b,04/12/2024 ET,Phase 2b 18-month data showed statistically significant results. Participants on PrimeC throughout the study showed a 33% slower disease progression and a 58% improvement in survival rates compared to … read more,23.99M
Add to portfolio,,,,,,,,
CGON,"CG Oncology, Inc.",$33.56 ,Cretostimogene - (BOND-003),BCG-unresponsive Non-Muscle Invasive Bladder Cancer (NMIBC) with Carcinoma in Situ ,Phase 3,05/12/2024 ET,"Phase 3 data presented at SUO showed a 74.5% CR rate at any time, a median response duration exceeding 27 months, and 97.3% PFS at 12 months with no Grade 3+ adverse events, noted December 5, 2024.",76.25M
Add to portfolio,,,BTD,,,,,
,,,FTD,,,,,
AZN,AstraZeneca PLC,$66.59 ,IMFINZI (Durvalumab) - (ADRIATIC),Small cell lung cancer (SCLC) limited disease ,Approved,05/12/2024 ET,"Approved December 5, 2024.",3.1B
Add to portfolio,,,View Clinical Trial Data,,,,,
GLUE,Monte Rosa Therapeutics Inc.,$8.83 ,MRT-2359,MYC-driven solid tumors ,Phase 2,05/12/2024 ET,"Phase 2 initial data demonstrated a favorable safety profile and targeted levels of GSPT1 degradation using a 21 days on, 7 days off drug dosing schedule in heavily pretreated solid tumor patients, no … read more",61.76M
Add to portfolio,,,ODD,,,,,
,,,FTD,,,,,
HEPA,Hepion Pharmaceuticals Inc.,$0.63 ,P2B001,Early-stage Parkinson's disease (PD) ,Phase 3,05/12/2024 ET,"Phase 3 data reported that treatment had significantly greater effect on the UPDRS Part II (Activities of Daily Living, or ADL), Part III (Motor), and Total (Parts II and III) scores versus placebo, n … read more",11.62M
Add to portfolio,,,,,,,,
URGN,UroGen Pharma Ltd.,$12.21 ,ZUSDURI (VesiGel UGN-102 (mitomycin)) - (ENVISION),Low grade non-muscle invasive bladder cancer (LG-NMIBC) ,Phase 3,05/12/2024 ET,"Phase 3 data from SUO reported a 79.6% complete response rate at 3 months in patients treated with UGN-102, noted December 5, 2024.",46.26M
Add to portfolio,,,View Clinical Trial Data,,,,,
MRUS,Merus N.V.,$43.86 ,BIZENGRI (zenocutuzumab-zbco),Solid tumors - NRG1+ NSCLC and PDAC cancer ,Approved,05/12/2024 ET,"Approved December 5, 2024.",75.63M
Add to portfolio,,,BTD,,,,,
,,,FTD,,,,,
,,,ODD,,,,,
GMAB,Genmab A/S,—,BIZENGRI (zenocutuzumab-zbco),Solid tumors - NRG1+ NSCLC and PDAC cancer ,Approved,05/12/2024 ET,"Approved December 5, 2024.",661.87M
Add to portfolio,,,BTD,,,,,
,,,FTD,,,,,
,,,ODD,,,,,
TARA,Protara Therapeutics Inc.,$6.02 ,TARA-002 - (ADVANCED-2),High-grade non-muscle invasive bladder cancer (NMIBC) patients with Bacillus Calmette-Guérin (BCG)-naïve and BCG-unresponsive carcinoma in situ (CIS) ,Phase 1/2,05/12/2024 ET,"Phase 1b/2 OLE data presented at the Annual Meeting of the SUO included a 72% six-month CR rate, 100% CR rate in BCG-unresponsive patients, and no Grade 2+ treatment-related AE. Durable responses wer … read more",38.58M
Add to portfolio,,,,,,,,
ELEV,Elevation Oncology Inc.,$0.59 ,EO-3021 (SYSA1801) with ramucirumab + dostarlimab,Advanced Unresectable or Metastatic Solid Tumors Likely to Express Claudin 18.2 ,Preclinical,05/12/2024 ET,Preclinical data reported that treatment with EO-3021 and a PD-1 inhibitor showed significantly greater tumor growth inhibition (TGI) at 79.9% compared to EO-3021 alone (33.8%) or a PD-1 inhibitor alo … read more,59.22M
Add to portfolio,,,FTD,,,,,
NVS,Novartis AG,$101.99 ,Fabhalta - (APPULSE-PNH),Paroxysmal nocturnal hemoglobinuria (PNH) ,Phase 3,06/12/2024 ET,"Phase 3b data reported that treatment improved the average hemoglobin (Hb) level versus baseline, noted December 6, 2024.",1.98B
Add to portfolio,,,,,,,,
BNTX,BioNTech SE,$121.72 ,BNT324/DB-1311,Solid tumors ,Phase 1/2,06/12/2024 ET,"Phase 1/2 data reported that the patients with SCLC with at least one post-baseline tumor assessment and who had received prior immunotherapy but no prior topoisomerase 1 inhibitor, the unconfirmed ob … read more",239.97M
Add to portfolio,,,FTD,,,,,
AZN,AstraZeneca PLC,$67.25 ,Datopotamab deruxtecan - (TROPION-Lung05),EGFR non-small cell lung cancer (NSCLC) ,Phase 3,06/12/2024 ET,"Phase 3 data reported a confirmed objective response rate (ORR) of 42.7%, noted December 6, 2024.",3.1B
Add to portfolio,,,BTD,,,,,
DSNKY,"Daiichi Sankyo Co., Ltd. ADR",$31.48 ,Datopotamab deruxtecan - (TROPION-Lung05),EGFR non-small cell lung cancer (NSCLC) ,Phase 3,06/12/2024 ET,"Phase 3 data reported a confirmed objective response rate (ORR) of 42.7%, noted December 6, 2024.",1.92B
Add to portfolio,,,BTD,,,,,
AZN,AstraZeneca PLC,$67.25 ,DATROWAY (datopotamab deruxtecan-dlnk)- (TROPION-Lung01),Non-small cell lung cancer (NSCLC) ,Phase 3,06/12/2024 ET,"Phase 3 data reported a confirmed objective response rate (ORR) of 42.7%, noted December 6, 2024.",3.1B
Add to portfolio,,,BTD,,,,,
PFE,Pfizer Inc.,$25.31 ,BHV-7000,Focal Epilepsy ,Phase 1,06/12/2024 ET,"Phase 1 data demonstrated excellent tolerability at all doses evaluated without central nervous system (CNS) adverse effects typically associated with other anti-seizure medications (ASMs), such as so … read more",5.69B
Add to portfolio,,,,,,,,
BHVN,Biohaven Ltd.,$44.80 ,BHV-7000,Focal Epilepsy ,Phase 1,06/12/2024 ET,"Phase 1 data demonstrated excellent tolerability at all doses evaluated without central nervous system (CNS) adverse effects typically associated with other anti-seizure medications (ASMs), such as so … read more",105.79M
Add to portfolio,,,,,,,,
MNOV,MediciNova Inc.,$2.34 ,Ibudilast (MN-166) - (COMBAT-ALS),Amyotrophic lateral sclerosis (ALS) ,Phase 2/3,06/12/2024 ET,"Phase 2b/3 trial update from International Symposium on ALS / MND reported positive correlations were observed between the 6-month and 12-month data for CAFS score (0.71), modified CAFS score (0.70), … read more",49.05M
Add to portfolio,,,,,,,,
XENE,Xenon Pharmaceuticals Inc.,$42.72 ,Azetukalner (XEN1101) - (X-TOLE2),Adult Focal Epilepsy ,Phase 3,06/12/2024 ET,Phase 3 OLE long-term safety and efficacy data presented at AES showed that drug achieved 85% sustained monthly seizure reduction at 36 months and one-year seizure freedom in 33% of patients. The drug … read more,77.11M
Add to portfolio,,,View Clinical Trial Data,,,,,
RAPP,Rapport Therapeutics Inc.,$20.46 ,RAP-219 - (PET),Drug-resistant focal epilepsy ,Phase 2a,06/12/2024 ET,Phase 2a Pk data presented at the American Epilepsy Society Annual Meeting showed 30% reduction in long episodes associated with a 50% or greater reduction in clinical seizures in a post-hoc analysis … read more,36.5M
Add to portfolio,,,,,,,,
STOK,Stoke Therapeutics Inc.,$13.27 ,Zorevunersen (STK-001),Dravet Syndrome ,Phase 1/2,06/12/2024 ET,"Phase 1/2 data presented at AES showed substantial and durable seizure reductions and cognitive and behavioral improvements. In studies, patients treated for over two years experienced an 87% median r … read more",54.8M
Add to portfolio,,,BTD,,,,,
ALT,Altimmune Inc.,$9.11 ,Pemvidutide - (MOMENTUM),"Non-alcoholic steatohepatitis (NASH)/ (MASH) - Healthy, Overweight and Obese Volunteers ",Phase 2,06/12/2024 ET,"Phase 2 data presentation reported a mean weight loss of 15.6% with pemvidutide 2.4 mg at Week 48, noted December 6, 2024.",88.26M
Add to portfolio,,,FTD,,,,,
,,,View Clinical Trial Data,,,,,
IPHA,Innate Pharma S.A.,$1.47 ,Lacutamab (IPH4102) - (TELLOMAK),"Mycosis Fungoides, Sézary Syndrome ",Phase 2,07/12/2024 ET,"Phase 2 data presented at ASH reported a clinically significant 2-point decrease on the VAS scale to mild by Week 13 (VAS<4), in Sézary Syndrome Patients, and improvement in Itch intensity from Week 5 … read more",92.16M
Add to portfolio,,,BTD,,,,,
,,,View Clinical Trial Data,,,,,
BEAM,Beam Therapeutics Inc.,$26.71 ,BEAM-101 - (BEACON),Sickle cell disease ,Phase 1/2,07/12/2024 ET,"Phase 1/2 data presented at ASH reported that all seven patients treated with BEAM-101 achieved hemoglobin F (HbF) induction of >60%, noted December 7, 2024.",101.16M
Add to portfolio,,,ODD,,,,,
,,,RMAT,,,,,
PSTX,Poseida Therapeutics Inc.,$9.36 ,P-BCMA-101 - (PRIME),Multiple myeloma ,Phase 2,07/12/2024 ET,"Phase 2 data presented at ASH reported that one patient achieved a partial response that deepened into a stringent complete response and remained in remission for nearly 2 years (22.5 months), noted D … read more",97.47M
Add to portfolio,,,,,,,,
AGIO,Agios Pharmaceuticals Inc.,$48.64 ,PYRUKYND (Mitapivat) - (ENERGIZE),Thalassemia ,sNDA Filing,08/12/2024 ET,"sNDA filing submitted on December 8, 2024.",58.1M
Add to portfolio,,,View Clinical Trial Data,,,,,
CCCC,C4 Therapeutics Inc.,$4.19 ,Cemsidomide (CFT7455),Hematologic malignancies ,Phase 1/2,08/12/2024 ET,"Phase 1/2 escalation data from ASH reported that across all dose levels explored, cemsidomide achieved a 38 percent ORR and 19 percent CMR rate, and in patients with PTCL, cemsidomide achieved a 44 pe … read more",71.17M
Add to portfolio,,,ODD,,,,,
IRON,Disc Medicine Inc.,$64.66 ,DISC-0974,Myelofibrosis (MF) patients with anemia ,Phase 1b,08/12/2024 ET,"Phase 1b data presented at ASH reported that 68% of baseline nTD patients achieved a hemoglobin increase of ≥1.5 g/dL during study period and 50% had sustained increases for ≥12 weeks, noted December … read more",34.77M
Add to portfolio,,,,,,,,
BEAM,Beam Therapeutics Inc.,$27.52 ,BEAM-103 - (ESCAPE),Sickle Cell Disease (SCD) ,Preclinical,08/12/2024 ET,"Preclinical data presented at ASH reported that all NHPs achieved >40% γ-globin, a key constituent of HbF, post-transplant, noted December 8, 2024.",101.16M
Add to portfolio,,,,,,,,
AGIO,Agios Pharmaceuticals Inc.,$48.64 ,Mitapivat - (ENERGIZE-T),Transfusion-dependent thalassemia ,Phase 3,08/12/2024 ET,"Phase 3 data presented at ASH reported that TRR was achieved by 30.4% (n=52/171) of patients in the mitapivat arm compared to 12.6% (n=11/87) of patients in the placebo arm, noted December 8, 2024.",58.1M
Add to portfolio,,,,,,,,
COGT,Cogent Biosciences Inc.,$9.67 ,Bezuclastinib - (APEX),Advanced Systemic Mastocytosis ,Phase 2,08/12/2024 ET,"Phase 2 presentation due at ASH reported 52% ORR per mIWG criteria, including 83% ORR for patients receiving 100 mg BID, noted December 8, 2024.",139.7M
Add to portfolio,,,View Clinical Trial Data,,,,,
AFMD,Affimed N.V.,$2.39 ,AFM13 + AlloNK (AB-101) - (LuminICE-203),"Classical Hodgkin Lymphoma (cHL), relapsed/refractory CD30-positive lymphoma ",Phase 2,08/12/2024 ET,"Phase 2 data presented at ASH demonstrated an overall response rate of 86% and complete response of 55% in 22 heavily pretreated patients with R/R cHL, noted December 8, 2024.",15.23M
Add to portfolio,,,RMAT,,,,,
SLS,SELLAS Life Sciences Group Inc.,$1.09 ,Tambiciclib (SLS009) (GFH009) with venetoclax,"Hematologic malignancies, acute myeloid leukemia (AML), chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL) and lymphoma ",Phase 2a,08/12/2024 ET,Phase 2a presented at ASH showed that Median Overall Survival (mOS) in the 30 mg BIW cohort for relapsed/refractory AML patients exceeds 7.7 months. Acute Myeloid Leukemia with Myelodysplasia-Related … read more,105.3M
Add to portfolio,,,ODD,,,,,
,,,FTD,,,,,
,,,RPDD,,,,,
ACLX,Arcellx Inc.,$82.95 ,CART-ddBCMA - (iMMagine-1),Multiple Myeloma ,Phase 2,09/12/2024 ET,"Phase 2 data presented at ASH reported 30.2-month median progression-free survival with a median follow-up of 38.1 months in the Phase 1 study of anito-cel; median overall survival not reached, noted … read more",55.46M
Add to portfolio,,,,,,,,
GILD,Gilead Sciences Inc.,$89.84 ,CART-ddBCMA - (iMMagine-1),Multiple Myeloma ,Phase 2,09/12/2024 ET,"Phase 2 data presented at ASH reported 30.2-month median progression-free survival with a median follow-up of 38.1 months in the Phase 1 study of anito-cel; median overall survival not reached, noted … read more",1.24B
Add to portfolio,,,,,,,,
MCRB,Seres Therapeutics Inc.,$0.86 ,SER-155,"Gastrointestinal infections, bacteremia and graft versus host disease (GvHD) ",Phase 1b,09/12/2024 ET,"Breakthrough Therapy designation (BTD) granted by the FDA, noted December 9, 2024.",8.75M
Add to portfolio,,,FTD,,,,,
,,,BTD,,,,,
OLMA,Olema Pharmaceuticals Inc.,$9.44 ,OP-3136,Breast Cancer ,IND-Enabling,09/12/2024 ET,"IND granted by the FDA, noted December 9, 2024.",68.63M
Add to portfolio,,,,,,,,
KURA,Kura Oncology Inc.,$10.53 ,Ziftomenib (in combination with SoC cytarabine/daunorubicin (7+3) and venetoclax/azacitidine (ven/aza))- (KOMET-007),Acute myeloid leukemia (AML) ,Phase 1a,09/12/2024 ET,"Phase 1a interim data presented at ASH showed 100% CR rate in NPM1-m and 83% CR rate in KMT2A-r 1L adverse risk AML with 7+3, noted December 9, 2024.",86.8M
Add to portfolio,,,,,,,,
KYKOF,Kyowa Kirin Co. Ltd.,—,Ziftomenib (in combination with SoC cytarabine/daunorubicin (7+3) and venetoclax/azacitidine (ven/aza))- (KOMET-007),Acute myeloid leukemia (AML) ,Phase 1a,09/12/2024 ET,"Phase 1a interim data presented at ASH showed 100% CR rate in NPM1-m and 83% CR rate in KMT2A-r 1L adverse risk AML with 7+3, noted December 9, 2024.",540M
Add to portfolio,,,,,,,,
MRK,Merck & Company Inc.,$102.96 ,KEYTRUDA (pembrolizumab) plus chemotherapy - (KEYLYNK-001),Advanced Epithelial Ovarian Cancer ,Phase 3,09/12/2024 ET,"Phase 3 data reported that trial met its primary endpoint, noted December 9, 2024.",2.5B
Add to portfolio,,,,,,,,
ENTA,Enanta Pharmaceuticals Inc.,$8.94 ,Zelicapavir (EDP-323) - (RSVPED),Respiratory Syncytial Virus RSV-A and RSV-B ,Phase 2,09/12/2024 ET,"Phase 2 data reported an antiviral effect for the primary and secondary virology endpoints in the overall population, with a viral load decline of 1.4 log at the end of treatment in Part 2, noted Dece … read more",21.38M
Add to portfolio,,,FTD,,,,,
COGT,Cogent Biosciences Inc.,$9.67 ,Bezuclastinib - (SUMMIT),Non-Advanced Systemic Mastocytosis ,Phase 2,09/12/2024 ET,"Phase 2 data presented at ASH included a 56% mean improvement in Total Symptom Score (TSS) at 24 weeks, with 76% of patients achieving a ≥50% TSS reduction and 95% of patients with elevated serum tryp … read more",139.7M
Add to portfolio,,,BTD,,,,,
,,,View Clinical Trial Data,,,,,
VTVT,vTv Therapeutics Inc.,$17.56 ,Azeliragon combined with stereotactic radiosurgery - (RAGE),Brain metastasis from breast cancer ,Phase 2,09/12/2024 ET,"Orphan drug designation granted on December 9, 2024.",3.19M
Add to portfolio,,,ODD,,,,,
VOR,Vor Biopharma Inc.,$1.04 ,Trem-cel + Mylotarg (VBP101),Acute myeloid leukemia (AML) ,Phase 1/2,09/12/2024 ET,"Phase 1/2 preliminary data presented at ASH suggests improved relapse-free survival compared to published groups of acute myeloid leukemia (AML) patients at high risk of relapse post-transplant, noted … read more",6.84M
Add to portfolio,,,,,,,,
PRTC,PureTech Health plc,$22.36 ,LYT-200,Relapsed/refractory AML and MDS ,Phase 1b,09/12/2024 ET,"Phase 1b data reported LYT-200 demonstrates clinical benefit as a single agent, with two partial responses and 59% of evaluable patients achieving stable disease or better, and in combination, two com … read more",24.17M
Add to portfolio,,,ODD,,,,,
,,,FTD,,,,,
RLMD,Relmada Therapeutics Inc.,$0.48 ,REL-1017 - (RELIANCE II),Major depressive disorder (MDD) ,Phase 3,09/12/2024 ET,"Phase 3 study discontinued, noted December 9, 2024.",33.19M
Add to portfolio,,,FTD,,,,,
RLMD,Relmada Therapeutics Inc.,$0.48 ,REL-1017 - (Relight),Major Depressive Disorder (MDD) ,Phase 3,09/12/2024 ET,"Phase 3 discontinued after recent data monitoring committee (DMC), noted December 9, 2024.",33.19M
Add to portfolio,,,,,,,,
BNOX,Bionomics Limited,$0.30 ,BNC210 - (ATTUNE),Post-Traumatic Stress Disorder (PTSD) ,Phase 2b,09/12/2024 ET,"Phase 2 data shared at the ACNP exhibited improved PTSD symptom severity at Week 12 with efficacy observed as early as Week 4, noted December 9, 2024.",2.36M
Add to portfolio,,,FTD,,,,,
SNDX,Syndax Pharmaceuticals Inc.,$15.56 ,Revuforj (revumenib) - (AUGMENT-101),Relapsed/refractory (R/R) acute leukemias ,Phase 2,09/12/2024 ET,"Phase 2 data presented at ASH from subgroup analyses (N=64) showed responses across all major subgroups, including heavily pretreated patients, noted December 9, 2024.",86.14M
Add to portfolio,,,FTD,,,,,
,,,BTD,,,,,
ADCT,ADC Therapeutics SA,$3.21 ,ZYNLONTA (loncastuximab tesirine-lpyl),Relapsed/refractory (r/r) marginal zone lymphoma (MZL) ,Phase 2,09/12/2024 ET,"Additional Phase 2 data presented at ASH showed best ORR of 97% and CR rate of 77% with 12-month PFS of 95%, data also presented at ASH on ZYNLONTA monotherapy in marginal zone lymphoma shows ORR of … read more",112.5M
Add to portfolio,,,,,,,,
MGTX,MeiraGTx Holdings plc,$6.48 ,AAV2-hAQP1 - (AQUAx2),Xerostomia ,Phase 1,09/12/2024 ET,"Regenerative Medicine Advanced Therapy (RMAT) designation granted by the FDA, noted December 9, 2024.",80.45M
Add to portfolio,,,FTD,,,,,
,,,RMAT,,,,,
SONN,Sonnet BioTherapeutics Holdings Inc.,$1.98 ,SON-1010 with Trabectedin - (SB101),Solid tumors ,Phase 1,09/12/2024 ET,"Phase 1 topline data in 21 evaluable patients, 48% achieved stable disease at four months, including one partial response with a 45% tumor reduction at the MTD. SON-1010 demonstrated favorable safety, … read more",6.75M
Add to portfolio,,,,,,,,
JNJ,Johnson & Johnson,$148.41 ,"DARZALEX FASPRO (daratumumab and hyaluronidase-fihj) in combination with bortezomib, lenalidomide and dexamethasone (D-VRd) - (CEPHEUS)",Newly diagnosed multiple myeloma (NDMM) ,Phase 3,09/12/2024 ET,"Phase 3 data reported that 85 percent of patients who achieved MRD negativity (10-6) with DARZALEX FASPRO® were progression free at 4.5 years, noted December 9, 2024.",2.41B
Add to portfolio,,,,,,,,
GILD,Gilead Sciences Inc.,$89.84 ,"YESCARTA (Axicabtagene Ciloleucel), KTE-C19 and utomilumab - (ZUMA-7)",Refractory Large B-cell Lymphoma ,Phase 1,09/12/2024 ET,"Phase 1 data from ASH reported that 71% overall survival rate, noted December 9, 2024.",1.24B
Add to portfolio,,,,,,,,
MOLN,Molecular Partners AG,$5.61 ,MP0621,Acute myeloid leukemia (AML) ,Preclinical,09/12/2024 ET,"Additional preclinical data presented at ASH reported that treatment demonstrated intended mechanism in vivo, achieving killing of cKit+ cells while reducing off-target effects seen with systemic anti … read more",40.36M
Add to portfolio,,,,,,,,
JNJ,Johnson & Johnson,$148.41 ,DARZALEX FASPRO (daratumumab and hyaluronidase-fihj) - (AQUILA),Active multiple myeloma ,Phase 3,09/12/2024 ET,"Phase 3 data reported that overall survival was also extended with DARZALEX FASPRO®, with 5-year survival rates of 93 percent versus 86.9 percent for active monitoring, noted December 9, 2024.",2.41B
Add to portfolio,,,,,,,,
AZN,AstraZeneca PLC,$67.62 ,Calquence (acalabrutinib) - (AMPLIFY),Chronic lymphocytic leukaemia (CLL) ,Phase 3,09/12/2024 ET,"Phase 3 data presented at ASH reported that treatment reduced the risk of disease progression or death by 58% versus standard of care, noted December 9, 2024.",3.1B
Add to portfolio,,,,,,,,
GMAB,Genmab A/S,$22.11 ,EPCORE (Epcoritamab) - (EPCORE NHL-2),Non-Hodgkin lymphoma (NHL) ,Phase 1b,09/12/2024 ET,Phase 1b/2 overall response rate (ORR) of 61 percent and complete response (CR) rate of 39 percent in heavily pretreated patients with relapsed or refractory (R/R) chronic lymphocytic leukemia (CLL) w … read more,661.87M
Add to portfolio,,,,,,,,
REGN,Regeneron Pharmaceuticals Inc.,$787.00 ,Pozelimab + Cemdisiran - (ACCESS-1),Paroxysmal Nocturnal Hemoglobinuria (PNH) ,Phase 3,09/12/2024 ET,"Phase 3 data reported that 96% achieved adequate LDH control (≤1.5 x ULN) across study visits, noted December 9, 2024.",105.1M
Add to portfolio,,,,,,,,
GLPG,Galapagos NV,$26.78 ,GLPG5101 - (ATALANTA-1),Relapsed/refractory Non-Hodgkin Lymphoma (rrNHL) ,Phase 1/2,09/12/2024 ET,"Phase 1/2 data presented at ASH reported that all 8 of 8 efficacy-evaluable patients responded to treatment (ORR and CRR 100%), noted December 9, 2024.",65.9M
Add to portfolio,,,RMAT,,,,,
MRK,Merck & Company Inc.,$102.96 ,NKTR-255 with BAVENCIO (avelumab) - (JAVELIN),Locally advanced or metastatic urothelial carcinoma (UC) ,Phase 2,09/12/2024 ET,"Phase 2 trial data reported that 73% of the NKTR-255 treatment group compared to 50% of the placebo group achieved a complete response at 6 months, noted December 9, 2024.",2.5B
Add to portfolio,,,,,,,,
NKTR,Nektar Therapeutics,$1.01 ,NKTR-255 with BAVENCIO (avelumab) - (JAVELIN),Locally advanced or metastatic urothelial carcinoma (UC) ,Phase 2,09/12/2024 ET,"Phase 2 trial data reported that 73% of the NKTR-255 treatment group compared to 50% of the placebo group achieved a complete response at 6 months, noted December 9, 2024.",19.02M
Add to portfolio,,,,,,,,
AMGN,Amgen Inc.,$275.38 ,BLINCYTO (blinatumomab) - (AALL1731),B-cell acute lymphoblastic leukemia (B-ALL) ,Phase 3,09/12/2024 ET,"Phase 3 data reported that among SR-Average patients, 3-year DFS was 97.5% for patients treated with BLINCYTO compared to 90.2% for those treated with only chemotherapy, noted December 9, 2024.",538.36M
Add to portfolio,,,,,,,,
INCY,Incyte Corporation,$72.11 ,Retifanlimab - (POD1UM-304),Non-small cell lung cancer (NSCLC) ,Phase 3,09/12/2024 ET,"Phase 3 data reported that the trial met its primary endpoint of overall survival (OS) and all secondary endpoints, noted December 9, 2024.",196.32M
Add to portfolio,,,View Clinical Trial Data,,,,,
MGNX,MacroGenics Inc.,$3.48 ,Retifanlimab - (POD1UM-304),Non-small cell lung cancer (NSCLC) ,Phase 3,09/12/2024 ET,"Phase 3 data reported that the trial met its primary endpoint of overall survival (OS) and all secondary endpoints, noted December 9, 2024.",63.21M
Add to portfolio,,,View Clinical Trial Data,,,,,
MRUS,Merus N.V.,$43.74 ,Petosemtamab (MCLA-158) - (LiGeR-HN1),PD-L1+ recurrent/metastatic head and neck squamous cell carcinoma (r/m HNSCC) ,Phase 1/2,09/12/2024 ET,"Phase 1/2 data reported that a confirmed overall response rate (ORR) 36%, noted December 9, 2024.",75.63M
Add to portfolio,,,BTD,,,,,
GMAB,Genmab A/S,—,Petosemtamab (MCLA-158) - (LiGeR-HN1),PD-L1+ recurrent/metastatic head and neck squamous cell carcinoma (r/m HNSCC) ,Phase 1/2,09/12/2024 ET,"Phase 1/2 data reported that a confirmed overall response rate (ORR) 36%, noted December 9, 2024.",661.87M
Add to portfolio,,,BTD,,,,,
ATHA,Athira Pharma Inc.,$0.62 ,ATH-1105,Amyotrophic Lateral Sclerosis (ALS) ,Phase 1,09/12/2024 ET,"Phase 1 data reported that treatment demonstrated neuroprotective activity through the MET receptor; following siRNA-mediated knockdown of MET, the neuroprotective effects of ATH-1105 on neuronal surv … read more",3.94M
Add to portfolio,,,,,,,,
CMRX,Chimerix Inc.,$0.87 ,Dordaviprone (ONC201) - (ACTION),H3 K27M-mutant diffuse midline glioma ,NDA Filing,09/12/2024 ET,"Pre-NDA meeting with FDA showing clinical data highlighting a 28% objective response rate, median response duration of 10.4 months, and significant reduction of the hallmark mutation, noted December 1 … read more",93.8M
Add to portfolio,,,,,,,,
JAZZ,Jazz Pharmaceuticals plc,—,Dordaviprone (ONC201) - (ACTION),H3 K27M-mutant diffuse midline glioma ,NDA Filing,09/12/2024 ET,"Pre-NDA meeting with FDA showing clinical data highlighting a 28% objective response rate, median response duration of 10.4 months, and significant reduction of the hallmark mutation, noted December 1 … read more",60.66M
Add to portfolio,,,,,,,,
CPIX,Cumberland Pharmaceuticals Inc.,$1.24 ,Acetadote (N-acetylcysteine for injection) (IV),Prevent or lessen liver injury after toxic quantities of acetaminophen. ,Approved,09/12/2024 ET,"FDA approved, noted December 9, 2024.",14.96M
Add to portfolio,,,,,,,,
FATE,Fate Therapeutics Inc.,$2.72 ,FT819,B-cell Leukemias and Lymphomas ,Phase 1b,09/12/2024 ET,"Phase 1b data presented at ASH showed that all 3 patients treated in first dose cohort administered fludarabine-free conditioning and show rapid, deep, and sustained B-cell depletion with favorable sa … read more",115.33M
Add to portfolio,,,RMAT,,,,,
BMEA,Biomea Fusion Inc.,$5.79 ,BMF-500 - (COVALENT-103),Acute myeloid leukemia (AML) ,Phase 1,09/12/2024 ET,"Phase 1 preliminary data supports BMF-500's potential as a transformative therapy for patients with FLT3 mutated relapsed or refractory (R/R) acute leukemia, noted December 9, 2024.",59.51M
Add to portfolio,,,,,,,,
NBTX,Nanobiotix S.A.,$3.00 ,NBTXR3 (JNJ-1900) - (MD Anderson trial/NANORAY Pancreas),"Non-Small Cell Lung Cancer (NSCLC), Pancreatic cancer ",Phase 1b,09/12/2024 ET,"Phase 1b updated data from investigators concluded that the encouraging oncologic outcomes coupled with a favorable safety profile warrant further evaluation in a randomized trial, 23 months median Ov … read more",47.43M
Add to portfolio,,,,,,,,
PTGX,Protagonist Therapeutics Inc.,$40.50 ,Rusfertide - (REVIVE),Polycythemia vera ,Phase 2,09/12/2024 ET,"Phase 2 final results presented at ASH showed that 54% of patients experience more than 2.5 years of durable hematocrit (Hct) control (<45%), decreased phlebotomy use, long-term tolerability, and impr … read more",62.21M
Add to portfolio,,,,,,,,
AFMD,Affimed N.V.,$2.39 ,AFM28 (CD123 / CD16A) - (AMF24-102),Relapsed/refractory Acute Myeloid Leukemia (r/r AML) and MDS ,Phase 1,09/12/2024 ET,"Phase 1 data due presented at ASH achieved a 40% composite complete remission rate (CRcR) at the highest dose level (300 mg) in heavily pretreated R/R AML patients, noted December 9, 2024.",15.23M
Add to portfolio,,,,,,,,
IRON,Disc Medicine Inc.,$64.66 ,Bitopertin - (BEACON),Erythropoietic Protoporphyria (EPP) ,Phase 2,09/12/2024 ET,"Phase 2 data presented at ASH showed that bitopertin significantly reduced protoporphyrin IX (PPIX) at low and high doses and in both adult and adolescent populations, noted December 9, 2024.",34.77M
Add to portfolio,,,,,,,,
IRON,Disc Medicine Inc.,$64.66 ,Bitopertin - (HELIOS),Erythropoietic Protoporphyria ,Phase 2,09/12/2024 ET,"Phase 2 trial updated analysis presented at ASH showed that bitopertin reduced PPIX in all prespecified subgroups across demographic and baseline patient characteristics, noted December 9, 2024.",34.77M
Add to portfolio,,,,,,,,
CRSP,CRISPR Therapeutics AG,$49.84 ,CTX112,Systemic lupus erythematosus (SLE) ,Phase 1/2,09/12/2024 ET,"Preliminary data presented at ASH demonstrated that CTX112 has the potential to provide meaningful clinical benefit with a well-tolerated safety profile using a standard lymphodepletion protocol, note … read more",90.95M
Add to portfolio,,,RMAT,,,,,
PSTX,Poseida Therapeutics Inc.,$9.44 ,P-BCMA-ALLO1,Multiple myeloma ,Phase 1,09/12/2024 ET,Phase 1 Optimized Lymphodepletion Cohort data presented at ASH showed new profiling of patient responses from the optimized lymphodepletion arm (Arm C) show consistent P-BCMA-ALLO1 cellular expansion … read more,97.47
Add to portfolio,,,ODD,,,,,
,,,RMAT,,,,,
RIGL,Rigel Pharmaceuticals Inc.,$23.16 ,R289,Myeloid dysplastic syndrome (MDS) ,Phase 1,09/12/2024 ET,"Phase 1 initial data presented at ASH demonstrated signs of preliminary clinical activity in elderly heavily pretreated LR-MDS patients, RBC-TI/HI-E responses occurred in 40% of evaluable TD patients … read more",17.94M
Add to portfolio,,,FTD,,,,,
,,,ODD,,,,,
EDIT,Editas Medicine Inc.,$2.23 ,Renizgamglogene autogedtemcel (reni-cel; EDIT-301) - (RUBY),Sickle Cell Disease ,Phase 1/2,09/12/2024 ET,Additional Phase 1/2 data presented at ASH was well-tolerated and continued to demonstrate a safety profile consistent with myeloablative busulfan conditioning and autologous hematopoietic stem cell t … read more,89.92M
Add to portfolio,,,,,,,,
MGX,Metagenomi Inc.,$4.17 ,MGX-001,Hemophilia A ,Preclinical,09/12/2024 ET,"Preclinical data presented at ASH reported that the mean FVIII activity of months 13-16.5 following LNP dosing was 71%, 7%, and 27% compared to mean FVIII activity of months 3-6 of 76%, 8% and 30%, no … read more",37.53M
Add to portfolio,,,,,,,,
LYEL,Lyell Immunopharma Inc.,$0.90 ,LYL314 (IMPT-314),Large B-cell lymphoma ,Phase 1/2,09/12/2024 ET,"Phase 1/2 trial data from ASH reported an objective response rate (ORR) of 94% and a complete response (CR) rate of 71%, noted December 9, 2024.",19.21M
Add to portfolio,,,RMAT,,,,,
BGNE,BeiGene Ltd.,$207.62 ,Sonrotoclax (BGB-11417),Chronic lymphocytic leukemia/small lymphocytic leukemia ,Phase 1b,09/12/2024 ET,"Phase 1/1b data presented at ASH reported that the combination achieved a 99% overall response rate (ORR), noted December 9, 2024.",106.62M
Add to portfolio,,,,,,,,
ONC,BeOne Medicines Ltd.,—,Sonrotoclax (BGB-11417),Chronic lymphocytic leukemia/small lymphocytic leukemia ,Phase 1b,09/12/2024 ET,"Phase 1/1b data presented at ASH reported that the combination achieved a 99% overall response rate (ORR), noted December 9, 2024.",110.03M
Add to portfolio,,,,,,,,
BGNE,BeiGene Ltd.,$207.62 ,BGB-16673-101 - (CaDAnCe-101),Relapsed or refractory (R/R) CLL/SLL ,Phase 1,09/12/2024 ET,"Phase 1 data presented at ASH reported an ORR of 94% at the 200mg dose, noted December 9, 2024.",106.62M
Add to portfolio,,,FTD,,,,,
ONC,BeOne Medicines Ltd.,—,BGB-16673-101 - (CaDAnCe-101),Relapsed or refractory (R/R) CLL/SLL ,Phase 1,09/12/2024 ET,"Phase 1 data presented at ASH reported an ORR of 94% at the 200mg dose, noted December 9, 2024.",110.03M
Add to portfolio,,,FTD,,,,,
KROS,Keros Therapeutics Inc.,$67.14 ,Elritercept with Ruxolitinib - (RESTORE),Myelofibrosis ,Phase 2,09/12/2024 ET,"Phase 2 data presented at ASH reported that 55.2% (n=48/87) of the mITT24 patients achieved an overall erythroid response over the first 24 weeks of treatment, noted December 9, 2024.",40.62M
Add to portfolio,,,,,,,,
NRIX,Nurix Therapeutics Inc.,$20.66 ,NX-5948,R/R Chronic Lymphocytic Leukemia (CLL) ,Phase 1a,09/12/2024 ET,"Phase 1a/1b data presented at ASH reported an 75.5% Objective Response Rate which increased to 84.2% in patients with at least two disease assessments, noted December 9, 2024.",76.88M
Add to portfolio,,,,,,,,
RXRX,Recursion Pharmaceuticals Inc.,$8.27 ,REC-617 - (ELUCIDATE),CDK7 inhibitor; Advanced Solid Tumors ,Phase 1,09/12/2024 ET,"Phase 1 monotherapy safety and PK/PD initial data from the AACR Special Conference reported 1 cPR and 4 SD, noted December 9, 2024.",434.15M
Add to portfolio,,,,,,,,
REGN,Regeneron Pharmaceuticals Inc.,$787.00 ,Odronextamab - (OLYMPIA),Non-Hodgkin Lymphoma (NHL) ,Phase 3,09/12/2024 ET,"Phase 3 data presented at ASH reported an objective response rate (ORR) of 89% and 67% CR rate, noted December 9, 2024.",105.1M
Add to portfolio,,,View Clinical Trial Data,,,,,
ZLAB,Zai Lab Limited,$28.91 ,Odronextamab - (OLYMPIA),Non-Hodgkin Lymphoma (NHL) ,Phase 3,09/12/2024 ET,"Phase 3 data presented at ASH reported an objective response rate (ORR) of 89% and 67% CR rate, noted December 9, 2024.",109.96M
Add to portfolio,,,View Clinical Trial Data,,,,,
OMER,Omeros Corporation,$11.38 ,Zaltenibart - (OMS906),Paroxysmal nocturnal hemoglobinuria (PNH) ,Phase 2,09/12/2024 ET,"Phase 2 proof of concept results presented at ASH showed that clinical data support Phase 3 enrollment to commence in early 2025, noted December 9, 2024.",68.06M
Add to portfolio,,,ODD,,,,,
,,,RPDD,,,,,
CRIS,Curis Inc.,$4.14 ,CA-4948 - (Take Aim Leukemia),Acute Myeloid Leukemia / Myelodysplastic Syndromes (MDS) ,Phase 1/2,09/12/2024 ET,"Phase 1/2 triplet data presented at ASH reported 10 objective responses (6 CRs, 2 CRi/CRh, and 2 MLFS) among 19 evaluable relapsed/refractory AML patients with FLT3 mutations, treated with the RP2D of … read more",12.5M
Add to portfolio,,,,,,,,
ARTL,Artelo Biosciences Inc.,$1.16 ,ART27.13 - (CAReS),Cancer-Related Anorexia and Weight Loss ,Phase 1,09/12/2024 ET,"Phase 1 of CAReS, ART27.13 at one month of treatment, two-thirds of participants showed evidence the drug was impacting their weight loss with either stabilization or reversal of weight loss associate … read more",1.32M
Add to portfolio,,,,,,,,
SLN,Silence Therapeutics Plc,$7.99 ,Divesiran (SLN124) - (SANRECO),Polycythemia Vera ,Phase 1,09/12/2024 ET,"Phase 2 dosing commenced and Phase 1 data reported at ASH continue to show substantial reduction in phlebotomy frequency and lowering of hematocrit levels in PV patients, noted December 9, 2024.",46.8M
Add to portfolio,,,FTD,,,,,
,,,ODD,,,,,
CRBP,Corbus Pharmaceuticals Holdings Inc.,$15.24 ,CRB-601,Solid tumors ,Phase 1,09/12/2024 ET,"Phase 1 clinical study initiated, noted December 9, 2024.",12.26M
Add to portfolio,,,,,,,,
NAMS,NewAmsterdam Pharma Company N.V.,$26.19 ,Obicetrapib - (BROADWAY),Heterozygous Familial Hypercholesterolemia and/or Established Atherosclerotic Cardiovascular Disease ,Phase 3,10/12/2024 ET,"Phase 3 study achieved primary endpoint of LS mean reduction vs placebo in LDL-C on top of maximally tolerated lipid modifying therapies at day 84 with statistically significant reduction, noted Decem … read more",112.63M
Add to portfolio,,,,,,,,
CRVO,CervoMed Inc.,$2.16 ,Neflamapimod - (RewinD-LB),Dementia with Lewy bodies (DLB) ,Phase 2b,10/12/2024 ET,"Phase 2b topline data did not demonstrate statistically significant effects versus placebo on primary and secondary endpoints at 16 weeks, noted December 10, 2024.",9.25M
Add to portfolio,,,ODD,,,,,
APGE,Apogee Therapeutics Inc.,$48.38 ,APG777 + APG333,"Healthy volunteers, Respiratory diseases ",Preclinical,10/12/2024 ET,"Preclinical proof-of-concept achieved for APG777 + APG333 combination with clinical trial planning underway in asthma and COPD patients, noted December 10, 2024.",59.6M
Add to portfolio,,,,,,,,
OLMA,Olema Pharmaceuticals Inc.,$9.64 ,Palazestrant (OP-1250) and ribociclib - (OPERA-02),Breast Cancer ,Phase 2,10/12/2024 ET,"Phase 1b/2 new data presented at SABCS demonstrated promising clinical activity, a safety profile consistent with ribociclib and endocrine therapy, and favorable tolerability, noted December 10, 2024 … read more",68.63M
Add to portfolio,,,,,,,,
QNTM,Quantum Biopharma Ltd.,$4.26 ,Lucid-21-302 - (Lucid-MS),"Healthy Volunteers, multiple sclerosis ",Phase 1,10/12/2024 ET,"Phase 1 safety review committee recommends commencing dosing of the second cohort, noted December 10, 2024.",3.82M
Add to portfolio,,,,,,,,
QURE,uniQure N.V.,$15.30 ,AMT-130,Huntington's disease ,Phase 1/2,10/12/2024 ET,"FDA agreed that data from ongoing Phase 1/2 studies compared to a natural history external control may serve as the primary basis for a Biologics License Application (BLA) for Accelerated Approval, no … read more",54.87M
Add to portfolio,,,RMAT,,,,,
,,,BTD,,,,,
,,,FTD,,,,,
,,,ODD,,,,,
ACIU,AC Immune SA,$3.14 ,ACI-24 (anti-Abeta vaccine) - (ABATE),Down syndrome ,Phase 1/2,10/12/2024 ET,Phase 1/2 results were generally safe and well tolerated in individuals with Down syndrome with no serious adverse events related to the study drug. No cases of amyloid-related imaging abnormalities o … read more,100.41M
Add to portfolio,,,,,,,,
TAK,Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of),$13.46 ,ACI-24 (anti-Abeta vaccine) - (ABATE),Down syndrome ,Phase 1/2,10/12/2024 ET,Phase 1/2 results were generally safe and well tolerated in individuals with Down syndrome with no serious adverse events related to the study drug. No cases of amyloid-related imaging abnormalities o … read more,3.15B
Add to portfolio,,,,,,,,
INAB,IN8bio Inc.,$0.31 ,INB-100,"Allogeneic hematopoietic stem cell transplantation (HSCT), leukemias undergoing haploidentical stem cell transplantation ",Phase 1,10/12/2024 ET,Phase 1b data presented at ASH continues to demonstrate durable complete remissions (CR) with no relapses observed in any acute myeloid leukemia (AML) patients including those with high-risk disease a … read more,4.54M
Add to portfolio,,,,,,,,
NVAX,Novavax Inc.,$8.77 ,COVID-19 vaccine (NVX-CoV2705),COVID-19-Influenza Combination (CIC) 2024-2025 ,Phase 3,10/12/2024 ET,"Phase 3 dosing initiated, noted December 10, 2024.",162.42M
Add to portfolio,,,,,,,,
ATYR,aTyr Pharma Inc.,$3.29 ,Efzofitimod - (EFZO-FIT),Pulmonary sarcoidosis ,Phase 3,10/12/2024 ET,"Phase 3 DSMB recommended that the study continue without any modifications, noted December 10, 2024.",97.99M
Add to portfolio,,,FTD,,,,,
,,,ODD,,,,,
LSTA,Lisata Therapeutics Inc.,$2.82 ,CEND‐1 - (CENDIFOX),Solid tumors ,Phase 1/2,10/12/2024 ET,"Phase 1b/2a all cohorts enrollment completed December 10, 2024.",8.76M
Add to portfolio,,,,,,,,
SLS,SELLAS Life Sciences Group Inc.,$1.04 ,Galinpepimut-S - (REGAL),Acute Myeloid Leukemia (AML) ,Phase 3,10/12/2024 ET,"Phase 3 study reached pre-specified threshold of 60 events (Deaths) initiating the interim analysis, noted December 10, 2024.",105.3M
Add to portfolio,,,RPDD,,,,,
,,,View Clinical Trial Data,,,,,
CLNN,Clene Inc.,$4.93 ,CNM-Au8 - (HEALEY ALS),Amyotrophic Lateral Sclerosis (ALS) ,Phase 2,10/12/2024 ET,Phase 2 FDA recommends that Clene leverage additional Neurofilament Light (NfL) data from its three Expanded Access Protocols (EAPs) and the HEALEY ALS Platform Trial to support earlier presented find … read more,9.99M
Add to portfolio,,,,,,,,
IMMP,Immutep Limited,$2.12 ,Eftilagimod alpha (efti) - (TACTI-004),1L Non-small cell lung cancer (NSCLC) ,Phase 3,10/12/2024 ET,"Phase 3 initiated, noted December 10, 2024.",147.19M
Add to portfolio,,,,,,,,
IMNN,Imunon Inc.,$0.90 ,IMNN-001 - (OVATION 2),Ovarian cancer ,Phase 2,10/12/2024 ET,"Updated Phase 2 data reported that the hazard ratio (HR) decreased from 0.74 to 0.69, with an increase in median overall survival (OS) from 11.1 to 13 months following treatment with IMNN-001 plus sta … read more",2.52M
Add to portfolio,,,,,,,,
STRO,Sutro Biopharma Inc.,$2.35 ,Luvelta - (REFRαME-O1),Platinum-resistant ovarian cancer (PROC) ,Phase 2/3,10/12/2024 ET,"Phase 2/3 trial data reported an 32% objective response rate (ORR) in evaluable patients at the 5.2 mg/kg starting dose, noted December 10, 2024.",84.77M
Add to portfolio,,,,,,,,
TCRX,TScan Therapeutics Inc.,$3.33 ,"TSC-100, TSC-101 - (ALLOHA)",Hematologic malignancies ,Phase 1,10/12/2024 ET,"Phase 1 data presented at ASH reported that event-free survival strongly favors the treatment arm (HR=0.30; p=0.04), and treatment-arm patients trend towards lower probability of relapse (HR=0.28; p=0 … read more",56.75M
Add to portfolio,,,RMAT,,,,,
SPRB,Spruce Biosciences Inc.,$0.54 ,Tildacerfont - (CAHptain-205),Pediatric Classic Congenital Adrenal Hyperplasia ,Phase 2,10/12/2024 ET,"Phase 2 topline study indicated that higher doses and twice-daily (BID) dosing might improve efficacy, showing trends toward androgen level reduction, Spruce to halt investment in tildacerfont and exp … read more",563.04K
Add to portfolio,,,,,,,,
SPRB,Spruce Biosciences Inc.,$0.54 ,Tildacerfont - (CAHmelia-204),Congenital Adrenal Hyperplasia (good disease control) ,Phase 2b,10/12/2024 ET,"Phase 2b study did not meet its primary endpoint of reducing glucocorticoid (GC) usage, with a placebo-adjusted reduction of only 0.7 mg/day. Spruce to halt investment in tildacerfont and explore stra … read more",563.04K
Add to portfolio,,,View Clinical Trial Data,,,,,
SIGA,SIGA Technologies Inc.,$6.47 ,Tecovirimat - (STOMP),Human Mpox Virus ,Phase 3,10/12/2024 ET,"Phase 3 interim analysis shows that tecovirimat did not improve time to lesion resolution compared to placebo in adults with mild to moderate clade II mpox, noted December 10, 2024.",71.61M
Add to portfolio,,,,,,,,
ALMS,Alumis Inc.,$8.39 ,izokibep,"Non-infectious, non-anterior uveitis ",Phase 2/3,10/12/2024 ET,"Phase 2b/3 trial of izokibep did not meet primary endpoint; secondary endpoints also did not achieve statistical significance, noted Decemeber 10, 2024. Based on these data, and previously announced g … read more",104.06M
Add to portfolio,,,,,,,,
IMMX,Immix Biopharma Inc.,$2.19 ,NXC-201 (HBI10101) - (NEXICART-1),relapsed/refractory multiple myeloma and relapsed/refractory AL amyloidosis ,Phase 1/2,10/12/2024 ET,"Phase 1/2 data presented at ASH showed that therapy demonstrated a 94% overall response rate, a favorable safety profile, and no grade 4 cytokine release syndrome or neurotoxicity events, noted Novemb … read more",28.83M
Add to portfolio,,,ODD,,,,,
XNCR,Xencor Inc.,$25.29 ,MONJUVI (tafasitamab) with REVLIMID (lenalidomide) and RITUXAN (rituximab),Follicular lymphoma (FL) / marginal zone lymphoma (MZL) ,Phase 3,10/12/2024 ET,"Phase 3 data presented at ASH showed that trial met its primary endpoint of progression-free survival (PFS) and key secondary endpoints, noted December 10, 2024.",71.32M
Add to portfolio,,,View Clinical Trial Data,,,,,
NVS,Novartis AG,$100.13 ,MONJUVI (tafasitamab) with REVLIMID (lenalidomide) and RITUXAN (rituximab),Follicular lymphoma (FL) / marginal zone lymphoma (MZL) ,Phase 3,10/12/2024 ET,"Phase 3 data presented at ASH showed that trial met its primary endpoint of progression-free survival (PFS) and key secondary endpoints, noted December 10, 2024.",1.98B
Add to portfolio,,,View Clinical Trial Data,,,,,
INCY,Incyte Corporation,$72.48 ,MONJUVI (tafasitamab) with REVLIMID (lenalidomide) and RITUXAN (rituximab),Follicular lymphoma (FL) / marginal zone lymphoma (MZL) ,Phase 3,10/12/2024 ET,"Phase 3 data presented at ASH showed that trial met its primary endpoint of progression-free survival (PFS) and key secondary endpoints, noted December 10, 2024.",196.32M
Add to portfolio,,,View Clinical Trial Data,,,,,
NXTC,NextCure Inc.,$1.13 ,LNCB74,B7-H4 expressing cancers ,IND-Enabling,10/12/2024 ET,"IND cleared by the FDA, noted December 10, 2024.",2.68M
Add to portfolio,,,,,,,,
ALXO,ALX Oncology Holdings Inc.,$1.58 ,Zanidatamab and Evorpacept (ALX148),HER2 Breast cancer and solid tumors ,Phase 1/2,10/12/2024 ET,Phase 1b/2 data to be presented at SABCS suggest that HER2-positive patients whose cancer has been heavily pretreated may benefit from CD47 inhibition via evorpacept's unique mechanism when combined w … read more,53.55M
Add to portfolio,,,,,,,,
ZYME,Zymeworks Inc.,$13.06 ,Zanidatamab and Evorpacept (ALX148),HER2 Breast cancer and solid tumors ,Phase 1/2,10/12/2024 ET,Phase 1b/2 data to be presented at SABCS suggest that HER2-positive patients whose cancer has been heavily pretreated may benefit from CD47 inhibition via evorpacept's unique mechanism when combined w … read more,75.17M
Add to portfolio,,,,,,,,
IMMX,Immix Biopharma Inc.,$2.19 ,NXC-201 (HBI10101) - (NEXICART-2),Relapsed/refractory AL Amyloidosis ,Phase 1/2,10/12/2024 ET,"Phase 1b/2 data reported a 75% (12/16) complete response (CR) rate observed in standard of care (Dara-CyBorD) relapsed/refractory AL Amyloidosis patients with median 4 lines of prior therapy, noted De … read more",28.83M
Add to portfolio,,,ODD,,,,,
,,,RMAT,,,,,
RLYB,Rallybio Corporation,$1.19 ,RLYB212,Fetal and neonatal alloimmune thrombocytopenia (FNAIT) ,Preclinical,10/12/2024 ET,"Preclinical data presented at ASH showed that treatment has the potential to be a safe and effective preventative therapeutic using innovative nonclinical models, noted December 10, 2024.",41.79M
Add to portfolio,,,,,,,,
RLYB,Rallybio Corporation,$1.19 ,RLYB332,Iron overload ,Preclinical,10/12/2024 ET,"Preclinical data presented at ASH demonstrated that single intravenous injections of RLYB332 to humanized FcRn mice had rapid and sustained effects on pharmacodynamic (PD) parameters, including serum … read more",41.79M
Add to portfolio,,,,,,,,
RLAY,Relay Therapeutics Inc.,$4.98 ,RLY-2608 + fulvestrant + ribociclib triplet combination - (ReDiscover),"PIK3CA (PI3Kα) mutant tumors, including HR+/HER2- breast cancer ",Phase 1,11/12/2024 ET,"Phase 1 efficacy data shared at SABCS reported a 39% confirmed ORR across all patients & 67% in patients with kinase mutations at RP2D, noted December 11, 2024.",172.41M
Add to portfolio,,,,,,,,
PHAR,Pharming Group N.V.,$9.27 ,Leniolisib - (pediactric),Activated phosphoinositide 3-kinase delta syndrome (APDS) ,Phase 3,11/12/2024 ET,"Phase 3 data reported improvement in lymphoproliferation and immunophenotype correction were seen across the four dose levels being investigated, noted December 11, 2024.",68.39M
Add to portfolio,,,,,,,,
CADL,Candel Therapeutics Inc.,$7.75 ,CAN-2409 - (ULYSSES),Prostate Cancer (Active Surveillance) ,Phase 3,11/12/2024 ET,Phase 2b clinical trial of monotherapy CAN-2409 in 190 patients with low-to-intermediate risk localized prostate cancer undergoing active surveillance showed numerical improvement in time to radical t … read more,54.9M
Add to portfolio,,,View Clinical Trial Data,,,,,
CADL,Candel Therapeutics Inc.,$7.75 ,CAN-2409 (aglatimagene besadenovec) combined with Valacyclovir,Prostate cancer ,Phase 2,11/12/2024 ET,"Phase 3 results for CAN-2409 viral immunotherapy in intermediate-to-high-risk localized prostate cancer, achieved its primary endpoint of significantly improved disease-free survival (DFS) when combin … read more",54.9M
Add to portfolio,,,FTD,,,,,
,,,RMAT,,,,,
,,,View Clinical Trial Data,,,,,
ADCT,ADC Therapeutics SA,$2.22 ,ZYNLONTA (Loncastuximab Tesirine-Ipyl) - (LOTIS-7),B-cell non-Hodgkin lymphoma ,Phase 1b,11/12/2024 ET,"Phase 1b data reported a clinically meaningful benefit with 94% best ORR and 72% CR rate, noted December 11, 2024.",112.5M
Add to portfolio,,,,,,,,
ARWR,Arrowhead Pharmaceuticals Inc.,$22.73 ,ARO-CFB,Complement Mediated Kidney Disease ,Phase 1/2,11/12/2024 ET,"Phase 1/2a data reported dose dependent reductions in circulating CFB protein by up to 90% with greater than 3 months duration, noted December 11, 2024.",138.26M
Add to portfolio,,,,,,,,
CELC,Celcuity Inc.,$12.85 ,Gedatolisib with Palbociclib and Letrozole,Early-Stage Breast Cancer ,Phase 1b,11/12/2024 ET,"Phase 1b trial presented at SABCS showed a median overall survival (OS) among patients with HR+, HER2- advanced breast cancer who were treatment-naïve in the advanced setting was 77.3 months, while me … read more",42.43M
Add to portfolio,,,,,,,,
PRLD,Prelude Therapeutics Incorporated,$0.94 ,PRT2527,Solid tumors and hematological malignancies ,Phase 1,11/12/2024 ET,"Phase 1 data reported an overall response rate (ORR) of 17.4% (4 of 23), with complete responses (CRs) observed in 3 patients (2 DLBCL, 1 MCL) and 2 partial responses (PRs) observed, noted December 11 … read more",56.6M
Add to portfolio,,,,,,,,
BPTH,Bio-Path Holdings Inc.,$0.72 ,BP1002,Refractory/relapsed lymphoma and chronic lymphocytic leukemia ,Phase 1,11/12/2024 ET,"Phase 1 study enrollment discontinued, noted December 11, 2024.",8.31M
Add to portfolio,,,,,,,,
ATXS,Astria Therapeutics Inc.,$10.50 ,Navenibart (STAR-0215) - (ALPHA-ORBIT),"Hereditary angioedema (HAE), healthy volunteers ",Phase 1/2,11/12/2024 ET,"Phase 1b/2 data results demonstrated reduction in the mean monthly attack rate of 90-95% at 6 months, favorable safety and tolerability profile, noted December 11, 2024.",56.43M
Add to portfolio,,,FTD,,,,,
,,,ODD,,,,,
ATXS,Astria Therapeutics Inc.,$10.50 ,STAR-0310,Healthy volunteers ,IND-Enabling,11/12/2024 ET,"IND cleared by the FDA, noted December 10, 2024.",56.43M
Add to portfolio,,,,,,,,
MBRX,Moleculin Biotech Inc.,$2.65 ,"Annamycin (MB-106) in combination with Cytarabine - (Ara-C, MIRACLE)",Acute Myeloid Leukemia (AML) ,Preclinical,11/12/2024 ET,"Preclinical data resulted in durable disease eradication up to 150 days post treatment in 20% of mice, noted December 11, 2024.",30.29M
Add to portfolio,,,ODD,,,,,
,,,FTD,,,,,
ANRO,Alto Neuroscience Inc.,$3.89 ,ALTO-300,Major Depressive Disorder (MDD) ,Preclinical,11/12/2024 ET,"New preclinical data presented at ACNP from a reverse translation study demonstrates the link between the mechanism of ALTO-300 and the EEG biomarker used for patient selection, noted December 11, 202 … read more",27.08M
Add to portfolio,,,,,,,,
JNJ,Johnson & Johnson,—,CAPLYTA (Lumateperone) - (Study 501),Major depressive disorder (MDD) ,Phase 3,11/12/2024 ET,"Phase 3 data reported that response rates for CAPLYTA were 45.6% vs. 24.0% for placebo (p<0.0001) and remission rates were 25.9% vs. 13.6% for placebo, noted December 11, 2024.",2.41B
Add to portfolio,,,View Clinical Trial Data,,,,,
JNJ,Johnson & Johnson,—,CAPLYTA (lumateperone) - (Study 502),Major depressive disorder (MDD) ,Phase 3,11/12/2024 ET,"Phase 3 data reported response rates for CAPLYTA were 40.1% vs. 25.3% for placebo (p<0.01) and remission rates were 25.0% vs. 13.5% for placebo, noted December 11, 2024.",2.41B
Add to portfolio,,,,,,,,
BCTX,BriaCell Therapeutics Corp.,$16.50 ,Bria-IMT - (BRIA-ABC),Advanced breast cancer ,Phase 2,11/12/2024 ET,"Phase 2 SABCS data reported a median overall survival (OS) to date of 13.4 months, noted December 11, 2024.",1.76M
Add to portfolio,,,,,,,,
AZN,AstraZeneca PLC,$66.46 ,LYNPARZA (olaparib) - (OlympiA),Early Breast Cancer ,Phase 3,11/12/2024 ET,"Phase 3 data reported that 87.5% of patients treated with LYNPARZA were alive at six-years vs. 83.2% in the comparator arm, noted December 11, 2024.",3.1B
Add to portfolio,,,,,,,,
MRK,Merck & Company Inc.,$98.95 ,LYNPARZA (olaparib) - (OlympiA),Early Breast Cancer ,Phase 3,11/12/2024 ET,"Phase 3 data reported that 87.5% of patients treated with LYNPARZA were alive at six-years vs. 83.2% in the comparator arm, noted December 11, 2024.",2.5B
Add to portfolio,,,,,,,,
CORT,Corcept Therapeutics Incorporated,$60.08 ,Dazucorilant (DAZALS),Amyotrophic Lateral Sclerosis (ALS) ,Phase 2,11/12/2024 ET,"Phase 2 trial did not meet its primary endpoint, noted December 11, 2024.",105.37M
Add to portfolio,,,,,,,,
ATOS,Atossa Therapeutics Inc.,$1.22 ,Z-Endoxifen - (Karisma),"Mammographic breast density (MBD), breast cancer ",Phase 2,11/12/2024 ET,"Phase 2 data showed that the 1 mg dose reduced MBD by 17.3 percentage points, while the 2 mg dose achieved a reduction of 23.5 percentage points, compared to a minimal change in the placebo group of 0 … read more",129.17M
Add to portfolio,,,,,,,,
GLUE,Monte Rosa Therapeutics Inc.,$8.51 ,MRT-9643,HR-positive/HER2-negative breast cancer ,Preclinical,11/12/2024 ET,"Preclinical data demonstrated that the company has superior selectivity compared to clinical-stage CDK2 inhibitors and induced robust downstream CDK2 pathway suppression, noted December 11, 2024.",61.76M
Add to portfolio,,,,,,,,
LLY,Eli Lilly and Company,$794.62 ,Inluriyo (imlunestrant),"ER+, HER2-, ESR1-mutated advanced or metastatic breast cancer ",Phase 3,11/12/2024 ET,"Phase 3 data presented at SABCS significantly reduced the risk of progression or death by 38% compared to standard endocrine therapy (ET) in patients with ESR1 mutations, noted December 11, 2024.",
Add to portfolio,,,,,,,,
IMCR,Immunocore Holdings plc,$30.77 ,KIMMTRAK (tebentafusp-tebn) - (ATOM),Uveal melanoma ,Phase 3,11/12/2024 ET,"Phase 3 trial initiated, noted December 11, 2024.",48.09M
Add to portfolio,,,,,,,,
JAGX,Jaguar Health Inc.,$1.28 ,Mytesi (crofelemer) - (OnTarget),Cancer Therapy-Related Diarrhea ,Phase 3,11/12/2024 ET,"Phase 3 subgroup results from SABCS reported that nearly half (47.1%) of crofelemer group patients were responders through 12 weeks, compared to 33.7% of those on placebo, noted December 11, 2024.",2.17M
Add to portfolio,,,View Clinical Trial Data,,,,,
ARVN,Arvinas Inc.,$19.74 ,Vepdegestrant (ARV-471) - (TACTIVE-U),Solid Tumors ,Phase 1b,12/12/2024 ET,"Phase 1b sub-study data reported a clinical benefit rate: 62.5%; overall response rate: 26.7%, noted December 12, 2024.",73.42M
Add to portfolio,,,,,,,,
ATOS,Atossa Therapeutics Inc.,$1.15 ,(Z)-endoxifen with abemaciclib (VERZENIO) - (EVANGELINE),Pre-menopausal women w/ early-stage estrogen receptor positive and Human Epidermal Growth Factor Receptor 2 negative breast cancer ,Phase 2,12/12/2024 ET,Phase 2 data from SABCS reported that 50 percent of patients (3/6) in the group that received 80 mg of (Z)-endoxifen with goserelin met the target steady-state plasma concentrations (Css) of 500–1000 … read more,129.17M
Add to portfolio,,,,,,,,
LLY,Eli Lilly and Company,$780.96 ,(Z)-endoxifen with abemaciclib (VERZENIO) - (EVANGELINE),Pre-menopausal women w/ early-stage estrogen receptor positive and Human Epidermal Growth Factor Receptor 2 negative breast cancer ,Phase 2,12/12/2024 ET,Phase 2 data from SABCS reported that 50 percent of patients (3/6) in the group that received 80 mg of (Z)-endoxifen with goserelin met the target steady-state plasma concentrations (Css) of 500–1000 … read more,946.46M
Add to portfolio,,,,,,,,
KROS,Keros Therapeutics Inc.,$18.43 ,Cibotercept (KER-012) - (TROPOS),Pulmonary arterial hypertension (PAH) and disorders associated with bone loss ,Phase 2,12/12/2024 ET,"Phase 2 trial voluntarily halted dosing in the 3.0 mg/kg and 4.5 mg/kg treatment arm due to the unanticipated observation of pericardial effusion adverse events in the trial, noted December 12, 2024.",40.62M
Add to portfolio,,,,,,,,
GUTS,"Fractyl Health, Inc.",$2.21 ,Rejuva (RJVA-001),Obesity and type 2 diabetes (T2D) ,Preclinical,12/12/2024 ET,"Preclinical data shared at the WCIRDC was successfully delivered in large animal Yucatan pig models at a low total viral dose, noted on December 12, 2024.",50.29M
Add to portfolio,,,,,,,,
TRVI,Trevi Therapeutics Inc.,$3.60 ,Haduvio - (CORAL),Chronic Cough in Idiopathic Pulmonary Fibrosis (IPF) ,Phase 2b,12/12/2024 ET,"Phase 2b SSRE result reported that it was recommended that the CORAL trial should continue as planned to maintain the pre-specified conditional power of 80% or greater, noted December 12, 2024.",121.78M
Add to portfolio,,,,,,,,
ELTX,Elicio Therapeutics Inc.,$4.99 ,ELI-002 (AMPLIFY-201),Solid Tumors ,Phase 2,12/12/2024 ET,"Phase 2 data presented include a 16.3-month median recurrence-free survival (mRFS) and 28.9-month median overall survival (mOS) from full study population, noted ESMO-IO on December 12, 2024.",16.34M
Add to portfolio,,,,,,,,
ANAB,AnaptysBio Inc.,$15.02 ,ANB032 - (ARISE-AD),Atopic dermatitis ,Phase 2b,12/12/2024 ET,"Phase 2b did not meet the primary and secondary endpoints in any of the doses studied in the global, AD trial and all further investment in ANB032 will be discontinued, noted December 12, 2024.",28M
Add to portfolio,,,,,,,,
APRE,Aprea Therapeutics Inc.,$3.52 ,ATRN-119 - (ABOYA-119),Solid tumors ,Phase 1/2,12/12/2024 ET,"Phase 1/2 dosing commenced, noted December 12, 2024.",5.83M
Add to portfolio,,,,,,,,
VRTX,Vertex Pharmaceuticals Incorporated,$464.12 ,Povetacicept (ALPN-303) - (RAINIER),"Lupus nephritis, IgA nephropathy ",Phase 1/2,12/12/2024 ET,"Phase 1b/2a data reported that 100% of patients achieved remission within 30 days, noted December 12, 2024.",256.39M
Add to portfolio,,,,,,,,
ALPN,Alpine Immune Sciences Inc.,—,Povetacicept (ALPN-303) - (RAINIER),"Lupus nephritis, IgA nephropathy ",Phase 1/2,12/12/2024 ET,"Phase 1b/2a data reported that 100% of patients achieved remission within 30 days, noted December 12, 2024.",68.6M
Add to portfolio,,,,,,,,
ITOS,iTeos Therapeutics Inc.,$7.95 ,Inupadenant (EOS-850) - (A2A-005),metastatic non-squamous non-small cell lung cancer (NSCLC) ,Phase 2,12/12/2024 ET,"Phase 2 topline data demonstrated a 63.9% overall response rate (ORR) and a median PFS of 7.7 months for all evaluable patients across the cohorts, noted December 12, 2024.",44.21M
Add to portfolio,,,,,,,,
PFE,Pfizer Inc.,$24.96 ,IBRANCE (palbociclib) - (PATINA),"HR+, HER2+ Metastatic Breast Cancer ",Phase 3,12/12/2024 ET,Phase 3 data reported that the median PFS was 44.3 months (95% CI: 32.4-60.9) for patients treated with IBRANCE in combination with anti-HER2 therapy (trastuzumab or trastuzumab plus pertuzumab) and e … read more,5.69B
Add to portfolio,,,,,,,,
IMMP,Immutep Limited,$2.24 ,Eftilagimod alpha (IMP321) and KEYTRUDA (pembrolizumab) - (TACTI-003),Head and neck squamous cell carcinoma (HNSCC) ,Phase 2b,12/12/2024 ET,"Phase 2b data presented on ESMO IO reported that the median overall survival (OS) has not yet been reached and the 12-month OS rate is 67%, both well above historical controls, noted December 12, 2024 … read more",147.19M
Add to portfolio,,,View Clinical Trial Data,,,,,
KRBP,Kiromic BioPharma Inc.,$0.95 ,Deltacel-01 - (KB-GDT-01),Stage 4 Metastatic Non-Small Cell Lung Cancer ,Phase 1,12/12/2024 ET,"Phase 1 interim data reported tumor reduction of 32% in patient #4, noted December 12, 2024.",1.53M
Add to portfolio,,,FTD,,,,,
ALXO,ALX Oncology Holdings Inc.,$1.42 ,Evorpacept with zanidatamab,Metastatic breast cancer ,Phase 1/2,12/12/2024 ET,"Phase 1b/2 data reported promising anti-tumor activity with an cORR of 55.6%, noted December 12, 2024.",53.55M
Add to portfolio,,,,,,,,
JAZZ,Jazz Pharmaceuticals plc,$123.60 ,Evorpacept with zanidatamab,Metastatic breast cancer ,Phase 1/2,12/12/2024 ET,"Phase 1b/2 data reported promising anti-tumor activity with an cORR of 55.6%, noted December 12, 2024.",60.66M
Add to portfolio,,,,,,,,
INTS,Intensity Therapeutics Inc.,$2.06 ,INT230-6 - (INVINCIBLE-2),Early stage breast cancer ,Phase 2,12/12/2024 ET,"Phase 2 results in tumors larger than 2 cm showed significant necrosis in 74% of subjects at the time of surgery, noted December 12, 2024.",47.06M
Add to portfolio,,,,,,,,
KRYS,Krystal Biotech Inc.,$173.40 ,KB408 - (SERPENTINE-1),Alpha-1 antitrypsin deficiency (AATD) ,Phase 1,12/12/2024 ET,"Phase 1 data reported a clinically meaningful proportion of conducting airway epithelial cells were transduced following administration of a single dose of KB408, with the percentage of cells positive … read more",28.94M
Add to portfolio,,,ODD,,,,,
KRYS,Krystal Biotech Inc.,$173.40 ,KB407 - (CORAL-1),Cystic Fibrosis ,Phase 1,12/12/2024 ET,"Phase 1 data reported that no serious adverse events have been reported, noted December 12, 2024.",28.94M
Add to portfolio,,,,,,,,
APTO,Aptose Biosciences Inc.,$5.78 ,Tuspetinib - (APTIVATE),Acute myeloid leukemia (AML) ,Preclinical,12/12/2024 ET,"Preclinical data reported that TUS potently killed AML lines (GI50 = 1.3 to 5.2 nM) and Ba/F3 cells expressing wildtype (GI50 = 9.1 nM) or various mutant forms of FLT3 (GI50 = 2.5 – 56 nM), noted Dece … read more",2.55M
Add to portfolio,,,,,,,,
BOLD,Boundless Bio Inc.,$2.95 ,BBI-355/BBI-825 - (POTENTIATE),Resistance gene amplifications ,Phase 1/2,12/12/2024 ET,"Company will not to continue dose escalation of Part 1 or to proceed into the Part 2 portion of the STARMAP trial, noted December 12, 2024.",22.39M
Add to portfolio,,,,,,,,
CORT,Corcept Therapeutics Incorporated,$56.33 ,Korlym - (CATALYST),Hypercortisolism (Cushing's Syndrome) and Difficult-to-Control Diabetes ,Phase 3,12/12/2024 ET,"Phase 4 trial met primary endpoint, noted December 12, 2024.",105.37M
Add to portfolio,,,,,,,,
BCYC,Bicycle Therapeutics plc,$20.11 ,Bicycle Toxin Conjugates zelenectide pevedotin (BT8009) - (Duravelo-2),Solid tumors ,Phase 2/3,12/12/2024 ET,"Data presented at SABCS reported an 60% overall response rate, noted December 12, 2024.",69.31M
Add to portfolio,,,FTD,,,,,
KZIA,Kazia Therapeutics Limited,$3.67 ,Paxalisib - (A071701),Brain Metastases ,Phase 2,12/12/2024 ET,"Phase 2 data presented reported minimal clinical activity, noted December 12, 2024.",1.36M
Add to portfolio,,,ODD,,,,,
RPTX,Repare Therapeutics Inc.,$1.77 ,Lunresertib (RP-6306) + Debio 0123 - (MYTHIC),Solid Tumors ,Phase 1,13/12/2024 ET,"Phase 1 trial achieved 25.9% overall response rate (ORR) in endometrial cancer and 37.5% in platinum-resistant ovarian cancer, noted December 13, 2024.",42.96M
Add to portfolio,,,FTD,,,,,
FBIO,Fortress Biotech Inc.,$1.94 ,UNLOXCYT (cosibelimab-ipdl),Cutaneous squamous cell carcinoma (CSCC) ,Approved,13/12/2024 ET,"Approved December 13, 2024.",29.75M
Add to portfolio,,,,,,,,
CKPT,Checkpoint Therapeutics Inc.,$3.67 ,UNLOXCYT (cosibelimab-ipdl),Cutaneous squamous cell carcinoma (CSCC) ,Approved,13/12/2024 ET,"Approved December 13, 2024.",87.02M
Add to portfolio,,,,,,,,
ROIV,Roivant Sciences Ltd.,$8.74 ,Tapinarof Cream 1%,Atopic dermatitis (AD) ,Approved,16/12/2024 ET,"Approved December 16, 2024.",682.88M
Add to portfolio,,,,,,,,
OGN,Organon & Co.,—,Tapinarof Cream 1%,Atopic dermatitis (AD) ,Approved,16/12/2024 ET,"Approved December 16, 2024.",259.97M
Add to portfolio,,,,,,,,
MNKD,MannKind Corporation,$6.27 ,Afrezza (Technosphere Insulin) - (INHALE-1),Pediatric type 1/2 diabetes ,Phase 3,16/12/2024 ET,Phase 3 data reported that in the intent-to-treat population (ITT) found that the between-group difference in mean HbA1c change over 26 weeks exceeded the prespecified non-inferiority margin of 0.4% ( … read more,306.83M
Add to portfolio,,,View Clinical Trial Data,,,,,
FHTX,Foghorn Therapeutics Inc.,$5.51 ,FHD-286,Acute myeloid leukemia (AML) ,Phase 1,16/12/2024 ET,"Phase 1 dose escalation trial combination reported that objective clinical responses were observed by standard response criteria. However, the observed response rate did not meet the Company's thresho … read more",56.53M
Add to portfolio,,,,,,,,
PRTC,PureTech Health plc,$22.15 ,Deupirfenidone (LYT-100) - (ELEVATE IPF),Idiopathic pulmonary fibrosis (IPF) ,Phase 2b,16/12/2024 ET,"Phase 2b topline data reported a strong, consistent and durable efficacy with a treatment effect versus placebo of 80.9% with favorable tolerability, noted December 16, 2024.",24.17M
Add to portfolio,,,,,,,,
RLFTF,RELIEF THERAPEUTICS HLDG AG,$4.90 ,PKU GOLIKE,Phenylketonuria (PKU) ,Phase 1,16/12/2024 ET,"Trial data reported that treatment administered as the last daily dose and compared to standard amino acid protein substitutes, improved metabolic control by reducing harmful phenylalanine (Phe) level … read more",12.58M
Add to portfolio,,,,,,,,
LRMR,Larimar Therapeutics Inc.,$4.83 ,Nomlabofusp (CTI-1601),Friedreich’s ataxia (FA) ,Phase 2,16/12/2024 ET,"Phase 2 data showed sustained increases in tissue frataxin (FXN) levels. Buccal cell FXN increased from 15% of healthy volunteer levels at baseline to 30% by Day 90, and skin cell FXN rose from 16% to … read more",85.59M
Add to portfolio,,,ODD,,,,,
MNMD,Mind Medicine (MindMed) Inc.,$7.40 ,"MM120 (lysergide D-tartrate, LSD) - (Voyage)",Generalized Anxiety Disorder (GAD) ,Phase 3,16/12/2024 ET,"Phase 3 dosing initiated, noted December 16, 2024.",75.55M
Add to portfolio,,,,,,,,
SNGX,Soligenix Inc.,$3.05 ,HyBryte - (FLASH2),Cutaneous T-Cell Lymphoma ,Phase 3,16/12/2024 ET,"Phase 3 18-week study initiated, noted December 16, 2024.",4.29M
Add to portfolio,,,,,,,,
BCAB,BioAtla Inc.,$1.35 ,Mecbotamab Vedotin (BA3011),Solid Tumors ,Phase 2,16/12/2024 ET,"Phase 2 enrollment completed with a registrational trial planned for 2H 2024. Phase 2 1-year OS was 58% for mKRAS vs. 23% for wtKRAS patients with an ORR of 28.6%, active across 9 mKRAS variants, not … read more",58.72M
Add to portfolio,,,View Clinical Trial Data,,,,,
ASND,Ascendis Pharma A/S,$136.60 ,TransCon hGH - (InsiGHTS),Turner Syndrome ,Phase 2,16/12/2024 ET,"Phase 2 topline results reported that all three TransCon hGH starting dose cohort showed a safety and tolerability profile comparable to daily somatropin, noted December 16, 2024.",60.69M
Add to portfolio,,,,,,,,
EWTX,Edgewise Therapeutics Inc.,$32.69 ,Sevasemten (EDG-5506) - (CANYON),Becker Muscular Dystrophy (BMD) ,Phase 2,16/12/2024 ET,"Phase 2 trial met its primary endpoint of reduction in circulating levels of creatine kinase (CK), a biomarker associated with skeletal muscle damage, in the largest Becker interventional trial to dat … read more",105.35M
Add to portfolio,,,ODD,,,,,
PEPG,PepGen Inc.,$4.51 ,PGN-EDO51 - (CONNECT2),Duchenne muscular dystrophy (DMD) ,Phase 2,16/12/2024 ET,"Phase 2 trial received a clinical hold notice from the FDA regarding its IND application, noted December 16, 2024.",32.8M
Add to portfolio,,,,,,,,
BHVN,Biohaven Ltd.,$41.44 ,BHV-1300,Healthy volunteers ,Phase 1,16/12/2024 ET,"Phase 1 achieved deep lowering of targeted IgG, with reductions > 60% in the lowest subcutaneous dose tested in the MAD, noted December 16, 2024.",105.79M
Add to portfolio,,,,,,,,
BHVN,Biohaven Ltd.,$41.44 ,Troriluzole (BHV4157-206-RWE),Spinocerebellar Ataxia ,sNDA Filing,16/12/2024 ET,"sNDA submitted to the FDA, noted December 16, 2024.",105.79M
Add to portfolio,,,,,,,,
RVPH,Reviva Pharmaceuticals Holdings Inc.,$2.30 ,Brilaroxazine - (RECOVER),Schizophrenia ,Phase 3,16/12/2024 ET,"Phase 3 long-term topline data from OLE demonstrated favorable long-term safety and robust broad-spectrum efficacy sustained over 1-year, the treatment generally well-tolerated with low rates of adver … read more",68M
Add to portfolio,,,,,,,,
SNY,Sanofi,—,MenQuadfi,Meningococcal disease ,Approved,17/12/2024 ET,"Approved December 17, 2024.",2.46B
Add to portfolio,,,,,,,,
SNY,Sanofi,$48.94 ,Duvakitug (TEV-'574/SAR447189) - (RELIEVE UCCD),Moderate-to-severe inflammatory bowel disease (IBD); this includes ulcerative colitis (UC) and Crohn's disease (CD) ,Phase 2b,17/12/2024 ET,"Phase 2b topline data reported that the trial met its primary endpoints, noted December 17, 2024.",2.46B
Add to portfolio,,,,,,,,
TEVA,Teva Pharmaceutical Industries Limited American Depositary Shares,$20.88 ,Duvakitug (TEV-'574/SAR447189) - (RELIEVE UCCD),Moderate-to-severe inflammatory bowel disease (IBD); this includes ulcerative colitis (UC) and Crohn's disease (CD) ,Phase 2b,17/12/2024 ET,"Phase 2b topline data reported that the trial met its primary endpoints, noted December 17, 2024.",1.15B
Add to portfolio,,,,,,,,
PSTV,PLUS THERAPEUTICS Inc.,$1.07 ,REYOBIQ (rhenium Re186 obisbemeda) - (ReSPECT-LM),Leptomeningeal metastases (LM) ,Phase 1,17/12/2024 ET,"Phase 1 data presented at SABCS reported that the best response rates (response only) were, CTC: 88% (7/8), noted December 17, 2024.",99.26M
Add to portfolio,,,FTD,,,,,
,,,ODD,,,,,
TNYA,Tenaya Therapeutics Inc.,$1.41 ,TN-201 - (MyPeak-1),Hypertrophic cardiomyopathy (HCM) ,Phase 1/2,17/12/2024 ET,"Phase 1/2 preliminary data from three patients in the first dose cohort of 3E13 vg/kg (Cohort 1) showed that TN-201 was generally well tolerated, with readily detectable vector DNA in the heart, evide … read more",162.98M
Add to portfolio,,,,,,,,
AFMD,Affimed N.V.,$1.51 ,AFM24-102 and TECENTRIQ (atezolizumab),"EGFR Expressing Solid Tumors, Non-small cell lung cancer, and Gastric/gastroesophageal junction (GEJ) cancer ",Phase 2,17/12/2024 ET,"Phase 2 results continue to demonstrate meaningful clinical activity in both NSCLC EGFRwt and EGFRmut patients with good tolerability, noted December 17, 2024.",15.23M
Add to portfolio,,,FTD,,,,,
TNXP,Tonix Pharmaceuticals Holding Corp.,$33.39 ,Tonmya (TNX-102 SL) - (RELIEF/RESILIENT),Fibromyalgia ,NDA Filing,17/12/2024 ET,"NDA accepted December 17, 2024.",8.77M
Add to portfolio,,,FTD,,,,,
BMEA,Biomea Fusion Inc.,$4.64 ,Icovamenib (BMF-219) - (COVALENT-111),Type 2 Diabetes ,Phase 2,17/12/2024 ET,"Phase 2 study met the primary endpoint, displaying a meaningful statistically significant placebo-corrected mean reduction in HbA1c in the prespecified per protocol patient population, noted December … read more",59.51M
Add to portfolio,,,,,,,,
IMMP,Immutep Limited,$2.13 ,IMP761,Autoimmune diseases ,Phase 1,17/12/2024 ET,"Phase 1 safety data reported no treatment related adverse events to date, noted December 17, 2024.",147.19M
Add to portfolio,,,,,,,,
ACTU,Actuate Therapeutics Inc.,$7.66 ,Elraglusib (9-ING-41) - (Actuate-1902),Ewing Sarcoma (Pediatric) ,Phase 1,17/12/2024 ET,"Phase 1 met primary endpoint of 1 year survival rate and median overall survival, noted December 17, 2024.",20.75M
Add to portfolio,,,RPDD,,,,,
LPCN,Lipocine Inc.,$5.21 ,LPCN 1148,"Liver cirrhosis, specifically prevention of OHE recurrence and treatment of sarcopenia ",Phase 2,17/12/2024 ET,"Fast track designation granted by the FDA, noted December 17, 2024.",5.42M
Add to portfolio,,,FTD,,,,,
,,,View Clinical Trial Data,,,,,
CORT,Corcept Therapeutics Incorporated,$55.14 ,Relacorilant - (GRADIENT),Cushing’s syndrome ,Phase 3,17/12/2024 ET,"Phase 3 long term extension data demonstrated that patients treated with relacorilant experienced clinically meaningful and durable cardiometabolic improvements and relacorilant was well-tolerated, w … read more",105.37M
Add to portfolio,,,View Clinical Trial Data,,,,,
SNTI,Senti Biosciences Inc.,$5.15 ,SN301A (SENTI-301A),Hepatocellular Carcinoma (HCC) ,Phase 1,17/12/2024 ET,"Phase 1 dosing commenced in mainland China, noted December 17, 2024.",26.16M
Add to portfolio,,,,,,,,
GPCR,Structure Therapeutics Inc.,$31.48 ,ACCG-2671,Obesity ,Preclinical,17/12/2024 ET,"Preclinical studies with ACCG-2671 demonstrate potent target engagement, robust weight loss, favorable safety profile and PK properties supportive of once-daily dosing in humans, noted December 17, 20 … read more",57.6M
Add to portfolio,,,,,,,,
MRUS,Merus N.V.,$44.90 ,Petosemtamab (MCLA-158),"Recurrent/metastatic (r/m) head and neck squamous cell carcinoma (HNSCC), Solid Tumors ",Phase 2,17/12/2024 ET,"Phase 2 OLE colorectal cancer cohort dosing commenced, noted December 17, 2024.",75.63M
Add to portfolio,,,BTD,,,,,
GMAB,Genmab A/S,—,Petosemtamab (MCLA-158),"Recurrent/metastatic (r/m) head and neck squamous cell carcinoma (HNSCC), Solid Tumors ",Phase 2,17/12/2024 ET,"Phase 2 OLE colorectal cancer cohort dosing commenced, noted December 17, 2024.",661.87M
Add to portfolio,,,BTD,,,,,
IMMX,Immix Biopharma Inc.,$2.29 ,NXC-201 (HBI10101) - (NEXICART-1),relapsed/refractory multiple myeloma and relapsed/refractory AL amyloidosis ,Phase 1/2,17/12/2024 ET,"Phase 1/2 data published at the JCO demonstrated compelling clinical activity, rapid and deep complete responses in frail and resistant relapsed/refractory AL Amyloidosis patients, noted December 17, … read more",28.83M
Add to portfolio,,,ODD,,,,,
CTNM,Contineum Therapeutics Inc.,$14.06 ,PIPE-791,Osteoarthritis and low back pain ,Phase 1b,17/12/2024 ET,"Phase 1b commenced, noted December 17, 2024",28.04M
Add to portfolio,,,,,,,,
TLSA,Tiziana Life Sciences Ltd,$0.99 ,Foralumab (Intranasal),Alzheimer’s Disease ,Phase 1,17/12/2024 ET,"Phase 1 dosing commenced, noted December 17, 2024.",111.46M
Add to portfolio,,,,,,,,
MTVA,MetaVia Inc.,$1.85 ,Vanoglipel (DA-1241),Metabolic dysfunction-associated steatohepatitis (MASH) ,Phase 2a,18/12/2024 ET,"Phase 2a data reported that DA-1241 (100mg) demonstrated a statistically significant reduction in alanine transaminase (ALT) levels at weeks 4 and 8, with a near statistically significant reduction at … read more",24.2M
Add to portfolio,,,,,,,,
CGTX,Cognition Therapeutics Inc.,$0.58 ,Zervimesine (CT1812) - (SHIMMER),Dementia with Lewy Bodies (DLB) ,Phase 2,18/12/2024 ET,"Phase 2 trial met its primary endpoint, noted December 18, 2024.",73.47M
Add to portfolio,,,,,,,,
CRVS,Corvus Pharmaceuticals Inc.,$4.70 ,Soquelitinib - (CPI-818),Moderate to severe atopic dermatitis ,Phase 1,18/12/2024 ET,"Phase 1 data reported that the soquelitinib mean EASI score reduction was 55.9% at 28 days (n=12) compared to mean EASI reduction of 27.0% in placebo. At day 58, continued improvement in the soqueliti … read more",74.51M
Add to portfolio,,,,,,,,
QNRX,Quoin Pharmaceuticals Ltd.,$0.56 ,QRX003 - (open label),Netherton Syndrome (NS) ,Phase 1,18/12/2024 ET,"Phase 1 data from the first subject being dosed twice daily is suggestive of clinical efficacy across a number of measured endpoints after six weeks of dosing with QRX003, which is the midpoint of tes … read more",588.17K
Add to portfolio,,,RPDD,,,,,
CHRS,Coherus Oncology Inc.,$1.57 ,Casdozokitug/toripalimab/bevacizumab,Unresectable locally advanced or metastatic hepatocellular carcinoma (HCC) ,Phase 2,18/12/2024 ET,"Phase 2 data reported an objective response rate of 25.3% versus 6.1% in the sorafenib group, a median progression-free survival of 5.8 months, and a median overall survival of 20 months, compared to … read more",116.23M
Add to portfolio,,,,,,,,
CHRO,Channel Therapeutics Corporation,$0.59 ,Bupivacaine (NaV1.7 Inhibitor),Acute and postoperative pain ,Preclinical,18/12/2024 ET,"Preclinical data reported that the trial met its endpoints, noted December 18, 2024.",6.6M
Add to portfolio,,,,,,,,
KRYS,Krystal Biotech Inc.,$156.64 ,KB707 - (KYANITE-1),Solid Tumors ,Phase 1,18/12/2024 ET,"Phase 1 initial data reported an objective response rate (ORR) of 27% and disease control rate (DCR) of 73%, noted December 18, 2024.",28.94M
Add to portfolio,,,FTD,,,,,
,,,RPDD,,,,,
VSTM,Verastem Inc.,$4.26 ,VS-6766 and LUMAKRAS (Sotorasib) - (RAMP 203),KRAS mutant non-small cell lung cancer (NSCLC) ,Phase 1/2,18/12/2024 ET,"Phase 1/2 data reported no dose-limiting toxicities (DLTs) have been observed in the triplet combination, noted December 18, 2024.",61.55M
Add to portfolio,,,FTD,,,,,
AMGN,Amgen Inc.,$256.68 ,VS-6766 and LUMAKRAS (Sotorasib) - (RAMP 203),KRAS mutant non-small cell lung cancer (NSCLC) ,Phase 1/2,18/12/2024 ET,"Phase 1/2 data reported no dose-limiting toxicities (DLTs) have been observed in the triplet combination, noted December 18, 2024.",538.36M
Add to portfolio,,,FTD,,,,,
SVRA,Savara Inc.,$3.02 ,MOLBREEVI (Molgradex) - (IMPALA-2),Autoimmune pulmonary alveolar proteinosis (aPAP) ,BLA Filing,18/12/2024 ET,"Rolling BLA submission initiated December 18, 2024.",172.84M
Add to portfolio,,,View Clinical Trial Data,,,,,
NBIX,Neurocrine Biosciences Inc.,$134.96 ,"CRENESSITY (Crinecerfont) - (CAHtalyst, capsule formulation)",Congenital Adrenal Hyperplasia (CAH) ,Approved,19/12/2024 ET,"Approved December 19, 2024.",99.71M
Add to portfolio,,,BTD,,,,,
,,,View Clinical Trial Data,,,,,
RHHBY,Roche Holding AG ADR,$34.24 ,Prasinezumab (PRX002) - (PADOVA),Parkinson's disease ,Phase 2b,19/12/2024 ET,"Phase 2b trial failed to meet its primary endpoint, noted December 19, 2024.",6.36B
Add to portfolio,,,View Clinical Trial Data,,,,,
PRTA,Prothena Corporation plc,$16.01 ,Prasinezumab (PRX002) - (PADOVA),Parkinson's disease ,Phase 2b,19/12/2024 ET,"Phase 2b trial failed to meet its primary endpoint, noted December 19, 2024.",53.83M
Add to portfolio,,,View Clinical Trial Data,,,,,
MESO,Mesoblast Limited,$16.76 ,RYONCIL (remestemcel-L),"Pediatric participants with acute graft versus host disease (aGVHD), following allogeneic hematopoietic stem cell transplant (HSCT) ",Approved,19/12/2024 ET,"Approved December 19, 2024.",128.12M
Add to portfolio,,,,,,,,
PLUR,Pluri Inc.,$4.40 ,RYONCIL (remestemcel-L),"Pediatric participants with acute graft versus host disease (aGVHD), following allogeneic hematopoietic stem cell transplant (HSCT) ",Approved,19/12/2024 ET,"Approved December 19, 2024.",8.16M
Add to portfolio,,,,,,,,
VRTX,Vertex Pharmaceuticals Incorporated,$396.64 ,Suzetrigine,Painful Lumbosacral Radiculopathy ,Phase 2,19/12/2024 ET,"Phase 2 trial met its primary endpoint, noted December 19, 2024.",256.39M
Add to portfolio,,,,,,,,
MRK,Merck & Company Inc.,$99.52 ,Doravirine/Islatravir (DOR/ISL) - (MK-8591A-051),HIV-1 Infection ,Phase 3,19/12/2024 ET,Phase 3 trial topline srudy demonstrated non-inferiority of DOR/ISL to baseline antiretroviral therapy (bART) andbictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) in virologically suppress … read more,2.5B
Add to portfolio,,,,,,,,
OCGN,"Ocugen, Inc.",$0.77 ,OCU410 - (ArMaDa),Geographic Atrophy (GA) ,Phase 1/2,19/12/2024 ET,"Phase 1/2 DSMB review noted no serious adverse events, noted December 19, 2024.",292.3M
Add to portfolio,,,,,,,,
BPTH,Bio-Path Holdings Inc.,$1.49 ,BP1001-A (Prexigebersen-A),Obesity in Type 2 diabetes patients ,Preclinical,19/12/2024 ET,"Preclinical data reported that BP1001-A reduced Grb2 protein expression in myoblast cells, noted December 19, 2024.",8.31M
Add to portfolio,,,,,,,,
MRK,Merck & Company Inc.,$99.52 ,Doravirine/Islatravir (DOR/ISL) - (MK-8591A-052),HIV-1 Infection ,Phase 3,19/12/2024 ET,"Phase 3 met primary efficacy endpoint at Week 48, the study demonstrated to be non-inferior to BIC/FTC/TAF in double-blind trial. The superiority criteria were not met in trial MK-8591A-052. Primary s … read more",2.5B
Add to portfolio,,,,,,,,
REGN,Regeneron Pharmaceuticals Inc.,$707.36 ,REGN9933 - (ROXI-VTE-I),Venous thromboembolism (VTE) ,Phase 2,19/12/2024 ET,"Phase 2 data reported that only 20 of 116 patients has VTE events, noted December 19, 2024.",105.1M
Add to portfolio,,,,,,,,
ACET,Adicet Bio Inc.,$0.86 ,ADI-270,"Solid tumors CAR T, relapsed/refractory renal cell carcinoma (RCC) ",Phase 1,19/12/2024 ET,"Phase 1 dosing commenced, noted December 19, 2024.",83.25M
Add to portfolio,,,FTD,,,,,
REGN,Regeneron Pharmaceuticals Inc.,$707.36 ,REGN7508 (ROXI-VTE-II),,Phase 2,19/12/2024 ET,"Phase 2 data reported that 8 of 113 patients patients with VTE events, noted December 19, 2024.",105.1M
Add to portfolio,,,,,,,,
GILD,Gilead Sciences Inc.,$91.09 ,Efarindodekin Alfa (XTX301),Solid tumors ,Phase 1,19/12/2024 ET,"Phase 1 preliminary safety data demonstrated an improved tolerability profile over historical data for rhIL-12, with no dose-limiting toxicities, noted December 19, 2024.",1.24B
Add to portfolio,,,,,,,,
XLO,Xilio Therapeutics Inc.,$0.94 ,Efarindodekin Alfa (XTX301),Solid tumors ,Phase 1,19/12/2024 ET,"Phase 1 preliminary safety data demonstrated an improved tolerability profile over historical data for rhIL-12, with no dose-limiting toxicities, noted December 19, 2024.",51.83M
Add to portfolio,,,,,,,,
ARMP,Armata Pharmaceuticals Inc.,$1.98 ,AP-PA02 - (Tailwind),Non-cystic fibrosis bronchiectasis (NCFB) ,Phase 2,19/12/2024 ET,"Phase 2 trial results demonstrated that inhaled AP-PA02 provides a durable reduction of Pseudomonas aeruginosa in the lung, with a favorable safety and tolerability profile, noted December 19, 2024.",36.23M
Add to portfolio,,,,,,,,
PTN,Palatin Technologies Inc.,$0.86 ,Bremelanotide - (BREAKOUT),Diabetic Kidney Disease ,Phase 2a,19/12/2024 ET,"Phase 2a showed that bremelanotide therapy for six months, in patients with established Type II diabetic nephropathy, resulted in positive and beneficial results for the majority of patients related t … read more",46.48M
Add to portfolio,,,,,,,,
PHIO,Phio Pharmaceuticals Corp.,$1.74 ,PH-762,Cutaneous Squamous Cell Carcinoma ,Phase 1b,19/12/2024 ET,"Phase 1b demonstrated encouraging safety profile in 2nd cohort with recommendation to escalate to next dose concentration, noted December 19, 2024.",5.73M
Add to portfolio,,,,,,,,
MRKR,Marker Therapeutics Inc.,$3.73 ,Neldaleucel (MT-601) - (APOLLO),Lymphoma who have failed or are ineligible to receive anti-CD19 CAR T cell treatment ,Phase 1,19/12/2024 ET,"Phase 1 showed that 78% of patients achieved objective response rates, with 44.4% demonstrating complete response (CR), noted December 19, 2024.",12.94M
Add to portfolio,,,,,,,,
PTCT,PTC Therapeutics Inc.,$45.25 ,Vatiquinone - (MOVE-FA),Friedreich ataxia ,NDA Filing,19/12/2024 ET,"NDA submitted to the FDA, noted December 19, 2024.",79.44M
Add to portfolio,,,View Clinical Trial Data,,,,,
CLDX,Celldex Therapeutics Inc.,$25.38 ,Barzolvolimab (CDX-0159),Atopic dermatitis (AD) ,Phase 2,19/12/2024 ET,"Phase 2 dosing commenced, noted December 19, 2024.",66.41M
Add to portfolio,,,,,,,,
IMMX,Immix Biopharma Inc.,$2.22 ,NXC-201 (HBI10101) - (NEXICART-2),Relapsed/refractory AL Amyloidosis ,Phase 1/2,19/12/2024 ET,"Phase 1b/2 data reported that all four patients treated with NXC-201 normalized their disease markers within 30 days of dosing, of which, two are already classified as complete responders (CR), and th … read more",28.83M
Add to portfolio,,,ODD,,,,,
,,,RMAT,,,,,
OMER,Omeros Corporation,$10.24 ,Narsoplimab,Hematopoietic stem cell-associated TMA (HSCT-TMA) ,Phase 3,19/12/2024 ET,"Trial met primary endpoint, noted December 19, 2024.",68.06M
Add to portfolio,,,,,,,,
IONS,Ionis Pharmaceuticals Inc.,$35.59 ,TRYNGOLZA (olezarsen),Familial Chylomicronemia Syndrome (FCS) ,Approved,19/12/2024 ET,"Approved December 19, 2024.",159.39M
Add to portfolio,,,ODD,,,,,
,,,View Clinical Trial Data,,,,,
RARE,Ultragenyx Pharmaceutical Inc.,$43.47 ,GTX-102 - (Aspire),Angelman Syndrome ,Phase 3,19/12/2024 ET,"Phase 3 dosing commenced, noted December 19, 2024.",96.37M
Add to portfolio,,,BTD,,,,,
ALMS,Alumis Inc.,$8.63 ,A-005,Central nervous system (CNS) penetrant TYK2 inhibitor ,Phase 1,19/12/2024 ET,"Phase 1 data demonstrated the ability to cross the human blood-brain barrier to address inflammation within the central nervous system (CNS), noted December 19, 2024.",104.06M
Add to portfolio,,,,,,,,
NVO,Novo Nordisk A/S,$85.00 ,AM833 (CagriSema) - (REDEFINE),Obesity ,Phase 3,20/12/2024 ET,"Phase 3 trial met its primary endpoint, noted December 20, 2024.",4.47B
Add to portfolio,,,View Clinical Trial Data,,,,,
GSK,GSK plc American Depositary Shares (Each representing two),$33.24 ,Zejula (niraparib) and Jemperli (dostarlimab) - (FIRST-ENGOT-OV44),First line advanced ovarian cancer ,Phase 3,20/12/2024 ET,"Phase 3 trial met primary endpoint, noted December 20, 2024.",2.03B
Add to portfolio,,,,,,,,
HUMA,Humacyte Inc.,$4.64 ,SYMVESS (acellular tissue engineered vessel-tyod),Extremity Vascular Trauma ,Approved,20/12/2024 ET,"Approval announced December 20, 2024.",158.37M
Add to portfolio,,,,,,,,
GALT,Galectin Therapeutics Inc.,$1.04 ,GR-MD-02 (belapectin) - (NAVIGATE),Non-alcoholic steatohepatitis (NASH) with cirrhosis ,Phase 2/3,20/12/2024 ET,"Phase 2b/3 topline data reported a statistically significant reduction (p-value < 0.05) in development of esophageal varices in 2mg/kg cohort compared to placebo, noted December 20, 2024.",64.06M
Add to portfolio,,,FTD,,,,,
,,,View Clinical Trial Data,,,,,
RYTM,Rhythm Pharmaceuticals Inc.,$56.12 ,IMCIVREE (setmelanotide),"Obesity due to biallelic POMC, PCSK1, LEPR deficiency, or BBS (ages 2-6 years old) ",Approved,20/12/2024 ET,"Approved December 20, 2024.",66.42M
Add to portfolio,,,View Clinical Trial Data,,,,,
PFE,Pfizer Inc.,$25.93 ,BRAFTOVI,BRAF V600E-Mutant Metastatic Colorectal Cancer ,Approved,20/12/2024 ET,"Approved December 20, 2024.",5.69B
Add to portfolio,,,,,,,,
VRTX,Vertex Pharmaceuticals Incorporated,$397.27 ,ALYFTREK (vanzacaftor/tezacaftor/deutivacaftor),Cystic fibrosis (CF) ages 6 years and older ,Approved,20/12/2024 ET,"FDA approved on December 20, 2024.",256.39M
Add to portfolio,,,,,,,,
LXRX,Lexicon Pharmaceuticals Inc.,$0.71 ,Zynquista (sotagliflozin),Type 1 Diabetes and chronic kidney disease (CKD) ,CRL,20/12/2024 ET,"CRL issued by FDA on December 20, 2024.",363.4M
Add to portfolio,,,,,,,,
LLY,Eli Lilly and Company,$766.40 ,Zepbound (Tirzepatide) - (SURMOUNT-OSA),Obstructive Sleep Apnea (OSA) ,Approved,20/12/2024 ET,"FDA Approved on December 20, 2024.",946.46M
Add to portfolio,,,FTD,,,,,
NBIX,Neurocrine Biosciences Inc.,$135.42 ,CRENESSITY (Crinecerfont) - (oral solution formulation),Classic congenital adrenal hyperplasia (CAH) ,Approved,20/12/2024 ET,"FDA Approved on December 20, 2024.",99.71M
Add to portfolio,,,,,,,,
BMY,Bristol-Myers Squibb Company,$56.96 ,Sotyktu (deucravacitinib) - (POETYK PsA-1),Psoriatic Arthritis ,Phase 3,23/12/2024 ET,"Phase 3 trial met its primary endpoint, noted December 23, 2024.",2.04B
Add to portfolio,,,,,,,,
BMY,Bristol-Myers Squibb Company,$56.96 ,Sotyktu (deucravacitinib) - (POETYK PsA-2),Psoriatic Arthritis ,Phase 3,23/12/2024 ET,"Phase 3 trial met its primary endpoint, noted December 23, 2024.",2.04B
Add to portfolio,,,,,,,,
WVE,Wave Life Sciences Ltd.,$13.12 ,NHBE GalNAc siRNA (WVE-007) - (INLIGHT),Obesity ,IND-Enabling,23/12/2024 ET,"CTA submitted, noted December 23, 2024.",159.14M
Add to portfolio,,,,,,,,
IMCR,Immunocore Holdings plc,$28.14 ,IMC-P115C (PRAME-A02 HLE),Solid tumors ,Phase 1,23/12/2024 ET,"Phase 1 dosing commenced, noted December 23, 2024.",48.09M
Add to portfolio,,,,,,,,
VYNE,VYNE Therapeutics Inc.,$2.57 ,VYN202,Moderate-to-severe plaque psoriasis ,Phase 1a,23/12/2024 ET,"Phase 1a topline results demonstrated a favorable safety and tolerability profile with no drug-related adverse events historically associated with earlier generation, less selective BET inhibitors, no … read more",25.47M
Add to portfolio,,,,,,,,
ARWR,Arrowhead Pharmaceuticals Inc.,$19.75 ,ARO-INHBE,Obesity ,Phase 1/2,23/12/2024 ET,"Phase 1/2a trial initiated, noted December 23, 2024.",138.26M
Add to portfolio,,,,,,,,
GKOS,Glaukos Corporation,$148.36 ,Epioxa (Epi-on),Progressive keratoconus ,NDA Filing,23/12/2024 ET,"NDA filing submitted to the FDA, noted December 23, 2024.",57.35M
Add to portfolio,,,,,,,,
XBIT,XBiotech Inc.,$4.50 ,Natrunix,Rheumatoid Arthritis ,Phase 2,23/12/2024 ET,"Phase 2 trial did not meet its primary endpoint, noted December 23, 2024.",30.49M
Add to portfolio,,,,,,,,
ZLDPF,Zealand Pharma A/S.,$100.09 ,Glepaglutideb - (EASE 1),Short bowel syndrome (SBS) ,CRL,23/12/2024 ET,"CRL announced on December 19, 2024.",70.69M
Add to portfolio,,,View Clinical Trial Data,,,,,
ASMB,Assembly Biosciences Inc.,$15.38 ,ABI-4334,Hepatitis B ,Phase 1b,26/12/2024 ET,"Phase 1b initial data reported that a mean decline in HBV DNA of 2.9 log10 IU/mL was observed, noted December 26, 2024.",7.67M
Add to portfolio,,,,,,,,
BGNE,BeiGene Ltd.,$181.89 ,TEVIMBRA (tislelizumab-jsgr) - (RATIONALE 305),Gastric or gastroesophageal junction (G/GEJ) adenocarcinoma ,Approved,27/12/2024 ET,"FDA Approved on December 27, 2024.",106.62M
Add to portfolio,,,View Clinical Trial Data,,,,,
ONC,BeOne Medicines Ltd.,—,TEVIMBRA (tislelizumab-jsgr) - (RATIONALE 305),Gastric or gastroesophageal junction (G/GEJ) adenocarcinoma ,Approved,27/12/2024 ET,"FDA Approved on December 27, 2024.",110.03M
Add to portfolio,,,View Clinical Trial Data,,,,,
PRFX,PainReform Ltd.,$3.50 ,PRF-110,Bunionectomy ,Phase 3,27/12/2024 ET,"Phase 3 trial did not meet the primary 72-hour endpoint due to unresolved data from the final 24-hour period. However, the drug showed statistically significant pain reduction in the first 48 hours, n … read more",1.89M
Add to portfolio,,,,,,,,
AXSM,Axsome Therapeutics Inc.,$84.78 ,AXS-05 (ADVANCE-2),Alzheimer's disease agitation ,Phase 3,30/12/2024 ET,"Phase 3 trial did not demonstrate statistical significance on primary endpoint, noted December 30, 2024.",49.9M
Add to portfolio,,,BTD,,,,,
NRXP,NRX Pharmaceuticals Inc.,$1.53 ,NRX-101,Bipolar Depression and Suicidal Ideation ,NDA Filing,30/12/2024 ET,"NDA initial section filed, noted December 30, 2024.",19.71M
Add to portfolio,,,BTD,,,,,
,,,FTD,,,,,
,,,View Clinical Trial Data,,,,,
CORT,Corcept Therapeutics Incorporated,$50.85 ,Relacorilant - (GRACE),Hypercortisolism (Cushing's Syndrome) ,NDA Filing,30/12/2024 ET,"NDA filing submitted December 30, 2024.",105.37M
Add to portfolio,,,,,,,,
NVS,Novartis AG,$97.33 ,Zolgensma Intravenous OAV101 (AVXS-101) - (STEER),Spinal muscular atrophy (SMA) Type 2 ,Phase 3,30/12/2024 ET,"Phase 3 trial met primary endpoint, noted December 30, 2024.",1.98B
Add to portfolio,,,View Clinical Trial Data,,,,,
PGEN,Precigen Inc.,$0.93 ,PAPZIMEOS (zopapogene imadenovec-drba),Recurrent Respiratory Papillomatosis (RRP) ,BLA Filing,30/12/2024 ET,"BLA rolling submission completed, noted December 30, 2024. The submission is in the initial 60-day review period, during which time the FDA will decide whether to accept the BLA for further review and … read more",297.97M
Add to portfolio,,,BTD,,,,,
,,,ODD,,,,,
CMRX,Chimerix Inc.,$3.44 ,Dordaviprone (ONC201) - (ACTION),H3 K27M-mutant diffuse midline glioma ,NDA Filing,30/12/2024 ET,"NDA submitted to FDA, noted December 30, 2024.",93.8M
Add to portfolio,,,,,,,,
JAZZ,Jazz Pharmaceuticals plc,—,Dordaviprone (ONC201) - (ACTION),H3 K27M-mutant diffuse midline glioma ,NDA Filing,30/12/2024 ET,"NDA submitted to FDA, noted December 30, 2024.",60.66M
Add to portfolio,,,,,,,,
AXSM,Axsome Therapeutics Inc.,$84.78 ,Dextromethorphan-bupropion (AXS-05) - (ACCORD-2),Agitation in patients with Alzheimer’s disease (AD) ,Phase 3,30/12/2024 ET,"Phase 3 trial in Alzheimer's disease agitation achieves primary endpoint compared to placebo, noted December 30, 2024.",49.9M
Add to portfolio,,,BTD,,,,,
NMRA,Neumora Therapeutics Inc.,$1.97 ,Navacaprant (NMRA-140) - (KOASTAL-1),Major depressive disorder ,Phase 3,02/01/2025 ET,"Phase 3 KOASTAL-1 data reported that the trial did not meet its primary endpoint with statistical significance, noted January 2, 2025.",161.95M
Add to portfolio,,,,,,,,
ANIP,ANI Pharmaceuticals Inc.,$55.44 ,Prucalopride Tablets - (Motegrity generic),(RLD) Motegrity Biosimilar ,Approved,02/01/2025 ET,"FDA ANDA approved on January 2, 2025.",21.7M
Add to portfolio,,,,,,,,
KZIA,Kazia Therapeutics Limited,$1.75 ,Paxalisib (GDC-0084) - (GBM AGILE),Glioblastoma multiforme ,Phase 2/3,02/01/2025 ET,"FDA feedback reported that data on OS would generally not be appropriate for accelerated approval, noted January 2, 2025.",1.36M
Add to portfolio,,,View Clinical Trial Data,,,,,
COCP,Cocrystal Pharma Inc.,$2.32 ,CC-42344,Influenza A ,Phase 2a,02/01/2025 ET,"Phase 2a data reported no SAEs and no drug-related discontinuations by study participants, noted January 2, 2025.",10.26M
Add to portfolio,,,,,,,,
PHIO,Phio Pharmaceuticals Corp.,$1.90 ,RXI-231,Hyperpigmentation ,Preclinical,02/01/2025 ET,"Preclinical data reported that RXI-231 significantly reduced tyrosinase mRNA expression, and correspondingly reduced in melanin content in both normal human melanocytes and the 3D human epidermal cult … read more",5.73M
Add to portfolio,,,,,,,,
CAPR,Capricor Therapeutics Inc.,$14.96 ,Deramiocel (CAP-1002) - (HOPE-2),Duchenne Muscular Dystrophy (DMD) ,BLA Filing,02/01/2025 ET,"BLA submission to the FDA completed, noted January 2, 2024.",45.72M
Add to portfolio,,,ODD,,,,,
KROS,Keros Therapeutics Inc.,$15.64 ,Cibotercept (KER-012) - (TROPOS),Pulmonary arterial hypertension (PAH) and disorders associated with bone loss ,Phase 2,05/01/2025 ET,"Phase 2 trial voluntarily halted all dosing due to new observations of pericardial effusion adverse events, noted January 15, 2025.",40.62M
Add to portfolio,,,,,,,,
OCS,Oculis Holding AG,$17.65 ,OCS-05 - (ACUITY),Acute optic neuritis ,Phase 2,06/01/2025 ET,"Phase 2 trial met primary safety endpoint, noted January 6, 2025.",43.66M
Add to portfolio,,,,,,,,
IMAB,I-MAB,$1.08 ,Uliledlimab (TJ004309),Solid tumors ,Phase 1,06/01/2025 ET,"Development of uliledlimab is being paused, noted January 6, 2025.",81.5M
Add to portfolio,,,,,,,,
VYNE,VYNE Therapeutics Inc.,$4.00 ,Repibresib Gel (VYN201),Vitiligo ,Phase 2b,06/01/2025 ET,"Phase 2b enrollment completed, noted January 6, 2024.",25.47M
Add to portfolio,,,,,,,,
RHHBY,Roche Holding AG ADR,$35.52 ,Amezalpat (TPST-1120) and OPDIVO (nivolumab),"Hepatocellular Carcinoma (HCC), Solid tumors ",Phase 1/2,06/01/2025 ET,"Orphan Drug Designation granted by the FDA, noted January 6, 2024.",6.36B
Add to portfolio,,,ODD,,,,,
,,,FTD,,,,,
TPST,Tempest Therapeutics Inc.,$0.95 ,Amezalpat (TPST-1120) and OPDIVO (nivolumab),"Hepatocellular Carcinoma (HCC), Solid tumors ",Phase 1/2,06/01/2025 ET,"Orphan Drug Designation granted by the FDA, noted January 6, 2024.",4.44M
Add to portfolio,,,ODD,,,,,
,,,FTD,,,,,
